The fluoroquinolones are a rapidly growing class of antibiotics with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria.
fluoroquinolones	4-19	antibiotics	52-62	false

These agents, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis.
norfloxacin	24-34	ciprofloxacin	37-49	false
norfloxacin	24-34	ofloxacin	52-60	false
norfloxacin	24-34	enoxacin	63-70	false
norfloxacin	24-34	lomefloxacin	77-88	false
ciprofloxacin	37-49	ofloxacin	52-60	false
ciprofloxacin	37-49	enoxacin	63-70	false
ciprofloxacin	37-49	lomefloxacin	77-88	false
ofloxacin	52-60	enoxacin	63-70	false
ofloxacin	52-60	lomefloxacin	77-88	false
enoxacin	63-70	lomefloxacin	77-88	false

Advantages offered by this class of antibiotics include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral antibiotics are generally used.
antibiotics	36-46	antibiotics	180-190	false

In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.
progestin-only oral contraceptives	79-112	POC	115-117	false
progestin-only oral contraceptives	79-112	norgestrel	166-175	false
progestin-only oral contraceptives	79-112	norethindrone	192-204	false
POC	115-117	norgestrel	166-175	false
POC	115-117	norethindrone	192-204	false
norgestrel	166-175	norethindrone	192-204	false

Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.
Ganoderma lucidum extract	26-50	antibiotics	87-97	false

To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.
GL	60-61	antibiotics	82-92	false
GL	60-61	ampicillin	95-104	false
GL	60-61	cefazolin	107-115	false
GL	60-61	oxytetracycline	118-132	false
GL	60-61	chloramphenicol	138-152	false
antibiotics	82-92	ampicillin	95-104	false
antibiotics	82-92	cefazolin	107-115	false
antibiotics	82-92	oxytetracycline	118-132	false
antibiotics	82-92	chloramphenicol	138-152	false
ampicillin	95-104	cefazolin	107-115	false
ampicillin	95-104	oxytetracycline	118-132	false
ampicillin	95-104	chloramphenicol	138-152	false
cefazolin	107-115	oxytetracycline	118-132	false
cefazolin	107-115	chloramphenicol	138-152	false
oxytetracycline	118-132	chloramphenicol	138-152	false

The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
GL	34-35	antibiotics	47-57	effect

Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
GL	28-29	cefazolin	49-57	effect

On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts.
amphetamine	69-79	heroin	247-252	false

However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.
alcohol	32-38	amphetamine	99-109	false
alcohol	32-38	heroin	114-119	false
amphetamine	99-109	heroin	114-119	false

Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.
contortrostatin	70-84	echistatin	141-150	false
contortrostatin	70-84	flavoridin	156-165	false
echistatin	141-150	flavoridin	156-165	false

The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells.
contortrostatin	28-42	echistatin	96-105	false
contortrostatin	28-42	flavoridin	111-120	false
echistatin	96-105	flavoridin	111-120	false

Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously.
Echistatin	0-9	contortrostatin	118-132	effect

Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells.
Flavoridin	0-9	contortrostatin	78-92	effect

Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A.
Diethyl pyrocarbonate	0-20	toxin A	94-100	false

Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel.
toxin A	16-22	diethyl pyrocarbonate	29-49	false

Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules.
toxin A	13-19	diethyl pyrocarbonate	34-54	false

The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment.
diethyl pyrocarbonate	15-35	hydroxylamine	58-70	false

Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.
toxin A	22-28	zinc	48-51	false
toxin A	22-28	toxin A	150-156	false
toxin A	22-28	zinc	164-167	false
zinc	48-51	toxin A	150-156	false
zinc	48-51	zinc	164-167	false
toxin A	150-156	zinc	164-167	false

Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
budesonide	42-51	Survanta	56-63	false
budesonide	42-51	lung surfactant	74-88	false
Survanta	56-63	lung surfactant	74-88	false

The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined.
pulmonary surfactant	16-35	Survanta	63-70	false
pulmonary surfactant	16-35	budesonide	121-130	false
Survanta	63-70	budesonide	121-130	false

Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments.
budesonide	21-30	ethanol	55-61	false

Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies.
Survanta	0-7	budesonide	48-57	false

Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate.
Survanta	0-7	sodium dodecyl sulfate	68-89	false

Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase.
budesonide	33-42	budesonide	121-130	false
budesonide	33-42	Survanta	144-151	false
budesonide	121-130	Survanta	144-151	false

As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects.
methamphetamine	141-155	METH	158-161	false

Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine.
METH	46-49	SCH-23390	234-242	effect
METH	46-49	atypical neuroleptic	258-277	false
METH	46-49	clozapine	279-287	false
SCH-23390	234-242	atypical neuroleptic	258-277	false
SCH-23390	234-242	clozapine	279-287	false
atypical neuroleptic	258-277	clozapine	279-287	false

The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
DCG-IV	15-20	L-CCG-1	26-32	false
DCG-IV	15-20	phencyclidine	39-51	false
DCG-IV	15-20	PCP	54-56	false
L-CCG-1	26-32	phencyclidine	39-51	false
L-CCG-1	26-32	PCP	54-56	false
phencyclidine	39-51	PCP	54-56	false

injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior.
phencyclidine	13-25	PCP	28-30	false

Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found.
DCG-IV	71-76	L-CCG-1	82-88	false
DCG-IV	71-76	PCP	134-136	false
L-CCG-1	82-88	PCP	134-136	false

The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion.
DCG-IV	15-20	PCP	68-70	effect

In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.
PCP	49-51	PCP	171-173	false
PCP	49-51	DCG-IV	176-181	false
PCP	49-51	L-CCG-1	188-194	false
PCP	171-173	DCG-IV	176-181	false
PCP	171-173	L-CCG-1	188-194	false
DCG-IV	176-181	L-CCG-1	188-194	false

Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
cocaine	33-39	pentobarbital	107-119	false

Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization.
pentobarbital	82-94	cocaine	225-231	false

18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
18-Methoxycoronaridine	0-21	18-MC	24-28	false
18-Methoxycoronaridine	0-21	ibogaine	35-42	false
18-MC	24-28	ibogaine	35-42	false

Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;
ibogaine	5-12	18-MC	26-30	false
ibogaine	5-12	morphine	92-99	false
ibogaine	5-12	cocaine	105-111	false
ibogaine	5-12	ethanol	149-155	false
ibogaine	5-12	nicotine	161-168	false
18-MC	26-30	morphine	92-99	false
18-MC	26-30	cocaine	105-111	false
18-MC	26-30	ethanol	149-155	false
18-MC	26-30	nicotine	161-168	false
morphine	92-99	cocaine	105-111	false
morphine	92-99	ethanol	149-155	false
morphine	92-99	nicotine	161-168	false
cocaine	105-111	ethanol	149-155	false
cocaine	105-111	nicotine	161-168	false
ethanol	149-155	nicotine	161-168	false

unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water).
ibogaine	7-14	18-MC	17-21	false

Both ibogaine and 18-MC ameliorate opioid withdrawal signs.
ibogaine	5-12	18-MC	18-22	false
ibogaine	5-12	opioid	35-40	false
18-MC	18-22	opioid	35-40	false

Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.
ibogaine	5-12	18-MC	18-22	false
ibogaine	5-12	ibogaine	101-108	false
18-MC	18-22	ibogaine	101-108	false

Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
ibogaine	5-12	18-MC	18-22	false
ibogaine	5-12	morphine	30-37	effect
ibogaine	5-12	nicotine	51-58	effect
18-MC	18-22	morphine	30-37	effect
18-MC	18-22	nicotine	51-58	effect
morphine	30-37	nicotine	51-58	false

only ibogaine enhances cocaine-induced increases in accumbal dopamine.
ibogaine	5-12	cocaine	23-29	effect

Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants.
ibogaine	5-12	18-MC	18-22	false

Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
Ibogaine	0-7	18-MC	25-29	false
Ibogaine	0-7	morphine	75-82	effect
18-MC	25-29	morphine	75-82	effect

both compounds attenuate morphine-induced locomotion in morphine-experienced rats.
morphine	25-32	morphine	56-63	false

Ibogaine, but not 18-MC, decreases heart rate at high doses.
Ibogaine	0-7	18-MC	18-22	false

While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.
18-MC	6-10	ibogaine	16-23	false
18-MC	6-10	18-MC	100-104	false
18-MC	6-10	ibogaine	137-144	false
ibogaine	16-23	18-MC	100-104	false
ibogaine	16-23	ibogaine	137-144	false
18-MC	100-104	ibogaine	137-144	false

Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite.
18-MC	5-9	ibogaine	15-22	false
18-MC	5-9	ibogaine	57-64	false
18-MC	5-9	18-MC	67-71	false
ibogaine	15-22	ibogaine	57-64	false
ibogaine	15-22	18-MC	67-71	false
ibogaine	57-64	18-MC	67-71	false

The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.
18-MC	22-26	ibogaine	124-131	false

Clinical implications of warfarin interactions with five sedatives.
warfarin	25-32	sedatives	57-65	int

The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.
anticoagulant	45-57	phenobarbital	75-87	false
anticoagulant	45-57	secobarbital	90-101	false
anticoagulant	45-57	glutethimide	104-115	false
anticoagulant	45-57	chloral hydrate	118-132	false
anticoagulant	45-57	methaqualone	138-149	false
anticoagulant	45-57	coumarin	209-216	false
phenobarbital	75-87	secobarbital	90-101	false
phenobarbital	75-87	glutethimide	104-115	false
phenobarbital	75-87	chloral hydrate	118-132	false
phenobarbital	75-87	methaqualone	138-149	false
phenobarbital	75-87	coumarin	209-216	false
secobarbital	90-101	glutethimide	104-115	false
secobarbital	90-101	chloral hydrate	118-132	false
secobarbital	90-101	methaqualone	138-149	false
secobarbital	90-101	coumarin	209-216	false
glutethimide	104-115	chloral hydrate	118-132	false
glutethimide	104-115	methaqualone	138-149	false
glutethimide	104-115	coumarin	209-216	false
chloral hydrate	118-132	methaqualone	138-149	false
chloral hydrate	118-132	coumarin	209-216	false
methaqualone	138-149	coumarin	209-216	false

Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide;
phenobarbital	67-79	secobarbital	82-93	false
phenobarbital	67-79	glutethimide	99-110	false
secobarbital	82-93	glutethimide	99-110	false

there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone.
chloral hydrate	81-95	methaqualone	101-112	false

Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
Barbiturates	0-11	glutethimide	17-28	false
Barbiturates	0-11	coumarin drugs	79-92	advise
glutethimide	17-28	coumarin drugs	79-92	advise

Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
Chloral hydrate	0-14	methaqualone	20-31	false
Chloral hydrate	0-14	anticoagulant agents	85-104	int
methaqualone	20-31	anticoagulant agents	85-104	int

It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
chloral hydrate	21-35	methaqualone	41-52	false
chloral hydrate	21-35	anticoagulant	151-163	false
methaqualone	41-52	anticoagulant	151-163	false

Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin.
thiazide diuretics	20-37	digoxin	92-98	false

Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.
clozapine	16-24	phencyclidine	30-42	false

Phencyclidine (PCP) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.
Phencyclidine	0-12	PCP	15-17	false

In the present study, the atypical antipsychotic clozapine was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.
atypical antipsychotic	26-47	clozapine	49-57	false
atypical antipsychotic	26-47	PCP	108-110	false
clozapine	49-57	PCP	108-110	false

PCP produced distinctive effects in each task: it substituted for the training dose in PCP discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.
PCP	0-2	PCP	87-89	false

Acute dosing with clozapine failed to alter the behavioral effects of PCP in either procedure even when tested up to doses that produced pharmacological effects alone.
clozapine	18-26	PCP	70-72	false

These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication.
clozapine	45-53	PCP	111-113	false

Since chronic dosing is required for therapeutic efficacy of antipsychotics, future studies should focus on investigation of chronic dosing effects of these drugs in combination with PCP.
antipsychotics	61-74	PCP	183-185	false

Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.
Resveratrol	0-10	noradrenaline	116-128	false
Resveratrol	0-10	KCl	148-150	false
noradrenaline	116-128	KCl	148-150	false

However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves.
L-NAME	9-14	reseveratrol	70-81	false

Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats.
Indomethacin	0-11	resveratrol	46-56	false

In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium.
noradrenaline	3-15	resveratrol	78-88	false

This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.
resveratrol	54-64	resveratrol	190-200	false

If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
indinavir	23-31	IDV	34-36	false
indinavir	23-31	didanosine	40-49	false
indinavir	23-31	IDV	67-69	false
IDV	34-36	didanosine	40-49	false
IDV	34-36	IDV	67-69	false
didanosine	40-49	IDV	67-69	false

Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
indinavir	29-37	didanosine	43-52	mechanism
indinavir	29-37	indinavir	101-109	false
indinavir	29-37	didanosine	145-154	false
indinavir	29-37	indinavir	171-179	false
didanosine	43-52	indinavir	101-109	false
didanosine	43-52	didanosine	145-154	false
didanosine	43-52	indinavir	171-179	false
indinavir	101-109	didanosine	145-154	false
indinavir	101-109	indinavir	171-179	false
didanosine	145-154	indinavir	171-179	false

We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration.
indinavir	12-20	indinavir	127-135	false
indinavir	12-20	indinavir	160-168	false
indinavir	12-20	didanosine	193-202	false
indinavir	127-135	indinavir	160-168	false
indinavir	127-135	didanosine	193-202	false
indinavir	160-168	didanosine	193-202	false

Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
indinavir	48-56	didanosine	74-83	mechanism

Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.
Indinavir	0-8	didanosine	87-96	advise

Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min.
Cytochalasin D	0-13	carbachol	75-83	effect

Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
Cytochalasin D	0-13	carbachol	29-37	effect

The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not <
mu-selective opioids	44-46;70-86	delta(1)-selective opioids	49-57;70-86	false
mu-selective opioids	44-46;70-86	kappa-selective opioids	64-86	false
delta(1)-selective opioids	49-57;70-86	kappa-selective opioids	64-86	false

Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
verapamil	15-23	bombesin	28-35	effect
verapamil	15-23	azoxymethane	109-120	false
bombesin	28-35	azoxymethane	109-120	false

BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.
bombesin	54-61	verapamil hydrochloride	67-89	false
bombesin	54-61	verapamil	92-100	false
bombesin	54-61	calcium channel blocker	106-128	false
bombesin	54-61	azoxymethane	214-225	false
bombesin	54-61	AOM	228-230	false
verapamil hydrochloride	67-89	verapamil	92-100	false
verapamil hydrochloride	67-89	calcium channel blocker	106-128	false
verapamil hydrochloride	67-89	azoxymethane	214-225	false
verapamil hydrochloride	67-89	AOM	228-230	false
verapamil	92-100	calcium channel blocker	106-128	false
verapamil	92-100	azoxymethane	214-225	false
verapamil	92-100	AOM	228-230	false
calcium channel blocker	106-128	azoxymethane	214-225	false
calcium channel blocker	106-128	AOM	228-230	false
azoxymethane	214-225	AOM	228-230	false

METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.
AOM	100-102	bombesin	159-166	false
AOM	100-102	verapamil	260-268	false
bombesin	159-166	verapamil	260-268	false

Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.
verapamil	9-17	bombesin	122-129	false

Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin.
Verapamil	0-8	bombesin	117-124	effect

In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
prostaglandin F2alpha	24-44	oxytocin	50-57	int

The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro.
prostaglandin F2alpha	19-39	oxytocin	55-62	false

In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha.
norepinephrine	34-47	oxytocin	53-60	false
norepinephrine	34-47	PGF2alpha	67-75	false
oxytocin	53-60	PGF2alpha	67-75	false

PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin.
PGF2alpha	0-8	oxytocin	93-100	effect

There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
PGF2alpha	39-47	oxytocin	91-98	effect

Carbamazepine overdose recognized by a tricyclic antidepressant assay.
Carbamazepine	0-12	tricyclic antidepressant	39-62	false

We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
carbamazepine	73-85	tricyclic antidepressant	112-135	effect
carbamazepine	73-85	carbamazepine	190-202	false
carbamazepine	73-85	tricyclic antidepressants	233-257	false
tricyclic antidepressant	112-135	carbamazepine	190-202	false
tricyclic antidepressant	112-135	tricyclic antidepressants	233-257	false
carbamazepine	190-202	tricyclic antidepressants	233-257	advise

Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
Cypermethrin	0-11	vitamin E	77-85	effect
Cypermethrin	0-11	allopurinol	90-100	effect
vitamin E	77-85	allopurinol	90-100	false

Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by cypermethrin, a Type II pyrethroid.
cypermethrin	213-224	Type II pyrethroid	229-246	false

Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
allopurinol	26-36	Vitamin E	57-65	false
allopurinol	26-36	cypermethrin	280-291	effect
Vitamin E	57-65	cypermethrin	280-291	effect

Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
cypermethrin	31-42	allopurinol	198-208	effect
cypermethrin	31-42	Vitamin E	214-222	effect
allopurinol	198-208	Vitamin E	214-222	false

In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.
ginsenosides	44-55	selective Ca(2+) channel blockers	129-161	false
ginsenosides	44-55	nimodipine	163-172	false
ginsenosides	44-55	omega-conotoxin GVIA	184-203	false
ginsenosides	44-55	omega-agatoxin IVA	218-235	false
selective Ca(2+) channel blockers	129-161	nimodipine	163-172	false
selective Ca(2+) channel blockers	129-161	omega-conotoxin GVIA	184-203	false
selective Ca(2+) channel blockers	129-161	omega-agatoxin IVA	218-235	false
nimodipine	163-172	omega-conotoxin GVIA	184-203	false
nimodipine	163-172	omega-agatoxin IVA	218-235	false
omega-conotoxin GVIA	184-203	omega-agatoxin IVA	218-235	false

Nimodipine had no effect on ginsenosides response.
Nimodipine	0-9	ginsenosides	28-39	false

These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.
ginsenosides	24-35	omega-conotoxin GVIA	135-154	false
ginsenosides	24-35	omega-agatoxin IVA	187-204	false
ginsenosides	24-35	nimodipine	237-246	false
ginsenosides	24-35	omega-conotoxin GVIA	248-267	false
ginsenosides	24-35	omega-agatoxin VIA	269-286	false
omega-conotoxin GVIA	135-154	omega-agatoxin IVA	187-204	false
omega-conotoxin GVIA	135-154	nimodipine	237-246	false
omega-conotoxin GVIA	135-154	omega-conotoxin GVIA	248-267	false
omega-conotoxin GVIA	135-154	omega-agatoxin VIA	269-286	false
omega-agatoxin IVA	187-204	nimodipine	237-246	false
omega-agatoxin IVA	187-204	omega-conotoxin GVIA	248-267	false
omega-agatoxin IVA	187-204	omega-agatoxin VIA	269-286	false
nimodipine	237-246	omega-conotoxin GVIA	248-267	false
nimodipine	237-246	omega-agatoxin VIA	269-286	false
omega-conotoxin GVIA	248-267	omega-agatoxin VIA	269-286	false

Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.
ginsenosides	71-82	ginseng	171-177	false

In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
KRM-1648	21-28	ofloxacin	68-76	false

The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.
benzoxazinorifamycin	30-49	KRM-1648	52-59	false
benzoxazinorifamycin	30-49	ofloxacin	98-106	false
KRM-1648	52-59	ofloxacin	98-106	false

ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively.
rifampicin	74-83	rifabutin	89-97	false

When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
ofloxacin	19-27	KRM-1648	30-37	effect
ofloxacin	19-27	rifampicin	143-152	false
ofloxacin	19-27	rifabutin	158-166	false
ofloxacin	19-27	ofloxacin	173-181	false
KRM-1648	30-37	rifampicin	143-152	false
KRM-1648	30-37	rifabutin	158-166	false
KRM-1648	30-37	ofloxacin	173-181	false
rifampicin	143-152	rifabutin	158-166	false
rifampicin	143-152	ofloxacin	173-181	effect
rifabutin	158-166	ofloxacin	173-181	effect

The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.
ruthenium red	15-27	RR	30-31	false
ruthenium red	15-27	inositol 1,4,5-trisphosphate	37-64	false
ruthenium red	15-27	InsP(3)	67-73	false
RR	30-31	inositol 1,4,5-trisphosphate	37-64	false
RR	30-31	InsP(3)	67-73	false
inositol 1,4,5-trisphosphate	37-64	InsP(3)	67-73	false

Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
InsP(3)	14-20	RR	36-37	effect

Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses.
RR	50-51	InsP(3)	80-86	effect

In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses.
RR	57-58	InsP(3)	77-83	false

In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.
RR	32-33	InsP(3)	94-100	false

Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
rofecoxib	10-18	digoxin	47-53	false

The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects.
rofecoxib	75-83	digoxin	129-135	false

Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose.
digoxin	44-50	digoxin	114-120	false

For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.
digoxin	4-10	rofecoxib	107-115	false
digoxin	4-10	digoxin	119-125	false
digoxin	4-10	digoxin	137-143	false
rofecoxib	107-115	digoxin	119-125	false
rofecoxib	107-115	digoxin	137-143	false
digoxin	119-125	digoxin	137-143	false

The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively.
rofecoxib	68-76	digoxin	80-86	false
rofecoxib	68-76	digoxin	102-108	false
digoxin	80-86	digoxin	102-108	false

The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively.
digoxin	61-67	rofecoxib	101-109	false

Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.
Rofecoxib	0-8	digoxin	102-108	false

Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
cyclophosphamide	12-27	doxorubicin	30-40	false
cyclophosphamide	12-27	vincristine	43-53	false
cyclophosphamide	12-27	prednisone	60-69	false
cyclophosphamide	12-27	highly active antiretroviral	89-116	false
doxorubicin	30-40	vincristine	43-53	false
doxorubicin	30-40	prednisone	60-69	false
doxorubicin	30-40	highly active antiretroviral	89-116	false
vincristine	43-53	prednisone	60-69	false
vincristine	43-53	highly active antiretroviral	89-116	false
prednisone	60-69	highly active antiretroviral	89-116	false

To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.
cyclophosphamide	244-259	doxorubicin	262-272	false
cyclophosphamide	244-259	vincristine	275-285	false
cyclophosphamide	244-259	prednisone	292-301	false
cyclophosphamide	244-259	cyclophosphamide	440-455	false
cyclophosphamide	244-259	doxorubicin	458-468	false
cyclophosphamide	244-259	teniposide	471-480	false
cyclophosphamide	244-259	prednisone	487-496	false
cyclophosphamide	244-259	vincristine	503-513	false
cyclophosphamide	244-259	bleomycin	520-528	false
cyclophosphamide	244-259	antiretroviral	549-562	false
doxorubicin	262-272	vincristine	275-285	false
doxorubicin	262-272	prednisone	292-301	false
doxorubicin	262-272	cyclophosphamide	440-455	false
doxorubicin	262-272	doxorubicin	458-468	false
doxorubicin	262-272	teniposide	471-480	false
doxorubicin	262-272	prednisone	487-496	false
doxorubicin	262-272	vincristine	503-513	false
doxorubicin	262-272	bleomycin	520-528	false
doxorubicin	262-272	antiretroviral	549-562	false
vincristine	275-285	prednisone	292-301	false
vincristine	275-285	cyclophosphamide	440-455	false
vincristine	275-285	doxorubicin	458-468	false
vincristine	275-285	teniposide	471-480	false
vincristine	275-285	prednisone	487-496	false
vincristine	275-285	vincristine	503-513	false
vincristine	275-285	bleomycin	520-528	false
vincristine	275-285	antiretroviral	549-562	false
prednisone	292-301	cyclophosphamide	440-455	false
prednisone	292-301	doxorubicin	458-468	false
prednisone	292-301	teniposide	471-480	false
prednisone	292-301	prednisone	487-496	false
prednisone	292-301	vincristine	503-513	false
prednisone	292-301	bleomycin	520-528	false
prednisone	292-301	antiretroviral	549-562	false
cyclophosphamide	440-455	doxorubicin	458-468	false
cyclophosphamide	440-455	teniposide	471-480	false
cyclophosphamide	440-455	prednisone	487-496	false
cyclophosphamide	440-455	vincristine	503-513	false
cyclophosphamide	440-455	bleomycin	520-528	false
cyclophosphamide	440-455	antiretroviral	549-562	false
doxorubicin	458-468	teniposide	471-480	false
doxorubicin	458-468	prednisone	487-496	false
doxorubicin	458-468	vincristine	503-513	false
doxorubicin	458-468	bleomycin	520-528	false
doxorubicin	458-468	antiretroviral	549-562	false
teniposide	471-480	prednisone	487-496	false
teniposide	471-480	vincristine	503-513	false
teniposide	471-480	bleomycin	520-528	false
teniposide	471-480	antiretroviral	549-562	false
prednisone	487-496	vincristine	503-513	false
prednisone	487-496	bleomycin	520-528	false
prednisone	487-496	antiretroviral	549-562	false
vincristine	503-513	bleomycin	520-528	false
vincristine	503-513	antiretroviral	549-562	false
bleomycin	520-528	antiretroviral	549-562	false

Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor.
Antiretroviral	0-13	reverse transcriptase inhibitors	41-72	false
Antiretroviral	0-13	protease inhibitor	82-99	false
reverse transcriptase inhibitors	41-72	protease inhibitor	82-99	false

However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs.
antiretroviral drugs	112-125;146-150	antineoplastic drugs	131-150	advise

Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents.
antidepressant drugs	15-34	hypoglycemic agents	106-124	int

Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.
Imipramine	0-9	moclobemide	22-32	false
Imipramine	0-9	clonazepam	46-55	false
Imipramine	0-9	fluoxetine	71-80	false
Imipramine	0-9	sertraline	93-102	false
moclobemide	22-32	clonazepam	46-55	false
moclobemide	22-32	fluoxetine	71-80	false
moclobemide	22-32	sertraline	93-102	false
clonazepam	46-55	fluoxetine	71-80	false
clonazepam	46-55	sertraline	93-102	false
fluoxetine	71-80	sertraline	93-102	false

An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min.
glucose	8-14	glucose	42-48	false

Imipramine and clonazepam did not change fasting or overload glycemia.
Imipramine	0-9	clonazepam	15-24	false

Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload.
Fluoxetine	0-9	moclobemide	15-25	false
Fluoxetine	0-9	glucose	43-49	false
moclobemide	15-25	glucose	43-49	false

Sertraline neutralized the increase of glycemia induced by oral glucose overload.
Sertraline	0-9	glucose	64-70	false

In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload.
glucose	149-155	glucose	180-186	false

Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats.
sertraline	7-16	glucose	61-67	false

Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
buforin II	12-21	azithromycin	53-64	false
buforin II	12-21	minocycline	70-80	false
azithromycin	53-64	minocycline	70-80	false

The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated.
buforin II	46-55	azithromycin	87-98	false
buforin II	46-55	minocycline	104-114	false
azithromycin	87-98	minocycline	104-114	false

Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested.
azithromycin	69-80	minocycline	85-95	false

Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
Buforin II	0-9	azithromycin	107-118	effect
Buforin II	0-9	minocycline	123-133	effect
azithromycin	107-118	minocycline	123-133	false

Effect of dofetillide on the pharmacokinetics of digoxin.
dofetillide	10-20	digoxin	49-55	false

The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study.
dofetilide	14-23	digoxin	65-71	false

Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo;
dofetilide	13-22	digoxin	105-111	false

therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.
dofetilide	22-31	digoxin	71-77	false

Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems.
anticonvulsant agents	50-70	phenobarbitone	81-94	false
anticonvulsant agents	50-70	phenytoin	100-108	false
phenobarbitone	81-94	phenytoin	100-108	false

Interaction of ketamine and halothane in rats.
ketamine	15-22	halothane	28-36	int

The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats.
ketamine	44-51	halothane	107-115	false

However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im.
halothane	9-17	ketamine	169-176	mechanism

The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1.
ketamine	57-64	ketamine	96-103	false

The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
ketamine	17-24	halothane	76-84	mechanism
ketamine	17-24	ketamine	96-103	false
halothane	76-84	ketamine	96-103	false

It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
ketamine	21-28	halothane	87-95	effect

The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
sodium carboxymethylcellulose	56-84	NaCMC	87-91	false
sodium carboxymethylcellulose	56-84	carboxymethylcellulose-cysteine	98-128	false
sodium carboxymethylcellulose	56-84	CMC-Cys	131-137	false
sodium carboxymethylcellulose	56-84	sodium fluorescein	183-200	false
sodium carboxymethylcellulose	56-84	NaFlu	203-207	false
sodium carboxymethylcellulose	56-84	bacitracin	235-244	false
sodium carboxymethylcellulose	56-84	insulin	250-256	false
NaCMC	87-91	carboxymethylcellulose-cysteine	98-128	false
NaCMC	87-91	CMC-Cys	131-137	false
NaCMC	87-91	sodium fluorescein	183-200	false
NaCMC	87-91	NaFlu	203-207	false
NaCMC	87-91	bacitracin	235-244	false
NaCMC	87-91	insulin	250-256	false
carboxymethylcellulose-cysteine	98-128	CMC-Cys	131-137	false
carboxymethylcellulose-cysteine	98-128	sodium fluorescein	183-200	false
carboxymethylcellulose-cysteine	98-128	NaFlu	203-207	false
carboxymethylcellulose-cysteine	98-128	bacitracin	235-244	false
carboxymethylcellulose-cysteine	98-128	insulin	250-256	false
CMC-Cys	131-137	sodium fluorescein	183-200	false
CMC-Cys	131-137	NaFlu	203-207	false
CMC-Cys	131-137	bacitracin	235-244	false
CMC-Cys	131-137	insulin	250-256	false
sodium fluorescein	183-200	NaFlu	203-207	false
sodium fluorescein	183-200	bacitracin	235-244	false
sodium fluorescein	183-200	insulin	250-256	false
NaFlu	203-207	bacitracin	235-244	false
NaFlu	203-207	insulin	250-256	false
bacitracin	235-244	insulin	250-256	false

Cysteine was covalently linked to carbodiimide activated NaCMC.
Cysteine	0-7	NaCMC	57-61	false

Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation.
NaCMC	11-15	NaFlu	108-112	false
NaCMC	11-15	NaCMC	134-138	false
NaCMC	11-15	cysteine	156-163	false
NaFlu	108-112	NaCMC	134-138	false
NaFlu	108-112	cysteine	156-163	false
NaCMC	134-138	cysteine	156-163	false

Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2.
CMC-Cys	32-38	cysteine	78-85	false
CMC-Cys	32-38	NaFlu	153-157	false
cysteine	78-85	NaFlu	153-157	false

NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone.
NaCMC	0-4	cysteine	42-49	false
NaCMC	0-4	NaFlu	95-99	false
NaCMC	0-4	NaCMC	113-117	false
cysteine	42-49	NaFlu	95-99	false
cysteine	42-49	NaCMC	113-117	false
NaFlu	95-99	NaCMC	113-117	false

Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3).
bacitracin	37-46	insulin	52-58	false
bacitracin	37-46	NaCMC	76-80	false
bacitracin	37-46	CMC-Cys	173-179	false
insulin	52-58	NaCMC	76-80	false
insulin	52-58	CMC-Cys	173-179	false
NaCMC	76-80	CMC-Cys	173-179	false

Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
NaCMC	15-19	cysteine	26-33	false
NaCMC	15-19	NaFlu	121-125	false
NaCMC	15-19	bacitracin	155-164	false
NaCMC	15-19	insulin	170-176	false
cysteine	26-33	NaFlu	121-125	false
cysteine	26-33	bacitracin	155-164	false
cysteine	26-33	insulin	170-176	false
NaFlu	121-125	bacitracin	155-164	false
NaFlu	121-125	insulin	170-176	false
bacitracin	155-164	insulin	170-176	false

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
amprenavir	36-45	rifabutin	51-59	false
amprenavir	36-45	rifampin	64-71	false
rifabutin	51-59	rifampin	64-71	false

The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).
amprenavir	92-101	rifabutin	117-125	false
amprenavir	92-101	rifampin	130-137	false
rifabutin	117-125	rifampin	130-137	false

All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.
amprenavir	22-31	rifabutin	123-131	false
amprenavir	22-31	rifampin	172-179	false
rifabutin	123-131	rifampin	172-179	false

Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.
amprenavir	23-32	rifabutin	39-47	false
amprenavir	23-32	amprenavir	84-93	false
amprenavir	23-32	rifampin	100-107	false
rifabutin	39-47	amprenavir	84-93	false
rifabutin	39-47	rifampin	100-107	false
amprenavir	84-93	rifampin	100-107	false

Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.
amprenavir	51-60	rifabutin	63-71	false
amprenavir	51-60	rifampin	78-85	false
amprenavir	51-60	25-O-desacetyl metabolites	97-122	false
rifabutin	63-71	rifampin	78-85	false
rifabutin	63-71	25-O-desacetyl metabolites	97-122	false
rifampin	78-85	25-O-desacetyl metabolites	97-122	false

Rifabutin did not significantly affect amprenavir's pharmacokinetics.
Rifabutin	0-8	amprenavir	39-48	false

Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
Amprenavir	0-9	rifabutin	89-97	mechanism
Amprenavir	0-9	25-O-desacetylrifabutin	131-153	mechanism
rifabutin	89-97	25-O-desacetylrifabutin	131-153	false

Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
Rifampin	0-7	amprenavir	48-57	mechanism
Rifampin	0-7	amprenavir	71-80	false
Rifampin	0-7	rifampin	99-106	false
amprenavir	48-57	amprenavir	71-80	false
amprenavir	48-57	rifampin	99-106	false
amprenavir	71-80	rifampin	99-106	false

The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively.
rifabutin	42-50	rifampin	56-63	false

Amprenavir plus rifampin was well tolerated.
Amprenavir	0-9	rifampin	16-23	false

Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.
Amprenavir	0-9	rifabutin	16-24	effect

Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.
Rifampin	0-7	amprenavir	55-64	mechanism

Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
Amprenavir	0-9	rifabutin	48-56	mechanism
Amprenavir	0-9	25-O-desacetylrifabutin	62-84	mechanism
rifabutin	48-56	25-O-desacetylrifabutin	62-84	false

Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.
Amprenavir	0-9	rifampin	35-42	false
Amprenavir	0-9	rifabutin	48-56	false
rifampin	35-42	rifabutin	48-56	false

The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers"
thiazolidinediones	4-21	rosiglitazone	24-36	false
thiazolidinediones	4-21	pioglitazone	42-53	false
thiazolidinediones	4-21	antidiabetic agents	77-95	false
rosiglitazone	24-36	pioglitazone	42-53	false
rosiglitazone	24-36	antidiabetic agents	77-95	false
pioglitazone	42-53	antidiabetic agents	77-95	false

In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month.
etofibrate	30-39	etofibrate	401-410	false

Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
Etofibrate	0-9	heparin	44-50	effect

The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.
gliftor	42-48	1,3-difluoroacetone	69-87	false
gliftor	42-48	(-)-erythro-fluorocitrate	92-116	false
1,3-difluoroacetone	69-87	(-)-erythro-fluorocitrate	92-116	false

The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide Gliftor (1,3-difluoro-2-propanol), was investigated in vivo and in vitro.
1,3-difluoroacetone	30-48	Gliftor	111-117	false
1,3-difluoroacetone	30-48	1,3-difluoro-2-propanol	120-142	false
Gliftor	111-117	1,3-difluoro-2-propanol	120-142	false

Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro.
1,3-difluoroacetone	91-109	(-)-erythro-fluorocitrate	114-138	false

Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation.
1,3-difluoroacetone	18-36	(-)-erythro-fluorocitrate	94-118	false

Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol.
1,3-difluoroacetone	19-37	(-)-erythro-fluorocitrate	88-112	false
1,3-difluoroacetone	19-37	1,3-difluoro-2-propanol	201-223	false
(-)-erythro-fluorocitrate	88-112	1,3-difluoro-2-propanol	201-223	false

We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol.
1,3-difluoro-2-propanol	38-60	1,3-difluoroacetone	65-83	false
1,3-difluoro-2-propanol	38-60	(-)-erythro-fluorocitrate	181-205	false
1,3-difluoro-2-propanol	38-60	1,3-difluoro-2-propanol	212-234	false
1,3-difluoroacetone	65-83	(-)-erythro-fluorocitrate	181-205	false
1,3-difluoroacetone	65-83	1,3-difluoro-2-propanol	212-234	false
(-)-erythro-fluorocitrate	181-205	1,3-difluoro-2-propanol	212-234	false

Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals.
4-methylpyrazole	24-39	1,3-difluoro-2-propanol	107-129	effect
4-methylpyrazole	24-39	(-)-erythro-fluorocitrate	162-186	false
4-methylpyrazole	24-39	1,3-difluoro-2-propanol	257-279	false
1,3-difluoro-2-propanol	107-129	(-)-erythro-fluorocitrate	162-186	false
1,3-difluoro-2-propanol	107-129	1,3-difluoro-2-propanol	257-279	false
(-)-erythro-fluorocitrate	162-186	1,3-difluoro-2-propanol	257-279	false

However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo.
4-methylpyrazole	27-42	1,3-difluoroacetone	96-114	false
4-methylpyrazole	27-42	(-)-erythro-fluorocitrate	174-198	false
1,3-difluoroacetone	96-114	(-)-erythro-fluorocitrate	174-198	false

We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
4-methylpyrazole	62-77	1,3-difluoro-2-propanol	108-130	effect
4-methylpyrazole	62-77	1,3-difluoro-2-propanol	224-246	false
4-methylpyrazole	62-77	1,3-difluoroacetone	251-269	false
1,3-difluoro-2-propanol	108-130	1,3-difluoro-2-propanol	224-246	false
1,3-difluoro-2-propanol	108-130	1,3-difluoroacetone	251-269	false
1,3-difluoro-2-propanol	224-246	1,3-difluoroacetone	251-269	false

Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
Green tea polyphenols	0-20	enhancers	32-40	false

n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid.
n-dodecyl gallate	0-16	tannic acid	128-138	false

Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
diltiazem	57-65	sirolimus	71-79	mechanism

AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects.
sirolimus	60-68	macrolide immunosuppressant	73-99	false
sirolimus	60-68	calcium channel blocker	132-154	false
sirolimus	60-68	diltiazem	156-164	false
macrolide immunosuppressant	73-99	calcium channel blocker	132-154	false
macrolide immunosuppressant	73-99	diltiazem	156-164	false
calcium channel blocker	132-154	diltiazem	156-164	false

Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists.
immunosuppressive drugs	82-104	calcium antagonists	154-172	false

METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together.
sirolimus	176-184	diltiazem	216-224	false

RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
sirolimus	66-74	diltiazem	253-261	mechanism
sirolimus	66-74	sirolimus	323-331	false
diltiazem	253-261	sirolimus	323-331	false

Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem.
sirolimus	54-62	sirolimus	111-119	false
sirolimus	54-62	diltiazem	136-144	false
sirolimus	111-119	diltiazem	136-144	mechanism

The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen.
diltiazem	87-95	desacetyldiltiazem	98-115	false
diltiazem	87-95	desmethyldiltiazem	122-139	false
diltiazem	87-95	sirolimus	182-190	false
diltiazem	87-95	diltiazem	231-239	false
desacetyldiltiazem	98-115	desmethyldiltiazem	122-139	false
desacetyldiltiazem	98-115	sirolimus	182-190	false
desacetyldiltiazem	98-115	diltiazem	231-239	false
desmethyldiltiazem	122-139	sirolimus	182-190	false
desmethyldiltiazem	122-139	diltiazem	231-239	false
sirolimus	182-190	diltiazem	231-239	false

CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus.
diltiazem	25-33	sirolimus	68-76	mechanism
diltiazem	25-33	sirolimus	145-153	false
sirolimus	68-76	sirolimus	145-153	false

Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
sirolimus	72-80	diltiazem	82-90	advise
sirolimus	72-80	sirolimus	117-125	false
diltiazem	82-90	sirolimus	117-125	false

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
Fluvoxamine	0-10	tolbutamide	63-73	mechanism

OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9.
fluvoxamine	64-74	tolbutamide	80-90	false
fluvoxamine	64-74	fluvoxamine	108-118	false
tolbutamide	80-90	fluvoxamine	108-118	false

Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC.
tolbutamide	24-34	tolbutamide	64-74	false
tolbutamide	24-34	4-hydroxytolbutamide	101-120	false
tolbutamide	24-34	carboxytolbutamide	126-143	false
tolbutamide	64-74	4-hydroxytolbutamide	101-120	false
tolbutamide	64-74	carboxytolbutamide	126-143	false
4-hydroxytolbutamide	101-120	carboxytolbutamide	126-143	false

RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.
fluvoxamine	31-41	tolbutamide	131-141	mechanism

The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).
4-hydroxytolbutamide	26-45	carboxytolbutamide	51-68	false
4-hydroxytolbutamide	26-45	tolbutamide	179-189	false
4-hydroxytolbutamide	26-45	tolbutamide	265-275	false
carboxytolbutamide	51-68	tolbutamide	179-189	false
carboxytolbutamide	51-68	tolbutamide	265-275	false
tolbutamide	179-189	tolbutamide	265-275	false

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
everolimus	27-36	cyclosporine	182-193	false

OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.
everolimus	82-91	cyclosporine	97-108	false
everolimus	82-91	ciclosporin	116-126	false
cyclosporine	97-108	ciclosporin	116-126	false

METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone.
everolimus	127-136	cyclosporine	197-208	false
everolimus	127-136	prednisone	214-223	false
cyclosporine	197-208	prednisone	214-223	false

Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.
everolimus	43-52	cyclosporine	58-69	false

Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA.
cyclosporine	25-36	everolimus	89-98	false

Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively).
Cyclosporine	0-11	everolimus	152-161	false

For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.
everolimus	22-31	cyclosporine	77-88	false

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
ADL 8-2698	0-9	morphine	114-121	effect

ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia.
ADL-8-2698	0-9	peripherally restricted opioid antagonist	22-62	false
ADL-8-2698	0-9	opioid	93-98	effect
peripherally restricted opioid antagonist	22-62	opioid	93-98	false

Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study.
morphine	157-164	ADL 8-2698	195-204	false
morphine	157-164	morphine	229-236	false
ADL 8-2698	195-204	morphine	229-236	false

Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004).
Morphine	0-7	ADL 8-2698	106-115	effect

Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo.
ADL 8-2698	89-98	morphine	134-141	false

Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002).
Morphine	0-7	ADL 8-2698	61-70	false

We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
ADL 8-2698	17-26	morphine	37-44	effect

Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
simvastatin	55-65	clarithromycin	71-84	effect

OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin.
clarithromycin	80-93	simvastatin	99-109	false

DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.
Clarithromycin	12-25	simvastatin	93-103	mechanism

The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis.
macrolide antibiotics	34-54	hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors	66-128	effect

CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
Macrolide antibiotics	13-33	HMG-CoA reductase inhibitors	61-88	false
Macrolide antibiotics	13-33	atorvastatin	128-139	mechanism
Macrolide antibiotics	13-33	cerivastatin	142-153	mechanism
Macrolide antibiotics	13-33	lovastatin	156-165	mechanism
Macrolide antibiotics	13-33	simvastatin	168-178	mechanism
HMG-CoA reductase inhibitors	61-88	atorvastatin	128-139	false
HMG-CoA reductase inhibitors	61-88	cerivastatin	142-153	false
HMG-CoA reductase inhibitors	61-88	lovastatin	156-165	false
HMG-CoA reductase inhibitors	61-88	simvastatin	168-178	false
atorvastatin	128-139	cerivastatin	142-153	false
atorvastatin	128-139	lovastatin	156-165	false
atorvastatin	128-139	simvastatin	168-178	false
cerivastatin	142-153	lovastatin	156-165	false
cerivastatin	142-153	simvastatin	168-178	false
lovastatin	156-165	simvastatin	168-178	false

The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
phenytoin	27-35	quetiapine	92-101	false

Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.
Quetiapine fumarate	0-18	Seroquel	22-29	false
Quetiapine fumarate	0-18	atypical antipsychotic	55-76	false
Seroquel	22-29	atypical antipsychotic	55-76	false

This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.
phenytoin	71-79	quetiapine	134-143	mechanism

Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.
Acetaminophen	0-12	lidocaine	15-23	false
Acetaminophen	0-12	phenobarbital	26-38	false
Acetaminophen	0-12	quinidine	41-49	false
Acetaminophen	0-12	theophylline	52-63	false
Acetaminophen	0-12	valproic acid	70-82	false
lidocaine	15-23	phenobarbital	26-38	false
lidocaine	15-23	quinidine	41-49	false
lidocaine	15-23	theophylline	52-63	false
lidocaine	15-23	valproic acid	70-82	false
phenobarbital	26-38	quinidine	41-49	false
phenobarbital	26-38	theophylline	52-63	false
phenobarbital	26-38	valproic acid	70-82	false
quinidine	41-49	theophylline	52-63	false
quinidine	41-49	valproic acid	70-82	false
theophylline	52-63	valproic acid	70-82	false

The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital.
acetaminophen	70-82	phenobarbital	84-96	false

acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
acetaminophen	0-12	theophylline	14-25	false
acetaminophen	0-12	lidocaine	28-36	false
acetaminophen	0-12	quinidine	38-46	false
acetaminophen	0-12	phenobarbital	49-61	false
acetaminophen	0-12	acetaminophen	63-75	false
acetaminophen	0-12	phenobarbital	78-90	false
acetaminophen	0-12	valproic acid	92-104	false
acetaminophen	0-12	quinidine	107-115	false
acetaminophen	0-12	lidocaine	117-125	false
acetaminophen	0-12	theophylline	128-139	false
acetaminophen	0-12	acetaminophen	141-153	false
acetaminophen	0-12	valproic acid	160-172	false
acetaminophen	0-12	phenobarbital	174-186	false
theophylline	14-25	lidocaine	28-36	false
theophylline	14-25	quinidine	38-46	false
theophylline	14-25	phenobarbital	49-61	false
theophylline	14-25	acetaminophen	63-75	false
theophylline	14-25	phenobarbital	78-90	false
theophylline	14-25	valproic acid	92-104	false
theophylline	14-25	quinidine	107-115	false
theophylline	14-25	lidocaine	117-125	false
theophylline	14-25	theophylline	128-139	false
theophylline	14-25	acetaminophen	141-153	false
theophylline	14-25	valproic acid	160-172	false
theophylline	14-25	phenobarbital	174-186	false
lidocaine	28-36	quinidine	38-46	false
lidocaine	28-36	phenobarbital	49-61	false
lidocaine	28-36	acetaminophen	63-75	false
lidocaine	28-36	phenobarbital	78-90	false
lidocaine	28-36	valproic acid	92-104	false
lidocaine	28-36	quinidine	107-115	false
lidocaine	28-36	lidocaine	117-125	false
lidocaine	28-36	theophylline	128-139	false
lidocaine	28-36	acetaminophen	141-153	false
lidocaine	28-36	valproic acid	160-172	false
lidocaine	28-36	phenobarbital	174-186	false
quinidine	38-46	phenobarbital	49-61	false
quinidine	38-46	acetaminophen	63-75	false
quinidine	38-46	phenobarbital	78-90	false
quinidine	38-46	valproic acid	92-104	false
quinidine	38-46	quinidine	107-115	false
quinidine	38-46	lidocaine	117-125	false
quinidine	38-46	theophylline	128-139	false
quinidine	38-46	acetaminophen	141-153	false
quinidine	38-46	valproic acid	160-172	false
quinidine	38-46	phenobarbital	174-186	false
phenobarbital	49-61	acetaminophen	63-75	false
phenobarbital	49-61	phenobarbital	78-90	false
phenobarbital	49-61	valproic acid	92-104	false
phenobarbital	49-61	quinidine	107-115	false
phenobarbital	49-61	lidocaine	117-125	false
phenobarbital	49-61	theophylline	128-139	false
phenobarbital	49-61	acetaminophen	141-153	false
phenobarbital	49-61	valproic acid	160-172	false
phenobarbital	49-61	phenobarbital	174-186	false
acetaminophen	63-75	phenobarbital	78-90	false
acetaminophen	63-75	valproic acid	92-104	false
acetaminophen	63-75	quinidine	107-115	false
acetaminophen	63-75	lidocaine	117-125	false
acetaminophen	63-75	theophylline	128-139	false
acetaminophen	63-75	acetaminophen	141-153	false
acetaminophen	63-75	valproic acid	160-172	false
acetaminophen	63-75	phenobarbital	174-186	false
phenobarbital	78-90	valproic acid	92-104	false
phenobarbital	78-90	quinidine	107-115	false
phenobarbital	78-90	lidocaine	117-125	false
phenobarbital	78-90	theophylline	128-139	false
phenobarbital	78-90	acetaminophen	141-153	false
phenobarbital	78-90	valproic acid	160-172	false
phenobarbital	78-90	phenobarbital	174-186	false
valproic acid	92-104	quinidine	107-115	false
valproic acid	92-104	lidocaine	117-125	false
valproic acid	92-104	theophylline	128-139	false
valproic acid	92-104	acetaminophen	141-153	false
valproic acid	92-104	valproic acid	160-172	false
valproic acid	92-104	phenobarbital	174-186	false
quinidine	107-115	lidocaine	117-125	false
quinidine	107-115	theophylline	128-139	false
quinidine	107-115	acetaminophen	141-153	false
quinidine	107-115	valproic acid	160-172	false
quinidine	107-115	phenobarbital	174-186	false
lidocaine	117-125	theophylline	128-139	false
lidocaine	117-125	acetaminophen	141-153	false
lidocaine	117-125	valproic acid	160-172	false
lidocaine	117-125	phenobarbital	174-186	false
theophylline	128-139	acetaminophen	141-153	false
theophylline	128-139	valproic acid	160-172	false
theophylline	128-139	phenobarbital	174-186	false
acetaminophen	141-153	valproic acid	160-172	false
acetaminophen	141-153	phenobarbital	174-186	false
valproic acid	160-172	phenobarbital	174-186	false

Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.
phenobarbital	24-36	quinidine	39-47	false
phenobarbital	24-36	theophylline	54-65	false
phenobarbital	24-36	ethanol	127-133	false
quinidine	39-47	theophylline	54-65	false
quinidine	39-47	ethanol	127-133	false
theophylline	54-65	ethanol	127-133	false

Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.
Acetaminophen	0-12	theophylline	40-51	mechanism

Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;
Theophylline	0-11	acetaminophen	38-50	mechanism

Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.
Valproic acid	0-12	phenobarbital	36-48	mechanism

Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
acetaminophen	15-27	theophylline	34-45	effect
acetaminophen	15-27	phenobarbital	48-60	false
acetaminophen	15-27	acetaminophen	67-79	false
acetaminophen	15-27	valproic acid	86-98	false
acetaminophen	15-27	phenobarbital	105-117	false
theophylline	34-45	phenobarbital	48-60	false
theophylline	34-45	acetaminophen	67-79	false
theophylline	34-45	valproic acid	86-98	false
theophylline	34-45	phenobarbital	105-117	false
phenobarbital	48-60	acetaminophen	67-79	effect
phenobarbital	48-60	valproic acid	86-98	false
phenobarbital	48-60	phenobarbital	105-117	false
acetaminophen	67-79	valproic acid	86-98	false
acetaminophen	67-79	phenobarbital	105-117	false
valproic acid	86-98	phenobarbital	105-117	effect

The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed.
phenytoin	27-35	fluvoxamine	93-103	false
phenytoin	27-35	phenytoin	154-162	false
phenytoin	27-35	drugs	174-178	false
fluvoxamine	93-103	phenytoin	154-162	false
fluvoxamine	93-103	drugs	174-178	false
phenytoin	154-162	drugs	174-178	false

During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed.
phenytoin	7-15	phenytoin	77-85	false

The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/*1 and 2C19*1/ *1).
CYP2C9	17-22	CYP2C9	127-132	false

The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.
CYP2C9	54-59	fluvoxamine	73-83	false

Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.
galangin	35-42	vancomycin	73-82	false

Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.
Glucose	0-6	insulin	12-18	false

AIMS/HYPOTHESIS: There is evidence that insulin and glucose cause renal and ocular vasodilation.
insulin	40-46	glucose	52-58	false

Haemodynamic effects of glucose and insulin were additive when somatostatin was co-administered but not under basal conditions.
glucose	24-30	insulin	36-42	false
glucose	24-30	somatostatin	63-74	false
insulin	36-42	somatostatin	63-74	false

CONCLUSIONS/INTERPRETATION: Glucose and insulin can exert additive vasodilator properties on renal and ocular circulation.
Glucose	28-34	insulin	40-46	false

Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
levofloxacin	28-39	oxycodone	45-53	false

Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
trovafloxacin	90-102	ciprofloxacin	108-120	false
trovafloxacin	90-102	opiate	174-179	mechanism
trovafloxacin	90-102	morphine	189-196	mechanism
ciprofloxacin	108-120	opiate	174-179	mechanism
ciprofloxacin	108-120	morphine	189-196	mechanism
opiate	174-179	morphine	189-196	false

This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures.
trovafloxacin	67-79	ciprofloxacin	85-97	false

The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin.
oxycodone	74-82	levofloxacin	88-99	false

1 hour after starting the oxycodone or levofloxacin 500 mg p.o.
oxycodone	26-34	levofloxacin	39-50	false

There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.
levofloxacin	173-184	levofloxacin	193-204	false
levofloxacin	173-184	oxycodone	206-214	false
levofloxacin	193-204	oxycodone	206-214	false

It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.
oxycodone	27-35	levofloxacin	41-52	false

Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
azithromycin	21-32	zidovudine	56-65	false
azithromycin	21-32	dideoxyinosine	71-84	false
zidovudine	56-65	dideoxyinosine	71-84	false

Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with zidovudine and dideoxyinosine.
azithromycin	80-91	zidovudine	110-119	false
azithromycin	80-91	dideoxyinosine	125-138	false
zidovudine	110-119	dideoxyinosine	125-138	false

The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.
zidovudine	4-13	azithromycin	56-67	false
zidovudine	4-13	zidovudine	180-189	false
azithromycin	56-67	zidovudine	180-189	false

Subjects treated with 200 mg of dideoxyinosine twice daily for 21 days received 1200 mg of azithromycin or an equivalent amount of placebo/day for Days 8 to 21.
dideoxyinosine	32-45	azithromycin	91-102	false

Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for zidovudine and on Days 7 and 21 for dideoxyinosine.
Antiretroviral	0-13	zidovudine	81-90	false
Antiretroviral	0-13	dideoxyinosine	117-130	false
zidovudine	81-90	dideoxyinosine	117-130	false

Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
Azithromycin	0-11	zidovudine	62-71	false
Azithromycin	0-11	zidovudine	114-123	mechanism
Azithromycin	0-11	zidovudine	196-205	mechanism
zidovudine	62-71	zidovudine	114-123	false
zidovudine	62-71	zidovudine	196-205	false
zidovudine	114-123	zidovudine	196-205	false

Azithromycin had no significant effect on dideoxyinosine pharmacokinetics.
Azithromycin	0-11	dideoxyinosine	42-55	false

Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both zidovudine and dideoxyinosine.
azithromycin	60-71	zidovudine	112-121	false
azithromycin	60-71	dideoxyinosine	127-140	false
zidovudine	112-121	dideoxyinosine	127-140	false

Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
diazepam	10-17	midazolam	23-31	false
diazepam	10-17	morphine	66-73	false
diazepam	10-17	metamizol	76-84	false
diazepam	10-17	indomethacin	90-101	false
midazolam	23-31	morphine	66-73	false
midazolam	23-31	metamizol	76-84	false
midazolam	23-31	indomethacin	90-101	false
morphine	66-73	metamizol	76-84	false
morphine	66-73	indomethacin	90-101	false
metamizol	76-84	indomethacin	90-101	false

The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
midazolam	17-25	diazepam	31-38	false
midazolam	17-25	morphine	69-76	false
midazolam	17-25	metamizol	90-98	false
midazolam	17-25	indomethacin	116-127	false
diazepam	31-38	morphine	69-76	false
diazepam	31-38	metamizol	90-98	false
diazepam	31-38	indomethacin	116-127	false
morphine	69-76	metamizol	90-98	false
morphine	69-76	indomethacin	116-127	false
metamizol	90-98	indomethacin	116-127	false

Benzodiazepines were administered to mice 30 min before applying the analgesic drugs.
Benzodiazepines	0-14	analgesic drugs	69-83	false

Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine.
Diazepam	0-7	morphine	60-67	effect
Diazepam	0-7	morphine	121-128	false
morphine	60-67	morphine	121-128	false

Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
diazepam	11-18	metamizol	60-68	effect
diazepam	11-18	indomethacin	104-115	effect
metamizol	60-68	indomethacin	104-115	false

Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
Midazolam	0-8	morphine	92-99	effect
Midazolam	0-8	metamizol	102-110	effect
Midazolam	0-8	indomethacin	146-157	effect
morphine	92-99	metamizol	102-110	false
morphine	92-99	indomethacin	146-157	false
metamizol	102-110	indomethacin	146-157	false

Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.
estradiol	13-21	progesterone	27-38	false
estradiol	13-21	noradrenaline	84-96	false
progesterone	27-38	noradrenaline	84-96	false

The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta.
estradiol	78-86	progesterone	96-107	false
estradiol	78-86	noradrenaline	128-140	false
progesterone	96-107	noradrenaline	128-140	false

injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days.
estradiol	45-53	progesterone	96-107	false

Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively).
estradiol	70-78	noradrenaline	109-121	effect

Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
estradiol	42-50	noradrenaline	80-92	effect
estradiol	42-50	progesterone	121-132	false
estradiol	42-50	progesterone	139-150	false
estradiol	42-50	estradiol	159-167	false
noradrenaline	80-92	progesterone	121-132	false
noradrenaline	80-92	progesterone	139-150	false
noradrenaline	80-92	estradiol	159-167	false
progesterone	121-132	progesterone	139-150	false
progesterone	121-132	estradiol	159-167	false
progesterone	139-150	estradiol	159-167	false

Since the arrival of oral erection-supporting medication, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of erection-supporting medication in particular.
erection-supporting medication	26-55	erection-supporting medication	163-192	false

Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
Sildenafil	0-9	long-acting nitrates	48-67	advise
Sildenafil	0-9	short-acting nitrates	92-112	advise
long-acting nitrates	48-67	short-acting nitrates	92-112	false

No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop diuretics and ACE inhibitors.
beta-receptor blockers	40-61	calcium antagonists	64-82	false
beta-receptor blockers	40-61	thiazide diuretics	85-92;103-111	false
beta-receptor blockers	40-61	loop diuretics	98-111	false
beta-receptor blockers	40-61	ACE inhibitors	117-130	false
calcium antagonists	64-82	thiazide diuretics	85-92;103-111	false
calcium antagonists	64-82	loop diuretics	98-111	false
calcium antagonists	64-82	ACE inhibitors	117-130	false
thiazide diuretics	85-92;103-111	loop diuretics	98-111	false
thiazide diuretics	85-92;103-111	ACE inhibitors	117-130	false
loop diuretics	98-111	ACE inhibitors	117-130	false

Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.
fluoxetine	33-42	cisapride	47-55	false

STUDY OBJECTIVE: To evaluate the effect of fluoxetine on the pharmacokinetics and cardiovascular safety of cisapride at steady state in healthy men.
fluoxetine	43-52	cisapride	107-115	false

and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52).
cisapride	26-34	fluoxetine	72-81	false

Coadministration of fluoxetine significantly decreased cisapride plasma concentrations.
fluoxetine	20-29	cisapride	55-63	mechanism

There were no clinically significant changes in corrected QT intervals during administration of cisapride alone or with fluoxetine.
cisapride	96-104	fluoxetine	120-129	false

Cisapride was well tolerated when administered alone or with fluoxetine.
Cisapride	0-8	fluoxetine	61-70	false

CONCLUSION: Cisapride can be administered safely to patients receiving low therapeutic dosages of fluoxetine.
Cisapride	12-20	fluoxetine	98-107	false

Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia.
Olanzapine	0-9	thienobenzodiazepine derivative	14-44	false
Olanzapine	0-9	second generation (atypical) antipsychotic agent	52-99	false
thienobenzodiazepine derivative	14-44	second generation (atypical) antipsychotic agent	52-99	false

In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms.
olanzapine	86-95	haloperidol	142-152	false

The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment.
olanzapine	76-85	haloperidol	97-107	false

In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
olanzapine	57-66	risperidone	72-82	false
olanzapine	57-66	olanzapine	85-94	false
olanzapine	57-66	risperidone	159-169	false
risperidone	72-82	olanzapine	85-94	false
risperidone	72-82	risperidone	159-169	false
olanzapine	85-94	risperidone	159-169	false

In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.
risperidone	75-85	olanzapine	117-126	false

Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol.
olanzapine	53-62	risperidone	204-214	false
olanzapine	53-62	haloperidol	219-229	false
risperidone	204-214	haloperidol	219-229	false

However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder.
olanzapine	99-108	risperidone	114-124	false

Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology.
olanzapine	30-39	olanzapine	158-167	false

Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone.
Olanzapine	0-9	haloperidol	79-89	false
Olanzapine	0-9	risperidone	95-105	false
haloperidol	79-89	risperidone	95-105	false

In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval.
olanzapine	13-22	clozapine	86-94	false
olanzapine	13-22	risperidone	155-165	false
clozapine	86-94	risperidone	155-165	false

In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine.
haloperidol	19-29	olanzapine	95-104	false
haloperidol	19-29	risperidone	206-216	false
haloperidol	19-29	olanzapine	284-293	false
olanzapine	95-104	risperidone	206-216	false
olanzapine	95-104	olanzapine	284-293	false
risperidone	206-216	olanzapine	284-293	false

Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol.
olanzapine	40-49	haloperidol	174-184	false

Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug.
risperidone	14-24	olanzapine	27-36	false

Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone.
Olanzapine	0-9	haloperidol	124-134	false
Olanzapine	0-9	risperidone	171-181	false
haloperidol	124-134	risperidone	171-181	false

CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia.
Olanzapine	13-22	haloperidol	83-93	false

The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
haloperidol	77-87	risperidone	93-103	false
haloperidol	77-87	olanzapine	180-189	false
risperidone	93-103	olanzapine	180-189	false

The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
non-nucleoside reverse transcriptase inhibitors	22-68	antiretroviral	73-86	false

The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.
non-nucleoside reverse transcriptase inhibitor	27-72	NNRTI	75-79	false
non-nucleoside reverse transcriptase inhibitor	27-72	antiretroviral	101-114	false
non-nucleoside reverse transcriptase inhibitor	27-72	protease inhibitor	147-164	false
non-nucleoside reverse transcriptase inhibitor	27-72	PI	167-168	false
NNRTI	75-79	antiretroviral	101-114	false
NNRTI	75-79	protease inhibitor	147-164	false
NNRTI	75-79	PI	167-168	false
antiretroviral	101-114	protease inhibitor	147-164	false
antiretroviral	101-114	PI	167-168	false
protease inhibitor	147-164	PI	167-168	false

NNRTI-based regimens may have several advantages over PI-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.
NNRTI	0-4	PI	54-55	false

No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, nevirapine or delavirdine).
efavirenz	90-98	nevirapine	101-110	false
efavirenz	90-98	delavirdine	115-125	false
nevirapine	101-110	delavirdine	115-125	false

Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.
efavirenz	5-13	nevirapine	19-28	false
efavirenz	5-13	PI	76-77	false
efavirenz	5-13	indinavir	79-87	false
efavirenz	5-13	nevirapine	166-175	false
efavirenz	5-13	efavirenz	216-224	false
nevirapine	19-28	PI	76-77	false
nevirapine	19-28	indinavir	79-87	false
nevirapine	19-28	nevirapine	166-175	false
nevirapine	19-28	efavirenz	216-224	false
PI	76-77	indinavir	79-87	false
PI	76-77	nevirapine	166-175	false
PI	76-77	efavirenz	216-224	false
indinavir	79-87	nevirapine	166-175	false
indinavir	79-87	efavirenz	216-224	false
nevirapine	166-175	efavirenz	216-224	false

A smaller 24-week study has suggested nevirapine may be superior to the PI nelfinavir.
nevirapine	38-47	PI	72-73	false
nevirapine	38-47	nelfinavir	75-84	false
PI	72-73	nelfinavir	75-84	false

Limited comparative data in patients with high viral loads treated with nevirapine- or delavirdine-based regimens currently exist.
nevirapine	72-81	delavirdine	87-97	false

The superiority of efavirenz over indinavir-based regimens has been observed in comparative data in a subset of patients with high viral loads.
efavirenz	19-27	indinavir	34-42	false

Efavirenz has demonstrated superiority over nelfinavir in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances.
Efavirenz	0-8	nelfinavir	44-53	false

METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction.
sildenafil	84-93	sildenafil	291-300	false
sildenafil	84-93	Viagra	303-308	false
sildenafil	291-300	Viagra	303-308	false

RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]).
Sildenafil	9-18	selective serotonin reuptake inhibitors	205-243	false
Sildenafil	9-18	SSRIs	246-250	false
selective serotonin reuptake inhibitors	205-243	SSRIs	246-250	false

however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy.
nitrate	81-87	sildenafil	179-188	effect

In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes sildenafil, may experience increased drug concentrations and possible toxicity from normal doses of sildenafil.
sildenafil	99-108	sildenafil	199-208	false

Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
hydrocortisone	6-19	d-amphetamine	76-88	false

However, the effects of stress and glucocorticoids on the subjective and behavioral effects of psychostimulants have not been well studied in humans.
glucocorticoids	35-49	psychostimulants	95-110	false

OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine.
hydrocortisone	44-57	d-amphetamine	116-128	false

METHODS: Hydrocortisone (100 mg) and d-amphetamine (20 mg) were administered orally to 16 healthy male and female volunteers in a four-session, placebo-controlled, within-subject, crossover design.
Hydrocortisone	9-22	d-amphetamine	37-49	false

However, hydrocortisone pretreatment did not affect any of the physiological, behavioral, or subjective effects of d-amphetamine.
hydrocortisone	9-22	d-amphetamine	115-127	false

CONCLUSIONS: In contrast to the effects of glucocorticoids in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of d-amphetamine in humans.
glucocorticoids	43-57	d-amphetamine	184-196	false

Interaction of clindamycin and gentamicin in vitro.
clindamycin	15-25	gentamicin	31-40	int

The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates.
clindamycin	41-51	gentamicin	57-66	false

Gentamicin did not interfere with the activity of clindamycin within the range of concentrations tested (0.1 to 100 mug/ml);
Gentamicin	0-9	clindamycin	50-60	false

Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains.
clindamycin	16-26	gentamicin	32-41	effect

All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml).
clindamycin	155-165	gentamicin	230-239	false

Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains.
clindamycin	16-26	gentamicin	32-41	effect

Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells.
amphotericin B	46-59	filipin	75-81	false

Among the polyene antibiotics, many, like filipin, cannot be used clinically because they are toxic;
polyene antibiotics	10-28	filipin	42-48	false

Both the toxicity of filipin and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;
filipin	21-27	amphotericin B	58-71	false
filipin	21-27	polyene antibiotics	170-188	false
amphotericin B	58-71	polyene antibiotics	170-188	false

filipin was more potent in lysing human red blood cells, whereas amphotericin B was more potent in inhibiting yeast cell growth;
filipin	0-6	amphotericin B	65-78	false

and (ii) the effects of filipin were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of amphotericin B were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.
filipin	24-30	amphotericin B	151-164	false

Studies on the mechanism of action of miconazole: effect of miconazole on respiration and cell permeability of Candida albicans.
miconazole	38-47	miconazole	60-69	false

The antifungal drug, miconazole nitrate, inhibits the growth of several species of Candida.
antifungal drug	4-18	miconazole nitrate	21-38	false

Effect of probenecid on the apparent volume of distribution and elimination of cloxacillin.
probenecid	10-19	cloxacillin	79-89	false

(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
penicillins	49-59	cephaloridine	65-77	false
penicillins	49-59	probenecid	111-120	mechanism
cephaloridine	65-77	probenecid	111-120	mechanism

To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.
probenecid	21-30	cloxacillin	75-85	false
probenecid	21-30	cloxacillin	124-134	false
probenecid	21-30	probenecid	274-283	false
cloxacillin	75-85	cloxacillin	124-134	false
cloxacillin	75-85	probenecid	274-283	false
cloxacillin	124-134	probenecid	274-283	false

No significant difference was found between the mean values of the volume of distribution of cloxacillin with and without probenecid (13.0 and 12.6 liters, respectively).
cloxacillin	93-103	probenecid	122-131	false

This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
probenecid	41-50	cloxacillin	74-84	mechanism

Many people use both alcohol and nicotine (i.e., cigarettes and other tobacco products).
alcohol	21-27	nicotine	33-40	false

The initiation of alcohol or nicotine use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.
alcohol	18-24	nicotine	29-36	false

Moreover, the mechanisms underlying the development of dependence may be similar for alcohol and nicotine.
alcohol	85-91	nicotine	97-104	false

[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration]

The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied.
radiopertechnetate	50-67	sodium perchlorate	72-89	false
radiopertechnetate	50-67	sodium perchlorate	170-187	false
radiopertechnetate	50-67	radiopertechnetate	267-284	false
sodium perchlorate	72-89	sodium perchlorate	170-187	false
sodium perchlorate	72-89	radiopertechnetate	267-284	false
sodium perchlorate	170-187	radiopertechnetate	267-284	false

An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate.
perchlorate	29-39	pertechnetate	116-128	false
perchlorate	29-39	radiopertechnetate	237-254	false
pertechnetate	116-128	radiopertechnetate	237-254	false

An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.
perchlorate	28-38	pertechnetate	116-128	mechanism

Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
Sirolimus	0-8	rapamycin	31-39	false

Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.
Sirolimus	0-8	immunosuppressants	37-54	false
Sirolimus	0-8	sirolimus	148-156	false
Sirolimus	0-8	cyclosporine	231-242	false
Sirolimus	0-8	tacrolimus	247-256	false
immunosuppressants	37-54	sirolimus	148-156	false
immunosuppressants	37-54	cyclosporine	231-242	false
immunosuppressants	37-54	tacrolimus	247-256	false
sirolimus	148-156	cyclosporine	231-242	false
sirolimus	148-156	tacrolimus	247-256	false
cyclosporine	231-242	tacrolimus	247-256	false

While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
sirolimus	97-105	cyclosporine	128-139	false
sirolimus	97-105	tacrolimus	144-153	false
sirolimus	97-105	cyclosporine	249-260	false
sirolimus	97-105	tacrolimus	265-274	false
cyclosporine	128-139	tacrolimus	144-153	false
cyclosporine	128-139	cyclosporine	249-260	false
cyclosporine	128-139	tacrolimus	265-274	false
tacrolimus	144-153	cyclosporine	249-260	false
tacrolimus	144-153	tacrolimus	265-274	false
cyclosporine	249-260	tacrolimus	265-274	false

The effects of chlordiazepoxide, amphetamine and cocaine on bar-press behavior in normal and genetically nervous dogs.
chlordiazepoxide	15-30	amphetamine	33-43	false
chlordiazepoxide	15-30	cocaine	49-55	false
amphetamine	33-43	cocaine	49-55	false

Studies on two strains of pointer dogs have demonstrated that administration of a benzodiazepine (chlordiazepoxide) facilitates acquisition of goal-directed behavior in "genetically nervous"
benzodiazepine	82-95	chlordiazepoxide	98-113	false

The concomitant administration of either cocaine or amphetamine, compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects.
cocaine	41-47	amphetamine	52-62	false

Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986.
Fluvastatin	0-10	synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor	25-100	false

It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.
HMGCoA reductase inhibitors	63-89	lovastatin	92-101	false
HMGCoA reductase inhibitors	63-89	simvastatin	104-114	false
HMGCoA reductase inhibitors	63-89	pravastatin	121-131	false
lovastatin	92-101	simvastatin	104-114	false
lovastatin	92-101	pravastatin	121-131	false
simvastatin	104-114	pravastatin	121-131	false

Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability.
Cholestyramine	0-13	fluvastatin	103-113	mechanism

Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy.
cholestyramine	41-54	fluvastatin	83-93	effect

Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of warfarin and fluvastatin.
warfarin	30-37	warfarin	132-139	false
warfarin	30-37	fluvastatin	145-155	false
warfarin	132-139	fluvastatin	145-155	false

Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.
niacin	46-51	propranolol	57-67	false
niacin	46-51	fluvastatin	105-115	false
niacin	46-51	digoxin	197-203	false
niacin	46-51	digoxin	267-273	false
propranolol	57-67	fluvastatin	105-115	false
propranolol	57-67	digoxin	197-203	false
propranolol	57-67	digoxin	267-273	false
fluvastatin	105-115	digoxin	197-203	false
fluvastatin	105-115	digoxin	267-273	false
digoxin	197-203	digoxin	267-273	false

Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.
coumaphos	32-40	coumaphos	68-76	false
coumaphos	32-40	bishydroxycoumarin	83-100	false
coumaphos	32-40	trichlorfon	103-113	false
coumaphos	32-40	phenobarbital sodium	120-139	false
coumaphos	68-76	bishydroxycoumarin	83-100	false
coumaphos	68-76	trichlorfon	103-113	false
coumaphos	68-76	phenobarbital sodium	120-139	false
bishydroxycoumarin	83-100	trichlorfon	103-113	false
bishydroxycoumarin	83-100	phenobarbital sodium	120-139	false
trichlorfon	103-113	phenobarbital sodium	120-139	false

Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.
coumaphos	37-45	bishydroxycoumarin	48-65	false
coumaphos	37-45	anticoagulant	71-83	false
coumaphos	37-45	trichlorfon	87-97	false
coumaphos	37-45	organophosphorous compound	103-128	false
coumaphos	37-45	phenobarbital sodium	136-155	false
bishydroxycoumarin	48-65	anticoagulant	71-83	false
bishydroxycoumarin	48-65	trichlorfon	87-97	false
bishydroxycoumarin	48-65	organophosphorous compound	103-128	false
bishydroxycoumarin	48-65	phenobarbital sodium	136-155	false
anticoagulant	71-83	trichlorfon	87-97	false
anticoagulant	71-83	organophosphorous compound	103-128	false
anticoagulant	71-83	phenobarbital sodium	136-155	false
trichlorfon	87-97	organophosphorous compound	103-128	false
trichlorfon	87-97	phenobarbital sodium	136-155	false
organophosphorous compound	103-128	phenobarbital sodium	136-155	false

A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers.
coumaphos	24-32	bishydroxy-coumarin	134-152	false

The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day.
trichlorfon	60-70	coumaphos	267-275	effect

In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present.
phenobarbital sodium	23-42	coumaphos	123-131	effect

Interaction of gentamycin and atracurium in anaesthetised horses.
gentamycin	15-24	atracurium	30-39	int

Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by atracurium infusion in 7 horses anaesthetised with halothane.
atracurium	101-110	halothane	152-160	false

Atracurium was again given by infusion to maintain 40% twitch for a second hour, then 2 mg gentamycin/kg bwt were given i.v.
Atracurium	0-9	gentamycin	91-100	false

Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03).
atracurium	65-74	atracurium	107-116	false
atracurium	65-74	gentamycin	123-132	false
atracurium	107-116	gentamycin	123-132	effect

Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin.
atracurium	72-81	atracurium	114-123	false
atracurium	72-81	gentamycin	130-139	false
atracurium	114-123	gentamycin	130-139	effect

At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin.
atracurium	55-64	atracurium	90-99	false
atracurium	55-64	gentamycin	106-115	false
atracurium	90-99	gentamycin	106-115	effect

It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.
gentamycin	32-41	atracurium	85-94	effect

Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
temazepam	30-38	ethanol	65-71	mechanism

The benzodiazepines are a family of anxiolytic and hypnotic drugs.
benzodiazepines	4-18	anxiolytic	36-45	false
benzodiazepines	4-18	hypnotic drugs	51-64	false
anxiolytic	36-45	hypnotic drugs	51-64	false

In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
temazepam	105-113	benzodiazepine	118-131	false
temazepam	105-113	ethanol	138-144	mechanism
benzodiazepine	118-131	ethanol	138-144	false

The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis.
alcohol	111-117	3-hydroxy-1,4-benzodiazepine	123-150	mechanism

Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.
Plenaxis	29-36	testosterone	83-94	false

Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.
MTX	50-52	NSAIDs	55-60	false
MTX	50-52	corticosteroids	63-77	false
MTX	50-52	TNF blocking agents	84-102	false
MTX	50-52	abatacept	122-130	false
NSAIDs	55-60	corticosteroids	63-77	false
NSAIDs	55-60	TNF blocking agents	84-102	false
NSAIDs	55-60	abatacept	122-130	false
corticosteroids	63-77	TNF blocking agents	84-102	false
corticosteroids	63-77	abatacept	122-130	false
TNF blocking agents	84-102	abatacept	122-130	false

The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
ORENCIA	115-121	MTX	124-126	false
ORENCIA	115-121	NSAIDs	129-134	false
ORENCIA	115-121	corticosteroids	137-151	false
ORENCIA	115-121	TNF blocking agents	154-172	false
ORENCIA	115-121	azathioprine	175-186	false
ORENCIA	115-121	chloroquine	189-199	false
ORENCIA	115-121	gold	202-205	false
ORENCIA	115-121	hydroxychloroquine	208-225	false
ORENCIA	115-121	leflunomide	228-238	false
ORENCIA	115-121	sulfasalazine	241-253	false
ORENCIA	115-121	anakinra	260-267	false
MTX	124-126	NSAIDs	129-134	false
MTX	124-126	corticosteroids	137-151	false
MTX	124-126	TNF blocking agents	154-172	false
MTX	124-126	azathioprine	175-186	false
MTX	124-126	chloroquine	189-199	false
MTX	124-126	gold	202-205	false
MTX	124-126	hydroxychloroquine	208-225	false
MTX	124-126	leflunomide	228-238	false
MTX	124-126	sulfasalazine	241-253	false
MTX	124-126	anakinra	260-267	false
NSAIDs	129-134	corticosteroids	137-151	false
NSAIDs	129-134	TNF blocking agents	154-172	false
NSAIDs	129-134	azathioprine	175-186	false
NSAIDs	129-134	chloroquine	189-199	false
NSAIDs	129-134	gold	202-205	false
NSAIDs	129-134	hydroxychloroquine	208-225	false
NSAIDs	129-134	leflunomide	228-238	false
NSAIDs	129-134	sulfasalazine	241-253	false
NSAIDs	129-134	anakinra	260-267	false
corticosteroids	137-151	TNF blocking agents	154-172	false
corticosteroids	137-151	azathioprine	175-186	false
corticosteroids	137-151	chloroquine	189-199	false
corticosteroids	137-151	gold	202-205	false
corticosteroids	137-151	hydroxychloroquine	208-225	false
corticosteroids	137-151	leflunomide	228-238	false
corticosteroids	137-151	sulfasalazine	241-253	false
corticosteroids	137-151	anakinra	260-267	false
TNF blocking agents	154-172	azathioprine	175-186	false
TNF blocking agents	154-172	chloroquine	189-199	false
TNF blocking agents	154-172	gold	202-205	false
TNF blocking agents	154-172	hydroxychloroquine	208-225	false
TNF blocking agents	154-172	leflunomide	228-238	false
TNF blocking agents	154-172	sulfasalazine	241-253	false
TNF blocking agents	154-172	anakinra	260-267	false
azathioprine	175-186	chloroquine	189-199	false
azathioprine	175-186	gold	202-205	false
azathioprine	175-186	hydroxychloroquine	208-225	false
azathioprine	175-186	leflunomide	228-238	false
azathioprine	175-186	sulfasalazine	241-253	false
azathioprine	175-186	anakinra	260-267	false
chloroquine	189-199	gold	202-205	false
chloroquine	189-199	hydroxychloroquine	208-225	false
chloroquine	189-199	leflunomide	228-238	false
chloroquine	189-199	sulfasalazine	241-253	false
chloroquine	189-199	anakinra	260-267	false
gold	202-205	hydroxychloroquine	208-225	false
gold	202-205	leflunomide	228-238	false
gold	202-205	sulfasalazine	241-253	false
gold	202-205	anakinra	260-267	false
hydroxychloroquine	208-225	leflunomide	228-238	false
hydroxychloroquine	208-225	sulfasalazine	241-253	false
hydroxychloroquine	208-225	anakinra	260-267	false
leflunomide	228-238	sulfasalazine	241-253	false
leflunomide	228-238	anakinra	260-267	false
sulfasalazine	241-253	anakinra	260-267	false

Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
TNF antagonist	31-44	ORENCIA	51-57	effect
TNF antagonist	31-44	TNF antagonists	179-193	false
ORENCIA	51-57	TNF antagonists	179-193	false

Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
ORENCIA	24-30	TNF antagonists	36-50	advise

There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
ORENCIA	70-76	anakinra	109-116	advise

These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
heparin	32-38	warfarin	41-48	false
heparin	32-38	beta-adrenergic receptor blockers	51-83	false
heparin	32-38	calcium channel antagonists	86-112	false
heparin	32-38	angiotensin converting enzyme inhibitors	115-154	false
heparin	32-38	nitrates	178-185	false
heparin	32-38	ticlopidine	188-198	false
heparin	32-38	aspirin	205-211	false
warfarin	41-48	beta-adrenergic receptor blockers	51-83	false
warfarin	41-48	calcium channel antagonists	86-112	false
warfarin	41-48	angiotensin converting enzyme inhibitors	115-154	false
warfarin	41-48	nitrates	178-185	false
warfarin	41-48	ticlopidine	188-198	false
warfarin	41-48	aspirin	205-211	false
beta-adrenergic receptor blockers	51-83	calcium channel antagonists	86-112	false
beta-adrenergic receptor blockers	51-83	angiotensin converting enzyme inhibitors	115-154	false
beta-adrenergic receptor blockers	51-83	nitrates	178-185	false
beta-adrenergic receptor blockers	51-83	ticlopidine	188-198	false
beta-adrenergic receptor blockers	51-83	aspirin	205-211	false
calcium channel antagonists	86-112	angiotensin converting enzyme inhibitors	115-154	false
calcium channel antagonists	86-112	nitrates	178-185	false
calcium channel antagonists	86-112	ticlopidine	188-198	false
calcium channel antagonists	86-112	aspirin	205-211	false
angiotensin converting enzyme inhibitors	115-154	nitrates	178-185	false
angiotensin converting enzyme inhibitors	115-154	ticlopidine	188-198	false
angiotensin converting enzyme inhibitors	115-154	aspirin	205-211	false
nitrates	178-185	ticlopidine	188-198	false
nitrates	178-185	aspirin	205-211	false
ticlopidine	188-198	aspirin	205-211	false

Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding.
Heparin	0-6	anticoagulants	15-28	false
Heparin	0-6	thrombolytics	31-43	false
Heparin	0-6	anti platelet agents	50-69	false
anticoagulants	15-28	thrombolytics	31-43	false
anticoagulants	15-28	anti platelet agents	50-69	false
thrombolytics	31-43	anti platelet agents	50-69	false

Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
diagnostic monoclonal antibodies	98-107;124-144	therapeutic monoclonal antibodies	112-144	false

The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.
alcohol	26-32	Acamprosate	38-48	false
alcohol	26-32	alcohol	97-103	false
alcohol	26-32	acamprosate	108-118	false
Acamprosate	38-48	alcohol	97-103	false
Acamprosate	38-48	acamprosate	108-118	false
alcohol	97-103	acamprosate	108-118	false

Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate.
disulfiram	56-65	diazepam	70-77	false
disulfiram	56-65	acamprosate	119-129	false
diazepam	70-77	acamprosate	119-129	false

Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
naltrexone	21-30	Acamprosate	37-47	mechanism
naltrexone	21-30	acamprosate	114-124	false
Acamprosate	37-47	acamprosate	114-124	false

The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.
naltrexone	24-33	6-beta-naltrexol	60-75	false
naltrexone	24-33	Acamprosate	126-136	false
6-beta-naltrexol	60-75	Acamprosate	126-136	false

Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
Acamprosate	93-103	anxiolytics	124-134	false
Acamprosate	93-103	hypnotics	137-145	false
Acamprosate	93-103	sedatives	151-159	false
Acamprosate	93-103	benzodiazepines	172-186	false
Acamprosate	93-103	non-opioid analgesics	193-213	false
anxiolytics	124-134	hypnotics	137-145	false
anxiolytics	124-134	sedatives	151-159	false
anxiolytics	124-134	benzodiazepines	172-186	false
anxiolytics	124-134	non-opioid analgesics	193-213	false
hypnotics	137-145	sedatives	151-159	false
hypnotics	137-145	benzodiazepines	172-186	false
hypnotics	137-145	non-opioid analgesics	193-213	false
sedatives	151-159	benzodiazepines	172-186	false
sedatives	151-159	non-opioid analgesics	193-213	false
benzodiazepines	172-186	non-opioid analgesics	193-213	false

Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
Acamprosate	16-26	antidepressants	47-61	effect

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
thiazides	24-32	diuretics	44-52	false
thiazides	24-32	corticosteroids	55-69	false
thiazides	24-32	phenothiazines	72-85	false
thiazides	24-32	thyroid products	88-103	false
thiazides	24-32	estrogens	106-114	false
thiazides	24-32	contraceptives	122-135	false
thiazides	24-32	phenytoin	138-146	false
thiazides	24-32	nicotinic acid	149-162	false
thiazides	24-32	sympathomimetics	165-180	false
thiazides	24-32	calcium channel-blocking drugs	183-212	false
thiazides	24-32	isoniazid	219-227	false
diuretics	44-52	corticosteroids	55-69	false
diuretics	44-52	phenothiazines	72-85	false
diuretics	44-52	thyroid products	88-103	false
diuretics	44-52	estrogens	106-114	false
diuretics	44-52	contraceptives	122-135	false
diuretics	44-52	phenytoin	138-146	false
diuretics	44-52	nicotinic acid	149-162	false
diuretics	44-52	sympathomimetics	165-180	false
diuretics	44-52	calcium channel-blocking drugs	183-212	false
diuretics	44-52	isoniazid	219-227	false
corticosteroids	55-69	phenothiazines	72-85	false
corticosteroids	55-69	thyroid products	88-103	false
corticosteroids	55-69	estrogens	106-114	false
corticosteroids	55-69	contraceptives	122-135	false
corticosteroids	55-69	phenytoin	138-146	false
corticosteroids	55-69	nicotinic acid	149-162	false
corticosteroids	55-69	sympathomimetics	165-180	false
corticosteroids	55-69	calcium channel-blocking drugs	183-212	false
corticosteroids	55-69	isoniazid	219-227	false
phenothiazines	72-85	thyroid products	88-103	false
phenothiazines	72-85	estrogens	106-114	false
phenothiazines	72-85	contraceptives	122-135	false
phenothiazines	72-85	phenytoin	138-146	false
phenothiazines	72-85	nicotinic acid	149-162	false
phenothiazines	72-85	sympathomimetics	165-180	false
phenothiazines	72-85	calcium channel-blocking drugs	183-212	false
phenothiazines	72-85	isoniazid	219-227	false
thyroid products	88-103	estrogens	106-114	false
thyroid products	88-103	contraceptives	122-135	false
thyroid products	88-103	phenytoin	138-146	false
thyroid products	88-103	nicotinic acid	149-162	false
thyroid products	88-103	sympathomimetics	165-180	false
thyroid products	88-103	calcium channel-blocking drugs	183-212	false
thyroid products	88-103	isoniazid	219-227	false
estrogens	106-114	contraceptives	122-135	false
estrogens	106-114	phenytoin	138-146	false
estrogens	106-114	nicotinic acid	149-162	false
estrogens	106-114	sympathomimetics	165-180	false
estrogens	106-114	calcium channel-blocking drugs	183-212	false
estrogens	106-114	isoniazid	219-227	false
contraceptives	122-135	phenytoin	138-146	false
contraceptives	122-135	nicotinic acid	149-162	false
contraceptives	122-135	sympathomimetics	165-180	false
contraceptives	122-135	calcium channel-blocking drugs	183-212	false
contraceptives	122-135	isoniazid	219-227	false
phenytoin	138-146	nicotinic acid	149-162	false
phenytoin	138-146	sympathomimetics	165-180	false
phenytoin	138-146	calcium channel-blocking drugs	183-212	false
phenytoin	138-146	isoniazid	219-227	false
nicotinic acid	149-162	sympathomimetics	165-180	false
nicotinic acid	149-162	calcium channel-blocking drugs	183-212	false
nicotinic acid	149-162	isoniazid	219-227	false
sympathomimetics	165-180	calcium channel-blocking drugs	183-212	false
sympathomimetics	165-180	isoniazid	219-227	false
calcium channel-blocking drugs	183-212	isoniazid	219-227	false

When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.
Acarbose	54-61	sulfonylureas	83-95	false
Acarbose	54-61	insulin	100-106	false
sulfonylureas	83-95	insulin	100-106	false

Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
Intestinal adsorbents	0-20	charcoal	30-37	false
Intestinal adsorbents	0-20	digestive enzyme preparations	44-72	false
Intestinal adsorbents	0-20	amylase	124-130	false
Intestinal adsorbents	0-20	pancreatin	133-142	false
Intestinal adsorbents	0-20	Acarbose	170-177	mechanism
charcoal	30-37	digestive enzyme preparations	44-72	false
charcoal	30-37	amylase	124-130	false
charcoal	30-37	pancreatin	133-142	false
charcoal	30-37	Acarbose	170-177	mechanism
digestive enzyme preparations	44-72	amylase	124-130	false
digestive enzyme preparations	44-72	pancreatin	133-142	false
digestive enzyme preparations	44-72	Acarbose	170-177	false
amylase	124-130	pancreatin	133-142	false
amylase	124-130	Acarbose	170-177	mechanism
pancreatin	133-142	Acarbose	170-177	mechanism

Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
Acarbose	0-7	digoxin	54-60	mechanism
Acarbose	0-7	digoxin	111-117	false
digoxin	54-60	digoxin	111-117	false

Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.
Acarbose	46-53	digoxin	123-129	false
Acarbose	46-53	nifedipine	132-141	false
Acarbose	46-53	propranolol	144-154	false
Acarbose	46-53	ranitidine	160-169	false
digoxin	123-129	nifedipine	132-141	false
digoxin	123-129	propranolol	144-154	false
digoxin	123-129	ranitidine	160-169	false
nifedipine	132-141	propranolol	144-154	false
nifedipine	132-141	ranitidine	160-169	false
propranolol	144-154	ranitidine	160-169	false

Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.
Acarbose	0-7	sulfonylurea	69-80	false
Acarbose	0-7	glyburide	82-90	false
sulfonylurea	69-80	glyburide	82-90	false

Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
Acarbose	0-7	digoxin	20-26	false
Acarbose	0-7	digoxin	79-85	false
Acarbose	0-7	digoxin	148-154	false
Acarbose	0-7	digoxin	240-246	false
digoxin	20-26	digoxin	79-85	false
digoxin	20-26	digoxin	148-154	false
digoxin	20-26	digoxin	240-246	false
digoxin	79-85	digoxin	148-154	false
digoxin	79-85	digoxin	240-246	false
digoxin	148-154	digoxin	240-246	false

The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.
metformin	14-22	Acarbose	46-53	false

However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
metformin	34-42	Acarbose	89-96	mechanism
metformin	34-42	metformin	141-149	false
Acarbose	89-96	metformin	141-149	mechanism

There is little if any clinically significant interaction between Acarbose and metformin.
Acarbose	66-73	metformin	79-87	false

Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
Catecholamine-depleting drugs	0-28	reserpine	39-47	false
Catecholamine-depleting drugs	0-28	beta-blocking agents	94-113	effect
reserpine	39-47	beta-blocking agents	94-113	effect

Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
acebutolol	22-31	catecholamine depletors	38-60	advise

Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
beta-adrenergic antagonists	79-105	alpha-adrenergic stimulants	111-137	effect

Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
beta-adrenoceptor blocking agents	43-75	nonsteroidal anti-inflammatory drugs	80-115	effect

No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
digoxin	33-39	hydrochlorothiazide	42-60	false
digoxin	33-39	hydralazine	63-73	false
digoxin	33-39	sulfinpyrazone	76-89	false
digoxin	33-39	contraceptives	97-110	false
digoxin	33-39	tolbutamide	113-123	false
digoxin	33-39	warfarin	129-136	false
hydrochlorothiazide	42-60	hydralazine	63-73	false
hydrochlorothiazide	42-60	sulfinpyrazone	76-89	false
hydrochlorothiazide	42-60	contraceptives	97-110	false
hydrochlorothiazide	42-60	tolbutamide	113-123	false
hydrochlorothiazide	42-60	warfarin	129-136	false
hydralazine	63-73	sulfinpyrazone	76-89	false
hydralazine	63-73	contraceptives	97-110	false
hydralazine	63-73	tolbutamide	113-123	false
hydralazine	63-73	warfarin	129-136	false
sulfinpyrazone	76-89	contraceptives	97-110	false
sulfinpyrazone	76-89	tolbutamide	113-123	false
sulfinpyrazone	76-89	warfarin	129-136	false
contraceptives	97-110	tolbutamide	113-123	false
contraceptives	97-110	warfarin	129-136	false
tolbutamide	113-123	warfarin	129-136	false

DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
DIAMOX	0-5	phenytoin	16-24	mechanism
DIAMOX	0-5	phenytoin	68-76	mechanism
phenytoin	16-24	phenytoin	68-76	false

By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
primidone	49-57	DIAMOX	60-65	false
primidone	49-57	primidone	104-112	false
DIAMOX	60-65	primidone	104-112	mechanism

Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
DIAMOX	74-79	primidone	103-111	advise

Acetazolamide may increase the effects of other folic acid antagonists.
Acetazolamide	0-12	folic acid antagonists	48-69	effect

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
Acetazolamide	0-12	amphetamine	45-55	mechanism

Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
Acetazolamide	0-12	quinidine	43-51	mechanism

Acetazolamide may prevent the urinary antiseptic effect of methenamine.
Acetazolamide	0-12	methenamine	59-69	effect

Acetazolamide increases lithium excretion and the lithium may be decreased.
Acetazolamide	0-12	lithium	24-30	mechanism
Acetazolamide	0-12	lithium	50-56	false
lithium	24-30	lithium	50-56	false

Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
Acetazolamide	0-12	sodium bicarbonate	18-35	effect

Acetazolamide may elevate cyclosporine levels.
Acetazolamide	0-12	cyclosporine	26-37	mechanism

Concomitant use with iron supplements may result in the reduced absorption of iron.
iron supplement	21-35	iron	78-81	false

Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
probenecid	21-30	acyclovir	37-45	mechanism

Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
Ethanol	0-6	etretinate	41-50	false
Ethanol	0-6	acitretin	95-103	false
Ethanol	0-6	ethanol	109-115	false
etretinate	41-50	acitretin	95-103	false
etretinate	41-50	ethanol	109-115	false
acitretin	95-103	ethanol	109-115	mechanism

Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
Glibenclamide	0-12	acitretin	56-64	false
Glibenclamide	0-12	glibenclamide	125-137	false
Glibenclamide	0-12	sulfonylurea	142-153	false
Glibenclamide	0-12	chlorpropamide	166-179	false
acitretin	56-64	glibenclamide	125-137	effect
acitretin	56-64	sulfonylurea	142-153	false
acitretin	56-64	chlorpropamide	166-179	false
glibenclamide	125-137	sulfonylurea	142-153	false
glibenclamide	125-137	chlorpropamide	166-179	false
sulfonylurea	142-153	chlorpropamide	166-179	false

Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.
glibenclamide	69-81	acitretin	111-119	false

Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives.
Hormonal Contraceptives	0-22	acitretin	103-111	false
Hormonal Contraceptives	0-22	combined oral contraceptives	117-144	false
acitretin	103-111	combined oral contraceptives	117-144	false

However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
acitretin	38-46	progestin	103-111	effect

Microdosed minipill progestin preparations are not recommended for use with Soriatane.
progestin	20-28	Soriatane	76-84	advise

It is not known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy.
progestational contraceptives	30-58	acitretin	140-148	false

Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
Methotrexate	0-11	methotrexate	94-105	false
Methotrexate	0-11	etretinate	111-120	false
methotrexate	94-105	etretinate	111-120	effect

Consequently, the combination of methotrexate with acitretin is also contraindicated.
methotrexate	33-44	acitretin	51-59	advise

Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
Phenytoin	0-8	acitretin	14-22	false
Phenytoin	0-8	phenytoin	51-59	false
Phenytoin	0-8	phenytoin	85-93	false
acitretin	14-22	phenytoin	51-59	mechanism
acitretin	14-22	phenytoin	85-93	false
phenytoin	51-59	phenytoin	85-93	false

Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
Tetracyclines	0-12	acitretin	26-34	false
Tetracyclines	0-12	tetracyclines	40-52	false
acitretin	26-34	tetracyclines	40-52	effect

Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
Vitamin A	0-8	retinoids	19-27	false
Vitamin A	0-8	vitamin A	60-68	false
Vitamin A	0-8	retinoids	88-96	false
Vitamin A	0-8	acitretin	103-111	false
retinoids	19-27	vitamin A	60-68	false
retinoids	19-27	retinoids	88-96	false
retinoids	19-27	acitretin	103-111	false
vitamin A	60-68	retinoids	88-96	false
vitamin A	60-68	acitretin	103-111	advise
retinoids	88-96	acitretin	103-111	advise

Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.
acitretin	66-74	cimetidine	80-89	false
acitretin	66-74	digoxin	92-98	false
acitretin	66-74	glyburide	104-112	false
cimetidine	80-89	digoxin	92-98	false
cimetidine	80-89	glyburide	104-112	false
digoxin	92-98	glyburide	104-112	false

Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.
acitretin	34-42	anticoagulants of the coumarin type	70-104	false
acitretin	34-42	warfarin	107-114	false
anticoagulants of the coumarin type	70-104	warfarin	107-114	false

Methotrexate: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX.
Methotrexate	0-11	HUMIRA	14-19	false
Methotrexate	0-11	MTX	90-92	false
HUMIRA	14-19	MTX	90-92	false

The data do not suggest the need for dose adjustment of either HUMIRA or MTX.
HUMIRA	63-68	MTX	73-75	false

Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
Anakinra	0-7	anakinra	39-46	false
Anakinra	0-7	interleukin-1 antagonist	52-75	false
Anakinra	0-7	TNF-blocking agent	90-107	false
anakinra	39-46	interleukin-1 antagonist	52-75	false
anakinra	39-46	TNF-blocking agent	90-107	effect
interleukin-1 antagonist	52-75	TNF-blocking agent	90-107	effect

The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.
anakinra	27-34	HUMIRA	61-66	false

Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
anakinra	30-37	TNF-blocking agents	50-68	effect
anakinra	30-37	HUMIRA	81-86	effect
TNF-blocking agents	50-68	HUMIRA	81-86	false

Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.
sulfur	72-77	resorcinol	80-89	false
sulfur	72-77	salicylic acid	95-108	false
sulfur	72-77	DIFFERIN	130-137	false
resorcinol	80-89	salicylic acid	95-108	false
resorcinol	80-89	DIFFERIN	130-137	false
salicylic acid	95-108	DIFFERIN	130-137	false

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
aminoglycosides	138-152	gentamicin	161-170	false
aminoglycosides	138-152	amikacin	173-180	false
aminoglycosides	138-152	amphotericin B	184-197	false
aminoglycosides	138-152	cyclosporine	200-211	false
aminoglycosides	138-152	non-steroidal anti-inflammatory	214-244	false
aminoglycosides	138-152	ibuprofen	259-267	false
aminoglycosides	138-152	tacrolimus	271-280	false
aminoglycosides	138-152	vancomycin	283-292	false
gentamicin	161-170	amikacin	173-180	false
gentamicin	161-170	amphotericin B	184-197	false
gentamicin	161-170	cyclosporine	200-211	false
gentamicin	161-170	non-steroidal anti-inflammatory	214-244	false
gentamicin	161-170	ibuprofen	259-267	false
gentamicin	161-170	tacrolimus	271-280	false
gentamicin	161-170	vancomycin	283-292	false
amikacin	173-180	amphotericin B	184-197	false
amikacin	173-180	cyclosporine	200-211	false
amikacin	173-180	non-steroidal anti-inflammatory	214-244	false
amikacin	173-180	ibuprofen	259-267	false
amikacin	173-180	tacrolimus	271-280	false
amikacin	173-180	vancomycin	283-292	false
amphotericin B	184-197	cyclosporine	200-211	false
amphotericin B	184-197	non-steroidal anti-inflammatory	214-244	false
amphotericin B	184-197	ibuprofen	259-267	false
amphotericin B	184-197	tacrolimus	271-280	false
amphotericin B	184-197	vancomycin	283-292	false
cyclosporine	200-211	non-steroidal anti-inflammatory	214-244	false
cyclosporine	200-211	ibuprofen	259-267	false
cyclosporine	200-211	tacrolimus	271-280	false
cyclosporine	200-211	vancomycin	283-292	false
non-steroidal anti-inflammatory	214-244	ibuprofen	259-267	false
non-steroidal anti-inflammatory	214-244	tacrolimus	271-280	false
non-steroidal anti-inflammatory	214-244	vancomycin	283-292	false
ibuprofen	259-267	tacrolimus	271-280	false
ibuprofen	259-267	vancomycin	283-292	false
tacrolimus	271-280	vancomycin	283-292	false

Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
Adenocard	12-20	adenosine	23-31	false
Adenocard	12-20	quinidine	121-129	false
Adenocard	12-20	beta-adrenergic blocking agents	132-162	false
Adenocard	12-20	calcium channel blocking agents	165-195	false
Adenocard	12-20	angiotensin converting enzyme inhibitors	202-241	false
adenosine	23-31	quinidine	121-129	false
adenosine	23-31	beta-adrenergic blocking agents	132-162	false
adenosine	23-31	calcium channel blocking agents	165-195	false
adenosine	23-31	angiotensin converting enzyme inhibitors	202-241	false
quinidine	121-129	beta-adrenergic blocking agents	132-162	false
quinidine	121-129	calcium channel blocking agents	165-195	false
quinidine	121-129	angiotensin converting enzyme inhibitors	202-241	false
beta-adrenergic blocking agents	132-162	calcium channel blocking agents	165-195	false
beta-adrenergic blocking agents	132-162	angiotensin converting enzyme inhibitors	202-241	false
calcium channel blocking agents	165-195	angiotensin converting enzyme inhibitors	202-241	false

Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
Digoxin	0-6	verapamil	12-20	false
Digoxin	0-6	Adenocard	100-108	effect
verapamil	12-20	Adenocard	100-108	effect

The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
Adenocard	11-19	digitalis	43-51	effect

The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
adenosine	15-23	methylxanthines	44-58	effect
adenosine	15-23	caffeine	68-75	effect
adenosine	15-23	theophylline	81-92	effect
methylxanthines	44-58	caffeine	68-75	false
methylxanthines	44-58	theophylline	81-92	false
caffeine	68-75	theophylline	81-92	false

In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
methylxanthines	25-39	adenosine	58-66	advise
methylxanthines	25-39	adenosine	87-95	advise
adenosine	58-66	adenosine	87-95	false

Adenosine effects are potentiated by dipyridamole.
Adenosine	0-8	dipyridamole	37-48	effect

Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
adenosine	23-31	dipyridamole	69-80	effect

As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
adenosine	25-33	carbamazepine	148-160	effect

Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended.
antifungal agents	23-39	ketoconazole	49-60	false
antifungal agents	23-39	itraconazole	65-76	false
ketoconazole	49-60	itraconazole	65-76	false

Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
Nafazodone	0-9	fluvoxamine	12-22	false
Nafazodone	0-9	cimetidine	25-34	false
Nafazodone	0-9	Xanax	46-50	advise
fluvoxamine	12-22	cimetidine	25-34	false
fluvoxamine	12-22	Xanax	46-50	advise
cimetidine	25-34	Xanax	46-50	advise

Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).
Fluoxetine	0-9	OCs	12-14	false
Fluoxetine	0-9	sertraline	17-26	false
Fluoxetine	0-9	diltiazem	29-37	false
Fluoxetine	0-9	macrolide antibiotics	40-60	false
OCs	12-14	sertraline	17-26	false
OCs	12-14	diltiazem	29-37	false
OCs	12-14	macrolide antibiotics	40-60	false
sertraline	17-26	diltiazem	29-37	false
sertraline	17-26	macrolide antibiotics	40-60	false
diltiazem	29-37	macrolide antibiotics	40-60	false

Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
Dexamethasone	0-12	albendazole sulfoxide	53-73	false
Dexamethasone	0-12	dexamethasone	107-119	false
Dexamethasone	0-12	albendazole	158-168	false
albendazole sulfoxide	53-73	dexamethasone	107-119	false
albendazole sulfoxide	53-73	albendazole	158-168	false
dexamethasone	107-119	albendazole	158-168	mechanism

Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
Praziquantel	0-11	praziquantel	32-43	false
Praziquantel	0-11	albendazole sulfoxide	128-148	false
Praziquantel	0-11	albendazole	245-255	false
praziquantel	32-43	albendazole sulfoxide	128-148	mechanism
praziquantel	32-43	albendazole	245-255	false
albendazole sulfoxide	128-148	albendazole	245-255	false

The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).
praziquantel	24-35	albendazole	84-94	false

Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
Cimetidine	0-9	Albendazole sulfoxide	12-32	false
Cimetidine	0-9	cimetidine	142-151	false
Cimetidine	0-9	albendazole	188-198	false
Albendazole sulfoxide	12-32	cimetidine	142-151	mechanism
Albendazole sulfoxide	12-32	albendazole	188-198	false
cimetidine	142-151	albendazole	188-198	false

Theophylline: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.
Theophylline	0-11	theophylline	38-49	false
Theophylline	0-11	aminophylline	52-64	false
Theophylline	0-11	albendazole	148-158	false
theophylline	38-49	aminophylline	52-64	false
theophylline	38-49	albendazole	148-158	false
aminophylline	52-64	albendazole	148-158	false

Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).
psychotropic drugs	76-93	narcotics	102-110	false
psychotropic drugs	76-93	analgesics	113-122	false
psychotropic drugs	76-93	antiemetics	125-135	false
psychotropic drugs	76-93	sedatives	138-146	false
psychotropic drugs	76-93	tranquilizers	149-161	false
narcotics	102-110	analgesics	113-122	false
narcotics	102-110	antiemetics	125-135	false
narcotics	102-110	sedatives	138-146	false
narcotics	102-110	tranquilizers	149-161	false
analgesics	113-122	antiemetics	125-135	false
analgesics	113-122	sedatives	138-146	false
analgesics	113-122	tranquilizers	149-161	false
antiemetics	125-135	sedatives	138-146	false
antiemetics	125-135	tranquilizers	149-161	false
sedatives	138-146	tranquilizers	149-161	false

Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
aminoglycosides	65-79	indomethacin	82-93	false
aminoglycosides	65-79	cytotoxic	115-123	false
aminoglycosides	65-79	doxorubicin	159-169	false
aminoglycosides	65-79	methotrexate	194-205	false
aminoglycosides	65-79	asparaginase	208-219	false
aminoglycosides	65-79	PROLEUKIN	235-243	effect
indomethacin	82-93	cytotoxic	115-123	false
indomethacin	82-93	doxorubicin	159-169	false
indomethacin	82-93	methotrexate	194-205	false
indomethacin	82-93	asparaginase	208-219	false
indomethacin	82-93	PROLEUKIN	235-243	effect
cytotoxic	115-123	doxorubicin	159-169	false
cytotoxic	115-123	methotrexate	194-205	false
cytotoxic	115-123	asparaginase	208-219	false
cytotoxic	115-123	PROLEUKIN	235-243	effect
doxorubicin	159-169	methotrexate	194-205	false
doxorubicin	159-169	asparaginase	208-219	false
doxorubicin	159-169	PROLEUKIN	235-243	effect
methotrexate	194-205	asparaginase	208-219	false
methotrexate	194-205	PROLEUKIN	235-243	effect
asparaginase	208-219	PROLEUKIN	235-243	effect

The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.
PROLEUKIN	27-35	antineoplastic agents	61-81	false

Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
PROLEUKIN	121-129	antineoplastic agents	135-155	effect
PROLEUKIN	121-129	dacarbazine	172-182	effect
PROLEUKIN	121-129	cis-platinum	185-196	effect
PROLEUKIN	121-129	tamoxifen	199-207	effect
PROLEUKIN	121-129	interferon-alfa	213-227	effect
antineoplastic agents	135-155	dacarbazine	172-182	false
antineoplastic agents	135-155	cis-platinum	185-196	false
antineoplastic agents	135-155	tamoxifen	199-207	false
antineoplastic agents	135-155	interferon-alfa	213-227	false
dacarbazine	172-182	cis-platinum	185-196	false
dacarbazine	172-182	tamoxifen	199-207	false
dacarbazine	172-182	interferon-alfa	213-227	false
cis-platinum	185-196	tamoxifen	199-207	false
cis-platinum	185-196	interferon-alfa	213-227	false
tamoxifen	199-207	interferon-alfa	213-227	false

Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
PROLEUKIN	161-169	interferon-alfa	175-189	effect

Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
interferon-alfa	140-154	PROLEUKIN	160-168	effect

Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
glucocorticoids	9-23	PROLEUKIN	51-59	effect
glucocorticoids	9-23	PROLEUKIN	212-220	false
glucocorticoids	9-23	PROLEUKIN	264-272	false
glucocorticoids	9-23	Beta-blockers	305-317	false
glucocorticoids	9-23	antihypertensives	329-345	false
glucocorticoids	9-23	PROLEUKIN	388-396	false
PROLEUKIN	51-59	PROLEUKIN	212-220	false
PROLEUKIN	51-59	PROLEUKIN	264-272	false
PROLEUKIN	51-59	Beta-blockers	305-317	false
PROLEUKIN	51-59	antihypertensives	329-345	false
PROLEUKIN	51-59	PROLEUKIN	388-396	false
PROLEUKIN	212-220	PROLEUKIN	264-272	false
PROLEUKIN	212-220	Beta-blockers	305-317	false
PROLEUKIN	212-220	antihypertensives	329-345	false
PROLEUKIN	212-220	PROLEUKIN	388-396	false
PROLEUKIN	264-272	Beta-blockers	305-317	false
PROLEUKIN	264-272	antihypertensives	329-345	false
PROLEUKIN	264-272	PROLEUKIN	388-396	false
Beta-blockers	305-317	antihypertensives	329-345	false
Beta-blockers	305-317	PROLEUKIN	388-396	effect
antihypertensives	329-345	PROLEUKIN	388-396	effect

Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
Iodinated Contrast Media	29-52	interleukin-2	154-166	false
Iodinated Contrast Media	29-52	radiographic iodinated contrast media	223-259	false
interleukin-2	154-166	radiographic iodinated contrast media	223-259	effect

The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.
AMEVIVE	52-58	immunosuppressive	103-119	false

Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).
AMEVIVE	20-26	AMEVIVE	188-194	false
AMEVIVE	20-26	AMEVIVE	268-274	false
AMEVIVE	188-194	AMEVIVE	268-274	false

An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies
Campath	22-28	antibodies	96-105	false

Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
ranitidine	12-21	alendronate	71-81	mechanism

Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
calcium	20-26	multivalent cations	38-56	false
calcium	20-26	alendronate	99-109	mechanism
multivalent cations	38-56	alendronate	99-109	mechanism

Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
ALFENTA	106-112	CNS depressants	156-170	effect
ALFENTA	106-112	barbiturates	180-191	effect
ALFENTA	106-112	tranquilizers	194-206	effect
ALFENTA	106-112	opioids	209-215	effect
ALFENTA	106-112	anesthetics	240-250	effect
CNS depressants	156-170	barbiturates	180-191	false
CNS depressants	156-170	tranquilizers	194-206	false
CNS depressants	156-170	opioids	209-215	false
CNS depressants	156-170	anesthetics	240-250	false
barbiturates	180-191	tranquilizers	194-206	false
barbiturates	180-191	opioids	209-215	false
barbiturates	180-191	anesthetics	240-250	false
tranquilizers	194-206	opioids	209-215	false
tranquilizers	194-206	anesthetics	240-250	false
opioids	209-215	anesthetics	240-250	false

Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
volatile inhalation anesthetics	60-90	ALFENTA	160-166	mechanism
volatile inhalation anesthetics	60-90	erythromycin	201-212	false
volatile inhalation anesthetics	60-90	ALFENTA	219-225	false
volatile inhalation anesthetics	60-90	ALFENTA	253-259	false
ALFENTA	160-166	erythromycin	201-212	false
ALFENTA	160-166	ALFENTA	219-225	false
ALFENTA	160-166	ALFENTA	253-259	false
erythromycin	201-212	ALFENTA	219-225	mechanism
erythromycin	201-212	ALFENTA	253-259	false
ALFENTA	219-225	ALFENTA	253-259	false

Cimetidine reduces the clearance of ALFENTA.
Cimetidine	0-9	ALFENTA	36-42	mechanism

Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.
ALFENTA	18-24	ALFENTA	109-115	false

Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.
UROXATRAL	85-93	alpha-blockers	105-118	false

However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
UROXATRAL	43-51	alpha-blockers	98-111	advise

Effects of Other Drugs on Aliskiren Based on in-vitro studies, aliskiren is metabolized by CYP 3A4.
Aliskiren	26-34	aliskiren	63-71	false

Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
lovastatin	21-30	atenolol	33-40	false
lovastatin	21-30	warfarin	43-50	false
lovastatin	21-30	furosemide	53-62	false
lovastatin	21-30	digoxin	65-71	false
lovastatin	21-30	celecoxib	74-82	false
lovastatin	21-30	hydrochlorothiazide	85-103	false
lovastatin	21-30	ramipril	106-113	false
lovastatin	21-30	valsartan	116-124	false
lovastatin	21-30	metformin	127-135	false
lovastatin	21-30	amlodipine	141-150	false
lovastatin	21-30	aliskiren	206-214	false
atenolol	33-40	warfarin	43-50	false
atenolol	33-40	furosemide	53-62	false
atenolol	33-40	digoxin	65-71	false
atenolol	33-40	celecoxib	74-82	false
atenolol	33-40	hydrochlorothiazide	85-103	false
atenolol	33-40	ramipril	106-113	false
atenolol	33-40	valsartan	116-124	false
atenolol	33-40	metformin	127-135	false
atenolol	33-40	amlodipine	141-150	false
atenolol	33-40	aliskiren	206-214	false
warfarin	43-50	furosemide	53-62	false
warfarin	43-50	digoxin	65-71	false
warfarin	43-50	celecoxib	74-82	false
warfarin	43-50	hydrochlorothiazide	85-103	false
warfarin	43-50	ramipril	106-113	false
warfarin	43-50	valsartan	116-124	false
warfarin	43-50	metformin	127-135	false
warfarin	43-50	amlodipine	141-150	false
warfarin	43-50	aliskiren	206-214	false
furosemide	53-62	digoxin	65-71	false
furosemide	53-62	celecoxib	74-82	false
furosemide	53-62	hydrochlorothiazide	85-103	false
furosemide	53-62	ramipril	106-113	false
furosemide	53-62	valsartan	116-124	false
furosemide	53-62	metformin	127-135	false
furosemide	53-62	amlodipine	141-150	false
furosemide	53-62	aliskiren	206-214	false
digoxin	65-71	celecoxib	74-82	false
digoxin	65-71	hydrochlorothiazide	85-103	false
digoxin	65-71	ramipril	106-113	false
digoxin	65-71	valsartan	116-124	false
digoxin	65-71	metformin	127-135	false
digoxin	65-71	amlodipine	141-150	false
digoxin	65-71	aliskiren	206-214	false
celecoxib	74-82	hydrochlorothiazide	85-103	false
celecoxib	74-82	ramipril	106-113	false
celecoxib	74-82	valsartan	116-124	false
celecoxib	74-82	metformin	127-135	false
celecoxib	74-82	amlodipine	141-150	false
celecoxib	74-82	aliskiren	206-214	false
hydrochlorothiazide	85-103	ramipril	106-113	false
hydrochlorothiazide	85-103	valsartan	116-124	false
hydrochlorothiazide	85-103	metformin	127-135	false
hydrochlorothiazide	85-103	amlodipine	141-150	false
hydrochlorothiazide	85-103	aliskiren	206-214	false
ramipril	106-113	valsartan	116-124	false
ramipril	106-113	metformin	127-135	false
ramipril	106-113	amlodipine	141-150	false
ramipril	106-113	aliskiren	206-214	false
valsartan	116-124	metformin	127-135	false
valsartan	116-124	amlodipine	141-150	false
valsartan	116-124	aliskiren	206-214	false
metformin	127-135	amlodipine	141-150	false
metformin	127-135	aliskiren	206-214	false
amlodipine	141-150	aliskiren	206-214	false

Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
irbesartan	21-30	aliskiren	40-48	mechanism

Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
atorvastatin	21-32	aliskiren	70-78	mechanism

Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
Ketoconazole	0-11	ketoconazole	54-65	false
Ketoconazole	0-11	aliskiren	72-80	false
Ketoconazole	0-11	aliskiren	142-150	false
ketoconazole	54-65	aliskiren	72-80	mechanism
ketoconazole	54-65	aliskiren	142-150	false
aliskiren	72-80	aliskiren	142-150	false

Effects of Aliskiren on Other Drugs Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.
Aliskiren	11-19	Aliskiren	36-44	false

Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
aliskiren	21-29	lovastatin	84-93	false
aliskiren	21-29	digoxin	96-102	false
aliskiren	21-29	valsartan	105-113	false
aliskiren	21-29	amlodipine	116-125	false
aliskiren	21-29	metformin	128-136	false
aliskiren	21-29	celecoxib	139-147	false
aliskiren	21-29	atenolol	150-157	false
aliskiren	21-29	atorvastatin	160-171	false
aliskiren	21-29	ramipril	174-181	false
aliskiren	21-29	hydrochlorothiazide	186-204	false
lovastatin	84-93	digoxin	96-102	false
lovastatin	84-93	valsartan	105-113	false
lovastatin	84-93	amlodipine	116-125	false
lovastatin	84-93	metformin	128-136	false
lovastatin	84-93	celecoxib	139-147	false
lovastatin	84-93	atenolol	150-157	false
lovastatin	84-93	atorvastatin	160-171	false
lovastatin	84-93	ramipril	174-181	false
lovastatin	84-93	hydrochlorothiazide	186-204	false
digoxin	96-102	valsartan	105-113	false
digoxin	96-102	amlodipine	116-125	false
digoxin	96-102	metformin	128-136	false
digoxin	96-102	celecoxib	139-147	false
digoxin	96-102	atenolol	150-157	false
digoxin	96-102	atorvastatin	160-171	false
digoxin	96-102	ramipril	174-181	false
digoxin	96-102	hydrochlorothiazide	186-204	false
valsartan	105-113	amlodipine	116-125	false
valsartan	105-113	metformin	128-136	false
valsartan	105-113	celecoxib	139-147	false
valsartan	105-113	atenolol	150-157	false
valsartan	105-113	atorvastatin	160-171	false
valsartan	105-113	ramipril	174-181	false
valsartan	105-113	hydrochlorothiazide	186-204	false
amlodipine	116-125	metformin	128-136	false
amlodipine	116-125	celecoxib	139-147	false
amlodipine	116-125	atenolol	150-157	false
amlodipine	116-125	atorvastatin	160-171	false
amlodipine	116-125	ramipril	174-181	false
amlodipine	116-125	hydrochlorothiazide	186-204	false
metformin	128-136	celecoxib	139-147	false
metformin	128-136	atenolol	150-157	false
metformin	128-136	atorvastatin	160-171	false
metformin	128-136	ramipril	174-181	false
metformin	128-136	hydrochlorothiazide	186-204	false
celecoxib	139-147	atenolol	150-157	false
celecoxib	139-147	atorvastatin	160-171	false
celecoxib	139-147	ramipril	174-181	false
celecoxib	139-147	hydrochlorothiazide	186-204	false
atenolol	150-157	atorvastatin	160-171	false
atenolol	150-157	ramipril	174-181	false
atenolol	150-157	hydrochlorothiazide	186-204	false
atorvastatin	160-171	ramipril	174-181	false
atorvastatin	160-171	hydrochlorothiazide	186-204	false
ramipril	174-181	hydrochlorothiazide	186-204	false

Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.
Warfarin	0-7	aliskiren	25-33	false
Warfarin	0-7	warfarin	38-45	false
aliskiren	25-33	warfarin	38-45	false

Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
Furosemide	0-9	aliskiren	17-25	false
Furosemide	0-9	furosemide	52-61	false
Furosemide	0-9	furosemide	84-93	false
aliskiren	17-25	furosemide	52-61	mechanism
aliskiren	17-25	furosemide	84-93	false
furosemide	52-61	furosemide	84-93	false

Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
Panretin	26-33	DEET	89-92	advise
Panretin	26-33	N-diethyl-m-toluamide	98-118	advise
DEET	89-92	N-diethyl-m-toluamide	98-118	false

Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation.
DEET	43-46	DEET	62-65	false

Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
antiretroviral agents	109-129	protease inhibitors	142-160	false
antiretroviral agents	109-129	macrolide antibiotics	163-183	false
antiretroviral agents	109-129	azole antifungals	190-206	false
antiretroviral agents	109-129	Panretin	223-230	false
protease inhibitors	142-160	macrolide antibiotics	163-183	false
protease inhibitors	142-160	azole antifungals	190-206	false
protease inhibitors	142-160	Panretin	223-230	false
macrolide antibiotics	163-183	azole antifungals	190-206	false
macrolide antibiotics	163-183	Panretin	223-230	false
azole antifungals	190-206	Panretin	223-230	false

Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
Mercaptopurine	0-13	Azathioprine	15-26	false
Mercaptopurine	0-13	Allopurinol	29-39	false
Mercaptopurine	0-13	mercaptopurine	77-90	false
Mercaptopurine	0-13	azathioprine	96-107	false
Mercaptopurine	0-13	6-thiouric acid	112-126	false
Azathioprine	15-26	Allopurinol	29-39	false
Azathioprine	15-26	mercaptopurine	77-90	false
Azathioprine	15-26	azathioprine	96-107	false
Azathioprine	15-26	6-thiouric acid	112-126	false
Allopurinol	29-39	mercaptopurine	77-90	mechanism
Allopurinol	29-39	azathioprine	96-107	mechanism
Allopurinol	29-39	6-thiouric acid	112-126	false
mercaptopurine	77-90	azathioprine	96-107	false
mercaptopurine	77-90	6-thiouric acid	112-126	false
azathioprine	96-107	6-thiouric acid	112-126	false

In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
mercaptopurine	22-35	Purinethol	38-47	false
mercaptopurine	22-35	azathioprine	53-64	false
mercaptopurine	22-35	Imuran	67-72	false
mercaptopurine	22-35	allopurinol	124-134	false
mercaptopurine	22-35	mercaptopurine	239-252	false
mercaptopurine	22-35	azathioprine	257-268	false
Purinethol	38-47	azathioprine	53-64	false
Purinethol	38-47	Imuran	67-72	false
Purinethol	38-47	allopurinol	124-134	false
Purinethol	38-47	mercaptopurine	239-252	false
Purinethol	38-47	azathioprine	257-268	false
azathioprine	53-64	Imuran	67-72	false
azathioprine	53-64	allopurinol	124-134	false
azathioprine	53-64	mercaptopurine	239-252	false
azathioprine	53-64	azathioprine	257-268	false
Imuran	67-72	allopurinol	124-134	false
Imuran	67-72	mercaptopurine	239-252	false
Imuran	67-72	azathioprine	257-268	false
allopurinol	124-134	mercaptopurine	239-252	advise
allopurinol	124-134	azathioprine	257-268	advise
mercaptopurine	239-252	azathioprine	257-268	false

Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.
mercaptopurine	34-47	azathioprine	52-63	false

Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.
Dicumarol	0-8	allopurinol	37-47	false
Dicumarol	0-8	anticoagulant	79-91	false
Dicumarol	0-8	dicumarol	94-102	false
allopurinol	37-47	anticoagulant	79-91	false
allopurinol	37-47	dicumarol	94-102	mechanism
anticoagulant	79-91	dicumarol	94-102	false

The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
allopurinol	94-104	dicumarol	138-146	false

Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
Uricosuric Agents	0-16	oxipurinol	42-51	false
Uricosuric Agents	0-16	uricosuric agents	82-98	false
Uricosuric Agents	0-16	oxipurinol	185-194	false
oxipurinol	42-51	uricosuric agents	82-98	false
oxipurinol	42-51	oxipurinol	185-194	false
uricosuric agents	82-98	oxipurinol	185-194	mechanism

The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
uricosuric agents	34-50	allopurinol	56-66	mechanism
uricosuric agents	34-50	allopurinol	243-253	false
allopurinol	56-66	allopurinol	243-253	false

Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.
allopurinol	112-122	uricosuric agents	153-169	false

Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
Thiazide Diuretics	0-17	allopurinol	60-70	false
Thiazide Diuretics	0-17	thiazide diuretics	76-93	false
Thiazide Diuretics	0-17	allopurinol	132-142	false
allopurinol	60-70	thiazide diuretics	76-93	effect
allopurinol	60-70	allopurinol	132-142	false
thiazide diuretics	76-93	allopurinol	132-142	false

Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
thiazide diuretics	172-189	allopurinol	195-205	advise

Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
Ampicillin	0-9	Amoxicillin	11-21	false
Ampicillin	0-9	ampicillin	109-118	false
Ampicillin	0-9	amoxicillin	123-133	false
Ampicillin	0-9	allopurinol	153-163	false
Amoxicillin	11-21	ampicillin	109-118	false
Amoxicillin	11-21	amoxicillin	123-133	false
Amoxicillin	11-21	allopurinol	153-163	false
ampicillin	109-118	amoxicillin	123-133	false
ampicillin	109-118	allopurinol	153-163	effect
amoxicillin	123-133	allopurinol	153-163	effect

Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
Cytotoxic Agents	0-15	cyclophosphamide	54-69	false
Cytotoxic Agents	0-15	cytotoxic agents	81-96	false
Cytotoxic Agents	0-15	allopurinol	192-202	false
cyclophosphamide	54-69	cytotoxic agents	81-96	false
cyclophosphamide	54-69	allopurinol	192-202	effect
cytotoxic agents	81-96	allopurinol	192-202	effect

However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.
allopurinol	86-96	cyclophosphamide	160-175	false
allopurinol	86-96	doxorubicin	178-188	false
allopurinol	86-96	bleomycin	191-199	false
allopurinol	86-96	procarbazine	202-213	false
allopurinol	86-96	mechlorethamine	222-236	false
cyclophosphamide	160-175	doxorubicin	178-188	false
cyclophosphamide	160-175	bleomycin	191-199	false
cyclophosphamide	160-175	procarbazine	202-213	false
cyclophosphamide	160-175	mechlorethamine	222-236	false
doxorubicin	178-188	bleomycin	191-199	false
doxorubicin	178-188	procarbazine	202-213	false
doxorubicin	178-188	mechlorethamine	222-236	false
bleomycin	191-199	procarbazine	202-213	false
bleomycin	191-199	mechlorethamine	222-236	false
procarbazine	202-213	mechlorethamine	222-236	false

Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
Chlorpropamide	0-13	Chlorpropamide	16-29	false
Chlorpropamide	0-13	allopurinol	69-79	false
Chlorpropamide	0-13	allopurinol	88-98	false
Chlorpropamide	0-13	chlorpropamide	104-117	false
Chlorpropamide	16-29	allopurinol	69-79	mechanism
Chlorpropamide	16-29	allopurinol	88-98	false
Chlorpropamide	16-29	chlorpropamide	104-117	false
allopurinol	69-79	allopurinol	88-98	false
allopurinol	69-79	chlorpropamide	104-117	false
allopurinol	88-98	chlorpropamide	104-117	mechanism

The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
allopurinol	73-83	chlorpropamide	89-102	effect

Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
Cyclosporin	0-10	cyclosporine	35-46	false
Cyclosporin	0-10	allopurinol sodium	106-123	false
cyclosporine	35-46	allopurinol sodium	106-123	mechanism

Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.
cyclosporine	14-25	cyclosporine	61-72	false

Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
ergotamine	80-89	ergot-type medications	105-126	false
ergotamine	80-89	dihydroergotamine	134-150	false
ergotamine	80-89	methysergide	155-166	false
ergotamine	80-89	AXERT	173-177	advise
ergot-type medications	105-126	dihydroergotamine	134-150	false
ergot-type medications	105-126	methysergide	155-166	false
ergot-type medications	105-126	AXERT	173-177	advise
dihydroergotamine	134-150	methysergide	155-166	false
dihydroergotamine	134-150	AXERT	173-177	advise
methysergide	155-166	AXERT	173-177	advise

Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
Monoamine Oxidase Inhibitors	0-27	moclobemide	50-60	false
Monoamine Oxidase Inhibitors	0-27	almotriptan	92-102	false
moclobemide	50-60	almotriptan	92-102	mechanism

Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
5-HT1B/1D Agonists	6-23	5-HT1B/1D agonists	50-67	false
5-HT1B/1D Agonists	6-23	AXERT	103-107	false
5-HT1B/1D agonists	50-67	AXERT	103-107	advise

Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.
Propanolol	0-9	almotriptan	36-46	false
Propanolol	0-9	propranolol	89-99	false
almotriptan	36-46	propranolol	89-99	false

Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
Selective Serotonin Reuptake Inhibitors	0-38	SSRIs	41-45	false
Selective Serotonin Reuptake Inhibitors	0-38	SSRIs	49-53	false
Selective Serotonin Reuptake Inhibitors	0-38	fluoxetine	62-71	false
Selective Serotonin Reuptake Inhibitors	0-38	fluvoxamine	74-84	false
Selective Serotonin Reuptake Inhibitors	0-38	paroxetine	87-96	false
Selective Serotonin Reuptake Inhibitors	0-38	sertraline	99-108	false
Selective Serotonin Reuptake Inhibitors	0-38	5-HT1 agonists	215-228	false
SSRIs	41-45	SSRIs	49-53	false
SSRIs	41-45	fluoxetine	62-71	false
SSRIs	41-45	fluvoxamine	74-84	false
SSRIs	41-45	paroxetine	87-96	false
SSRIs	41-45	sertraline	99-108	false
SSRIs	41-45	5-HT1 agonists	215-228	false
SSRIs	49-53	fluoxetine	62-71	false
SSRIs	49-53	fluvoxamine	74-84	false
SSRIs	49-53	paroxetine	87-96	false
SSRIs	49-53	sertraline	99-108	false
SSRIs	49-53	5-HT1 agonists	215-228	effect
fluoxetine	62-71	fluvoxamine	74-84	false
fluoxetine	62-71	paroxetine	87-96	false
fluoxetine	62-71	sertraline	99-108	false
fluoxetine	62-71	5-HT1 agonists	215-228	effect
fluvoxamine	74-84	paroxetine	87-96	false
fluvoxamine	74-84	sertraline	99-108	false
fluvoxamine	74-84	5-HT1 agonists	215-228	effect
paroxetine	87-96	sertraline	99-108	false
paroxetine	87-96	5-HT1 agonists	215-228	effect
sertraline	99-108	5-HT1 agonists	215-228	effect

If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
AXERT	30-34	SSRI	43-46	advise

Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
Verapamil	0-8	almotriptan	31-41	false
Verapamil	0-8	verapamil	47-55	false
Verapamil	0-8	almotriptan	112-122	false
almotriptan	31-41	verapamil	47-55	mechanism
almotriptan	31-41	almotriptan	112-122	false
verapamil	47-55	almotriptan	112-122	false

Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
almotriptan	20-30	ketoconazole	64-75	mechanism
almotriptan	20-30	almotriptan	235-245	false
ketoconazole	64-75	almotriptan	235-245	false

Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
almotriptan	33-43	itraconazole	87-98	false
almotriptan	33-43	ritonavir	101-109	false
almotriptan	33-43	erythromycin	116-127	false
almotriptan	33-43	almotriptan	175-185	false
almotriptan	33-43	almotriptan	208-218	false
itraconazole	87-98	ritonavir	101-109	false
itraconazole	87-98	erythromycin	116-127	false
itraconazole	87-98	almotriptan	175-185	false
itraconazole	87-98	almotriptan	208-218	advise
ritonavir	101-109	erythromycin	116-127	false
ritonavir	101-109	almotriptan	175-185	false
ritonavir	101-109	almotriptan	208-218	advise
erythromycin	116-127	almotriptan	175-185	false
erythromycin	116-127	almotriptan	208-218	advise
almotriptan	175-185	almotriptan	208-218	false

Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron.
alosetron	8-16	alosetron	156-164	false

In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.
fluvoxamine	64-74	alosetron	160-168	false

Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
Fluvoxamine	0-10	alosetron	27-35	mechanism

Concomitant administration of alosetron and fluvoxamine is contraindicated.
alosetron	30-38	fluvoxamine	44-54	advise

Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
alosetron	30-38	quinolone antibiotics	82-102	advise
alosetron	30-38	cimetidine	108-117	advise
quinolone antibiotics	82-102	cimetidine	108-117	false

In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.
ketoconazole	64-75	alosetron	133-141	false

Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
Ketoconazole	0-11	alosetron	28-36	mechanism

Caution should be used when alosetron and ketoconazole are administered concomitantly.
alosetron	28-36	ketoconazole	42-53	advise

Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
alosetron	20-28	clarithromycin	68-81	advise
alosetron	20-28	telithromycin	84-96	advise
alosetron	20-28	protease inhibitors	99-117	advise
alosetron	20-28	voriconazole	120-131	advise
alosetron	20-28	itraconazole	138-149	advise
clarithromycin	68-81	telithromycin	84-96	false
clarithromycin	68-81	protease inhibitors	99-117	false
clarithromycin	68-81	voriconazole	120-131	false
clarithromycin	68-81	itraconazole	138-149	false
telithromycin	84-96	protease inhibitors	99-117	false
telithromycin	84-96	voriconazole	120-131	false
telithromycin	84-96	itraconazole	138-149	false
protease inhibitors	99-117	voriconazole	120-131	false
protease inhibitors	99-117	itraconazole	138-149	false
voriconazole	120-131	itraconazole	138-149	false

Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
alosetron	26-34	isoniazid	131-139	effect
alosetron	26-34	procainamide	142-153	effect
alosetron	26-34	hydralazine	160-170	effect
isoniazid	131-139	procainamide	142-153	false
isoniazid	131-139	hydralazine	160-170	false
procainamide	142-153	hydralazine	160-170	false

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).
alosetron	26-34	contraceptive agents	110-129	false
alosetron	26-34	ethinyl estradiol	131-147	false
alosetron	26-34	levonorgestrel	153-166	false
contraceptive agents	110-129	ethinyl estradiol	131-147	false
contraceptive agents	110-129	levonorgestrel	153-166	false
ethinyl estradiol	131-147	levonorgestrel	153-166	false

A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.
alosetron	53-61	cisapride	88-96	false

The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
benzodiazepines	4-18	alprazolam	31-40	false
benzodiazepines	4-18	psychotropic medications	115-138	effect
benzodiazepines	4-18	anticonvulsants	141-155	effect
benzodiazepines	4-18	antihistaminics	158-172	effect
benzodiazepines	4-18	ethanol	175-181	effect
alprazolam	31-40	psychotropic medications	115-138	effect
alprazolam	31-40	anticonvulsants	141-155	effect
alprazolam	31-40	antihistaminics	158-172	effect
alprazolam	31-40	ethanol	175-181	effect
psychotropic medications	115-138	anticonvulsants	141-155	false
psychotropic medications	115-138	antihistaminics	158-172	false
psychotropic medications	115-138	ethanol	175-181	false
anticonvulsants	141-155	antihistaminics	158-172	false
anticonvulsants	141-155	ethanol	175-181	false
antihistaminics	158-172	ethanol	175-181	false

The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
imipramine	42-51	desipramine	57-67	false
imipramine	42-51	alprazolam	182-191	mechanism
desipramine	57-67	alprazolam	182-191	mechanism

Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A: The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
Alprazolam	19-28	alprazolam	85-94	false

Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
Alprazolam	120-129	alprazolam	184-193	false
Alprazolam	120-129	fluoxetine	217-226	false
Alprazolam	120-129	alprazolam	233-242	false
Alprazolam	120-129	alprazolam	290-299	false
alprazolam	184-193	fluoxetine	217-226	false
alprazolam	184-193	alprazolam	233-242	false
alprazolam	184-193	alprazolam	290-299	false
fluoxetine	217-226	alprazolam	233-242	mechanism
fluoxetine	217-226	alprazolam	290-299	false
alprazolam	233-242	alprazolam	290-299	false

Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
propoxyphene	20-31	alprazolam	79-88	mechanism

Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
contraceptives	25-38	alprazolam	86-95	mechanism

Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
benzodiazepines	107-121	alprazolam	148-157	false
benzodiazepines	107-121	alprazolam	200-209	false
benzodiazepines	107-121	benzodiazepines	220-234	false
benzodiazepines	107-121	alprazolam	289-298	false
benzodiazepines	107-121	benzodiazepines	342-356	false
benzodiazepines	107-121	alprazolam	369-378	false
benzodiazepines	107-121	alprazolam	421-430	false
benzodiazepines	107-121	diltiazem	451-459	false
benzodiazepines	107-121	isoniazid	462-470	false
benzodiazepines	107-121	macrolide antibiotics	473-493	false
benzodiazepines	107-121	erythromycin	503-514	false
benzodiazepines	107-121	clarithromycin	520-533	false
alprazolam	148-157	alprazolam	200-209	false
alprazolam	148-157	benzodiazepines	220-234	false
alprazolam	148-157	alprazolam	289-298	false
alprazolam	148-157	benzodiazepines	342-356	false
alprazolam	148-157	alprazolam	369-378	false
alprazolam	148-157	alprazolam	421-430	false
alprazolam	148-157	diltiazem	451-459	false
alprazolam	148-157	isoniazid	462-470	false
alprazolam	148-157	macrolide antibiotics	473-493	false
alprazolam	148-157	erythromycin	503-514	false
alprazolam	148-157	clarithromycin	520-533	false
alprazolam	200-209	benzodiazepines	220-234	false
alprazolam	200-209	alprazolam	289-298	false
alprazolam	200-209	benzodiazepines	342-356	false
alprazolam	200-209	alprazolam	369-378	false
alprazolam	200-209	alprazolam	421-430	false
alprazolam	200-209	diltiazem	451-459	false
alprazolam	200-209	isoniazid	462-470	false
alprazolam	200-209	macrolide antibiotics	473-493	false
alprazolam	200-209	erythromycin	503-514	false
alprazolam	200-209	clarithromycin	520-533	false
benzodiazepines	220-234	alprazolam	289-298	false
benzodiazepines	220-234	benzodiazepines	342-356	false
benzodiazepines	220-234	alprazolam	369-378	false
benzodiazepines	220-234	alprazolam	421-430	false
benzodiazepines	220-234	diltiazem	451-459	false
benzodiazepines	220-234	isoniazid	462-470	false
benzodiazepines	220-234	macrolide antibiotics	473-493	false
benzodiazepines	220-234	erythromycin	503-514	false
benzodiazepines	220-234	clarithromycin	520-533	false
alprazolam	289-298	benzodiazepines	342-356	false
alprazolam	289-298	alprazolam	369-378	false
alprazolam	289-298	alprazolam	421-430	false
alprazolam	289-298	diltiazem	451-459	false
alprazolam	289-298	isoniazid	462-470	false
alprazolam	289-298	macrolide antibiotics	473-493	false
alprazolam	289-298	erythromycin	503-514	false
alprazolam	289-298	clarithromycin	520-533	false
benzodiazepines	342-356	alprazolam	369-378	false
benzodiazepines	342-356	alprazolam	421-430	false
benzodiazepines	342-356	diltiazem	451-459	false
benzodiazepines	342-356	isoniazid	462-470	false
benzodiazepines	342-356	macrolide antibiotics	473-493	false
benzodiazepines	342-356	erythromycin	503-514	false
benzodiazepines	342-356	clarithromycin	520-533	false
alprazolam	369-378	alprazolam	421-430	false
alprazolam	369-378	diltiazem	451-459	false
alprazolam	369-378	isoniazid	462-470	false
alprazolam	369-378	macrolide antibiotics	473-493	false
alprazolam	369-378	erythromycin	503-514	false
alprazolam	369-378	clarithromycin	520-533	false
alprazolam	421-430	diltiazem	451-459	int
alprazolam	421-430	isoniazid	462-470	int
alprazolam	421-430	macrolide antibiotics	473-493	int
alprazolam	421-430	erythromycin	503-514	int
alprazolam	421-430	clarithromycin	520-533	int
diltiazem	451-459	isoniazid	462-470	false
diltiazem	451-459	macrolide antibiotics	473-493	false
diltiazem	451-459	erythromycin	503-514	false
diltiazem	451-459	clarithromycin	520-533	false
isoniazid	462-470	macrolide antibiotics	473-493	false
isoniazid	462-470	erythromycin	503-514	false
isoniazid	462-470	clarithromycin	520-533	false
macrolide antibiotics	473-493	erythromycin	503-514	false
macrolide antibiotics	473-493	clarithromycin	520-533	false
erythromycin	503-514	clarithromycin	520-533	false

Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
alprazolam	30-39	alprazolam	82-91	false
alprazolam	30-39	sertraline	112-121	false
alprazolam	30-39	paroxetine	127-136	false
alprazolam	82-91	sertraline	112-121	int
alprazolam	82-91	paroxetine	127-136	int
sertraline	112-121	paroxetine	127-136	false

Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
benzodiazepines	30-44	alprazolam	57-66	false
benzodiazepines	30-44	ergotamine	123-132	int
benzodiazepines	30-44	cyclosporine	135-146	int
benzodiazepines	30-44	amiodarone	149-158	int
benzodiazepines	30-44	nicardipine	161-171	int
benzodiazepines	30-44	nifedipine	178-187	int
alprazolam	57-66	ergotamine	123-132	int
alprazolam	57-66	cyclosporine	135-146	int
alprazolam	57-66	amiodarone	149-158	int
alprazolam	57-66	nicardipine	161-171	int
alprazolam	57-66	nifedipine	178-187	int
ergotamine	123-132	cyclosporine	135-146	false
ergotamine	123-132	amiodarone	149-158	false
ergotamine	123-132	nicardipine	161-171	false
ergotamine	123-132	nifedipine	178-187	false
cyclosporine	135-146	amiodarone	149-158	false
cyclosporine	135-146	nicardipine	161-171	false
cyclosporine	135-146	nifedipine	178-187	false
amiodarone	149-158	nicardipine	161-171	false
amiodarone	149-158	nifedipine	178-187	false
nicardipine	161-171	nifedipine	178-187	false

Standard therapy includes antibiotics, such as penicillin and gentamicin;
antibiotics	26-36	penicillin	47-56	false
antibiotics	26-36	gentamicin	62-71	false
penicillin	47-56	gentamicin	62-71	false

vasopressors, such as dopamine and isoproterenol;
vasopressors	0-11	dopamine	22-29	false
vasopressors	0-11	isoproterenol	35-47	false
dopamine	22-29	isoproterenol	35-47	false

and diuretics, such as furosemide.
diuretics	4-12	furosemide	23-32	false

Caverject: The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents has not been formally studied.
Caverject	0-8	alprostadil	76-86	false

In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
heparin	40-46	vitamin K antagonists	52-72	false
heparin	40-46	acetylsalicylic acid	119-138	false
heparin	40-46	dipyridamole	141-152	false
heparin	40-46	Abciximab	158-166	false
heparin	40-46	Activase	246-253	effect
vitamin K antagonists	52-72	acetylsalicylic acid	119-138	false
vitamin K antagonists	52-72	dipyridamole	141-152	false
vitamin K antagonists	52-72	Abciximab	158-166	false
vitamin K antagonists	52-72	Activase	246-253	effect
acetylsalicylic acid	119-138	dipyridamole	141-152	false
acetylsalicylic acid	119-138	Abciximab	158-166	false
acetylsalicylic acid	119-138	Activase	246-253	int
dipyridamole	141-152	Abciximab	158-166	false
dipyridamole	141-152	Activase	246-253	effect
Abciximab	158-166	Activase	246-253	effect

Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
Antithrombotics	7-21	Aspirin	23-29	false
Antithrombotics	7-21	heparin	35-41	false
Antithrombotics	7-21	Activase	112-119	false
Aspirin	23-29	heparin	35-41	false
Aspirin	23-29	Activase	112-119	false
heparin	35-41	Activase	112-119	false

Because heparin, aspirin, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
heparin	8-14	aspirin	17-23	false
heparin	8-14	Activase	29-36	false
aspirin	17-23	Activase	29-36	false

The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.
heparin	23-29	aspirin	34-40	false

Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
HEXALEN	29-35	antidepressants of the MAO inhibitor class	41-82	effect
HEXALEN	29-35	Cimetidine	125-134	false
HEXALEN	29-35	altretamine	191-201	false
antidepressants of the MAO inhibitor class	41-82	Cimetidine	125-134	false
antidepressants of the MAO inhibitor class	41-82	altretamine	191-201	false
Cimetidine	125-134	altretamine	191-201	mechanism

Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
HEXALEN	32-38	cisplatin	44-52	effect
HEXALEN	32-38	pyridoxine	68-77	false
HEXALEN	32-38	pyridoxine	112-121	false
cisplatin	44-52	pyridoxine	68-77	false
cisplatin	44-52	pyridoxine	112-121	false
pyridoxine	68-77	pyridoxine	112-121	false

however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
pyridoxine	65-74	HEXALEN	108-114	advise
pyridoxine	65-74	cisplatin	123-131	advise
HEXALEN	108-114	cisplatin	123-131	false

Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
amantadine	37-46	central nervous system stimulants	82-114	advise

Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.
ETHYOL	63-68	antihypertensive medications	92-119	advise

When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
amiloride	5-13	angiotensin-converting enzyme inhibitor	57-95	effect

Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
Lithium	0-6	diuretics	43-51	advise

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
non-steroidal anti-inflammatory agent	42-78	loop diuretics	150-153;187-195	effect
non-steroidal anti-inflammatory agent	42-78	potassium-sparing diuretics	156-172;187-195	effect
non-steroidal anti-inflammatory agent	42-78	thiazide diuretics	178-195	effect
loop diuretics	150-153;187-195	potassium-sparing diuretics	156-172;187-195	false
loop diuretics	150-153;187-195	thiazide diuretics	178-195	false
potassium-sparing diuretics	156-172;187-195	thiazide diuretics	178-195	false

Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
MIDAMOR	16-22	non-steroidal anti-inflammatory agents	28-65	advise
MIDAMOR	16-22	diuretic	172-179	false
non-steroidal anti-inflammatory agents	28-65	diuretic	172-179	false

Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
indomethacin	6-17	potassium-sparing diuretics	23-49	effect
indomethacin	6-17	MIDAMOR	62-68	effect
potassium-sparing diuretics	23-49	MIDAMOR	62-68	false

Cytadren accelerates the metabolism of dexamethasone;
Cytadren	0-7	dexamethasone	39-51	mechanism

therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.
glucocorticoid	14-27	hydrocortisone	52-65	false

Aminoglutethimide diminishes the effect of coumarin and warfarin.
Aminoglutethimide	0-16	coumarin	43-50	effect
Aminoglutethimide	0-16	warfarin	56-63	effect
coumarin	43-50	warfarin	56-63	false

Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
PAH	32-34	sulfonamides	103-114	effect
PAH	32-34	procaine	117-124	effect
PAH	32-34	thiazolesulfone	130-144	effect
sulfonamides	103-114	procaine	117-124	false
sulfonamides	103-114	thiazolesulfone	130-144	false
procaine	117-124	thiazolesulfone	130-144	false

Probenecid depresses tubular secretion of certain weak acids such as PAH.
Probenecid	0-9	PAH	69-71	mechanism

Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
probenecid	30-39	PAH	79-81	effect

It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
photosensitizing agents	61-83	griseofulvin	93-104	false
photosensitizing agents	61-83	thiazide diuretics	107-124	false
photosensitizing agents	61-83	sulfonylureas	127-139	false
photosensitizing agents	61-83	phenothiazines	142-155	false
photosensitizing agents	61-83	sulfonamides	158-169	false
photosensitizing agents	61-83	tetracyclines	175-187	false
photosensitizing agents	61-83	LEVULAN KERASTICK	272-288	effect
griseofulvin	93-104	thiazide diuretics	107-124	false
griseofulvin	93-104	sulfonylureas	127-139	false
griseofulvin	93-104	phenothiazines	142-155	false
griseofulvin	93-104	sulfonamides	158-169	false
griseofulvin	93-104	tetracyclines	175-187	false
griseofulvin	93-104	LEVULAN KERASTICK	272-288	effect
thiazide diuretics	107-124	sulfonylureas	127-139	false
thiazide diuretics	107-124	phenothiazines	142-155	false
thiazide diuretics	107-124	sulfonamides	158-169	false
thiazide diuretics	107-124	tetracyclines	175-187	false
thiazide diuretics	107-124	LEVULAN KERASTICK	272-288	effect
sulfonylureas	127-139	phenothiazines	142-155	false
sulfonylureas	127-139	sulfonamides	158-169	false
sulfonylureas	127-139	tetracyclines	175-187	false
sulfonylureas	127-139	LEVULAN KERASTICK	272-288	effect
phenothiazines	142-155	sulfonamides	158-169	false
phenothiazines	142-155	tetracyclines	175-187	false
phenothiazines	142-155	LEVULAN KERASTICK	272-288	effect
sulfonamides	158-169	tetracyclines	175-187	false
sulfonamides	158-169	LEVULAN KERASTICK	272-288	effect
tetracyclines	175-187	LEVULAN KERASTICK	272-288	effect

Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
Aminosalicylic acid	0-18	digoxin	47-53	mechanism
Aminosalicylic acid	0-18	Lanoxin	56-62	mechanism
Aminosalicylic acid	0-18	Lanoxicaps	65-74	false
digoxin	47-53	Lanoxin	56-62	false
digoxin	47-53	Lanoxicaps	65-74	false
Lanoxin	56-62	Lanoxicaps	65-74	false

In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
digoxin	32-38	aminosalicylic acid	53-71	advise
digoxin	32-38	digoxin	90-96	false
aminosalicylic acid	53-71	digoxin	90-96	false

Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
Aminosalicylic acid	0-18	vitamin B12	56-66	mechanism

Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
vitamin B12	33-43	aminosalicylic acid	69-87	advise

Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.
Amiodarone	0-9	desethylamiodarone	29-46	false

In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone.
amiodarone	46-55	amiodarone	192-201	false

Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.
amiodarone	6-15	amiodarone	166-175	false

Reported examples include the following: Protease Inhibitors: Protease inhibitors are known to inhibit CYP3A4 to varying degrees.
Protease Inhibitors	41-59	Protease inhibitors	62-80	false

A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
amiodarone	36-45	indinavir	58-66	mechanism
amiodarone	36-45	amiodarone	118-127	false
indinavir	58-66	amiodarone	118-127	false

Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
amiodarone	15-24	amiodarone	61-70	false
amiodarone	15-24	protease inhibitor	111-128	false
amiodarone	61-70	protease inhibitor	111-128	advise

Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
Histamine H2 antagonists	0-23	Cimetidine	26-35	mechanism
Histamine H2 antagonists	0-23	amiodarone	76-85	false
Cimetidine	26-35	amiodarone	76-85	false

Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone.
amiodarone	73-82	amiodarone	152-161	false

This information should be considered when changing from intravenous amiodarone to oral amiodarone .
amiodarone	69-78	amiodarone	88-97	false

Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.
Amiodarone	0-9	CYP1A2	58-63	false
Amiodarone	0-9	CYP2C9	66-71	false
Amiodarone	0-9	CYP2D6	74-79	false
Amiodarone	0-9	CYP3A4	86-91	false
CYP1A2	58-63	CYP2C9	66-71	false
CYP1A2	58-63	CYP2D6	74-79	false
CYP1A2	58-63	CYP3A4	86-91	false
CYP2C9	66-71	CYP2D6	74-79	false
CYP2C9	66-71	CYP3A4	86-91	false
CYP2D6	74-79	CYP3A4	86-91	false

Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
Immunosuppressive	61-77	Cyclosporine	81-92	false
Immunosuppressive	61-77	CYP3A4	95-100	false
Immunosuppressive	61-77	amiodarone	151-160	false
Immunosuppressive	61-77	cyclosporine	238-249	false
Immunosuppressive	61-77	cyclosporine	314-325	false
Cyclosporine	81-92	CYP3A4	95-100	false
Cyclosporine	81-92	amiodarone	151-160	false
Cyclosporine	81-92	cyclosporine	238-249	false
Cyclosporine	81-92	cyclosporine	314-325	false
CYP3A4	95-100	amiodarone	151-160	false
CYP3A4	95-100	cyclosporine	238-249	false
CYP3A4	95-100	cyclosporine	314-325	false
amiodarone	151-160	cyclosporine	238-249	false
amiodarone	151-160	cyclosporine	314-325	false
cyclosporine	238-249	cyclosporine	314-325	false

HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
HMG-CoA Reductase Inhibitors	0-27	Simvastatin	30-40	false
HMG-CoA Reductase Inhibitors	0-27	CYP3A4	43-48	false
HMG-CoA Reductase Inhibitors	0-27	amiodarone	81-90	false
Simvastatin	30-40	CYP3A4	43-48	false
Simvastatin	30-40	amiodarone	81-90	false
CYP3A4	43-48	amiodarone	81-90	false

Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.
Cardiac glycosides	17-34	digoxin	59-65	false
Cardiac glycosides	17-34	amiodarone	99-108	false
Cardiac glycosides	17-34	digoxin	152-158	false
digoxin	59-65	amiodarone	99-108	false
digoxin	59-65	digoxin	152-158	false
amiodarone	99-108	digoxin	152-158	false

Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.
Amiodarone	0-9	digoxin	36-42	false
Amiodarone	0-9	digoxin	64-70	false
digoxin	36-42	digoxin	64-70	false

On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
amiodarone	26-35	digitalis	51-59	advise

Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.
Antiarrhythmics	0-14	antiarrhythmic	23-36	false
Antiarrhythmics	0-14	quinidine	53-61	false
Antiarrhythmics	0-14	procainamide	64-75	false
Antiarrhythmics	0-14	disopyramide	78-89	false
Antiarrhythmics	0-14	phenytoin	96-104	false
Antiarrhythmics	0-14	amiodarone	140-149	false
antiarrhythmic	23-36	quinidine	53-61	false
antiarrhythmic	23-36	procainamide	64-75	false
antiarrhythmic	23-36	disopyramide	78-89	false
antiarrhythmic	23-36	phenytoin	96-104	false
antiarrhythmic	23-36	amiodarone	140-149	false
quinidine	53-61	procainamide	64-75	false
quinidine	53-61	disopyramide	78-89	false
quinidine	53-61	phenytoin	96-104	false
quinidine	53-61	amiodarone	140-149	false
procainamide	64-75	disopyramide	78-89	false
procainamide	64-75	phenytoin	96-104	false
procainamide	64-75	amiodarone	140-149	false
disopyramide	78-89	phenytoin	96-104	false
disopyramide	78-89	amiodarone	140-149	false
phenytoin	96-104	amiodarone	140-149	false

There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone.
quinidine	65-73	procainamide	76-87	false
quinidine	65-73	phenytoin	94-102	false
quinidine	65-73	amiodarone	136-145	false
procainamide	76-87	phenytoin	94-102	false
procainamide	76-87	amiodarone	136-145	false
phenytoin	94-102	amiodarone	136-145	false

Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.
Amiodarone	0-9	quinidine	36-44	false
Amiodarone	0-9	quinidine	56-64	false
quinidine	36-44	quinidine	56-64	false

Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.
Amiodarone	0-9	procainamide	36-47	false
Amiodarone	0-9	procainamide	109-120	false
Amiodarone	0-9	procainamide	135-146	false
procainamide	36-47	procainamide	109-120	false
procainamide	36-47	procainamide	135-146	false
procainamide	109-120	procainamide	135-146	false

Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone.
Quinidine	0-8	amiodarone	97-106	false

Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone;
flecainide	17-26	amiodarone	83-92	false

because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.
flecainide	31-40	drugs	72-76	false

Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.
amiodarone	15-24	antiarrhythmic	37-50	false
amiodarone	15-24	amiodarone	218-227	false
antiarrhythmic	37-50	amiodarone	218-227	false

During transfer to oral amiodarone, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone.
amiodarone	24-33	amiodarone	157-166	false

The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.
antiarrhythmic	33-46	amiodarone	94-103	false

In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.
amiodarone	3-12	antiarrhythmic	54-67	false

Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
Antihypertensives	0-16	Amiodarone	19-28	false
Antihypertensives	0-16	receptor	82-89	false
Antihypertensives	0-16	propranolol	114-124	false
Antihypertensives	0-16	CYP3A4	129-134	false
Antihypertensives	0-16	calcium channel	150-164	false
Antihypertensives	0-16	verapamil	185-193	false
Antihypertensives	0-16	CYP3A4	198-203	false
Antihypertensives	0-16	diltiazem	220-228	false
Antihypertensives	0-16	CYP3A4	233-238	false
Amiodarone	19-28	receptor	82-89	false
Amiodarone	19-28	propranolol	114-124	false
Amiodarone	19-28	CYP3A4	129-134	false
Amiodarone	19-28	calcium channel	150-164	false
Amiodarone	19-28	verapamil	185-193	false
Amiodarone	19-28	CYP3A4	198-203	false
Amiodarone	19-28	diltiazem	220-228	false
Amiodarone	19-28	CYP3A4	233-238	false
receptor	82-89	propranolol	114-124	false
receptor	82-89	CYP3A4	129-134	false
receptor	82-89	calcium channel	150-164	false
receptor	82-89	verapamil	185-193	false
receptor	82-89	CYP3A4	198-203	false
receptor	82-89	diltiazem	220-228	false
receptor	82-89	CYP3A4	233-238	false
propranolol	114-124	CYP3A4	129-134	false
propranolol	114-124	calcium channel	150-164	false
propranolol	114-124	verapamil	185-193	false
propranolol	114-124	CYP3A4	198-203	false
propranolol	114-124	diltiazem	220-228	false
propranolol	114-124	CYP3A4	233-238	false
CYP3A4	129-134	calcium channel	150-164	false
CYP3A4	129-134	verapamil	185-193	false
CYP3A4	129-134	CYP3A4	198-203	false
CYP3A4	129-134	diltiazem	220-228	false
CYP3A4	129-134	CYP3A4	233-238	false
calcium channel	150-164	verapamil	185-193	false
calcium channel	150-164	CYP3A4	198-203	false
calcium channel	150-164	diltiazem	220-228	false
calcium channel	150-164	CYP3A4	233-238	false
verapamil	185-193	CYP3A4	198-203	false
verapamil	185-193	diltiazem	220-228	false
verapamil	185-193	CYP3A4	233-238	false
CYP3A4	198-203	diltiazem	220-228	false
CYP3A4	198-203	CYP3A4	233-238	false
diltiazem	220-228	CYP3A4	233-238	false

Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
Anticoagulants	0-13	warfarin	32-39	false
Anticoagulants	0-13	CYP2C9	47-52	false
Anticoagulants	0-13	CYP3A4	58-63	false
Anticoagulants	0-13	anticoagulant	76-88	false
Anticoagulants	0-13	amiodarone	143-152	false
warfarin	32-39	CYP2C9	47-52	false
warfarin	32-39	CYP3A4	58-63	false
warfarin	32-39	anticoagulant	76-88	false
warfarin	32-39	amiodarone	143-152	false
CYP2C9	47-52	CYP3A4	58-63	false
CYP2C9	47-52	anticoagulant	76-88	false
CYP2C9	47-52	amiodarone	143-152	false
CYP3A4	58-63	anticoagulant	76-88	false
CYP3A4	58-63	amiodarone	143-152	false
anticoagulant	76-88	amiodarone	143-152	false

Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
warfarin	40-47	amiodarone	54-63	false
warfarin	40-47	anticoagulant	139-151	false
amiodarone	54-63	anticoagulant	139-151	false

Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
drugs	5-9	amiodarone	64-73	false
drugs	5-9	CYP3A4	107-112	false
amiodarone	64-73	CYP3A4	107-112	false

Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.
Antibiotics	61-71	Rifampin	74-81	false
Antibiotics	61-71	CYP3A4	106-111	false
Rifampin	74-81	CYP3A4	106-111	false

Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.
rifampin	18-25	amiodarone	51-60	false
rifampin	18-25	amiodarone	127-136	false
rifampin	18-25	desethylamiodarone	142-159	false
amiodarone	51-60	amiodarone	127-136	false
amiodarone	51-60	desethylamiodarone	142-159	false
amiodarone	127-136	desethylamiodarone	142-159	false

Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.
amiodarone	6-15	CYP3A4	36-41	false
amiodarone	6-15	amiodarone	121-130	false
amiodarone	6-15	amiodarone	156-165	false
CYP3A4	36-41	amiodarone	121-130	false
CYP3A4	36-41	amiodarone	156-165	false
amiodarone	121-130	amiodarone	156-165	false

Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.
amiodarone	33-42	Fentanyl	45-52	false
amiodarone	33-42	CYP3A4	55-60	false
amiodarone	33-42	amiodarone	93-102	false
Fentanyl	45-52	CYP3A4	55-60	false
Fentanyl	45-52	amiodarone	93-102	false
CYP3A4	55-60	amiodarone	93-102	false

Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.
amiodarone	46-55	lidocaine	77-85	false
amiodarone	46-55	CYP3A4	88-93	false
amiodarone	46-55	anesthesia	122-131	false
lidocaine	77-85	CYP3A4	88-93	false
lidocaine	77-85	anesthesia	122-131	false
CYP3A4	88-93	anesthesia	122-131	false

Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.
lidocaine	35-43	amiodarone	126-135	false

Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.
Dextromethorphan	0-15	CYP2D6	41-46	false
Dextromethorphan	0-15	CYP3A4	52-57	false
CYP2D6	41-46	CYP3A4	52-57	false

Amiodarone inhibits CYP2D6.
Amiodarone	0-9	CYP2D6	20-25	false

Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.
Cholestyramine	0-13	amiodarone	54-63	false
Cholestyramine	0-13	t1	101-102	false
amiodarone	54-63	t1	101-102	false

Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation.
Fluoroquinolones	0-15	macrolide antibiotics	18-38	false

There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.
amiodarone	85-94	fluoroquinolones	101-116	false
amiodarone	85-94	macrolide antibiotics	119-139	false
fluoroquinolones	101-116	macrolide antibiotics	119-139	false

Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, diltiazem, and verapamil.
propranolol	110-120	diltiazem	123-131	false
propranolol	110-120	verapamil	138-146	false
diltiazem	123-131	verapamil	138-146	false

In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.
Cordarone	70-78	phenytoin	117-125	false
Cordarone	70-78	dextromethorphan	128-143	false
Cordarone	70-78	methotrexate	150-161	false
phenytoin	117-125	dextromethorphan	128-143	false
phenytoin	117-125	methotrexate	150-161	false
dextromethorphan	128-143	methotrexate	150-161	false

Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	69-93	TCAs	96-99	false

cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	0-9	antidepressants	66-80	false
cimetidine	0-9	phenothiazines	83-96	false
cimetidine	0-9	Type 1C antiarrhythmics	107-129	false
cimetidine	0-9	propafenone	131-141	false
cimetidine	0-9	flecainide	147-156	false
antidepressants	66-80	phenothiazines	83-96	false
antidepressants	66-80	Type 1C antiarrhythmics	107-129	false
antidepressants	66-80	propafenone	131-141	false
antidepressants	66-80	flecainide	147-156	false
phenothiazines	83-96	Type 1C antiarrhythmics	107-129	false
phenothiazines	83-96	propafenone	131-141	false
phenothiazines	83-96	flecainide	147-156	false
Type 1C antiarrhythmics	107-129	propafenone	131-141	false
Type 1C antiarrhythmics	107-129	flecainide	147-156	false
propafenone	131-141	flecainide	147-156	false

While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
serotonin reuptake inhibitors	24-52	SSRIs	55-59	false
serotonin reuptake inhibitors	24-52	fluoxetine	69-78	false
serotonin reuptake inhibitors	24-52	sertraline	81-90	false
serotonin reuptake inhibitors	24-52	paroxetine	97-106	false
SSRIs	55-59	fluoxetine	69-78	false
SSRIs	55-59	sertraline	81-90	false
SSRIs	55-59	paroxetine	97-106	false
fluoxetine	69-78	sertraline	81-90	false
fluoxetine	69-78	paroxetine	97-106	false
sertraline	81-90	paroxetine	97-106	false

The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
SSRI	20-23	TCA	25-27	effect
SSRI	20-23	SSRI	141-144	false
TCA	25-27	SSRI	141-144	false

Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
TCAs	62-65	SSRIs	83-87	advise

Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	19-43	tricyclic antidepressant	156-179	false

It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.
TCA	27-29	TCA	56-58	false

Monoamine Oxidase Inhibitors: Guanethidine or similarly acting compounds;
Monoamine Oxidase Inhibitors	0-27	Guanethidine	30-41	false

alcohol, barbiturates and other CNS depressants;
alcohol	0-6	barbiturates	9-20	false
alcohol	0-6	CNS depressants	32-46	false
barbiturates	9-20	CNS depressants	32-46	false

and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
disulfiram	4-13	amitriptyline HCl	20-36	false
disulfiram	4-13	anticholinergic	52-66	false
disulfiram	4-13	sympathomimetic	78-92	false
disulfiram	4-13	epinephrine	111-121	false
disulfiram	4-13	anesthetics	143-153	false
amitriptyline HCl	20-36	anticholinergic	52-66	false
amitriptyline HCl	20-36	sympathomimetic	78-92	false
amitriptyline HCl	20-36	epinephrine	111-121	false
amitriptyline HCl	20-36	anesthetics	143-153	false
anticholinergic	52-66	sympathomimetic	78-92	false
anticholinergic	52-66	epinephrine	111-121	false
anticholinergic	52-66	anesthetics	143-153	false
sympathomimetic	78-92	epinephrine	111-121	false
sympathomimetic	78-92	anesthetics	143-153	false
epinephrine	111-121	anesthetics	143-153	false

Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
amitriptyline HCl	36-52	anticholinergic	75-89	effect
amitriptyline HCl	36-52	neuroleptic	106-116	false
anticholinergic	75-89	neuroleptic	106-116	false

Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
tricyclic antidepressants	45-69	anticholinergic	91-105	effect

Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
Cimetidine	0-9	tricyclic antidepressants	63-87	mechanism
Cimetidine	0-9	drugs	171-175	false
tricyclic antidepressants	63-87	drugs	171-175	false

Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
tricyclic antidepressants	59-83	cimetidine	114-123	effect

Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
tricyclic antidepressants	30-54	anticholinergic	121-135	false
tricyclic antidepressants	30-54	cimetidine	162-171	mechanism
tricyclic antidepressants	30-54	drug	190-193	false
anticholinergic	121-135	cimetidine	162-171	false
anticholinergic	121-135	drug	190-193	false
cimetidine	162-171	drug	190-193	false

Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
cimetidine	19-28	tricyclic antidepressants	68-92	false
cimetidine	19-28	cimetidine	98-107	false
cimetidine	19-28	antidepressants	160-174	false
tricyclic antidepressants	68-92	cimetidine	98-107	mechanism
tricyclic antidepressants	68-92	antidepressants	160-174	false
cimetidine	98-107	antidepressants	160-174	false

Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
ethchlorvynol	83-95	amitriptyline HCl	116-132	effect

When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
amphotericin B	70-83	Antineoplastic agents	86-106	effect

Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.
Antineoplastic agents	0-20	nitrogen mustard	30-45	false

Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
Corticosteroids	0-14	Corticotropin	20-32	false
Corticosteroids	0-14	ACTH	35-38	false
Corticosteroids	0-14	amphotericin B	57-70	effect
Corticotropin	20-32	ACTH	35-38	false
Corticotropin	20-32	amphotericin B	57-70	effect
ACTH	35-38	amphotericin B	57-70	effect

Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
Digitalis glycosides	0-19	amphotericin B	22-35	false
Digitalis glycosides	0-19	digitalis	72-80	false
amphotericin B	22-35	digitalis	72-80	effect

Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
Flucytosine	0-10	amphotericin B	51-64	false
Flucytosine	0-10	flucytosine	130-140	false
amphotericin B	51-64	flucytosine	130-140	effect

Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
Imidazoles	0-9	ketoconazole	19-30	false
Imidazoles	0-9	miconazole	33-42	false
Imidazoles	0-9	clotrimazole	45-56	false
Imidazoles	0-9	fluconazole	59-69	false
Imidazoles	0-9	amphotericin B	131-144	false
Imidazoles	0-9	imidazoles	150-159	false
Imidazoles	0-9	imidazoles	174-183	false
Imidazoles	0-9	amphotericin B	217-230	false
ketoconazole	19-30	miconazole	33-42	false
ketoconazole	19-30	clotrimazole	45-56	false
ketoconazole	19-30	fluconazole	59-69	false
ketoconazole	19-30	amphotericin B	131-144	false
ketoconazole	19-30	imidazoles	150-159	false
ketoconazole	19-30	imidazoles	174-183	false
ketoconazole	19-30	amphotericin B	217-230	false
miconazole	33-42	clotrimazole	45-56	false
miconazole	33-42	fluconazole	59-69	false
miconazole	33-42	amphotericin B	131-144	false
miconazole	33-42	imidazoles	150-159	false
miconazole	33-42	imidazoles	174-183	false
miconazole	33-42	amphotericin B	217-230	false
clotrimazole	45-56	fluconazole	59-69	false
clotrimazole	45-56	amphotericin B	131-144	false
clotrimazole	45-56	imidazoles	150-159	false
clotrimazole	45-56	imidazoles	174-183	false
clotrimazole	45-56	amphotericin B	217-230	false
fluconazole	59-69	amphotericin B	131-144	false
fluconazole	59-69	imidazoles	150-159	false
fluconazole	59-69	imidazoles	174-183	false
fluconazole	59-69	amphotericin B	217-230	false
amphotericin B	131-144	imidazoles	150-159	false
amphotericin B	131-144	imidazoles	174-183	false
amphotericin B	131-144	amphotericin B	217-230	false
imidazoles	150-159	imidazoles	174-183	false
imidazoles	150-159	amphotericin B	217-230	false
imidazoles	174-183	amphotericin B	217-230	effect

Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
aminoglycosides	46-60	cyclosporine	63-74	false
aminoglycosides	46-60	pentamidine	81-91	false
cyclosporine	63-74	pentamidine	81-91	false

Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
Skeletal muscle relaxants	0-24	amphotericin B	27-40	false
Skeletal muscle relaxants	0-24	skeletal muscle relaxants	99-123	false
Skeletal muscle relaxants	0-24	tubocurarine	132-143	false
amphotericin B	27-40	skeletal muscle relaxants	99-123	effect
amphotericin B	27-40	tubocurarine	132-143	effect
skeletal muscle relaxants	99-123	tubocurarine	132-143	false

Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
Leukocyte transfusions	0-21	amphotericin B	101-114	false
Leukocyte transfusions	0-21	leukocyte transfusions	120-141	false
amphotericin B	101-114	leukocyte transfusions	120-141	effect

Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
Bacteriostatic Antibiotics	0-25	Chloramphenicol	28-42	false
Bacteriostatic Antibiotics	0-25	erythromycins	45-57	false
Bacteriostatic Antibiotics	0-25	sulfonamides	60-71	false
Bacteriostatic Antibiotics	0-25	tetracyclines	77-89	false
Bacteriostatic Antibiotics	0-25	penicillins	137-147	false
Chloramphenicol	28-42	erythromycins	45-57	false
Chloramphenicol	28-42	sulfonamides	60-71	false
Chloramphenicol	28-42	tetracyclines	77-89	false
Chloramphenicol	28-42	penicillins	137-147	effect
erythromycins	45-57	sulfonamides	60-71	false
erythromycins	45-57	tetracyclines	77-89	false
erythromycins	45-57	penicillins	137-147	effect
sulfonamides	60-71	tetracyclines	77-89	false
sulfonamides	60-71	penicillins	137-147	effect
tetracyclines	77-89	penicillins	137-147	effect

Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
Probenecid	0-9	ampicillin	52-61	mechanism
Probenecid	0-9	ampicillin	106-115	false
ampicillin	52-61	ampicillin	106-115	false

Drug/Laboratory Test Interaction After treatment with ampicillin, a false-positive reaction for glucose in the urine may occur with copper sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.
ampicillin	54-63	copper sulfate	132-145	false

HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.
HIV Protease Inhibitors	0-22	amprenavir	39-48	false
HIV Protease Inhibitors	0-22	HIV protease inhibitors	88-110	false
amprenavir	39-48	HIV protease inhibitors	88-110	false

Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
Indinavir	0-8	amprenavir	109-118	mechanism

Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
Saquinavir	0-9	amprenavir	127-136	mechanism

Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
Nelfinavir	0-9	amprenavir	110-119	mechanism

Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
Methadone	0-8	amprenavir	31-40	false
Methadone	0-8	methadone	46-54	false
Methadone	0-8	methadone	86-94	false
amprenavir	31-40	methadone	46-54	effect
amprenavir	31-40	methadone	86-94	false
methadone	46-54	methadone	86-94	false

Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
amprenavir	20-29	methadone	35-43	mechanism
amprenavir	20-29	amprenavir	148-157	false
methadone	35-43	amprenavir	148-157	false

Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
Amprenavir	37-46	ritonavir	61-69	effect

Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
Amprenavir	97-106	ritonavir	112-120	advise

For comprehensive information concerning laboratory test alterations associated with ritonavir, physicians should refer to the complete prescribing information for NORVIR (ritonavir).
ritonavir	85-93	NORVIR	164-169	false
ritonavir	85-93	ritonavir	172-180	false
NORVIR	164-169	ritonavir	172-180	false

Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
amyl nitrite	7-18	alcohol	35-41	effect

In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin.
digoxin	61-67	warfarin	73-80	false
digoxin	61-67	anagrelide	117-126	false
digoxin	61-67	anagrelide	138-147	false
digoxin	61-67	digoxin	177-183	false
digoxin	61-67	warfarin	188-195	false
warfarin	73-80	anagrelide	117-126	false
warfarin	73-80	anagrelide	138-147	false
warfarin	73-80	digoxin	177-183	false
warfarin	73-80	warfarin	188-195	false
anagrelide	117-126	anagrelide	138-147	false
anagrelide	117-126	digoxin	177-183	false
anagrelide	117-126	warfarin	188-195	false
anagrelide	138-147	digoxin	177-183	false
anagrelide	138-147	warfarin	188-195	false
digoxin	177-183	warfarin	188-195	false

Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
anagrelide	122-131	aspirin	157-163	false
anagrelide	122-131	acetaminophen	166-178	false
anagrelide	122-131	furosemide	181-190	false
anagrelide	122-131	iron	193-196	false
anagrelide	122-131	ranitidine	199-208	false
anagrelide	122-131	hydroxyurea	211-221	false
anagrelide	122-131	allopurinol	228-238	false
aspirin	157-163	acetaminophen	166-178	false
aspirin	157-163	furosemide	181-190	false
aspirin	157-163	iron	193-196	false
aspirin	157-163	ranitidine	199-208	false
aspirin	157-163	hydroxyurea	211-221	false
aspirin	157-163	allopurinol	228-238	false
acetaminophen	166-178	furosemide	181-190	false
acetaminophen	166-178	iron	193-196	false
acetaminophen	166-178	ranitidine	199-208	false
acetaminophen	166-178	hydroxyurea	211-221	false
acetaminophen	166-178	allopurinol	228-238	false
furosemide	181-190	iron	193-196	false
furosemide	181-190	ranitidine	199-208	false
furosemide	181-190	hydroxyurea	211-221	false
furosemide	181-190	allopurinol	228-238	false
iron	193-196	ranitidine	199-208	false
iron	193-196	hydroxyurea	211-221	false
iron	193-196	allopurinol	228-238	false
ranitidine	199-208	hydroxyurea	211-221	false
ranitidine	199-208	allopurinol	228-238	false
hydroxyurea	211-221	allopurinol	228-238	false

An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated.
anagrelide	78-87	aspirin	145-151	false

No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed.
anagrelide	60-69	acetylsalicylic acid	75-94	false

Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
Anagrelide	0-9	aspirin	123-129	effect

It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
fluvoxamine	78-88	anagrelide	176-185	mechanism

Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
Anagrelide	0-9	theophylline	213-224	mechanism

The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
milrinone	76-84	enoximone	87-95	false
milrinone	76-84	amrinone	98-105	false
milrinone	76-84	olprinone	108-116	false
milrinone	76-84	cilostazol	122-131	false
milrinone	76-84	anagrelide	155-164	effect
enoximone	87-95	amrinone	98-105	false
enoximone	87-95	olprinone	108-116	false
enoximone	87-95	cilostazol	122-131	false
enoximone	87-95	anagrelide	155-164	effect
amrinone	98-105	olprinone	108-116	false
amrinone	98-105	cilostazol	122-131	false
amrinone	98-105	anagrelide	155-164	effect
olprinone	108-116	cilostazol	122-131	false
olprinone	108-116	anagrelide	155-164	effect
cilostazol	122-131	anagrelide	155-164	effect

There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
sucralfate	51-60	anagrelide	81-90	mechanism

Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
methotrexate	132-143	Kineret	148-154	false

In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
Kineret	92-98	etanercept	104-113	effect
Kineret	92-98	etanercept	211-220	false
etanercept	104-113	etanercept	211-220	false

Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).
Kineret	50-56	etanercept	62-71	effect

Anastrozole did not alter the pharmacokinetics of antipyrine.
Anastrozole	0-10	antipyrine	50-59	false

Although there have been no formal interaction studies other than with antipyrine, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.
antipyrine	71-80	ARIMIDEX	184-191	false

An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.
warfarin	26-33	anastrozole	78-88	false
warfarin	26-33	warfarin	93-100	false
anastrozole	78-88	warfarin	93-100	false

At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.
ARIMIDEX	55-62	tamoxifen	68-76	false
ARIMIDEX	55-62	tamoxifen	138-146	false
tamoxifen	68-76	tamoxifen	138-146	false

Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
tamoxifen	67-75	anastrozole	109-119	advise

Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
anastrozole	21-31	tamoxifen	37-45	mechanism
anastrozole	21-31	anastrozole	74-84	false
anastrozole	21-31	anastrozole	141-151	false
tamoxifen	37-45	anastrozole	74-84	false
tamoxifen	37-45	anastrozole	141-151	false
anastrozole	74-84	anastrozole	141-151	false

Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
Estrogen	0-7	ARIMIDEX	54-61	advise

Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
anileridine	32-42	opioids	73-79	advise
anileridine	32-42	sedatives	82-90	advise
anileridine	32-42	phenothiazines	93-106	advise
anileridine	32-42	anesthetics	112-122	advise
opioids	73-79	sedatives	82-90	false
opioids	73-79	phenothiazines	93-106	false
opioids	73-79	anesthetics	112-122	false
sedatives	82-90	phenothiazines	93-106	false
sedatives	82-90	anesthetics	112-122	false
phenothiazines	93-106	anesthetics	112-122	false

Addition or deletion of any drug from the therapeutic regimen of patients receiving oral anticoagulants may affect patient response to the anticoagulant.
anticoagulants	89-102	anticoagulant	139-151	false

For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
cholestyramine	19-32	anticoagulants	94-107	mechanism
cholestyramine	19-32	vitamin K	113-121	mechanism
anticoagulants	94-107	vitamin K	113-121	false

Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
Chloral hydrate	0-14	anticoagulant	78-90	mechanism

Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
anticoagulant	47-59	adrenocortical steroids	143-165	effect

Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
anticoagulant	47-59	adrenocortical steroids	143-165	effect
anticoagulant	47-59	alcohol	167-173	effect
anticoagulant	47-59	antacids	176-183	effect
anticoagulant	47-59	antihistamines	185-198	effect
anticoagulant	47-59	barbiturates	200-211	effect
anticoagulant	47-59	carbamazepine	213-225	effect
anticoagulant	47-59	chloral hydrate	227-241	effect
anticoagulant	47-59	chlordiazepoxide	244-259	effect
anticoagulant	47-59	cholestyramine	261-274	effect
anticoagulant	47-59	vitamin K	289-297	effect
anticoagulant	47-59	diuretics	299-307	effect
anticoagulant	47-59	ethchlorvynol	310-322	effect
anticoagulant	47-59	glutethimide	324-335	effect
anticoagulant	47-59	griseofulvin	337-348	effect
anticoagulant	47-59	haloperidol	350-360	effect
anticoagulant	47-59	meprobamate	362-372	effect
anticoagulant	47-59	contraceptives	379-392	effect
anticoagulant	47-59	paraldehyde	394-404	effect
anticoagulant	47-59	primidone	406-414	effect
anticoagulant	47-59	ranitidine	416-425	effect
anticoagulant	47-59	rifampin	428-435	effect
anticoagulant	47-59	vitamin C	480-488	effect
anticoagulant	47-59	warfarin sodium	490-504	effect
adrenocortical steroids	143-165	alcohol	167-173	false
adrenocortical steroids	143-165	antacids	176-183	false
adrenocortical steroids	143-165	antihistamines	185-198	false
adrenocortical steroids	143-165	barbiturates	200-211	false
adrenocortical steroids	143-165	carbamazepine	213-225	false
adrenocortical steroids	143-165	chloral hydrate	227-241	false
adrenocortical steroids	143-165	chlordiazepoxide	244-259	false
adrenocortical steroids	143-165	cholestyramine	261-274	false
adrenocortical steroids	143-165	vitamin K	289-297	false
adrenocortical steroids	143-165	diuretics	299-307	false
adrenocortical steroids	143-165	ethchlorvynol	310-322	false
adrenocortical steroids	143-165	glutethimide	324-335	false
adrenocortical steroids	143-165	griseofulvin	337-348	false
adrenocortical steroids	143-165	haloperidol	350-360	false
adrenocortical steroids	143-165	meprobamate	362-372	false
adrenocortical steroids	143-165	contraceptives	379-392	false
adrenocortical steroids	143-165	paraldehyde	394-404	false
adrenocortical steroids	143-165	primidone	406-414	false
adrenocortical steroids	143-165	ranitidine	416-425	false
adrenocortical steroids	143-165	rifampin	428-435	false
adrenocortical steroids	143-165	vitamin C	480-488	false
adrenocortical steroids	143-165	warfarin sodium	490-504	false
alcohol	167-173	antacids	176-183	false
alcohol	167-173	antihistamines	185-198	false
alcohol	167-173	barbiturates	200-211	false
alcohol	167-173	carbamazepine	213-225	false
alcohol	167-173	chloral hydrate	227-241	false
alcohol	167-173	chlordiazepoxide	244-259	false
alcohol	167-173	cholestyramine	261-274	false
alcohol	167-173	vitamin K	289-297	false
alcohol	167-173	diuretics	299-307	false
alcohol	167-173	ethchlorvynol	310-322	false
alcohol	167-173	glutethimide	324-335	false
alcohol	167-173	griseofulvin	337-348	false
alcohol	167-173	haloperidol	350-360	false
alcohol	167-173	meprobamate	362-372	false
alcohol	167-173	contraceptives	379-392	false
alcohol	167-173	paraldehyde	394-404	false
alcohol	167-173	primidone	406-414	false
alcohol	167-173	ranitidine	416-425	false
alcohol	167-173	rifampin	428-435	false
alcohol	167-173	vitamin C	480-488	false
alcohol	167-173	warfarin sodium	490-504	false
antacids	176-183	antihistamines	185-198	false
antacids	176-183	barbiturates	200-211	false
antacids	176-183	carbamazepine	213-225	false
antacids	176-183	chloral hydrate	227-241	false
antacids	176-183	chlordiazepoxide	244-259	false
antacids	176-183	cholestyramine	261-274	false
antacids	176-183	vitamin K	289-297	false
antacids	176-183	diuretics	299-307	false
antacids	176-183	ethchlorvynol	310-322	false
antacids	176-183	glutethimide	324-335	false
antacids	176-183	griseofulvin	337-348	false
antacids	176-183	haloperidol	350-360	false
antacids	176-183	meprobamate	362-372	false
antacids	176-183	contraceptives	379-392	false
antacids	176-183	paraldehyde	394-404	false
antacids	176-183	primidone	406-414	false
antacids	176-183	ranitidine	416-425	false
antacids	176-183	rifampin	428-435	false
antacids	176-183	vitamin C	480-488	false
antacids	176-183	warfarin sodium	490-504	false
antihistamines	185-198	barbiturates	200-211	false
antihistamines	185-198	carbamazepine	213-225	false
antihistamines	185-198	chloral hydrate	227-241	false
antihistamines	185-198	chlordiazepoxide	244-259	false
antihistamines	185-198	cholestyramine	261-274	false
antihistamines	185-198	vitamin K	289-297	false
antihistamines	185-198	diuretics	299-307	false
antihistamines	185-198	ethchlorvynol	310-322	false
antihistamines	185-198	glutethimide	324-335	false
antihistamines	185-198	griseofulvin	337-348	false
antihistamines	185-198	haloperidol	350-360	false
antihistamines	185-198	meprobamate	362-372	false
antihistamines	185-198	contraceptives	379-392	false
antihistamines	185-198	paraldehyde	394-404	false
antihistamines	185-198	primidone	406-414	false
antihistamines	185-198	ranitidine	416-425	false
antihistamines	185-198	rifampin	428-435	false
antihistamines	185-198	vitamin C	480-488	false
antihistamines	185-198	warfarin sodium	490-504	false
barbiturates	200-211	carbamazepine	213-225	false
barbiturates	200-211	chloral hydrate	227-241	false
barbiturates	200-211	chlordiazepoxide	244-259	false
barbiturates	200-211	cholestyramine	261-274	false
barbiturates	200-211	vitamin K	289-297	false
barbiturates	200-211	diuretics	299-307	false
barbiturates	200-211	ethchlorvynol	310-322	false
barbiturates	200-211	glutethimide	324-335	false
barbiturates	200-211	griseofulvin	337-348	false
barbiturates	200-211	haloperidol	350-360	false
barbiturates	200-211	meprobamate	362-372	false
barbiturates	200-211	contraceptives	379-392	false
barbiturates	200-211	paraldehyde	394-404	false
barbiturates	200-211	primidone	406-414	false
barbiturates	200-211	ranitidine	416-425	false
barbiturates	200-211	rifampin	428-435	false
barbiturates	200-211	vitamin C	480-488	false
barbiturates	200-211	warfarin sodium	490-504	false
carbamazepine	213-225	chloral hydrate	227-241	false
carbamazepine	213-225	chlordiazepoxide	244-259	false
carbamazepine	213-225	cholestyramine	261-274	false
carbamazepine	213-225	vitamin K	289-297	false
carbamazepine	213-225	diuretics	299-307	false
carbamazepine	213-225	ethchlorvynol	310-322	false
carbamazepine	213-225	glutethimide	324-335	false
carbamazepine	213-225	griseofulvin	337-348	false
carbamazepine	213-225	haloperidol	350-360	false
carbamazepine	213-225	meprobamate	362-372	false
carbamazepine	213-225	contraceptives	379-392	false
carbamazepine	213-225	paraldehyde	394-404	false
carbamazepine	213-225	primidone	406-414	false
carbamazepine	213-225	ranitidine	416-425	false
carbamazepine	213-225	rifampin	428-435	false
carbamazepine	213-225	vitamin C	480-488	false
carbamazepine	213-225	warfarin sodium	490-504	false
chloral hydrate	227-241	chlordiazepoxide	244-259	false
chloral hydrate	227-241	cholestyramine	261-274	false
chloral hydrate	227-241	vitamin K	289-297	false
chloral hydrate	227-241	diuretics	299-307	false
chloral hydrate	227-241	ethchlorvynol	310-322	false
chloral hydrate	227-241	glutethimide	324-335	false
chloral hydrate	227-241	griseofulvin	337-348	false
chloral hydrate	227-241	haloperidol	350-360	false
chloral hydrate	227-241	meprobamate	362-372	false
chloral hydrate	227-241	contraceptives	379-392	false
chloral hydrate	227-241	paraldehyde	394-404	false
chloral hydrate	227-241	primidone	406-414	false
chloral hydrate	227-241	ranitidine	416-425	false
chloral hydrate	227-241	rifampin	428-435	false
chloral hydrate	227-241	vitamin C	480-488	false
chloral hydrate	227-241	warfarin sodium	490-504	false
chlordiazepoxide	244-259	cholestyramine	261-274	false
chlordiazepoxide	244-259	vitamin K	289-297	false
chlordiazepoxide	244-259	diuretics	299-307	false
chlordiazepoxide	244-259	ethchlorvynol	310-322	false
chlordiazepoxide	244-259	glutethimide	324-335	false
chlordiazepoxide	244-259	griseofulvin	337-348	false
chlordiazepoxide	244-259	haloperidol	350-360	false
chlordiazepoxide	244-259	meprobamate	362-372	false
chlordiazepoxide	244-259	contraceptives	379-392	false
chlordiazepoxide	244-259	paraldehyde	394-404	false
chlordiazepoxide	244-259	primidone	406-414	false
chlordiazepoxide	244-259	ranitidine	416-425	false
chlordiazepoxide	244-259	rifampin	428-435	false
chlordiazepoxide	244-259	vitamin C	480-488	false
chlordiazepoxide	244-259	warfarin sodium	490-504	false
cholestyramine	261-274	vitamin K	289-297	false
cholestyramine	261-274	diuretics	299-307	false
cholestyramine	261-274	ethchlorvynol	310-322	false
cholestyramine	261-274	glutethimide	324-335	false
cholestyramine	261-274	griseofulvin	337-348	false
cholestyramine	261-274	haloperidol	350-360	false
cholestyramine	261-274	meprobamate	362-372	false
cholestyramine	261-274	contraceptives	379-392	false
cholestyramine	261-274	paraldehyde	394-404	false
cholestyramine	261-274	primidone	406-414	false
cholestyramine	261-274	ranitidine	416-425	false
cholestyramine	261-274	rifampin	428-435	false
cholestyramine	261-274	vitamin C	480-488	false
cholestyramine	261-274	warfarin sodium	490-504	false
vitamin K	289-297	diuretics	299-307	false
vitamin K	289-297	ethchlorvynol	310-322	false
vitamin K	289-297	glutethimide	324-335	false
vitamin K	289-297	griseofulvin	337-348	false
vitamin K	289-297	haloperidol	350-360	false
vitamin K	289-297	meprobamate	362-372	false
vitamin K	289-297	contraceptives	379-392	false
vitamin K	289-297	paraldehyde	394-404	false
vitamin K	289-297	primidone	406-414	false
vitamin K	289-297	ranitidine	416-425	false
vitamin K	289-297	rifampin	428-435	false
vitamin K	289-297	vitamin C	480-488	false
vitamin K	289-297	warfarin sodium	490-504	false
diuretics	299-307	ethchlorvynol	310-322	false
diuretics	299-307	glutethimide	324-335	false
diuretics	299-307	griseofulvin	337-348	false
diuretics	299-307	haloperidol	350-360	false
diuretics	299-307	meprobamate	362-372	false
diuretics	299-307	contraceptives	379-392	false
diuretics	299-307	paraldehyde	394-404	false
diuretics	299-307	primidone	406-414	false
diuretics	299-307	ranitidine	416-425	false
diuretics	299-307	rifampin	428-435	false
diuretics	299-307	vitamin C	480-488	false
diuretics	299-307	warfarin sodium	490-504	false
ethchlorvynol	310-322	glutethimide	324-335	false
ethchlorvynol	310-322	griseofulvin	337-348	false
ethchlorvynol	310-322	haloperidol	350-360	false
ethchlorvynol	310-322	meprobamate	362-372	false
ethchlorvynol	310-322	contraceptives	379-392	false
ethchlorvynol	310-322	paraldehyde	394-404	false
ethchlorvynol	310-322	primidone	406-414	false
ethchlorvynol	310-322	ranitidine	416-425	false
ethchlorvynol	310-322	rifampin	428-435	false
ethchlorvynol	310-322	vitamin C	480-488	false
ethchlorvynol	310-322	warfarin sodium	490-504	false
glutethimide	324-335	griseofulvin	337-348	false
glutethimide	324-335	haloperidol	350-360	false
glutethimide	324-335	meprobamate	362-372	false
glutethimide	324-335	contraceptives	379-392	false
glutethimide	324-335	paraldehyde	394-404	false
glutethimide	324-335	primidone	406-414	false
glutethimide	324-335	ranitidine	416-425	false
glutethimide	324-335	rifampin	428-435	false
glutethimide	324-335	vitamin C	480-488	false
glutethimide	324-335	warfarin sodium	490-504	false
griseofulvin	337-348	haloperidol	350-360	false
griseofulvin	337-348	meprobamate	362-372	false
griseofulvin	337-348	contraceptives	379-392	false
griseofulvin	337-348	paraldehyde	394-404	false
griseofulvin	337-348	primidone	406-414	false
griseofulvin	337-348	ranitidine	416-425	false
griseofulvin	337-348	rifampin	428-435	false
griseofulvin	337-348	vitamin C	480-488	false
griseofulvin	337-348	warfarin sodium	490-504	false
haloperidol	350-360	meprobamate	362-372	false
haloperidol	350-360	contraceptives	379-392	false
haloperidol	350-360	paraldehyde	394-404	false
haloperidol	350-360	primidone	406-414	false
haloperidol	350-360	ranitidine	416-425	false
haloperidol	350-360	rifampin	428-435	false
haloperidol	350-360	vitamin C	480-488	false
haloperidol	350-360	warfarin sodium	490-504	false
meprobamate	362-372	contraceptives	379-392	false
meprobamate	362-372	paraldehyde	394-404	false
meprobamate	362-372	primidone	406-414	false
meprobamate	362-372	ranitidine	416-425	false
meprobamate	362-372	rifampin	428-435	false
meprobamate	362-372	vitamin C	480-488	false
meprobamate	362-372	warfarin sodium	490-504	false
contraceptives	379-392	paraldehyde	394-404	false
contraceptives	379-392	primidone	406-414	false
contraceptives	379-392	ranitidine	416-425	false
contraceptives	379-392	rifampin	428-435	false
contraceptives	379-392	vitamin C	480-488	false
contraceptives	379-392	warfarin sodium	490-504	false
paraldehyde	394-404	primidone	406-414	false
paraldehyde	394-404	ranitidine	416-425	false
paraldehyde	394-404	rifampin	428-435	false
paraldehyde	394-404	vitamin C	480-488	false
paraldehyde	394-404	warfarin sodium	490-504	false
primidone	406-414	ranitidine	416-425	false
primidone	406-414	rifampin	428-435	false
primidone	406-414	vitamin C	480-488	false
primidone	406-414	warfarin sodium	490-504	false
ranitidine	416-425	rifampin	428-435	false
ranitidine	416-425	vitamin C	480-488	false
ranitidine	416-425	warfarin sodium	490-504	false
rifampin	428-435	vitamin C	480-488	false
rifampin	428-435	warfarin sodium	490-504	false
vitamin C	480-488	warfarin sodium	490-504	false

Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
anticoagulant	40-52	alcohol	115-121	effect

salicylates;sulfinpyrazone;
salicylates	0-10	sulfinpyrazone	12-25	false

trimethoprim/sulfamethoxazole;
trimethoprim	0-11	sulfamethoxazole	13-28	false

Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
anticoagulant	40-52	alcohol	115-121	effect
anticoagulant	40-52	allopurinol	124-134	effect
anticoagulant	40-52	aminosalicylic acid	136-154	effect
anticoagulant	40-52	amiodarone	156-165	effect
anticoagulant	40-52	anabolic steroids	167-183	effect
anticoagulant	40-52	antibiotics	185-195	effect
anticoagulant	40-52	bromelains	197-206	effect
anticoagulant	40-52	chloral hydrate	208-222	effect
anticoagulant	40-52	chlorpropamide	225-238	effect
anticoagulant	40-52	chymotrypsin	240-251	effect
anticoagulant	40-52	cimetidine	253-262	effect
anticoagulant	40-52	cinchophen	264-273	effect
anticoagulant	40-52	clofibrate	275-284	effect
anticoagulant	40-52	dextran	286-292	effect
anticoagulant	40-52	dextrothyroxine	294-308	effect
anticoagulant	40-52	diazoxide	310-318	effect
anticoagulant	40-52	diflunisal	341-350	effect
anticoagulant	40-52	disulfiram	352-361	effect
anticoagulant	40-52	ethacrynic acid	394-408	effect
anticoagulant	40-52	fenoprofen	410-419	effect
anticoagulant	40-52	glucagon	421-428	effect
anticoagulant	40-52	ibuprofen	448-456	effect
anticoagulant	40-52	indomethacin	458-469	effect
anticoagulant	40-52	influenza virus vaccine	471-493	effect
anticoagulant	40-52	anesthetics	506-516	effect
anticoagulant	40-52	mefenamic acid	518-531	effect
anticoagulant	40-52	methyldopa	533-542	effect
anticoagulant	40-52	methylphenidate	544-558	effect
anticoagulant	40-52	metronidazole	560-572	effect
anticoagulant	40-52	miconazole	574-583	effect
anticoagulant	40-52	monoamine oxidase inhibitors	585-612	effect
anticoagulant	40-52	nalidixic acid	614-627	effect
anticoagulant	40-52	naproxen	629-636	effect
anticoagulant	40-52	oxolinic acid	638-650	effect
anticoagulant	40-52	oxyphenbutazone	652-666	effect
anticoagulant	40-52	pentoxifylline	668-681	effect
anticoagulant	40-52	phenylbutazone	683-696	effect
anticoagulant	40-52	phenyramidol	698-709	effect
anticoagulant	40-52	phenytoin	711-719	effect
anticoagulant	40-52	prolonged narcotics	743-761	effect
anticoagulant	40-52	pyrazolones	763-773	effect
anticoagulant	40-52	quinidine	775-783	effect
anticoagulant	40-52	quinine	785-791	effect
anticoagulant	40-52	ranitidine	793-802	effect
anticoagulant	40-52	salicylates	805-815	effect
anticoagulant	40-52	sulfinpyrazone	817-830	effect
anticoagulant	40-52	sulfonamides	832-843	effect
anticoagulant	40-52	sulindac	858-865	effect
anticoagulant	40-52	thyroid drugs	867-879	effect
anticoagulant	40-52	tolbutamide	881-891	effect
anticoagulant	40-52	triclofos sodium	893-908	effect
anticoagulant	40-52	trimethoprim	910-921	effect
anticoagulant	40-52	sulfamethoxazole	923-938	effect
anticoagulant	40-52	warfarin sodium	983-997	effect
alcohol	115-121	allopurinol	124-134	false
alcohol	115-121	aminosalicylic acid	136-154	false
alcohol	115-121	amiodarone	156-165	false
alcohol	115-121	anabolic steroids	167-183	false
alcohol	115-121	antibiotics	185-195	false
alcohol	115-121	bromelains	197-206	false
alcohol	115-121	chloral hydrate	208-222	false
alcohol	115-121	chlorpropamide	225-238	false
alcohol	115-121	chymotrypsin	240-251	false
alcohol	115-121	cimetidine	253-262	false
alcohol	115-121	cinchophen	264-273	false
alcohol	115-121	clofibrate	275-284	false
alcohol	115-121	dextran	286-292	false
alcohol	115-121	dextrothyroxine	294-308	false
alcohol	115-121	diazoxide	310-318	false
alcohol	115-121	diflunisal	341-350	false
alcohol	115-121	disulfiram	352-361	false
alcohol	115-121	ethacrynic acid	394-408	false
alcohol	115-121	fenoprofen	410-419	false
alcohol	115-121	glucagon	421-428	false
alcohol	115-121	ibuprofen	448-456	false
alcohol	115-121	indomethacin	458-469	false
alcohol	115-121	influenza virus vaccine	471-493	false
alcohol	115-121	anesthetics	506-516	false
alcohol	115-121	mefenamic acid	518-531	false
alcohol	115-121	methyldopa	533-542	false
alcohol	115-121	methylphenidate	544-558	false
alcohol	115-121	metronidazole	560-572	false
alcohol	115-121	miconazole	574-583	false
alcohol	115-121	monoamine oxidase inhibitors	585-612	false
alcohol	115-121	nalidixic acid	614-627	false
alcohol	115-121	naproxen	629-636	false
alcohol	115-121	oxolinic acid	638-650	false
alcohol	115-121	oxyphenbutazone	652-666	false
alcohol	115-121	pentoxifylline	668-681	false
alcohol	115-121	phenylbutazone	683-696	false
alcohol	115-121	phenyramidol	698-709	false
alcohol	115-121	phenytoin	711-719	false
alcohol	115-121	prolonged narcotics	743-761	false
alcohol	115-121	pyrazolones	763-773	false
alcohol	115-121	quinidine	775-783	false
alcohol	115-121	quinine	785-791	false
alcohol	115-121	ranitidine	793-802	false
alcohol	115-121	salicylates	805-815	false
alcohol	115-121	sulfinpyrazone	817-830	false
alcohol	115-121	sulfonamides	832-843	false
alcohol	115-121	sulindac	858-865	false
alcohol	115-121	thyroid drugs	867-879	false
alcohol	115-121	tolbutamide	881-891	false
alcohol	115-121	triclofos sodium	893-908	false
alcohol	115-121	trimethoprim	910-921	false
alcohol	115-121	sulfamethoxazole	923-938	false
alcohol	115-121	warfarin sodium	983-997	false
allopurinol	124-134	aminosalicylic acid	136-154	false
allopurinol	124-134	amiodarone	156-165	false
allopurinol	124-134	anabolic steroids	167-183	false
allopurinol	124-134	antibiotics	185-195	false
allopurinol	124-134	bromelains	197-206	false
allopurinol	124-134	chloral hydrate	208-222	false
allopurinol	124-134	chlorpropamide	225-238	false
allopurinol	124-134	chymotrypsin	240-251	false
allopurinol	124-134	cimetidine	253-262	false
allopurinol	124-134	cinchophen	264-273	false
allopurinol	124-134	clofibrate	275-284	false
allopurinol	124-134	dextran	286-292	false
allopurinol	124-134	dextrothyroxine	294-308	false
allopurinol	124-134	diazoxide	310-318	false
allopurinol	124-134	diflunisal	341-350	false
allopurinol	124-134	disulfiram	352-361	false
allopurinol	124-134	ethacrynic acid	394-408	false
allopurinol	124-134	fenoprofen	410-419	false
allopurinol	124-134	glucagon	421-428	false
allopurinol	124-134	ibuprofen	448-456	false
allopurinol	124-134	indomethacin	458-469	false
allopurinol	124-134	influenza virus vaccine	471-493	false
allopurinol	124-134	anesthetics	506-516	false
allopurinol	124-134	mefenamic acid	518-531	false
allopurinol	124-134	methyldopa	533-542	false
allopurinol	124-134	methylphenidate	544-558	false
allopurinol	124-134	metronidazole	560-572	false
allopurinol	124-134	miconazole	574-583	false
allopurinol	124-134	monoamine oxidase inhibitors	585-612	false
allopurinol	124-134	nalidixic acid	614-627	false
allopurinol	124-134	naproxen	629-636	false
allopurinol	124-134	oxolinic acid	638-650	false
allopurinol	124-134	oxyphenbutazone	652-666	false
allopurinol	124-134	pentoxifylline	668-681	false
allopurinol	124-134	phenylbutazone	683-696	false
allopurinol	124-134	phenyramidol	698-709	false
allopurinol	124-134	phenytoin	711-719	false
allopurinol	124-134	prolonged narcotics	743-761	false
allopurinol	124-134	pyrazolones	763-773	false
allopurinol	124-134	quinidine	775-783	false
allopurinol	124-134	quinine	785-791	false
allopurinol	124-134	ranitidine	793-802	false
allopurinol	124-134	salicylates	805-815	false
allopurinol	124-134	sulfinpyrazone	817-830	false
allopurinol	124-134	sulfonamides	832-843	false
allopurinol	124-134	sulindac	858-865	false
allopurinol	124-134	thyroid drugs	867-879	false
allopurinol	124-134	tolbutamide	881-891	false
allopurinol	124-134	triclofos sodium	893-908	false
allopurinol	124-134	trimethoprim	910-921	false
allopurinol	124-134	sulfamethoxazole	923-938	false
allopurinol	124-134	warfarin sodium	983-997	false
aminosalicylic acid	136-154	amiodarone	156-165	false
aminosalicylic acid	136-154	anabolic steroids	167-183	false
aminosalicylic acid	136-154	antibiotics	185-195	false
aminosalicylic acid	136-154	bromelains	197-206	false
aminosalicylic acid	136-154	chloral hydrate	208-222	false
aminosalicylic acid	136-154	chlorpropamide	225-238	false
aminosalicylic acid	136-154	chymotrypsin	240-251	false
aminosalicylic acid	136-154	cimetidine	253-262	false
aminosalicylic acid	136-154	cinchophen	264-273	false
aminosalicylic acid	136-154	clofibrate	275-284	false
aminosalicylic acid	136-154	dextran	286-292	false
aminosalicylic acid	136-154	dextrothyroxine	294-308	false
aminosalicylic acid	136-154	diazoxide	310-318	false
aminosalicylic acid	136-154	diflunisal	341-350	false
aminosalicylic acid	136-154	disulfiram	352-361	false
aminosalicylic acid	136-154	ethacrynic acid	394-408	false
aminosalicylic acid	136-154	fenoprofen	410-419	false
aminosalicylic acid	136-154	glucagon	421-428	false
aminosalicylic acid	136-154	ibuprofen	448-456	false
aminosalicylic acid	136-154	indomethacin	458-469	false
aminosalicylic acid	136-154	influenza virus vaccine	471-493	false
aminosalicylic acid	136-154	anesthetics	506-516	false
aminosalicylic acid	136-154	mefenamic acid	518-531	false
aminosalicylic acid	136-154	methyldopa	533-542	false
aminosalicylic acid	136-154	methylphenidate	544-558	false
aminosalicylic acid	136-154	metronidazole	560-572	false
aminosalicylic acid	136-154	miconazole	574-583	false
aminosalicylic acid	136-154	monoamine oxidase inhibitors	585-612	false
aminosalicylic acid	136-154	nalidixic acid	614-627	false
aminosalicylic acid	136-154	naproxen	629-636	false
aminosalicylic acid	136-154	oxolinic acid	638-650	false
aminosalicylic acid	136-154	oxyphenbutazone	652-666	false
aminosalicylic acid	136-154	pentoxifylline	668-681	false
aminosalicylic acid	136-154	phenylbutazone	683-696	false
aminosalicylic acid	136-154	phenyramidol	698-709	false
aminosalicylic acid	136-154	phenytoin	711-719	false
aminosalicylic acid	136-154	prolonged narcotics	743-761	false
aminosalicylic acid	136-154	pyrazolones	763-773	false
aminosalicylic acid	136-154	quinidine	775-783	false
aminosalicylic acid	136-154	quinine	785-791	false
aminosalicylic acid	136-154	ranitidine	793-802	false
aminosalicylic acid	136-154	salicylates	805-815	false
aminosalicylic acid	136-154	sulfinpyrazone	817-830	false
aminosalicylic acid	136-154	sulfonamides	832-843	false
aminosalicylic acid	136-154	sulindac	858-865	false
aminosalicylic acid	136-154	thyroid drugs	867-879	false
aminosalicylic acid	136-154	tolbutamide	881-891	false
aminosalicylic acid	136-154	triclofos sodium	893-908	false
aminosalicylic acid	136-154	trimethoprim	910-921	false
aminosalicylic acid	136-154	sulfamethoxazole	923-938	false
aminosalicylic acid	136-154	warfarin sodium	983-997	false
amiodarone	156-165	anabolic steroids	167-183	false
amiodarone	156-165	antibiotics	185-195	false
amiodarone	156-165	bromelains	197-206	false
amiodarone	156-165	chloral hydrate	208-222	false
amiodarone	156-165	chlorpropamide	225-238	false
amiodarone	156-165	chymotrypsin	240-251	false
amiodarone	156-165	cimetidine	253-262	false
amiodarone	156-165	cinchophen	264-273	false
amiodarone	156-165	clofibrate	275-284	false
amiodarone	156-165	dextran	286-292	false
amiodarone	156-165	dextrothyroxine	294-308	false
amiodarone	156-165	diazoxide	310-318	false
amiodarone	156-165	diflunisal	341-350	false
amiodarone	156-165	disulfiram	352-361	false
amiodarone	156-165	ethacrynic acid	394-408	false
amiodarone	156-165	fenoprofen	410-419	false
amiodarone	156-165	glucagon	421-428	false
amiodarone	156-165	ibuprofen	448-456	false
amiodarone	156-165	indomethacin	458-469	false
amiodarone	156-165	influenza virus vaccine	471-493	false
amiodarone	156-165	anesthetics	506-516	false
amiodarone	156-165	mefenamic acid	518-531	false
amiodarone	156-165	methyldopa	533-542	false
amiodarone	156-165	methylphenidate	544-558	false
amiodarone	156-165	metronidazole	560-572	false
amiodarone	156-165	miconazole	574-583	false
amiodarone	156-165	monoamine oxidase inhibitors	585-612	false
amiodarone	156-165	nalidixic acid	614-627	false
amiodarone	156-165	naproxen	629-636	false
amiodarone	156-165	oxolinic acid	638-650	false
amiodarone	156-165	oxyphenbutazone	652-666	false
amiodarone	156-165	pentoxifylline	668-681	false
amiodarone	156-165	phenylbutazone	683-696	false
amiodarone	156-165	phenyramidol	698-709	false
amiodarone	156-165	phenytoin	711-719	false
amiodarone	156-165	prolonged narcotics	743-761	false
amiodarone	156-165	pyrazolones	763-773	false
amiodarone	156-165	quinidine	775-783	false
amiodarone	156-165	quinine	785-791	false
amiodarone	156-165	ranitidine	793-802	false
amiodarone	156-165	salicylates	805-815	false
amiodarone	156-165	sulfinpyrazone	817-830	false
amiodarone	156-165	sulfonamides	832-843	false
amiodarone	156-165	sulindac	858-865	false
amiodarone	156-165	thyroid drugs	867-879	false
amiodarone	156-165	tolbutamide	881-891	false
amiodarone	156-165	triclofos sodium	893-908	false
amiodarone	156-165	trimethoprim	910-921	false
amiodarone	156-165	sulfamethoxazole	923-938	false
amiodarone	156-165	warfarin sodium	983-997	false
anabolic steroids	167-183	antibiotics	185-195	false
anabolic steroids	167-183	bromelains	197-206	false
anabolic steroids	167-183	chloral hydrate	208-222	false
anabolic steroids	167-183	chlorpropamide	225-238	false
anabolic steroids	167-183	chymotrypsin	240-251	false
anabolic steroids	167-183	cimetidine	253-262	false
anabolic steroids	167-183	cinchophen	264-273	false
anabolic steroids	167-183	clofibrate	275-284	false
anabolic steroids	167-183	dextran	286-292	false
anabolic steroids	167-183	dextrothyroxine	294-308	false
anabolic steroids	167-183	diazoxide	310-318	false
anabolic steroids	167-183	diflunisal	341-350	false
anabolic steroids	167-183	disulfiram	352-361	false
anabolic steroids	167-183	ethacrynic acid	394-408	false
anabolic steroids	167-183	fenoprofen	410-419	false
anabolic steroids	167-183	glucagon	421-428	false
anabolic steroids	167-183	ibuprofen	448-456	false
anabolic steroids	167-183	indomethacin	458-469	false
anabolic steroids	167-183	influenza virus vaccine	471-493	false
anabolic steroids	167-183	anesthetics	506-516	false
anabolic steroids	167-183	mefenamic acid	518-531	false
anabolic steroids	167-183	methyldopa	533-542	false
anabolic steroids	167-183	methylphenidate	544-558	false
anabolic steroids	167-183	metronidazole	560-572	false
anabolic steroids	167-183	miconazole	574-583	false
anabolic steroids	167-183	monoamine oxidase inhibitors	585-612	false
anabolic steroids	167-183	nalidixic acid	614-627	false
anabolic steroids	167-183	naproxen	629-636	false
anabolic steroids	167-183	oxolinic acid	638-650	false
anabolic steroids	167-183	oxyphenbutazone	652-666	false
anabolic steroids	167-183	pentoxifylline	668-681	false
anabolic steroids	167-183	phenylbutazone	683-696	false
anabolic steroids	167-183	phenyramidol	698-709	false
anabolic steroids	167-183	phenytoin	711-719	false
anabolic steroids	167-183	prolonged narcotics	743-761	false
anabolic steroids	167-183	pyrazolones	763-773	false
anabolic steroids	167-183	quinidine	775-783	false
anabolic steroids	167-183	quinine	785-791	false
anabolic steroids	167-183	ranitidine	793-802	false
anabolic steroids	167-183	salicylates	805-815	false
anabolic steroids	167-183	sulfinpyrazone	817-830	false
anabolic steroids	167-183	sulfonamides	832-843	false
anabolic steroids	167-183	sulindac	858-865	false
anabolic steroids	167-183	thyroid drugs	867-879	false
anabolic steroids	167-183	tolbutamide	881-891	false
anabolic steroids	167-183	triclofos sodium	893-908	false
anabolic steroids	167-183	trimethoprim	910-921	false
anabolic steroids	167-183	sulfamethoxazole	923-938	false
anabolic steroids	167-183	warfarin sodium	983-997	false
antibiotics	185-195	bromelains	197-206	false
antibiotics	185-195	chloral hydrate	208-222	false
antibiotics	185-195	chlorpropamide	225-238	false
antibiotics	185-195	chymotrypsin	240-251	false
antibiotics	185-195	cimetidine	253-262	false
antibiotics	185-195	cinchophen	264-273	false
antibiotics	185-195	clofibrate	275-284	false
antibiotics	185-195	dextran	286-292	false
antibiotics	185-195	dextrothyroxine	294-308	false
antibiotics	185-195	diazoxide	310-318	false
antibiotics	185-195	diflunisal	341-350	false
antibiotics	185-195	disulfiram	352-361	false
antibiotics	185-195	ethacrynic acid	394-408	false
antibiotics	185-195	fenoprofen	410-419	false
antibiotics	185-195	glucagon	421-428	false
antibiotics	185-195	ibuprofen	448-456	false
antibiotics	185-195	indomethacin	458-469	false
antibiotics	185-195	influenza virus vaccine	471-493	false
antibiotics	185-195	anesthetics	506-516	false
antibiotics	185-195	mefenamic acid	518-531	false
antibiotics	185-195	methyldopa	533-542	false
antibiotics	185-195	methylphenidate	544-558	false
antibiotics	185-195	metronidazole	560-572	false
antibiotics	185-195	miconazole	574-583	false
antibiotics	185-195	monoamine oxidase inhibitors	585-612	false
antibiotics	185-195	nalidixic acid	614-627	false
antibiotics	185-195	naproxen	629-636	false
antibiotics	185-195	oxolinic acid	638-650	false
antibiotics	185-195	oxyphenbutazone	652-666	false
antibiotics	185-195	pentoxifylline	668-681	false
antibiotics	185-195	phenylbutazone	683-696	false
antibiotics	185-195	phenyramidol	698-709	false
antibiotics	185-195	phenytoin	711-719	false
antibiotics	185-195	prolonged narcotics	743-761	false
antibiotics	185-195	pyrazolones	763-773	false
antibiotics	185-195	quinidine	775-783	false
antibiotics	185-195	quinine	785-791	false
antibiotics	185-195	ranitidine	793-802	false
antibiotics	185-195	salicylates	805-815	false
antibiotics	185-195	sulfinpyrazone	817-830	false
antibiotics	185-195	sulfonamides	832-843	false
antibiotics	185-195	sulindac	858-865	false
antibiotics	185-195	thyroid drugs	867-879	false
antibiotics	185-195	tolbutamide	881-891	false
antibiotics	185-195	triclofos sodium	893-908	false
antibiotics	185-195	trimethoprim	910-921	false
antibiotics	185-195	sulfamethoxazole	923-938	false
antibiotics	185-195	warfarin sodium	983-997	false
bromelains	197-206	chloral hydrate	208-222	false
bromelains	197-206	chlorpropamide	225-238	false
bromelains	197-206	chymotrypsin	240-251	false
bromelains	197-206	cimetidine	253-262	false
bromelains	197-206	cinchophen	264-273	false
bromelains	197-206	clofibrate	275-284	false
bromelains	197-206	dextran	286-292	false
bromelains	197-206	dextrothyroxine	294-308	false
bromelains	197-206	diazoxide	310-318	false
bromelains	197-206	diflunisal	341-350	false
bromelains	197-206	disulfiram	352-361	false
bromelains	197-206	ethacrynic acid	394-408	false
bromelains	197-206	fenoprofen	410-419	false
bromelains	197-206	glucagon	421-428	false
bromelains	197-206	ibuprofen	448-456	false
bromelains	197-206	indomethacin	458-469	false
bromelains	197-206	influenza virus vaccine	471-493	false
bromelains	197-206	anesthetics	506-516	false
bromelains	197-206	mefenamic acid	518-531	false
bromelains	197-206	methyldopa	533-542	false
bromelains	197-206	methylphenidate	544-558	false
bromelains	197-206	metronidazole	560-572	false
bromelains	197-206	miconazole	574-583	false
bromelains	197-206	monoamine oxidase inhibitors	585-612	false
bromelains	197-206	nalidixic acid	614-627	false
bromelains	197-206	naproxen	629-636	false
bromelains	197-206	oxolinic acid	638-650	false
bromelains	197-206	oxyphenbutazone	652-666	false
bromelains	197-206	pentoxifylline	668-681	false
bromelains	197-206	phenylbutazone	683-696	false
bromelains	197-206	phenyramidol	698-709	false
bromelains	197-206	phenytoin	711-719	false
bromelains	197-206	prolonged narcotics	743-761	false
bromelains	197-206	pyrazolones	763-773	false
bromelains	197-206	quinidine	775-783	false
bromelains	197-206	quinine	785-791	false
bromelains	197-206	ranitidine	793-802	false
bromelains	197-206	salicylates	805-815	false
bromelains	197-206	sulfinpyrazone	817-830	false
bromelains	197-206	sulfonamides	832-843	false
bromelains	197-206	sulindac	858-865	false
bromelains	197-206	thyroid drugs	867-879	false
bromelains	197-206	tolbutamide	881-891	false
bromelains	197-206	triclofos sodium	893-908	false
bromelains	197-206	trimethoprim	910-921	false
bromelains	197-206	sulfamethoxazole	923-938	false
bromelains	197-206	warfarin sodium	983-997	false
chloral hydrate	208-222	chlorpropamide	225-238	false
chloral hydrate	208-222	chymotrypsin	240-251	false
chloral hydrate	208-222	cimetidine	253-262	false
chloral hydrate	208-222	cinchophen	264-273	false
chloral hydrate	208-222	clofibrate	275-284	false
chloral hydrate	208-222	dextran	286-292	false
chloral hydrate	208-222	dextrothyroxine	294-308	false
chloral hydrate	208-222	diazoxide	310-318	false
chloral hydrate	208-222	diflunisal	341-350	false
chloral hydrate	208-222	disulfiram	352-361	false
chloral hydrate	208-222	ethacrynic acid	394-408	false
chloral hydrate	208-222	fenoprofen	410-419	false
chloral hydrate	208-222	glucagon	421-428	false
chloral hydrate	208-222	ibuprofen	448-456	false
chloral hydrate	208-222	indomethacin	458-469	false
chloral hydrate	208-222	influenza virus vaccine	471-493	false
chloral hydrate	208-222	anesthetics	506-516	false
chloral hydrate	208-222	mefenamic acid	518-531	false
chloral hydrate	208-222	methyldopa	533-542	false
chloral hydrate	208-222	methylphenidate	544-558	false
chloral hydrate	208-222	metronidazole	560-572	false
chloral hydrate	208-222	miconazole	574-583	false
chloral hydrate	208-222	monoamine oxidase inhibitors	585-612	false
chloral hydrate	208-222	nalidixic acid	614-627	false
chloral hydrate	208-222	naproxen	629-636	false
chloral hydrate	208-222	oxolinic acid	638-650	false
chloral hydrate	208-222	oxyphenbutazone	652-666	false
chloral hydrate	208-222	pentoxifylline	668-681	false
chloral hydrate	208-222	phenylbutazone	683-696	false
chloral hydrate	208-222	phenyramidol	698-709	false
chloral hydrate	208-222	phenytoin	711-719	false
chloral hydrate	208-222	prolonged narcotics	743-761	false
chloral hydrate	208-222	pyrazolones	763-773	false
chloral hydrate	208-222	quinidine	775-783	false
chloral hydrate	208-222	quinine	785-791	false
chloral hydrate	208-222	ranitidine	793-802	false
chloral hydrate	208-222	salicylates	805-815	false
chloral hydrate	208-222	sulfinpyrazone	817-830	false
chloral hydrate	208-222	sulfonamides	832-843	false
chloral hydrate	208-222	sulindac	858-865	false
chloral hydrate	208-222	thyroid drugs	867-879	false
chloral hydrate	208-222	tolbutamide	881-891	false
chloral hydrate	208-222	triclofos sodium	893-908	false
chloral hydrate	208-222	trimethoprim	910-921	false
chloral hydrate	208-222	sulfamethoxazole	923-938	false
chloral hydrate	208-222	warfarin sodium	983-997	false
chlorpropamide	225-238	chymotrypsin	240-251	false
chlorpropamide	225-238	cimetidine	253-262	false
chlorpropamide	225-238	cinchophen	264-273	false
chlorpropamide	225-238	clofibrate	275-284	false
chlorpropamide	225-238	dextran	286-292	false
chlorpropamide	225-238	dextrothyroxine	294-308	false
chlorpropamide	225-238	diazoxide	310-318	false
chlorpropamide	225-238	diflunisal	341-350	false
chlorpropamide	225-238	disulfiram	352-361	false
chlorpropamide	225-238	ethacrynic acid	394-408	false
chlorpropamide	225-238	fenoprofen	410-419	false
chlorpropamide	225-238	glucagon	421-428	false
chlorpropamide	225-238	ibuprofen	448-456	false
chlorpropamide	225-238	indomethacin	458-469	false
chlorpropamide	225-238	influenza virus vaccine	471-493	false
chlorpropamide	225-238	anesthetics	506-516	false
chlorpropamide	225-238	mefenamic acid	518-531	false
chlorpropamide	225-238	methyldopa	533-542	false
chlorpropamide	225-238	methylphenidate	544-558	false
chlorpropamide	225-238	metronidazole	560-572	false
chlorpropamide	225-238	miconazole	574-583	false
chlorpropamide	225-238	monoamine oxidase inhibitors	585-612	false
chlorpropamide	225-238	nalidixic acid	614-627	false
chlorpropamide	225-238	naproxen	629-636	false
chlorpropamide	225-238	oxolinic acid	638-650	false
chlorpropamide	225-238	oxyphenbutazone	652-666	false
chlorpropamide	225-238	pentoxifylline	668-681	false
chlorpropamide	225-238	phenylbutazone	683-696	false
chlorpropamide	225-238	phenyramidol	698-709	false
chlorpropamide	225-238	phenytoin	711-719	false
chlorpropamide	225-238	prolonged narcotics	743-761	false
chlorpropamide	225-238	pyrazolones	763-773	false
chlorpropamide	225-238	quinidine	775-783	false
chlorpropamide	225-238	quinine	785-791	false
chlorpropamide	225-238	ranitidine	793-802	false
chlorpropamide	225-238	salicylates	805-815	false
chlorpropamide	225-238	sulfinpyrazone	817-830	false
chlorpropamide	225-238	sulfonamides	832-843	false
chlorpropamide	225-238	sulindac	858-865	false
chlorpropamide	225-238	thyroid drugs	867-879	false
chlorpropamide	225-238	tolbutamide	881-891	false
chlorpropamide	225-238	triclofos sodium	893-908	false
chlorpropamide	225-238	trimethoprim	910-921	false
chlorpropamide	225-238	sulfamethoxazole	923-938	false
chlorpropamide	225-238	warfarin sodium	983-997	false
chymotrypsin	240-251	cimetidine	253-262	false
chymotrypsin	240-251	cinchophen	264-273	false
chymotrypsin	240-251	clofibrate	275-284	false
chymotrypsin	240-251	dextran	286-292	false
chymotrypsin	240-251	dextrothyroxine	294-308	false
chymotrypsin	240-251	diazoxide	310-318	false
chymotrypsin	240-251	diflunisal	341-350	false
chymotrypsin	240-251	disulfiram	352-361	false
chymotrypsin	240-251	ethacrynic acid	394-408	false
chymotrypsin	240-251	fenoprofen	410-419	false
chymotrypsin	240-251	glucagon	421-428	false
chymotrypsin	240-251	ibuprofen	448-456	false
chymotrypsin	240-251	indomethacin	458-469	false
chymotrypsin	240-251	influenza virus vaccine	471-493	false
chymotrypsin	240-251	anesthetics	506-516	false
chymotrypsin	240-251	mefenamic acid	518-531	false
chymotrypsin	240-251	methyldopa	533-542	false
chymotrypsin	240-251	methylphenidate	544-558	false
chymotrypsin	240-251	metronidazole	560-572	false
chymotrypsin	240-251	miconazole	574-583	false
chymotrypsin	240-251	monoamine oxidase inhibitors	585-612	false
chymotrypsin	240-251	nalidixic acid	614-627	false
chymotrypsin	240-251	naproxen	629-636	false
chymotrypsin	240-251	oxolinic acid	638-650	false
chymotrypsin	240-251	oxyphenbutazone	652-666	false
chymotrypsin	240-251	pentoxifylline	668-681	false
chymotrypsin	240-251	phenylbutazone	683-696	false
chymotrypsin	240-251	phenyramidol	698-709	false
chymotrypsin	240-251	phenytoin	711-719	false
chymotrypsin	240-251	prolonged narcotics	743-761	false
chymotrypsin	240-251	pyrazolones	763-773	false
chymotrypsin	240-251	quinidine	775-783	false
chymotrypsin	240-251	quinine	785-791	false
chymotrypsin	240-251	ranitidine	793-802	false
chymotrypsin	240-251	salicylates	805-815	false
chymotrypsin	240-251	sulfinpyrazone	817-830	false
chymotrypsin	240-251	sulfonamides	832-843	false
chymotrypsin	240-251	sulindac	858-865	false
chymotrypsin	240-251	thyroid drugs	867-879	false
chymotrypsin	240-251	tolbutamide	881-891	false
chymotrypsin	240-251	triclofos sodium	893-908	false
chymotrypsin	240-251	trimethoprim	910-921	false
chymotrypsin	240-251	sulfamethoxazole	923-938	false
chymotrypsin	240-251	warfarin sodium	983-997	false
cimetidine	253-262	cinchophen	264-273	false
cimetidine	253-262	clofibrate	275-284	false
cimetidine	253-262	dextran	286-292	false
cimetidine	253-262	dextrothyroxine	294-308	false
cimetidine	253-262	diazoxide	310-318	false
cimetidine	253-262	diflunisal	341-350	false
cimetidine	253-262	disulfiram	352-361	false
cimetidine	253-262	ethacrynic acid	394-408	false
cimetidine	253-262	fenoprofen	410-419	false
cimetidine	253-262	glucagon	421-428	false
cimetidine	253-262	ibuprofen	448-456	false
cimetidine	253-262	indomethacin	458-469	false
cimetidine	253-262	influenza virus vaccine	471-493	false
cimetidine	253-262	anesthetics	506-516	false
cimetidine	253-262	mefenamic acid	518-531	false
cimetidine	253-262	methyldopa	533-542	false
cimetidine	253-262	methylphenidate	544-558	false
cimetidine	253-262	metronidazole	560-572	false
cimetidine	253-262	miconazole	574-583	false
cimetidine	253-262	monoamine oxidase inhibitors	585-612	false
cimetidine	253-262	nalidixic acid	614-627	false
cimetidine	253-262	naproxen	629-636	false
cimetidine	253-262	oxolinic acid	638-650	false
cimetidine	253-262	oxyphenbutazone	652-666	false
cimetidine	253-262	pentoxifylline	668-681	false
cimetidine	253-262	phenylbutazone	683-696	false
cimetidine	253-262	phenyramidol	698-709	false
cimetidine	253-262	phenytoin	711-719	false
cimetidine	253-262	prolonged narcotics	743-761	false
cimetidine	253-262	pyrazolones	763-773	false
cimetidine	253-262	quinidine	775-783	false
cimetidine	253-262	quinine	785-791	false
cimetidine	253-262	ranitidine	793-802	false
cimetidine	253-262	salicylates	805-815	false
cimetidine	253-262	sulfinpyrazone	817-830	false
cimetidine	253-262	sulfonamides	832-843	false
cimetidine	253-262	sulindac	858-865	false
cimetidine	253-262	thyroid drugs	867-879	false
cimetidine	253-262	tolbutamide	881-891	false
cimetidine	253-262	triclofos sodium	893-908	false
cimetidine	253-262	trimethoprim	910-921	false
cimetidine	253-262	sulfamethoxazole	923-938	false
cimetidine	253-262	warfarin sodium	983-997	false
cinchophen	264-273	clofibrate	275-284	false
cinchophen	264-273	dextran	286-292	false
cinchophen	264-273	dextrothyroxine	294-308	false
cinchophen	264-273	diazoxide	310-318	false
cinchophen	264-273	diflunisal	341-350	false
cinchophen	264-273	disulfiram	352-361	false
cinchophen	264-273	ethacrynic acid	394-408	false
cinchophen	264-273	fenoprofen	410-419	false
cinchophen	264-273	glucagon	421-428	false
cinchophen	264-273	ibuprofen	448-456	false
cinchophen	264-273	indomethacin	458-469	false
cinchophen	264-273	influenza virus vaccine	471-493	false
cinchophen	264-273	anesthetics	506-516	false
cinchophen	264-273	mefenamic acid	518-531	false
cinchophen	264-273	methyldopa	533-542	false
cinchophen	264-273	methylphenidate	544-558	false
cinchophen	264-273	metronidazole	560-572	false
cinchophen	264-273	miconazole	574-583	false
cinchophen	264-273	monoamine oxidase inhibitors	585-612	false
cinchophen	264-273	nalidixic acid	614-627	false
cinchophen	264-273	naproxen	629-636	false
cinchophen	264-273	oxolinic acid	638-650	false
cinchophen	264-273	oxyphenbutazone	652-666	false
cinchophen	264-273	pentoxifylline	668-681	false
cinchophen	264-273	phenylbutazone	683-696	false
cinchophen	264-273	phenyramidol	698-709	false
cinchophen	264-273	phenytoin	711-719	false
cinchophen	264-273	prolonged narcotics	743-761	false
cinchophen	264-273	pyrazolones	763-773	false
cinchophen	264-273	quinidine	775-783	false
cinchophen	264-273	quinine	785-791	false
cinchophen	264-273	ranitidine	793-802	false
cinchophen	264-273	salicylates	805-815	false
cinchophen	264-273	sulfinpyrazone	817-830	false
cinchophen	264-273	sulfonamides	832-843	false
cinchophen	264-273	sulindac	858-865	false
cinchophen	264-273	thyroid drugs	867-879	false
cinchophen	264-273	tolbutamide	881-891	false
cinchophen	264-273	triclofos sodium	893-908	false
cinchophen	264-273	trimethoprim	910-921	false
cinchophen	264-273	sulfamethoxazole	923-938	false
cinchophen	264-273	warfarin sodium	983-997	false
clofibrate	275-284	dextran	286-292	false
clofibrate	275-284	dextrothyroxine	294-308	false
clofibrate	275-284	diazoxide	310-318	false
clofibrate	275-284	diflunisal	341-350	false
clofibrate	275-284	disulfiram	352-361	false
clofibrate	275-284	ethacrynic acid	394-408	false
clofibrate	275-284	fenoprofen	410-419	false
clofibrate	275-284	glucagon	421-428	false
clofibrate	275-284	ibuprofen	448-456	false
clofibrate	275-284	indomethacin	458-469	false
clofibrate	275-284	influenza virus vaccine	471-493	false
clofibrate	275-284	anesthetics	506-516	false
clofibrate	275-284	mefenamic acid	518-531	false
clofibrate	275-284	methyldopa	533-542	false
clofibrate	275-284	methylphenidate	544-558	false
clofibrate	275-284	metronidazole	560-572	false
clofibrate	275-284	miconazole	574-583	false
clofibrate	275-284	monoamine oxidase inhibitors	585-612	false
clofibrate	275-284	nalidixic acid	614-627	false
clofibrate	275-284	naproxen	629-636	false
clofibrate	275-284	oxolinic acid	638-650	false
clofibrate	275-284	oxyphenbutazone	652-666	false
clofibrate	275-284	pentoxifylline	668-681	false
clofibrate	275-284	phenylbutazone	683-696	false
clofibrate	275-284	phenyramidol	698-709	false
clofibrate	275-284	phenytoin	711-719	false
clofibrate	275-284	prolonged narcotics	743-761	false
clofibrate	275-284	pyrazolones	763-773	false
clofibrate	275-284	quinidine	775-783	false
clofibrate	275-284	quinine	785-791	false
clofibrate	275-284	ranitidine	793-802	false
clofibrate	275-284	salicylates	805-815	false
clofibrate	275-284	sulfinpyrazone	817-830	false
clofibrate	275-284	sulfonamides	832-843	false
clofibrate	275-284	sulindac	858-865	false
clofibrate	275-284	thyroid drugs	867-879	false
clofibrate	275-284	tolbutamide	881-891	false
clofibrate	275-284	triclofos sodium	893-908	false
clofibrate	275-284	trimethoprim	910-921	false
clofibrate	275-284	sulfamethoxazole	923-938	false
clofibrate	275-284	warfarin sodium	983-997	false
dextran	286-292	dextrothyroxine	294-308	false
dextran	286-292	diazoxide	310-318	false
dextran	286-292	diflunisal	341-350	false
dextran	286-292	disulfiram	352-361	false
dextran	286-292	ethacrynic acid	394-408	false
dextran	286-292	fenoprofen	410-419	false
dextran	286-292	glucagon	421-428	false
dextran	286-292	ibuprofen	448-456	false
dextran	286-292	indomethacin	458-469	false
dextran	286-292	influenza virus vaccine	471-493	false
dextran	286-292	anesthetics	506-516	false
dextran	286-292	mefenamic acid	518-531	false
dextran	286-292	methyldopa	533-542	false
dextran	286-292	methylphenidate	544-558	false
dextran	286-292	metronidazole	560-572	false
dextran	286-292	miconazole	574-583	false
dextran	286-292	monoamine oxidase inhibitors	585-612	false
dextran	286-292	nalidixic acid	614-627	false
dextran	286-292	naproxen	629-636	false
dextran	286-292	oxolinic acid	638-650	false
dextran	286-292	oxyphenbutazone	652-666	false
dextran	286-292	pentoxifylline	668-681	false
dextran	286-292	phenylbutazone	683-696	false
dextran	286-292	phenyramidol	698-709	false
dextran	286-292	phenytoin	711-719	false
dextran	286-292	prolonged narcotics	743-761	false
dextran	286-292	pyrazolones	763-773	false
dextran	286-292	quinidine	775-783	false
dextran	286-292	quinine	785-791	false
dextran	286-292	ranitidine	793-802	false
dextran	286-292	salicylates	805-815	false
dextran	286-292	sulfinpyrazone	817-830	false
dextran	286-292	sulfonamides	832-843	false
dextran	286-292	sulindac	858-865	false
dextran	286-292	thyroid drugs	867-879	false
dextran	286-292	tolbutamide	881-891	false
dextran	286-292	triclofos sodium	893-908	false
dextran	286-292	trimethoprim	910-921	false
dextran	286-292	sulfamethoxazole	923-938	false
dextran	286-292	warfarin sodium	983-997	false
dextrothyroxine	294-308	diazoxide	310-318	false
dextrothyroxine	294-308	diflunisal	341-350	false
dextrothyroxine	294-308	disulfiram	352-361	false
dextrothyroxine	294-308	ethacrynic acid	394-408	false
dextrothyroxine	294-308	fenoprofen	410-419	false
dextrothyroxine	294-308	glucagon	421-428	false
dextrothyroxine	294-308	ibuprofen	448-456	false
dextrothyroxine	294-308	indomethacin	458-469	false
dextrothyroxine	294-308	influenza virus vaccine	471-493	false
dextrothyroxine	294-308	anesthetics	506-516	false
dextrothyroxine	294-308	mefenamic acid	518-531	false
dextrothyroxine	294-308	methyldopa	533-542	false
dextrothyroxine	294-308	methylphenidate	544-558	false
dextrothyroxine	294-308	metronidazole	560-572	false
dextrothyroxine	294-308	miconazole	574-583	false
dextrothyroxine	294-308	monoamine oxidase inhibitors	585-612	false
dextrothyroxine	294-308	nalidixic acid	614-627	false
dextrothyroxine	294-308	naproxen	629-636	false
dextrothyroxine	294-308	oxolinic acid	638-650	false
dextrothyroxine	294-308	oxyphenbutazone	652-666	false
dextrothyroxine	294-308	pentoxifylline	668-681	false
dextrothyroxine	294-308	phenylbutazone	683-696	false
dextrothyroxine	294-308	phenyramidol	698-709	false
dextrothyroxine	294-308	phenytoin	711-719	false
dextrothyroxine	294-308	prolonged narcotics	743-761	false
dextrothyroxine	294-308	pyrazolones	763-773	false
dextrothyroxine	294-308	quinidine	775-783	false
dextrothyroxine	294-308	quinine	785-791	false
dextrothyroxine	294-308	ranitidine	793-802	false
dextrothyroxine	294-308	salicylates	805-815	false
dextrothyroxine	294-308	sulfinpyrazone	817-830	false
dextrothyroxine	294-308	sulfonamides	832-843	false
dextrothyroxine	294-308	sulindac	858-865	false
dextrothyroxine	294-308	thyroid drugs	867-879	false
dextrothyroxine	294-308	tolbutamide	881-891	false
dextrothyroxine	294-308	triclofos sodium	893-908	false
dextrothyroxine	294-308	trimethoprim	910-921	false
dextrothyroxine	294-308	sulfamethoxazole	923-938	false
dextrothyroxine	294-308	warfarin sodium	983-997	false
diazoxide	310-318	diflunisal	341-350	false
diazoxide	310-318	disulfiram	352-361	false
diazoxide	310-318	ethacrynic acid	394-408	false
diazoxide	310-318	fenoprofen	410-419	false
diazoxide	310-318	glucagon	421-428	false
diazoxide	310-318	ibuprofen	448-456	false
diazoxide	310-318	indomethacin	458-469	false
diazoxide	310-318	influenza virus vaccine	471-493	false
diazoxide	310-318	anesthetics	506-516	false
diazoxide	310-318	mefenamic acid	518-531	false
diazoxide	310-318	methyldopa	533-542	false
diazoxide	310-318	methylphenidate	544-558	false
diazoxide	310-318	metronidazole	560-572	false
diazoxide	310-318	miconazole	574-583	false
diazoxide	310-318	monoamine oxidase inhibitors	585-612	false
diazoxide	310-318	nalidixic acid	614-627	false
diazoxide	310-318	naproxen	629-636	false
diazoxide	310-318	oxolinic acid	638-650	false
diazoxide	310-318	oxyphenbutazone	652-666	false
diazoxide	310-318	pentoxifylline	668-681	false
diazoxide	310-318	phenylbutazone	683-696	false
diazoxide	310-318	phenyramidol	698-709	false
diazoxide	310-318	phenytoin	711-719	false
diazoxide	310-318	prolonged narcotics	743-761	false
diazoxide	310-318	pyrazolones	763-773	false
diazoxide	310-318	quinidine	775-783	false
diazoxide	310-318	quinine	785-791	false
diazoxide	310-318	ranitidine	793-802	false
diazoxide	310-318	salicylates	805-815	false
diazoxide	310-318	sulfinpyrazone	817-830	false
diazoxide	310-318	sulfonamides	832-843	false
diazoxide	310-318	sulindac	858-865	false
diazoxide	310-318	thyroid drugs	867-879	false
diazoxide	310-318	tolbutamide	881-891	false
diazoxide	310-318	triclofos sodium	893-908	false
diazoxide	310-318	trimethoprim	910-921	false
diazoxide	310-318	sulfamethoxazole	923-938	false
diazoxide	310-318	warfarin sodium	983-997	false
diflunisal	341-350	disulfiram	352-361	false
diflunisal	341-350	ethacrynic acid	394-408	false
diflunisal	341-350	fenoprofen	410-419	false
diflunisal	341-350	glucagon	421-428	false
diflunisal	341-350	ibuprofen	448-456	false
diflunisal	341-350	indomethacin	458-469	false
diflunisal	341-350	influenza virus vaccine	471-493	false
diflunisal	341-350	anesthetics	506-516	false
diflunisal	341-350	mefenamic acid	518-531	false
diflunisal	341-350	methyldopa	533-542	false
diflunisal	341-350	methylphenidate	544-558	false
diflunisal	341-350	metronidazole	560-572	false
diflunisal	341-350	miconazole	574-583	false
diflunisal	341-350	monoamine oxidase inhibitors	585-612	false
diflunisal	341-350	nalidixic acid	614-627	false
diflunisal	341-350	naproxen	629-636	false
diflunisal	341-350	oxolinic acid	638-650	false
diflunisal	341-350	oxyphenbutazone	652-666	false
diflunisal	341-350	pentoxifylline	668-681	false
diflunisal	341-350	phenylbutazone	683-696	false
diflunisal	341-350	phenyramidol	698-709	false
diflunisal	341-350	phenytoin	711-719	false
diflunisal	341-350	prolonged narcotics	743-761	false
diflunisal	341-350	pyrazolones	763-773	false
diflunisal	341-350	quinidine	775-783	false
diflunisal	341-350	quinine	785-791	false
diflunisal	341-350	ranitidine	793-802	false
diflunisal	341-350	salicylates	805-815	false
diflunisal	341-350	sulfinpyrazone	817-830	false
diflunisal	341-350	sulfonamides	832-843	false
diflunisal	341-350	sulindac	858-865	false
diflunisal	341-350	thyroid drugs	867-879	false
diflunisal	341-350	tolbutamide	881-891	false
diflunisal	341-350	triclofos sodium	893-908	false
diflunisal	341-350	trimethoprim	910-921	false
diflunisal	341-350	sulfamethoxazole	923-938	false
diflunisal	341-350	warfarin sodium	983-997	false
disulfiram	352-361	ethacrynic acid	394-408	false
disulfiram	352-361	fenoprofen	410-419	false
disulfiram	352-361	glucagon	421-428	false
disulfiram	352-361	ibuprofen	448-456	false
disulfiram	352-361	indomethacin	458-469	false
disulfiram	352-361	influenza virus vaccine	471-493	false
disulfiram	352-361	anesthetics	506-516	false
disulfiram	352-361	mefenamic acid	518-531	false
disulfiram	352-361	methyldopa	533-542	false
disulfiram	352-361	methylphenidate	544-558	false
disulfiram	352-361	metronidazole	560-572	false
disulfiram	352-361	miconazole	574-583	false
disulfiram	352-361	monoamine oxidase inhibitors	585-612	false
disulfiram	352-361	nalidixic acid	614-627	false
disulfiram	352-361	naproxen	629-636	false
disulfiram	352-361	oxolinic acid	638-650	false
disulfiram	352-361	oxyphenbutazone	652-666	false
disulfiram	352-361	pentoxifylline	668-681	false
disulfiram	352-361	phenylbutazone	683-696	false
disulfiram	352-361	phenyramidol	698-709	false
disulfiram	352-361	phenytoin	711-719	false
disulfiram	352-361	prolonged narcotics	743-761	false
disulfiram	352-361	pyrazolones	763-773	false
disulfiram	352-361	quinidine	775-783	false
disulfiram	352-361	quinine	785-791	false
disulfiram	352-361	ranitidine	793-802	false
disulfiram	352-361	salicylates	805-815	false
disulfiram	352-361	sulfinpyrazone	817-830	false
disulfiram	352-361	sulfonamides	832-843	false
disulfiram	352-361	sulindac	858-865	false
disulfiram	352-361	thyroid drugs	867-879	false
disulfiram	352-361	tolbutamide	881-891	false
disulfiram	352-361	triclofos sodium	893-908	false
disulfiram	352-361	trimethoprim	910-921	false
disulfiram	352-361	sulfamethoxazole	923-938	false
disulfiram	352-361	warfarin sodium	983-997	false
ethacrynic acid	394-408	fenoprofen	410-419	false
ethacrynic acid	394-408	glucagon	421-428	false
ethacrynic acid	394-408	ibuprofen	448-456	false
ethacrynic acid	394-408	indomethacin	458-469	false
ethacrynic acid	394-408	influenza virus vaccine	471-493	false
ethacrynic acid	394-408	anesthetics	506-516	false
ethacrynic acid	394-408	mefenamic acid	518-531	false
ethacrynic acid	394-408	methyldopa	533-542	false
ethacrynic acid	394-408	methylphenidate	544-558	false
ethacrynic acid	394-408	metronidazole	560-572	false
ethacrynic acid	394-408	miconazole	574-583	false
ethacrynic acid	394-408	monoamine oxidase inhibitors	585-612	false
ethacrynic acid	394-408	nalidixic acid	614-627	false
ethacrynic acid	394-408	naproxen	629-636	false
ethacrynic acid	394-408	oxolinic acid	638-650	false
ethacrynic acid	394-408	oxyphenbutazone	652-666	false
ethacrynic acid	394-408	pentoxifylline	668-681	false
ethacrynic acid	394-408	phenylbutazone	683-696	false
ethacrynic acid	394-408	phenyramidol	698-709	false
ethacrynic acid	394-408	phenytoin	711-719	false
ethacrynic acid	394-408	prolonged narcotics	743-761	false
ethacrynic acid	394-408	pyrazolones	763-773	false
ethacrynic acid	394-408	quinidine	775-783	false
ethacrynic acid	394-408	quinine	785-791	false
ethacrynic acid	394-408	ranitidine	793-802	false
ethacrynic acid	394-408	salicylates	805-815	false
ethacrynic acid	394-408	sulfinpyrazone	817-830	false
ethacrynic acid	394-408	sulfonamides	832-843	false
ethacrynic acid	394-408	sulindac	858-865	false
ethacrynic acid	394-408	thyroid drugs	867-879	false
ethacrynic acid	394-408	tolbutamide	881-891	false
ethacrynic acid	394-408	triclofos sodium	893-908	false
ethacrynic acid	394-408	trimethoprim	910-921	false
ethacrynic acid	394-408	sulfamethoxazole	923-938	false
ethacrynic acid	394-408	warfarin sodium	983-997	false
fenoprofen	410-419	glucagon	421-428	false
fenoprofen	410-419	ibuprofen	448-456	false
fenoprofen	410-419	indomethacin	458-469	false
fenoprofen	410-419	influenza virus vaccine	471-493	false
fenoprofen	410-419	anesthetics	506-516	false
fenoprofen	410-419	mefenamic acid	518-531	false
fenoprofen	410-419	methyldopa	533-542	false
fenoprofen	410-419	methylphenidate	544-558	false
fenoprofen	410-419	metronidazole	560-572	false
fenoprofen	410-419	miconazole	574-583	false
fenoprofen	410-419	monoamine oxidase inhibitors	585-612	false
fenoprofen	410-419	nalidixic acid	614-627	false
fenoprofen	410-419	naproxen	629-636	false
fenoprofen	410-419	oxolinic acid	638-650	false
fenoprofen	410-419	oxyphenbutazone	652-666	false
fenoprofen	410-419	pentoxifylline	668-681	false
fenoprofen	410-419	phenylbutazone	683-696	false
fenoprofen	410-419	phenyramidol	698-709	false
fenoprofen	410-419	phenytoin	711-719	false
fenoprofen	410-419	prolonged narcotics	743-761	false
fenoprofen	410-419	pyrazolones	763-773	false
fenoprofen	410-419	quinidine	775-783	false
fenoprofen	410-419	quinine	785-791	false
fenoprofen	410-419	ranitidine	793-802	false
fenoprofen	410-419	salicylates	805-815	false
fenoprofen	410-419	sulfinpyrazone	817-830	false
fenoprofen	410-419	sulfonamides	832-843	false
fenoprofen	410-419	sulindac	858-865	false
fenoprofen	410-419	thyroid drugs	867-879	false
fenoprofen	410-419	tolbutamide	881-891	false
fenoprofen	410-419	triclofos sodium	893-908	false
fenoprofen	410-419	trimethoprim	910-921	false
fenoprofen	410-419	sulfamethoxazole	923-938	false
fenoprofen	410-419	warfarin sodium	983-997	false
glucagon	421-428	ibuprofen	448-456	false
glucagon	421-428	indomethacin	458-469	false
glucagon	421-428	influenza virus vaccine	471-493	false
glucagon	421-428	anesthetics	506-516	false
glucagon	421-428	mefenamic acid	518-531	false
glucagon	421-428	methyldopa	533-542	false
glucagon	421-428	methylphenidate	544-558	false
glucagon	421-428	metronidazole	560-572	false
glucagon	421-428	miconazole	574-583	false
glucagon	421-428	monoamine oxidase inhibitors	585-612	false
glucagon	421-428	nalidixic acid	614-627	false
glucagon	421-428	naproxen	629-636	false
glucagon	421-428	oxolinic acid	638-650	false
glucagon	421-428	oxyphenbutazone	652-666	false
glucagon	421-428	pentoxifylline	668-681	false
glucagon	421-428	phenylbutazone	683-696	false
glucagon	421-428	phenyramidol	698-709	false
glucagon	421-428	phenytoin	711-719	false
glucagon	421-428	prolonged narcotics	743-761	false
glucagon	421-428	pyrazolones	763-773	false
glucagon	421-428	quinidine	775-783	false
glucagon	421-428	quinine	785-791	false
glucagon	421-428	ranitidine	793-802	false
glucagon	421-428	salicylates	805-815	false
glucagon	421-428	sulfinpyrazone	817-830	false
glucagon	421-428	sulfonamides	832-843	false
glucagon	421-428	sulindac	858-865	false
glucagon	421-428	thyroid drugs	867-879	false
glucagon	421-428	tolbutamide	881-891	false
glucagon	421-428	triclofos sodium	893-908	false
glucagon	421-428	trimethoprim	910-921	false
glucagon	421-428	sulfamethoxazole	923-938	false
glucagon	421-428	warfarin sodium	983-997	false
ibuprofen	448-456	indomethacin	458-469	false
ibuprofen	448-456	influenza virus vaccine	471-493	false
ibuprofen	448-456	anesthetics	506-516	false
ibuprofen	448-456	mefenamic acid	518-531	false
ibuprofen	448-456	methyldopa	533-542	false
ibuprofen	448-456	methylphenidate	544-558	false
ibuprofen	448-456	metronidazole	560-572	false
ibuprofen	448-456	miconazole	574-583	false
ibuprofen	448-456	monoamine oxidase inhibitors	585-612	false
ibuprofen	448-456	nalidixic acid	614-627	false
ibuprofen	448-456	naproxen	629-636	false
ibuprofen	448-456	oxolinic acid	638-650	false
ibuprofen	448-456	oxyphenbutazone	652-666	false
ibuprofen	448-456	pentoxifylline	668-681	false
ibuprofen	448-456	phenylbutazone	683-696	false
ibuprofen	448-456	phenyramidol	698-709	false
ibuprofen	448-456	phenytoin	711-719	false
ibuprofen	448-456	prolonged narcotics	743-761	false
ibuprofen	448-456	pyrazolones	763-773	false
ibuprofen	448-456	quinidine	775-783	false
ibuprofen	448-456	quinine	785-791	false
ibuprofen	448-456	ranitidine	793-802	false
ibuprofen	448-456	salicylates	805-815	false
ibuprofen	448-456	sulfinpyrazone	817-830	false
ibuprofen	448-456	sulfonamides	832-843	false
ibuprofen	448-456	sulindac	858-865	false
ibuprofen	448-456	thyroid drugs	867-879	false
ibuprofen	448-456	tolbutamide	881-891	false
ibuprofen	448-456	triclofos sodium	893-908	false
ibuprofen	448-456	trimethoprim	910-921	false
ibuprofen	448-456	sulfamethoxazole	923-938	false
ibuprofen	448-456	warfarin sodium	983-997	false
indomethacin	458-469	influenza virus vaccine	471-493	false
indomethacin	458-469	anesthetics	506-516	false
indomethacin	458-469	mefenamic acid	518-531	false
indomethacin	458-469	methyldopa	533-542	false
indomethacin	458-469	methylphenidate	544-558	false
indomethacin	458-469	metronidazole	560-572	false
indomethacin	458-469	miconazole	574-583	false
indomethacin	458-469	monoamine oxidase inhibitors	585-612	false
indomethacin	458-469	nalidixic acid	614-627	false
indomethacin	458-469	naproxen	629-636	false
indomethacin	458-469	oxolinic acid	638-650	false
indomethacin	458-469	oxyphenbutazone	652-666	false
indomethacin	458-469	pentoxifylline	668-681	false
indomethacin	458-469	phenylbutazone	683-696	false
indomethacin	458-469	phenyramidol	698-709	false
indomethacin	458-469	phenytoin	711-719	false
indomethacin	458-469	prolonged narcotics	743-761	false
indomethacin	458-469	pyrazolones	763-773	false
indomethacin	458-469	quinidine	775-783	false
indomethacin	458-469	quinine	785-791	false
indomethacin	458-469	ranitidine	793-802	false
indomethacin	458-469	salicylates	805-815	false
indomethacin	458-469	sulfinpyrazone	817-830	false
indomethacin	458-469	sulfonamides	832-843	false
indomethacin	458-469	sulindac	858-865	false
indomethacin	458-469	thyroid drugs	867-879	false
indomethacin	458-469	tolbutamide	881-891	false
indomethacin	458-469	triclofos sodium	893-908	false
indomethacin	458-469	trimethoprim	910-921	false
indomethacin	458-469	sulfamethoxazole	923-938	false
indomethacin	458-469	warfarin sodium	983-997	false
influenza virus vaccine	471-493	anesthetics	506-516	false
influenza virus vaccine	471-493	mefenamic acid	518-531	false
influenza virus vaccine	471-493	methyldopa	533-542	false
influenza virus vaccine	471-493	methylphenidate	544-558	false
influenza virus vaccine	471-493	metronidazole	560-572	false
influenza virus vaccine	471-493	miconazole	574-583	false
influenza virus vaccine	471-493	monoamine oxidase inhibitors	585-612	false
influenza virus vaccine	471-493	nalidixic acid	614-627	false
influenza virus vaccine	471-493	naproxen	629-636	false
influenza virus vaccine	471-493	oxolinic acid	638-650	false
influenza virus vaccine	471-493	oxyphenbutazone	652-666	false
influenza virus vaccine	471-493	pentoxifylline	668-681	false
influenza virus vaccine	471-493	phenylbutazone	683-696	false
influenza virus vaccine	471-493	phenyramidol	698-709	false
influenza virus vaccine	471-493	phenytoin	711-719	false
influenza virus vaccine	471-493	prolonged narcotics	743-761	false
influenza virus vaccine	471-493	pyrazolones	763-773	false
influenza virus vaccine	471-493	quinidine	775-783	false
influenza virus vaccine	471-493	quinine	785-791	false
influenza virus vaccine	471-493	ranitidine	793-802	false
influenza virus vaccine	471-493	salicylates	805-815	false
influenza virus vaccine	471-493	sulfinpyrazone	817-830	false
influenza virus vaccine	471-493	sulfonamides	832-843	false
influenza virus vaccine	471-493	sulindac	858-865	false
influenza virus vaccine	471-493	thyroid drugs	867-879	false
influenza virus vaccine	471-493	tolbutamide	881-891	false
influenza virus vaccine	471-493	triclofos sodium	893-908	false
influenza virus vaccine	471-493	trimethoprim	910-921	false
influenza virus vaccine	471-493	sulfamethoxazole	923-938	false
influenza virus vaccine	471-493	warfarin sodium	983-997	false
anesthetics	506-516	mefenamic acid	518-531	false
anesthetics	506-516	methyldopa	533-542	false
anesthetics	506-516	methylphenidate	544-558	false
anesthetics	506-516	metronidazole	560-572	false
anesthetics	506-516	miconazole	574-583	false
anesthetics	506-516	monoamine oxidase inhibitors	585-612	false
anesthetics	506-516	nalidixic acid	614-627	false
anesthetics	506-516	naproxen	629-636	false
anesthetics	506-516	oxolinic acid	638-650	false
anesthetics	506-516	oxyphenbutazone	652-666	false
anesthetics	506-516	pentoxifylline	668-681	false
anesthetics	506-516	phenylbutazone	683-696	false
anesthetics	506-516	phenyramidol	698-709	false
anesthetics	506-516	phenytoin	711-719	false
anesthetics	506-516	prolonged narcotics	743-761	false
anesthetics	506-516	pyrazolones	763-773	false
anesthetics	506-516	quinidine	775-783	false
anesthetics	506-516	quinine	785-791	false
anesthetics	506-516	ranitidine	793-802	false
anesthetics	506-516	salicylates	805-815	false
anesthetics	506-516	sulfinpyrazone	817-830	false
anesthetics	506-516	sulfonamides	832-843	false
anesthetics	506-516	sulindac	858-865	false
anesthetics	506-516	thyroid drugs	867-879	false
anesthetics	506-516	tolbutamide	881-891	false
anesthetics	506-516	triclofos sodium	893-908	false
anesthetics	506-516	trimethoprim	910-921	false
anesthetics	506-516	sulfamethoxazole	923-938	false
anesthetics	506-516	warfarin sodium	983-997	false
mefenamic acid	518-531	methyldopa	533-542	false
mefenamic acid	518-531	methylphenidate	544-558	false
mefenamic acid	518-531	metronidazole	560-572	false
mefenamic acid	518-531	miconazole	574-583	false
mefenamic acid	518-531	monoamine oxidase inhibitors	585-612	false
mefenamic acid	518-531	nalidixic acid	614-627	false
mefenamic acid	518-531	naproxen	629-636	false
mefenamic acid	518-531	oxolinic acid	638-650	false
mefenamic acid	518-531	oxyphenbutazone	652-666	false
mefenamic acid	518-531	pentoxifylline	668-681	false
mefenamic acid	518-531	phenylbutazone	683-696	false
mefenamic acid	518-531	phenyramidol	698-709	false
mefenamic acid	518-531	phenytoin	711-719	false
mefenamic acid	518-531	prolonged narcotics	743-761	false
mefenamic acid	518-531	pyrazolones	763-773	false
mefenamic acid	518-531	quinidine	775-783	false
mefenamic acid	518-531	quinine	785-791	false
mefenamic acid	518-531	ranitidine	793-802	false
mefenamic acid	518-531	salicylates	805-815	false
mefenamic acid	518-531	sulfinpyrazone	817-830	false
mefenamic acid	518-531	sulfonamides	832-843	false
mefenamic acid	518-531	sulindac	858-865	false
mefenamic acid	518-531	thyroid drugs	867-879	false
mefenamic acid	518-531	tolbutamide	881-891	false
mefenamic acid	518-531	triclofos sodium	893-908	false
mefenamic acid	518-531	trimethoprim	910-921	false
mefenamic acid	518-531	sulfamethoxazole	923-938	false
mefenamic acid	518-531	warfarin sodium	983-997	false
methyldopa	533-542	methylphenidate	544-558	false
methyldopa	533-542	metronidazole	560-572	false
methyldopa	533-542	miconazole	574-583	false
methyldopa	533-542	monoamine oxidase inhibitors	585-612	false
methyldopa	533-542	nalidixic acid	614-627	false
methyldopa	533-542	naproxen	629-636	false
methyldopa	533-542	oxolinic acid	638-650	false
methyldopa	533-542	oxyphenbutazone	652-666	false
methyldopa	533-542	pentoxifylline	668-681	false
methyldopa	533-542	phenylbutazone	683-696	false
methyldopa	533-542	phenyramidol	698-709	false
methyldopa	533-542	phenytoin	711-719	false
methyldopa	533-542	prolonged narcotics	743-761	false
methyldopa	533-542	pyrazolones	763-773	false
methyldopa	533-542	quinidine	775-783	false
methyldopa	533-542	quinine	785-791	false
methyldopa	533-542	ranitidine	793-802	false
methyldopa	533-542	salicylates	805-815	false
methyldopa	533-542	sulfinpyrazone	817-830	false
methyldopa	533-542	sulfonamides	832-843	false
methyldopa	533-542	sulindac	858-865	false
methyldopa	533-542	thyroid drugs	867-879	false
methyldopa	533-542	tolbutamide	881-891	false
methyldopa	533-542	triclofos sodium	893-908	false
methyldopa	533-542	trimethoprim	910-921	false
methyldopa	533-542	sulfamethoxazole	923-938	false
methyldopa	533-542	warfarin sodium	983-997	false
methylphenidate	544-558	metronidazole	560-572	false
methylphenidate	544-558	miconazole	574-583	false
methylphenidate	544-558	monoamine oxidase inhibitors	585-612	false
methylphenidate	544-558	nalidixic acid	614-627	false
methylphenidate	544-558	naproxen	629-636	false
methylphenidate	544-558	oxolinic acid	638-650	false
methylphenidate	544-558	oxyphenbutazone	652-666	false
methylphenidate	544-558	pentoxifylline	668-681	false
methylphenidate	544-558	phenylbutazone	683-696	false
methylphenidate	544-558	phenyramidol	698-709	false
methylphenidate	544-558	phenytoin	711-719	false
methylphenidate	544-558	prolonged narcotics	743-761	false
methylphenidate	544-558	pyrazolones	763-773	false
methylphenidate	544-558	quinidine	775-783	false
methylphenidate	544-558	quinine	785-791	false
methylphenidate	544-558	ranitidine	793-802	false
methylphenidate	544-558	salicylates	805-815	false
methylphenidate	544-558	sulfinpyrazone	817-830	false
methylphenidate	544-558	sulfonamides	832-843	false
methylphenidate	544-558	sulindac	858-865	false
methylphenidate	544-558	thyroid drugs	867-879	false
methylphenidate	544-558	tolbutamide	881-891	false
methylphenidate	544-558	triclofos sodium	893-908	false
methylphenidate	544-558	trimethoprim	910-921	false
methylphenidate	544-558	sulfamethoxazole	923-938	false
methylphenidate	544-558	warfarin sodium	983-997	false
metronidazole	560-572	miconazole	574-583	false
metronidazole	560-572	monoamine oxidase inhibitors	585-612	false
metronidazole	560-572	nalidixic acid	614-627	false
metronidazole	560-572	naproxen	629-636	false
metronidazole	560-572	oxolinic acid	638-650	false
metronidazole	560-572	oxyphenbutazone	652-666	false
metronidazole	560-572	pentoxifylline	668-681	false
metronidazole	560-572	phenylbutazone	683-696	false
metronidazole	560-572	phenyramidol	698-709	false
metronidazole	560-572	phenytoin	711-719	false
metronidazole	560-572	prolonged narcotics	743-761	false
metronidazole	560-572	pyrazolones	763-773	false
metronidazole	560-572	quinidine	775-783	false
metronidazole	560-572	quinine	785-791	false
metronidazole	560-572	ranitidine	793-802	false
metronidazole	560-572	salicylates	805-815	false
metronidazole	560-572	sulfinpyrazone	817-830	false
metronidazole	560-572	sulfonamides	832-843	false
metronidazole	560-572	sulindac	858-865	false
metronidazole	560-572	thyroid drugs	867-879	false
metronidazole	560-572	tolbutamide	881-891	false
metronidazole	560-572	triclofos sodium	893-908	false
metronidazole	560-572	trimethoprim	910-921	false
metronidazole	560-572	sulfamethoxazole	923-938	false
metronidazole	560-572	warfarin sodium	983-997	false
miconazole	574-583	monoamine oxidase inhibitors	585-612	false
miconazole	574-583	nalidixic acid	614-627	false
miconazole	574-583	naproxen	629-636	false
miconazole	574-583	oxolinic acid	638-650	false
miconazole	574-583	oxyphenbutazone	652-666	false
miconazole	574-583	pentoxifylline	668-681	false
miconazole	574-583	phenylbutazone	683-696	false
miconazole	574-583	phenyramidol	698-709	false
miconazole	574-583	phenytoin	711-719	false
miconazole	574-583	prolonged narcotics	743-761	false
miconazole	574-583	pyrazolones	763-773	false
miconazole	574-583	quinidine	775-783	false
miconazole	574-583	quinine	785-791	false
miconazole	574-583	ranitidine	793-802	false
miconazole	574-583	salicylates	805-815	false
miconazole	574-583	sulfinpyrazone	817-830	false
miconazole	574-583	sulfonamides	832-843	false
miconazole	574-583	sulindac	858-865	false
miconazole	574-583	thyroid drugs	867-879	false
miconazole	574-583	tolbutamide	881-891	false
miconazole	574-583	triclofos sodium	893-908	false
miconazole	574-583	trimethoprim	910-921	false
miconazole	574-583	sulfamethoxazole	923-938	false
miconazole	574-583	warfarin sodium	983-997	false
monoamine oxidase inhibitors	585-612	nalidixic acid	614-627	false
monoamine oxidase inhibitors	585-612	naproxen	629-636	false
monoamine oxidase inhibitors	585-612	oxolinic acid	638-650	false
monoamine oxidase inhibitors	585-612	oxyphenbutazone	652-666	false
monoamine oxidase inhibitors	585-612	pentoxifylline	668-681	false
monoamine oxidase inhibitors	585-612	phenylbutazone	683-696	false
monoamine oxidase inhibitors	585-612	phenyramidol	698-709	false
monoamine oxidase inhibitors	585-612	phenytoin	711-719	false
monoamine oxidase inhibitors	585-612	prolonged narcotics	743-761	false
monoamine oxidase inhibitors	585-612	pyrazolones	763-773	false
monoamine oxidase inhibitors	585-612	quinidine	775-783	false
monoamine oxidase inhibitors	585-612	quinine	785-791	false
monoamine oxidase inhibitors	585-612	ranitidine	793-802	false
monoamine oxidase inhibitors	585-612	salicylates	805-815	false
monoamine oxidase inhibitors	585-612	sulfinpyrazone	817-830	false
monoamine oxidase inhibitors	585-612	sulfonamides	832-843	false
monoamine oxidase inhibitors	585-612	sulindac	858-865	false
monoamine oxidase inhibitors	585-612	thyroid drugs	867-879	false
monoamine oxidase inhibitors	585-612	tolbutamide	881-891	false
monoamine oxidase inhibitors	585-612	triclofos sodium	893-908	false
monoamine oxidase inhibitors	585-612	trimethoprim	910-921	false
monoamine oxidase inhibitors	585-612	sulfamethoxazole	923-938	false
monoamine oxidase inhibitors	585-612	warfarin sodium	983-997	false
nalidixic acid	614-627	naproxen	629-636	false
nalidixic acid	614-627	oxolinic acid	638-650	false
nalidixic acid	614-627	oxyphenbutazone	652-666	false
nalidixic acid	614-627	pentoxifylline	668-681	false
nalidixic acid	614-627	phenylbutazone	683-696	false
nalidixic acid	614-627	phenyramidol	698-709	false
nalidixic acid	614-627	phenytoin	711-719	false
nalidixic acid	614-627	prolonged narcotics	743-761	false
nalidixic acid	614-627	pyrazolones	763-773	false
nalidixic acid	614-627	quinidine	775-783	false
nalidixic acid	614-627	quinine	785-791	false
nalidixic acid	614-627	ranitidine	793-802	false
nalidixic acid	614-627	salicylates	805-815	false
nalidixic acid	614-627	sulfinpyrazone	817-830	false
nalidixic acid	614-627	sulfonamides	832-843	false
nalidixic acid	614-627	sulindac	858-865	false
nalidixic acid	614-627	thyroid drugs	867-879	false
nalidixic acid	614-627	tolbutamide	881-891	false
nalidixic acid	614-627	triclofos sodium	893-908	false
nalidixic acid	614-627	trimethoprim	910-921	false
nalidixic acid	614-627	sulfamethoxazole	923-938	false
nalidixic acid	614-627	warfarin sodium	983-997	false
naproxen	629-636	oxolinic acid	638-650	false
naproxen	629-636	oxyphenbutazone	652-666	false
naproxen	629-636	pentoxifylline	668-681	false
naproxen	629-636	phenylbutazone	683-696	false
naproxen	629-636	phenyramidol	698-709	false
naproxen	629-636	phenytoin	711-719	false
naproxen	629-636	prolonged narcotics	743-761	false
naproxen	629-636	pyrazolones	763-773	false
naproxen	629-636	quinidine	775-783	false
naproxen	629-636	quinine	785-791	false
naproxen	629-636	ranitidine	793-802	false
naproxen	629-636	salicylates	805-815	false
naproxen	629-636	sulfinpyrazone	817-830	false
naproxen	629-636	sulfonamides	832-843	false
naproxen	629-636	sulindac	858-865	false
naproxen	629-636	thyroid drugs	867-879	false
naproxen	629-636	tolbutamide	881-891	false
naproxen	629-636	triclofos sodium	893-908	false
naproxen	629-636	trimethoprim	910-921	false
naproxen	629-636	sulfamethoxazole	923-938	false
naproxen	629-636	warfarin sodium	983-997	false
oxolinic acid	638-650	oxyphenbutazone	652-666	false
oxolinic acid	638-650	pentoxifylline	668-681	false
oxolinic acid	638-650	phenylbutazone	683-696	false
oxolinic acid	638-650	phenyramidol	698-709	false
oxolinic acid	638-650	phenytoin	711-719	false
oxolinic acid	638-650	prolonged narcotics	743-761	false
oxolinic acid	638-650	pyrazolones	763-773	false
oxolinic acid	638-650	quinidine	775-783	false
oxolinic acid	638-650	quinine	785-791	false
oxolinic acid	638-650	ranitidine	793-802	false
oxolinic acid	638-650	salicylates	805-815	false
oxolinic acid	638-650	sulfinpyrazone	817-830	false
oxolinic acid	638-650	sulfonamides	832-843	false
oxolinic acid	638-650	sulindac	858-865	false
oxolinic acid	638-650	thyroid drugs	867-879	false
oxolinic acid	638-650	tolbutamide	881-891	false
oxolinic acid	638-650	triclofos sodium	893-908	false
oxolinic acid	638-650	trimethoprim	910-921	false
oxolinic acid	638-650	sulfamethoxazole	923-938	false
oxolinic acid	638-650	warfarin sodium	983-997	false
oxyphenbutazone	652-666	pentoxifylline	668-681	false
oxyphenbutazone	652-666	phenylbutazone	683-696	false
oxyphenbutazone	652-666	phenyramidol	698-709	false
oxyphenbutazone	652-666	phenytoin	711-719	false
oxyphenbutazone	652-666	prolonged narcotics	743-761	false
oxyphenbutazone	652-666	pyrazolones	763-773	false
oxyphenbutazone	652-666	quinidine	775-783	false
oxyphenbutazone	652-666	quinine	785-791	false
oxyphenbutazone	652-666	ranitidine	793-802	false
oxyphenbutazone	652-666	salicylates	805-815	false
oxyphenbutazone	652-666	sulfinpyrazone	817-830	false
oxyphenbutazone	652-666	sulfonamides	832-843	false
oxyphenbutazone	652-666	sulindac	858-865	false
oxyphenbutazone	652-666	thyroid drugs	867-879	false
oxyphenbutazone	652-666	tolbutamide	881-891	false
oxyphenbutazone	652-666	triclofos sodium	893-908	false
oxyphenbutazone	652-666	trimethoprim	910-921	false
oxyphenbutazone	652-666	sulfamethoxazole	923-938	false
oxyphenbutazone	652-666	warfarin sodium	983-997	false
pentoxifylline	668-681	phenylbutazone	683-696	false
pentoxifylline	668-681	phenyramidol	698-709	false
pentoxifylline	668-681	phenytoin	711-719	false
pentoxifylline	668-681	prolonged narcotics	743-761	false
pentoxifylline	668-681	pyrazolones	763-773	false
pentoxifylline	668-681	quinidine	775-783	false
pentoxifylline	668-681	quinine	785-791	false
pentoxifylline	668-681	ranitidine	793-802	false
pentoxifylline	668-681	salicylates	805-815	false
pentoxifylline	668-681	sulfinpyrazone	817-830	false
pentoxifylline	668-681	sulfonamides	832-843	false
pentoxifylline	668-681	sulindac	858-865	false
pentoxifylline	668-681	thyroid drugs	867-879	false
pentoxifylline	668-681	tolbutamide	881-891	false
pentoxifylline	668-681	triclofos sodium	893-908	false
pentoxifylline	668-681	trimethoprim	910-921	false
pentoxifylline	668-681	sulfamethoxazole	923-938	false
pentoxifylline	668-681	warfarin sodium	983-997	false
phenylbutazone	683-696	phenyramidol	698-709	false
phenylbutazone	683-696	phenytoin	711-719	false
phenylbutazone	683-696	prolonged narcotics	743-761	false
phenylbutazone	683-696	pyrazolones	763-773	false
phenylbutazone	683-696	quinidine	775-783	false
phenylbutazone	683-696	quinine	785-791	false
phenylbutazone	683-696	ranitidine	793-802	false
phenylbutazone	683-696	salicylates	805-815	false
phenylbutazone	683-696	sulfinpyrazone	817-830	false
phenylbutazone	683-696	sulfonamides	832-843	false
phenylbutazone	683-696	sulindac	858-865	false
phenylbutazone	683-696	thyroid drugs	867-879	false
phenylbutazone	683-696	tolbutamide	881-891	false
phenylbutazone	683-696	triclofos sodium	893-908	false
phenylbutazone	683-696	trimethoprim	910-921	false
phenylbutazone	683-696	sulfamethoxazole	923-938	false
phenylbutazone	683-696	warfarin sodium	983-997	false
phenyramidol	698-709	phenytoin	711-719	false
phenyramidol	698-709	prolonged narcotics	743-761	false
phenyramidol	698-709	pyrazolones	763-773	false
phenyramidol	698-709	quinidine	775-783	false
phenyramidol	698-709	quinine	785-791	false
phenyramidol	698-709	ranitidine	793-802	false
phenyramidol	698-709	salicylates	805-815	false
phenyramidol	698-709	sulfinpyrazone	817-830	false
phenyramidol	698-709	sulfonamides	832-843	false
phenyramidol	698-709	sulindac	858-865	false
phenyramidol	698-709	thyroid drugs	867-879	false
phenyramidol	698-709	tolbutamide	881-891	false
phenyramidol	698-709	triclofos sodium	893-908	false
phenyramidol	698-709	trimethoprim	910-921	false
phenyramidol	698-709	sulfamethoxazole	923-938	false
phenyramidol	698-709	warfarin sodium	983-997	false
phenytoin	711-719	prolonged narcotics	743-761	false
phenytoin	711-719	pyrazolones	763-773	false
phenytoin	711-719	quinidine	775-783	false
phenytoin	711-719	quinine	785-791	false
phenytoin	711-719	ranitidine	793-802	false
phenytoin	711-719	salicylates	805-815	false
phenytoin	711-719	sulfinpyrazone	817-830	false
phenytoin	711-719	sulfonamides	832-843	false
phenytoin	711-719	sulindac	858-865	false
phenytoin	711-719	thyroid drugs	867-879	false
phenytoin	711-719	tolbutamide	881-891	false
phenytoin	711-719	triclofos sodium	893-908	false
phenytoin	711-719	trimethoprim	910-921	false
phenytoin	711-719	sulfamethoxazole	923-938	false
phenytoin	711-719	warfarin sodium	983-997	false
prolonged narcotics	743-761	pyrazolones	763-773	false
prolonged narcotics	743-761	quinidine	775-783	false
prolonged narcotics	743-761	quinine	785-791	false
prolonged narcotics	743-761	ranitidine	793-802	false
prolonged narcotics	743-761	salicylates	805-815	false
prolonged narcotics	743-761	sulfinpyrazone	817-830	false
prolonged narcotics	743-761	sulfonamides	832-843	false
prolonged narcotics	743-761	sulindac	858-865	false
prolonged narcotics	743-761	thyroid drugs	867-879	false
prolonged narcotics	743-761	tolbutamide	881-891	false
prolonged narcotics	743-761	triclofos sodium	893-908	false
prolonged narcotics	743-761	trimethoprim	910-921	false
prolonged narcotics	743-761	sulfamethoxazole	923-938	false
prolonged narcotics	743-761	warfarin sodium	983-997	false
pyrazolones	763-773	quinidine	775-783	false
pyrazolones	763-773	quinine	785-791	false
pyrazolones	763-773	ranitidine	793-802	false
pyrazolones	763-773	salicylates	805-815	false
pyrazolones	763-773	sulfinpyrazone	817-830	false
pyrazolones	763-773	sulfonamides	832-843	false
pyrazolones	763-773	sulindac	858-865	false
pyrazolones	763-773	thyroid drugs	867-879	false
pyrazolones	763-773	tolbutamide	881-891	false
pyrazolones	763-773	triclofos sodium	893-908	false
pyrazolones	763-773	trimethoprim	910-921	false
pyrazolones	763-773	sulfamethoxazole	923-938	false
pyrazolones	763-773	warfarin sodium	983-997	false
quinidine	775-783	quinine	785-791	false
quinidine	775-783	ranitidine	793-802	false
quinidine	775-783	salicylates	805-815	false
quinidine	775-783	sulfinpyrazone	817-830	false
quinidine	775-783	sulfonamides	832-843	false
quinidine	775-783	sulindac	858-865	false
quinidine	775-783	thyroid drugs	867-879	false
quinidine	775-783	tolbutamide	881-891	false
quinidine	775-783	triclofos sodium	893-908	false
quinidine	775-783	trimethoprim	910-921	false
quinidine	775-783	sulfamethoxazole	923-938	false
quinidine	775-783	warfarin sodium	983-997	false
quinine	785-791	ranitidine	793-802	false
quinine	785-791	salicylates	805-815	false
quinine	785-791	sulfinpyrazone	817-830	false
quinine	785-791	sulfonamides	832-843	false
quinine	785-791	sulindac	858-865	false
quinine	785-791	thyroid drugs	867-879	false
quinine	785-791	tolbutamide	881-891	false
quinine	785-791	triclofos sodium	893-908	false
quinine	785-791	trimethoprim	910-921	false
quinine	785-791	sulfamethoxazole	923-938	false
quinine	785-791	warfarin sodium	983-997	false
ranitidine	793-802	salicylates	805-815	false
ranitidine	793-802	sulfinpyrazone	817-830	false
ranitidine	793-802	sulfonamides	832-843	false
ranitidine	793-802	sulindac	858-865	false
ranitidine	793-802	thyroid drugs	867-879	false
ranitidine	793-802	tolbutamide	881-891	false
ranitidine	793-802	triclofos sodium	893-908	false
ranitidine	793-802	trimethoprim	910-921	false
ranitidine	793-802	sulfamethoxazole	923-938	false
ranitidine	793-802	warfarin sodium	983-997	false
salicylates	805-815	sulfinpyrazone	817-830	false
salicylates	805-815	sulfonamides	832-843	false
salicylates	805-815	sulindac	858-865	false
salicylates	805-815	thyroid drugs	867-879	false
salicylates	805-815	tolbutamide	881-891	false
salicylates	805-815	triclofos sodium	893-908	false
salicylates	805-815	trimethoprim	910-921	false
salicylates	805-815	sulfamethoxazole	923-938	false
salicylates	805-815	warfarin sodium	983-997	false
sulfinpyrazone	817-830	sulfonamides	832-843	false
sulfinpyrazone	817-830	sulindac	858-865	false
sulfinpyrazone	817-830	thyroid drugs	867-879	false
sulfinpyrazone	817-830	tolbutamide	881-891	false
sulfinpyrazone	817-830	triclofos sodium	893-908	false
sulfinpyrazone	817-830	trimethoprim	910-921	false
sulfinpyrazone	817-830	sulfamethoxazole	923-938	false
sulfinpyrazone	817-830	warfarin sodium	983-997	false
sulfonamides	832-843	sulindac	858-865	false
sulfonamides	832-843	thyroid drugs	867-879	false
sulfonamides	832-843	tolbutamide	881-891	false
sulfonamides	832-843	triclofos sodium	893-908	false
sulfonamides	832-843	trimethoprim	910-921	false
sulfonamides	832-843	sulfamethoxazole	923-938	false
sulfonamides	832-843	warfarin sodium	983-997	false
sulindac	858-865	thyroid drugs	867-879	false
sulindac	858-865	tolbutamide	881-891	false
sulindac	858-865	triclofos sodium	893-908	false
sulindac	858-865	trimethoprim	910-921	false
sulindac	858-865	sulfamethoxazole	923-938	false
sulindac	858-865	warfarin sodium	983-997	false
thyroid drugs	867-879	tolbutamide	881-891	false
thyroid drugs	867-879	triclofos sodium	893-908	false
thyroid drugs	867-879	trimethoprim	910-921	false
thyroid drugs	867-879	sulfamethoxazole	923-938	false
thyroid drugs	867-879	warfarin sodium	983-997	false
tolbutamide	881-891	triclofos sodium	893-908	false
tolbutamide	881-891	trimethoprim	910-921	false
tolbutamide	881-891	sulfamethoxazole	923-938	false
tolbutamide	881-891	warfarin sodium	983-997	false
triclofos sodium	893-908	trimethoprim	910-921	false
triclofos sodium	893-908	sulfamethoxazole	923-938	false
triclofos sodium	893-908	warfarin sodium	983-997	false
trimethoprim	910-921	sulfamethoxazole	923-938	false
trimethoprim	910-921	warfarin sodium	983-997	false
sulfamethoxazole	923-938	warfarin sodium	983-997	false

Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
anticoagulants	5-18	hypoglycemic agents	62-80	mechanism
anticoagulants	5-18	tolbutamide	87-97	mechanism
anticoagulants	5-18	chlorpropamide	103-116	mechanism
hypoglycemic agents	62-80	tolbutamide	87-97	false
hypoglycemic agents	62-80	chlorpropamide	103-116	false
tolbutamide	87-97	chlorpropamide	103-116	false

Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
anticoagulants	13-26	phenytoin	73-81	mechanism
anticoagulants	13-26	anticonvulsant	104-117	false
anticoagulants	13-26	anticoagulant	142-154	false
anticoagulants	13-26	phenytoin	160-168	false
phenytoin	73-81	anticonvulsant	104-117	false
phenytoin	73-81	anticoagulant	142-154	false
phenytoin	73-81	phenytoin	160-168	false
anticonvulsant	104-117	anticoagulant	142-154	false
anticonvulsant	104-117	phenytoin	160-168	false
anticoagulant	142-154	phenytoin	160-168	mechanism

Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
antineoplastic agents	91-111	aspirin	160-166	false
antineoplastic agents	91-111	non-steroidal anti-inflammatory drugs	178-214	false
antineoplastic agents	91-111	dipyridamole	217-228	false
antineoplastic agents	91-111	hydrochloroquine	231-246	false
antineoplastic agents	91-111	clofibrate	249-258	false
antineoplastic agents	91-111	dextran	261-267	false
antineoplastic agents	91-111	anticoagulants	317-330	effect
aspirin	160-166	non-steroidal anti-inflammatory drugs	178-214	false
aspirin	160-166	dipyridamole	217-228	false
aspirin	160-166	hydrochloroquine	231-246	false
aspirin	160-166	clofibrate	249-258	false
aspirin	160-166	dextran	261-267	false
aspirin	160-166	anticoagulants	317-330	effect
non-steroidal anti-inflammatory drugs	178-214	dipyridamole	217-228	false
non-steroidal anti-inflammatory drugs	178-214	hydrochloroquine	231-246	false
non-steroidal anti-inflammatory drugs	178-214	clofibrate	249-258	false
non-steroidal anti-inflammatory drugs	178-214	dextran	261-267	false
non-steroidal anti-inflammatory drugs	178-214	anticoagulants	317-330	effect
dipyridamole	217-228	hydrochloroquine	231-246	false
dipyridamole	217-228	clofibrate	249-258	false
dipyridamole	217-228	dextran	261-267	false
dipyridamole	217-228	anticoagulants	317-330	effect
hydrochloroquine	231-246	clofibrate	249-258	false
hydrochloroquine	231-246	dextran	261-267	false
hydrochloroquine	231-246	anticoagulants	317-330	effect
clofibrate	249-258	dextran	261-267	false
clofibrate	249-258	anticoagulants	317-330	effect
dextran	261-267	anticoagulants	317-330	effect

The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
antiplatelet medication	81-92;112-121	anticoagulant medication	98-121	advise

Drug/Laboratory Test Interferences: Dicumarol and indanedione anticoagulants, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
Dicumarol	36-44	indanedione anticoagulants	50-75	false
Dicumarol	36-44	anisindione	88-98	false
indanedione anticoagulants	50-75	anisindione	88-98	false

5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
5HT3 Antagonists	0-15	apomorphine	90-100	false
5HT3 Antagonists	0-15	ondansetron	124-134	false
5HT3 Antagonists	0-15	apomorphine	160-170	false
5HT3 Antagonists	0-15	5HT3 antagonist class	190-210	false
5HT3 Antagonists	0-15	ondansetron	237-247	false
5HT3 Antagonists	0-15	granisetron	250-260	false
5HT3 Antagonists	0-15	dolasetron	263-272	false
5HT3 Antagonists	0-15	palonosetron	275-286	false
5HT3 Antagonists	0-15	alosetron	293-301	false
apomorphine	90-100	ondansetron	124-134	effect
apomorphine	90-100	apomorphine	160-170	false
apomorphine	90-100	5HT3 antagonist class	190-210	false
apomorphine	90-100	ondansetron	237-247	false
apomorphine	90-100	granisetron	250-260	false
apomorphine	90-100	dolasetron	263-272	false
apomorphine	90-100	palonosetron	275-286	false
apomorphine	90-100	alosetron	293-301	false
ondansetron	124-134	apomorphine	160-170	false
ondansetron	124-134	5HT3 antagonist class	190-210	false
ondansetron	124-134	ondansetron	237-247	false
ondansetron	124-134	granisetron	250-260	false
ondansetron	124-134	dolasetron	263-272	false
ondansetron	124-134	palonosetron	275-286	false
ondansetron	124-134	alosetron	293-301	false
apomorphine	160-170	5HT3 antagonist class	190-210	advise
apomorphine	160-170	ondansetron	237-247	advise
apomorphine	160-170	granisetron	250-260	advise
apomorphine	160-170	dolasetron	263-272	advise
apomorphine	160-170	palonosetron	275-286	advise
apomorphine	160-170	alosetron	293-301	advise
5HT3 antagonist class	190-210	ondansetron	237-247	false
5HT3 antagonist class	190-210	granisetron	250-260	false
5HT3 antagonist class	190-210	dolasetron	263-272	false
5HT3 antagonist class	190-210	palonosetron	275-286	false
5HT3 antagonist class	190-210	alosetron	293-301	false
ondansetron	237-247	granisetron	250-260	false
ondansetron	237-247	dolasetron	263-272	false
ondansetron	237-247	palonosetron	275-286	false
ondansetron	237-247	alosetron	293-301	false
granisetron	250-260	dolasetron	263-272	false
granisetron	250-260	palonosetron	275-286	false
granisetron	250-260	alosetron	293-301	false
dolasetron	263-272	palonosetron	275-286	false
dolasetron	263-272	alosetron	293-301	false
palonosetron	275-286	alosetron	293-301	false

Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
Antihypertensive Medication	0-26	Vasodilators	33-44	false
Antihypertensive Medication	0-26	antihypertensive medications	141-168	false
Antihypertensive Medication	0-26	vasodilators	173-184	false
Vasodilators	33-44	antihypertensive medications	141-168	false
Vasodilators	33-44	vasodilators	173-184	false
antihypertensive medications	141-168	vasodilators	173-184	effect

Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
Dopamine Antagonists	0-19	apomorphine	28-38	false
Dopamine Antagonists	0-19	dopamine agonist	45-60	false
Dopamine Antagonists	0-19	dopamine antagonists	83-102	false
Dopamine Antagonists	0-19	neuroleptics	117-128	false
Dopamine Antagonists	0-19	phenothiazines	131-144	false
Dopamine Antagonists	0-19	butyrophenones	147-160	false
Dopamine Antagonists	0-19	thioxanthenes	163-175	false
Dopamine Antagonists	0-19	metoclopramide	181-194	false
Dopamine Antagonists	0-19	APOKYN	231-236	false
apomorphine	28-38	dopamine agonist	45-60	false
apomorphine	28-38	dopamine antagonists	83-102	false
apomorphine	28-38	neuroleptics	117-128	false
apomorphine	28-38	phenothiazines	131-144	false
apomorphine	28-38	butyrophenones	147-160	false
apomorphine	28-38	thioxanthenes	163-175	false
apomorphine	28-38	metoclopramide	181-194	false
apomorphine	28-38	APOKYN	231-236	false
dopamine agonist	45-60	dopamine antagonists	83-102	false
dopamine agonist	45-60	neuroleptics	117-128	false
dopamine agonist	45-60	phenothiazines	131-144	false
dopamine agonist	45-60	butyrophenones	147-160	false
dopamine agonist	45-60	thioxanthenes	163-175	false
dopamine agonist	45-60	metoclopramide	181-194	false
dopamine agonist	45-60	APOKYN	231-236	false
dopamine antagonists	83-102	neuroleptics	117-128	false
dopamine antagonists	83-102	phenothiazines	131-144	false
dopamine antagonists	83-102	butyrophenones	147-160	false
dopamine antagonists	83-102	thioxanthenes	163-175	false
dopamine antagonists	83-102	metoclopramide	181-194	effect
dopamine antagonists	83-102	APOKYN	231-236	false
neuroleptics	117-128	phenothiazines	131-144	false
neuroleptics	117-128	butyrophenones	147-160	false
neuroleptics	117-128	thioxanthenes	163-175	false
neuroleptics	117-128	metoclopramide	181-194	false
neuroleptics	117-128	APOKYN	231-236	false
phenothiazines	131-144	butyrophenones	147-160	false
phenothiazines	131-144	thioxanthenes	163-175	false
phenothiazines	131-144	metoclopramide	181-194	false
phenothiazines	131-144	APOKYN	231-236	effect
butyrophenones	147-160	thioxanthenes	163-175	false
butyrophenones	147-160	metoclopramide	181-194	false
butyrophenones	147-160	APOKYN	231-236	effect
thioxanthenes	163-175	metoclopramide	181-194	false
thioxanthenes	163-175	APOKYN	231-236	effect
metoclopramide	181-194	APOKYN	231-236	effect

Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
neuroleptics	54-65	dopamine agonists	91-107	advise

Apraclonidine should not be used in patients receiving MAO inhibitors..
Apraclonidine	0-12	MAO inhibitors	55-68	advise

Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
IOPIDINE	130-137	CNS depressants	224-238	advise
IOPIDINE	130-137	alcohol	241-247	advise
IOPIDINE	130-137	barbiturates	250-261	advise
IOPIDINE	130-137	opiates	264-270	advise
IOPIDINE	130-137	sedatives	273-281	advise
IOPIDINE	130-137	anesthetics	284-294	advise
CNS depressants	224-238	alcohol	241-247	false
CNS depressants	224-238	barbiturates	250-261	false
CNS depressants	224-238	opiates	264-270	false
CNS depressants	224-238	sedatives	273-281	false
CNS depressants	224-238	anesthetics	284-294	false
alcohol	241-247	barbiturates	250-261	false
alcohol	241-247	opiates	264-270	false
alcohol	241-247	sedatives	273-281	false
alcohol	241-247	anesthetics	284-294	false
barbiturates	250-261	opiates	264-270	false
barbiturates	250-261	sedatives	273-281	false
barbiturates	250-261	anesthetics	284-294	false
opiates	264-270	sedatives	273-281	false
opiates	264-270	anesthetics	284-294	false
sedatives	273-281	anesthetics	284-294	false

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
Tricyclic antidepressants	0-24	clonidine	89-97	effect

An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
clonidine	82-90	neuroleptic	96-106	effect

Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
apraclonidine	6-18	beta-blockers	88-100	advise
apraclonidine	6-18	antihypertensives	129-145	advise
apraclonidine	6-18	cardiac glycosides	152-169	advise
beta-blockers	88-100	antihypertensives	129-145	false
beta-blockers	88-100	cardiac glycosides	152-169	false
antihypertensives	129-145	cardiac glycosides	152-169	false

Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
Aprepitant	0-9	S(-) warfarin	54-66	mechanism
Aprepitant	0-9	tolbutamide	72-82	mechanism
S(-) warfarin	54-66	tolbutamide	72-82	false

Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
Aprepitant	20-29	phenytoin	115-123	mechanism

Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.
Aprepitant	0-9	Aprepitant	148-157	false
Aprepitant	0-9	digoxin	164-170	false
Aprepitant	148-157	digoxin	164-170	false

5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.
5-HT3 antagonists	0-16	aprepitant	57-66	false
5-HT3 antagonists	0-16	ondansetron	137-147	false
5-HT3 antagonists	0-16	granisetron	152-162	false
aprepitant	57-66	ondansetron	137-147	false
aprepitant	57-66	granisetron	152-162	false
ondansetron	137-147	granisetron	152-162	false

Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
Corticosteroids	0-14	Dexamethasone	17-29	false
Corticosteroids	0-14	Aprepitant	32-41	false
Corticosteroids	0-14	dexamethasone	82-94	false
Corticosteroids	0-14	Aprepitant	141-150	false
Corticosteroids	0-14	dexamethasone	181-193	false
Corticosteroids	0-14	dexamethasone	267-279	false
Dexamethasone	17-29	Aprepitant	32-41	false
Dexamethasone	17-29	dexamethasone	82-94	false
Dexamethasone	17-29	Aprepitant	141-150	false
Dexamethasone	17-29	dexamethasone	181-193	false
Dexamethasone	17-29	dexamethasone	267-279	false
Aprepitant	32-41	dexamethasone	82-94	mechanism
Aprepitant	32-41	Aprepitant	141-150	false
Aprepitant	32-41	dexamethasone	181-193	false
Aprepitant	32-41	dexamethasone	267-279	false
dexamethasone	82-94	Aprepitant	141-150	false
dexamethasone	82-94	dexamethasone	181-193	false
dexamethasone	82-94	dexamethasone	267-279	false
Aprepitant	141-150	dexamethasone	181-193	mechanism
Aprepitant	141-150	dexamethasone	267-279	false
dexamethasone	181-193	dexamethasone	267-279	false

The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
dexamethasone	9-21	Aprepitant	93-102	advise
dexamethasone	9-21	dexamethasone	129-141	false
dexamethasone	9-21	Aprepitant	194-203	false
Aprepitant	93-102	dexamethasone	129-141	false
Aprepitant	93-102	Aprepitant	194-203	false
dexamethasone	129-141	Aprepitant	194-203	false

The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
dexamethasone	18-30	Aprepitant	70-79	mechanism
dexamethasone	18-30	dexamethasone	134-146	false
Aprepitant	70-79	dexamethasone	134-146	false

Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
Aprepitant	0-9	methylprednisolone	107-124	mechanism
Aprepitant	0-9	methylprednisolone	200-217	false
methylprednisolone	107-124	methylprednisolone	200-217	false

The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
methylprednisolone	7-24	methylprednisolone	84-101	false
methylprednisolone	7-24	Aprepitant	172-181	advise
methylprednisolone	7-24	methylprednisolone	207-224	false
methylprednisolone	7-24	Aprepitant	277-286	false
methylprednisolone	84-101	Aprepitant	172-181	advise
methylprednisolone	84-101	methylprednisolone	207-224	false
methylprednisolone	84-101	Aprepitant	277-286	false
Aprepitant	172-181	methylprednisolone	207-224	false
Aprepitant	172-181	Aprepitant	277-286	false
methylprednisolone	207-224	Aprepitant	277-286	false

Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.
Warfarin	0-7	Aprepitant	34-43	false
Warfarin	0-7	warfarin	152-159	false
Aprepitant	34-43	warfarin	152-159	false

Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
Aprepitant	32-41	R(+) warfarin	64-67;77-84	false
Aprepitant	32-41	S(-) warfarin	72-84	false
Aprepitant	32-41	S(-)warfarin	135-146	false
Aprepitant	32-41	Aprepitant	335-344	false
R(+) warfarin	64-67;77-84	S(-) warfarin	72-84	false
R(+) warfarin	64-67;77-84	S(-)warfarin	135-146	false
R(+) warfarin	64-67;77-84	Aprepitant	335-344	false
S(-) warfarin	72-84	S(-)warfarin	135-146	false
S(-) warfarin	72-84	Aprepitant	335-344	false
S(-)warfarin	135-146	Aprepitant	335-344	mechanism

In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
warfarin	23-30	Aprepitant	193-202	advise

Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
Tolbutamide	0-10	Aprepitant	13-22	false
Tolbutamide	0-10	tolbutamide	107-117	false
Tolbutamide	0-10	tolbutamide	212-222	false
Tolbutamide	0-10	Aprepitant	308-317	false
Aprepitant	13-22	tolbutamide	107-117	false
Aprepitant	13-22	tolbutamide	212-222	false
Aprepitant	13-22	Aprepitant	308-317	false
tolbutamide	107-117	tolbutamide	212-222	false
tolbutamide	107-117	Aprepitant	308-317	false
tolbutamide	212-222	Aprepitant	308-317	mechanism

Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
contraceptives	5-18	Aprepitant	21-30	false
contraceptives	5-18	contraceptive	100-112	false
contraceptives	5-18	ethinyl estradiol	135-151	false
contraceptives	5-18	norethindrone	165-177	false
contraceptives	5-18	ethinyl estradiol	201-217	false
contraceptives	5-18	norethindrone	252-264	false
Aprepitant	21-30	contraceptive	100-112	false
Aprepitant	21-30	ethinyl estradiol	135-151	mechanism
Aprepitant	21-30	norethindrone	165-177	mechanism
Aprepitant	21-30	ethinyl estradiol	201-217	false
Aprepitant	21-30	norethindrone	252-264	false
contraceptive	100-112	ethinyl estradiol	135-151	false
contraceptive	100-112	norethindrone	165-177	false
contraceptive	100-112	ethinyl estradiol	201-217	false
contraceptive	100-112	norethindrone	252-264	false
ethinyl estradiol	135-151	norethindrone	165-177	false
ethinyl estradiol	135-151	ethinyl estradiol	201-217	false
ethinyl estradiol	135-151	norethindrone	252-264	false
norethindrone	165-177	ethinyl estradiol	201-217	false
norethindrone	165-177	norethindrone	252-264	false
ethinyl estradiol	201-217	norethindrone	252-264	false

therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
contraceptives	32-45	Aprepitant	72-81	effect

Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
Aprepitant	28-37	contraceptives	69-82	advise

Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
Midazolam	0-8	Aprepitant	11-20	false
Midazolam	0-8	midazolam	43-51	false
Midazolam	0-8	midazolam	155-163	false
Midazolam	0-8	Aprepitant	224-233	false
Aprepitant	11-20	midazolam	43-51	mechanism
Aprepitant	11-20	midazolam	155-163	false
Aprepitant	11-20	Aprepitant	224-233	false
midazolam	43-51	midazolam	155-163	false
midazolam	43-51	Aprepitant	224-233	false
midazolam	155-163	Aprepitant	224-233	false

The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
midazolam	60-68	benzodiazepines	79-93	false
midazolam	60-68	alprazolam	119-128	false
midazolam	60-68	triazolam	131-139	false
midazolam	60-68	Aprepitant	202-211	advise
benzodiazepines	79-93	alprazolam	119-128	false
benzodiazepines	79-93	triazolam	131-139	false
benzodiazepines	79-93	Aprepitant	202-211	advise
alprazolam	119-128	triazolam	131-139	false
alprazolam	119-128	Aprepitant	202-211	advise
triazolam	131-139	Aprepitant	202-211	advise

In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.
midazolam	52-60	Aprepitant	63-72	false
midazolam	52-60	midazolam	138-146	false
midazolam	52-60	Aprepitant	218-227	false
Aprepitant	63-72	midazolam	138-146	false
Aprepitant	63-72	Aprepitant	218-227	false
midazolam	138-146	Aprepitant	218-227	false

Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
Aprepitant	0-9	midazolam	32-40	mechanism
Aprepitant	0-9	midazolam	83-91	mechanism
Aprepitant	0-9	Aprepitant	135-144	false
midazolam	32-40	midazolam	83-91	false
midazolam	32-40	Aprepitant	135-144	false
midazolam	83-91	Aprepitant	135-144	false

therefore, coadministration of Aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant.
Aprepitant	31-40	aprepitant	131-140	false

Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
Aprepitant	44-53	ketoconazole	92-103	advise
Aprepitant	44-53	itraconazole	106-117	advise
Aprepitant	44-53	nefazodone	120-129	advise
Aprepitant	44-53	troleandomycin	132-145	advise
Aprepitant	44-53	clarithromycin	148-161	advise
Aprepitant	44-53	ritonavir	164-172	advise
Aprepitant	44-53	nelfinavir	175-184	advise
ketoconazole	92-103	itraconazole	106-117	false
ketoconazole	92-103	nefazodone	120-129	false
ketoconazole	92-103	troleandomycin	132-145	false
ketoconazole	92-103	clarithromycin	148-161	false
ketoconazole	92-103	ritonavir	164-172	false
ketoconazole	92-103	nelfinavir	175-184	false
itraconazole	106-117	nefazodone	120-129	false
itraconazole	106-117	troleandomycin	132-145	false
itraconazole	106-117	clarithromycin	148-161	false
itraconazole	106-117	ritonavir	164-172	false
itraconazole	106-117	nelfinavir	175-184	false
nefazodone	120-129	troleandomycin	132-145	false
nefazodone	120-129	clarithromycin	148-161	false
nefazodone	120-129	ritonavir	164-172	false
nefazodone	120-129	nelfinavir	175-184	false
troleandomycin	132-145	clarithromycin	148-161	false
troleandomycin	132-145	ritonavir	164-172	false
troleandomycin	132-145	nelfinavir	175-184	false
clarithromycin	148-161	ritonavir	164-172	false
clarithromycin	148-161	nelfinavir	175-184	false
ritonavir	164-172	nelfinavir	175-184	false

Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
diltiazem	42-50	aprepitant	107-116	advise

therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
Aprepitant	31-40	rifampin	97-104	mechanism
Aprepitant	31-40	carbamazepine	107-119	false
Aprepitant	31-40	phenytoin	122-130	mechanism
Aprepitant	31-40	aprepitant	180-189	mechanism
Aprepitant	31-40	Aprepitant	232-241	false
rifampin	97-104	carbamazepine	107-119	false
rifampin	97-104	phenytoin	122-130	false
rifampin	97-104	aprepitant	180-189	false
rifampin	97-104	Aprepitant	232-241	false
carbamazepine	107-119	phenytoin	122-130	false
carbamazepine	107-119	aprepitant	180-189	false
carbamazepine	107-119	Aprepitant	232-241	false
phenytoin	122-130	aprepitant	180-189	false
phenytoin	122-130	Aprepitant	232-241	false
aprepitant	180-189	Aprepitant	232-241	false

Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a
Ketoconazole	0-11	Aprepitant	43-52	false

Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
Ketoconazole	0-11	Aprepitant	43-52	false
Ketoconazole	0-11	ketoconazole	116-127	false
Ketoconazole	0-11	aprepitant	168-177	false
Ketoconazole	0-11	aprepitant	245-254	false
Aprepitant	43-52	ketoconazole	116-127	mechanism
Aprepitant	43-52	aprepitant	168-177	false
Aprepitant	43-52	aprepitant	245-254	false
ketoconazole	116-127	aprepitant	168-177	false
ketoconazole	116-127	aprepitant	245-254	false
aprepitant	168-177	aprepitant	245-254	false

Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
Rifampin	0-7	Aprepitant	39-48	false
Rifampin	0-7	rifampin	112-119	false
Rifampin	0-7	aprepitant	158-167	false
Aprepitant	39-48	rifampin	112-119	mechanism
Aprepitant	39-48	aprepitant	158-167	false
rifampin	112-119	aprepitant	158-167	false

Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant.
Aprepitant	20-29	Aprepitant	140-149	false

Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
Diltiazem	0-8	aprepitant	77-86	false
Diltiazem	0-8	diltiazem	178-186	false
Diltiazem	0-8	aprepitant	254-263	false
Diltiazem	0-8	diltiazem	309-317	false
aprepitant	77-86	diltiazem	178-186	mechanism
aprepitant	77-86	aprepitant	254-263	false
aprepitant	77-86	diltiazem	309-317	false
diltiazem	178-186	aprepitant	254-263	false
diltiazem	178-186	diltiazem	309-317	false
aprepitant	254-263	diltiazem	309-317	false

Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
Paroxetine	0-9	aprepitant	52-61	false
Paroxetine	0-9	paroxetine	151-160	false
Paroxetine	0-9	aprepitant	270-279	false
Paroxetine	0-9	paroxetine	285-294	false
aprepitant	52-61	paroxetine	151-160	mechanism
aprepitant	52-61	aprepitant	270-279	false
aprepitant	52-61	paroxetine	285-294	false
paroxetine	151-160	aprepitant	270-279	false
paroxetine	151-160	paroxetine	285-294	false
aprepitant	270-279	paroxetine	285-294	false

Beta-adrenergic blocking agents: concurrent use may blunt the response to arbutamine.
Beta-adrenergic blocking agents	0-30	arbutamine	74-83	false

Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
Beta-adrenergic blocking agents	0-30	arbutamine	91-100	advise

Antiarrhythmic agents, class I (such as flecainide, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.
Antiarrhythmic agents, class I	0-29	flecainide	40-49	false
Antiarrhythmic agents, class I	0-29	lidocaine	52-60	false
Antiarrhythmic agents, class I	0-29	quinidine	66-74	false
Antiarrhythmic agents, class I	0-29	arbutamine	98-107	false
flecainide	40-49	lidocaine	52-60	false
flecainide	40-49	quinidine	66-74	false
flecainide	40-49	arbutamine	98-107	false
lidocaine	52-60	quinidine	66-74	false
lidocaine	52-60	arbutamine	98-107	false
quinidine	66-74	arbutamine	98-107	false

Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
Antidepressants	0-14	tricyclic	17-25	false
Antidepressants	0-14	atropine	29-36	false
Antidepressants	0-14	anticholinergic agents	47-68	false
Antidepressants	0-14	digitalis glycosides	74-93	false
Antidepressants	0-14	arbutamine	116-125	false
tricyclic	17-25	atropine	29-36	false
tricyclic	17-25	anticholinergic agents	47-68	false
tricyclic	17-25	digitalis glycosides	74-93	false
tricyclic	17-25	arbutamine	116-125	false
atropine	29-36	anticholinergic agents	47-68	false
atropine	29-36	digitalis glycosides	74-93	false
atropine	29-36	arbutamine	116-125	false
anticholinergic agents	47-68	digitalis glycosides	74-93	false
anticholinergic agents	47-68	arbutamine	116-125	false
digitalis glycosides	74-93	arbutamine	116-125	false

Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
Anticoagulants	0-13	platelet aggregation inhibitors	75-105	false
Anticoagulants	0-13	nonsteroidal anti-inflammatory drugs	115-150	false
Anticoagulants	0-13	NSAIDs	153-158	false
Anticoagulants	0-13	aspirin	166-172	false
Anticoagulants	0-13	ardeparin	245-253	effect
platelet aggregation inhibitors	75-105	nonsteroidal anti-inflammatory drugs	115-150	false
platelet aggregation inhibitors	75-105	NSAIDs	153-158	false
platelet aggregation inhibitors	75-105	aspirin	166-172	false
platelet aggregation inhibitors	75-105	ardeparin	245-253	effect
nonsteroidal anti-inflammatory drugs	115-150	NSAIDs	153-158	false
nonsteroidal anti-inflammatory drugs	115-150	aspirin	166-172	false
nonsteroidal anti-inflammatory drugs	115-150	ardeparin	245-253	effect
NSAIDs	153-158	aspirin	166-172	false
NSAIDs	153-158	ardeparin	245-253	effect
aspirin	166-172	ardeparin	245-253	effect

If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
adrenergic drugs	14-29	BROVANA	166-172	advise

When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.
paroxetine	5-14	BROVANA	72-78	false

Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
methylxanthines	27-41	aminophylline	44-56	false
methylxanthines	27-41	theophylline	59-70	false
methylxanthines	27-41	steroids	74-81	false
methylxanthines	27-41	diuretics	87-95	false
methylxanthines	27-41	adrenergic agonists	138-156	effect
aminophylline	44-56	theophylline	59-70	false
aminophylline	44-56	steroids	74-81	false
aminophylline	44-56	diuretics	87-95	false
aminophylline	44-56	adrenergic agonists	138-156	effect
theophylline	59-70	steroids	74-81	false
theophylline	59-70	diuretics	87-95	false
theophylline	59-70	adrenergic agonists	138-156	effect
steroids	74-81	diuretics	87-95	false
steroids	74-81	adrenergic agonists	138-156	effect
diuretics	87-95	adrenergic agonists	138-156	effect

The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
non-potassium sparing diuretics	78-108	loop diuretics	119-122;136-144	false
non-potassium sparing diuretics	78-108	thiazide diuretics	127-144	false
non-potassium sparing diuretics	78-108	beta-agonists	174-186	effect
non-potassium sparing diuretics	78-108	beta-agonist	233-244	false
loop diuretics	119-122;136-144	thiazide diuretics	127-144	false
loop diuretics	119-122;136-144	beta-agonists	174-186	effect
loop diuretics	119-122;136-144	beta-agonist	233-244	false
thiazide diuretics	127-144	beta-agonists	174-186	effect
thiazide diuretics	127-144	beta-agonist	233-244	false
beta-agonists	174-186	beta-agonist	233-244	false

Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
beta-agonists	113-125	non-potassium sparing diuretics	132-162	advise

BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
BROVANA	0-6	beta2-agonists	23-36	false
BROVANA	0-6	monoamine oxidase inhibitors	114-141	advise
BROVANA	0-6	tricyclic antidepressants	144-168	advise
BROVANA	0-6	adrenergic agonists	236-254	false
beta2-agonists	23-36	monoamine oxidase inhibitors	114-141	advise
beta2-agonists	23-36	tricyclic antidepressants	144-168	advise
beta2-agonists	23-36	adrenergic agonists	236-254	false
monoamine oxidase inhibitors	114-141	tricyclic antidepressants	144-168	false
monoamine oxidase inhibitors	114-141	adrenergic agonists	236-254	effect
tricyclic antidepressants	144-168	adrenergic agonists	236-254	effect

The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.
methylxanthines	59-73	aminophylline	82-94	false
methylxanthines	59-73	theophylline	97-108	false
methylxanthines	59-73	BROVANA	133-139	false
aminophylline	82-94	theophylline	97-108	false
aminophylline	82-94	BROVANA	133-139	false
theophylline	97-108	BROVANA	133-139	false

In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.
BROVANA	64-70	BROVANA	154-160	false
BROVANA	64-70	theophylline	201-212	false
BROVANA	154-160	theophylline	201-212	false

In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.
BROVANA	65-71	BROVANA	93-99	false
BROVANA	65-71	theophylline	140-151	false
BROVANA	93-99	theophylline	140-151	false

Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
Beta-adrenergic receptor antagonists	0-35	beta-blockers	38-50	false
Beta-adrenergic receptor antagonists	0-35	BROVANA	57-63	effect
beta-blockers	38-50	BROVANA	57-63	effect

Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
Beta-blockers	0-12	beta-agonists	56-68	effect

Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
Heparin	0-6	heparin	15-21	false
Heparin	0-6	heparin	59-65	false
Heparin	0-6	Argatroban	118-127	false
Heparin	0-6	heparin	133-139	false
heparin	15-21	heparin	59-65	false
heparin	15-21	Argatroban	118-127	false
heparin	15-21	heparin	133-139	false
heparin	59-65	Argatroban	118-127	false
heparin	59-65	heparin	133-139	false
Argatroban	118-127	heparin	133-139	false

However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.
Argatroban	12-21	heparin	61-67	false
Argatroban	12-21	Argatroban	167-176	false
heparin	61-67	Argatroban	167-176	false

Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
Aspirin	0-6	Acetaminophen	8-20	false
Aspirin	0-6	Argatroban	116-125	false
Aspirin	0-6	aspirin	158-164	false
Aspirin	0-6	Argatroban	227-236	false
Aspirin	0-6	acetaminophen	268-280	false
Aspirin	0-6	Argatroban	380-389	false
Acetaminophen	8-20	Argatroban	116-125	false
Acetaminophen	8-20	aspirin	158-164	false
Acetaminophen	8-20	Argatroban	227-236	false
Acetaminophen	8-20	acetaminophen	268-280	false
Acetaminophen	8-20	Argatroban	380-389	false
Argatroban	116-125	aspirin	158-164	false
Argatroban	116-125	Argatroban	227-236	false
Argatroban	116-125	acetaminophen	268-280	false
Argatroban	116-125	Argatroban	380-389	false
aspirin	158-164	Argatroban	227-236	false
aspirin	158-164	acetaminophen	268-280	false
aspirin	158-164	Argatroban	380-389	false
Argatroban	227-236	acetaminophen	268-280	false
Argatroban	227-236	Argatroban	380-389	false
acetaminophen	268-280	Argatroban	380-389	false

Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated.
anticoagulant agents	5-24	Argatroban	74-83	false
anticoagulant agents	5-24	warfarin	89-96	false
Argatroban	74-83	warfarin	89-96	false

However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
Argatroban	32-41	warfarin	47-54	effect

Thrombolytic agents: The safety and effectiveness of Argatroban with thrombolytic agents have not been established.
Thrombolytic agents	0-18	Argatroban	53-62	false
Thrombolytic agents	0-18	thrombolytic agents	69-87	false
Argatroban	53-62	thrombolytic agents	69-87	false

Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
Argatroban	38-47	antiplatelet agents	54-72	effect
Argatroban	38-47	thrombolytics	75-87	effect
Argatroban	38-47	anticoagulants	100-113	effect
antiplatelet agents	54-72	thrombolytics	75-87	false
antiplatelet agents	54-72	anticoagulants	100-113	false
thrombolytics	75-87	anticoagulants	100-113	false

Drug-drug interactions have not been observed between Argatroban and digoxin or erythromycin.
Argatroban	54-63	digoxin	69-75	false
Argatroban	54-63	erythromycin	80-91	false
digoxin	69-75	erythromycin	80-91	false

Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
aripiprazole	56-67	ABILIFY	98-104	false
aripiprazole	56-67	centrally acting drugs	141-162	false
aripiprazole	56-67	alcohol	168-174	false
ABILIFY	98-104	centrally acting drugs	141-162	advise
ABILIFY	98-104	alcohol	168-174	advise
centrally acting drugs	141-162	alcohol	168-174	false

1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
aripiprazole	35-46	antihypertensive agents	99-121	effect

Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
ABILIFY	36-42	Aripiprazole	44-55	false

Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
carbamazepine	31-43	aripiprazole	73-84	mechanism

Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
ketoconazole	26-37	quinidine	55-63	false
ketoconazole	26-37	fluoxetine	66-75	false
ketoconazole	26-37	paroxetine	81-90	false
ketoconazole	26-37	aripiprazole	105-116	mechanism
quinidine	55-63	fluoxetine	66-75	false
quinidine	55-63	paroxetine	81-90	false
quinidine	55-63	aripiprazole	105-116	mechanism
fluoxetine	66-75	paroxetine	81-90	false
fluoxetine	66-75	aripiprazole	105-116	mechanism
paroxetine	81-90	aripiprazole	105-116	mechanism

Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
Ketoconazole	0-11	ketoconazole	34-45	false
Ketoconazole	0-11	aripiprazole	100-111	false
Ketoconazole	0-11	aripiprazole	134-145	false
ketoconazole	34-45	aripiprazole	100-111	mechanism
ketoconazole	34-45	aripiprazole	134-145	false
aripiprazole	100-111	aripiprazole	134-145	false

When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
ketoconazole	35-46	aripiprazole	53-64	advise
ketoconazole	35-46	aripiprazole	74-85	false
aripiprazole	53-64	aripiprazole	74-85	false

Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
Quinidine	0-8	aripiprazole	54-65	false
Quinidine	0-8	quinidine	72-80	false
Quinidine	0-8	aripiprazole	159-170	false
Quinidine	0-8	dehydroaripiprazole	228-246	false
aripiprazole	54-65	quinidine	72-80	mechanism
aripiprazole	54-65	aripiprazole	159-170	false
aripiprazole	54-65	dehydroaripiprazole	228-246	false
quinidine	72-80	aripiprazole	159-170	false
quinidine	72-80	dehydroaripiprazole	228-246	false
aripiprazole	159-170	dehydroaripiprazole	228-246	false

Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
Aripiprazole	0-11	quinidine	102-110	false
Aripiprazole	0-11	aripiprazole	117-128	false
quinidine	102-110	aripiprazole	117-128	advise

Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.
fluoxetine	48-57	paroxetine	62-71	false

Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
Carbamazepine	0-12	carbamazepine	35-47	false
Carbamazepine	0-12	aripiprazole	93-104	false
Carbamazepine	0-12	aripiprazole	188-199	false
Carbamazepine	0-12	dehydro-aripiprazole	228-247	false
carbamazepine	35-47	aripiprazole	93-104	mechanism
carbamazepine	35-47	aripiprazole	188-199	false
carbamazepine	35-47	dehydro-aripiprazole	228-247	false
aripiprazole	93-104	aripiprazole	188-199	false
aripiprazole	93-104	dehydro-aripiprazole	228-247	false
aripiprazole	188-199	dehydro-aripiprazole	228-247	false

When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
carbamazepine	5-17	aripiprazole	31-42	advise
carbamazepine	5-17	aripiprazole	53-64	false
aripiprazole	31-42	aripiprazole	53-64	false

When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
carbamazepine	5-17	aripiprazole	62-73	advise

No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).
famotidine	36-45	valproate	48-56	false
famotidine	36-45	lithium	62-68	false
famotidine	36-45	aripiprazole	106-117	false
valproate	48-56	lithium	62-68	false
valproate	48-56	aripiprazole	106-117	false
lithium	62-68	aripiprazole	106-117	false

Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
ABILIFY	14-20	Aripiprazole	44-55	false

In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.
aripiprazole	46-57	dextromethorphan	110-125	false
aripiprazole	46-57	warfarin	137-144	false
aripiprazole	46-57	omeprazole	157-166	false
aripiprazole	46-57	warfarin	169-176	false
aripiprazole	46-57	dextromethorphan	192-207	false
dextromethorphan	110-125	warfarin	137-144	false
dextromethorphan	110-125	omeprazole	157-166	false
dextromethorphan	110-125	warfarin	169-176	false
dextromethorphan	110-125	dextromethorphan	192-207	false
warfarin	137-144	omeprazole	157-166	false
warfarin	137-144	warfarin	169-176	false
warfarin	137-144	dextromethorphan	192-207	false
omeprazole	157-166	warfarin	169-176	false
omeprazole	157-166	dextromethorphan	192-207	false
warfarin	169-176	dextromethorphan	192-207	false

Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
aripiprazole	14-25	dehydroaripiprazole	31-49	false

Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
Alcohol	0-6	aripiprazole	53-64	false
Alcohol	0-6	ethanol	86-92	false
Alcohol	0-6	ethanol	126-132	false
aripiprazole	53-64	ethanol	86-92	false
aripiprazole	53-64	ethanol	126-132	false
ethanol	86-92	ethanol	126-132	false

As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
alcohol	75-81	ABILIFY	96-102	advise

Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
TRISENOX	24-31	antiarrhythmics	121-135	advise
TRISENOX	24-31	thioridazine	140-151	advise
TRISENOX	24-31	diuretics	200-208	advise
TRISENOX	24-31	amphotericin B	213-226	advise
antiarrhythmics	121-135	thioridazine	140-151	false
antiarrhythmics	121-135	diuretics	200-208	false
antiarrhythmics	121-135	amphotericin B	213-226	false
thioridazine	140-151	diuretics	200-208	false
thioridazine	140-151	amphotericin B	213-226	false
diuretics	200-208	amphotericin B	213-226	false

Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
ELSPAR	48-53	methotrexate	93-104	effect
ELSPAR	48-53	methotrexate	143-154	false
methotrexate	93-104	methotrexate	143-154	false

These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
methotrexate	64-75	ELSPAR	82-87	advise
methotrexate	64-75	ELSPAR	121-126	false
ELSPAR	82-87	ELSPAR	121-126	false

Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
Uricosuric Agents	0-16	Aspirin	19-25	false
Uricosuric Agents	0-16	probenecid	55-64	false
Uricosuric Agents	0-16	sulfinpyrazone	67-80	false
Uricosuric Agents	0-16	phenylbutazone	87-100	false
Aspirin	19-25	probenecid	55-64	effect
Aspirin	19-25	sulfinpyrazone	67-80	effect
Aspirin	19-25	phenylbutazone	87-100	effect
probenecid	55-64	sulfinpyrazone	67-80	false
probenecid	55-64	phenylbutazone	87-100	false
sulfinpyrazone	67-80	phenylbutazone	87-100	false

Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
Alcohol	0-6	aspirin	39-45	effect

Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
Corticosteroids	0-14	aspirin	49-55	effect

Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
Pyrazolone Derivatives	0-21	phenylbutazone	24-37	false
Pyrazolone Derivatives	0-21	oxyphenbutazone	40-54	false
Pyrazolone Derivatives	0-21	dipyrone	70-77	false
Pyrazolone Derivatives	0-21	aspirin	113-119	effect
phenylbutazone	24-37	oxyphenbutazone	40-54	false
phenylbutazone	24-37	dipyrone	70-77	false
phenylbutazone	24-37	aspirin	113-119	effect
oxyphenbutazone	40-54	dipyrone	70-77	false
oxyphenbutazone	40-54	aspirin	113-119	effect
dipyrone	70-77	aspirin	113-119	effect

Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
Nonsteroidal Antiinflammatory	0-28	Aspirin	38-44	false
Nonsteroidal Antiinflammatory	0-28	nonsteroidal anti-inflammatory	103-132	false
Aspirin	38-44	nonsteroidal anti-inflammatory	103-132	advise

Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.
aspirin	31-37	salicylate	79-88	false

Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
Phenobarbital	0-12	aspirin	25-31	mechanism

Phenytoin: Serum phenytoin levels may be increased by aspirin.
Phenytoin	0-8	phenytoin	17-25	false
Phenytoin	0-8	aspirin	54-60	false
phenytoin	17-25	aspirin	54-60	effect

Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
Propranolol	0-10	aspirins	26-33	effect

Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
Antacids	0-7	Aspirin	25-31	false
Antacids	0-7	antacids	71-78	false
Aspirin	25-31	antacids	71-78	advise

Ketoconazole/Itraconazole, Macrolides, Including Erythromycin
Ketoconazole	0-11	Itraconazole	13-24	false
Ketoconazole	0-11	Macrolides	27-36	false
Ketoconazole	0-11	Erythromycin	49-60	false
Itraconazole	13-24	Macrolides	27-36	false
Itraconazole	13-24	Erythromycin	49-60	false
Macrolides	27-36	Erythromycin	49-60	false

Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	35-43	beta-blocking agent	90-108	effect

Calcium channel blockers may also have an additive effect when given with TENORMIN .
Calcium channel blockers	0-23	TENORMIN	74-81	effect

Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
Beta blockers	0-12	clonidine	89-97	effect

If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.
beta blocker	41-52	clonidine	120-128	advise

If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
clonidine	13-21	beta-blocker	26-37	false
clonidine	13-21	beta blockers	68-80	false
clonidine	13-21	clonidine	123-131	false
beta-blocker	26-37	beta blockers	68-80	false
beta-blocker	26-37	clonidine	123-131	false
beta blockers	68-80	clonidine	123-131	advise

Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
indomethacin	64-75	beta blockers	118-130	effect

Information on concurrent usage of atenolol and aspirin is limited.
atenolol	35-42	aspirin	48-54	false

Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.
aspirin	106-112	beta blockers	118-130	false

Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
Albuterol	23-31	STRATTERA	35-43	false
Albuterol	23-31	albuterol	160-168	false
Albuterol	23-31	beta2 agonists	180-193	false
Albuterol	23-31	albuterol	218-226	false
STRATTERA	35-43	albuterol	160-168	advise
STRATTERA	35-43	beta2 agonists	180-193	false
STRATTERA	35-43	albuterol	218-226	false
albuterol	160-168	beta2 agonists	180-193	false
albuterol	160-168	albuterol	218-226	false
beta2 agonists	180-193	albuterol	218-226	false

CYP2D6 inhibitors - Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine.
Atomoxetine	20-30	4-hydroxyatomoxetine	82-101	false

Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
STRATTERA	21-29	paroxetine	98-107	advise
STRATTERA	21-29	fluoxetine	110-119	advise
STRATTERA	21-29	quinidine	126-134	advise
paroxetine	98-107	fluoxetine	110-119	false
paroxetine	98-107	quinidine	126-134	false
fluoxetine	110-119	quinidine	126-134	false

In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
paroxetine	31-40	fluoxetine	45-54	false
paroxetine	31-40	atomoxetine	68-78	mechanism
paroxetine	31-40	atomoxetine	157-167	false
fluoxetine	45-54	atomoxetine	68-78	mechanism
fluoxetine	45-54	atomoxetine	157-167	false
atomoxetine	68-78	atomoxetine	157-167	false

The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), erythromycin, azole antifungals.
cyclosporine	110-121	fibric acid derivatives	124-146	false
cyclosporine	110-121	niacin	149-154	false
cyclosporine	110-121	nicotinic acid	157-170	false
cyclosporine	110-121	erythromycin	174-185	false
cyclosporine	110-121	azole antifungals	188-204	false
fibric acid derivatives	124-146	niacin	149-154	false
fibric acid derivatives	124-146	nicotinic acid	157-170	false
fibric acid derivatives	124-146	erythromycin	174-185	false
fibric acid derivatives	124-146	azole antifungals	188-204	false
niacin	149-154	nicotinic acid	157-170	false
niacin	149-154	erythromycin	174-185	false
niacin	149-154	azole antifungals	188-204	false
nicotinic acid	157-170	erythromycin	174-185	false
nicotinic acid	157-170	azole antifungals	188-204	false
erythromycin	174-185	azole antifungals	188-204	false

Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
Antacid	0-6	atorvastatin	14-25	false
Antacid	0-6	Maalox TC	31-39	false
Antacid	0-6	atorvastatin	98-109	false
atorvastatin	14-25	Maalox TC	31-39	mechanism
atorvastatin	14-25	atorvastatin	98-109	false
Maalox TC	31-39	atorvastatin	98-109	false

Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
Antipyrine	0-9	atorvastatin	20-31	false
Antipyrine	0-9	antipyrine	73-82	false
Antipyrine	0-9	drugs	109-113	false
atorvastatin	20-31	antipyrine	73-82	false
atorvastatin	20-31	drugs	109-113	false
antipyrine	73-82	drugs	109-113	false

Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
Colestipol	0-9	atorvastatin	37-48	false
Colestipol	0-9	colestipol	83-92	false
Colestipol	0-9	atorvastatin	98-109	false
atorvastatin	37-48	colestipol	83-92	false
atorvastatin	37-48	atorvastatin	98-109	false
colestipol	83-92	atorvastatin	98-109	mechanism

However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
atorvastatin	42-53	colestipol	59-68	effect

Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
Cimetidine	0-9	Atorvastatin	12-23	false
Cimetidine	0-9	cimetidine	107-116	false
Atorvastatin	12-23	cimetidine	107-116	false

Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
Digoxin	0-6	atorvastatin	32-43	false
Digoxin	0-6	digoxin	49-55	false
Digoxin	0-6	digoxin	98-104	false
atorvastatin	32-43	digoxin	49-55	mechanism
atorvastatin	32-43	digoxin	98-104	false
digoxin	49-55	digoxin	98-104	false

Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
Erythromycin	0-11	atorvastatin	63-74	false
Erythromycin	0-11	atorvastatin	129-140	false
Erythromycin	0-11	erythromycin	146-157	false
atorvastatin	63-74	atorvastatin	129-140	false
atorvastatin	63-74	erythromycin	146-157	false
atorvastatin	129-140	erythromycin	146-157	mechanism

Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
Contraceptives	5-18	atorvastatin	41-52	false
Contraceptives	5-18	contraceptive	66-78	false
Contraceptives	5-18	norethindrone	105-117	false
Contraceptives	5-18	ethinyl estradiol	123-139	false
atorvastatin	41-52	contraceptive	66-78	mechanism
atorvastatin	41-52	norethindrone	105-117	mechanism
atorvastatin	41-52	ethinyl estradiol	123-139	mechanism
contraceptive	66-78	norethindrone	105-117	false
contraceptive	66-78	ethinyl estradiol	123-139	false
norethindrone	105-117	ethinyl estradiol	123-139	false

These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
contraceptive	60-72	atorvastatin	93-104	advise

Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
Warfarin	0-7	Atorvastatin	10-21	false
Warfarin	0-7	warfarin	128-135	false
Atorvastatin	10-21	warfarin	128-135	false

Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
HMG-CoA reductase inhibitor	34-60	ketoconazole	184-195	advise
HMG-CoA reductase inhibitor	34-60	spironolactone	198-211	advise
HMG-CoA reductase inhibitor	34-60	cimetidine	218-227	advise
ketoconazole	184-195	spironolactone	198-211	false
ketoconazole	184-195	cimetidine	218-227	false
spironolactone	198-211	cimetidine	218-227	false

The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.
atovaquone	40-49	phenytoin	132-140	false
atovaquone	40-49	phenytoin	178-186	false
atovaquone	40-49	atovaquone	216-225	false
phenytoin	132-140	phenytoin	178-186	false
phenytoin	132-140	atovaquone	216-225	false
phenytoin	178-186	atovaquone	216-225	false

Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
Rifampin	0-7	rifampin	30-37	false
Rifampin	0-7	MEPRON	43-48	false
Rifampin	0-7	atovaquone	127-136	false
rifampin	30-37	MEPRON	43-48	mechanism
rifampin	30-37	atovaquone	127-136	false
MEPRON	43-48	atovaquone	127-136	false

Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
rifampin	16-23	MEPRON	86-91	advise

Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.
Rifabutin	0-8	rifamycin	19-27	false
Rifabutin	0-8	rifampin	57-64	false
Rifabutin	0-8	rifampin	126-133	false
rifamycin	19-27	rifampin	57-64	false
rifamycin	19-27	rifampin	126-133	false
rifampin	57-64	rifampin	126-133	false

No interaction trials have been conducted with MEPRON and rifabutin.
MEPRON	47-52	rifabutin	58-66	false

Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
TRACRIUM	61-68	enflurane	79-87	effect

certain antibiotics, especially the aminoglycosides and polymyxins;
antibiotics	8-18	aminoglycosides	36-50	false
antibiotics	8-18	polymyxins	56-65	false
aminoglycosides	36-50	polymyxins	56-65	false

Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
TRACRIUM	61-68	enflurane	79-87	effect
TRACRIUM	61-68	isoflurane	89-98	effect
TRACRIUM	61-68	halothane	100-108	effect
TRACRIUM	61-68	antibiotics	118-128	effect
TRACRIUM	61-68	aminoglycosides	146-160	effect
TRACRIUM	61-68	polymyxins	166-175	effect
TRACRIUM	61-68	lithium	177-183	effect
TRACRIUM	61-68	magnesium	185-193	effect
TRACRIUM	61-68	procainamide	201-212	effect
TRACRIUM	61-68	quinidine	218-226	effect
enflurane	79-87	isoflurane	89-98	false
enflurane	79-87	halothane	100-108	false
enflurane	79-87	antibiotics	118-128	false
enflurane	79-87	aminoglycosides	146-160	false
enflurane	79-87	polymyxins	166-175	false
enflurane	79-87	lithium	177-183	false
enflurane	79-87	magnesium	185-193	false
enflurane	79-87	procainamide	201-212	false
enflurane	79-87	quinidine	218-226	false
isoflurane	89-98	halothane	100-108	false
isoflurane	89-98	antibiotics	118-128	false
isoflurane	89-98	aminoglycosides	146-160	false
isoflurane	89-98	polymyxins	166-175	false
isoflurane	89-98	lithium	177-183	false
isoflurane	89-98	magnesium	185-193	false
isoflurane	89-98	procainamide	201-212	false
isoflurane	89-98	quinidine	218-226	false
halothane	100-108	antibiotics	118-128	false
halothane	100-108	aminoglycosides	146-160	false
halothane	100-108	polymyxins	166-175	false
halothane	100-108	lithium	177-183	false
halothane	100-108	magnesium	185-193	false
halothane	100-108	procainamide	201-212	false
halothane	100-108	quinidine	218-226	false
antibiotics	118-128	aminoglycosides	146-160	false
antibiotics	118-128	polymyxins	166-175	false
antibiotics	118-128	lithium	177-183	false
antibiotics	118-128	magnesium	185-193	false
antibiotics	118-128	procainamide	201-212	false
antibiotics	118-128	quinidine	218-226	false
aminoglycosides	146-160	polymyxins	166-175	false
aminoglycosides	146-160	lithium	177-183	false
aminoglycosides	146-160	magnesium	185-193	false
aminoglycosides	146-160	procainamide	201-212	false
aminoglycosides	146-160	quinidine	218-226	false
polymyxins	166-175	lithium	177-183	false
polymyxins	166-175	magnesium	185-193	false
polymyxins	166-175	procainamide	201-212	false
polymyxins	166-175	quinidine	218-226	false
lithium	177-183	magnesium	185-193	false
lithium	177-183	procainamide	201-212	false
lithium	177-183	quinidine	218-226	false
magnesium	185-193	procainamide	201-212	false
magnesium	185-193	quinidine	218-226	false
procainamide	201-212	quinidine	218-226	false

The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
succinylcholine	28-42	TRACRIUM	160-167	effect

TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.
TRACRIUM	0-7	succinylcholine	71-85	advise

When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
atropine	5-12	pralidoxime	18-28	effect
atropine	5-12	atropine	194-201	false
atropine	5-12	pralidoxime	225-235	false
atropine	5-12	atropine	266-273	false
pralidoxime	18-28	atropine	194-201	false
pralidoxime	18-28	pralidoxime	225-235	false
pralidoxime	18-28	atropine	266-273	false
atropine	194-201	pralidoxime	225-235	false
atropine	194-201	atropine	266-273	false
pralidoxime	225-235	atropine	266-273	effect

The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
atropine	147-154	pralidoxime	160-170	advise

Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
barbiturates	6-17	anticholinesterases	42-60	advise

Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
Auranofin	0-8	gold medication	82-96	advise
Auranofin	0-8	Solganal	109-116	advise
Auranofin	0-8	Myochrysine	122-132	advise
gold medication	82-96	Solganal	109-116	false
gold medication	82-96	Myochrysine	122-132	false
Solganal	109-116	Myochrysine	122-132	false

Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
Auranofin	0-8	penicillamine	43-55	advise
Auranofin	0-8	Depen	58-62	advise
Auranofin	0-8	Cuprimine	65-73	advise
penicillamine	43-55	Depen	58-62	false
penicillamine	43-55	Cuprimine	65-73	false
Depen	58-62	Cuprimine	65-73	false

MAO inhibitors prolong and intensify the effects of antihistamines.
MAO inhibitors	0-13	antihistamines	52-65	effect

Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
antihistamines	19-32	alcohol	39-45	effect
antihistamines	19-32	tricyclic antidepressants	48-72	effect
antihistamines	19-32	barbiturates	75-86	effect
antihistamines	19-32	central nervous system depressants	98-131	effect
alcohol	39-45	tricyclic antidepressants	48-72	false
alcohol	39-45	barbiturates	75-86	false
alcohol	39-45	central nervous system depressants	98-131	false
tricyclic antidepressants	48-72	barbiturates	75-86	false
tricyclic antidepressants	48-72	central nervous system depressants	98-131	false
barbiturates	75-86	central nervous system depressants	98-131	false

When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
sympathomimetic drugs	5-25	monoamine oxidase inhibitors	59-86	effect

The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
methyldopa	32-41	mecamylamine	44-55	false
methyldopa	32-41	reserpine	58-66	false
methyldopa	32-41	veratrum alkaloids	73-90	false
methyldopa	32-41	sympathomimetics	110-125	effect
mecamylamine	44-55	reserpine	58-66	false
mecamylamine	44-55	veratrum alkaloids	73-90	false
mecamylamine	44-55	sympathomimetics	110-125	effect
reserpine	58-66	veratrum alkaloids	73-90	false
reserpine	58-66	sympathomimetics	110-125	effect
veratrum alkaloids	73-90	sympathomimetics	110-125	effect

Beta-adrenergic blocking agents may also interact with sympathomimetics.
Beta-adrenergic blocking agents	0-30	sympathomimetics	55-70	int

Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
pseudoephedrine	52-66	digitalis	95-103	effect

Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
Antacids	0-7	pseudoephedrine	44-58	mechanism
Antacids	0-7	kaolin	67-72	false
pseudoephedrine	44-58	kaolin	67-72	mechanism

Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
Allopurinol	9-19	azathioprine	66-77	false
Allopurinol	9-19	allopurinol	95-105	false
azathioprine	66-77	allopurinol	95-105	mechanism

Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
azathioprine	19-30	allopurinol	36-46	advise
azathioprine	19-30	azathioprine	94-105	false
allopurinol	36-46	azathioprine	94-105	false

Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
Angiotensln Converting Enzyme Inhibitors	9-48	angiotensin converting enzyme inhibitors	62-101	false
Angiotensln Converting Enzyme Inhibitors	9-48	azathioprine	142-153	false
angiotensin converting enzyme inhibitors	62-101	azathioprine	142-153	effect

Co-administration of nelfinavir at steady-state with a single dose of azithromycin.
nelfinavir	21-30	azithromycin	70-81	false

Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
nelfinavir	21-30	azithromycin	70-81	effect
nelfinavir	21-30	azithromycin	125-136	false
azithromycin	70-81	azithromycin	125-136	false

Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
azithromycin	30-41	nelfinavir	100-109	advise
azithromycin	30-41	azithromycin	155-166	false
nelfinavir	100-109	azithromycin	155-166	false

Azithromycin did not affect the prothrombin time response to a single dose of warfarin.
Azithromycin	0-11	warfarin	78-85	false

However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
azithromycin	111-122	warfarin	128-135	advise

Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
macrolides	18-27	warfarin	33-40	effect

When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
azithromycin	32-43	atorvastatin	92-103	mechanism
azithromycin	32-43	carbamazepine	106-118	mechanism
azithromycin	32-43	cetirizine	121-130	mechanism
azithromycin	32-43	didanosine	133-142	mechanism
azithromycin	32-43	efavirenz	145-153	mechanism
azithromycin	32-43	fluconazole	156-166	mechanism
azithromycin	32-43	indinavir	169-177	mechanism
azithromycin	32-43	midazolam	180-188	mechanism
azithromycin	32-43	rifabutin	191-199	mechanism
azithromycin	32-43	sildenafil	202-211	mechanism
azithromycin	32-43	theophylline	214-225	mechanism
azithromycin	32-43	triazolam	251-259	mechanism
azithromycin	32-43	trimethoprim	262-273	mechanism
azithromycin	32-43	sulfamethoxazole	275-290	mechanism
azithromycin	32-43	zidovudine	295-304	mechanism
atorvastatin	92-103	carbamazepine	106-118	false
atorvastatin	92-103	cetirizine	121-130	false
atorvastatin	92-103	didanosine	133-142	false
atorvastatin	92-103	efavirenz	145-153	false
atorvastatin	92-103	fluconazole	156-166	false
atorvastatin	92-103	indinavir	169-177	false
atorvastatin	92-103	midazolam	180-188	false
atorvastatin	92-103	rifabutin	191-199	false
atorvastatin	92-103	sildenafil	202-211	false
atorvastatin	92-103	theophylline	214-225	false
atorvastatin	92-103	triazolam	251-259	false
atorvastatin	92-103	trimethoprim	262-273	false
atorvastatin	92-103	sulfamethoxazole	275-290	false
atorvastatin	92-103	zidovudine	295-304	false
carbamazepine	106-118	cetirizine	121-130	false
carbamazepine	106-118	didanosine	133-142	false
carbamazepine	106-118	efavirenz	145-153	false
carbamazepine	106-118	fluconazole	156-166	false
carbamazepine	106-118	indinavir	169-177	false
carbamazepine	106-118	midazolam	180-188	false
carbamazepine	106-118	rifabutin	191-199	false
carbamazepine	106-118	sildenafil	202-211	false
carbamazepine	106-118	theophylline	214-225	false
carbamazepine	106-118	triazolam	251-259	false
carbamazepine	106-118	trimethoprim	262-273	false
carbamazepine	106-118	sulfamethoxazole	275-290	false
carbamazepine	106-118	zidovudine	295-304	false
cetirizine	121-130	didanosine	133-142	false
cetirizine	121-130	efavirenz	145-153	false
cetirizine	121-130	fluconazole	156-166	false
cetirizine	121-130	indinavir	169-177	false
cetirizine	121-130	midazolam	180-188	false
cetirizine	121-130	rifabutin	191-199	false
cetirizine	121-130	sildenafil	202-211	false
cetirizine	121-130	theophylline	214-225	false
cetirizine	121-130	triazolam	251-259	false
cetirizine	121-130	trimethoprim	262-273	false
cetirizine	121-130	sulfamethoxazole	275-290	false
cetirizine	121-130	zidovudine	295-304	false
didanosine	133-142	efavirenz	145-153	false
didanosine	133-142	fluconazole	156-166	false
didanosine	133-142	indinavir	169-177	false
didanosine	133-142	midazolam	180-188	false
didanosine	133-142	rifabutin	191-199	false
didanosine	133-142	sildenafil	202-211	false
didanosine	133-142	theophylline	214-225	false
didanosine	133-142	triazolam	251-259	false
didanosine	133-142	trimethoprim	262-273	false
didanosine	133-142	sulfamethoxazole	275-290	false
didanosine	133-142	zidovudine	295-304	false
efavirenz	145-153	fluconazole	156-166	false
efavirenz	145-153	indinavir	169-177	false
efavirenz	145-153	midazolam	180-188	false
efavirenz	145-153	rifabutin	191-199	false
efavirenz	145-153	sildenafil	202-211	false
efavirenz	145-153	theophylline	214-225	false
efavirenz	145-153	triazolam	251-259	false
efavirenz	145-153	trimethoprim	262-273	false
efavirenz	145-153	sulfamethoxazole	275-290	false
efavirenz	145-153	zidovudine	295-304	false
fluconazole	156-166	indinavir	169-177	false
fluconazole	156-166	midazolam	180-188	false
fluconazole	156-166	rifabutin	191-199	false
fluconazole	156-166	sildenafil	202-211	false
fluconazole	156-166	theophylline	214-225	false
fluconazole	156-166	triazolam	251-259	false
fluconazole	156-166	trimethoprim	262-273	false
fluconazole	156-166	sulfamethoxazole	275-290	false
fluconazole	156-166	zidovudine	295-304	false
indinavir	169-177	midazolam	180-188	false
indinavir	169-177	rifabutin	191-199	false
indinavir	169-177	sildenafil	202-211	false
indinavir	169-177	theophylline	214-225	false
indinavir	169-177	triazolam	251-259	false
indinavir	169-177	trimethoprim	262-273	false
indinavir	169-177	sulfamethoxazole	275-290	false
indinavir	169-177	zidovudine	295-304	false
midazolam	180-188	rifabutin	191-199	false
midazolam	180-188	sildenafil	202-211	false
midazolam	180-188	theophylline	214-225	false
midazolam	180-188	triazolam	251-259	false
midazolam	180-188	trimethoprim	262-273	false
midazolam	180-188	sulfamethoxazole	275-290	false
midazolam	180-188	zidovudine	295-304	false
rifabutin	191-199	sildenafil	202-211	false
rifabutin	191-199	theophylline	214-225	false
rifabutin	191-199	triazolam	251-259	false
rifabutin	191-199	trimethoprim	262-273	false
rifabutin	191-199	sulfamethoxazole	275-290	false
rifabutin	191-199	zidovudine	295-304	false
sildenafil	202-211	theophylline	214-225	false
sildenafil	202-211	triazolam	251-259	false
sildenafil	202-211	trimethoprim	262-273	false
sildenafil	202-211	sulfamethoxazole	275-290	false
sildenafil	202-211	zidovudine	295-304	false
theophylline	214-225	triazolam	251-259	false
theophylline	214-225	trimethoprim	262-273	false
theophylline	214-225	sulfamethoxazole	275-290	false
theophylline	214-225	zidovudine	295-304	false
triazolam	251-259	trimethoprim	262-273	false
triazolam	251-259	sulfamethoxazole	275-290	false
triazolam	251-259	zidovudine	295-304	false
trimethoprim	262-273	sulfamethoxazole	275-290	false
trimethoprim	262-273	zidovudine	295-304	false
sulfamethoxazole	275-290	zidovudine	295-304	false

Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
efavirenz	23-31	fluconazole	36-46	false
efavirenz	23-31	azithromycin	95-106	mechanism
fluconazole	36-46	azithromycin	95-106	mechanism

Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.
azithromycin	66-77	Digoxin	162-168	false
azithromycin	66-77	digoxin	179-185	false
Digoxin	162-168	digoxin	179-185	false

Ergotamine or dihydroergotamine acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Ergotamine	0-9	dihydroergotamine	14-30	false

Cyclosporine, hexobarbital and phenytoin concentrations.
Cyclosporine	0-11	hexobarbital	14-25	false
Cyclosporine	0-11	phenytoin	31-39	false
hexobarbital	14-25	phenytoin	31-39	false

Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
Azlocillin	0-9	amikacin	57-64	advise
Azlocillin	0-9	ciprofloxacin	67-79	advise
Azlocillin	0-9	gentamicin	82-91	advise
Azlocillin	0-9	netilmicin	94-103	advise
Azlocillin	0-9	tobramycin	109-118	advise
amikacin	57-64	ciprofloxacin	67-79	false
amikacin	57-64	gentamicin	82-91	false
amikacin	57-64	netilmicin	94-103	false
amikacin	57-64	tobramycin	109-118	false
ciprofloxacin	67-79	gentamicin	82-91	false
ciprofloxacin	67-79	netilmicin	94-103	false
ciprofloxacin	67-79	tobramycin	109-118	false
gentamicin	82-91	netilmicin	94-103	false
gentamicin	82-91	tobramycin	109-118	false
netilmicin	94-103	tobramycin	109-118	false

Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
baclofen	47-54	morphine	79-86	effect

SIDE EFFECTS (KEMSTRO) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).
KEMSTRO	14-20	baclofen	78-85	false

The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.
KEMSTROTM	41-49	baclofen	81-88	false

No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.
COLAZAL	52-58	antibiotics	100-110	false
COLAZAL	52-58	mesalamine	164-173	false
antibiotics	100-110	mesalamine	164-173	false

No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.
Simulect	37-44	cyclosporine	102-113	false
Simulect	37-44	corticosteroids	116-130	false
Simulect	37-44	azathioprine	144-155	false
Simulect	37-44	mycophenolate mofetil	160-180	false
cyclosporine	102-113	corticosteroids	116-130	false
cyclosporine	102-113	azathioprine	144-155	false
cyclosporine	102-113	mycophenolate mofetil	160-180	false
corticosteroids	116-130	azathioprine	144-155	false
corticosteroids	116-130	mycophenolate mofetil	160-180	false
azathioprine	144-155	mycophenolate mofetil	160-180	false

Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
Simulect	24-31	azathioprine	76-87	mechanism
Simulect	24-31	mycophenolate mofetil	93-113	mechanism
Simulect	24-31	cyclosporine	168-179	false
Simulect	24-31	corticosteroids	201-215	false
azathioprine	76-87	mycophenolate mofetil	93-113	false
azathioprine	76-87	cyclosporine	168-179	false
azathioprine	76-87	corticosteroids	201-215	false
mycophenolate mofetil	93-113	cyclosporine	168-179	false
mycophenolate mofetil	93-113	corticosteroids	201-215	false
cyclosporine	168-179	corticosteroids	201-215	false

Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
Simulect	37-44	azathioprine	82-93	false
Simulect	37-44	mycophenolate mofetil	111-131	false
azathioprine	82-93	mycophenolate mofetil	111-131	false

The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.
Simulect	73-80	azathioprine	130-141	false
Simulect	73-80	corticosteroids	144-158	false
Simulect	73-80	cyclosporine	161-172	false
Simulect	73-80	mycophenolate mofetil	175-195	false
Simulect	73-80	muromonab-CD3	202-214	false
azathioprine	130-141	corticosteroids	144-158	false
azathioprine	130-141	cyclosporine	161-172	false
azathioprine	130-141	mycophenolate mofetil	175-195	false
azathioprine	130-141	muromonab-CD3	202-214	false
corticosteroids	144-158	cyclosporine	161-172	false
corticosteroids	144-158	mycophenolate mofetil	175-195	false
corticosteroids	144-158	muromonab-CD3	202-214	false
cyclosporine	161-172	mycophenolate mofetil	175-195	false
cyclosporine	161-172	muromonab-CD3	202-214	false
mycophenolate mofetil	175-195	muromonab-CD3	202-214	false

Albuterol, Antihistamines, antidiabetic drugs, diuretics, digitalis.
Albuterol	0-8	Antihistamines	11-24	false
Albuterol	0-8	antidiabetic drugs	27-44	false
Albuterol	0-8	diuretics	47-55	false
Albuterol	0-8	digitalis	58-66	false
Antihistamines	11-24	antidiabetic drugs	27-44	false
Antihistamines	11-24	diuretics	47-55	false
Antihistamines	11-24	digitalis	58-66	false
antidiabetic drugs	27-44	diuretics	47-55	false
antidiabetic drugs	27-44	digitalis	58-66	false
diuretics	47-55	digitalis	58-66	false

Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.
Diuretics	0-8	diuretics	23-31	false
Diuretics	0-8	Lotensin	203-210	false
diuretics	23-31	Lotensin	203-210	effect

The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
Lotensin	44-51	diuretic	98-105	false
Lotensin	44-51	Lotensin	175-182	false
diuretic	98-105	Lotensin	175-182	advise

Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
Potassium	0-8	Potassium-Sparing Diuretics	26-52	false
Potassium	0-8	thiazide diuretics	102-119	false
Potassium-Sparing Diuretics	26-52	thiazide diuretics	102-119	effect

Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
Potassium-sparing diuretics	0-26	spironolactone	29-42	false
Potassium-sparing diuretics	0-26	amiloride	45-53	false
Potassium-sparing diuretics	0-26	triamterene	56-66	false
Potassium-sparing diuretics	0-26	potassium	84-92	false
spironolactone	29-42	amiloride	45-53	false
spironolactone	29-42	triamterene	56-66	false
spironolactone	29-42	potassium	84-92	false
amiloride	45-53	triamterene	56-66	false
amiloride	45-53	potassium	84-92	false
triamterene	56-66	potassium	84-92	false

Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
Anticoagulants	5-18	warfarin	45-52	false
Anticoagulants	5-18	acenocoumarol	58-70	false
Anticoagulants	5-18	anticoagulants	181-194	false
warfarin	45-52	acenocoumarol	58-70	false
warfarin	45-52	anticoagulants	181-194	false
acenocoumarol	58-70	anticoagulants	181-194	false

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
Lithium	0-6	lithium	25-31	false
Lithium	0-6	lithium	56-62	false
Lithium	0-6	ACE inhibitors	114-127	false
Lithium	0-6	lithium	149-155	false
lithium	25-31	lithium	56-62	false
lithium	25-31	ACE inhibitors	114-127	false
lithium	25-31	lithium	149-155	false
lithium	56-62	ACE inhibitors	114-127	false
lithium	56-62	lithium	149-155	false
ACE inhibitors	114-127	lithium	149-155	mechanism

If a diuretic is also used, the risk of lithium toxicity may be increased.
diuretic	5-12	lithium	40-46	effect

Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.
Lotensin	73-80	hydrochlorothiazide	118-136	false
Lotensin	73-80	chlorthalidone	139-152	false
Lotensin	73-80	furosemide	155-164	false
Lotensin	73-80	digoxin	167-173	false
Lotensin	73-80	propranolol	176-186	false
Lotensin	73-80	atenolol	189-196	false
Lotensin	73-80	naproxen	199-206	false
Lotensin	73-80	cimetidine	212-221	false
hydrochlorothiazide	118-136	chlorthalidone	139-152	false
hydrochlorothiazide	118-136	furosemide	155-164	false
hydrochlorothiazide	118-136	digoxin	167-173	false
hydrochlorothiazide	118-136	propranolol	176-186	false
hydrochlorothiazide	118-136	atenolol	189-196	false
hydrochlorothiazide	118-136	naproxen	199-206	false
hydrochlorothiazide	118-136	cimetidine	212-221	false
chlorthalidone	139-152	furosemide	155-164	false
chlorthalidone	139-152	digoxin	167-173	false
chlorthalidone	139-152	propranolol	176-186	false
chlorthalidone	139-152	atenolol	189-196	false
chlorthalidone	139-152	naproxen	199-206	false
chlorthalidone	139-152	cimetidine	212-221	false
furosemide	155-164	digoxin	167-173	false
furosemide	155-164	propranolol	176-186	false
furosemide	155-164	atenolol	189-196	false
furosemide	155-164	naproxen	199-206	false
furosemide	155-164	cimetidine	212-221	false
digoxin	167-173	propranolol	176-186	false
digoxin	167-173	atenolol	189-196	false
digoxin	167-173	naproxen	199-206	false
digoxin	167-173	cimetidine	212-221	false
propranolol	176-186	atenolol	189-196	false
propranolol	176-186	naproxen	199-206	false
propranolol	176-186	cimetidine	212-221	false
atenolol	189-196	naproxen	199-206	false
atenolol	189-196	cimetidine	212-221	false
naproxen	199-206	cimetidine	212-221	false

Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
Lotensin	0-7	beta-adrenergic-blocking agents	42-72	false
Lotensin	0-7	calcium-channel-blocking agents	75-105	false
Lotensin	0-7	diuretics	108-116	false
Lotensin	0-7	digoxin	119-125	false
Lotensin	0-7	hydralazine	132-142	false
beta-adrenergic-blocking agents	42-72	calcium-channel-blocking agents	75-105	false
beta-adrenergic-blocking agents	42-72	diuretics	108-116	false
beta-adrenergic-blocking agents	42-72	digoxin	119-125	false
beta-adrenergic-blocking agents	42-72	hydralazine	132-142	false
calcium-channel-blocking agents	75-105	diuretics	108-116	false
calcium-channel-blocking agents	75-105	digoxin	119-125	false
calcium-channel-blocking agents	75-105	hydralazine	132-142	false
diuretics	108-116	digoxin	119-125	false
diuretics	108-116	hydralazine	132-142	false
digoxin	119-125	hydralazine	132-142	false

Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
Benazepril	0-9	ACE inhibitors	23-36	false
Benazepril	0-9	beta-adrenergic blockers	79-102	effect
ACE inhibitors	23-36	beta-adrenergic blockers	79-102	effect

May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
cholestyramine	33-46	colestipol	49-58	false
cholestyramine	33-46	thiazide diuretics	70-87	effect
cholestyramine	33-46	diuretic	105-112	false
colestipol	49-58	thiazide diuretics	70-87	effect
colestipol	49-58	diuretic	105-112	false
thiazide diuretics	70-87	diuretic	105-112	false

Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
Bentiromide	0-10	acetaminophen	30-42	int
Bentiromide	0-10	Tylenol	51-57	int
Bentiromide	0-10	chloramphenicol	61-75	int
Bentiromide	0-10	Chloromycetin	84-96	int
Bentiromide	0-10	anesthetics	106-116	int
Bentiromide	0-10	benzocaine	125-134	int
Bentiromide	0-10	lidocaine	140-148	int
Bentiromide	0-10	para-aminobenzoic acid	152-173	int
Bentiromide	0-10	PABA	176-179	int
Bentiromide	0-10	multivitamins	233-245	int
Bentiromide	0-10	procainamide	249-260	int
Bentiromide	0-10	Pronestyl	269-277	int
Bentiromide	0-10	sulfonamides	281-292	int
Bentiromide	0-10	thiazide diuretics	313-330	int
acetaminophen	30-42	Tylenol	51-57	false
acetaminophen	30-42	chloramphenicol	61-75	false
acetaminophen	30-42	Chloromycetin	84-96	false
acetaminophen	30-42	anesthetics	106-116	false
acetaminophen	30-42	benzocaine	125-134	false
acetaminophen	30-42	lidocaine	140-148	false
acetaminophen	30-42	para-aminobenzoic acid	152-173	false
acetaminophen	30-42	PABA	176-179	false
acetaminophen	30-42	multivitamins	233-245	false
acetaminophen	30-42	procainamide	249-260	false
acetaminophen	30-42	Pronestyl	269-277	false
acetaminophen	30-42	sulfonamides	281-292	false
acetaminophen	30-42	thiazide diuretics	313-330	false
Tylenol	51-57	chloramphenicol	61-75	false
Tylenol	51-57	Chloromycetin	84-96	false
Tylenol	51-57	anesthetics	106-116	false
Tylenol	51-57	benzocaine	125-134	false
Tylenol	51-57	lidocaine	140-148	false
Tylenol	51-57	para-aminobenzoic acid	152-173	false
Tylenol	51-57	PABA	176-179	false
Tylenol	51-57	multivitamins	233-245	false
Tylenol	51-57	procainamide	249-260	false
Tylenol	51-57	Pronestyl	269-277	false
Tylenol	51-57	sulfonamides	281-292	false
Tylenol	51-57	thiazide diuretics	313-330	false
chloramphenicol	61-75	Chloromycetin	84-96	false
chloramphenicol	61-75	anesthetics	106-116	false
chloramphenicol	61-75	benzocaine	125-134	false
chloramphenicol	61-75	lidocaine	140-148	false
chloramphenicol	61-75	para-aminobenzoic acid	152-173	false
chloramphenicol	61-75	PABA	176-179	false
chloramphenicol	61-75	multivitamins	233-245	false
chloramphenicol	61-75	procainamide	249-260	false
chloramphenicol	61-75	Pronestyl	269-277	false
chloramphenicol	61-75	sulfonamides	281-292	false
chloramphenicol	61-75	thiazide diuretics	313-330	false
Chloromycetin	84-96	anesthetics	106-116	false
Chloromycetin	84-96	benzocaine	125-134	false
Chloromycetin	84-96	lidocaine	140-148	false
Chloromycetin	84-96	para-aminobenzoic acid	152-173	false
Chloromycetin	84-96	PABA	176-179	false
Chloromycetin	84-96	multivitamins	233-245	false
Chloromycetin	84-96	procainamide	249-260	false
Chloromycetin	84-96	Pronestyl	269-277	false
Chloromycetin	84-96	sulfonamides	281-292	false
Chloromycetin	84-96	thiazide diuretics	313-330	false
anesthetics	106-116	benzocaine	125-134	false
anesthetics	106-116	lidocaine	140-148	false
anesthetics	106-116	para-aminobenzoic acid	152-173	false
anesthetics	106-116	PABA	176-179	false
anesthetics	106-116	multivitamins	233-245	false
anesthetics	106-116	procainamide	249-260	false
anesthetics	106-116	Pronestyl	269-277	false
anesthetics	106-116	sulfonamides	281-292	false
anesthetics	106-116	thiazide diuretics	313-330	false
benzocaine	125-134	lidocaine	140-148	false
benzocaine	125-134	para-aminobenzoic acid	152-173	false
benzocaine	125-134	PABA	176-179	false
benzocaine	125-134	multivitamins	233-245	false
benzocaine	125-134	procainamide	249-260	false
benzocaine	125-134	Pronestyl	269-277	false
benzocaine	125-134	sulfonamides	281-292	false
benzocaine	125-134	thiazide diuretics	313-330	false
lidocaine	140-148	para-aminobenzoic acid	152-173	false
lidocaine	140-148	PABA	176-179	false
lidocaine	140-148	multivitamins	233-245	false
lidocaine	140-148	procainamide	249-260	false
lidocaine	140-148	Pronestyl	269-277	false
lidocaine	140-148	sulfonamides	281-292	false
lidocaine	140-148	thiazide diuretics	313-330	false
para-aminobenzoic acid	152-173	PABA	176-179	false
para-aminobenzoic acid	152-173	multivitamins	233-245	false
para-aminobenzoic acid	152-173	procainamide	249-260	false
para-aminobenzoic acid	152-173	Pronestyl	269-277	false
para-aminobenzoic acid	152-173	sulfonamides	281-292	false
para-aminobenzoic acid	152-173	thiazide diuretics	313-330	false
PABA	176-179	multivitamins	233-245	false
PABA	176-179	procainamide	249-260	false
PABA	176-179	Pronestyl	269-277	false
PABA	176-179	sulfonamides	281-292	false
PABA	176-179	thiazide diuretics	313-330	false
multivitamins	233-245	procainamide	249-260	false
multivitamins	233-245	Pronestyl	269-277	false
multivitamins	233-245	sulfonamides	281-292	false
multivitamins	233-245	thiazide diuretics	313-330	false
procainamide	249-260	Pronestyl	269-277	false
procainamide	249-260	sulfonamides	281-292	false
procainamide	249-260	thiazide diuretics	313-330	false
Pronestyl	269-277	sulfonamides	281-292	false
Pronestyl	269-277	thiazide diuretics	313-330	false
sulfonamides	281-292	thiazide diuretics	313-330	false

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
sympathomimetic amines	39-60	monoamine oxidase inhibitors	122-149	effect

DIDREX should not be used concomitantly with other CNS stimulants.
DIDREX	0-5	CNS stimulants	51-64	advise

Amphetamines may decrease the hypotensive effect of antihypertensives.
Amphetamines	0-11	antihypertensives	52-68	effect

Amphetamines may enhance the effects of tricyclic antidepressants.
Amphetamines	0-11	tricyclic antidepressants	40-64	effect

Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
Urinary acidifying	0-17	amphetamines	74-85	mechanism

Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
Benzthiazide	0-11	alcohol	31-37	int
Benzthiazide	0-11	blood thinner	40-52	int
Benzthiazide	0-11	decongestant drugs	56-73	int
Benzthiazide	0-11	lithium	129-135	int
Benzthiazide	0-11	norepinephrine	138-151	int
Benzthiazide	0-11	NSAIDs	154-159	int
Benzthiazide	0-11	Aleve	166-170	int
Benzthiazide	0-11	Ibuprofen	175-183	int
alcohol	31-37	blood thinner	40-52	false
alcohol	31-37	decongestant drugs	56-73	false
alcohol	31-37	lithium	129-135	false
alcohol	31-37	norepinephrine	138-151	false
alcohol	31-37	NSAIDs	154-159	false
alcohol	31-37	Aleve	166-170	false
alcohol	31-37	Ibuprofen	175-183	false
blood thinner	40-52	decongestant drugs	56-73	false
blood thinner	40-52	lithium	129-135	false
blood thinner	40-52	norepinephrine	138-151	false
blood thinner	40-52	NSAIDs	154-159	false
blood thinner	40-52	Aleve	166-170	false
blood thinner	40-52	Ibuprofen	175-183	false
decongestant drugs	56-73	lithium	129-135	false
decongestant drugs	56-73	norepinephrine	138-151	false
decongestant drugs	56-73	NSAIDs	154-159	false
decongestant drugs	56-73	Aleve	166-170	false
decongestant drugs	56-73	Ibuprofen	175-183	false
lithium	129-135	norepinephrine	138-151	false
lithium	129-135	NSAIDs	154-159	false
lithium	129-135	Aleve	166-170	false
lithium	129-135	Ibuprofen	175-183	false
norepinephrine	138-151	NSAIDs	154-159	false
norepinephrine	138-151	Aleve	166-170	false
norepinephrine	138-151	Ibuprofen	175-183	false
NSAIDs	154-159	Aleve	166-170	false
NSAIDs	154-159	Ibuprofen	175-183	false
Aleve	166-170	Ibuprofen	175-183	false

Antipsychotic drugs such as phenothiazines or haloperidol;
Antipsychotic drugs	0-18	phenothiazines	28-41	false
Antipsychotic drugs	0-18	haloperidol	46-56	false
phenothiazines	28-41	haloperidol	46-56	false

Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.
Nitrates	0-7	Bepridil	33-40	false
Nitrates	0-7	nitrates	70-77	false
Bepridil	33-40	nitrates	70-77	false

Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.
nitroglycerin	11-23	Bepridil	98-105	false

Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina.
Beta-blocking Agents	0-19	Bepridil	45-52	false
Beta-blocking Agents	0-19	beta-blocking agents	58-77	false
Bepridil	45-52	beta-blocking agents	58-77	false

Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
Digoxin	0-6	bepridil hydrochloride	54-75	false
Digoxin	0-6	digoxin	197-203	false
bepridil hydrochloride	54-75	digoxin	197-203	mechanism

Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.
bepridil hydrochloride	63-84	digoxin	90-96	false

Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.
Hypoglycemics	5-17	Bepridil	20-27	false
Hypoglycemics	5-17	insulin	156-162	false
Hypoglycemics	5-17	hypoglycemic agents	172-190	false
Bepridil	20-27	insulin	156-162	false
Bepridil	20-27	hypoglycemic agents	172-190	false
insulin	156-162	hypoglycemic agents	172-190	false

In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
bepridil hydrochloride	86-107	anti-arrhythmic agents	120-141	false
bepridil hydrochloride	86-107	quinidine	151-159	false
bepridil hydrochloride	86-107	procainamide	165-176	false
bepridil hydrochloride	86-107	cardiac glycosides	179-196	false
bepridil hydrochloride	86-107	tricyclic anti-depressants	202-227	false
anti-arrhythmic agents	120-141	quinidine	151-159	false
anti-arrhythmic agents	120-141	procainamide	165-176	false
anti-arrhythmic agents	120-141	cardiac glycosides	179-196	false
anti-arrhythmic agents	120-141	tricyclic anti-depressants	202-227	false
quinidine	151-159	procainamide	165-176	false
quinidine	151-159	cardiac glycosides	179-196	false
quinidine	151-159	tricyclic anti-depressants	202-227	false
procainamide	165-176	cardiac glycosides	179-196	false
procainamide	165-176	tricyclic anti-depressants	202-227	false
cardiac glycosides	179-196	tricyclic anti-depressants	202-227	false

Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
Anti-arrhythmics	0-15	tricyclic anti-depressants	21-46	false
Anti-arrhythmics	0-15	bepridil hydrochloride	115-136	effect
tricyclic anti-depressants	21-46	bepridil hydrochloride	115-136	effect

Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
Cardiac glycosides	0-17	bepridil hydrochloride	88-109	effect

The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide.
Kerlone	50-56	cimetidine	101-110	false
Kerlone	50-56	nifedipine	113-122	false
Kerlone	50-56	chlorthalidone	125-138	false
Kerlone	50-56	hydrochlorothiazide	145-163	false
cimetidine	101-110	nifedipine	113-122	false
cimetidine	101-110	chlorthalidone	125-138	false
cimetidine	101-110	hydrochlorothiazide	145-163	false
nifedipine	113-122	chlorthalidone	125-138	false
nifedipine	113-122	hydrochlorothiazide	145-163	false
chlorthalidone	125-138	hydrochlorothiazide	145-163	false

Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.
Kerlone	30-36	anticoagulant	52-64	false
Kerlone	30-36	warfarin	66-73	false
Kerlone	30-36	warfarin	136-143	false
anticoagulant	52-64	warfarin	66-73	false
anticoagulant	52-64	warfarin	136-143	false
warfarin	66-73	warfarin	136-143	false

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	37-45	beta-blocking	92-104	effect

Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
beta-blockers	66-78	clonidine	84-92	advise
beta-blockers	66-78	beta-blocker	112-123	false
beta-blockers	66-78	clonidine	206-214	false
clonidine	84-92	beta-blocker	112-123	false
clonidine	84-92	clonidine	206-214	false
beta-blocker	112-123	clonidine	206-214	advise

Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
calcium antagonists	37-55	beta-adrenergic blocking agents	89-119	advise

Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
beta-adrenergic blocking agents	116-146	calcium antagonist	161-178	effect

Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.
calcium antagonist	44-61	dihydropyridine derivative	70-95	false
calcium antagonist	44-61	nifedipine	104-113	false
calcium antagonist	44-61	verapamil	249-257	false
calcium antagonist	44-61	diltiazem	262-270	false
dihydropyridine derivative	70-95	nifedipine	104-113	false
dihydropyridine derivative	70-95	verapamil	249-257	false
dihydropyridine derivative	70-95	diltiazem	262-270	false
nifedipine	104-113	verapamil	249-257	false
nifedipine	104-113	diltiazem	262-270	false
verapamil	249-257	diltiazem	262-270	false

Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
beta-blockers	69-81	epinephrine	104-114	effect
beta-blockers	69-81	beta-blockers	156-168	false
epinephrine	104-114	beta-blockers	156-168	false

In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.
irinotecan	55-64	5-FU	66-69	false
irinotecan	55-64	leucovorin	71-80	false
irinotecan	55-64	AVASTIN	110-116	false
5-FU	66-69	leucovorin	71-80	false
5-FU	66-69	AVASTIN	110-116	false
leucovorin	71-80	AVASTIN	110-116	false

Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN.
Irinotecan	0-9	AVASTIN	101-107	false

The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.
SN38	22-25	irinotecan	53-62	false
SN38	22-25	AVASTIN	144-150	false
irinotecan	53-62	AVASTIN	144-150	false

Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.
SN38	90-93	irinotecan	135-144	false
SN38	90-93	AVASTIN	150-156	false
irinotecan	135-144	AVASTIN	150-156	false

On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
bexarotene	34-43	ketoconazole	69-80	false
bexarotene	34-43	itraconazole	83-94	false
bexarotene	34-43	erythromycin	97-108	false
bexarotene	34-43	gemfibrozil	111-121	false
bexarotene	34-43	bexarotene	237-246	false
ketoconazole	69-80	itraconazole	83-94	false
ketoconazole	69-80	erythromycin	97-108	false
ketoconazole	69-80	gemfibrozil	111-121	false
ketoconazole	69-80	bexarotene	237-246	mechanism
itraconazole	83-94	erythromycin	97-108	false
itraconazole	83-94	gemfibrozil	111-121	false
itraconazole	83-94	bexarotene	237-246	mechanism
erythromycin	97-108	gemfibrozil	111-121	false
erythromycin	97-108	bexarotene	237-246	mechanism
gemfibrozil	111-121	bexarotene	237-246	mechanism

Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
rifampin	13-20	phenytoin	23-31	false
rifampin	13-20	phenobarbital	34-46	false
rifampin	13-20	bexarotene	123-132	mechanism
phenytoin	23-31	phenobarbital	34-46	false
phenytoin	23-31	bexarotene	123-132	mechanism
phenobarbital	34-46	bexarotene	123-132	mechanism

Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
Targretin	30-38	gemfibrozil	53-63	mechanism
Targretin	30-38	bexarotene	127-136	false
Targretin	30-38	gemfibrozil	212-222	false
gemfibrozil	53-63	bexarotene	127-136	false
gemfibrozil	53-63	gemfibrozil	212-222	false
bexarotene	127-136	gemfibrozil	212-222	false

Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.
bexarotene	26-35	atorvastatin	85-96	false

Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
gemfibrozil	30-40	Targretin	47-55	advise

When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
Bezalip	5-11	Bezalip retard	16-29	false
Bezalip	5-11	Bezalip	146-152	false
Bezalip	5-11	Bezalip retard	158-171	false
Bezalip	5-11	anticoagulants of the coumarin type	199-233	false
Bezalip retard	16-29	Bezalip	146-152	false
Bezalip retard	16-29	Bezalip retard	158-171	false
Bezalip retard	16-29	anticoagulants of the coumarin type	199-233	false
Bezalip	146-152	Bezalip retard	158-171	false
Bezalip	146-152	anticoagulants of the coumarin type	199-233	effect
Bezalip retard	158-171	anticoagulants of the coumarin type	199-233	effect

For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
anticoagulant	33-45	Bezalip	108-114	advise
anticoagulant	33-45	Bezalip	119-125	advise
Bezalip	108-114	Bezalip	119-125	false

- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
sulphonylureas	16-29	insulin	35-41	false
sulphonylureas	16-29	Bezalip	62-68	effect
sulphonylureas	16-29	Bezalip retard	73-86	effect
insulin	35-41	Bezalip	62-68	effect
insulin	35-41	Bezalip retard	73-86	effect
Bezalip	62-68	Bezalip retard	73-86	false

- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.
immuno-suppressant	211-228	bezafibrate	254-264	effect

- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
Bezalip	7-13	Bezalip retard	18-31	false
Bezalip	7-13	anion-exchange resins	59-79	advise
Bezalip	7-13	cholestryramine	87-101	advise
Bezalip	7-13	Bezalip	209-215	false
Bezalip	7-13	Bezalip retard	220-233	false
Bezalip retard	18-31	anion-exchange resins	59-79	advise
Bezalip retard	18-31	cholestryramine	87-101	advise
Bezalip retard	18-31	Bezalip	209-215	false
Bezalip retard	18-31	Bezalip retard	220-233	false
anion-exchange resins	59-79	cholestryramine	87-101	false
anion-exchange resins	59-79	Bezalip	209-215	false
anion-exchange resins	59-79	Bezalip retard	220-233	false
cholestryramine	87-101	Bezalip	209-215	false
cholestryramine	87-101	Bezalip retard	220-233	false
Bezalip	209-215	Bezalip retard	220-233	false

- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
Perhexiline hydrogen maleate	2-29	MAO-inhibitors	34-47	false
Perhexiline hydrogen maleate	2-29	Bezalip	117-123	advise
Perhexiline hydrogen maleate	2-29	Bezalip retard	128-141	advise
MAO-inhibitors	34-47	Bezalip	117-123	advise
MAO-inhibitors	34-47	Bezalip retard	128-141	advise
Bezalip	117-123	Bezalip retard	128-141	false

In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
CASODEX	28-34	coumarin anticoagulant	49-70	mechanism
CASODEX	28-34	warfarin	82-89	mechanism
coumarin anticoagulant	49-70	warfarin	82-89	false

It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
CASODEX	26-32	coumarin anticoagulants	75-97	advise
CASODEX	26-32	anticoagulant	168-180	advise
coumarin anticoagulants	75-97	anticoagulant	168-180	false

Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
anticholinergic	31-45	AKINETON	102-109	false
anticholinergic	31-45	narcotic analgesics	212-230	effect
anticholinergic	31-45	meperidine	240-249	effect
anticholinergic	31-45	phenothiazines	256-269	effect
anticholinergic	31-45	antipsychotics	281-294	effect
anticholinergic	31-45	tricyclic antidepressants	297-321	effect
anticholinergic	31-45	antiarrhythmics	332-346	effect
anticholinergic	31-45	quinidine	360-368	effect
anticholinergic	31-45	antihistamines	381-394	effect
AKINETON	102-109	narcotic analgesics	212-230	effect
AKINETON	102-109	meperidine	240-249	effect
AKINETON	102-109	phenothiazines	256-269	effect
AKINETON	102-109	antipsychotics	281-294	effect
AKINETON	102-109	tricyclic antidepressants	297-321	effect
AKINETON	102-109	antiarrhythmics	332-346	effect
AKINETON	102-109	quinidine	360-368	effect
AKINETON	102-109	antihistamines	381-394	effect
narcotic analgesics	212-230	meperidine	240-249	false
narcotic analgesics	212-230	phenothiazines	256-269	false
narcotic analgesics	212-230	antipsychotics	281-294	false
narcotic analgesics	212-230	tricyclic antidepressants	297-321	false
narcotic analgesics	212-230	antiarrhythmics	332-346	false
narcotic analgesics	212-230	quinidine	360-368	false
narcotic analgesics	212-230	antihistamines	381-394	false
meperidine	240-249	phenothiazines	256-269	false
meperidine	240-249	antipsychotics	281-294	false
meperidine	240-249	tricyclic antidepressants	297-321	false
meperidine	240-249	antiarrhythmics	332-346	false
meperidine	240-249	quinidine	360-368	false
meperidine	240-249	antihistamines	381-394	false
phenothiazines	256-269	antipsychotics	281-294	false
phenothiazines	256-269	tricyclic antidepressants	297-321	false
phenothiazines	256-269	antiarrhythmics	332-346	false
phenothiazines	256-269	quinidine	360-368	false
phenothiazines	256-269	antihistamines	381-394	false
antipsychotics	281-294	tricyclic antidepressants	297-321	false
antipsychotics	281-294	antiarrhythmics	332-346	false
antipsychotics	281-294	quinidine	360-368	false
antipsychotics	281-294	antihistamines	381-394	false
tricyclic antidepressants	297-321	antiarrhythmics	332-346	false
tricyclic antidepressants	297-321	quinidine	360-368	false
tricyclic antidepressants	297-321	antihistamines	381-394	false
antiarrhythmics	332-346	quinidine	360-368	false
antiarrhythmics	332-346	antihistamines	381-394	false
quinidine	360-368	antihistamines	381-394	false

ZEBETA should not be combined with other beta-blocking agents.
ZEBETA	0-5	beta-blocking agents	41-60	advise

Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
reserpine	58-66	guanethidine	71-82	false
reserpine	58-66	ZEBETA	167-172	effect
guanethidine	71-82	ZEBETA	167-172	effect

In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
clonidine	46-54	ZEBETA	112-117	false
clonidine	46-54	clonidine	177-185	false
ZEBETA	112-117	clonidine	177-185	advise

ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
ZEBETA	0-5	myocardial depressants	37-58	advise
ZEBETA	0-5	calcium antagonists	108-126	advise
ZEBETA	0-5	phenylalkylamine	149-164	advise
ZEBETA	0-5	verapamil	167-175	advise
ZEBETA	0-5	benzothiazepine	182-196	advise
ZEBETA	0-5	diltiazem	199-207	advise
ZEBETA	0-5	antiarrhythmic agents	223-243	advise
ZEBETA	0-5	disopyramide	254-265	advise
myocardial depressants	37-58	calcium antagonists	108-126	false
myocardial depressants	37-58	phenylalkylamine	149-164	false
myocardial depressants	37-58	verapamil	167-175	false
myocardial depressants	37-58	benzothiazepine	182-196	false
myocardial depressants	37-58	diltiazem	199-207	false
myocardial depressants	37-58	antiarrhythmic agents	223-243	false
myocardial depressants	37-58	disopyramide	254-265	false
calcium antagonists	108-126	phenylalkylamine	149-164	false
calcium antagonists	108-126	verapamil	167-175	false
calcium antagonists	108-126	benzothiazepine	182-196	false
calcium antagonists	108-126	diltiazem	199-207	false
calcium antagonists	108-126	antiarrhythmic agents	223-243	false
calcium antagonists	108-126	disopyramide	254-265	false
phenylalkylamine	149-164	verapamil	167-175	false
phenylalkylamine	149-164	benzothiazepine	182-196	false
phenylalkylamine	149-164	diltiazem	199-207	false
phenylalkylamine	149-164	antiarrhythmic agents	223-243	false
phenylalkylamine	149-164	disopyramide	254-265	false
verapamil	167-175	benzothiazepine	182-196	false
verapamil	167-175	diltiazem	199-207	false
verapamil	167-175	antiarrhythmic agents	223-243	false
verapamil	167-175	disopyramide	254-265	false
benzothiazepine	182-196	diltiazem	199-207	false
benzothiazepine	182-196	antiarrhythmic agents	223-243	false
benzothiazepine	182-196	disopyramide	254-265	false
diltiazem	199-207	antiarrhythmic agents	223-243	false
diltiazem	199-207	disopyramide	254-265	false
antiarrhythmic agents	223-243	disopyramide	254-265	false

Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
rifampin	18-25	ZEBETA	64-69	mechanism
rifampin	18-25	ZEBETA	122-127	false
ZEBETA	64-69	ZEBETA	122-127	false

Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine.
thiazide diuretics	118-135	digoxin	138-144	false
thiazide diuretics	118-135	cimetidine	151-160	false
digoxin	138-144	cimetidine	151-160	false

There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.
ZEBETA	23-28	warfarin	81-88	false

If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
steroid	24-30	bitolterol	46-55	advise
steroid	24-30	steroid	111-117	false
bitolterol	46-55	steroid	111-117	advise

This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
bitolterol	12-21	steroid	81-87	effect

In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
Angiomax	73-80	heparin	87-93	effect
Angiomax	73-80	warfarin	96-103	effect
Angiomax	73-80	thrombolytics	106-118	effect
heparin	87-93	warfarin	96-103	false
heparin	87-93	thrombolytics	106-118	false
warfarin	96-103	thrombolytics	106-118	false

There is no experience with co-administration of Angiomax and plasma expanders such as dextran.
Angiomax	49-56	dextran	87-93	false

Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.
Angiomax	32-39	bivalirudin	135-145	false

Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.
antibiotic	8-17	cisplatin	20-28	false
antibiotic	8-17	cyclosporine	31-42	false
antibiotic	8-17	diuretic	45-52	false
antibiotic	8-17	foscarnet	55-63	false
antibiotic	8-17	vaccines	70-77	false
cisplatin	20-28	cyclosporine	31-42	false
cisplatin	20-28	diuretic	45-52	false
cisplatin	20-28	foscarnet	55-63	false
cisplatin	20-28	vaccines	70-77	false
cyclosporine	31-42	diuretic	45-52	false
cyclosporine	31-42	foscarnet	55-63	false
cyclosporine	31-42	vaccines	70-77	false
diuretic	45-52	foscarnet	55-63	false
diuretic	45-52	vaccines	70-77	false
foscarnet	55-63	vaccines	70-77	false

Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
antidiabetic agents	17-35	VELCADE	47-53	advise
antidiabetic agents	17-35	antidiabetic medication	160-182	false
VELCADE	47-53	antidiabetic medication	160-182	false

Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
Hormonal Contraceptives	0-22	Contraceptives	82-95	false
Hormonal Contraceptives	0-22	bosentan	158-165	false
Hormonal Contraceptives	0-22	hormonal contraceptive	180-201	false
Hormonal Contraceptives	0-22	Ortho-Novum	203-213	false
Hormonal Contraceptives	0-22	norethindrone	245-257	false
Hormonal Contraceptives	0-22	ethinyl estradiol	263-279	false
Contraceptives	82-95	bosentan	158-165	false
Contraceptives	82-95	hormonal contraceptive	180-201	false
Contraceptives	82-95	Ortho-Novum	203-213	false
Contraceptives	82-95	norethindrone	245-257	false
Contraceptives	82-95	ethinyl estradiol	263-279	false
bosentan	158-165	hormonal contraceptive	180-201	false
bosentan	158-165	Ortho-Novum	203-213	mechanism
bosentan	158-165	norethindrone	245-257	false
bosentan	158-165	ethinyl estradiol	263-279	false
hormonal contraceptive	180-201	Ortho-Novum	203-213	false
hormonal contraceptive	180-201	norethindrone	245-257	false
hormonal contraceptive	180-201	ethinyl estradiol	263-279	false
Ortho-Novum	203-213	norethindrone	245-257	false
Ortho-Novum	203-213	ethinyl estradiol	263-279	false
norethindrone	245-257	ethinyl estradiol	263-279	false

Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
hormonal contraceptives	11-33	TRACLEER	125-132	effect

Specific interaction studies have demonstrated the following: Cyclosporine A: During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold.
Cyclosporine A	62-75	bosentan	155-162	false

Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
bosentan	13-20	cyclosporine A	92-105	mechanism

The concomitant administration of bosentan and cyclosporine A is contraindicated.
bosentan	34-41	cyclosporine A	47-60	advise

Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.
bosentan	21-28	cyclosporine A	69-82	mechanism

Tacrolimus: Co-administration of tacrolimus and bosentan has not been studied in man.
Tacrolimus	0-9	tacrolimus	33-42	false
Tacrolimus	0-9	bosentan	48-55	false
tacrolimus	33-42	bosentan	48-55	false

Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
tacrolimus	21-30	bosentan	36-43	mechanism
tacrolimus	21-30	bosentan	101-108	false
bosentan	36-43	bosentan	101-108	false

Caution should be exercised if tacrolimus and bosentan are used together.
tacrolimus	31-40	bosentan	46-53	advise

Glyburide: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide.
Glyburide	0-8	glyburide	125-133	false

Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
TRACLEER	45-52	glyburide	58-66	advise
TRACLEER	45-52	hypoglycemic agents	104-122	false
glyburide	58-66	hypoglycemic agents	104-122	false

Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
bosentan	21-28	glyburide	69-77	mechanism

Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
Bosentan	0-7	hypoglycemic agents	72-90	mechanism

Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
Ketoconazole	0-11	bosentan	35-42	false
Ketoconazole	0-11	ketoconazole	62-73	false
Ketoconazole	0-11	bosentan	142-149	false
bosentan	35-42	ketoconazole	62-73	mechanism
bosentan	35-42	bosentan	142-149	false
ketoconazole	62-73	bosentan	142-149	false

No dose adjustment of bosentan is necessary, but increased effects of bosentan should be considered.
bosentan	22-29	bosentan	70-77	false

Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
Simvastatin	0-10	Statins	22-28	false
Simvastatin	0-10	bosentan	52-59	false
Simvastatin	0-10	simvastatin	100-110	false
Statins	22-28	bosentan	52-59	false
Statins	22-28	simvastatin	100-110	false
bosentan	52-59	simvastatin	100-110	mechanism

Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
Bosentan	0-7	statins	67-73	mechanism
Bosentan	0-7	lovastatin	127-136	mechanism
Bosentan	0-7	atorvastatin	142-153	mechanism
statins	67-73	lovastatin	127-136	false
statins	67-73	atorvastatin	142-153	false
lovastatin	127-136	atorvastatin	142-153	false

Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
statins	34-40	TRACLEER	89-96	advise
statins	34-40	statin	130-135	false
TRACLEER	89-96	statin	130-135	false

Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
Warfarin	0-7	bosentan	31-38	false
Warfarin	0-7	S-warfarin	109-118	false
Warfarin	0-7	R-warfarin	145-154	false
bosentan	31-38	S-warfarin	109-118	mechanism
bosentan	31-38	R-warfarin	145-154	mechanism
S-warfarin	109-118	R-warfarin	145-154	false

Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
bosentan	55-62	warfarin	68-75	false
bosentan	55-62	warfarin	177-184	false
bosentan	55-62	warfarin	262-269	false
bosentan	55-62	bosentan	359-366	false
warfarin	68-75	warfarin	177-184	false
warfarin	68-75	warfarin	262-269	false
warfarin	68-75	bosentan	359-366	false
warfarin	177-184	warfarin	262-269	false
warfarin	177-184	bosentan	359-366	false
warfarin	262-269	bosentan	359-366	false

Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
Digoxin	0-6	Nimodipine	9-18	false
Digoxin	0-6	Losartan	24-31	false
Digoxin	0-6	Bosentan	34-41	false
Digoxin	0-6	digoxin	96-102	false
Digoxin	0-6	nimodipine	108-117	false
Digoxin	0-6	losartan	124-131	false
Digoxin	0-6	bosentan	179-186	false
Nimodipine	9-18	Losartan	24-31	false
Nimodipine	9-18	Bosentan	34-41	false
Nimodipine	9-18	digoxin	96-102	false
Nimodipine	9-18	nimodipine	108-117	false
Nimodipine	9-18	losartan	124-131	false
Nimodipine	9-18	bosentan	179-186	false
Losartan	24-31	Bosentan	34-41	false
Losartan	24-31	digoxin	96-102	false
Losartan	24-31	nimodipine	108-117	false
Losartan	24-31	losartan	124-131	false
Losartan	24-31	bosentan	179-186	false
Bosentan	34-41	digoxin	96-102	false
Bosentan	34-41	nimodipine	108-117	false
Bosentan	34-41	losartan	124-131	false
Bosentan	34-41	bosentan	179-186	false
digoxin	96-102	nimodipine	108-117	false
digoxin	96-102	losartan	124-131	false
digoxin	96-102	bosentan	179-186	false
nimodipine	108-117	losartan	124-131	false
nimodipine	108-117	bosentan	179-186	false
losartan	124-131	bosentan	179-186	false

Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
BOTOX	21-25	aminoglycosides	31-45	advise
BOTOX	21-25	curare-like compounds	114-134	advise
BOTOX	21-25	toxin	196-200	false
aminoglycosides	31-45	curare-like compounds	114-134	false
aminoglycosides	31-45	toxin	196-200	false
curare-like compounds	114-134	toxin	196-200	false

Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
botulinum toxin	81-95	botulinum toxin	165-179	effect

Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
MYOBLOC	21-27	aminoglycosides	33-47	advise
MYOBLOC	21-27	curare-like compounds	116-136	advise
MYOBLOC	21-27	toxin	198-202	false
aminoglycosides	33-47	curare-like compounds	116-136	false
aminoglycosides	33-47	toxin	198-202	false
curare-like compounds	116-136	toxin	198-202	false

Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
Digitalis	0-8	Bretylium Tosylate	88-105	effect

The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
catecholamines	23-36	dopamine	46-53	false
catecholamines	23-36	norepinephrine	58-71	false
catecholamines	23-36	Bretylium Tosylate	89-106	effect
dopamine	46-53	norepinephrine	58-71	false
dopamine	46-53	Bretylium Tosylate	89-106	effect
norepinephrine	58-71	Bretylium Tosylate	89-106	effect

Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.
lidocaine	80-88	Bretylium Tosylate	94-111	false

Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
ALPHAGAN P	72-81	CNS depressants	143-157	advise
ALPHAGAN P	72-81	alcohol	160-166	advise
ALPHAGAN P	72-81	barbiturates	169-180	advise
ALPHAGAN P	72-81	opiates	183-189	advise
ALPHAGAN P	72-81	sedatives	192-200	advise
ALPHAGAN P	72-81	anesthetics	206-216	advise
CNS depressants	143-157	alcohol	160-166	false
CNS depressants	143-157	barbiturates	169-180	false
CNS depressants	143-157	opiates	183-189	false
CNS depressants	143-157	sedatives	192-200	false
CNS depressants	143-157	anesthetics	206-216	false
alcohol	160-166	barbiturates	169-180	false
alcohol	160-166	opiates	183-189	false
alcohol	160-166	sedatives	192-200	false
alcohol	160-166	anesthetics	206-216	false
barbiturates	169-180	opiates	183-189	false
barbiturates	169-180	sedatives	192-200	false
barbiturates	169-180	anesthetics	206-216	false
opiates	183-189	sedatives	192-200	false
opiates	183-189	anesthetics	206-216	false
sedatives	192-200	anesthetics	206-216	false

Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.
beta-blockers	43-55	anti-hypertensives	84-101	false
beta-blockers	43-55	cardiac glycosides	110-127	false
anti-hypertensives	84-101	cardiac glycosides	110-127	false

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
Tricyclic antidepressants	0-24	clonidine	89-97	effect
Tricyclic antidepressants	0-24	ALPHAGAN P	163-172	false
clonidine	89-97	ALPHAGAN P	163-172	false

AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.
AZOPT	0-4	brinzolamide	7-18	false
AZOPT	0-4	carbonic anhydrase inhibitor	57-84	false
brinzolamide	7-18	carbonic anhydrase inhibitor	57-84	false

However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
carbonic anhydrase inhibitors	39-67	salicylate	135-144	int

Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.
AZOPT	94-98	brinzolamide	101-112	false

The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
bromocriptine mesylate	18-39	alcohol	116-122	false
bromocriptine mesylate	18-39	bromocriptine mesylate	159-180	false
alcohol	116-122	bromocriptine mesylate	159-180	effect

Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
Bromocriptine mesylate	0-21	dopamine antagonists	41-60	int
Bromocriptine mesylate	0-21	butyrophenones	63-76	int
dopamine antagonists	41-60	butyrophenones	63-76	false

Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
bromocriptine mesylate	64-85	phenothiazines	88-101	effect
bromocriptine mesylate	64-85	haloperidol	104-114	effect
bromocriptine mesylate	64-85	metoclopramide	117-130	effect
bromocriptine mesylate	64-85	pimozide	133-140	effect
phenothiazines	88-101	haloperidol	104-114	false
phenothiazines	88-101	metoclopramide	117-130	false
phenothiazines	88-101	pimozide	133-140	false
haloperidol	104-114	metoclopramide	117-130	false
haloperidol	104-114	pimozide	133-140	false
metoclopramide	117-130	pimozide	133-140	false

Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
bromocriptine mesylate	19-40	ergot alkaloids	53-67	advise

Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
Dexbrompheniramine	0-17	alcohol	37-43	effect
Dexbrompheniramine	0-17	CNS depressants	54-68	effect
Dexbrompheniramine	0-17	antihistamines	144-157	false
Dexbrompheniramine	0-17	anticholinergics	161-176	effect
Dexbrompheniramine	0-17	antihistamines	323-336	false
Dexbrompheniramine	0-17	monoamine oxidase (MAO) inhibitors	344-377	effect
Dexbrompheniramine	0-17	antihistamines	400-413	false
Dexbrompheniramine	0-17	antihistamines	491-504	false
alcohol	37-43	CNS depressants	54-68	false
alcohol	37-43	antihistamines	144-157	false
alcohol	37-43	anticholinergics	161-176	false
alcohol	37-43	antihistamines	323-336	false
alcohol	37-43	monoamine oxidase (MAO) inhibitors	344-377	false
alcohol	37-43	antihistamines	400-413	false
alcohol	37-43	antihistamines	491-504	false
CNS depressants	54-68	antihistamines	144-157	false
CNS depressants	54-68	anticholinergics	161-176	false
CNS depressants	54-68	antihistamines	323-336	false
CNS depressants	54-68	monoamine oxidase (MAO) inhibitors	344-377	false
CNS depressants	54-68	antihistamines	400-413	false
CNS depressants	54-68	antihistamines	491-504	false
antihistamines	144-157	anticholinergics	161-176	false
antihistamines	144-157	antihistamines	323-336	false
antihistamines	144-157	monoamine oxidase (MAO) inhibitors	344-377	false
antihistamines	144-157	antihistamines	400-413	false
antihistamines	144-157	antihistamines	491-504	false
anticholinergics	161-176	antihistamines	323-336	false
anticholinergics	161-176	monoamine oxidase (MAO) inhibitors	344-377	false
anticholinergics	161-176	antihistamines	400-413	false
anticholinergics	161-176	antihistamines	491-504	false
antihistamines	323-336	monoamine oxidase (MAO) inhibitors	344-377	false
antihistamines	323-336	antihistamines	400-413	false
antihistamines	323-336	antihistamines	491-504	false
monoamine oxidase (MAO) inhibitors	344-377	antihistamines	400-413	false
monoamine oxidase (MAO) inhibitors	344-377	antihistamines	491-504	false
antihistamines	400-413	antihistamines	491-504	false

This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
alcohol	28-34	CNS depressants	45-59	false
alcohol	28-34	antihistamines	135-148	false
alcohol	28-34	anticholinergics	152-167	false
alcohol	28-34	antihistamines	314-327	false
alcohol	28-34	monoamine oxidase (MAO) inhibitors	335-368	false
alcohol	28-34	antihistamines	391-404	false
alcohol	28-34	antihistamines	482-495	false
CNS depressants	45-59	antihistamines	135-148	false
CNS depressants	45-59	anticholinergics	152-167	false
CNS depressants	45-59	antihistamines	314-327	false
CNS depressants	45-59	monoamine oxidase (MAO) inhibitors	335-368	false
CNS depressants	45-59	antihistamines	391-404	false
CNS depressants	45-59	antihistamines	482-495	false
antihistamines	135-148	anticholinergics	152-167	false
antihistamines	135-148	antihistamines	314-327	false
antihistamines	135-148	monoamine oxidase (MAO) inhibitors	335-368	false
antihistamines	135-148	antihistamines	391-404	false
antihistamines	135-148	antihistamines	482-495	false
anticholinergics	152-167	antihistamines	314-327	false
anticholinergics	152-167	monoamine oxidase (MAO) inhibitors	335-368	false
anticholinergics	152-167	antihistamines	391-404	false
anticholinergics	152-167	antihistamines	482-495	false
antihistamines	314-327	monoamine oxidase (MAO) inhibitors	335-368	false
antihistamines	314-327	antihistamines	391-404	false
antihistamines	314-327	antihistamines	482-495	false
monoamine oxidase (MAO) inhibitors	335-368	antihistamines	391-404	false
monoamine oxidase (MAO) inhibitors	335-368	antihistamines	482-495	false
antihistamines	391-404	antihistamines	482-495	false

Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
ketoconazole	35-46	budesonide	192-201	mechanism

If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
ketoconazole	57-68	intraconazole	71-83	false
ketoconazole	57-68	ritonavir	86-94	false
ketoconazole	57-68	indinavir	97-105	false
ketoconazole	57-68	saquinavir	108-117	false
ketoconazole	57-68	erythromycin	120-131	false
ketoconazole	57-68	budesonide	171-180	advise
intraconazole	71-83	ritonavir	86-94	false
intraconazole	71-83	indinavir	97-105	false
intraconazole	71-83	saquinavir	108-117	false
intraconazole	71-83	erythromycin	120-131	false
intraconazole	71-83	budesonide	171-180	advise
ritonavir	86-94	indinavir	97-105	false
ritonavir	86-94	saquinavir	108-117	false
ritonavir	86-94	erythromycin	120-131	false
ritonavir	86-94	budesonide	171-180	advise
indinavir	97-105	saquinavir	108-117	false
indinavir	97-105	erythromycin	120-131	false
indinavir	97-105	budesonide	171-180	advise
saquinavir	108-117	erythromycin	120-131	false
saquinavir	108-117	budesonide	171-180	advise
erythromycin	120-131	budesonide	171-180	advise

- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.
bumetanide	125-134	aminoglycoside antibiotics	156-181	advise

- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
Lithium	2-8	Lithium	11-17	false
Lithium	2-8	diuretics	54-62	false
Lithium	2-8	bumetanide	73-82	false
Lithium	2-8	lithium	148-154	false
Lithium	11-17	diuretics	54-62	advise
Lithium	11-17	bumetanide	73-82	advise
Lithium	11-17	lithium	148-154	false
diuretics	54-62	bumetanide	73-82	false
diuretics	54-62	lithium	148-154	false
bumetanide	73-82	lithium	148-154	false

- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
Probenecid	2-11	probenecid	32-41	false
Probenecid	2-11	bumetanide	103-112	false
probenecid	32-41	bumetanide	103-112	effect

This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
probenecid	28-37	bumetanide	42-51	mechanism
probenecid	28-37	bumetanide	196-205	false
bumetanide	42-51	bumetanide	196-205	false

Thus, probenecid should not be administered concurrently with bumetanide.
probenecid	6-15	bumetanide	62-71	advise

- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
Indomethacin	2-13	Indomethacin	16-27	false
Indomethacin	2-13	bumetanide	99-108	false
Indomethacin	2-13	bumetanide	137-146	false
Indomethacin	16-27	bumetanide	99-108	mechanism
Indomethacin	16-27	bumetanide	137-146	effect
bumetanide	99-108	bumetanide	137-146	false

- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
Antihypertensives	2-18	Bumetanide	21-30	false
Antihypertensives	2-18	antihypertensive drugs	69-90	false
Bumetanide	21-30	antihypertensive drugs	69-90	effect

- Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels.
Digoxin	2-8	digoxin	65-71	false

- Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.
Anticoagulants	2-15	bumetanide	59-68	false
Anticoagulants	2-15	warfarin	91-98	false
bumetanide	59-68	warfarin	91-98	false

The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
anesthetic solutions	28-47	epinephrine	60-70	false
anesthetic solutions	28-47	norepinephrine	75-88	false
anesthetic solutions	28-47	monoamine oxidase inhibitors	112-139	false
anesthetic solutions	28-47	tricyclic antidepressants	144-168	false
epinephrine	60-70	norepinephrine	75-88	false
epinephrine	60-70	monoamine oxidase inhibitors	112-139	effect
epinephrine	60-70	tricyclic antidepressants	144-168	effect
norepinephrine	75-88	monoamine oxidase inhibitors	112-139	effect
norepinephrine	75-88	tricyclic antidepressants	144-168	effect
monoamine oxidase inhibitors	112-139	tricyclic antidepressants	144-168	false

Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
vasopressor drugs	29-45	ergot-type oxytocic drugs	54-78	false

Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
Phenothiazines	0-13	butyrophenones	19-32	false
Phenothiazines	0-13	epinephrine	78-88	effect
butyrophenones	19-32	epinephrine	78-88	effect

Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4.
Buprenorphine	0-12	norbuprenorphine	32-47	false

Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g.
buprenorphine	65-77	azole antifungals	127-143	false

ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
ketoconazole	0-11	macrolide antibiotics	15-35	false
ketoconazole	0-11	erythromycin	43-54	false
ketoconazole	0-11	HIV protease inhibitors	62-84	false
ketoconazole	0-11	ritonavir	92-100	false
ketoconazole	0-11	indinavir	103-111	false
ketoconazole	0-11	saquinavir	117-126	false
ketoconazole	0-11	SUBUTEX	155-161	false
ketoconazole	0-11	SUBOXONE	166-173	false
macrolide antibiotics	15-35	erythromycin	43-54	false
macrolide antibiotics	15-35	HIV protease inhibitors	62-84	false
macrolide antibiotics	15-35	ritonavir	92-100	false
macrolide antibiotics	15-35	indinavir	103-111	false
macrolide antibiotics	15-35	saquinavir	117-126	false
macrolide antibiotics	15-35	SUBUTEX	155-161	false
macrolide antibiotics	15-35	SUBOXONE	166-173	false
erythromycin	43-54	HIV protease inhibitors	62-84	false
erythromycin	43-54	ritonavir	92-100	false
erythromycin	43-54	indinavir	103-111	false
erythromycin	43-54	saquinavir	117-126	false
erythromycin	43-54	SUBUTEX	155-161	false
erythromycin	43-54	SUBOXONE	166-173	false
HIV protease inhibitors	62-84	ritonavir	92-100	false
HIV protease inhibitors	62-84	indinavir	103-111	false
HIV protease inhibitors	62-84	saquinavir	117-126	false
HIV protease inhibitors	62-84	SUBUTEX	155-161	false
HIV protease inhibitors	62-84	SUBOXONE	166-173	false
ritonavir	92-100	indinavir	103-111	false
ritonavir	92-100	saquinavir	117-126	false
ritonavir	92-100	SUBUTEX	155-161	false
ritonavir	92-100	SUBOXONE	166-173	false
indinavir	103-111	saquinavir	117-126	false
indinavir	103-111	SUBUTEX	155-161	false
indinavir	103-111	SUBOXONE	166-173	false
saquinavir	117-126	SUBUTEX	155-161	false
saquinavir	117-126	SUBOXONE	166-173	false
SUBUTEX	155-161	SUBOXONE	166-173	false

Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
buprenorphine	64-76	benzodiazepines	82-96	int

There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
buprenorphine	141-153	benzodiazepines	159-173	effect

In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.
buprenorphine	24-36	SUBUTEX	79-85	false

SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
SUBUTEX	0-6	SUBOXONE	12-19	false
SUBUTEX	0-6	benzodiazepines	70-84	advise
SUBOXONE	12-19	benzodiazepines	70-84	advise

Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
benzodiazepines	92-106	SUBOXONE	135-142	advise
benzodiazepines	92-106	SUBUTEX	147-153	advise
SUBOXONE	135-142	SUBUTEX	147-153	false

Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs.
WELLBUTRIN	59-68	WELLBUTRIN	187-196	false

In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.
bupropion	31-39	hydroxybupropion	69-84	false

Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
WELLBUTRIN	63-72	orphenadrine	124-135	int
WELLBUTRIN	63-72	cyclophosphamide	141-156	int
orphenadrine	124-135	cyclophosphamide	141-156	false

The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.
threohydrobupropion	4-22	bupropion	38-46	false

The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.
cimetidine	45-54	bupropion	83-91	false

Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.
cimetidine	97-106	bupropion	133-141	false
cimetidine	97-106	hydroxybupropion	147-162	false
bupropion	133-141	hydroxybupropion	147-162	false

However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.
threohydrobupropion	105-123	erythrohydrobupropion	129-149	false

While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
bupropion	77-85	carbamazepine	94-106	mechanism
bupropion	77-85	phenobarbital	109-121	mechanism
bupropion	77-85	phenytoin	124-132	mechanism
carbamazepine	94-106	phenobarbital	109-121	false
carbamazepine	94-106	phenytoin	124-132	false
phenobarbital	109-121	phenytoin	124-132	false

Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.
antidepressants	78-92	tricyclics	107-116	false
antidepressants	78-92	beta-blockers	120-132	false
antidepressants	78-92	antiarrhythmics	135-149	false
antidepressants	78-92	antipsychotics	156-169	false
tricyclics	107-116	beta-blockers	120-132	false
tricyclics	107-116	antiarrhythmics	135-149	false
tricyclics	107-116	antipsychotics	156-169	false
beta-blockers	120-132	antiarrhythmics	135-149	false
beta-blockers	120-132	antipsychotics	156-169	false
antiarrhythmics	135-149	antipsychotics	156-169	false

Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.
bupropion	9-17	bupropion	57-65	false
bupropion	9-17	hydroxybupropion	71-86	false
bupropion	57-65	hydroxybupropion	71-86	false

In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
bupropion	125-133	desipramine	198-208	mechanism
bupropion	125-133	desipramine	247-257	false
desipramine	198-208	desipramine	247-257	false

Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
bupropion	32-40	antidepressants	112-126	advise
bupropion	32-40	nortriptyline	135-147	advise
bupropion	32-40	imipramine	150-159	advise
bupropion	32-40	desipramine	162-172	advise
bupropion	32-40	paroxetine	175-184	advise
bupropion	32-40	fluoxetine	187-196	advise
bupropion	32-40	sertraline	199-208	advise
bupropion	32-40	antipsychotics	212-225	advise
bupropion	32-40	haloperidol	234-244	advise
bupropion	32-40	risperidone	247-257	advise
bupropion	32-40	thioridazine	260-271	advise
bupropion	32-40	beta-blockers	275-287	advise
bupropion	32-40	metoprolol	296-305	advise
bupropion	32-40	Type 1C antiarrhythmics	313-335	advise
bupropion	32-40	propafenone	344-354	advise
bupropion	32-40	flecainide	357-366	advise
antidepressants	112-126	nortriptyline	135-147	false
antidepressants	112-126	imipramine	150-159	false
antidepressants	112-126	desipramine	162-172	false
antidepressants	112-126	paroxetine	175-184	false
antidepressants	112-126	fluoxetine	187-196	false
antidepressants	112-126	sertraline	199-208	false
antidepressants	112-126	antipsychotics	212-225	false
antidepressants	112-126	haloperidol	234-244	false
antidepressants	112-126	risperidone	247-257	false
antidepressants	112-126	thioridazine	260-271	false
antidepressants	112-126	beta-blockers	275-287	false
antidepressants	112-126	metoprolol	296-305	false
antidepressants	112-126	Type 1C antiarrhythmics	313-335	false
antidepressants	112-126	propafenone	344-354	false
antidepressants	112-126	flecainide	357-366	false
nortriptyline	135-147	imipramine	150-159	false
nortriptyline	135-147	desipramine	162-172	false
nortriptyline	135-147	paroxetine	175-184	false
nortriptyline	135-147	fluoxetine	187-196	false
nortriptyline	135-147	sertraline	199-208	false
nortriptyline	135-147	antipsychotics	212-225	false
nortriptyline	135-147	haloperidol	234-244	false
nortriptyline	135-147	risperidone	247-257	false
nortriptyline	135-147	thioridazine	260-271	false
nortriptyline	135-147	beta-blockers	275-287	false
nortriptyline	135-147	metoprolol	296-305	false
nortriptyline	135-147	Type 1C antiarrhythmics	313-335	false
nortriptyline	135-147	propafenone	344-354	false
nortriptyline	135-147	flecainide	357-366	false
imipramine	150-159	desipramine	162-172	false
imipramine	150-159	paroxetine	175-184	false
imipramine	150-159	fluoxetine	187-196	false
imipramine	150-159	sertraline	199-208	false
imipramine	150-159	antipsychotics	212-225	false
imipramine	150-159	haloperidol	234-244	false
imipramine	150-159	risperidone	247-257	false
imipramine	150-159	thioridazine	260-271	false
imipramine	150-159	beta-blockers	275-287	false
imipramine	150-159	metoprolol	296-305	false
imipramine	150-159	Type 1C antiarrhythmics	313-335	false
imipramine	150-159	propafenone	344-354	false
imipramine	150-159	flecainide	357-366	false
desipramine	162-172	paroxetine	175-184	false
desipramine	162-172	fluoxetine	187-196	false
desipramine	162-172	sertraline	199-208	false
desipramine	162-172	antipsychotics	212-225	false
desipramine	162-172	haloperidol	234-244	false
desipramine	162-172	risperidone	247-257	false
desipramine	162-172	thioridazine	260-271	false
desipramine	162-172	beta-blockers	275-287	false
desipramine	162-172	metoprolol	296-305	false
desipramine	162-172	Type 1C antiarrhythmics	313-335	false
desipramine	162-172	propafenone	344-354	false
desipramine	162-172	flecainide	357-366	false
paroxetine	175-184	fluoxetine	187-196	false
paroxetine	175-184	sertraline	199-208	false
paroxetine	175-184	antipsychotics	212-225	false
paroxetine	175-184	haloperidol	234-244	false
paroxetine	175-184	risperidone	247-257	false
paroxetine	175-184	thioridazine	260-271	false
paroxetine	175-184	beta-blockers	275-287	false
paroxetine	175-184	metoprolol	296-305	false
paroxetine	175-184	Type 1C antiarrhythmics	313-335	false
paroxetine	175-184	propafenone	344-354	false
paroxetine	175-184	flecainide	357-366	false
fluoxetine	187-196	sertraline	199-208	false
fluoxetine	187-196	antipsychotics	212-225	false
fluoxetine	187-196	haloperidol	234-244	false
fluoxetine	187-196	risperidone	247-257	false
fluoxetine	187-196	thioridazine	260-271	false
fluoxetine	187-196	beta-blockers	275-287	false
fluoxetine	187-196	metoprolol	296-305	false
fluoxetine	187-196	Type 1C antiarrhythmics	313-335	false
fluoxetine	187-196	propafenone	344-354	false
fluoxetine	187-196	flecainide	357-366	false
sertraline	199-208	antipsychotics	212-225	false
sertraline	199-208	haloperidol	234-244	false
sertraline	199-208	risperidone	247-257	false
sertraline	199-208	thioridazine	260-271	false
sertraline	199-208	beta-blockers	275-287	false
sertraline	199-208	metoprolol	296-305	false
sertraline	199-208	Type 1C antiarrhythmics	313-335	false
sertraline	199-208	propafenone	344-354	false
sertraline	199-208	flecainide	357-366	false
antipsychotics	212-225	haloperidol	234-244	false
antipsychotics	212-225	risperidone	247-257	false
antipsychotics	212-225	thioridazine	260-271	false
antipsychotics	212-225	beta-blockers	275-287	false
antipsychotics	212-225	metoprolol	296-305	false
antipsychotics	212-225	Type 1C antiarrhythmics	313-335	false
antipsychotics	212-225	propafenone	344-354	false
antipsychotics	212-225	flecainide	357-366	false
haloperidol	234-244	risperidone	247-257	false
haloperidol	234-244	thioridazine	260-271	false
haloperidol	234-244	beta-blockers	275-287	false
haloperidol	234-244	metoprolol	296-305	false
haloperidol	234-244	Type 1C antiarrhythmics	313-335	false
haloperidol	234-244	propafenone	344-354	false
haloperidol	234-244	flecainide	357-366	false
risperidone	247-257	thioridazine	260-271	false
risperidone	247-257	beta-blockers	275-287	false
risperidone	247-257	metoprolol	296-305	false
risperidone	247-257	Type 1C antiarrhythmics	313-335	false
risperidone	247-257	propafenone	344-354	false
risperidone	247-257	flecainide	357-366	false
thioridazine	260-271	beta-blockers	275-287	false
thioridazine	260-271	metoprolol	296-305	false
thioridazine	260-271	Type 1C antiarrhythmics	313-335	false
thioridazine	260-271	propafenone	344-354	false
thioridazine	260-271	flecainide	357-366	false
beta-blockers	275-287	metoprolol	296-305	false
beta-blockers	275-287	Type 1C antiarrhythmics	313-335	false
beta-blockers	275-287	propafenone	344-354	false
beta-blockers	275-287	flecainide	357-366	false
metoprolol	296-305	Type 1C antiarrhythmics	313-335	false
metoprolol	296-305	propafenone	344-354	false
metoprolol	296-305	flecainide	357-366	false
Type 1C antiarrhythmics	313-335	propafenone	344-354	false
Type 1C antiarrhythmics	313-335	flecainide	357-366	false
propafenone	344-354	flecainide	357-366	false

MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
MAO Inhibitors	0-13	bupropion	74-82	false
MAO Inhibitors	0-13	MAO inhibitor	103-115	false
MAO Inhibitors	0-13	phenelzine	117-126	false
bupropion	74-82	MAO inhibitor	103-115	false
bupropion	74-82	phenelzine	117-126	effect
MAO inhibitor	103-115	phenelzine	117-126	false

Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
Levodopa	0-7	Amantadine	13-22	false
Levodopa	0-7	bupropion	119-127	false
Levodopa	0-7	levodopa	154-161	false
Levodopa	0-7	amantadine	166-175	false
Amantadine	13-22	bupropion	119-127	false
Amantadine	13-22	levodopa	154-161	false
Amantadine	13-22	amantadine	166-175	false
bupropion	119-127	levodopa	154-161	effect
bupropion	119-127	amantadine	166-175	effect
levodopa	154-161	amantadine	166-175	false

Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
WELLBUTRIN	18-27	levodopa	66-73	advise
WELLBUTRIN	18-27	amantadine	78-87	advise
levodopa	66-73	amantadine	78-87	false

Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
WELLBUTRIN	65-74	antipsychotics	94-107	advise
WELLBUTRIN	65-74	antidepressants	116-130	advise
WELLBUTRIN	65-74	theophylline	133-144	advise
WELLBUTRIN	65-74	steroids	156-163	advise
antipsychotics	94-107	antidepressants	116-130	false
antipsychotics	94-107	theophylline	133-144	false
antipsychotics	94-107	steroids	156-163	false
antidepressants	116-130	theophylline	133-144	false
antidepressants	116-130	steroids	156-163	false
theophylline	133-144	steroids	156-163	false

Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
Alcohol	0-6	alcohol	114-120	false
Alcohol	0-6	alcohol	162-168	false
Alcohol	0-6	WELLBUTRIN	192-201	false
alcohol	114-120	alcohol	162-168	false
alcohol	114-120	WELLBUTRIN	192-201	false
alcohol	162-168	WELLBUTRIN	192-201	effect

The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
alcohol	19-25	WELLBUTRIN	49-58	advise

It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
buspirone hydrochloride	23-45	MAO inhibitors	78-91	advise
buspirone hydrochloride	23-45	buspirone HCl	146-158	false
buspirone hydrochloride	23-45	psychotropic drugs	176-193	false
buspirone hydrochloride	23-45	buspirone HCl	241-253	false
MAO inhibitors	78-91	buspirone HCl	146-158	false
MAO inhibitors	78-91	psychotropic drugs	176-193	false
MAO inhibitors	78-91	buspirone HCl	241-253	false
buspirone HCl	146-158	psychotropic drugs	176-193	false
buspirone HCl	146-158	buspirone HCl	241-253	false
psychotropic drugs	176-193	buspirone HCl	241-253	false

There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
trazodone hydrochloride	59-81	Desyrel	84-90	false
trazodone hydrochloride	59-81	buspirone HCl	97-109	effect
Desyrel	84-90	buspirone HCl	97-109	effect

In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
buspirone HCl	63-75	haloperidol	81-91	mechanism
buspirone HCl	63-75	haloperidol	121-131	false
haloperidol	81-91	haloperidol	121-131	false

In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.
buspirone	10-18	phenytoin	63-71	false
buspirone	10-18	propranolol	74-84	false
buspirone	10-18	warfarin	91-98	false
phenytoin	63-71	propranolol	74-84	false
phenytoin	63-71	warfarin	91-98	false
propranolol	74-84	warfarin	91-98	false

However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
buspirone	70-78	warfarin	131-138	effect

The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.
phenytoin	43-51	phenobarbital	54-66	false
phenytoin	43-51	digoxin	69-75	false
phenytoin	43-51	levothyroxine sodium	82-101	false
phenobarbital	54-66	digoxin	69-75	false
phenobarbital	54-66	levothyroxine sodium	82-101	false
digoxin	69-75	levothyroxine sodium	82-101	false

In vitro, buspirone may displace less firmly bound drugs like digoxin.
buspirone	10-18	digoxin	62-68	mechanism

Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.
Itraconazole	0-11	busulfan	23-30	mechanism

Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
Fluconazole	0-10	5-HT3 antiemetics	21-37	false
Fluconazole	0-10	ondansetron	39-49	false
Fluconazole	0-10	Zofran	52-57	false
Fluconazole	0-10	granisetron	64-74	false
Fluconazole	0-10	Kytril	77-82	false
Fluconazole	0-10	BUSULFEX	109-116	false
5-HT3 antiemetics	21-37	ondansetron	39-49	false
5-HT3 antiemetics	21-37	Zofran	52-57	false
5-HT3 antiemetics	21-37	granisetron	64-74	false
5-HT3 antiemetics	21-37	Kytril	77-82	false
5-HT3 antiemetics	21-37	BUSULFEX	109-116	false
ondansetron	39-49	Zofran	52-57	false
ondansetron	39-49	granisetron	64-74	false
ondansetron	39-49	Kytril	77-82	false
ondansetron	39-49	BUSULFEX	109-116	false
Zofran	52-57	granisetron	64-74	false
Zofran	52-57	Kytril	77-82	false
Zofran	52-57	BUSULFEX	109-116	false
granisetron	64-74	Kytril	77-82	false
granisetron	64-74	BUSULFEX	109-116	false
Kytril	77-82	BUSULFEX	109-116	false

Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
Phenytoin	0-8	busulfan	37-44	mechanism

Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
BUSULFEX	30-37	phenytoin	77-85	mechanism
BUSULFEX	30-37	BUSULFEX	105-112	false
BUSULFEX	30-37	phenytoin	206-214	false
phenytoin	77-85	BUSULFEX	105-112	false
phenytoin	77-85	phenytoin	206-214	false
BUSULFEX	105-112	phenytoin	206-214	false

Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
busulfan	8-15	acetaminophen	86-98	false
busulfan	8-15	BUSULFEX	140-147	false
busulfan	8-15	busulfan	171-178	false
busulfan	8-15	acetaminophen	223-235	false
acetaminophen	86-98	BUSULFEX	140-147	mechanism
acetaminophen	86-98	busulfan	171-178	false
acetaminophen	86-98	acetaminophen	223-235	false
BUSULFEX	140-147	busulfan	171-178	false
BUSULFEX	140-147	acetaminophen	223-235	false
busulfan	171-178	acetaminophen	223-235	false

Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
anticoagulants	87-100	blood thinner	103-115	false
anticoagulants	87-100	carbamazepine	120-132	false
anticoagulants	87-100	corticotropin	135-147	false
anticoagulants	87-100	barbiturates	150-161	false
anticoagulants	87-100	central nervous system (CNS) depressants	209-248	false
anticoagulants	87-100	barbiturates	278-289	false
anticoagulants	87-100	divalproex sodium	340-356	false
anticoagulants	87-100	valproic acid	359-371	false
anticoagulants	87-100	barbiturates	401-412	false
anticoagulants	87-100	contraceptives	488-501	false
anticoagulants	87-100	estrogens	514-522	false
anticoagulants	87-100	barbiturates	525-536	false
anticoagulants	87-100	contraceptives	583-596	false
blood thinner	103-115	carbamazepine	120-132	false
blood thinner	103-115	corticotropin	135-147	false
blood thinner	103-115	barbiturates	150-161	false
blood thinner	103-115	central nervous system (CNS) depressants	209-248	false
blood thinner	103-115	barbiturates	278-289	false
blood thinner	103-115	divalproex sodium	340-356	false
blood thinner	103-115	valproic acid	359-371	false
blood thinner	103-115	barbiturates	401-412	false
blood thinner	103-115	contraceptives	488-501	false
blood thinner	103-115	estrogens	514-522	false
blood thinner	103-115	barbiturates	525-536	false
blood thinner	103-115	contraceptives	583-596	false
carbamazepine	120-132	corticotropin	135-147	false
carbamazepine	120-132	barbiturates	150-161	false
carbamazepine	120-132	central nervous system (CNS) depressants	209-248	false
carbamazepine	120-132	barbiturates	278-289	false
carbamazepine	120-132	divalproex sodium	340-356	false
carbamazepine	120-132	valproic acid	359-371	false
carbamazepine	120-132	barbiturates	401-412	false
carbamazepine	120-132	contraceptives	488-501	false
carbamazepine	120-132	estrogens	514-522	false
carbamazepine	120-132	barbiturates	525-536	false
carbamazepine	120-132	contraceptives	583-596	false
corticotropin	135-147	barbiturates	150-161	false
corticotropin	135-147	central nervous system (CNS) depressants	209-248	false
corticotropin	135-147	barbiturates	278-289	false
corticotropin	135-147	divalproex sodium	340-356	false
corticotropin	135-147	valproic acid	359-371	false
corticotropin	135-147	barbiturates	401-412	false
corticotropin	135-147	contraceptives	488-501	false
corticotropin	135-147	estrogens	514-522	false
corticotropin	135-147	barbiturates	525-536	false
corticotropin	135-147	contraceptives	583-596	false
barbiturates	150-161	central nervous system (CNS) depressants	209-248	false
barbiturates	150-161	barbiturates	278-289	false
barbiturates	150-161	divalproex sodium	340-356	false
barbiturates	150-161	valproic acid	359-371	false
barbiturates	150-161	barbiturates	401-412	false
barbiturates	150-161	contraceptives	488-501	false
barbiturates	150-161	estrogens	514-522	false
barbiturates	150-161	barbiturates	525-536	false
barbiturates	150-161	contraceptives	583-596	false
central nervous system (CNS) depressants	209-248	barbiturates	278-289	false
central nervous system (CNS) depressants	209-248	divalproex sodium	340-356	false
central nervous system (CNS) depressants	209-248	valproic acid	359-371	false
central nervous system (CNS) depressants	209-248	barbiturates	401-412	false
central nervous system (CNS) depressants	209-248	contraceptives	488-501	false
central nervous system (CNS) depressants	209-248	estrogens	514-522	false
central nervous system (CNS) depressants	209-248	barbiturates	525-536	false
central nervous system (CNS) depressants	209-248	contraceptives	583-596	false
barbiturates	278-289	divalproex sodium	340-356	false
barbiturates	278-289	valproic acid	359-371	false
barbiturates	278-289	barbiturates	401-412	false
barbiturates	278-289	contraceptives	488-501	false
barbiturates	278-289	estrogens	514-522	false
barbiturates	278-289	barbiturates	525-536	false
barbiturates	278-289	contraceptives	583-596	false
divalproex sodium	340-356	valproic acid	359-371	false
divalproex sodium	340-356	barbiturates	401-412	false
divalproex sodium	340-356	contraceptives	488-501	false
divalproex sodium	340-356	estrogens	514-522	false
divalproex sodium	340-356	barbiturates	525-536	false
divalproex sodium	340-356	contraceptives	583-596	false
valproic acid	359-371	barbiturates	401-412	false
valproic acid	359-371	contraceptives	488-501	false
valproic acid	359-371	estrogens	514-522	false
valproic acid	359-371	barbiturates	525-536	false
valproic acid	359-371	contraceptives	583-596	false
barbiturates	401-412	contraceptives	488-501	false
barbiturates	401-412	estrogens	514-522	false
barbiturates	401-412	barbiturates	525-536	false
barbiturates	401-412	contraceptives	583-596	false
contraceptives	488-501	estrogens	514-522	false
contraceptives	488-501	barbiturates	525-536	false
contraceptives	488-501	contraceptives	583-596	false
estrogens	514-522	barbiturates	525-536	false
estrogens	514-522	contraceptives	583-596	false
barbiturates	525-536	contraceptives	583-596	effect

The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
butalbital	19-28	monoamine oxidase (MAO) inhibitors	49-82	effect

Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
Butalbital	0-9	acetaminophen	12-24	false
Butalbital	0-9	caffeine	30-37	false
Butalbital	0-9	narcotic analgesic	73-90	effect
Butalbital	0-9	alcohol	94-100	effect
Butalbital	0-9	anesthetics	111-121	effect
Butalbital	0-9	tranquilizers	124-136	effect
Butalbital	0-9	chlordiazepoxide	146-161	effect
Butalbital	0-9	sedative-hypnotics	164-181	effect
Butalbital	0-9	CNS depressants	193-207	effect
acetaminophen	12-24	caffeine	30-37	false
acetaminophen	12-24	narcotic analgesic	73-90	effect
acetaminophen	12-24	alcohol	94-100	effect
acetaminophen	12-24	anesthetics	111-121	effect
acetaminophen	12-24	tranquilizers	124-136	effect
acetaminophen	12-24	chlordiazepoxide	146-161	effect
acetaminophen	12-24	sedative-hypnotics	164-181	effect
acetaminophen	12-24	CNS depressants	193-207	effect
caffeine	30-37	narcotic analgesic	73-90	effect
caffeine	30-37	alcohol	94-100	effect
caffeine	30-37	anesthetics	111-121	effect
caffeine	30-37	tranquilizers	124-136	effect
caffeine	30-37	chlordiazepoxide	146-161	effect
caffeine	30-37	sedative-hypnotics	164-181	effect
caffeine	30-37	CNS depressants	193-207	effect
narcotic analgesic	73-90	alcohol	94-100	false
narcotic analgesic	73-90	anesthetics	111-121	false
narcotic analgesic	73-90	tranquilizers	124-136	false
narcotic analgesic	73-90	chlordiazepoxide	146-161	false
narcotic analgesic	73-90	sedative-hypnotics	164-181	false
narcotic analgesic	73-90	CNS depressants	193-207	false
alcohol	94-100	anesthetics	111-121	false
alcohol	94-100	tranquilizers	124-136	false
alcohol	94-100	chlordiazepoxide	146-161	false
alcohol	94-100	sedative-hypnotics	164-181	false
alcohol	94-100	CNS depressants	193-207	false
anesthetics	111-121	tranquilizers	124-136	false
anesthetics	111-121	chlordiazepoxide	146-161	false
anesthetics	111-121	sedative-hypnotics	164-181	false
anesthetics	111-121	CNS depressants	193-207	false
tranquilizers	124-136	chlordiazepoxide	146-161	false
tranquilizers	124-136	sedative-hypnotics	164-181	false
tranquilizers	124-136	CNS depressants	193-207	false
chlordiazepoxide	146-161	sedative-hypnotics	164-181	false
chlordiazepoxide	146-161	CNS depressants	193-207	false
sedative-hypnotics	164-181	CNS depressants	193-207	false

Potential drug interactions between Mentax (butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.
Mentax	36-41	butenafine HCl	44-57	false

Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
butorphanol	18-28	central nervous system depressants	35-68	effect
butorphanol	18-28	alcohol	77-83	effect
butorphanol	18-28	barbiturates	86-97	effect
butorphanol	18-28	tranquilizers	100-112	effect
butorphanol	18-28	antihistamines	119-132	effect
butorphanol	18-28	central nervous system depressant	159-191	false
central nervous system depressants	35-68	alcohol	77-83	false
central nervous system depressants	35-68	barbiturates	86-97	false
central nervous system depressants	35-68	tranquilizers	100-112	false
central nervous system depressants	35-68	antihistamines	119-132	false
central nervous system depressants	35-68	central nervous system depressant	159-191	false
alcohol	77-83	barbiturates	86-97	false
alcohol	77-83	tranquilizers	100-112	false
alcohol	77-83	antihistamines	119-132	false
alcohol	77-83	central nervous system depressant	159-191	false
barbiturates	86-97	tranquilizers	100-112	false
barbiturates	86-97	antihistamines	119-132	false
barbiturates	86-97	central nervous system depressant	159-191	false
tranquilizers	100-112	antihistamines	119-132	false
tranquilizers	100-112	central nervous system depressant	159-191	false
antihistamines	119-132	central nervous system depressant	159-191	false

When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids.
butorphanol	52-62	opioids	231-237	false

In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.
butorphanol	62-72	STADOL NS	90-98	false
butorphanol	62-72	sumatriptan	180-190	false
STADOL NS	90-98	sumatriptan	180-190	false

However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
butorphanol	73-83	STADOL NS	179-187	false
butorphanol	73-83	sumatriptan	237-247	false
STADOL NS	179-187	sumatriptan	237-247	mechanism

When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
STADOL NS	9-17	sumatriptan	57-67	mechanism
STADOL NS	9-17	butorphanol	93-103	false
sumatriptan	57-67	butorphanol	93-103	false

In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL NS.
sumatriptan	45-55	STADOL NS	91-99	false

These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
STADOL NS	51-59	sumatriptan	117-127	effect

The safety of using STADOL NS and IMITREX (sumatriptan) Nasal Spray during the same episode of migraine has not been established.
STADOL NS	20-28	IMITREX	34-40	false
STADOL NS	20-28	sumatriptan	43-53	false
IMITREX	34-40	sumatriptan	43-53	false

The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).
butorphanol	39-49	STADOL NS	67-75	false
butorphanol	39-49	cimetidine	122-131	false
STADOL NS	67-75	cimetidine	122-131	false

Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.
STADOL NS	34-42	butorphanol	50-60	false
STADOL NS	34-42	cimetidine	122-131	false
butorphanol	50-60	cimetidine	122-131	false

It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
butorphanol	34-44	erythromycin	126-137	advise

The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.
STADOL NS	16-24	nasal vasoconstrictor	88-108	false
STADOL NS	16-24	oxymetazoline	111-123	false
nasal vasoconstrictor	88-108	oxymetazoline	111-123	false

Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
STADOL NS	48-56	nasal vasoconstrictor	122-142	effect

No information is available about the use of butorphanol concurrently with MAO inhibitors.
butorphanol	45-55	MAO inhibitors	75-88	false

DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
DOSTINEX	0-7	phenothiazines	78-91	advise
DOSTINEX	0-7	butyrophenones	94-107	advise
DOSTINEX	0-7	thioxanthines	110-122	advise
DOSTINEX	0-7	metoclopramide	128-141	advise
phenothiazines	78-91	butyrophenones	94-107	false
phenothiazines	78-91	thioxanthines	110-122	false
phenothiazines	78-91	metoclopramide	128-141	false
butyrophenones	94-107	thioxanthines	110-122	false
butyrophenones	94-107	metoclopramide	128-141	false
thioxanthines	110-122	metoclopramide	128-141	false

Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
caffeine	36-43	caffeine	126-133	false
caffeine	36-43	cimetidine	154-163	advise
caffeine	36-43	ketoconazole	169-180	advise
caffeine	36-43	caffeine	194-201	false
caffeine	36-43	caffeine	273-280	false
caffeine	36-43	phenobarbital	301-313	false
caffeine	36-43	phenytoin	319-327	false
caffeine	126-133	cimetidine	154-163	false
caffeine	126-133	ketoconazole	169-180	false
caffeine	126-133	caffeine	194-201	false
caffeine	126-133	caffeine	273-280	false
caffeine	126-133	phenobarbital	301-313	false
caffeine	126-133	phenytoin	319-327	false
cimetidine	154-163	ketoconazole	169-180	false
cimetidine	154-163	caffeine	194-201	false
cimetidine	154-163	caffeine	273-280	false
cimetidine	154-163	phenobarbital	301-313	false
cimetidine	154-163	phenytoin	319-327	false
ketoconazole	169-180	caffeine	194-201	false
ketoconazole	169-180	caffeine	273-280	false
ketoconazole	169-180	phenobarbital	301-313	false
ketoconazole	169-180	phenytoin	319-327	false
caffeine	194-201	caffeine	273-280	false
caffeine	194-201	phenobarbital	301-313	advise
caffeine	194-201	phenytoin	319-327	advise
caffeine	273-280	phenobarbital	301-313	false
caffeine	273-280	phenytoin	319-327	false
phenobarbital	301-313	phenytoin	319-327	false

Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
Caffeine	0-7	ketoprofen	40-49	effect

Interconversion between caffeine and theophylline has been reported in preterm neonates.
caffeine	24-31	theophylline	37-48	false

Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
vitamin D analogues	17-35	Vitamin D2	38-47	false
vitamin D analogues	17-35	Vitamin D3	50-59	false
vitamin D analogues	17-35	Calcitriol	62-71	false
vitamin D analogues	17-35	Calcidiol	78-86	false
vitamin D analogues	17-35	Cholestyramine	90-103	false
vitamin D analogues	17-35	Cholestyramine	106-119	false
vitamin D analogues	17-35	fat soluble vitamins	174-193	false
Vitamin D2	38-47	Vitamin D3	50-59	false
Vitamin D2	38-47	Calcitriol	62-71	false
Vitamin D2	38-47	Calcidiol	78-86	false
Vitamin D2	38-47	Cholestyramine	90-103	false
Vitamin D2	38-47	Cholestyramine	106-119	false
Vitamin D2	38-47	fat soluble vitamins	174-193	false
Vitamin D3	50-59	Calcitriol	62-71	false
Vitamin D3	50-59	Calcidiol	78-86	false
Vitamin D3	50-59	Cholestyramine	90-103	false
Vitamin D3	50-59	Cholestyramine	106-119	false
Vitamin D3	50-59	fat soluble vitamins	174-193	false
Calcitriol	62-71	Calcidiol	78-86	false
Calcitriol	62-71	Cholestyramine	90-103	false
Calcitriol	62-71	Cholestyramine	106-119	false
Calcitriol	62-71	fat soluble vitamins	174-193	false
Calcidiol	78-86	Cholestyramine	90-103	false
Calcidiol	78-86	Cholestyramine	106-119	false
Calcidiol	78-86	fat soluble vitamins	174-193	false
Cholestyramine	90-103	Cholestyramine	106-119	false
Cholestyramine	90-103	fat soluble vitamins	174-193	false
Cholestyramine	106-119	fat soluble vitamins	174-193	mechanism

Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
Phenytoin	0-8	Phenobarbital	10-22	false
Phenytoin	0-8	phenytoin	49-57	false
Phenytoin	0-8	phenobarbital	62-74	false
Phenytoin	0-8	vitamin D	117-125	false
Phenytoin	0-8	calcitriol	171-180	false
Phenobarbital	10-22	phenytoin	49-57	false
Phenobarbital	10-22	phenobarbital	62-74	false
Phenobarbital	10-22	vitamin D	117-125	false
Phenobarbital	10-22	calcitriol	171-180	false
phenytoin	49-57	phenobarbital	62-74	false
phenytoin	49-57	vitamin D	117-125	false
phenytoin	49-57	calcitriol	171-180	mechanism
phenobarbital	62-74	vitamin D	117-125	false
phenobarbital	62-74	calcitriol	171-180	mechanism
vitamin D	117-125	calcitriol	171-180	false

Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
calcitriol	21-30	Rocaltrol	80-88	false

Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
Thiazides	0-8	Thiazides	11-19	false

Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
thiazides	63-71	vitamin D	78-86	effect

Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
Digitalis	0-8	Vitamin D	11-19	false
Digitalis	0-8	digitalis	95-103	false
Vitamin D	11-19	digitalis	95-103	advise

Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
Ketoconazole	0-11	Ketoconazole	14-25	false
Ketoconazole	0-11	vitamin D	79-87	false
Ketoconazole	14-25	vitamin D	79-87	mechanism

However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
ketoconazole	45-56	vitamin D	63-71	false

Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
Corticosteroids	0-14	vitamin D analogues	72-90	false
Corticosteroids	0-14	corticosteroids	131-145	false
vitamin D analogues	72-90	corticosteroids	131-145	mechanism

Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
Vitamin D	0-8	vitamin D analogues	46-64	false

Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
Calcium	0-6	calcium	55-61	false

Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
Magnesium	0-8	Magnesium	11-19	false
Magnesium	0-8	antacids	50-57	false
Magnesium	0-8	vitamin D	140-148	false
Magnesium	11-19	antacids	50-57	false
Magnesium	11-19	vitamin D	140-148	advise
antacids	50-57	vitamin D	140-148	advise

Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
vitamin D analogues	17-35	Vitamin D2	38-47	false
vitamin D analogues	17-35	Vitamin D3	50-59	false
vitamin D analogues	17-35	Calcitriol	62-71	false
vitamin D analogues	17-35	Calcidiol	78-86	false
vitamin D analogues	17-35	Cholestyramine	90-103	false
vitamin D analogues	17-35	Cholestyramine	106-119	false
vitamin D analogues	17-35	fat soluble vitamins	174-193	false
Vitamin D2	38-47	Vitamin D3	50-59	false
Vitamin D2	38-47	Calcitriol	62-71	false
Vitamin D2	38-47	Calcidiol	78-86	false
Vitamin D2	38-47	Cholestyramine	90-103	false
Vitamin D2	38-47	Cholestyramine	106-119	false
Vitamin D2	38-47	fat soluble vitamins	174-193	false
Vitamin D3	50-59	Calcitriol	62-71	false
Vitamin D3	50-59	Calcidiol	78-86	false
Vitamin D3	50-59	Cholestyramine	90-103	false
Vitamin D3	50-59	Cholestyramine	106-119	false
Vitamin D3	50-59	fat soluble vitamins	174-193	false
Calcitriol	62-71	Calcidiol	78-86	false
Calcitriol	62-71	Cholestyramine	90-103	false
Calcitriol	62-71	Cholestyramine	106-119	false
Calcitriol	62-71	fat soluble vitamins	174-193	false
Calcidiol	78-86	Cholestyramine	90-103	false
Calcidiol	78-86	Cholestyramine	106-119	false
Calcidiol	78-86	fat soluble vitamins	174-193	false
Cholestyramine	90-103	Cholestyramine	106-119	false
Cholestyramine	90-103	fat soluble vitamins	174-193	false
Cholestyramine	106-119	fat soluble vitamins	174-193	mechanism

Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
Phenytoin	0-8	Phenobarbital	10-22	false
Phenytoin	0-8	phenytoin	49-57	false
Phenytoin	0-8	phenobarbital	62-74	false
Phenytoin	0-8	vitamin D	117-125	false
Phenytoin	0-8	calcitriol	171-180	false
Phenobarbital	10-22	phenytoin	49-57	false
Phenobarbital	10-22	phenobarbital	62-74	false
Phenobarbital	10-22	vitamin D	117-125	false
Phenobarbital	10-22	calcitriol	171-180	false
phenytoin	49-57	phenobarbital	62-74	false
phenytoin	49-57	vitamin D	117-125	false
phenytoin	49-57	calcitriol	171-180	mechanism
phenobarbital	62-74	vitamin D	117-125	false
phenobarbital	62-74	calcitriol	171-180	mechanism
vitamin D	117-125	calcitriol	171-180	false

Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
calcitriol	21-30	Rocaltrol	80-88	false

Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
Thiazides	0-8	Thiazides	11-19	false
Thiazides	0-8	calcium	75-81	false
Thiazides	11-19	calcium	75-81	false

Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
thiazides	63-71	vitamin D	78-86	effect

Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
Digitalis	0-8	Vitamin D	11-19	false
Digitalis	0-8	digitalis	95-103	false
Vitamin D	11-19	digitalis	95-103	advise

Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
Ketoconazole	0-11	Ketoconazole	14-25	false
Ketoconazole	0-11	vitamin D	79-87	false
Ketoconazole	14-25	vitamin D	79-87	mechanism

However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
ketoconazole	45-56	vitamin D	63-71	false

Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
Corticosteroids	0-14	vitamin D analogues	72-90	false
Corticosteroids	0-14	corticosteroids	131-145	false
vitamin D analogues	72-90	corticosteroids	131-145	mechanism

Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
Vitamin D	0-8	vitamin D analogues	46-64	false

Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
Calcium	0-6	calcium	55-61	false

Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
Magnesium	0-8	Magnesium	11-19	false
Magnesium	0-8	antacids	50-57	false
Magnesium	0-8	vitamin D	140-148	false
Magnesium	11-19	antacids	50-57	false
Magnesium	11-19	vitamin D	140-148	advise
antacids	50-57	vitamin D	140-148	advise

Concomitant use with other calcium-containing medicines (including antacids) may cause too much calcium in the blood or urine, which may increase the chance of side effects.
calcium	27-33	antacids	67-74	false
calcium	27-33	calcium	96-102	false
antacids	67-74	calcium	96-102	false

Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
calcium acetate	6-20	digitalis glycosides	27-46	effect
calcium acetate	6-20	calcium	99-105	false
digitalis glycosides	27-46	calcium	99-105	false

May interact with cefamandole naftate, cephalothin sodium, magnesium sulfate, prednisolone sodium succinate, and prochlorperazine edisylate.
cefamandole naftate	18-36	cephalothin sodium	39-56	false
cefamandole naftate	18-36	magnesium sulfate	59-75	false
cefamandole naftate	18-36	prednisolone sodium succinate	78-106	false
cefamandole naftate	18-36	prochlorperazine edisylate	113-138	false
cephalothin sodium	39-56	magnesium sulfate	59-75	false
cephalothin sodium	39-56	prednisolone sodium succinate	78-106	false
cephalothin sodium	39-56	prochlorperazine edisylate	113-138	false
magnesium sulfate	59-75	prednisolone sodium succinate	78-106	false
magnesium sulfate	59-75	prochlorperazine edisylate	113-138	false
prednisolone sodium succinate	78-106	prochlorperazine edisylate	113-138	false

No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
candesartan cilexetil	66-86	glyburide	119-127	false
candesartan cilexetil	66-86	nifedipine	130-139	false
candesartan cilexetil	66-86	digoxin	142-148	false
candesartan cilexetil	66-86	warfarin	151-158	false
candesartan cilexetil	66-86	hydrochlorothiazide	161-179	false
candesartan cilexetil	66-86	contraceptives	191-204	false
candesartan cilexetil	66-86	enalapril	243-251	false
glyburide	119-127	nifedipine	130-139	false
glyburide	119-127	digoxin	142-148	false
glyburide	119-127	warfarin	151-158	false
glyburide	119-127	hydrochlorothiazide	161-179	false
glyburide	119-127	contraceptives	191-204	false
glyburide	119-127	enalapril	243-251	false
nifedipine	130-139	digoxin	142-148	false
nifedipine	130-139	warfarin	151-158	false
nifedipine	130-139	hydrochlorothiazide	161-179	false
nifedipine	130-139	contraceptives	191-204	false
nifedipine	130-139	enalapril	243-251	false
digoxin	142-148	warfarin	151-158	false
digoxin	142-148	hydrochlorothiazide	161-179	false
digoxin	142-148	contraceptives	191-204	false
digoxin	142-148	enalapril	243-251	false
warfarin	151-158	hydrochlorothiazide	161-179	false
warfarin	151-158	contraceptives	191-204	false
warfarin	151-158	enalapril	243-251	false
hydrochlorothiazide	161-179	contraceptives	191-204	false
hydrochlorothiazide	161-179	enalapril	243-251	false
contraceptives	191-204	enalapril	243-251	false

Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
Lithium	0-6	lithium	38-44	false
Lithium	0-6	lithium	130-136	false
Lithium	0-6	ACE inhibitors	143-156	false
Lithium	0-6	angiotensin II receptor antagonists	173-207	false
lithium	38-44	lithium	130-136	false
lithium	38-44	ACE inhibitors	143-156	false
lithium	38-44	angiotensin II receptor antagonists	173-207	false
lithium	130-136	ACE inhibitors	143-156	mechanism
lithium	130-136	angiotensin II receptor antagonists	173-207	mechanism
ACE inhibitors	143-156	angiotensin II receptor antagonists	173-207	false

An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
lithium	21-27	lithium	98-104	false
lithium	21-27	ATACAND	111-117	false
lithium	21-27	lithium	151-157	false
lithium	98-104	ATACAND	111-117	mechanism
lithium	98-104	lithium	151-157	false
ATACAND	111-117	lithium	151-157	false

Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
Antacid	0-6	aluminum hydroxide	26-43	false
Antacid	0-6	magnesium hydroxide	50-68	false
Antacid	0-6	antacid	81-87	false
Antacid	0-6	Maalox	90-95	false
Antacid	0-6	capecitabine	126-137	false
aluminum hydroxide	26-43	magnesium hydroxide	50-68	false
aluminum hydroxide	26-43	antacid	81-87	false
aluminum hydroxide	26-43	Maalox	90-95	false
aluminum hydroxide	26-43	capecitabine	126-137	false
magnesium hydroxide	50-68	antacid	81-87	false
magnesium hydroxide	50-68	Maalox	90-95	false
magnesium hydroxide	50-68	capecitabine	126-137	false
antacid	81-87	Maalox	90-95	false
antacid	81-87	capecitabine	126-137	false
Maalox	90-95	capecitabine	126-137	false

There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);
capecitabine	55-66	5-DFCR	88-93	false

there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL).
5-DFUR	48-53	5-FU	56-59	false
5-DFUR	48-53	FBAL	65-68	false
5-FU	56-59	FBAL	65-68	false

Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
Coumarin Anticoagulants	0-22	capecitabine	109-120	false
Coumarin Anticoagulants	0-22	coumarin-derivative anticoagulants	141-174	false
Coumarin Anticoagulants	0-22	warfarin	184-191	false
Coumarin Anticoagulants	0-22	phenprocoumon	197-209	false
capecitabine	109-120	coumarin-derivative anticoagulants	141-174	effect
capecitabine	109-120	warfarin	184-191	false
capecitabine	109-120	phenprocoumon	197-209	effect
coumarin-derivative anticoagulants	141-174	warfarin	184-191	false
coumarin-derivative anticoagulants	141-174	phenprocoumon	197-209	false
warfarin	184-191	phenprocoumon	197-209	false

Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
coumarin-derivative anticoagulants	16-49	capecitabine	70-81	advise

Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
Leucovorin	0-9	5-fluorouracil	33-46	false
Leucovorin	0-9	leucovorin	97-106	false
5-fluorouracil	33-46	leucovorin	97-106	mechanism

Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
leucovorin	116-125	fluorouracil	131-142	effect

Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
Diuretic	26-33	diuretics	56-64	false
Diuretic	26-33	diuretic	95-102	false
Diuretic	26-33	captopril	338-346	false
diuretics	56-64	diuretic	95-102	false
diuretics	56-64	captopril	338-346	effect
diuretic	95-102	captopril	338-346	false

The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
captopril	44-52	diuretic	99-106	effect
captopril	44-52	captopril	199-207	false
captopril	44-52	captopril	210-218	false
diuretic	99-106	captopril	199-207	false
diuretic	99-106	captopril	210-218	false
captopril	199-207	captopril	210-218	false

Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;
vasodilators	83-94	captopril	118-126	false

therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
nitroglycerin	11-23	nitrates	34-41	false
nitroglycerin	11-23	captopril	174-182	advise
nitrates	34-41	captopril	174-182	advise

Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
Captopril	29-37	antihypertensive agents	69-91	effect

For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
diuretics	13-21	thiazides	30-38	false

Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics.
captopril	148-156	diuretics	172-180	false

Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.
ganglionic blocking agents	56-81	adrenergic neuron blocking agents	86-118	false

Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
Beta-adrenergic blocking drugs	0-29	captopril	75-83	effect

Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
Potassium-sparing diuretics	0-26	spironolactone	36-49	false
Potassium-sparing diuretics	0-26	triamterene	52-62	false
Potassium-sparing diuretics	0-26	amiloride	68-76	false
Potassium-sparing diuretics	0-26	potassium	82-90	false
spironolactone	36-49	triamterene	52-62	false
spironolactone	36-49	amiloride	68-76	false
spironolactone	36-49	potassium	82-90	false
triamterene	52-62	amiloride	68-76	false
triamterene	52-62	potassium	82-90	false
amiloride	68-76	potassium	82-90	false

Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
indomethacin	75-86	captopril	130-138	effect

Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
nonsteroidal anti-inflammatory agents	6-42	aspirin	51-57	false

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
Lithium	0-6	lithium	25-31	false
Lithium	0-6	lithium	56-62	false
Lithium	0-6	lithium	126-132	false
Lithium	0-6	ACE inhibitor	138-150	false
lithium	25-31	lithium	56-62	false
lithium	25-31	lithium	126-132	false
lithium	25-31	ACE inhibitor	138-150	false
lithium	56-62	lithium	126-132	false
lithium	56-62	ACE inhibitor	138-150	false
lithium	126-132	ACE inhibitor	138-150	effect

If a diuretic is also used, it may increase the risk of lithium toxicity.
diuretic	5-12	lithium	56-62	effect

Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
Cardiac Glycosides	0-17	captopril	102-110	false
Cardiac Glycosides	0-17	digoxin	112-118	false
captopril	102-110	digoxin	112-118	false

Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
Loop Diuretics	0-13	Furosemide	16-25	false
Loop Diuretics	0-13	captopril	58-66	false
Loop Diuretics	0-13	captopril	107-115	false
Furosemide	16-25	captopril	58-66	false
Furosemide	16-25	captopril	107-115	false
captopril	58-66	captopril	107-115	false

Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.
Allopurinol	0-10	captopril	108-116	false
Allopurinol	0-10	allopurinol	122-132	false
captopril	108-116	allopurinol	122-132	false

Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase.
Carbamazepine	72-84	carbamazepine 10,11-epoxide	151-177	false

Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
EQUETROTM	102-110	Acetazolamide	131-143	mechanism
EQUETROTM	102-110	azole antifungals	146-162	mechanism
EQUETROTM	102-110	cimetidine	165-174	mechanism
EQUETROTM	102-110	clarithromycin	177-190	mechanism
EQUETROTM	102-110	dalfopristin	196-207	mechanism
EQUETROTM	102-110	danazol	210-216	mechanism
EQUETROTM	102-110	delavirdine	219-229	mechanism
EQUETROTM	102-110	diltiazem	232-240	mechanism
EQUETROTM	102-110	erythromycin	243-254	mechanism
EQUETROTM	102-110	fluoxetine	260-269	mechanism
EQUETROTM	102-110	fluvoxamine	272-282	mechanism
EQUETROTM	102-110	isoniazid	303-311	mechanism
EQUETROTM	102-110	itraconazole	314-325	mechanism
EQUETROTM	102-110	ketoconazole	328-339	mechanism
EQUETROTM	102-110	loratadine	342-351	mechanism
EQUETROTM	102-110	nefazodone	354-363	mechanism
EQUETROTM	102-110	niacinamide	366-376	mechanism
EQUETROTM	102-110	nicotinamide	379-390	mechanism
EQUETROTM	102-110	protease inhibitors	393-411	mechanism
EQUETROTM	102-110	propoxyphene	414-425	mechanism
EQUETROTM	102-110	quinine	428-434	mechanism
EQUETROTM	102-110	quinupristin	437-448	mechanism
EQUETROTM	102-110	troleandomycin	451-464	mechanism
EQUETROTM	102-110	valproate	467-475	mechanism
EQUETROTM	102-110	verapamil	481-489	mechanism
EQUETROTM	102-110	zileuton	492-499	mechanism
Acetazolamide	131-143	azole antifungals	146-162	false
Acetazolamide	131-143	cimetidine	165-174	false
Acetazolamide	131-143	clarithromycin	177-190	false
Acetazolamide	131-143	dalfopristin	196-207	false
Acetazolamide	131-143	danazol	210-216	false
Acetazolamide	131-143	delavirdine	219-229	false
Acetazolamide	131-143	diltiazem	232-240	false
Acetazolamide	131-143	erythromycin	243-254	false
Acetazolamide	131-143	fluoxetine	260-269	false
Acetazolamide	131-143	fluvoxamine	272-282	false
Acetazolamide	131-143	isoniazid	303-311	false
Acetazolamide	131-143	itraconazole	314-325	false
Acetazolamide	131-143	ketoconazole	328-339	false
Acetazolamide	131-143	loratadine	342-351	false
Acetazolamide	131-143	nefazodone	354-363	false
Acetazolamide	131-143	niacinamide	366-376	false
Acetazolamide	131-143	nicotinamide	379-390	false
Acetazolamide	131-143	protease inhibitors	393-411	false
Acetazolamide	131-143	propoxyphene	414-425	false
Acetazolamide	131-143	quinine	428-434	false
Acetazolamide	131-143	quinupristin	437-448	false
Acetazolamide	131-143	troleandomycin	451-464	false
Acetazolamide	131-143	valproate	467-475	false
Acetazolamide	131-143	verapamil	481-489	false
Acetazolamide	131-143	zileuton	492-499	false
azole antifungals	146-162	cimetidine	165-174	false
azole antifungals	146-162	clarithromycin	177-190	false
azole antifungals	146-162	dalfopristin	196-207	false
azole antifungals	146-162	danazol	210-216	false
azole antifungals	146-162	delavirdine	219-229	false
azole antifungals	146-162	diltiazem	232-240	false
azole antifungals	146-162	erythromycin	243-254	false
azole antifungals	146-162	fluoxetine	260-269	false
azole antifungals	146-162	fluvoxamine	272-282	false
azole antifungals	146-162	isoniazid	303-311	false
azole antifungals	146-162	itraconazole	314-325	false
azole antifungals	146-162	ketoconazole	328-339	false
azole antifungals	146-162	loratadine	342-351	false
azole antifungals	146-162	nefazodone	354-363	false
azole antifungals	146-162	niacinamide	366-376	false
azole antifungals	146-162	nicotinamide	379-390	false
azole antifungals	146-162	protease inhibitors	393-411	false
azole antifungals	146-162	propoxyphene	414-425	false
azole antifungals	146-162	quinine	428-434	false
azole antifungals	146-162	quinupristin	437-448	false
azole antifungals	146-162	troleandomycin	451-464	false
azole antifungals	146-162	valproate	467-475	false
azole antifungals	146-162	verapamil	481-489	false
azole antifungals	146-162	zileuton	492-499	false
cimetidine	165-174	clarithromycin	177-190	false
cimetidine	165-174	dalfopristin	196-207	false
cimetidine	165-174	danazol	210-216	false
cimetidine	165-174	delavirdine	219-229	false
cimetidine	165-174	diltiazem	232-240	false
cimetidine	165-174	erythromycin	243-254	false
cimetidine	165-174	fluoxetine	260-269	false
cimetidine	165-174	fluvoxamine	272-282	false
cimetidine	165-174	isoniazid	303-311	false
cimetidine	165-174	itraconazole	314-325	false
cimetidine	165-174	ketoconazole	328-339	false
cimetidine	165-174	loratadine	342-351	false
cimetidine	165-174	nefazodone	354-363	false
cimetidine	165-174	niacinamide	366-376	false
cimetidine	165-174	nicotinamide	379-390	false
cimetidine	165-174	protease inhibitors	393-411	false
cimetidine	165-174	propoxyphene	414-425	false
cimetidine	165-174	quinine	428-434	false
cimetidine	165-174	quinupristin	437-448	false
cimetidine	165-174	troleandomycin	451-464	false
cimetidine	165-174	valproate	467-475	false
cimetidine	165-174	verapamil	481-489	false
cimetidine	165-174	zileuton	492-499	false
clarithromycin	177-190	dalfopristin	196-207	false
clarithromycin	177-190	danazol	210-216	false
clarithromycin	177-190	delavirdine	219-229	false
clarithromycin	177-190	diltiazem	232-240	false
clarithromycin	177-190	erythromycin	243-254	false
clarithromycin	177-190	fluoxetine	260-269	false
clarithromycin	177-190	fluvoxamine	272-282	false
clarithromycin	177-190	isoniazid	303-311	false
clarithromycin	177-190	itraconazole	314-325	false
clarithromycin	177-190	ketoconazole	328-339	false
clarithromycin	177-190	loratadine	342-351	false
clarithromycin	177-190	nefazodone	354-363	false
clarithromycin	177-190	niacinamide	366-376	false
clarithromycin	177-190	nicotinamide	379-390	false
clarithromycin	177-190	protease inhibitors	393-411	false
clarithromycin	177-190	propoxyphene	414-425	false
clarithromycin	177-190	quinine	428-434	false
clarithromycin	177-190	quinupristin	437-448	false
clarithromycin	177-190	troleandomycin	451-464	false
clarithromycin	177-190	valproate	467-475	false
clarithromycin	177-190	verapamil	481-489	false
clarithromycin	177-190	zileuton	492-499	false
dalfopristin	196-207	danazol	210-216	false
dalfopristin	196-207	delavirdine	219-229	false
dalfopristin	196-207	diltiazem	232-240	false
dalfopristin	196-207	erythromycin	243-254	false
dalfopristin	196-207	fluoxetine	260-269	false
dalfopristin	196-207	fluvoxamine	272-282	false
dalfopristin	196-207	isoniazid	303-311	false
dalfopristin	196-207	itraconazole	314-325	false
dalfopristin	196-207	ketoconazole	328-339	false
dalfopristin	196-207	loratadine	342-351	false
dalfopristin	196-207	nefazodone	354-363	false
dalfopristin	196-207	niacinamide	366-376	false
dalfopristin	196-207	nicotinamide	379-390	false
dalfopristin	196-207	protease inhibitors	393-411	false
dalfopristin	196-207	propoxyphene	414-425	false
dalfopristin	196-207	quinine	428-434	false
dalfopristin	196-207	quinupristin	437-448	false
dalfopristin	196-207	troleandomycin	451-464	false
dalfopristin	196-207	valproate	467-475	false
dalfopristin	196-207	verapamil	481-489	false
dalfopristin	196-207	zileuton	492-499	false
danazol	210-216	delavirdine	219-229	false
danazol	210-216	diltiazem	232-240	false
danazol	210-216	erythromycin	243-254	false
danazol	210-216	fluoxetine	260-269	false
danazol	210-216	fluvoxamine	272-282	false
danazol	210-216	isoniazid	303-311	false
danazol	210-216	itraconazole	314-325	false
danazol	210-216	ketoconazole	328-339	false
danazol	210-216	loratadine	342-351	false
danazol	210-216	nefazodone	354-363	false
danazol	210-216	niacinamide	366-376	false
danazol	210-216	nicotinamide	379-390	false
danazol	210-216	protease inhibitors	393-411	false
danazol	210-216	propoxyphene	414-425	false
danazol	210-216	quinine	428-434	false
danazol	210-216	quinupristin	437-448	false
danazol	210-216	troleandomycin	451-464	false
danazol	210-216	valproate	467-475	false
danazol	210-216	verapamil	481-489	false
danazol	210-216	zileuton	492-499	false
delavirdine	219-229	diltiazem	232-240	false
delavirdine	219-229	erythromycin	243-254	false
delavirdine	219-229	fluoxetine	260-269	false
delavirdine	219-229	fluvoxamine	272-282	false
delavirdine	219-229	isoniazid	303-311	false
delavirdine	219-229	itraconazole	314-325	false
delavirdine	219-229	ketoconazole	328-339	false
delavirdine	219-229	loratadine	342-351	false
delavirdine	219-229	nefazodone	354-363	false
delavirdine	219-229	niacinamide	366-376	false
delavirdine	219-229	nicotinamide	379-390	false
delavirdine	219-229	protease inhibitors	393-411	false
delavirdine	219-229	propoxyphene	414-425	false
delavirdine	219-229	quinine	428-434	false
delavirdine	219-229	quinupristin	437-448	false
delavirdine	219-229	troleandomycin	451-464	false
delavirdine	219-229	valproate	467-475	false
delavirdine	219-229	verapamil	481-489	false
delavirdine	219-229	zileuton	492-499	false
diltiazem	232-240	erythromycin	243-254	false
diltiazem	232-240	fluoxetine	260-269	false
diltiazem	232-240	fluvoxamine	272-282	false
diltiazem	232-240	isoniazid	303-311	false
diltiazem	232-240	itraconazole	314-325	false
diltiazem	232-240	ketoconazole	328-339	false
diltiazem	232-240	loratadine	342-351	false
diltiazem	232-240	nefazodone	354-363	false
diltiazem	232-240	niacinamide	366-376	false
diltiazem	232-240	nicotinamide	379-390	false
diltiazem	232-240	protease inhibitors	393-411	false
diltiazem	232-240	propoxyphene	414-425	false
diltiazem	232-240	quinine	428-434	false
diltiazem	232-240	quinupristin	437-448	false
diltiazem	232-240	troleandomycin	451-464	false
diltiazem	232-240	valproate	467-475	false
diltiazem	232-240	verapamil	481-489	false
diltiazem	232-240	zileuton	492-499	false
erythromycin	243-254	fluoxetine	260-269	false
erythromycin	243-254	fluvoxamine	272-282	false
erythromycin	243-254	isoniazid	303-311	false
erythromycin	243-254	itraconazole	314-325	false
erythromycin	243-254	ketoconazole	328-339	false
erythromycin	243-254	loratadine	342-351	false
erythromycin	243-254	nefazodone	354-363	false
erythromycin	243-254	niacinamide	366-376	false
erythromycin	243-254	nicotinamide	379-390	false
erythromycin	243-254	protease inhibitors	393-411	false
erythromycin	243-254	propoxyphene	414-425	false
erythromycin	243-254	quinine	428-434	false
erythromycin	243-254	quinupristin	437-448	false
erythromycin	243-254	troleandomycin	451-464	false
erythromycin	243-254	valproate	467-475	false
erythromycin	243-254	verapamil	481-489	false
erythromycin	243-254	zileuton	492-499	false
fluoxetine	260-269	fluvoxamine	272-282	false
fluoxetine	260-269	isoniazid	303-311	false
fluoxetine	260-269	itraconazole	314-325	false
fluoxetine	260-269	ketoconazole	328-339	false
fluoxetine	260-269	loratadine	342-351	false
fluoxetine	260-269	nefazodone	354-363	false
fluoxetine	260-269	niacinamide	366-376	false
fluoxetine	260-269	nicotinamide	379-390	false
fluoxetine	260-269	protease inhibitors	393-411	false
fluoxetine	260-269	propoxyphene	414-425	false
fluoxetine	260-269	quinine	428-434	false
fluoxetine	260-269	quinupristin	437-448	false
fluoxetine	260-269	troleandomycin	451-464	false
fluoxetine	260-269	valproate	467-475	false
fluoxetine	260-269	verapamil	481-489	false
fluoxetine	260-269	zileuton	492-499	false
fluvoxamine	272-282	isoniazid	303-311	false
fluvoxamine	272-282	itraconazole	314-325	false
fluvoxamine	272-282	ketoconazole	328-339	false
fluvoxamine	272-282	loratadine	342-351	false
fluvoxamine	272-282	nefazodone	354-363	false
fluvoxamine	272-282	niacinamide	366-376	false
fluvoxamine	272-282	nicotinamide	379-390	false
fluvoxamine	272-282	protease inhibitors	393-411	false
fluvoxamine	272-282	propoxyphene	414-425	false
fluvoxamine	272-282	quinine	428-434	false
fluvoxamine	272-282	quinupristin	437-448	false
fluvoxamine	272-282	troleandomycin	451-464	false
fluvoxamine	272-282	valproate	467-475	false
fluvoxamine	272-282	verapamil	481-489	false
fluvoxamine	272-282	zileuton	492-499	false
isoniazid	303-311	itraconazole	314-325	false
isoniazid	303-311	ketoconazole	328-339	false
isoniazid	303-311	loratadine	342-351	false
isoniazid	303-311	nefazodone	354-363	false
isoniazid	303-311	niacinamide	366-376	false
isoniazid	303-311	nicotinamide	379-390	false
isoniazid	303-311	protease inhibitors	393-411	false
isoniazid	303-311	propoxyphene	414-425	false
isoniazid	303-311	quinine	428-434	false
isoniazid	303-311	quinupristin	437-448	false
isoniazid	303-311	troleandomycin	451-464	false
isoniazid	303-311	valproate	467-475	false
isoniazid	303-311	verapamil	481-489	false
isoniazid	303-311	zileuton	492-499	false
itraconazole	314-325	ketoconazole	328-339	false
itraconazole	314-325	loratadine	342-351	false
itraconazole	314-325	nefazodone	354-363	false
itraconazole	314-325	niacinamide	366-376	false
itraconazole	314-325	nicotinamide	379-390	false
itraconazole	314-325	protease inhibitors	393-411	false
itraconazole	314-325	propoxyphene	414-425	false
itraconazole	314-325	quinine	428-434	false
itraconazole	314-325	quinupristin	437-448	false
itraconazole	314-325	troleandomycin	451-464	false
itraconazole	314-325	valproate	467-475	false
itraconazole	314-325	verapamil	481-489	false
itraconazole	314-325	zileuton	492-499	false
ketoconazole	328-339	loratadine	342-351	false
ketoconazole	328-339	nefazodone	354-363	false
ketoconazole	328-339	niacinamide	366-376	false
ketoconazole	328-339	nicotinamide	379-390	false
ketoconazole	328-339	protease inhibitors	393-411	false
ketoconazole	328-339	propoxyphene	414-425	false
ketoconazole	328-339	quinine	428-434	false
ketoconazole	328-339	quinupristin	437-448	false
ketoconazole	328-339	troleandomycin	451-464	false
ketoconazole	328-339	valproate	467-475	false
ketoconazole	328-339	verapamil	481-489	false
ketoconazole	328-339	zileuton	492-499	false
loratadine	342-351	nefazodone	354-363	false
loratadine	342-351	niacinamide	366-376	false
loratadine	342-351	nicotinamide	379-390	false
loratadine	342-351	protease inhibitors	393-411	false
loratadine	342-351	propoxyphene	414-425	false
loratadine	342-351	quinine	428-434	false
loratadine	342-351	quinupristin	437-448	false
loratadine	342-351	troleandomycin	451-464	false
loratadine	342-351	valproate	467-475	false
loratadine	342-351	verapamil	481-489	false
loratadine	342-351	zileuton	492-499	false
nefazodone	354-363	niacinamide	366-376	false
nefazodone	354-363	nicotinamide	379-390	false
nefazodone	354-363	protease inhibitors	393-411	false
nefazodone	354-363	propoxyphene	414-425	false
nefazodone	354-363	quinine	428-434	false
nefazodone	354-363	quinupristin	437-448	false
nefazodone	354-363	troleandomycin	451-464	false
nefazodone	354-363	valproate	467-475	false
nefazodone	354-363	verapamil	481-489	false
nefazodone	354-363	zileuton	492-499	false
niacinamide	366-376	nicotinamide	379-390	false
niacinamide	366-376	protease inhibitors	393-411	false
niacinamide	366-376	propoxyphene	414-425	false
niacinamide	366-376	quinine	428-434	false
niacinamide	366-376	quinupristin	437-448	false
niacinamide	366-376	troleandomycin	451-464	false
niacinamide	366-376	valproate	467-475	false
niacinamide	366-376	verapamil	481-489	false
niacinamide	366-376	zileuton	492-499	false
nicotinamide	379-390	protease inhibitors	393-411	false
nicotinamide	379-390	propoxyphene	414-425	false
nicotinamide	379-390	quinine	428-434	false
nicotinamide	379-390	quinupristin	437-448	false
nicotinamide	379-390	troleandomycin	451-464	false
nicotinamide	379-390	valproate	467-475	false
nicotinamide	379-390	verapamil	481-489	false
nicotinamide	379-390	zileuton	492-499	false
protease inhibitors	393-411	propoxyphene	414-425	false
protease inhibitors	393-411	quinine	428-434	false
protease inhibitors	393-411	quinupristin	437-448	false
protease inhibitors	393-411	troleandomycin	451-464	false
protease inhibitors	393-411	valproate	467-475	false
protease inhibitors	393-411	verapamil	481-489	false
protease inhibitors	393-411	zileuton	492-499	false
propoxyphene	414-425	quinine	428-434	false
propoxyphene	414-425	quinupristin	437-448	false
propoxyphene	414-425	troleandomycin	451-464	false
propoxyphene	414-425	valproate	467-475	false
propoxyphene	414-425	verapamil	481-489	false
propoxyphene	414-425	zileuton	492-499	false
quinine	428-434	quinupristin	437-448	false
quinine	428-434	troleandomycin	451-464	false
quinine	428-434	valproate	467-475	false
quinine	428-434	verapamil	481-489	false
quinine	428-434	zileuton	492-499	false
quinupristin	437-448	troleandomycin	451-464	false
quinupristin	437-448	valproate	467-475	false
quinupristin	437-448	verapamil	481-489	false
quinupristin	437-448	zileuton	492-499	false
troleandomycin	451-464	valproate	467-475	false
troleandomycin	451-464	verapamil	481-489	false
troleandomycin	451-464	zileuton	492-499	false
valproate	467-475	verapamil	481-489	false
valproate	467-475	zileuton	492-499	false
verapamil	481-489	zileuton	492-499	false

Thus, if a patient has been titrated to a stable dosage of EQUETROTM, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for EQUETROTM may be necessary.
EQUETROTM	59-67	EQUETROTM	219-227	false

Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
EQUETROTM	97-105	Cisplatin	126-134	mechanism
EQUETROTM	97-105	doxorubicin HCL	137-151	mechanism
EQUETROTM	97-105	felbamate	154-162	mechanism
EQUETROTM	97-105	rifampin	165-172	mechanism
EQUETROTM	97-105	phenobarbital	175-187	mechanism
EQUETROTM	97-105	Phenytoin	190-198	mechanism
EQUETROTM	97-105	primidone	204-212	mechanism
EQUETROTM	97-105	methsuximide	215-226	mechanism
EQUETROTM	97-105	theophylline	233-244	mechanism
EQUETROTM	97-105	EQUETROTM	305-313	false
EQUETROTM	97-105	EQUETROTM	441-449	false
Cisplatin	126-134	doxorubicin HCL	137-151	false
Cisplatin	126-134	felbamate	154-162	false
Cisplatin	126-134	rifampin	165-172	false
Cisplatin	126-134	phenobarbital	175-187	false
Cisplatin	126-134	Phenytoin	190-198	false
Cisplatin	126-134	primidone	204-212	false
Cisplatin	126-134	methsuximide	215-226	false
Cisplatin	126-134	theophylline	233-244	false
Cisplatin	126-134	EQUETROTM	305-313	false
Cisplatin	126-134	EQUETROTM	441-449	false
doxorubicin HCL	137-151	felbamate	154-162	false
doxorubicin HCL	137-151	rifampin	165-172	false
doxorubicin HCL	137-151	phenobarbital	175-187	false
doxorubicin HCL	137-151	Phenytoin	190-198	false
doxorubicin HCL	137-151	primidone	204-212	false
doxorubicin HCL	137-151	methsuximide	215-226	false
doxorubicin HCL	137-151	theophylline	233-244	false
doxorubicin HCL	137-151	EQUETROTM	305-313	false
doxorubicin HCL	137-151	EQUETROTM	441-449	false
felbamate	154-162	rifampin	165-172	false
felbamate	154-162	phenobarbital	175-187	false
felbamate	154-162	Phenytoin	190-198	false
felbamate	154-162	primidone	204-212	false
felbamate	154-162	methsuximide	215-226	false
felbamate	154-162	theophylline	233-244	false
felbamate	154-162	EQUETROTM	305-313	false
felbamate	154-162	EQUETROTM	441-449	false
rifampin	165-172	phenobarbital	175-187	false
rifampin	165-172	Phenytoin	190-198	false
rifampin	165-172	primidone	204-212	false
rifampin	165-172	methsuximide	215-226	false
rifampin	165-172	theophylline	233-244	false
rifampin	165-172	EQUETROTM	305-313	false
rifampin	165-172	EQUETROTM	441-449	false
phenobarbital	175-187	Phenytoin	190-198	false
phenobarbital	175-187	primidone	204-212	false
phenobarbital	175-187	methsuximide	215-226	false
phenobarbital	175-187	theophylline	233-244	false
phenobarbital	175-187	EQUETROTM	305-313	false
phenobarbital	175-187	EQUETROTM	441-449	false
Phenytoin	190-198	primidone	204-212	false
Phenytoin	190-198	methsuximide	215-226	false
Phenytoin	190-198	theophylline	233-244	false
Phenytoin	190-198	EQUETROTM	305-313	false
Phenytoin	190-198	EQUETROTM	441-449	false
primidone	204-212	methsuximide	215-226	false
primidone	204-212	theophylline	233-244	false
primidone	204-212	EQUETROTM	305-313	false
primidone	204-212	EQUETROTM	441-449	false
methsuximide	215-226	theophylline	233-244	false
methsuximide	215-226	EQUETROTM	305-313	false
methsuximide	215-226	EQUETROTM	441-449	false
theophylline	233-244	EQUETROTM	305-313	false
theophylline	233-244	EQUETROTM	441-449	false
EQUETROTM	305-313	EQUETROTM	441-449	false

Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes Carbamazepine is known to induce CYP1A2 and CYP3A4.
Carbamazepine	48-60	Carbamazepine	106-118	false

Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
EQUETROTM	96-104	Acetaminophen	157-169	mechanism
EQUETROTM	96-104	alprazolam	172-181	mechanism
EQUETROTM	96-104	amitriptyline	184-196	mechanism
EQUETROTM	96-104	bupropion	199-207	mechanism
EQUETROTM	96-104	buspirone	210-218	mechanism
EQUETROTM	96-104	citalopram	221-230	mechanism
EQUETROTM	96-104	clobazam	233-240	mechanism
EQUETROTM	96-104	clonazepam	243-252	mechanism
EQUETROTM	96-104	clozapine	255-263	mechanism
EQUETROTM	96-104	cyclosporin	266-276	mechanism
EQUETROTM	96-104	delavirdine	279-289	mechanism
EQUETROTM	96-104	desipramine	292-302	mechanism
EQUETROTM	96-104	diazepam	305-312	mechanism
EQUETROTM	96-104	dicumarol	315-323	mechanism
EQUETROTM	96-104	doxycycline	326-336	mechanism
EQUETROTM	96-104	ethosuximide	339-350	mechanism
EQUETROTM	96-104	felbamate	353-361	mechanism
EQUETROTM	96-104	felodipine	364-373	mechanism
EQUETROTM	96-104	glucocorticoids	376-390	mechanism
EQUETROTM	96-104	haloperidol	393-403	mechanism
EQUETROTM	96-104	itraconazole	406-417	mechanism
EQUETROTM	96-104	lamotrigine	420-430	mechanism
EQUETROTM	96-104	levothyroxine	433-445	mechanism
EQUETROTM	96-104	lorazepam	448-456	mechanism
EQUETROTM	96-104	methadone	459-467	mechanism
EQUETROTM	96-104	midazolam	470-478	mechanism
EQUETROTM	96-104	mirtazapine	481-491	mechanism
EQUETROTM	96-104	nortriptyline	494-506	mechanism
EQUETROTM	96-104	olanzapine	509-518	mechanism
EQUETROTM	96-104	contraceptives	526-539	mechanism
EQUETROTM	96-104	oxcarbazepine	545-557	mechanism
EQUETROTM	96-104	Phenytoin	560-568	mechanism
EQUETROTM	96-104	praziquantel	574-585	mechanism
EQUETROTM	96-104	protease inhibitors	588-606	mechanism
EQUETROTM	96-104	quetiapine	609-618	mechanism
EQUETROTM	96-104	risperidone	621-631	mechanism
EQUETROTM	96-104	theophylline	634-645	mechanism
EQUETROTM	96-104	topiramate	648-657	mechanism
EQUETROTM	96-104	tiagabine	660-668	mechanism
EQUETROTM	96-104	tramadol	671-678	mechanism
EQUETROTM	96-104	triazolam	681-689	mechanism
EQUETROTM	96-104	valproate	692-700	mechanism
EQUETROTM	96-104	warfarin	703-710	mechanism
EQUETROTM	96-104	ziprasidone	717-727	mechanism
EQUETROTM	96-104	zonisamide	734-743	mechanism
Acetaminophen	157-169	alprazolam	172-181	false
Acetaminophen	157-169	amitriptyline	184-196	false
Acetaminophen	157-169	bupropion	199-207	false
Acetaminophen	157-169	buspirone	210-218	false
Acetaminophen	157-169	citalopram	221-230	false
Acetaminophen	157-169	clobazam	233-240	false
Acetaminophen	157-169	clonazepam	243-252	false
Acetaminophen	157-169	clozapine	255-263	false
Acetaminophen	157-169	cyclosporin	266-276	false
Acetaminophen	157-169	delavirdine	279-289	false
Acetaminophen	157-169	desipramine	292-302	false
Acetaminophen	157-169	diazepam	305-312	false
Acetaminophen	157-169	dicumarol	315-323	false
Acetaminophen	157-169	doxycycline	326-336	false
Acetaminophen	157-169	ethosuximide	339-350	false
Acetaminophen	157-169	felbamate	353-361	false
Acetaminophen	157-169	felodipine	364-373	false
Acetaminophen	157-169	glucocorticoids	376-390	false
Acetaminophen	157-169	haloperidol	393-403	false
Acetaminophen	157-169	itraconazole	406-417	false
Acetaminophen	157-169	lamotrigine	420-430	false
Acetaminophen	157-169	levothyroxine	433-445	false
Acetaminophen	157-169	lorazepam	448-456	false
Acetaminophen	157-169	methadone	459-467	false
Acetaminophen	157-169	midazolam	470-478	false
Acetaminophen	157-169	mirtazapine	481-491	false
Acetaminophen	157-169	nortriptyline	494-506	false
Acetaminophen	157-169	olanzapine	509-518	false
Acetaminophen	157-169	contraceptives	526-539	false
Acetaminophen	157-169	oxcarbazepine	545-557	false
Acetaminophen	157-169	Phenytoin	560-568	false
Acetaminophen	157-169	praziquantel	574-585	false
Acetaminophen	157-169	protease inhibitors	588-606	false
Acetaminophen	157-169	quetiapine	609-618	false
Acetaminophen	157-169	risperidone	621-631	false
Acetaminophen	157-169	theophylline	634-645	false
Acetaminophen	157-169	topiramate	648-657	false
Acetaminophen	157-169	tiagabine	660-668	false
Acetaminophen	157-169	tramadol	671-678	false
Acetaminophen	157-169	triazolam	681-689	false
Acetaminophen	157-169	valproate	692-700	false
Acetaminophen	157-169	warfarin	703-710	false
Acetaminophen	157-169	ziprasidone	717-727	false
Acetaminophen	157-169	zonisamide	734-743	false
alprazolam	172-181	amitriptyline	184-196	false
alprazolam	172-181	bupropion	199-207	false
alprazolam	172-181	buspirone	210-218	false
alprazolam	172-181	citalopram	221-230	false
alprazolam	172-181	clobazam	233-240	false
alprazolam	172-181	clonazepam	243-252	false
alprazolam	172-181	clozapine	255-263	false
alprazolam	172-181	cyclosporin	266-276	false
alprazolam	172-181	delavirdine	279-289	false
alprazolam	172-181	desipramine	292-302	false
alprazolam	172-181	diazepam	305-312	false
alprazolam	172-181	dicumarol	315-323	false
alprazolam	172-181	doxycycline	326-336	false
alprazolam	172-181	ethosuximide	339-350	false
alprazolam	172-181	felbamate	353-361	false
alprazolam	172-181	felodipine	364-373	false
alprazolam	172-181	glucocorticoids	376-390	false
alprazolam	172-181	haloperidol	393-403	false
alprazolam	172-181	itraconazole	406-417	false
alprazolam	172-181	lamotrigine	420-430	false
alprazolam	172-181	levothyroxine	433-445	false
alprazolam	172-181	lorazepam	448-456	false
alprazolam	172-181	methadone	459-467	false
alprazolam	172-181	midazolam	470-478	false
alprazolam	172-181	mirtazapine	481-491	false
alprazolam	172-181	nortriptyline	494-506	false
alprazolam	172-181	olanzapine	509-518	false
alprazolam	172-181	contraceptives	526-539	false
alprazolam	172-181	oxcarbazepine	545-557	false
alprazolam	172-181	Phenytoin	560-568	false
alprazolam	172-181	praziquantel	574-585	false
alprazolam	172-181	protease inhibitors	588-606	false
alprazolam	172-181	quetiapine	609-618	false
alprazolam	172-181	risperidone	621-631	false
alprazolam	172-181	theophylline	634-645	false
alprazolam	172-181	topiramate	648-657	false
alprazolam	172-181	tiagabine	660-668	false
alprazolam	172-181	tramadol	671-678	false
alprazolam	172-181	triazolam	681-689	false
alprazolam	172-181	valproate	692-700	false
alprazolam	172-181	warfarin	703-710	false
alprazolam	172-181	ziprasidone	717-727	false
alprazolam	172-181	zonisamide	734-743	false
amitriptyline	184-196	bupropion	199-207	false
amitriptyline	184-196	buspirone	210-218	false
amitriptyline	184-196	citalopram	221-230	false
amitriptyline	184-196	clobazam	233-240	false
amitriptyline	184-196	clonazepam	243-252	false
amitriptyline	184-196	clozapine	255-263	false
amitriptyline	184-196	cyclosporin	266-276	false
amitriptyline	184-196	delavirdine	279-289	false
amitriptyline	184-196	desipramine	292-302	false
amitriptyline	184-196	diazepam	305-312	false
amitriptyline	184-196	dicumarol	315-323	false
amitriptyline	184-196	doxycycline	326-336	false
amitriptyline	184-196	ethosuximide	339-350	false
amitriptyline	184-196	felbamate	353-361	false
amitriptyline	184-196	felodipine	364-373	false
amitriptyline	184-196	glucocorticoids	376-390	false
amitriptyline	184-196	haloperidol	393-403	false
amitriptyline	184-196	itraconazole	406-417	false
amitriptyline	184-196	lamotrigine	420-430	false
amitriptyline	184-196	levothyroxine	433-445	false
amitriptyline	184-196	lorazepam	448-456	false
amitriptyline	184-196	methadone	459-467	false
amitriptyline	184-196	midazolam	470-478	false
amitriptyline	184-196	mirtazapine	481-491	false
amitriptyline	184-196	nortriptyline	494-506	false
amitriptyline	184-196	olanzapine	509-518	false
amitriptyline	184-196	contraceptives	526-539	false
amitriptyline	184-196	oxcarbazepine	545-557	false
amitriptyline	184-196	Phenytoin	560-568	false
amitriptyline	184-196	praziquantel	574-585	false
amitriptyline	184-196	protease inhibitors	588-606	false
amitriptyline	184-196	quetiapine	609-618	false
amitriptyline	184-196	risperidone	621-631	false
amitriptyline	184-196	theophylline	634-645	false
amitriptyline	184-196	topiramate	648-657	false
amitriptyline	184-196	tiagabine	660-668	false
amitriptyline	184-196	tramadol	671-678	false
amitriptyline	184-196	triazolam	681-689	false
amitriptyline	184-196	valproate	692-700	false
amitriptyline	184-196	warfarin	703-710	false
amitriptyline	184-196	ziprasidone	717-727	false
amitriptyline	184-196	zonisamide	734-743	false
bupropion	199-207	buspirone	210-218	false
bupropion	199-207	citalopram	221-230	false
bupropion	199-207	clobazam	233-240	false
bupropion	199-207	clonazepam	243-252	false
bupropion	199-207	clozapine	255-263	false
bupropion	199-207	cyclosporin	266-276	false
bupropion	199-207	delavirdine	279-289	false
bupropion	199-207	desipramine	292-302	false
bupropion	199-207	diazepam	305-312	false
bupropion	199-207	dicumarol	315-323	false
bupropion	199-207	doxycycline	326-336	false
bupropion	199-207	ethosuximide	339-350	false
bupropion	199-207	felbamate	353-361	false
bupropion	199-207	felodipine	364-373	false
bupropion	199-207	glucocorticoids	376-390	false
bupropion	199-207	haloperidol	393-403	false
bupropion	199-207	itraconazole	406-417	false
bupropion	199-207	lamotrigine	420-430	false
bupropion	199-207	levothyroxine	433-445	false
bupropion	199-207	lorazepam	448-456	false
bupropion	199-207	methadone	459-467	false
bupropion	199-207	midazolam	470-478	false
bupropion	199-207	mirtazapine	481-491	false
bupropion	199-207	nortriptyline	494-506	false
bupropion	199-207	olanzapine	509-518	false
bupropion	199-207	contraceptives	526-539	false
bupropion	199-207	oxcarbazepine	545-557	false
bupropion	199-207	Phenytoin	560-568	false
bupropion	199-207	praziquantel	574-585	false
bupropion	199-207	protease inhibitors	588-606	false
bupropion	199-207	quetiapine	609-618	false
bupropion	199-207	risperidone	621-631	false
bupropion	199-207	theophylline	634-645	false
bupropion	199-207	topiramate	648-657	false
bupropion	199-207	tiagabine	660-668	false
bupropion	199-207	tramadol	671-678	false
bupropion	199-207	triazolam	681-689	false
bupropion	199-207	valproate	692-700	false
bupropion	199-207	warfarin	703-710	false
bupropion	199-207	ziprasidone	717-727	false
bupropion	199-207	zonisamide	734-743	false
buspirone	210-218	citalopram	221-230	false
buspirone	210-218	clobazam	233-240	false
buspirone	210-218	clonazepam	243-252	false
buspirone	210-218	clozapine	255-263	false
buspirone	210-218	cyclosporin	266-276	false
buspirone	210-218	delavirdine	279-289	false
buspirone	210-218	desipramine	292-302	false
buspirone	210-218	diazepam	305-312	false
buspirone	210-218	dicumarol	315-323	false
buspirone	210-218	doxycycline	326-336	false
buspirone	210-218	ethosuximide	339-350	false
buspirone	210-218	felbamate	353-361	false
buspirone	210-218	felodipine	364-373	false
buspirone	210-218	glucocorticoids	376-390	false
buspirone	210-218	haloperidol	393-403	false
buspirone	210-218	itraconazole	406-417	false
buspirone	210-218	lamotrigine	420-430	false
buspirone	210-218	levothyroxine	433-445	false
buspirone	210-218	lorazepam	448-456	false
buspirone	210-218	methadone	459-467	false
buspirone	210-218	midazolam	470-478	false
buspirone	210-218	mirtazapine	481-491	false
buspirone	210-218	nortriptyline	494-506	false
buspirone	210-218	olanzapine	509-518	false
buspirone	210-218	contraceptives	526-539	false
buspirone	210-218	oxcarbazepine	545-557	false
buspirone	210-218	Phenytoin	560-568	false
buspirone	210-218	praziquantel	574-585	false
buspirone	210-218	protease inhibitors	588-606	false
buspirone	210-218	quetiapine	609-618	false
buspirone	210-218	risperidone	621-631	false
buspirone	210-218	theophylline	634-645	false
buspirone	210-218	topiramate	648-657	false
buspirone	210-218	tiagabine	660-668	false
buspirone	210-218	tramadol	671-678	false
buspirone	210-218	triazolam	681-689	false
buspirone	210-218	valproate	692-700	false
buspirone	210-218	warfarin	703-710	false
buspirone	210-218	ziprasidone	717-727	false
buspirone	210-218	zonisamide	734-743	false
citalopram	221-230	clobazam	233-240	false
citalopram	221-230	clonazepam	243-252	false
citalopram	221-230	clozapine	255-263	false
citalopram	221-230	cyclosporin	266-276	false
citalopram	221-230	delavirdine	279-289	false
citalopram	221-230	desipramine	292-302	false
citalopram	221-230	diazepam	305-312	false
citalopram	221-230	dicumarol	315-323	false
citalopram	221-230	doxycycline	326-336	false
citalopram	221-230	ethosuximide	339-350	false
citalopram	221-230	felbamate	353-361	false
citalopram	221-230	felodipine	364-373	false
citalopram	221-230	glucocorticoids	376-390	false
citalopram	221-230	haloperidol	393-403	false
citalopram	221-230	itraconazole	406-417	false
citalopram	221-230	lamotrigine	420-430	false
citalopram	221-230	levothyroxine	433-445	false
citalopram	221-230	lorazepam	448-456	false
citalopram	221-230	methadone	459-467	false
citalopram	221-230	midazolam	470-478	false
citalopram	221-230	mirtazapine	481-491	false
citalopram	221-230	nortriptyline	494-506	false
citalopram	221-230	olanzapine	509-518	false
citalopram	221-230	contraceptives	526-539	false
citalopram	221-230	oxcarbazepine	545-557	false
citalopram	221-230	Phenytoin	560-568	false
citalopram	221-230	praziquantel	574-585	false
citalopram	221-230	protease inhibitors	588-606	false
citalopram	221-230	quetiapine	609-618	false
citalopram	221-230	risperidone	621-631	false
citalopram	221-230	theophylline	634-645	false
citalopram	221-230	topiramate	648-657	false
citalopram	221-230	tiagabine	660-668	false
citalopram	221-230	tramadol	671-678	false
citalopram	221-230	triazolam	681-689	false
citalopram	221-230	valproate	692-700	false
citalopram	221-230	warfarin	703-710	false
citalopram	221-230	ziprasidone	717-727	false
citalopram	221-230	zonisamide	734-743	false
clobazam	233-240	clonazepam	243-252	false
clobazam	233-240	clozapine	255-263	false
clobazam	233-240	cyclosporin	266-276	false
clobazam	233-240	delavirdine	279-289	false
clobazam	233-240	desipramine	292-302	false
clobazam	233-240	diazepam	305-312	false
clobazam	233-240	dicumarol	315-323	false
clobazam	233-240	doxycycline	326-336	false
clobazam	233-240	ethosuximide	339-350	false
clobazam	233-240	felbamate	353-361	false
clobazam	233-240	felodipine	364-373	false
clobazam	233-240	glucocorticoids	376-390	false
clobazam	233-240	haloperidol	393-403	false
clobazam	233-240	itraconazole	406-417	false
clobazam	233-240	lamotrigine	420-430	false
clobazam	233-240	levothyroxine	433-445	false
clobazam	233-240	lorazepam	448-456	false
clobazam	233-240	methadone	459-467	false
clobazam	233-240	midazolam	470-478	false
clobazam	233-240	mirtazapine	481-491	false
clobazam	233-240	nortriptyline	494-506	false
clobazam	233-240	olanzapine	509-518	false
clobazam	233-240	contraceptives	526-539	false
clobazam	233-240	oxcarbazepine	545-557	false
clobazam	233-240	Phenytoin	560-568	false
clobazam	233-240	praziquantel	574-585	false
clobazam	233-240	protease inhibitors	588-606	false
clobazam	233-240	quetiapine	609-618	false
clobazam	233-240	risperidone	621-631	false
clobazam	233-240	theophylline	634-645	false
clobazam	233-240	topiramate	648-657	false
clobazam	233-240	tiagabine	660-668	false
clobazam	233-240	tramadol	671-678	false
clobazam	233-240	triazolam	681-689	false
clobazam	233-240	valproate	692-700	false
clobazam	233-240	warfarin	703-710	false
clobazam	233-240	ziprasidone	717-727	false
clobazam	233-240	zonisamide	734-743	false
clonazepam	243-252	clozapine	255-263	false
clonazepam	243-252	cyclosporin	266-276	false
clonazepam	243-252	delavirdine	279-289	false
clonazepam	243-252	desipramine	292-302	false
clonazepam	243-252	diazepam	305-312	false
clonazepam	243-252	dicumarol	315-323	false
clonazepam	243-252	doxycycline	326-336	false
clonazepam	243-252	ethosuximide	339-350	false
clonazepam	243-252	felbamate	353-361	false
clonazepam	243-252	felodipine	364-373	false
clonazepam	243-252	glucocorticoids	376-390	false
clonazepam	243-252	haloperidol	393-403	false
clonazepam	243-252	itraconazole	406-417	false
clonazepam	243-252	lamotrigine	420-430	false
clonazepam	243-252	levothyroxine	433-445	false
clonazepam	243-252	lorazepam	448-456	false
clonazepam	243-252	methadone	459-467	false
clonazepam	243-252	midazolam	470-478	false
clonazepam	243-252	mirtazapine	481-491	false
clonazepam	243-252	nortriptyline	494-506	false
clonazepam	243-252	olanzapine	509-518	false
clonazepam	243-252	contraceptives	526-539	false
clonazepam	243-252	oxcarbazepine	545-557	false
clonazepam	243-252	Phenytoin	560-568	false
clonazepam	243-252	praziquantel	574-585	false
clonazepam	243-252	protease inhibitors	588-606	false
clonazepam	243-252	quetiapine	609-618	false
clonazepam	243-252	risperidone	621-631	false
clonazepam	243-252	theophylline	634-645	false
clonazepam	243-252	topiramate	648-657	false
clonazepam	243-252	tiagabine	660-668	false
clonazepam	243-252	tramadol	671-678	false
clonazepam	243-252	triazolam	681-689	false
clonazepam	243-252	valproate	692-700	false
clonazepam	243-252	warfarin	703-710	false
clonazepam	243-252	ziprasidone	717-727	false
clonazepam	243-252	zonisamide	734-743	false
clozapine	255-263	cyclosporin	266-276	false
clozapine	255-263	delavirdine	279-289	false
clozapine	255-263	desipramine	292-302	false
clozapine	255-263	diazepam	305-312	false
clozapine	255-263	dicumarol	315-323	false
clozapine	255-263	doxycycline	326-336	false
clozapine	255-263	ethosuximide	339-350	false
clozapine	255-263	felbamate	353-361	false
clozapine	255-263	felodipine	364-373	false
clozapine	255-263	glucocorticoids	376-390	false
clozapine	255-263	haloperidol	393-403	false
clozapine	255-263	itraconazole	406-417	false
clozapine	255-263	lamotrigine	420-430	false
clozapine	255-263	levothyroxine	433-445	false
clozapine	255-263	lorazepam	448-456	false
clozapine	255-263	methadone	459-467	false
clozapine	255-263	midazolam	470-478	false
clozapine	255-263	mirtazapine	481-491	false
clozapine	255-263	nortriptyline	494-506	false
clozapine	255-263	olanzapine	509-518	false
clozapine	255-263	contraceptives	526-539	false
clozapine	255-263	oxcarbazepine	545-557	false
clozapine	255-263	Phenytoin	560-568	false
clozapine	255-263	praziquantel	574-585	false
clozapine	255-263	protease inhibitors	588-606	false
clozapine	255-263	quetiapine	609-618	false
clozapine	255-263	risperidone	621-631	false
clozapine	255-263	theophylline	634-645	false
clozapine	255-263	topiramate	648-657	false
clozapine	255-263	tiagabine	660-668	false
clozapine	255-263	tramadol	671-678	false
clozapine	255-263	triazolam	681-689	false
clozapine	255-263	valproate	692-700	false
clozapine	255-263	warfarin	703-710	false
clozapine	255-263	ziprasidone	717-727	false
clozapine	255-263	zonisamide	734-743	false
cyclosporin	266-276	delavirdine	279-289	false
cyclosporin	266-276	desipramine	292-302	false
cyclosporin	266-276	diazepam	305-312	false
cyclosporin	266-276	dicumarol	315-323	false
cyclosporin	266-276	doxycycline	326-336	false
cyclosporin	266-276	ethosuximide	339-350	false
cyclosporin	266-276	felbamate	353-361	false
cyclosporin	266-276	felodipine	364-373	false
cyclosporin	266-276	glucocorticoids	376-390	false
cyclosporin	266-276	haloperidol	393-403	false
cyclosporin	266-276	itraconazole	406-417	false
cyclosporin	266-276	lamotrigine	420-430	false
cyclosporin	266-276	levothyroxine	433-445	false
cyclosporin	266-276	lorazepam	448-456	false
cyclosporin	266-276	methadone	459-467	false
cyclosporin	266-276	midazolam	470-478	false
cyclosporin	266-276	mirtazapine	481-491	false
cyclosporin	266-276	nortriptyline	494-506	false
cyclosporin	266-276	olanzapine	509-518	false
cyclosporin	266-276	contraceptives	526-539	false
cyclosporin	266-276	oxcarbazepine	545-557	false
cyclosporin	266-276	Phenytoin	560-568	false
cyclosporin	266-276	praziquantel	574-585	false
cyclosporin	266-276	protease inhibitors	588-606	false
cyclosporin	266-276	quetiapine	609-618	false
cyclosporin	266-276	risperidone	621-631	false
cyclosporin	266-276	theophylline	634-645	false
cyclosporin	266-276	topiramate	648-657	false
cyclosporin	266-276	tiagabine	660-668	false
cyclosporin	266-276	tramadol	671-678	false
cyclosporin	266-276	triazolam	681-689	false
cyclosporin	266-276	valproate	692-700	false
cyclosporin	266-276	warfarin	703-710	false
cyclosporin	266-276	ziprasidone	717-727	false
cyclosporin	266-276	zonisamide	734-743	false
delavirdine	279-289	desipramine	292-302	false
delavirdine	279-289	diazepam	305-312	false
delavirdine	279-289	dicumarol	315-323	false
delavirdine	279-289	doxycycline	326-336	false
delavirdine	279-289	ethosuximide	339-350	false
delavirdine	279-289	felbamate	353-361	false
delavirdine	279-289	felodipine	364-373	false
delavirdine	279-289	glucocorticoids	376-390	false
delavirdine	279-289	haloperidol	393-403	false
delavirdine	279-289	itraconazole	406-417	false
delavirdine	279-289	lamotrigine	420-430	false
delavirdine	279-289	levothyroxine	433-445	false
delavirdine	279-289	lorazepam	448-456	false
delavirdine	279-289	methadone	459-467	false
delavirdine	279-289	midazolam	470-478	false
delavirdine	279-289	mirtazapine	481-491	false
delavirdine	279-289	nortriptyline	494-506	false
delavirdine	279-289	olanzapine	509-518	false
delavirdine	279-289	contraceptives	526-539	false
delavirdine	279-289	oxcarbazepine	545-557	false
delavirdine	279-289	Phenytoin	560-568	false
delavirdine	279-289	praziquantel	574-585	false
delavirdine	279-289	protease inhibitors	588-606	false
delavirdine	279-289	quetiapine	609-618	false
delavirdine	279-289	risperidone	621-631	false
delavirdine	279-289	theophylline	634-645	false
delavirdine	279-289	topiramate	648-657	false
delavirdine	279-289	tiagabine	660-668	false
delavirdine	279-289	tramadol	671-678	false
delavirdine	279-289	triazolam	681-689	false
delavirdine	279-289	valproate	692-700	false
delavirdine	279-289	warfarin	703-710	false
delavirdine	279-289	ziprasidone	717-727	false
delavirdine	279-289	zonisamide	734-743	false
desipramine	292-302	diazepam	305-312	false
desipramine	292-302	dicumarol	315-323	false
desipramine	292-302	doxycycline	326-336	false
desipramine	292-302	ethosuximide	339-350	false
desipramine	292-302	felbamate	353-361	false
desipramine	292-302	felodipine	364-373	false
desipramine	292-302	glucocorticoids	376-390	false
desipramine	292-302	haloperidol	393-403	false
desipramine	292-302	itraconazole	406-417	false
desipramine	292-302	lamotrigine	420-430	false
desipramine	292-302	levothyroxine	433-445	false
desipramine	292-302	lorazepam	448-456	false
desipramine	292-302	methadone	459-467	false
desipramine	292-302	midazolam	470-478	false
desipramine	292-302	mirtazapine	481-491	false
desipramine	292-302	nortriptyline	494-506	false
desipramine	292-302	olanzapine	509-518	false
desipramine	292-302	contraceptives	526-539	false
desipramine	292-302	oxcarbazepine	545-557	false
desipramine	292-302	Phenytoin	560-568	false
desipramine	292-302	praziquantel	574-585	false
desipramine	292-302	protease inhibitors	588-606	false
desipramine	292-302	quetiapine	609-618	false
desipramine	292-302	risperidone	621-631	false
desipramine	292-302	theophylline	634-645	false
desipramine	292-302	topiramate	648-657	false
desipramine	292-302	tiagabine	660-668	false
desipramine	292-302	tramadol	671-678	false
desipramine	292-302	triazolam	681-689	false
desipramine	292-302	valproate	692-700	false
desipramine	292-302	warfarin	703-710	false
desipramine	292-302	ziprasidone	717-727	false
desipramine	292-302	zonisamide	734-743	false
diazepam	305-312	dicumarol	315-323	false
diazepam	305-312	doxycycline	326-336	false
diazepam	305-312	ethosuximide	339-350	false
diazepam	305-312	felbamate	353-361	false
diazepam	305-312	felodipine	364-373	false
diazepam	305-312	glucocorticoids	376-390	false
diazepam	305-312	haloperidol	393-403	false
diazepam	305-312	itraconazole	406-417	false
diazepam	305-312	lamotrigine	420-430	false
diazepam	305-312	levothyroxine	433-445	false
diazepam	305-312	lorazepam	448-456	false
diazepam	305-312	methadone	459-467	false
diazepam	305-312	midazolam	470-478	false
diazepam	305-312	mirtazapine	481-491	false
diazepam	305-312	nortriptyline	494-506	false
diazepam	305-312	olanzapine	509-518	false
diazepam	305-312	contraceptives	526-539	false
diazepam	305-312	oxcarbazepine	545-557	false
diazepam	305-312	Phenytoin	560-568	false
diazepam	305-312	praziquantel	574-585	false
diazepam	305-312	protease inhibitors	588-606	false
diazepam	305-312	quetiapine	609-618	false
diazepam	305-312	risperidone	621-631	false
diazepam	305-312	theophylline	634-645	false
diazepam	305-312	topiramate	648-657	false
diazepam	305-312	tiagabine	660-668	false
diazepam	305-312	tramadol	671-678	false
diazepam	305-312	triazolam	681-689	false
diazepam	305-312	valproate	692-700	false
diazepam	305-312	warfarin	703-710	false
diazepam	305-312	ziprasidone	717-727	false
diazepam	305-312	zonisamide	734-743	false
dicumarol	315-323	doxycycline	326-336	false
dicumarol	315-323	ethosuximide	339-350	false
dicumarol	315-323	felbamate	353-361	false
dicumarol	315-323	felodipine	364-373	false
dicumarol	315-323	glucocorticoids	376-390	false
dicumarol	315-323	haloperidol	393-403	false
dicumarol	315-323	itraconazole	406-417	false
dicumarol	315-323	lamotrigine	420-430	false
dicumarol	315-323	levothyroxine	433-445	false
dicumarol	315-323	lorazepam	448-456	false
dicumarol	315-323	methadone	459-467	false
dicumarol	315-323	midazolam	470-478	false
dicumarol	315-323	mirtazapine	481-491	false
dicumarol	315-323	nortriptyline	494-506	false
dicumarol	315-323	olanzapine	509-518	false
dicumarol	315-323	contraceptives	526-539	false
dicumarol	315-323	oxcarbazepine	545-557	false
dicumarol	315-323	Phenytoin	560-568	false
dicumarol	315-323	praziquantel	574-585	false
dicumarol	315-323	protease inhibitors	588-606	false
dicumarol	315-323	quetiapine	609-618	false
dicumarol	315-323	risperidone	621-631	false
dicumarol	315-323	theophylline	634-645	false
dicumarol	315-323	topiramate	648-657	false
dicumarol	315-323	tiagabine	660-668	false
dicumarol	315-323	tramadol	671-678	false
dicumarol	315-323	triazolam	681-689	false
dicumarol	315-323	valproate	692-700	false
dicumarol	315-323	warfarin	703-710	false
dicumarol	315-323	ziprasidone	717-727	false
dicumarol	315-323	zonisamide	734-743	false
doxycycline	326-336	ethosuximide	339-350	false
doxycycline	326-336	felbamate	353-361	false
doxycycline	326-336	felodipine	364-373	false
doxycycline	326-336	glucocorticoids	376-390	false
doxycycline	326-336	haloperidol	393-403	false
doxycycline	326-336	itraconazole	406-417	false
doxycycline	326-336	lamotrigine	420-430	false
doxycycline	326-336	levothyroxine	433-445	false
doxycycline	326-336	lorazepam	448-456	false
doxycycline	326-336	methadone	459-467	false
doxycycline	326-336	midazolam	470-478	false
doxycycline	326-336	mirtazapine	481-491	false
doxycycline	326-336	nortriptyline	494-506	false
doxycycline	326-336	olanzapine	509-518	false
doxycycline	326-336	contraceptives	526-539	false
doxycycline	326-336	oxcarbazepine	545-557	false
doxycycline	326-336	Phenytoin	560-568	false
doxycycline	326-336	praziquantel	574-585	false
doxycycline	326-336	protease inhibitors	588-606	false
doxycycline	326-336	quetiapine	609-618	false
doxycycline	326-336	risperidone	621-631	false
doxycycline	326-336	theophylline	634-645	false
doxycycline	326-336	topiramate	648-657	false
doxycycline	326-336	tiagabine	660-668	false
doxycycline	326-336	tramadol	671-678	false
doxycycline	326-336	triazolam	681-689	false
doxycycline	326-336	valproate	692-700	false
doxycycline	326-336	warfarin	703-710	false
doxycycline	326-336	ziprasidone	717-727	false
doxycycline	326-336	zonisamide	734-743	false
ethosuximide	339-350	felbamate	353-361	false
ethosuximide	339-350	felodipine	364-373	false
ethosuximide	339-350	glucocorticoids	376-390	false
ethosuximide	339-350	haloperidol	393-403	false
ethosuximide	339-350	itraconazole	406-417	false
ethosuximide	339-350	lamotrigine	420-430	false
ethosuximide	339-350	levothyroxine	433-445	false
ethosuximide	339-350	lorazepam	448-456	false
ethosuximide	339-350	methadone	459-467	false
ethosuximide	339-350	midazolam	470-478	false
ethosuximide	339-350	mirtazapine	481-491	false
ethosuximide	339-350	nortriptyline	494-506	false
ethosuximide	339-350	olanzapine	509-518	false
ethosuximide	339-350	contraceptives	526-539	false
ethosuximide	339-350	oxcarbazepine	545-557	false
ethosuximide	339-350	Phenytoin	560-568	false
ethosuximide	339-350	praziquantel	574-585	false
ethosuximide	339-350	protease inhibitors	588-606	false
ethosuximide	339-350	quetiapine	609-618	false
ethosuximide	339-350	risperidone	621-631	false
ethosuximide	339-350	theophylline	634-645	false
ethosuximide	339-350	topiramate	648-657	false
ethosuximide	339-350	tiagabine	660-668	false
ethosuximide	339-350	tramadol	671-678	false
ethosuximide	339-350	triazolam	681-689	false
ethosuximide	339-350	valproate	692-700	false
ethosuximide	339-350	warfarin	703-710	false
ethosuximide	339-350	ziprasidone	717-727	false
ethosuximide	339-350	zonisamide	734-743	false
felbamate	353-361	felodipine	364-373	false
felbamate	353-361	glucocorticoids	376-390	false
felbamate	353-361	haloperidol	393-403	false
felbamate	353-361	itraconazole	406-417	false
felbamate	353-361	lamotrigine	420-430	false
felbamate	353-361	levothyroxine	433-445	false
felbamate	353-361	lorazepam	448-456	false
felbamate	353-361	methadone	459-467	false
felbamate	353-361	midazolam	470-478	false
felbamate	353-361	mirtazapine	481-491	false
felbamate	353-361	nortriptyline	494-506	false
felbamate	353-361	olanzapine	509-518	false
felbamate	353-361	contraceptives	526-539	false
felbamate	353-361	oxcarbazepine	545-557	false
felbamate	353-361	Phenytoin	560-568	false
felbamate	353-361	praziquantel	574-585	false
felbamate	353-361	protease inhibitors	588-606	false
felbamate	353-361	quetiapine	609-618	false
felbamate	353-361	risperidone	621-631	false
felbamate	353-361	theophylline	634-645	false
felbamate	353-361	topiramate	648-657	false
felbamate	353-361	tiagabine	660-668	false
felbamate	353-361	tramadol	671-678	false
felbamate	353-361	triazolam	681-689	false
felbamate	353-361	valproate	692-700	false
felbamate	353-361	warfarin	703-710	false
felbamate	353-361	ziprasidone	717-727	false
felbamate	353-361	zonisamide	734-743	false
felodipine	364-373	glucocorticoids	376-390	false
felodipine	364-373	haloperidol	393-403	false
felodipine	364-373	itraconazole	406-417	false
felodipine	364-373	lamotrigine	420-430	false
felodipine	364-373	levothyroxine	433-445	false
felodipine	364-373	lorazepam	448-456	false
felodipine	364-373	methadone	459-467	false
felodipine	364-373	midazolam	470-478	false
felodipine	364-373	mirtazapine	481-491	false
felodipine	364-373	nortriptyline	494-506	false
felodipine	364-373	olanzapine	509-518	false
felodipine	364-373	contraceptives	526-539	false
felodipine	364-373	oxcarbazepine	545-557	false
felodipine	364-373	Phenytoin	560-568	false
felodipine	364-373	praziquantel	574-585	false
felodipine	364-373	protease inhibitors	588-606	false
felodipine	364-373	quetiapine	609-618	false
felodipine	364-373	risperidone	621-631	false
felodipine	364-373	theophylline	634-645	false
felodipine	364-373	topiramate	648-657	false
felodipine	364-373	tiagabine	660-668	false
felodipine	364-373	tramadol	671-678	false
felodipine	364-373	triazolam	681-689	false
felodipine	364-373	valproate	692-700	false
felodipine	364-373	warfarin	703-710	false
felodipine	364-373	ziprasidone	717-727	false
felodipine	364-373	zonisamide	734-743	false
glucocorticoids	376-390	haloperidol	393-403	false
glucocorticoids	376-390	itraconazole	406-417	false
glucocorticoids	376-390	lamotrigine	420-430	false
glucocorticoids	376-390	levothyroxine	433-445	false
glucocorticoids	376-390	lorazepam	448-456	false
glucocorticoids	376-390	methadone	459-467	false
glucocorticoids	376-390	midazolam	470-478	false
glucocorticoids	376-390	mirtazapine	481-491	false
glucocorticoids	376-390	nortriptyline	494-506	false
glucocorticoids	376-390	olanzapine	509-518	false
glucocorticoids	376-390	contraceptives	526-539	false
glucocorticoids	376-390	oxcarbazepine	545-557	false
glucocorticoids	376-390	Phenytoin	560-568	false
glucocorticoids	376-390	praziquantel	574-585	false
glucocorticoids	376-390	protease inhibitors	588-606	false
glucocorticoids	376-390	quetiapine	609-618	false
glucocorticoids	376-390	risperidone	621-631	false
glucocorticoids	376-390	theophylline	634-645	false
glucocorticoids	376-390	topiramate	648-657	false
glucocorticoids	376-390	tiagabine	660-668	false
glucocorticoids	376-390	tramadol	671-678	false
glucocorticoids	376-390	triazolam	681-689	false
glucocorticoids	376-390	valproate	692-700	false
glucocorticoids	376-390	warfarin	703-710	false
glucocorticoids	376-390	ziprasidone	717-727	false
glucocorticoids	376-390	zonisamide	734-743	false
haloperidol	393-403	itraconazole	406-417	false
haloperidol	393-403	lamotrigine	420-430	false
haloperidol	393-403	levothyroxine	433-445	false
haloperidol	393-403	lorazepam	448-456	false
haloperidol	393-403	methadone	459-467	false
haloperidol	393-403	midazolam	470-478	false
haloperidol	393-403	mirtazapine	481-491	false
haloperidol	393-403	nortriptyline	494-506	false
haloperidol	393-403	olanzapine	509-518	false
haloperidol	393-403	contraceptives	526-539	false
haloperidol	393-403	oxcarbazepine	545-557	false
haloperidol	393-403	Phenytoin	560-568	false
haloperidol	393-403	praziquantel	574-585	false
haloperidol	393-403	protease inhibitors	588-606	false
haloperidol	393-403	quetiapine	609-618	false
haloperidol	393-403	risperidone	621-631	false
haloperidol	393-403	theophylline	634-645	false
haloperidol	393-403	topiramate	648-657	false
haloperidol	393-403	tiagabine	660-668	false
haloperidol	393-403	tramadol	671-678	false
haloperidol	393-403	triazolam	681-689	false
haloperidol	393-403	valproate	692-700	false
haloperidol	393-403	warfarin	703-710	false
haloperidol	393-403	ziprasidone	717-727	false
haloperidol	393-403	zonisamide	734-743	false
itraconazole	406-417	lamotrigine	420-430	false
itraconazole	406-417	levothyroxine	433-445	false
itraconazole	406-417	lorazepam	448-456	false
itraconazole	406-417	methadone	459-467	false
itraconazole	406-417	midazolam	470-478	false
itraconazole	406-417	mirtazapine	481-491	false
itraconazole	406-417	nortriptyline	494-506	false
itraconazole	406-417	olanzapine	509-518	false
itraconazole	406-417	contraceptives	526-539	false
itraconazole	406-417	oxcarbazepine	545-557	false
itraconazole	406-417	Phenytoin	560-568	false
itraconazole	406-417	praziquantel	574-585	false
itraconazole	406-417	protease inhibitors	588-606	false
itraconazole	406-417	quetiapine	609-618	false
itraconazole	406-417	risperidone	621-631	false
itraconazole	406-417	theophylline	634-645	false
itraconazole	406-417	topiramate	648-657	false
itraconazole	406-417	tiagabine	660-668	false
itraconazole	406-417	tramadol	671-678	false
itraconazole	406-417	triazolam	681-689	false
itraconazole	406-417	valproate	692-700	false
itraconazole	406-417	warfarin	703-710	false
itraconazole	406-417	ziprasidone	717-727	false
itraconazole	406-417	zonisamide	734-743	false
lamotrigine	420-430	levothyroxine	433-445	false
lamotrigine	420-430	lorazepam	448-456	false
lamotrigine	420-430	methadone	459-467	false
lamotrigine	420-430	midazolam	470-478	false
lamotrigine	420-430	mirtazapine	481-491	false
lamotrigine	420-430	nortriptyline	494-506	false
lamotrigine	420-430	olanzapine	509-518	false
lamotrigine	420-430	contraceptives	526-539	false
lamotrigine	420-430	oxcarbazepine	545-557	false
lamotrigine	420-430	Phenytoin	560-568	false
lamotrigine	420-430	praziquantel	574-585	false
lamotrigine	420-430	protease inhibitors	588-606	false
lamotrigine	420-430	quetiapine	609-618	false
lamotrigine	420-430	risperidone	621-631	false
lamotrigine	420-430	theophylline	634-645	false
lamotrigine	420-430	topiramate	648-657	false
lamotrigine	420-430	tiagabine	660-668	false
lamotrigine	420-430	tramadol	671-678	false
lamotrigine	420-430	triazolam	681-689	false
lamotrigine	420-430	valproate	692-700	false
lamotrigine	420-430	warfarin	703-710	false
lamotrigine	420-430	ziprasidone	717-727	false
lamotrigine	420-430	zonisamide	734-743	false
levothyroxine	433-445	lorazepam	448-456	false
levothyroxine	433-445	methadone	459-467	false
levothyroxine	433-445	midazolam	470-478	false
levothyroxine	433-445	mirtazapine	481-491	false
levothyroxine	433-445	nortriptyline	494-506	false
levothyroxine	433-445	olanzapine	509-518	false
levothyroxine	433-445	contraceptives	526-539	false
levothyroxine	433-445	oxcarbazepine	545-557	false
levothyroxine	433-445	Phenytoin	560-568	false
levothyroxine	433-445	praziquantel	574-585	false
levothyroxine	433-445	protease inhibitors	588-606	false
levothyroxine	433-445	quetiapine	609-618	false
levothyroxine	433-445	risperidone	621-631	false
levothyroxine	433-445	theophylline	634-645	false
levothyroxine	433-445	topiramate	648-657	false
levothyroxine	433-445	tiagabine	660-668	false
levothyroxine	433-445	tramadol	671-678	false
levothyroxine	433-445	triazolam	681-689	false
levothyroxine	433-445	valproate	692-700	false
levothyroxine	433-445	warfarin	703-710	false
levothyroxine	433-445	ziprasidone	717-727	false
levothyroxine	433-445	zonisamide	734-743	false
lorazepam	448-456	methadone	459-467	false
lorazepam	448-456	midazolam	470-478	false
lorazepam	448-456	mirtazapine	481-491	false
lorazepam	448-456	nortriptyline	494-506	false
lorazepam	448-456	olanzapine	509-518	false
lorazepam	448-456	contraceptives	526-539	false
lorazepam	448-456	oxcarbazepine	545-557	false
lorazepam	448-456	Phenytoin	560-568	false
lorazepam	448-456	praziquantel	574-585	false
lorazepam	448-456	protease inhibitors	588-606	false
lorazepam	448-456	quetiapine	609-618	false
lorazepam	448-456	risperidone	621-631	false
lorazepam	448-456	theophylline	634-645	false
lorazepam	448-456	topiramate	648-657	false
lorazepam	448-456	tiagabine	660-668	false
lorazepam	448-456	tramadol	671-678	false
lorazepam	448-456	triazolam	681-689	false
lorazepam	448-456	valproate	692-700	false
lorazepam	448-456	warfarin	703-710	false
lorazepam	448-456	ziprasidone	717-727	false
lorazepam	448-456	zonisamide	734-743	false
methadone	459-467	midazolam	470-478	false
methadone	459-467	mirtazapine	481-491	false
methadone	459-467	nortriptyline	494-506	false
methadone	459-467	olanzapine	509-518	false
methadone	459-467	contraceptives	526-539	false
methadone	459-467	oxcarbazepine	545-557	false
methadone	459-467	Phenytoin	560-568	false
methadone	459-467	praziquantel	574-585	false
methadone	459-467	protease inhibitors	588-606	false
methadone	459-467	quetiapine	609-618	false
methadone	459-467	risperidone	621-631	false
methadone	459-467	theophylline	634-645	false
methadone	459-467	topiramate	648-657	false
methadone	459-467	tiagabine	660-668	false
methadone	459-467	tramadol	671-678	false
methadone	459-467	triazolam	681-689	false
methadone	459-467	valproate	692-700	false
methadone	459-467	warfarin	703-710	false
methadone	459-467	ziprasidone	717-727	false
methadone	459-467	zonisamide	734-743	false
midazolam	470-478	mirtazapine	481-491	false
midazolam	470-478	nortriptyline	494-506	false
midazolam	470-478	olanzapine	509-518	false
midazolam	470-478	contraceptives	526-539	false
midazolam	470-478	oxcarbazepine	545-557	false
midazolam	470-478	Phenytoin	560-568	false
midazolam	470-478	praziquantel	574-585	false
midazolam	470-478	protease inhibitors	588-606	false
midazolam	470-478	quetiapine	609-618	false
midazolam	470-478	risperidone	621-631	false
midazolam	470-478	theophylline	634-645	false
midazolam	470-478	topiramate	648-657	false
midazolam	470-478	tiagabine	660-668	false
midazolam	470-478	tramadol	671-678	false
midazolam	470-478	triazolam	681-689	false
midazolam	470-478	valproate	692-700	false
midazolam	470-478	warfarin	703-710	false
midazolam	470-478	ziprasidone	717-727	false
midazolam	470-478	zonisamide	734-743	false
mirtazapine	481-491	nortriptyline	494-506	false
mirtazapine	481-491	olanzapine	509-518	false
mirtazapine	481-491	contraceptives	526-539	false
mirtazapine	481-491	oxcarbazepine	545-557	false
mirtazapine	481-491	Phenytoin	560-568	false
mirtazapine	481-491	praziquantel	574-585	false
mirtazapine	481-491	protease inhibitors	588-606	false
mirtazapine	481-491	quetiapine	609-618	false
mirtazapine	481-491	risperidone	621-631	false
mirtazapine	481-491	theophylline	634-645	false
mirtazapine	481-491	topiramate	648-657	false
mirtazapine	481-491	tiagabine	660-668	false
mirtazapine	481-491	tramadol	671-678	false
mirtazapine	481-491	triazolam	681-689	false
mirtazapine	481-491	valproate	692-700	false
mirtazapine	481-491	warfarin	703-710	false
mirtazapine	481-491	ziprasidone	717-727	false
mirtazapine	481-491	zonisamide	734-743	false
nortriptyline	494-506	olanzapine	509-518	false
nortriptyline	494-506	contraceptives	526-539	false
nortriptyline	494-506	oxcarbazepine	545-557	false
nortriptyline	494-506	Phenytoin	560-568	false
nortriptyline	494-506	praziquantel	574-585	false
nortriptyline	494-506	protease inhibitors	588-606	false
nortriptyline	494-506	quetiapine	609-618	false
nortriptyline	494-506	risperidone	621-631	false
nortriptyline	494-506	theophylline	634-645	false
nortriptyline	494-506	topiramate	648-657	false
nortriptyline	494-506	tiagabine	660-668	false
nortriptyline	494-506	tramadol	671-678	false
nortriptyline	494-506	triazolam	681-689	false
nortriptyline	494-506	valproate	692-700	false
nortriptyline	494-506	warfarin	703-710	false
nortriptyline	494-506	ziprasidone	717-727	false
nortriptyline	494-506	zonisamide	734-743	false
olanzapine	509-518	contraceptives	526-539	false
olanzapine	509-518	oxcarbazepine	545-557	false
olanzapine	509-518	Phenytoin	560-568	false
olanzapine	509-518	praziquantel	574-585	false
olanzapine	509-518	protease inhibitors	588-606	false
olanzapine	509-518	quetiapine	609-618	false
olanzapine	509-518	risperidone	621-631	false
olanzapine	509-518	theophylline	634-645	false
olanzapine	509-518	topiramate	648-657	false
olanzapine	509-518	tiagabine	660-668	false
olanzapine	509-518	tramadol	671-678	false
olanzapine	509-518	triazolam	681-689	false
olanzapine	509-518	valproate	692-700	false
olanzapine	509-518	warfarin	703-710	false
olanzapine	509-518	ziprasidone	717-727	false
olanzapine	509-518	zonisamide	734-743	false
contraceptives	526-539	oxcarbazepine	545-557	false
contraceptives	526-539	Phenytoin	560-568	false
contraceptives	526-539	praziquantel	574-585	false
contraceptives	526-539	protease inhibitors	588-606	false
contraceptives	526-539	quetiapine	609-618	false
contraceptives	526-539	risperidone	621-631	false
contraceptives	526-539	theophylline	634-645	false
contraceptives	526-539	topiramate	648-657	false
contraceptives	526-539	tiagabine	660-668	false
contraceptives	526-539	tramadol	671-678	false
contraceptives	526-539	triazolam	681-689	false
contraceptives	526-539	valproate	692-700	false
contraceptives	526-539	warfarin	703-710	false
contraceptives	526-539	ziprasidone	717-727	false
contraceptives	526-539	zonisamide	734-743	false
oxcarbazepine	545-557	Phenytoin	560-568	false
oxcarbazepine	545-557	praziquantel	574-585	false
oxcarbazepine	545-557	protease inhibitors	588-606	false
oxcarbazepine	545-557	quetiapine	609-618	false
oxcarbazepine	545-557	risperidone	621-631	false
oxcarbazepine	545-557	theophylline	634-645	false
oxcarbazepine	545-557	topiramate	648-657	false
oxcarbazepine	545-557	tiagabine	660-668	false
oxcarbazepine	545-557	tramadol	671-678	false
oxcarbazepine	545-557	triazolam	681-689	false
oxcarbazepine	545-557	valproate	692-700	false
oxcarbazepine	545-557	warfarin	703-710	false
oxcarbazepine	545-557	ziprasidone	717-727	false
oxcarbazepine	545-557	zonisamide	734-743	false
Phenytoin	560-568	praziquantel	574-585	false
Phenytoin	560-568	protease inhibitors	588-606	false
Phenytoin	560-568	quetiapine	609-618	false
Phenytoin	560-568	risperidone	621-631	false
Phenytoin	560-568	theophylline	634-645	false
Phenytoin	560-568	topiramate	648-657	false
Phenytoin	560-568	tiagabine	660-668	false
Phenytoin	560-568	tramadol	671-678	false
Phenytoin	560-568	triazolam	681-689	false
Phenytoin	560-568	valproate	692-700	false
Phenytoin	560-568	warfarin	703-710	false
Phenytoin	560-568	ziprasidone	717-727	false
Phenytoin	560-568	zonisamide	734-743	false
praziquantel	574-585	protease inhibitors	588-606	false
praziquantel	574-585	quetiapine	609-618	false
praziquantel	574-585	risperidone	621-631	false
praziquantel	574-585	theophylline	634-645	false
praziquantel	574-585	topiramate	648-657	false
praziquantel	574-585	tiagabine	660-668	false
praziquantel	574-585	tramadol	671-678	false
praziquantel	574-585	triazolam	681-689	false
praziquantel	574-585	valproate	692-700	false
praziquantel	574-585	warfarin	703-710	false
praziquantel	574-585	ziprasidone	717-727	false
praziquantel	574-585	zonisamide	734-743	false
protease inhibitors	588-606	quetiapine	609-618	false
protease inhibitors	588-606	risperidone	621-631	false
protease inhibitors	588-606	theophylline	634-645	false
protease inhibitors	588-606	topiramate	648-657	false
protease inhibitors	588-606	tiagabine	660-668	false
protease inhibitors	588-606	tramadol	671-678	false
protease inhibitors	588-606	triazolam	681-689	false
protease inhibitors	588-606	valproate	692-700	false
protease inhibitors	588-606	warfarin	703-710	false
protease inhibitors	588-606	ziprasidone	717-727	false
protease inhibitors	588-606	zonisamide	734-743	false
quetiapine	609-618	risperidone	621-631	false
quetiapine	609-618	theophylline	634-645	false
quetiapine	609-618	topiramate	648-657	false
quetiapine	609-618	tiagabine	660-668	false
quetiapine	609-618	tramadol	671-678	false
quetiapine	609-618	triazolam	681-689	false
quetiapine	609-618	valproate	692-700	false
quetiapine	609-618	warfarin	703-710	false
quetiapine	609-618	ziprasidone	717-727	false
quetiapine	609-618	zonisamide	734-743	false
risperidone	621-631	theophylline	634-645	false
risperidone	621-631	topiramate	648-657	false
risperidone	621-631	tiagabine	660-668	false
risperidone	621-631	tramadol	671-678	false
risperidone	621-631	triazolam	681-689	false
risperidone	621-631	valproate	692-700	false
risperidone	621-631	warfarin	703-710	false
risperidone	621-631	ziprasidone	717-727	false
risperidone	621-631	zonisamide	734-743	false
theophylline	634-645	topiramate	648-657	false
theophylline	634-645	tiagabine	660-668	false
theophylline	634-645	tramadol	671-678	false
theophylline	634-645	triazolam	681-689	false
theophylline	634-645	valproate	692-700	false
theophylline	634-645	warfarin	703-710	false
theophylline	634-645	ziprasidone	717-727	false
theophylline	634-645	zonisamide	734-743	false
topiramate	648-657	tiagabine	660-668	false
topiramate	648-657	tramadol	671-678	false
topiramate	648-657	triazolam	681-689	false
topiramate	648-657	valproate	692-700	false
topiramate	648-657	warfarin	703-710	false
topiramate	648-657	ziprasidone	717-727	false
topiramate	648-657	zonisamide	734-743	false
tiagabine	660-668	tramadol	671-678	false
tiagabine	660-668	triazolam	681-689	false
tiagabine	660-668	valproate	692-700	false
tiagabine	660-668	warfarin	703-710	false
tiagabine	660-668	ziprasidone	717-727	false
tiagabine	660-668	zonisamide	734-743	false
tramadol	671-678	triazolam	681-689	false
tramadol	671-678	valproate	692-700	false
tramadol	671-678	warfarin	703-710	false
tramadol	671-678	ziprasidone	717-727	false
tramadol	671-678	zonisamide	734-743	false
triazolam	681-689	valproate	692-700	false
triazolam	681-689	warfarin	703-710	false
triazolam	681-689	ziprasidone	717-727	false
triazolam	681-689	zonisamide	734-743	false
valproate	692-700	warfarin	703-710	false
valproate	692-700	ziprasidone	717-727	false
valproate	692-700	zonisamide	734-743	false
warfarin	703-710	ziprasidone	717-727	false
warfarin	703-710	zonisamide	734-743	false
ziprasidone	717-727	zonisamide	734-743	false

Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
Carbamazepine	48-60	EQUETROTM	63-71	false
Carbamazepine	48-60	Clomipramine HCl	126-141	false
Carbamazepine	48-60	Phenytoin	144-152	false
Carbamazepine	48-60	primidone	162-170	false
Carbamazepine	48-60	EQUETROTM	314-322	false
EQUETROTM	63-71	Clomipramine HCl	126-141	mechanism
EQUETROTM	63-71	Phenytoin	144-152	mechanism
EQUETROTM	63-71	primidone	162-170	mechanism
EQUETROTM	63-71	EQUETROTM	314-322	false
Clomipramine HCl	126-141	Phenytoin	144-152	false
Clomipramine HCl	126-141	primidone	162-170	false
Clomipramine HCl	126-141	EQUETROTM	314-322	false
Phenytoin	144-152	primidone	162-170	false
Phenytoin	144-152	EQUETROTM	314-322	false
primidone	162-170	EQUETROTM	314-322	false

Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
Carbamazepine	50-62	carbamazepine	94-106	false
Carbamazepine	50-62	lithium	112-118	false
carbamazepine	94-106	lithium	112-118	effect

Given the anticonvulsant properties of carbamazepine, EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants.
carbamazepine	39-51	EQUETROTM	54-62	false
carbamazepine	39-51	anticonvulsants	128-142	false
EQUETROTM	54-62	anticonvulsants	128-142	false

Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
anti-malarial drugs	14-32	chloroquine	43-53	false
anti-malarial drugs	14-32	mefloquine	59-68	false
anti-malarial drugs	14-32	carbamazepine	102-114	effect
chloroquine	43-53	mefloquine	59-68	false
chloroquine	43-53	carbamazepine	102-114	effect
mefloquine	59-68	carbamazepine	102-114	effect

Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
EQUETROTM	63-71	centrally acting drugs	93-114	advise
EQUETROTM	63-71	alcohol	120-126	advise
centrally acting drugs	93-114	alcohol	120-126	false

Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
Geocillin	0-8	carbenicillin indanyl sodium	11-38	false
Geocillin	0-8	probenecid	117-126	mechanism
carbenicillin indanyl sodium	11-38	probenecid	117-126	mechanism

Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.
LODOSYN	89-95	Carbidopa	98-106	false
LODOSYN	89-95	levodopa	120-127	false
LODOSYN	89-95	carbidopa	132-140	false
LODOSYN	89-95	levodopa	142-149	false
Carbidopa	98-106	levodopa	120-127	false
Carbidopa	98-106	carbidopa	132-140	false
Carbidopa	98-106	levodopa	142-149	false
levodopa	120-127	carbidopa	132-140	false
levodopa	120-127	levodopa	142-149	false
carbidopa	132-140	levodopa	142-149	false

Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
Dopamine D2 receptor antagonists	0-31	phenothiazines	40-53	false
Dopamine D2 receptor antagonists	0-31	butyrophenones	56-69	false
Dopamine D2 receptor antagonists	0-31	risperidone	72-82	false
Dopamine D2 receptor antagonists	0-31	isoniazid	89-97	false
Dopamine D2 receptor antagonists	0-31	levodopa	137-144	effect
phenothiazines	40-53	butyrophenones	56-69	false
phenothiazines	40-53	risperidone	72-82	false
phenothiazines	40-53	isoniazid	89-97	false
phenothiazines	40-53	levodopa	137-144	effect
butyrophenones	56-69	risperidone	72-82	false
butyrophenones	56-69	isoniazid	89-97	false
butyrophenones	56-69	levodopa	137-144	effect
risperidone	72-82	isoniazid	89-97	false
risperidone	72-82	levodopa	137-144	effect
isoniazid	89-97	levodopa	137-144	effect

In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
levodopa	39-46	phenytoin	107-115	effect
levodopa	39-46	papaverine	121-130	effect
phenytoin	107-115	papaverine	121-130	false

Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
LODOSYN	33-39	levodopa	45-52	false
LODOSYN	33-39	carbidopa	57-65	false
LODOSYN	33-39	levodopa	67-74	false
levodopa	45-52	carbidopa	57-65	false
levodopa	45-52	levodopa	67-74	false
carbidopa	57-65	levodopa	67-74	false

Iron salts may reduce the bioavailability of carbidopa and levodopa.
Iron	0-3	carbidopa	45-53	mechanism
Iron	0-3	levodopa	59-66	mechanism
carbidopa	45-53	levodopa	59-66	false

Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
metoclopramide	9-22	levodopa	60-67	mechanism
metoclopramide	9-22	metoclopramide	101-114	false
levodopa	60-67	metoclopramide	101-114	false

Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
Iodine	0-5	iodine	10-15	false
Iodine	0-5	Carbimazole	51-61	effect
Iodine	0-5	iodine	71-76	false
Iodine	0-5	Carbimazole	116-126	false
iodine	10-15	Carbimazole	51-61	false
iodine	10-15	iodine	71-76	false
iodine	10-15	Carbimazole	116-126	false
Carbimazole	51-61	iodine	71-76	false
Carbimazole	51-61	Carbimazole	116-126	false
iodine	71-76	Carbimazole	116-126	effect

Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
digoxin	23-29	digitoxin	35-43	false
digoxin	23-29	antithyroid agents	77-94	mechanism
digitoxin	35-43	antithyroid agents	77-94	mechanism

Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
Antithyroid agents	0-17	sodium iodide I131	52-69	effect
Antithyroid agents	0-17	Carbimazole	142-152	false
sodium iodide I131	52-69	Carbimazole	142-152	false

Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
Antihistamines	0-13	tricyclic antidepressants	42-66	effect
Antihistamines	0-13	barbiturates	69-80	effect
Antihistamines	0-13	alcohol	83-89	effect
Antihistamines	0-13	CNS depressants	102-116	effect
tricyclic antidepressants	42-66	barbiturates	69-80	false
tricyclic antidepressants	42-66	alcohol	83-89	false
tricyclic antidepressants	42-66	CNS depressants	102-116	false
barbiturates	69-80	alcohol	83-89	false
barbiturates	69-80	CNS depressants	102-116	false
alcohol	83-89	CNS depressants	102-116	false

MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
MAO inhibitors	0-13	antihistamines	68-81	effect

Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
Sympathomimetic amines	0-21	reserpine	66-74	effect
Sympathomimetic amines	0-21	veratrum alkaloids	77-94	effect
Sympathomimetic amines	0-21	methyldopa	97-106	effect
Sympathomimetic amines	0-21	mecamylamine	112-123	effect
reserpine	66-74	veratrum alkaloids	77-94	false
reserpine	66-74	methyldopa	97-106	false
reserpine	66-74	mecamylamine	112-123	false
veratrum alkaloids	77-94	methyldopa	97-106	false
veratrum alkaloids	77-94	mecamylamine	112-123	false
methyldopa	97-106	mecamylamine	112-123	false

Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
sympathomimetics	11-26	MAO inhibitors	47-60	effect
sympathomimetics	11-26	beta adrenergic blockers	66-89	effect
MAO inhibitors	47-60	beta adrenergic blockers	66-89	false

HEMABATE may augment the activity of other oxytocic agents.
HEMABATE	0-7	oxytocic agents	43-57	effect

Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
Ocupress	0-7	beta-adrenergic blocking agent	69-98	advise

Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
beta-blocker	55-66	reserpine	144-152	advise

poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
debrisoquin	21-31	carvedilol	50-59	false
debrisoquin	21-31	quinidine	103-111	false
debrisoquin	21-31	fluoxetine	114-123	false
debrisoquin	21-31	paroxetine	126-135	false
debrisoquin	21-31	propafenone	142-152	false
debrisoquin	21-31	carvedilol	263-272	false
carvedilol	50-59	quinidine	103-111	false
carvedilol	50-59	fluoxetine	114-123	false
carvedilol	50-59	paroxetine	126-135	false
carvedilol	50-59	propafenone	142-152	false
carvedilol	50-59	carvedilol	263-272	false
quinidine	103-111	fluoxetine	114-123	false
quinidine	103-111	paroxetine	126-135	false
quinidine	103-111	propafenone	142-152	false
quinidine	103-111	carvedilol	263-272	effect
fluoxetine	114-123	paroxetine	126-135	false
fluoxetine	114-123	propafenone	142-152	false
fluoxetine	114-123	carvedilol	263-272	effect
paroxetine	126-135	propafenone	142-152	false
paroxetine	126-135	carvedilol	263-272	effect
propafenone	142-152	carvedilol	263-272	effect

Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
agents with b-blocking properties	53-85	reserpine	137-145	effect
agents with b-blocking properties	53-85	monoamine oxidase inhibitors	151-178	effect
reserpine	137-145	monoamine oxidase inhibitors	151-178	false

Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
Clonidine	0-8	clonidine	41-49	false
Clonidine	0-8	agents with b-blocking properties	56-88	false
clonidine	41-49	agents with b-blocking properties	56-88	effect

When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
agents with b-blocking properties	32-64	clonidine	70-78	advise
agents with b-blocking properties	32-64	b-blocking agent	105-120	false
clonidine	70-78	b-blocking agent	105-120	false

Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
Cyclosporine	0-11	cyclosporine	46-57	false
Cyclosporine	0-11	carvedilol	112-121	false
cyclosporine	46-57	carvedilol	112-121	mechanism

In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.
cyclosporine	38-49	cyclosporine	90-101	false

Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
cyclosporine	96-107	carvedilol	165-174	advise
cyclosporine	96-107	cyclosporine	205-216	false
carvedilol	165-174	cyclosporine	205-216	advise

Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
Digoxin	0-6	Digoxin	9-15	false
Digoxin	0-6	digoxin	64-70	false
Digoxin	0-6	carvedilol	76-85	false
Digoxin	9-15	digoxin	64-70	false
Digoxin	9-15	carvedilol	76-85	false
digoxin	64-70	carvedilol	76-85	mechanism

Both digoxin and COREG slow AV conduction.
digoxin	5-11	COREG	17-21	effect

Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
digoxin	35-41	COREG	103-107	advise

Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
Rifampin	47-54	carvedilol	89-98	mechanism

Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
Calcium Channel Blockers	0-23	COREG	128-132	false
Calcium Channel Blockers	0-23	diltiazem	158-166	false
COREG	128-132	diltiazem	158-166	effect

As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
agents with b-blocking properties	14-46	COREG	52-56	false
agents with b-blocking properties	14-46	calcium channel blockers	92-115	false
agents with b-blocking properties	14-46	verapamil	124-132	false
agents with b-blocking properties	14-46	diltiazem	137-145	false
COREG	52-56	calcium channel blockers	92-115	false
COREG	52-56	verapamil	124-132	advise
COREG	52-56	diltiazem	137-145	advise
calcium channel blockers	92-115	verapamil	124-132	false
calcium channel blockers	92-115	diltiazem	137-145	false
verapamil	124-132	diltiazem	137-145	false

Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
Insulin	0-6	Hypoglycemics	16-28	false
Insulin	0-6	Agents with b-blocking properties	31-63	false
Insulin	0-6	insulin	112-118	false
Insulin	0-6	hypoglycemics	129-141	false
Hypoglycemics	16-28	Agents with b-blocking properties	31-63	false
Hypoglycemics	16-28	insulin	112-118	false
Hypoglycemics	16-28	hypoglycemics	129-141	false
Agents with b-blocking properties	31-63	insulin	112-118	effect
Agents with b-blocking properties	31-63	hypoglycemics	129-141	effect
insulin	112-118	hypoglycemics	129-141	false

Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.
insulin	30-36	hypoglycemics	46-58	false

Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
CANCIDAS	73-80	itraconazole	101-112	false
CANCIDAS	73-80	amphotericin B	115-128	false
CANCIDAS	73-80	mycophenolate	131-143	false
CANCIDAS	73-80	nelfinavir	146-155	false
CANCIDAS	73-80	tacrolimus	161-170	false
itraconazole	101-112	amphotericin B	115-128	false
itraconazole	101-112	mycophenolate	131-143	false
itraconazole	101-112	nelfinavir	146-155	false
itraconazole	101-112	tacrolimus	161-170	false
amphotericin B	115-128	mycophenolate	131-143	false
amphotericin B	115-128	nelfinavir	146-155	false
amphotericin B	115-128	tacrolimus	161-170	false
mycophenolate	131-143	nelfinavir	146-155	false
mycophenolate	131-143	tacrolimus	161-170	false
nelfinavir	146-155	tacrolimus	161-170	false

CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.
CANCIDAS	0-7	itraconazole	50-61	false
CANCIDAS	0-7	amphotericin B	64-77	false
itraconazole	50-61	amphotericin B	64-77	false

CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
CANCIDAS	0-7	tacrolimus	38-47	mechanism
CANCIDAS	0-7	tacrolimus	183-192	false
CANCIDAS	0-7	CANCIDAS	268-275	false
CANCIDAS	0-7	tacrolimus	344-353	false
tacrolimus	38-47	tacrolimus	183-192	false
tacrolimus	38-47	CANCIDAS	268-275	false
tacrolimus	38-47	tacrolimus	344-353	false
tacrolimus	183-192	CANCIDAS	268-275	false
tacrolimus	183-192	tacrolimus	344-353	false
CANCIDAS	268-275	tacrolimus	344-353	false

For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
tacrolimus	62-71	tacrolimus	110-119	false

In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
cyclosporine	25-36	caspofungin	99-109	mechanism

CANCIDAS did not increase the plasma levels of cyclosporine.
CANCIDAS	0-7	cyclosporine	47-58	false

There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
CANCIDAS	57-64	cyclosporine	70-81	effect

A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.
rifampin	35-42	caspofungin	94-104	mechanism

Patients on rifampin should receive 70 mg of CANCIDAS daily.
rifampin	12-19	CANCIDAS	45-52	advise

In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
efavirenz	146-154	nevirapine	157-166	false
efavirenz	146-154	phenytoin	169-177	false
efavirenz	146-154	dexamethasone	180-192	false
efavirenz	146-154	carbamazepine	198-210	false
efavirenz	146-154	CANCIDAS	218-225	mechanism
efavirenz	146-154	caspofungin	277-287	false
nevirapine	157-166	phenytoin	169-177	false
nevirapine	157-166	dexamethasone	180-192	false
nevirapine	157-166	carbamazepine	198-210	false
nevirapine	157-166	CANCIDAS	218-225	mechanism
nevirapine	157-166	caspofungin	277-287	false
phenytoin	169-177	dexamethasone	180-192	false
phenytoin	169-177	carbamazepine	198-210	false
phenytoin	169-177	CANCIDAS	218-225	mechanism
phenytoin	169-177	caspofungin	277-287	false
dexamethasone	180-192	carbamazepine	198-210	false
dexamethasone	180-192	CANCIDAS	218-225	mechanism
dexamethasone	180-192	caspofungin	277-287	false
carbamazepine	198-210	CANCIDAS	218-225	mechanism
carbamazepine	198-210	caspofungin	277-287	false
CANCIDAS	218-225	caspofungin	277-287	false

When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
CANCIDAS	5-12	efavirenz	74-82	advise
CANCIDAS	5-12	nevirapine	85-94	advise
CANCIDAS	5-12	phenytoin	97-105	advise
CANCIDAS	5-12	dexamethasone	108-120	advise
CANCIDAS	5-12	carbamazepine	126-138	advise
CANCIDAS	5-12	CANCIDAS	173-180	false
efavirenz	74-82	nevirapine	85-94	false
efavirenz	74-82	phenytoin	97-105	false
efavirenz	74-82	dexamethasone	108-120	false
efavirenz	74-82	carbamazepine	126-138	false
efavirenz	74-82	CANCIDAS	173-180	false
nevirapine	85-94	phenytoin	97-105	false
nevirapine	85-94	dexamethasone	108-120	false
nevirapine	85-94	carbamazepine	126-138	false
nevirapine	85-94	CANCIDAS	173-180	false
phenytoin	97-105	dexamethasone	108-120	false
phenytoin	97-105	carbamazepine	126-138	false
phenytoin	97-105	CANCIDAS	173-180	false
dexamethasone	108-120	carbamazepine	126-138	false
dexamethasone	108-120	CANCIDAS	173-180	false
carbamazepine	126-138	CANCIDAS	173-180	false

Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
Probenecid	0-9	cephalosporins	51-64	mechanism
Probenecid	0-9	cephalosporin	132-144	false
cephalosporins	51-64	cephalosporin	132-144	false

Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
Antacids	0-7	aluminum	10-17	false
Antacids	0-7	magnesium	23-31	false
Antacids	0-7	cefdinir	83-90	false
Antacids	0-7	Maalox TC	112-120	false
aluminum	10-17	magnesium	23-31	false
aluminum	10-17	cefdinir	83-90	false
aluminum	10-17	Maalox TC	112-120	false
magnesium	23-31	cefdinir	83-90	false
magnesium	23-31	Maalox TC	112-120	false
cefdinir	83-90	Maalox TC	112-120	mechanism

There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.
cefdinir	36-43	antacid	69-75	false
cefdinir	36-43	cefdinir	125-132	false
antacid	69-75	cefdinir	125-132	false

If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.
antacids	3-10	OMNICEF	32-38	false
antacids	3-10	OMNICEF	49-55	false
antacids	3-10	antacid	110-116	false
OMNICEF	32-38	OMNICEF	49-55	false
OMNICEF	32-38	antacid	110-116	false
OMNICEF	49-55	antacid	110-116	advise

Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
Probenecid	0-9	b-lactam antibiotics	26-45	false
Probenecid	0-9	probenecid	48-57	false
Probenecid	0-9	cefdinir	91-98	false
Probenecid	0-9	cefdinir	169-176	false
b-lactam antibiotics	26-45	probenecid	48-57	false
b-lactam antibiotics	26-45	cefdinir	91-98	mechanism
b-lactam antibiotics	26-45	cefdinir	169-176	false
probenecid	48-57	cefdinir	91-98	mechanism
probenecid	48-57	cefdinir	169-176	false
cefdinir	91-98	cefdinir	169-176	false

Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
Iron Supplements	0-15	Iron	42-45	false
Iron Supplements	0-15	cefdinir	77-84	false
Iron Supplements	0-15	iron supplement	105-119	false
Iron Supplements	0-15	iron	151-154	false
Iron Supplements	0-15	vitamins	170-177	false
Iron Supplements	0-15	iron	216-219	false
Iron	42-45	cefdinir	77-84	false
Iron	42-45	iron supplement	105-119	false
Iron	42-45	iron	151-154	false
Iron	42-45	vitamins	170-177	false
Iron	42-45	iron	216-219	false
cefdinir	77-84	iron supplement	105-119	false
cefdinir	77-84	iron	151-154	mechanism
cefdinir	77-84	vitamins	170-177	false
cefdinir	77-84	iron	216-219	mechanism
iron supplement	105-119	iron	151-154	false
iron supplement	105-119	vitamins	170-177	false
iron supplement	105-119	iron	216-219	false
iron	151-154	vitamins	170-177	false
iron	151-154	iron	216-219	false
vitamins	170-177	iron	216-219	false

If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
iron supplements	3-18	OMNICEF	40-46	false
iron supplements	3-18	OMNICEF	57-63	advise
OMNICEF	40-46	OMNICEF	57-63	false

The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.
iron	52-55	iron	68-71	false
iron	52-55	cefdinir	105-112	false
iron	68-71	cefdinir	105-112	false

Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.
iron	27-30	iron	75-78	false
iron	27-30	cefdinir	115-122	false
iron	75-78	cefdinir	115-122	false

Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.
OMNICEF	11-17	iron	64-67	false

The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
cefdinir	77-84	iron	116-119	mechanism

Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.
nitroprusside	112-124	nitroferricyanide	152-168	false

Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
Contraceptives	5-18	cefditoren pivoxil	38-55	false
Contraceptives	5-18	ethinyl estradiol	98-114	false
Contraceptives	5-18	contraceptives	155-168	false
cefditoren pivoxil	38-55	ethinyl estradiol	98-114	false
cefditoren pivoxil	38-55	contraceptives	155-168	false
ethinyl estradiol	98-114	contraceptives	155-168	false

Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
cefditoren pivoxil	76-93	antacids	123-130	advise

H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
H2-Receptor Antagonists	0-22	famotidine	90-99	false
H2-Receptor Antagonists	0-22	cefditoren pivoxil	164-181	false
famotidine	90-99	cefditoren pivoxil	164-181	mechanism

Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.
cefditoren pivoxil	76-93	H2 receptor antagonists	123-145	false

Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
Probenecid	0-9	b-lactam antibiotics	26-45	false
Probenecid	0-9	probenecid	69-78	false
Probenecid	0-9	cefditoren pivoxil	85-102	false
Probenecid	0-9	cefditoren	154-163	false
b-lactam antibiotics	26-45	probenecid	69-78	false
b-lactam antibiotics	26-45	cefditoren pivoxil	85-102	mechanism
b-lactam antibiotics	26-45	cefditoren	154-163	false
probenecid	69-78	cefditoren pivoxil	85-102	mechanism
probenecid	69-78	cefditoren	154-163	false
cefditoren pivoxil	85-102	cefditoren	154-163	false

Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
aminoglycosides	62-76	MAXIPIME	106-113	advise
aminoglycosides	62-76	aminoglycoside antibiotics	187-212	false
MAXIPIME	106-113	aminoglycoside antibiotics	187-212	false

Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
cephalosporins	79-92	diuretics	106-114	effect
cephalosporins	79-92	furosemide	124-133	effect
diuretics	106-114	furosemide	124-133	false

Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
Carbamazepine	0-12	carbamazepine	24-36	false
Carbamazepine	0-12	SUPRAX	97-102	false
carbamazepine	24-36	SUPRAX	97-102	mechanism

Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
Warfarin	0-7	Anticoagulants	13-26	false
Warfarin	0-7	cefixime	115-122	effect
Anticoagulants	13-26	cefixime	115-122	effect

Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.
nitroprusside	112-124	nitroferricyanide	151-167	false

Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
cephalosporins	83-96	aminoglycoside antibiotics	102-127	effect

Drug/Laboratory Test Interactions Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombs test.
Cephalosporins	34-47	cefotaxime sodium	60-76	false

If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
CEFOTAN	3-9	aminoglycoside	18-31	effect

As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.
cephalosporins	14-27	cefotetan	53-61	false

Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
cephalosporins	83-96	aminoglycoside antibiotics	102-127	effect

Drug/Laboratory Test Interactions As with cephalothin, high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff  reaction, and produce false increases of modest degree in the levels of creatinine reported.
cephalothin	42-52	cefoxitin	78-86	false

Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
aminoglycoside antibiotics	73-98	cephalosporin antibiotics	104-128	effect

Concomitant administration of probenecid doubled the AUC for cefprozil.
probenecid	30-39	cefprozil	61-69	mechanism

The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.
cefprozil	50-58	antacid	118-124	false

Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
cephalosporins	73-86	aminoglycoside antibiotics	93-118	effect
cephalosporins	73-86	diuretics	130-138	effect
cephalosporins	73-86	furosemide	148-157	effect
aminoglycoside antibiotics	93-118	diuretics	130-138	false
aminoglycoside antibiotics	93-118	furosemide	148-157	false
diuretics	130-138	furosemide	148-157	false

Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics.
aminoglycosides	82-96	aminoglycosidic antibiotics	208-234	false

Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
Chloramphenicol	0-14	beta-lactam antibiotics	53-75	effect
Chloramphenicol	0-14	ceftazidime	88-98	effect
beta-lactam antibiotics	53-75	ceftazidime	88-98	false

Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.
Theophylline	0-11	ceftibuten	74-83	false

With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).
ceftibuten	25-34	theophylline	103-114	false

The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.
ceftibuten	14-23	theophylline	52-63	false

Antacids or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.
Antacids	0-7	H 2 -receptor antagonists	12-36	false
Antacids	0-7	ceftibuten	100-109	false
H 2 -receptor antagonists	12-36	ceftibuten	100-109	false

A single dose of liquid antacid did not affect the C max or AUC of ceftibuten;
antacid	24-30	ceftibuten	67-76	false

however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
ranitidine	19-28	ceftibuten	60-69	mechanism
ranitidine	19-28	ceftibuten	88-97	mechanism
ceftibuten	60-69	ceftibuten	88-97	false

The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40  g/mL.
ceftibuten	81-90	ceftibuten	168-177	false

Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
Cefizox	51-57	cephalosporins	139-152	false
Cefizox	51-57	aminoglycosides	158-172	false
cephalosporins	139-152	aminoglycosides	158-172	effect

Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
celecoxib	22-30	fluconazole	90-100	int
celecoxib	22-30	lithium	106-112	int
fluconazole	90-100	lithium	106-112	false

Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
nonsteroidal anti-inflammatory drugs	16-51	NSAIDs	54-59	false
nonsteroidal anti-inflammatory drugs	16-51	furosemide	107-116	int
nonsteroidal anti-inflammatory drugs	16-51	ACE inhibitors	122-135	int
NSAIDs	54-59	furosemide	107-116	int
NSAIDs	54-59	ACE inhibitors	122-135	int
furosemide	107-116	ACE inhibitors	122-135	false

The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
celecoxib	12-20	glyburide	73-81	false
celecoxib	12-20	ketoconazole	84-95	false
celecoxib	12-20	methotrexate	98-109	false
celecoxib	12-20	phenytoin	112-120	false
celecoxib	12-20	tolbutamide	123-133	false
celecoxib	12-20	warfarin	140-147	false
glyburide	73-81	ketoconazole	84-95	false
glyburide	73-81	methotrexate	98-109	false
glyburide	73-81	phenytoin	112-120	false
glyburide	73-81	tolbutamide	123-133	false
glyburide	73-81	warfarin	140-147	false
ketoconazole	84-95	methotrexate	98-109	false
ketoconazole	84-95	phenytoin	112-120	false
ketoconazole	84-95	tolbutamide	123-133	false
ketoconazole	84-95	warfarin	140-147	false
methotrexate	98-109	phenytoin	112-120	false
methotrexate	98-109	tolbutamide	123-133	false
methotrexate	98-109	warfarin	140-147	false
phenytoin	112-120	tolbutamide	123-133	false
phenytoin	112-120	warfarin	140-147	false
tolbutamide	123-133	warfarin	140-147	false

ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
ACE inhibitors	0-13	NSAIDs	37-42	false
ACE inhibitors	0-13	Angiotensin Converting Enzyme (ACE) inhibitors	88-133	false
NSAIDs	37-42	Angiotensin Converting Enzyme (ACE) inhibitors	88-133	effect

This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
CELEBREX	66-73	ACE-inhibitors	94-107	advise

Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	0-9	NSAIDs	86-91	false
Furosemide	0-9	furosemide	130-139	false
Furosemide	0-9	thiazides	145-153	false
NSAIDs	86-91	furosemide	130-139	effect
NSAIDs	86-91	thiazides	145-153	effect
furosemide	130-139	thiazides	145-153	false

Aspirin: CELEBREX can be used with low dose aspirin.
Aspirin	0-6	CELEBREX	9-16	false
Aspirin	0-6	aspirin	44-50	false
CELEBREX	9-16	aspirin	44-50	advise

However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
aspirin	39-45	CELEBREX	52-59	effect
aspirin	39-45	CELEBREX	153-160	false
CELEBREX	52-59	CELEBREX	153-160	false

Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.
CELEBREX	41-48	aspirin	74-80	false

Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
Fluconazole	0-10	fluconazole	43-53	false
Fluconazole	0-10	celecoxib	103-111	false
fluconazole	43-53	celecoxib	103-111	mechanism

This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
celecoxib	42-50	fluconazole	79-89	mechanism

CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
CELEBREX	0-7	fluconazole	83-93	advise

Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
Lithium	0-6	lithium	69-75	false
Lithium	0-6	lithium	141-147	false
Lithium	0-6	CELEBREX	165-172	false
Lithium	0-6	lithium	219-225	false
lithium	69-75	lithium	141-147	false
lithium	69-75	CELEBREX	165-172	false
lithium	69-75	lithium	219-225	false
lithium	141-147	CELEBREX	165-172	mechanism
lithium	141-147	lithium	219-225	false
CELEBREX	165-172	lithium	219-225	false

Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
lithium	12-18	CELEBREX	63-70	advise

Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.
Methotrexate	0-11	methotrexate	78-89	false
Methotrexate	0-11	CELEBREX	92-99	false
Methotrexate	0-11	methotrexate	162-173	false
methotrexate	78-89	CELEBREX	92-99	false
methotrexate	78-89	methotrexate	162-173	false
CELEBREX	92-99	methotrexate	162-173	false

Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
Warfarin	0-7	celecoxib	24-32	false
Warfarin	0-7	warfarin	66-73	false
Warfarin	0-7	warfarin	153-160	false
celecoxib	24-32	warfarin	66-73	false
celecoxib	24-32	warfarin	153-160	false
warfarin	66-73	warfarin	153-160	false

In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.
celecoxib	19-27	warfarin	71-78	false

However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
CELEBREX	51-58	warfarin	65-72	advise

Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
Metformin	0-8	cephalexin	60-69	false
Metformin	0-8	metformin	75-83	false
Metformin	0-8	metformin	93-101	false
Metformin	0-8	metformin	179-187	false
cephalexin	60-69	metformin	75-83	mechanism
cephalexin	60-69	metformin	93-101	false
cephalexin	60-69	metformin	179-187	false
metformin	75-83	metformin	93-101	false
metformin	75-83	metformin	179-187	false
metformin	93-101	metformin	179-187	false

No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.
cephalexin	53-62	metformin	68-76	false

Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
cephalexin	103-112	metformin	118-126	mechanism

Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
metformin	63-71	cephalexin	121-130	false
metformin	63-71	metformin	136-144	false
cephalexin	121-130	metformin	136-144	advise

Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
Probenecid	0-9	b-lactams	26-34	false
Probenecid	0-9	cephalexin	60-69	false
Probenecid	0-9	probenecid	87-96	false
b-lactams	26-34	cephalexin	60-69	false
b-lactams	26-34	probenecid	87-96	false
cephalexin	60-69	probenecid	87-96	mechanism

Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.
Immunosuppressive Drugs	0-22	Fibric Acid Derivatives	25-47	false
Immunosuppressive Drugs	0-22	Niacin	50-55	false
Immunosuppressive Drugs	0-22	Nicotinic Acid	58-71	false
Immunosuppressive Drugs	0-22	Erythromycin	74-85	false
Immunosuppressive Drugs	0-22	Azole Antifungals	88-104	false
Fibric Acid Derivatives	25-47	Niacin	50-55	false
Fibric Acid Derivatives	25-47	Nicotinic Acid	58-71	false
Fibric Acid Derivatives	25-47	Erythromycin	74-85	false
Fibric Acid Derivatives	25-47	Azole Antifungals	88-104	false
Niacin	50-55	Nicotinic Acid	58-71	false
Niacin	50-55	Erythromycin	74-85	false
Niacin	50-55	Azole Antifungals	88-104	false
Nicotinic Acid	58-71	Erythromycin	74-85	false
Nicotinic Acid	58-71	Azole Antifungals	88-104	false
Erythromycin	74-85	Azole Antifungals	88-104	false

ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.
ANTACID	0-6	Magnesium-Aluminum Hydroxide	9-36	false
ANTACID	0-6	Cerivastatin	40-51	false
ANTACID	0-6	antacid	117-123	false
Magnesium-Aluminum Hydroxide	9-36	Cerivastatin	40-51	false
Magnesium-Aluminum Hydroxide	9-36	antacid	117-123	false
Cerivastatin	40-51	antacid	117-123	false

CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.
CIMETlDINE	0-9	Cerivastatin	12-23	false
CIMETlDINE	0-9	cimetidine	89-98	false
Cerivastatin	12-23	cimetidine	89-98	false

CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.
CHOLESTYRAMINE	0-13	cholestyramine	65-78	false
CHOLESTYRAMINE	0-13	cerivastatin sodium	107-125	false
cholestyramine	65-78	cerivastatin sodium	107-125	false

In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
cerivastatin sodium	57-75	cholestyramine	86-99	mechanism
cerivastatin sodium	57-75	cerivastatin sodium	189-207	false
cholestyramine	86-99	cerivastatin sodium	189-207	false

However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
cholestyramine	53-66	cerivastatin sodium	110-128	mechanism
cholestyramine	53-66	cerivastatin	210-221	false
cholestyramine	53-66	cerivastatin sodium	304-322	false
cerivastatin sodium	110-128	cerivastatin	210-221	false
cerivastatin sodium	110-128	cerivastatin sodium	304-322	false
cerivastatin	210-221	cerivastatin sodium	304-322	false

Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.
cerivastatin sodium	58-76	cholestyramine	99-112	false
cerivastatin sodium	58-76	cerivastatin sodium	213-231	false
cholestyramine	99-112	cerivastatin sodium	213-231	false

DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
DIGOXIN	0-6	digoxin	16-22	false
DIGOXIN	0-6	digoxin	35-41	false
DIGOXIN	0-6	cerivastatin sodium	118-136	false
digoxin	16-22	digoxin	35-41	false
digoxin	16-22	cerivastatin sodium	118-136	false
digoxin	35-41	cerivastatin sodium	118-136	false

Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.
Cerivastatin	0-11	digoxin	82-88	false

WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.
WARFARIN	0-7	warfarin	32-39	false
WARFARIN	0-7	cerivastatin	45-56	false
WARFARIN	0-7	warfarin	191-198	false
warfarin	32-39	cerivastatin	45-56	false
warfarin	32-39	warfarin	191-198	false
cerivastatin	45-56	warfarin	191-198	false

The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.
warfarin	52-59	cerivastatin sodium	108-126	false

Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.
warfarin	21-28	cerivastatin	34-45	false
warfarin	21-28	cerivastatin sodium	85-103	false
cerivastatin	34-45	cerivastatin sodium	85-103	false

ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
ERYTHROMYCIN	0-11	cerivastatin	61-72	false
ERYTHROMYCIN	0-11	erythromycin	176-187	false
cerivastatin	61-72	erythromycin	176-187	mechanism

OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
cerivastatin sodium	106-124	angiotensin- converting enzyme (ACE) inhibitors	154-200	false
cerivastatin sodium	106-124	betablockers	203-214	false
cerivastatin sodium	106-124	calcium-channel blockers	217-240	false
cerivastatin sodium	106-124	diuretics	243-251	false
cerivastatin sodium	106-124	nonsteroidal anti-inflammatory drugs	258-293	false
cerivastatin sodium	106-124	NSAIDs	296-301	false
angiotensin- converting enzyme (ACE) inhibitors	154-200	betablockers	203-214	false
angiotensin- converting enzyme (ACE) inhibitors	154-200	calcium-channel blockers	217-240	false
angiotensin- converting enzyme (ACE) inhibitors	154-200	diuretics	243-251	false
angiotensin- converting enzyme (ACE) inhibitors	154-200	nonsteroidal anti-inflammatory drugs	258-293	false
angiotensin- converting enzyme (ACE) inhibitors	154-200	NSAIDs	296-301	false
betablockers	203-214	calcium-channel blockers	217-240	false
betablockers	203-214	diuretics	243-251	false
betablockers	203-214	nonsteroidal anti-inflammatory drugs	258-293	false
betablockers	203-214	NSAIDs	296-301	false
calcium-channel blockers	217-240	diuretics	243-251	false
calcium-channel blockers	217-240	nonsteroidal anti-inflammatory drugs	258-293	false
calcium-channel blockers	217-240	NSAIDs	296-301	false
diuretics	243-251	nonsteroidal anti-inflammatory drugs	258-293	false
diuretics	243-251	NSAIDs	296-301	false
nonsteroidal anti-inflammatory drugs	258-293	NSAIDs	296-301	false

Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.
cetirizine	41-50	pseudoephedrine	82-96	false
cetirizine	41-50	antipyrine	99-108	false
cetirizine	41-50	ketoconazole	111-122	false
cetirizine	41-50	erythromycin	125-136	false
cetirizine	41-50	azithromycin	142-153	false
pseudoephedrine	82-96	antipyrine	99-108	false
pseudoephedrine	82-96	ketoconazole	111-122	false
pseudoephedrine	82-96	erythromycin	125-136	false
pseudoephedrine	82-96	azithromycin	142-153	false
antipyrine	99-108	ketoconazole	111-122	false
antipyrine	99-108	erythromycin	125-136	false
antipyrine	99-108	azithromycin	142-153	false
ketoconazole	111-122	erythromycin	125-136	false
ketoconazole	111-122	azithromycin	142-153	false
erythromycin	125-136	azithromycin	142-153	false

In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
theophylline	28-39	cetirizine	76-85	mechanism
theophylline	28-39	cetirizine	153-162	false
cetirizine	76-85	cetirizine	153-162	false

The disposition of theophylline was not altered by concomitant cetirizine administration.
theophylline	19-30	cetirizine	63-72	false

Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.
theophylline	89-100	azithromycin	117-128	false
theophylline	89-100	pseudoephedrine	131-145	false
theophylline	89-100	ketoconazole	148-159	false
theophylline	89-100	erythromycin	165-176	false
azithromycin	117-128	pseudoephedrine	131-145	false
azithromycin	117-128	ketoconazole	148-159	false
azithromycin	117-128	erythromycin	165-176	false
pseudoephedrine	131-145	ketoconazole	148-159	false
pseudoephedrine	131-145	erythromycin	165-176	false
ketoconazole	148-159	erythromycin	165-176	false

There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
cetirizine	47-56	theophylline	85-96	mechanism

A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan.
ERBITUX	48-54	irinotecan	93-102	false

There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan.
ERBITUX	66-72	irinotecan	78-87	false

Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
Cevimeline	0-9	beta adrenergic antagonists	66-92	advise

Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.
anticoagulants	208-221	chlordiazepoxide	227-242	effect

The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
alcohol	23-29	central nervous system depressants	40-73	false

The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
anesthetic solutions	28-47	epinephrine	60-70	false
anesthetic solutions	28-47	norepinephrine	75-88	false
anesthetic solutions	28-47	monoamine oxidase inhibitors	112-139	false
anesthetic solutions	28-47	tricyclic antidepressants	142-166	effect
anesthetic solutions	28-47	phenothiazines	171-184	effect
epinephrine	60-70	norepinephrine	75-88	false
epinephrine	60-70	monoamine oxidase inhibitors	112-139	effect
epinephrine	60-70	tricyclic antidepressants	142-166	effect
epinephrine	60-70	phenothiazines	171-184	effect
norepinephrine	75-88	monoamine oxidase inhibitors	112-139	effect
norepinephrine	75-88	tricyclic antidepressants	142-166	effect
norepinephrine	75-88	phenothiazines	171-184	effect
monoamine oxidase inhibitors	112-139	tricyclic antidepressants	142-166	false
monoamine oxidase inhibitors	112-139	phenothiazines	171-184	false
tricyclic antidepressants	142-166	phenothiazines	171-184	false

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
vasopressor drugs	29-45	ergot-type oxytocic drugs	114-138	effect

Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.
chloroprocaine	11-24	sulfonamide drug	73-88	advise

Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
Ethoxzolamide	0-12	tricyclics	41-50	effect
Ethoxzolamide	0-12	amphetamines	53-64	effect
Ethoxzolamide	0-12	procainamide	67-78	effect
Ethoxzolamide	0-12	quinidine	85-93	effect
tricyclics	41-50	amphetamines	53-64	false
tricyclics	41-50	procainamide	67-78	false
tricyclics	41-50	quinidine	85-93	false
amphetamines	53-64	procainamide	67-78	false
amphetamines	53-64	quinidine	85-93	false
procainamide	67-78	quinidine	85-93	false

It may increase excretion of barbiturates, lithium, and ASA and may also increase the toxicity of salicylates.
barbiturates	29-40	lithium	43-49	false
barbiturates	29-40	ASA	56-58	false
barbiturates	29-40	salicylates	98-108	false
lithium	43-49	ASA	56-58	false
lithium	43-49	salicylates	98-108	false
ASA	56-58	salicylates	98-108	false

Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
ethoxzolamide	20-32	diuretics	45-53	effect
ethoxzolamide	20-32	amphotericin B	56-69	effect
ethoxzolamide	20-32	corticosteroids	76-90	effect
diuretics	45-53	amphotericin B	56-69	false
diuretics	45-53	corticosteroids	76-90	false
amphotericin B	56-69	corticosteroids	76-90	false

Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.
Acetaminophen	0-12	synthetic estrogens	52-70	mechanism

Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.
hormonal contraceptives	12-34	acetaminophen	82-94	mechanism

Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.
Acitretin	0-8	progestin	66-74	effect

Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.
Aminoglutethimide	0-16	progestins	50-59	mechanism

Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
Antibiotics	0-10	ampicillin	13-22	false
Antibiotics	0-10	tetracycline	25-36	false
Antibiotics	0-10	antibiotics	173-183	false
Antibiotics	0-10	synthetic steroids	213-230	false
ampicillin	13-22	tetracycline	25-36	false
ampicillin	13-22	antibiotics	173-183	false
ampicillin	13-22	synthetic steroids	213-230	false
tetracycline	25-36	antibiotics	173-183	false
tetracycline	25-36	synthetic steroids	213-230	false
antibiotics	173-183	synthetic steroids	213-230	false

Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.
Anticoagulants	0-13	hormonal contraceptives	28-50	false
Anticoagulants	0-13	coumarin derivatives	92-111	false
hormonal contraceptives	28-50	coumarin derivatives	92-111	effect

Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
Anticonvulsants	0-14	carbamazepine	17-29	false
Anticonvulsants	0-14	felbamate	32-40	false
Anticonvulsants	0-14	phenobarbital	43-55	false
Anticonvulsants	0-14	phenytoin	58-66	false
Anticonvulsants	0-14	topiramate	69-78	false
Anticonvulsants	0-14	ethinyl estradiol	109-125	mechanism
Anticonvulsants	0-14	progestins	139-148	mechanism
carbamazepine	17-29	felbamate	32-40	false
carbamazepine	17-29	phenobarbital	43-55	false
carbamazepine	17-29	phenytoin	58-66	false
carbamazepine	17-29	topiramate	69-78	false
carbamazepine	17-29	ethinyl estradiol	109-125	mechanism
carbamazepine	17-29	progestins	139-148	mechanism
felbamate	32-40	phenobarbital	43-55	false
felbamate	32-40	phenytoin	58-66	false
felbamate	32-40	topiramate	69-78	false
felbamate	32-40	ethinyl estradiol	109-125	mechanism
felbamate	32-40	progestins	139-148	mechanism
phenobarbital	43-55	phenytoin	58-66	false
phenobarbital	43-55	topiramate	69-78	false
phenobarbital	43-55	ethinyl estradiol	109-125	mechanism
phenobarbital	43-55	progestins	139-148	mechanism
phenytoin	58-66	topiramate	69-78	false
phenytoin	58-66	ethinyl estradiol	109-125	mechanism
phenytoin	58-66	progestins	139-148	mechanism
topiramate	69-78	ethinyl estradiol	109-125	mechanism
topiramate	69-78	progestins	139-148	mechanism
ethinyl estradiol	109-125	progestins	139-148	false

Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
Ascorbic acid	0-12	ascorbic acid	24-36	false
Ascorbic acid	0-12	vitamin C	39-47	false
Ascorbic acid	0-12	synthetic estrogens	113-131	false
ascorbic acid	24-36	vitamin C	39-47	false
ascorbic acid	24-36	synthetic estrogens	113-131	mechanism
vitamin C	39-47	synthetic estrogens	113-131	mechanism

Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
Atorvastatin	0-11	Atorvastatin	14-25	false
Atorvastatin	0-11	norethindrone	49-61	false
Atorvastatin	0-11	ethinyl estradiol	67-83	false
Atorvastatin	14-25	norethindrone	49-61	mechanism
Atorvastatin	14-25	ethinyl estradiol	67-83	mechanism
norethindrone	49-61	ethinyl estradiol	67-83	false

Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
Benzodiazepines	0-14	hormonal contraceptives	29-51	false
Benzodiazepines	0-14	benzodiazepines	88-102	false
Benzodiazepines	0-14	alprazolam	105-114	false
Benzodiazepines	0-14	chlordiazepoxide	117-132	false
Benzodiazepines	0-14	diazepam	135-142	false
Benzodiazepines	0-14	lorazepam	183-191	false
Benzodiazepines	0-14	oxazepam	194-201	false
Benzodiazepines	0-14	temazepam	204-212	false
hormonal contraceptives	29-51	benzodiazepines	88-102	mechanism
hormonal contraceptives	29-51	alprazolam	105-114	mechanism
hormonal contraceptives	29-51	chlordiazepoxide	117-132	mechanism
hormonal contraceptives	29-51	diazepam	135-142	mechanism
hormonal contraceptives	29-51	lorazepam	183-191	mechanism
hormonal contraceptives	29-51	oxazepam	194-201	mechanism
hormonal contraceptives	29-51	temazepam	204-212	mechanism
benzodiazepines	88-102	alprazolam	105-114	false
benzodiazepines	88-102	chlordiazepoxide	117-132	false
benzodiazepines	88-102	diazepam	135-142	false
benzodiazepines	88-102	lorazepam	183-191	false
benzodiazepines	88-102	oxazepam	194-201	false
benzodiazepines	88-102	temazepam	204-212	false
alprazolam	105-114	chlordiazepoxide	117-132	false
alprazolam	105-114	diazepam	135-142	false
alprazolam	105-114	lorazepam	183-191	false
alprazolam	105-114	oxazepam	194-201	false
alprazolam	105-114	temazepam	204-212	false
chlordiazepoxide	117-132	diazepam	135-142	false
chlordiazepoxide	117-132	lorazepam	183-191	false
chlordiazepoxide	117-132	oxazepam	194-201	false
chlordiazepoxide	117-132	temazepam	204-212	false
diazepam	135-142	lorazepam	183-191	false
diazepam	135-142	oxazepam	194-201	false
diazepam	135-142	temazepam	204-212	false
lorazepam	183-191	oxazepam	194-201	false
lorazepam	183-191	temazepam	204-212	false
oxazepam	194-201	temazepam	204-212	false

Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.
Clofibric acid	0-13	hormonal contraceptives	28-50	false
Clofibric acid	0-13	clofibric acid	82-95	false
hormonal contraceptives	28-50	clofibric acid	82-95	mechanism

Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;
Cyclosporine	0-11	hormonal contraceptives	26-48	false
Cyclosporine	0-11	cyclosporine	80-91	false
hormonal contraceptives	26-48	cyclosporine	80-91	mechanism

Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.
aminoglutethimide	25-41	carbamazepine	44-56	false
aminoglutethimide	25-41	nafcillin	59-67	false
aminoglutethimide	25-41	nevirapine	70-79	false
aminoglutethimide	25-41	phenobarbital	82-94	false
aminoglutethimide	25-41	phenytoin	97-105	false
aminoglutethimide	25-41	rifamycins	112-121	false
carbamazepine	44-56	nafcillin	59-67	false
carbamazepine	44-56	nevirapine	70-79	false
carbamazepine	44-56	phenobarbital	82-94	false
carbamazepine	44-56	phenytoin	97-105	false
carbamazepine	44-56	rifamycins	112-121	false
nafcillin	59-67	nevirapine	70-79	false
nafcillin	59-67	phenobarbital	82-94	false
nafcillin	59-67	phenytoin	97-105	false
nafcillin	59-67	rifamycins	112-121	false
nevirapine	70-79	phenobarbital	82-94	false
nevirapine	70-79	phenytoin	97-105	false
nevirapine	70-79	rifamycins	112-121	false
phenobarbital	82-94	phenytoin	97-105	false
phenobarbital	82-94	rifamycins	112-121	false
phenytoin	97-105	rifamycins	112-121	false

Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;
Griseofulvin	0-11	Griseofulvin	14-25	false
Griseofulvin	0-11	combination hormonal contraceptives	56-90	false
Griseofulvin	14-25	combination hormonal contraceptives	56-90	mechanism

Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
Morphine	0-7	hormonal contraceptives	22-44	false
Morphine	0-7	morphine	76-83	false
hormonal contraceptives	22-44	morphine	76-83	mechanism

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
Non-nucleoside reverse transcriptase inhibitors	0-46	NNRTIs	49-54	false
Non-nucleoside reverse transcriptase inhibitors	0-46	Nevirapine	58-67	false
Non-nucleoside reverse transcriptase inhibitors	0-46	combination hormonal contraceptives	99-133	false
NNRTIs	49-54	Nevirapine	58-67	false
NNRTIs	49-54	combination hormonal contraceptives	99-133	false
Nevirapine	58-67	combination hormonal contraceptives	99-133	mechanism

Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
Prednisolone	0-11	Ethinyl estradiol	14-30	false
Prednisolone	0-11	prednisolone	62-73	false
Ethinyl estradiol	14-30	prednisolone	62-73	mechanism

Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
Protease inhibitors	0-18	Amprenavir	21-30	false
Protease inhibitors	0-18	lopinavir	33-41	false
Protease inhibitors	0-18	nelfinavir	44-53	false
Protease inhibitors	0-18	ritonavir	60-68	false
Protease inhibitors	0-18	combination hormonal contraceptives	115-149	false
Amprenavir	21-30	lopinavir	33-41	false
Amprenavir	21-30	nelfinavir	44-53	false
Amprenavir	21-30	ritonavir	60-68	false
Amprenavir	21-30	combination hormonal contraceptives	115-149	mechanism
lopinavir	33-41	nelfinavir	44-53	false
lopinavir	33-41	ritonavir	60-68	false
lopinavir	33-41	combination hormonal contraceptives	115-149	mechanism
nelfinavir	44-53	ritonavir	60-68	false
nelfinavir	44-53	combination hormonal contraceptives	115-149	mechanism
ritonavir	60-68	combination hormonal contraceptives	115-149	mechanism

Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.
Indinavir	0-8	combination hormonal contraceptives	54-88	mechanism

Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
Rifampin	0-7	Rifampin	10-17	false
Rifampin	0-7	ethinyl estradiol	47-63	false
Rifampin	0-7	progestins	74-83	false
Rifampin	0-7	norethindrone	86-98	false
Rifampin	10-17	ethinyl estradiol	47-63	mechanism
Rifampin	10-17	progestins	74-83	mechanism
Rifampin	10-17	norethindrone	86-98	mechanism
ethinyl estradiol	47-63	progestins	74-83	false
ethinyl estradiol	47-63	norethindrone	86-98	false
progestins	74-83	norethindrone	86-98	false

Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.
Salicylic acid	0-13	hormonal contraceptives	28-50	false
Salicylic acid	0-13	salicylic acid	82-95	false
hormonal contraceptives	28-50	salicylic acid	82-95	mechanism

Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.
Selegiline	0-9	Combination hormonal contraceptives	12-46	false
Selegiline	0-9	selegiline	88-97	false
Combination hormonal contraceptives	12-46	selegiline	88-97	mechanism

Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.
Theophylline	0-11	Ethinyl estradiol	14-30	false
Theophylline	0-11	theophylline	62-73	false
Ethinyl estradiol	14-30	theophylline	62-73	mechanism

Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
Tricyclic antidepressants	0-24	amitriptyline	27-39	false
Tricyclic antidepressants	0-24	imipramine	42-51	false
Tricyclic antidepressants	0-24	nortriptyline	54-66	false
Tricyclic antidepressants	0-24	combination hormonal contraceptives	101-135	mechanism
Tricyclic antidepressants	0-24	antidepressant	166-179	false
amitriptyline	27-39	imipramine	42-51	false
amitriptyline	27-39	nortriptyline	54-66	false
amitriptyline	27-39	combination hormonal contraceptives	101-135	mechanism
amitriptyline	27-39	antidepressant	166-179	false
imipramine	42-51	nortriptyline	54-66	false
imipramine	42-51	combination hormonal contraceptives	101-135	mechanism
imipramine	42-51	antidepressant	166-179	false
nortriptyline	54-66	combination hormonal contraceptives	101-135	mechanism
nortriptyline	54-66	antidepressant	166-179	false
combination hormonal contraceptives	101-135	antidepressant	166-179	false

ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
ETHANOL	0-6	caffeine	62-69	false
ETHANOL	0-6	combination hormonal contraceptives	90-124	false
ETHANOL	0-6	caffeine	153-160	false
caffeine	62-69	combination hormonal contraceptives	90-124	false
caffeine	62-69	caffeine	153-160	false
combination hormonal contraceptives	90-124	caffeine	153-160	effect

Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;
ethinyl estradiol	27-43	progesterone	94-105	false

There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
etidronate	100-109	warfarin	124-131	effect

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
ACE-inhibitors	0-13	NSAIDs	36-41	false
ACE-inhibitors	0-13	ACE-inhibitors	87-100	false
NSAIDs	36-41	ACE-inhibitors	87-100	effect

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
NSAIDs	66-71	ACE-inhibitors	92-105	advise

Antacids: The concomitant administration of antacids has no apparent effect on the extent of absorption of Lodine.
Antacids	0-7	antacids	44-51	false
Antacids	0-7	Lodine	107-112	false
antacids	44-51	Lodine	107-112	false

Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
Aspirin	0-6	Lodine	14-19	false
Aspirin	0-6	aspirin	42-48	false
Aspirin	0-6	etodolac	114-121	false
Lodine	14-19	aspirin	42-48	mechanism
Lodine	14-19	etodolac	114-121	false
aspirin	42-48	etodolac	114-121	false

however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
NSAIDs	23-28	Lodine	61-66	false
NSAIDs	23-28	aspirin	72-78	false
Lodine	61-66	aspirin	72-78	advise

Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
Lodine	36-41	NSAIDs	55-60	false
Lodine	36-41	cyclosporine	192-203	mechanism
Lodine	36-41	digoxin	206-212	mechanism
Lodine	36-41	methotrexate	215-226	mechanism
NSAIDs	55-60	cyclosporine	192-203	mechanism
NSAIDs	55-60	digoxin	206-212	mechanism
NSAIDs	55-60	methotrexate	215-226	mechanism
cyclosporine	192-203	digoxin	206-212	false
cyclosporine	192-203	methotrexate	215-226	false
digoxin	206-212	methotrexate	215-226	false

Patients receiving these drugs who are given Lodine, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.
Lodine	45-50	NSAID	66-70	false

Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide.
Diuretics	0-8	furosemide	87-96	false
Diuretics	0-8	hydrochlorothiazide	101-119	false
furosemide	87-96	hydrochlorothiazide	101-119	false

Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
Lodine	86-91	furosemide	130-139	effect
Lodine	86-91	thiazides	145-153	effect
furosemide	130-139	thiazides	145-153	false

Glyburide: Etodolac has no apparent pharmacokinetic interaction when administered with glyburide.
Glyburide	0-8	Etodolac	11-18	false
Glyburide	0-8	glyburide	87-95	false
Etodolac	11-18	glyburide	87-95	false

Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	0-6	NSAIDs	9-14	false
Lithium	0-6	lithium	53-59	false
Lithium	0-6	lithium	93-99	false
NSAIDs	9-14	lithium	53-59	mechanism
NSAIDs	9-14	lithium	93-99	false
lithium	53-59	lithium	93-99	false

Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
NSAIDs	11-16	lithium	22-28	effect
NSAIDs	11-16	lithium	112-118	false
lithium	22-28	lithium	112-118	false

Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
Phenylbutazone	0-13	Phenylbutazone	16-29	false
Phenylbutazone	0-13	etodolac	86-93	false
Phenylbutazone	16-29	etodolac	86-93	mechanism

Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
etodolac	54-61	phenylbutazone	107-120	advise

Phenytoin: Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin.
Phenytoin	0-8	Etodolac	11-18	false
Phenytoin	0-8	phenytoin	87-95	false
Etodolac	11-18	phenytoin	87-95	false

Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
Warfarin	0-7	warfarin	25-32	false
Warfarin	0-7	NSAIDs	38-43	false
warfarin	25-32	NSAIDs	38-43	effect

Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
warfarin	88-95	Lodine	101-106	mechanism
warfarin	88-95	etodolac	110-117	mechanism
warfarin	88-95	warfarin	179-186	false
warfarin	88-95	warfarin	238-245	false
Lodine	101-106	etodolac	110-117	false
Lodine	101-106	warfarin	179-186	false
Lodine	101-106	warfarin	238-245	false
etodolac	110-117	warfarin	179-186	false
etodolac	110-117	warfarin	238-245	false
warfarin	179-186	warfarin	238-245	false

There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Lodine as measured by prothrombin time.
warfarin	69-76	warfarin	101-108	false
warfarin	69-76	Lodine	128-133	false
warfarin	101-108	Lodine	128-133	false

Thus, concomitant therapy with warfarin and Lodine should not require dosage adjustment of either drug.
warfarin	31-38	Lodine	44-49	false

However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
etodolac	148-155	warfarin	196-203	effect

Drug/Laboratory Test Interactions The urine of patients who take Lodine can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of etodolac.
Lodine	65-70	etodolac	187-194	false

Probenecid    Prolonged action of etomidate
Probenecid	0-9	etomidate	34-42	false

Zimelidine    etomidate antagonism
Zimelidine	0-9	etomidate	14-22	false

Aminophylline     Etomidate antagonism
Aminophylline	0-12	Etomidate	18-26	false

Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
Etonogestrel	0-11	acetaminophen	58-70	int
Etonogestrel	0-11	Tylenol	73-79	int
Etonogestrel	0-11	antibiotics	83-93	int
Etonogestrel	0-11	ampicillin	103-112	int
Etonogestrel	0-11	tetracycline	118-129	int
Etonogestrel	0-11	anticonvulsants	132-146	int
Etonogestrel	0-11	Dilantin	149-156	int
Etonogestrel	0-11	Phenobarbital	159-171	int
Etonogestrel	0-11	Tegretol	174-181	int
Etonogestrel	0-11	Trileptal	184-192	int
Etonogestrel	0-11	Topamax	195-201	int
Etonogestrel	0-11	Felbatol	204-211	int
Etonogestrel	0-11	antifungals	215-225	int
Etonogestrel	0-11	Gris-PEG	228-235	int
Etonogestrel	0-11	Nizoral	238-244	int
Etonogestrel	0-11	Sporanox	247-254	int
Etonogestrel	0-11	atorvastatin	258-269	int
Etonogestrel	0-11	Lipitor	272-278	int
Etonogestrel	0-11	clofibrate	282-291	int
Etonogestrel	0-11	Atromid-S	294-302	int
Etonogestrel	0-11	cyclosporine	306-317	int
Etonogestrel	0-11	Neoral	320-325	int
Etonogestrel	0-11	Sandimmune	328-337	int
Etonogestrel	0-11	protease inhibitors	365-383	int
Etonogestrel	0-11	Agenerase	386-394	int
Etonogestrel	0-11	Crixivan	397-404	int
Etonogestrel	0-11	Fortovase	407-415	int
Etonogestrel	0-11	Invirase	418-425	int
Etonogestrel	0-11	Kaletra	428-434	int
Etonogestrel	0-11	Norvir	437-442	int
Etonogestrel	0-11	Viracept	445-452	int
Etonogestrel	0-11	morphine	456-463	int
Etonogestrel	0-11	Astramorph	466-475	int
Etonogestrel	0-11	Kadian	478-483	int
Etonogestrel	0-11	MS Contin	486-494	int
Etonogestrel	0-11	phenylbutazone	498-511	int
Etonogestrel	0-11	prednisolone	514-525	int
Etonogestrel	0-11	Prelone	528-534	int
Etonogestrel	0-11	rifadin	538-544	int
Etonogestrel	0-11	rifampin	547-554	int
Etonogestrel	0-11	temazepam	574-582	int
Etonogestrel	0-11	theophylline	585-596	int
Etonogestrel	0-11	Theo-Dur	599-606	int
Etonogestrel	0-11	vitamin C	614-622	int
acetaminophen	58-70	Tylenol	73-79	false
acetaminophen	58-70	antibiotics	83-93	false
acetaminophen	58-70	ampicillin	103-112	false
acetaminophen	58-70	tetracycline	118-129	false
acetaminophen	58-70	anticonvulsants	132-146	false
acetaminophen	58-70	Dilantin	149-156	false
acetaminophen	58-70	Phenobarbital	159-171	false
acetaminophen	58-70	Tegretol	174-181	false
acetaminophen	58-70	Trileptal	184-192	false
acetaminophen	58-70	Topamax	195-201	false
acetaminophen	58-70	Felbatol	204-211	false
acetaminophen	58-70	antifungals	215-225	false
acetaminophen	58-70	Gris-PEG	228-235	false
acetaminophen	58-70	Nizoral	238-244	false
acetaminophen	58-70	Sporanox	247-254	false
acetaminophen	58-70	atorvastatin	258-269	false
acetaminophen	58-70	Lipitor	272-278	false
acetaminophen	58-70	clofibrate	282-291	false
acetaminophen	58-70	Atromid-S	294-302	false
acetaminophen	58-70	cyclosporine	306-317	false
acetaminophen	58-70	Neoral	320-325	false
acetaminophen	58-70	Sandimmune	328-337	false
acetaminophen	58-70	protease inhibitors	365-383	false
acetaminophen	58-70	Agenerase	386-394	false
acetaminophen	58-70	Crixivan	397-404	false
acetaminophen	58-70	Fortovase	407-415	false
acetaminophen	58-70	Invirase	418-425	false
acetaminophen	58-70	Kaletra	428-434	false
acetaminophen	58-70	Norvir	437-442	false
acetaminophen	58-70	Viracept	445-452	false
acetaminophen	58-70	morphine	456-463	false
acetaminophen	58-70	Astramorph	466-475	false
acetaminophen	58-70	Kadian	478-483	false
acetaminophen	58-70	MS Contin	486-494	false
acetaminophen	58-70	phenylbutazone	498-511	false
acetaminophen	58-70	prednisolone	514-525	false
acetaminophen	58-70	Prelone	528-534	false
acetaminophen	58-70	rifadin	538-544	false
acetaminophen	58-70	rifampin	547-554	false
acetaminophen	58-70	temazepam	574-582	false
acetaminophen	58-70	theophylline	585-596	false
acetaminophen	58-70	Theo-Dur	599-606	false
acetaminophen	58-70	vitamin C	614-622	false
Tylenol	73-79	antibiotics	83-93	false
Tylenol	73-79	ampicillin	103-112	false
Tylenol	73-79	tetracycline	118-129	false
Tylenol	73-79	anticonvulsants	132-146	false
Tylenol	73-79	Dilantin	149-156	false
Tylenol	73-79	Phenobarbital	159-171	false
Tylenol	73-79	Tegretol	174-181	false
Tylenol	73-79	Trileptal	184-192	false
Tylenol	73-79	Topamax	195-201	false
Tylenol	73-79	Felbatol	204-211	false
Tylenol	73-79	antifungals	215-225	false
Tylenol	73-79	Gris-PEG	228-235	false
Tylenol	73-79	Nizoral	238-244	false
Tylenol	73-79	Sporanox	247-254	false
Tylenol	73-79	atorvastatin	258-269	false
Tylenol	73-79	Lipitor	272-278	false
Tylenol	73-79	clofibrate	282-291	false
Tylenol	73-79	Atromid-S	294-302	false
Tylenol	73-79	cyclosporine	306-317	false
Tylenol	73-79	Neoral	320-325	false
Tylenol	73-79	Sandimmune	328-337	false
Tylenol	73-79	protease inhibitors	365-383	false
Tylenol	73-79	Agenerase	386-394	false
Tylenol	73-79	Crixivan	397-404	false
Tylenol	73-79	Fortovase	407-415	false
Tylenol	73-79	Invirase	418-425	false
Tylenol	73-79	Kaletra	428-434	false
Tylenol	73-79	Norvir	437-442	false
Tylenol	73-79	Viracept	445-452	false
Tylenol	73-79	morphine	456-463	false
Tylenol	73-79	Astramorph	466-475	false
Tylenol	73-79	Kadian	478-483	false
Tylenol	73-79	MS Contin	486-494	false
Tylenol	73-79	phenylbutazone	498-511	false
Tylenol	73-79	prednisolone	514-525	false
Tylenol	73-79	Prelone	528-534	false
Tylenol	73-79	rifadin	538-544	false
Tylenol	73-79	rifampin	547-554	false
Tylenol	73-79	temazepam	574-582	false
Tylenol	73-79	theophylline	585-596	false
Tylenol	73-79	Theo-Dur	599-606	false
Tylenol	73-79	vitamin C	614-622	false
antibiotics	83-93	ampicillin	103-112	false
antibiotics	83-93	tetracycline	118-129	false
antibiotics	83-93	anticonvulsants	132-146	false
antibiotics	83-93	Dilantin	149-156	false
antibiotics	83-93	Phenobarbital	159-171	false
antibiotics	83-93	Tegretol	174-181	false
antibiotics	83-93	Trileptal	184-192	false
antibiotics	83-93	Topamax	195-201	false
antibiotics	83-93	Felbatol	204-211	false
antibiotics	83-93	antifungals	215-225	false
antibiotics	83-93	Gris-PEG	228-235	false
antibiotics	83-93	Nizoral	238-244	false
antibiotics	83-93	Sporanox	247-254	false
antibiotics	83-93	atorvastatin	258-269	false
antibiotics	83-93	Lipitor	272-278	false
antibiotics	83-93	clofibrate	282-291	false
antibiotics	83-93	Atromid-S	294-302	false
antibiotics	83-93	cyclosporine	306-317	false
antibiotics	83-93	Neoral	320-325	false
antibiotics	83-93	Sandimmune	328-337	false
antibiotics	83-93	protease inhibitors	365-383	false
antibiotics	83-93	Agenerase	386-394	false
antibiotics	83-93	Crixivan	397-404	false
antibiotics	83-93	Fortovase	407-415	false
antibiotics	83-93	Invirase	418-425	false
antibiotics	83-93	Kaletra	428-434	false
antibiotics	83-93	Norvir	437-442	false
antibiotics	83-93	Viracept	445-452	false
antibiotics	83-93	morphine	456-463	false
antibiotics	83-93	Astramorph	466-475	false
antibiotics	83-93	Kadian	478-483	false
antibiotics	83-93	MS Contin	486-494	false
antibiotics	83-93	phenylbutazone	498-511	false
antibiotics	83-93	prednisolone	514-525	false
antibiotics	83-93	Prelone	528-534	false
antibiotics	83-93	rifadin	538-544	false
antibiotics	83-93	rifampin	547-554	false
antibiotics	83-93	temazepam	574-582	false
antibiotics	83-93	theophylline	585-596	false
antibiotics	83-93	Theo-Dur	599-606	false
antibiotics	83-93	vitamin C	614-622	false
ampicillin	103-112	tetracycline	118-129	false
ampicillin	103-112	anticonvulsants	132-146	false
ampicillin	103-112	Dilantin	149-156	false
ampicillin	103-112	Phenobarbital	159-171	false
ampicillin	103-112	Tegretol	174-181	false
ampicillin	103-112	Trileptal	184-192	false
ampicillin	103-112	Topamax	195-201	false
ampicillin	103-112	Felbatol	204-211	false
ampicillin	103-112	antifungals	215-225	false
ampicillin	103-112	Gris-PEG	228-235	false
ampicillin	103-112	Nizoral	238-244	false
ampicillin	103-112	Sporanox	247-254	false
ampicillin	103-112	atorvastatin	258-269	false
ampicillin	103-112	Lipitor	272-278	false
ampicillin	103-112	clofibrate	282-291	false
ampicillin	103-112	Atromid-S	294-302	false
ampicillin	103-112	cyclosporine	306-317	false
ampicillin	103-112	Neoral	320-325	false
ampicillin	103-112	Sandimmune	328-337	false
ampicillin	103-112	protease inhibitors	365-383	false
ampicillin	103-112	Agenerase	386-394	false
ampicillin	103-112	Crixivan	397-404	false
ampicillin	103-112	Fortovase	407-415	false
ampicillin	103-112	Invirase	418-425	false
ampicillin	103-112	Kaletra	428-434	false
ampicillin	103-112	Norvir	437-442	false
ampicillin	103-112	Viracept	445-452	false
ampicillin	103-112	morphine	456-463	false
ampicillin	103-112	Astramorph	466-475	false
ampicillin	103-112	Kadian	478-483	false
ampicillin	103-112	MS Contin	486-494	false
ampicillin	103-112	phenylbutazone	498-511	false
ampicillin	103-112	prednisolone	514-525	false
ampicillin	103-112	Prelone	528-534	false
ampicillin	103-112	rifadin	538-544	false
ampicillin	103-112	rifampin	547-554	false
ampicillin	103-112	temazepam	574-582	false
ampicillin	103-112	theophylline	585-596	false
ampicillin	103-112	Theo-Dur	599-606	false
ampicillin	103-112	vitamin C	614-622	false
tetracycline	118-129	anticonvulsants	132-146	false
tetracycline	118-129	Dilantin	149-156	false
tetracycline	118-129	Phenobarbital	159-171	false
tetracycline	118-129	Tegretol	174-181	false
tetracycline	118-129	Trileptal	184-192	false
tetracycline	118-129	Topamax	195-201	false
tetracycline	118-129	Felbatol	204-211	false
tetracycline	118-129	antifungals	215-225	false
tetracycline	118-129	Gris-PEG	228-235	false
tetracycline	118-129	Nizoral	238-244	false
tetracycline	118-129	Sporanox	247-254	false
tetracycline	118-129	atorvastatin	258-269	false
tetracycline	118-129	Lipitor	272-278	false
tetracycline	118-129	clofibrate	282-291	false
tetracycline	118-129	Atromid-S	294-302	false
tetracycline	118-129	cyclosporine	306-317	false
tetracycline	118-129	Neoral	320-325	false
tetracycline	118-129	Sandimmune	328-337	false
tetracycline	118-129	protease inhibitors	365-383	false
tetracycline	118-129	Agenerase	386-394	false
tetracycline	118-129	Crixivan	397-404	false
tetracycline	118-129	Fortovase	407-415	false
tetracycline	118-129	Invirase	418-425	false
tetracycline	118-129	Kaletra	428-434	false
tetracycline	118-129	Norvir	437-442	false
tetracycline	118-129	Viracept	445-452	false
tetracycline	118-129	morphine	456-463	false
tetracycline	118-129	Astramorph	466-475	false
tetracycline	118-129	Kadian	478-483	false
tetracycline	118-129	MS Contin	486-494	false
tetracycline	118-129	phenylbutazone	498-511	false
tetracycline	118-129	prednisolone	514-525	false
tetracycline	118-129	Prelone	528-534	false
tetracycline	118-129	rifadin	538-544	false
tetracycline	118-129	rifampin	547-554	false
tetracycline	118-129	temazepam	574-582	false
tetracycline	118-129	theophylline	585-596	false
tetracycline	118-129	Theo-Dur	599-606	false
tetracycline	118-129	vitamin C	614-622	false
anticonvulsants	132-146	Dilantin	149-156	false
anticonvulsants	132-146	Phenobarbital	159-171	false
anticonvulsants	132-146	Tegretol	174-181	false
anticonvulsants	132-146	Trileptal	184-192	false
anticonvulsants	132-146	Topamax	195-201	false
anticonvulsants	132-146	Felbatol	204-211	false
anticonvulsants	132-146	antifungals	215-225	false
anticonvulsants	132-146	Gris-PEG	228-235	false
anticonvulsants	132-146	Nizoral	238-244	false
anticonvulsants	132-146	Sporanox	247-254	false
anticonvulsants	132-146	atorvastatin	258-269	false
anticonvulsants	132-146	Lipitor	272-278	false
anticonvulsants	132-146	clofibrate	282-291	false
anticonvulsants	132-146	Atromid-S	294-302	false
anticonvulsants	132-146	cyclosporine	306-317	false
anticonvulsants	132-146	Neoral	320-325	false
anticonvulsants	132-146	Sandimmune	328-337	false
anticonvulsants	132-146	protease inhibitors	365-383	false
anticonvulsants	132-146	Agenerase	386-394	false
anticonvulsants	132-146	Crixivan	397-404	false
anticonvulsants	132-146	Fortovase	407-415	false
anticonvulsants	132-146	Invirase	418-425	false
anticonvulsants	132-146	Kaletra	428-434	false
anticonvulsants	132-146	Norvir	437-442	false
anticonvulsants	132-146	Viracept	445-452	false
anticonvulsants	132-146	morphine	456-463	false
anticonvulsants	132-146	Astramorph	466-475	false
anticonvulsants	132-146	Kadian	478-483	false
anticonvulsants	132-146	MS Contin	486-494	false
anticonvulsants	132-146	phenylbutazone	498-511	false
anticonvulsants	132-146	prednisolone	514-525	false
anticonvulsants	132-146	Prelone	528-534	false
anticonvulsants	132-146	rifadin	538-544	false
anticonvulsants	132-146	rifampin	547-554	false
anticonvulsants	132-146	temazepam	574-582	false
anticonvulsants	132-146	theophylline	585-596	false
anticonvulsants	132-146	Theo-Dur	599-606	false
anticonvulsants	132-146	vitamin C	614-622	false
Dilantin	149-156	Phenobarbital	159-171	false
Dilantin	149-156	Tegretol	174-181	false
Dilantin	149-156	Trileptal	184-192	false
Dilantin	149-156	Topamax	195-201	false
Dilantin	149-156	Felbatol	204-211	false
Dilantin	149-156	antifungals	215-225	false
Dilantin	149-156	Gris-PEG	228-235	false
Dilantin	149-156	Nizoral	238-244	false
Dilantin	149-156	Sporanox	247-254	false
Dilantin	149-156	atorvastatin	258-269	false
Dilantin	149-156	Lipitor	272-278	false
Dilantin	149-156	clofibrate	282-291	false
Dilantin	149-156	Atromid-S	294-302	false
Dilantin	149-156	cyclosporine	306-317	false
Dilantin	149-156	Neoral	320-325	false
Dilantin	149-156	Sandimmune	328-337	false
Dilantin	149-156	protease inhibitors	365-383	false
Dilantin	149-156	Agenerase	386-394	false
Dilantin	149-156	Crixivan	397-404	false
Dilantin	149-156	Fortovase	407-415	false
Dilantin	149-156	Invirase	418-425	false
Dilantin	149-156	Kaletra	428-434	false
Dilantin	149-156	Norvir	437-442	false
Dilantin	149-156	Viracept	445-452	false
Dilantin	149-156	morphine	456-463	false
Dilantin	149-156	Astramorph	466-475	false
Dilantin	149-156	Kadian	478-483	false
Dilantin	149-156	MS Contin	486-494	false
Dilantin	149-156	phenylbutazone	498-511	false
Dilantin	149-156	prednisolone	514-525	false
Dilantin	149-156	Prelone	528-534	false
Dilantin	149-156	rifadin	538-544	false
Dilantin	149-156	rifampin	547-554	false
Dilantin	149-156	temazepam	574-582	false
Dilantin	149-156	theophylline	585-596	false
Dilantin	149-156	Theo-Dur	599-606	false
Dilantin	149-156	vitamin C	614-622	false
Phenobarbital	159-171	Tegretol	174-181	false
Phenobarbital	159-171	Trileptal	184-192	false
Phenobarbital	159-171	Topamax	195-201	false
Phenobarbital	159-171	Felbatol	204-211	false
Phenobarbital	159-171	antifungals	215-225	false
Phenobarbital	159-171	Gris-PEG	228-235	false
Phenobarbital	159-171	Nizoral	238-244	false
Phenobarbital	159-171	Sporanox	247-254	false
Phenobarbital	159-171	atorvastatin	258-269	false
Phenobarbital	159-171	Lipitor	272-278	false
Phenobarbital	159-171	clofibrate	282-291	false
Phenobarbital	159-171	Atromid-S	294-302	false
Phenobarbital	159-171	cyclosporine	306-317	false
Phenobarbital	159-171	Neoral	320-325	false
Phenobarbital	159-171	Sandimmune	328-337	false
Phenobarbital	159-171	protease inhibitors	365-383	false
Phenobarbital	159-171	Agenerase	386-394	false
Phenobarbital	159-171	Crixivan	397-404	false
Phenobarbital	159-171	Fortovase	407-415	false
Phenobarbital	159-171	Invirase	418-425	false
Phenobarbital	159-171	Kaletra	428-434	false
Phenobarbital	159-171	Norvir	437-442	false
Phenobarbital	159-171	Viracept	445-452	false
Phenobarbital	159-171	morphine	456-463	false
Phenobarbital	159-171	Astramorph	466-475	false
Phenobarbital	159-171	Kadian	478-483	false
Phenobarbital	159-171	MS Contin	486-494	false
Phenobarbital	159-171	phenylbutazone	498-511	false
Phenobarbital	159-171	prednisolone	514-525	false
Phenobarbital	159-171	Prelone	528-534	false
Phenobarbital	159-171	rifadin	538-544	false
Phenobarbital	159-171	rifampin	547-554	false
Phenobarbital	159-171	temazepam	574-582	false
Phenobarbital	159-171	theophylline	585-596	false
Phenobarbital	159-171	Theo-Dur	599-606	false
Phenobarbital	159-171	vitamin C	614-622	false
Tegretol	174-181	Trileptal	184-192	false
Tegretol	174-181	Topamax	195-201	false
Tegretol	174-181	Felbatol	204-211	false
Tegretol	174-181	antifungals	215-225	false
Tegretol	174-181	Gris-PEG	228-235	false
Tegretol	174-181	Nizoral	238-244	false
Tegretol	174-181	Sporanox	247-254	false
Tegretol	174-181	atorvastatin	258-269	false
Tegretol	174-181	Lipitor	272-278	false
Tegretol	174-181	clofibrate	282-291	false
Tegretol	174-181	Atromid-S	294-302	false
Tegretol	174-181	cyclosporine	306-317	false
Tegretol	174-181	Neoral	320-325	false
Tegretol	174-181	Sandimmune	328-337	false
Tegretol	174-181	protease inhibitors	365-383	false
Tegretol	174-181	Agenerase	386-394	false
Tegretol	174-181	Crixivan	397-404	false
Tegretol	174-181	Fortovase	407-415	false
Tegretol	174-181	Invirase	418-425	false
Tegretol	174-181	Kaletra	428-434	false
Tegretol	174-181	Norvir	437-442	false
Tegretol	174-181	Viracept	445-452	false
Tegretol	174-181	morphine	456-463	false
Tegretol	174-181	Astramorph	466-475	false
Tegretol	174-181	Kadian	478-483	false
Tegretol	174-181	MS Contin	486-494	false
Tegretol	174-181	phenylbutazone	498-511	false
Tegretol	174-181	prednisolone	514-525	false
Tegretol	174-181	Prelone	528-534	false
Tegretol	174-181	rifadin	538-544	false
Tegretol	174-181	rifampin	547-554	false
Tegretol	174-181	temazepam	574-582	false
Tegretol	174-181	theophylline	585-596	false
Tegretol	174-181	Theo-Dur	599-606	false
Tegretol	174-181	vitamin C	614-622	false
Trileptal	184-192	Topamax	195-201	false
Trileptal	184-192	Felbatol	204-211	false
Trileptal	184-192	antifungals	215-225	false
Trileptal	184-192	Gris-PEG	228-235	false
Trileptal	184-192	Nizoral	238-244	false
Trileptal	184-192	Sporanox	247-254	false
Trileptal	184-192	atorvastatin	258-269	false
Trileptal	184-192	Lipitor	272-278	false
Trileptal	184-192	clofibrate	282-291	false
Trileptal	184-192	Atromid-S	294-302	false
Trileptal	184-192	cyclosporine	306-317	false
Trileptal	184-192	Neoral	320-325	false
Trileptal	184-192	Sandimmune	328-337	false
Trileptal	184-192	protease inhibitors	365-383	false
Trileptal	184-192	Agenerase	386-394	false
Trileptal	184-192	Crixivan	397-404	false
Trileptal	184-192	Fortovase	407-415	false
Trileptal	184-192	Invirase	418-425	false
Trileptal	184-192	Kaletra	428-434	false
Trileptal	184-192	Norvir	437-442	false
Trileptal	184-192	Viracept	445-452	false
Trileptal	184-192	morphine	456-463	false
Trileptal	184-192	Astramorph	466-475	false
Trileptal	184-192	Kadian	478-483	false
Trileptal	184-192	MS Contin	486-494	false
Trileptal	184-192	phenylbutazone	498-511	false
Trileptal	184-192	prednisolone	514-525	false
Trileptal	184-192	Prelone	528-534	false
Trileptal	184-192	rifadin	538-544	false
Trileptal	184-192	rifampin	547-554	false
Trileptal	184-192	temazepam	574-582	false
Trileptal	184-192	theophylline	585-596	false
Trileptal	184-192	Theo-Dur	599-606	false
Trileptal	184-192	vitamin C	614-622	false
Topamax	195-201	Felbatol	204-211	false
Topamax	195-201	antifungals	215-225	false
Topamax	195-201	Gris-PEG	228-235	false
Topamax	195-201	Nizoral	238-244	false
Topamax	195-201	Sporanox	247-254	false
Topamax	195-201	atorvastatin	258-269	false
Topamax	195-201	Lipitor	272-278	false
Topamax	195-201	clofibrate	282-291	false
Topamax	195-201	Atromid-S	294-302	false
Topamax	195-201	cyclosporine	306-317	false
Topamax	195-201	Neoral	320-325	false
Topamax	195-201	Sandimmune	328-337	false
Topamax	195-201	protease inhibitors	365-383	false
Topamax	195-201	Agenerase	386-394	false
Topamax	195-201	Crixivan	397-404	false
Topamax	195-201	Fortovase	407-415	false
Topamax	195-201	Invirase	418-425	false
Topamax	195-201	Kaletra	428-434	false
Topamax	195-201	Norvir	437-442	false
Topamax	195-201	Viracept	445-452	false
Topamax	195-201	morphine	456-463	false
Topamax	195-201	Astramorph	466-475	false
Topamax	195-201	Kadian	478-483	false
Topamax	195-201	MS Contin	486-494	false
Topamax	195-201	phenylbutazone	498-511	false
Topamax	195-201	prednisolone	514-525	false
Topamax	195-201	Prelone	528-534	false
Topamax	195-201	rifadin	538-544	false
Topamax	195-201	rifampin	547-554	false
Topamax	195-201	temazepam	574-582	false
Topamax	195-201	theophylline	585-596	false
Topamax	195-201	Theo-Dur	599-606	false
Topamax	195-201	vitamin C	614-622	false
Felbatol	204-211	antifungals	215-225	false
Felbatol	204-211	Gris-PEG	228-235	false
Felbatol	204-211	Nizoral	238-244	false
Felbatol	204-211	Sporanox	247-254	false
Felbatol	204-211	atorvastatin	258-269	false
Felbatol	204-211	Lipitor	272-278	false
Felbatol	204-211	clofibrate	282-291	false
Felbatol	204-211	Atromid-S	294-302	false
Felbatol	204-211	cyclosporine	306-317	false
Felbatol	204-211	Neoral	320-325	false
Felbatol	204-211	Sandimmune	328-337	false
Felbatol	204-211	protease inhibitors	365-383	false
Felbatol	204-211	Agenerase	386-394	false
Felbatol	204-211	Crixivan	397-404	false
Felbatol	204-211	Fortovase	407-415	false
Felbatol	204-211	Invirase	418-425	false
Felbatol	204-211	Kaletra	428-434	false
Felbatol	204-211	Norvir	437-442	false
Felbatol	204-211	Viracept	445-452	false
Felbatol	204-211	morphine	456-463	false
Felbatol	204-211	Astramorph	466-475	false
Felbatol	204-211	Kadian	478-483	false
Felbatol	204-211	MS Contin	486-494	false
Felbatol	204-211	phenylbutazone	498-511	false
Felbatol	204-211	prednisolone	514-525	false
Felbatol	204-211	Prelone	528-534	false
Felbatol	204-211	rifadin	538-544	false
Felbatol	204-211	rifampin	547-554	false
Felbatol	204-211	temazepam	574-582	false
Felbatol	204-211	theophylline	585-596	false
Felbatol	204-211	Theo-Dur	599-606	false
Felbatol	204-211	vitamin C	614-622	false
antifungals	215-225	Gris-PEG	228-235	false
antifungals	215-225	Nizoral	238-244	false
antifungals	215-225	Sporanox	247-254	false
antifungals	215-225	atorvastatin	258-269	false
antifungals	215-225	Lipitor	272-278	false
antifungals	215-225	clofibrate	282-291	false
antifungals	215-225	Atromid-S	294-302	false
antifungals	215-225	cyclosporine	306-317	false
antifungals	215-225	Neoral	320-325	false
antifungals	215-225	Sandimmune	328-337	false
antifungals	215-225	protease inhibitors	365-383	false
antifungals	215-225	Agenerase	386-394	false
antifungals	215-225	Crixivan	397-404	false
antifungals	215-225	Fortovase	407-415	false
antifungals	215-225	Invirase	418-425	false
antifungals	215-225	Kaletra	428-434	false
antifungals	215-225	Norvir	437-442	false
antifungals	215-225	Viracept	445-452	false
antifungals	215-225	morphine	456-463	false
antifungals	215-225	Astramorph	466-475	false
antifungals	215-225	Kadian	478-483	false
antifungals	215-225	MS Contin	486-494	false
antifungals	215-225	phenylbutazone	498-511	false
antifungals	215-225	prednisolone	514-525	false
antifungals	215-225	Prelone	528-534	false
antifungals	215-225	rifadin	538-544	false
antifungals	215-225	rifampin	547-554	false
antifungals	215-225	temazepam	574-582	false
antifungals	215-225	theophylline	585-596	false
antifungals	215-225	Theo-Dur	599-606	false
antifungals	215-225	vitamin C	614-622	false
Gris-PEG	228-235	Nizoral	238-244	false
Gris-PEG	228-235	Sporanox	247-254	false
Gris-PEG	228-235	atorvastatin	258-269	false
Gris-PEG	228-235	Lipitor	272-278	false
Gris-PEG	228-235	clofibrate	282-291	false
Gris-PEG	228-235	Atromid-S	294-302	false
Gris-PEG	228-235	cyclosporine	306-317	false
Gris-PEG	228-235	Neoral	320-325	false
Gris-PEG	228-235	Sandimmune	328-337	false
Gris-PEG	228-235	protease inhibitors	365-383	false
Gris-PEG	228-235	Agenerase	386-394	false
Gris-PEG	228-235	Crixivan	397-404	false
Gris-PEG	228-235	Fortovase	407-415	false
Gris-PEG	228-235	Invirase	418-425	false
Gris-PEG	228-235	Kaletra	428-434	false
Gris-PEG	228-235	Norvir	437-442	false
Gris-PEG	228-235	Viracept	445-452	false
Gris-PEG	228-235	morphine	456-463	false
Gris-PEG	228-235	Astramorph	466-475	false
Gris-PEG	228-235	Kadian	478-483	false
Gris-PEG	228-235	MS Contin	486-494	false
Gris-PEG	228-235	phenylbutazone	498-511	false
Gris-PEG	228-235	prednisolone	514-525	false
Gris-PEG	228-235	Prelone	528-534	false
Gris-PEG	228-235	rifadin	538-544	false
Gris-PEG	228-235	rifampin	547-554	false
Gris-PEG	228-235	temazepam	574-582	false
Gris-PEG	228-235	theophylline	585-596	false
Gris-PEG	228-235	Theo-Dur	599-606	false
Gris-PEG	228-235	vitamin C	614-622	false
Nizoral	238-244	Sporanox	247-254	false
Nizoral	238-244	atorvastatin	258-269	false
Nizoral	238-244	Lipitor	272-278	false
Nizoral	238-244	clofibrate	282-291	false
Nizoral	238-244	Atromid-S	294-302	false
Nizoral	238-244	cyclosporine	306-317	false
Nizoral	238-244	Neoral	320-325	false
Nizoral	238-244	Sandimmune	328-337	false
Nizoral	238-244	protease inhibitors	365-383	false
Nizoral	238-244	Agenerase	386-394	false
Nizoral	238-244	Crixivan	397-404	false
Nizoral	238-244	Fortovase	407-415	false
Nizoral	238-244	Invirase	418-425	false
Nizoral	238-244	Kaletra	428-434	false
Nizoral	238-244	Norvir	437-442	false
Nizoral	238-244	Viracept	445-452	false
Nizoral	238-244	morphine	456-463	false
Nizoral	238-244	Astramorph	466-475	false
Nizoral	238-244	Kadian	478-483	false
Nizoral	238-244	MS Contin	486-494	false
Nizoral	238-244	phenylbutazone	498-511	false
Nizoral	238-244	prednisolone	514-525	false
Nizoral	238-244	Prelone	528-534	false
Nizoral	238-244	rifadin	538-544	false
Nizoral	238-244	rifampin	547-554	false
Nizoral	238-244	temazepam	574-582	false
Nizoral	238-244	theophylline	585-596	false
Nizoral	238-244	Theo-Dur	599-606	false
Nizoral	238-244	vitamin C	614-622	false
Sporanox	247-254	atorvastatin	258-269	false
Sporanox	247-254	Lipitor	272-278	false
Sporanox	247-254	clofibrate	282-291	false
Sporanox	247-254	Atromid-S	294-302	false
Sporanox	247-254	cyclosporine	306-317	false
Sporanox	247-254	Neoral	320-325	false
Sporanox	247-254	Sandimmune	328-337	false
Sporanox	247-254	protease inhibitors	365-383	false
Sporanox	247-254	Agenerase	386-394	false
Sporanox	247-254	Crixivan	397-404	false
Sporanox	247-254	Fortovase	407-415	false
Sporanox	247-254	Invirase	418-425	false
Sporanox	247-254	Kaletra	428-434	false
Sporanox	247-254	Norvir	437-442	false
Sporanox	247-254	Viracept	445-452	false
Sporanox	247-254	morphine	456-463	false
Sporanox	247-254	Astramorph	466-475	false
Sporanox	247-254	Kadian	478-483	false
Sporanox	247-254	MS Contin	486-494	false
Sporanox	247-254	phenylbutazone	498-511	false
Sporanox	247-254	prednisolone	514-525	false
Sporanox	247-254	Prelone	528-534	false
Sporanox	247-254	rifadin	538-544	false
Sporanox	247-254	rifampin	547-554	false
Sporanox	247-254	temazepam	574-582	false
Sporanox	247-254	theophylline	585-596	false
Sporanox	247-254	Theo-Dur	599-606	false
Sporanox	247-254	vitamin C	614-622	false
atorvastatin	258-269	Lipitor	272-278	false
atorvastatin	258-269	clofibrate	282-291	false
atorvastatin	258-269	Atromid-S	294-302	false
atorvastatin	258-269	cyclosporine	306-317	false
atorvastatin	258-269	Neoral	320-325	false
atorvastatin	258-269	Sandimmune	328-337	false
atorvastatin	258-269	protease inhibitors	365-383	false
atorvastatin	258-269	Agenerase	386-394	false
atorvastatin	258-269	Crixivan	397-404	false
atorvastatin	258-269	Fortovase	407-415	false
atorvastatin	258-269	Invirase	418-425	false
atorvastatin	258-269	Kaletra	428-434	false
atorvastatin	258-269	Norvir	437-442	false
atorvastatin	258-269	Viracept	445-452	false
atorvastatin	258-269	morphine	456-463	false
atorvastatin	258-269	Astramorph	466-475	false
atorvastatin	258-269	Kadian	478-483	false
atorvastatin	258-269	MS Contin	486-494	false
atorvastatin	258-269	phenylbutazone	498-511	false
atorvastatin	258-269	prednisolone	514-525	false
atorvastatin	258-269	Prelone	528-534	false
atorvastatin	258-269	rifadin	538-544	false
atorvastatin	258-269	rifampin	547-554	false
atorvastatin	258-269	temazepam	574-582	false
atorvastatin	258-269	theophylline	585-596	false
atorvastatin	258-269	Theo-Dur	599-606	false
atorvastatin	258-269	vitamin C	614-622	false
Lipitor	272-278	clofibrate	282-291	false
Lipitor	272-278	Atromid-S	294-302	false
Lipitor	272-278	cyclosporine	306-317	false
Lipitor	272-278	Neoral	320-325	false
Lipitor	272-278	Sandimmune	328-337	false
Lipitor	272-278	protease inhibitors	365-383	false
Lipitor	272-278	Agenerase	386-394	false
Lipitor	272-278	Crixivan	397-404	false
Lipitor	272-278	Fortovase	407-415	false
Lipitor	272-278	Invirase	418-425	false
Lipitor	272-278	Kaletra	428-434	false
Lipitor	272-278	Norvir	437-442	false
Lipitor	272-278	Viracept	445-452	false
Lipitor	272-278	morphine	456-463	false
Lipitor	272-278	Astramorph	466-475	false
Lipitor	272-278	Kadian	478-483	false
Lipitor	272-278	MS Contin	486-494	false
Lipitor	272-278	phenylbutazone	498-511	false
Lipitor	272-278	prednisolone	514-525	false
Lipitor	272-278	Prelone	528-534	false
Lipitor	272-278	rifadin	538-544	false
Lipitor	272-278	rifampin	547-554	false
Lipitor	272-278	temazepam	574-582	false
Lipitor	272-278	theophylline	585-596	false
Lipitor	272-278	Theo-Dur	599-606	false
Lipitor	272-278	vitamin C	614-622	false
clofibrate	282-291	Atromid-S	294-302	false
clofibrate	282-291	cyclosporine	306-317	false
clofibrate	282-291	Neoral	320-325	false
clofibrate	282-291	Sandimmune	328-337	false
clofibrate	282-291	protease inhibitors	365-383	false
clofibrate	282-291	Agenerase	386-394	false
clofibrate	282-291	Crixivan	397-404	false
clofibrate	282-291	Fortovase	407-415	false
clofibrate	282-291	Invirase	418-425	false
clofibrate	282-291	Kaletra	428-434	false
clofibrate	282-291	Norvir	437-442	false
clofibrate	282-291	Viracept	445-452	false
clofibrate	282-291	morphine	456-463	false
clofibrate	282-291	Astramorph	466-475	false
clofibrate	282-291	Kadian	478-483	false
clofibrate	282-291	MS Contin	486-494	false
clofibrate	282-291	phenylbutazone	498-511	false
clofibrate	282-291	prednisolone	514-525	false
clofibrate	282-291	Prelone	528-534	false
clofibrate	282-291	rifadin	538-544	false
clofibrate	282-291	rifampin	547-554	false
clofibrate	282-291	temazepam	574-582	false
clofibrate	282-291	theophylline	585-596	false
clofibrate	282-291	Theo-Dur	599-606	false
clofibrate	282-291	vitamin C	614-622	false
Atromid-S	294-302	cyclosporine	306-317	false
Atromid-S	294-302	Neoral	320-325	false
Atromid-S	294-302	Sandimmune	328-337	false
Atromid-S	294-302	protease inhibitors	365-383	false
Atromid-S	294-302	Agenerase	386-394	false
Atromid-S	294-302	Crixivan	397-404	false
Atromid-S	294-302	Fortovase	407-415	false
Atromid-S	294-302	Invirase	418-425	false
Atromid-S	294-302	Kaletra	428-434	false
Atromid-S	294-302	Norvir	437-442	false
Atromid-S	294-302	Viracept	445-452	false
Atromid-S	294-302	morphine	456-463	false
Atromid-S	294-302	Astramorph	466-475	false
Atromid-S	294-302	Kadian	478-483	false
Atromid-S	294-302	MS Contin	486-494	false
Atromid-S	294-302	phenylbutazone	498-511	false
Atromid-S	294-302	prednisolone	514-525	false
Atromid-S	294-302	Prelone	528-534	false
Atromid-S	294-302	rifadin	538-544	false
Atromid-S	294-302	rifampin	547-554	false
Atromid-S	294-302	temazepam	574-582	false
Atromid-S	294-302	theophylline	585-596	false
Atromid-S	294-302	Theo-Dur	599-606	false
Atromid-S	294-302	vitamin C	614-622	false
cyclosporine	306-317	Neoral	320-325	false
cyclosporine	306-317	Sandimmune	328-337	false
cyclosporine	306-317	protease inhibitors	365-383	false
cyclosporine	306-317	Agenerase	386-394	false
cyclosporine	306-317	Crixivan	397-404	false
cyclosporine	306-317	Fortovase	407-415	false
cyclosporine	306-317	Invirase	418-425	false
cyclosporine	306-317	Kaletra	428-434	false
cyclosporine	306-317	Norvir	437-442	false
cyclosporine	306-317	Viracept	445-452	false
cyclosporine	306-317	morphine	456-463	false
cyclosporine	306-317	Astramorph	466-475	false
cyclosporine	306-317	Kadian	478-483	false
cyclosporine	306-317	MS Contin	486-494	false
cyclosporine	306-317	phenylbutazone	498-511	false
cyclosporine	306-317	prednisolone	514-525	false
cyclosporine	306-317	Prelone	528-534	false
cyclosporine	306-317	rifadin	538-544	false
cyclosporine	306-317	rifampin	547-554	false
cyclosporine	306-317	temazepam	574-582	false
cyclosporine	306-317	theophylline	585-596	false
cyclosporine	306-317	Theo-Dur	599-606	false
cyclosporine	306-317	vitamin C	614-622	false
Neoral	320-325	Sandimmune	328-337	false
Neoral	320-325	protease inhibitors	365-383	false
Neoral	320-325	Agenerase	386-394	false
Neoral	320-325	Crixivan	397-404	false
Neoral	320-325	Fortovase	407-415	false
Neoral	320-325	Invirase	418-425	false
Neoral	320-325	Kaletra	428-434	false
Neoral	320-325	Norvir	437-442	false
Neoral	320-325	Viracept	445-452	false
Neoral	320-325	morphine	456-463	false
Neoral	320-325	Astramorph	466-475	false
Neoral	320-325	Kadian	478-483	false
Neoral	320-325	MS Contin	486-494	false
Neoral	320-325	phenylbutazone	498-511	false
Neoral	320-325	prednisolone	514-525	false
Neoral	320-325	Prelone	528-534	false
Neoral	320-325	rifadin	538-544	false
Neoral	320-325	rifampin	547-554	false
Neoral	320-325	temazepam	574-582	false
Neoral	320-325	theophylline	585-596	false
Neoral	320-325	Theo-Dur	599-606	false
Neoral	320-325	vitamin C	614-622	false
Sandimmune	328-337	protease inhibitors	365-383	false
Sandimmune	328-337	Agenerase	386-394	false
Sandimmune	328-337	Crixivan	397-404	false
Sandimmune	328-337	Fortovase	407-415	false
Sandimmune	328-337	Invirase	418-425	false
Sandimmune	328-337	Kaletra	428-434	false
Sandimmune	328-337	Norvir	437-442	false
Sandimmune	328-337	Viracept	445-452	false
Sandimmune	328-337	morphine	456-463	false
Sandimmune	328-337	Astramorph	466-475	false
Sandimmune	328-337	Kadian	478-483	false
Sandimmune	328-337	MS Contin	486-494	false
Sandimmune	328-337	phenylbutazone	498-511	false
Sandimmune	328-337	prednisolone	514-525	false
Sandimmune	328-337	Prelone	528-534	false
Sandimmune	328-337	rifadin	538-544	false
Sandimmune	328-337	rifampin	547-554	false
Sandimmune	328-337	temazepam	574-582	false
Sandimmune	328-337	theophylline	585-596	false
Sandimmune	328-337	Theo-Dur	599-606	false
Sandimmune	328-337	vitamin C	614-622	false
protease inhibitors	365-383	Agenerase	386-394	false
protease inhibitors	365-383	Crixivan	397-404	false
protease inhibitors	365-383	Fortovase	407-415	false
protease inhibitors	365-383	Invirase	418-425	false
protease inhibitors	365-383	Kaletra	428-434	false
protease inhibitors	365-383	Norvir	437-442	false
protease inhibitors	365-383	Viracept	445-452	false
protease inhibitors	365-383	morphine	456-463	false
protease inhibitors	365-383	Astramorph	466-475	false
protease inhibitors	365-383	Kadian	478-483	false
protease inhibitors	365-383	MS Contin	486-494	false
protease inhibitors	365-383	phenylbutazone	498-511	false
protease inhibitors	365-383	prednisolone	514-525	false
protease inhibitors	365-383	Prelone	528-534	false
protease inhibitors	365-383	rifadin	538-544	false
protease inhibitors	365-383	rifampin	547-554	false
protease inhibitors	365-383	temazepam	574-582	false
protease inhibitors	365-383	theophylline	585-596	false
protease inhibitors	365-383	Theo-Dur	599-606	false
protease inhibitors	365-383	vitamin C	614-622	false
Agenerase	386-394	Crixivan	397-404	false
Agenerase	386-394	Fortovase	407-415	false
Agenerase	386-394	Invirase	418-425	false
Agenerase	386-394	Kaletra	428-434	false
Agenerase	386-394	Norvir	437-442	false
Agenerase	386-394	Viracept	445-452	false
Agenerase	386-394	morphine	456-463	false
Agenerase	386-394	Astramorph	466-475	false
Agenerase	386-394	Kadian	478-483	false
Agenerase	386-394	MS Contin	486-494	false
Agenerase	386-394	phenylbutazone	498-511	false
Agenerase	386-394	prednisolone	514-525	false
Agenerase	386-394	Prelone	528-534	false
Agenerase	386-394	rifadin	538-544	false
Agenerase	386-394	rifampin	547-554	false
Agenerase	386-394	temazepam	574-582	false
Agenerase	386-394	theophylline	585-596	false
Agenerase	386-394	Theo-Dur	599-606	false
Agenerase	386-394	vitamin C	614-622	false
Crixivan	397-404	Fortovase	407-415	false
Crixivan	397-404	Invirase	418-425	false
Crixivan	397-404	Kaletra	428-434	false
Crixivan	397-404	Norvir	437-442	false
Crixivan	397-404	Viracept	445-452	false
Crixivan	397-404	morphine	456-463	false
Crixivan	397-404	Astramorph	466-475	false
Crixivan	397-404	Kadian	478-483	false
Crixivan	397-404	MS Contin	486-494	false
Crixivan	397-404	phenylbutazone	498-511	false
Crixivan	397-404	prednisolone	514-525	false
Crixivan	397-404	Prelone	528-534	false
Crixivan	397-404	rifadin	538-544	false
Crixivan	397-404	rifampin	547-554	false
Crixivan	397-404	temazepam	574-582	false
Crixivan	397-404	theophylline	585-596	false
Crixivan	397-404	Theo-Dur	599-606	false
Crixivan	397-404	vitamin C	614-622	false
Fortovase	407-415	Invirase	418-425	false
Fortovase	407-415	Kaletra	428-434	false
Fortovase	407-415	Norvir	437-442	false
Fortovase	407-415	Viracept	445-452	false
Fortovase	407-415	morphine	456-463	false
Fortovase	407-415	Astramorph	466-475	false
Fortovase	407-415	Kadian	478-483	false
Fortovase	407-415	MS Contin	486-494	false
Fortovase	407-415	phenylbutazone	498-511	false
Fortovase	407-415	prednisolone	514-525	false
Fortovase	407-415	Prelone	528-534	false
Fortovase	407-415	rifadin	538-544	false
Fortovase	407-415	rifampin	547-554	false
Fortovase	407-415	temazepam	574-582	false
Fortovase	407-415	theophylline	585-596	false
Fortovase	407-415	Theo-Dur	599-606	false
Fortovase	407-415	vitamin C	614-622	false
Invirase	418-425	Kaletra	428-434	false
Invirase	418-425	Norvir	437-442	false
Invirase	418-425	Viracept	445-452	false
Invirase	418-425	morphine	456-463	false
Invirase	418-425	Astramorph	466-475	false
Invirase	418-425	Kadian	478-483	false
Invirase	418-425	MS Contin	486-494	false
Invirase	418-425	phenylbutazone	498-511	false
Invirase	418-425	prednisolone	514-525	false
Invirase	418-425	Prelone	528-534	false
Invirase	418-425	rifadin	538-544	false
Invirase	418-425	rifampin	547-554	false
Invirase	418-425	temazepam	574-582	false
Invirase	418-425	theophylline	585-596	false
Invirase	418-425	Theo-Dur	599-606	false
Invirase	418-425	vitamin C	614-622	false
Kaletra	428-434	Norvir	437-442	false
Kaletra	428-434	Viracept	445-452	false
Kaletra	428-434	morphine	456-463	false
Kaletra	428-434	Astramorph	466-475	false
Kaletra	428-434	Kadian	478-483	false
Kaletra	428-434	MS Contin	486-494	false
Kaletra	428-434	phenylbutazone	498-511	false
Kaletra	428-434	prednisolone	514-525	false
Kaletra	428-434	Prelone	528-534	false
Kaletra	428-434	rifadin	538-544	false
Kaletra	428-434	rifampin	547-554	false
Kaletra	428-434	temazepam	574-582	false
Kaletra	428-434	theophylline	585-596	false
Kaletra	428-434	Theo-Dur	599-606	false
Kaletra	428-434	vitamin C	614-622	false
Norvir	437-442	Viracept	445-452	false
Norvir	437-442	morphine	456-463	false
Norvir	437-442	Astramorph	466-475	false
Norvir	437-442	Kadian	478-483	false
Norvir	437-442	MS Contin	486-494	false
Norvir	437-442	phenylbutazone	498-511	false
Norvir	437-442	prednisolone	514-525	false
Norvir	437-442	Prelone	528-534	false
Norvir	437-442	rifadin	538-544	false
Norvir	437-442	rifampin	547-554	false
Norvir	437-442	temazepam	574-582	false
Norvir	437-442	theophylline	585-596	false
Norvir	437-442	Theo-Dur	599-606	false
Norvir	437-442	vitamin C	614-622	false
Viracept	445-452	morphine	456-463	false
Viracept	445-452	Astramorph	466-475	false
Viracept	445-452	Kadian	478-483	false
Viracept	445-452	MS Contin	486-494	false
Viracept	445-452	phenylbutazone	498-511	false
Viracept	445-452	prednisolone	514-525	false
Viracept	445-452	Prelone	528-534	false
Viracept	445-452	rifadin	538-544	false
Viracept	445-452	rifampin	547-554	false
Viracept	445-452	temazepam	574-582	false
Viracept	445-452	theophylline	585-596	false
Viracept	445-452	Theo-Dur	599-606	false
Viracept	445-452	vitamin C	614-622	false
morphine	456-463	Astramorph	466-475	false
morphine	456-463	Kadian	478-483	false
morphine	456-463	MS Contin	486-494	false
morphine	456-463	phenylbutazone	498-511	false
morphine	456-463	prednisolone	514-525	false
morphine	456-463	Prelone	528-534	false
morphine	456-463	rifadin	538-544	false
morphine	456-463	rifampin	547-554	false
morphine	456-463	temazepam	574-582	false
morphine	456-463	theophylline	585-596	false
morphine	456-463	Theo-Dur	599-606	false
morphine	456-463	vitamin C	614-622	false
Astramorph	466-475	Kadian	478-483	false
Astramorph	466-475	MS Contin	486-494	false
Astramorph	466-475	phenylbutazone	498-511	false
Astramorph	466-475	prednisolone	514-525	false
Astramorph	466-475	Prelone	528-534	false
Astramorph	466-475	rifadin	538-544	false
Astramorph	466-475	rifampin	547-554	false
Astramorph	466-475	temazepam	574-582	false
Astramorph	466-475	theophylline	585-596	false
Astramorph	466-475	Theo-Dur	599-606	false
Astramorph	466-475	vitamin C	614-622	false
Kadian	478-483	MS Contin	486-494	false
Kadian	478-483	phenylbutazone	498-511	false
Kadian	478-483	prednisolone	514-525	false
Kadian	478-483	Prelone	528-534	false
Kadian	478-483	rifadin	538-544	false
Kadian	478-483	rifampin	547-554	false
Kadian	478-483	temazepam	574-582	false
Kadian	478-483	theophylline	585-596	false
Kadian	478-483	Theo-Dur	599-606	false
Kadian	478-483	vitamin C	614-622	false
MS Contin	486-494	phenylbutazone	498-511	false
MS Contin	486-494	prednisolone	514-525	false
MS Contin	486-494	Prelone	528-534	false
MS Contin	486-494	rifadin	538-544	false
MS Contin	486-494	rifampin	547-554	false
MS Contin	486-494	temazepam	574-582	false
MS Contin	486-494	theophylline	585-596	false
MS Contin	486-494	Theo-Dur	599-606	false
MS Contin	486-494	vitamin C	614-622	false
phenylbutazone	498-511	prednisolone	514-525	false
phenylbutazone	498-511	Prelone	528-534	false
phenylbutazone	498-511	rifadin	538-544	false
phenylbutazone	498-511	rifampin	547-554	false
phenylbutazone	498-511	temazepam	574-582	false
phenylbutazone	498-511	theophylline	585-596	false
phenylbutazone	498-511	Theo-Dur	599-606	false
phenylbutazone	498-511	vitamin C	614-622	false
prednisolone	514-525	Prelone	528-534	false
prednisolone	514-525	rifadin	538-544	false
prednisolone	514-525	rifampin	547-554	false
prednisolone	514-525	temazepam	574-582	false
prednisolone	514-525	theophylline	585-596	false
prednisolone	514-525	Theo-Dur	599-606	false
prednisolone	514-525	vitamin C	614-622	false
Prelone	528-534	rifadin	538-544	false
Prelone	528-534	rifampin	547-554	false
Prelone	528-534	temazepam	574-582	false
Prelone	528-534	theophylline	585-596	false
Prelone	528-534	Theo-Dur	599-606	false
Prelone	528-534	vitamin C	614-622	false
rifadin	538-544	rifampin	547-554	false
rifadin	538-544	temazepam	574-582	false
rifadin	538-544	theophylline	585-596	false
rifadin	538-544	Theo-Dur	599-606	false
rifadin	538-544	vitamin C	614-622	false
rifampin	547-554	temazepam	574-582	false
rifampin	547-554	theophylline	585-596	false
rifampin	547-554	Theo-Dur	599-606	false
rifampin	547-554	vitamin C	614-622	false
temazepam	574-582	theophylline	585-596	false
temazepam	574-582	Theo-Dur	599-606	false
temazepam	574-582	vitamin C	614-622	false
theophylline	585-596	Theo-Dur	599-606	false
theophylline	585-596	vitamin C	614-622	false
Theo-Dur	599-606	vitamin C	614-622	false

Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).
ETOPOPHOS	47-55	levamisole hydrochloride	124-147	advise

High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
cyclosporin A	10-22	etoposide	92-100	mechanism
cyclosporin A	10-22	etoposide	132-140	false
cyclosporin A	10-22	etoposide	198-206	false
cyclosporin A	10-22	etoposide	220-228	false
etoposide	92-100	etoposide	132-140	false
etoposide	92-100	etoposide	198-206	false
etoposide	92-100	etoposide	220-228	false
etoposide	132-140	etoposide	198-206	false
etoposide	132-140	etoposide	220-228	false
etoposide	198-206	etoposide	220-228	false

Exemestane is extensively metabolized by CYP 3A4, but coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics.
Exemestane	0-9	ketoconazole	74-85	false
Exemestane	0-9	exemestane	148-157	false
ketoconazole	74-85	exemestane	148-157	false

Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
rifampicin	42-51	phenytoin	54-62	false
rifampicin	42-51	carbamazepine	65-77	false
rifampicin	42-51	phenobarbital	80-92	false
rifampicin	42-51	exemestane	154-163	mechanism
phenytoin	54-62	carbamazepine	65-77	false
phenytoin	54-62	phenobarbital	80-92	false
phenytoin	54-62	exemestane	154-163	mechanism
carbamazepine	65-77	phenobarbital	80-92	false
carbamazepine	65-77	exemestane	154-163	mechanism
phenobarbital	80-92	exemestane	154-163	mechanism

Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
probenecid	20-29	penciclovir	154-164	mechanism

The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase.
6-deoxy penciclovir	18-36	penciclovir	41-51	false

Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.
warfarin	32-39	theophylline	42-53	false
warfarin	32-39	phenytoin	56-64	false
warfarin	32-39	diazepam	67-74	false
warfarin	32-39	aminopyrine	77-87	false
warfarin	32-39	antipyrine	93-102	false
theophylline	42-53	phenytoin	56-64	false
theophylline	42-53	diazepam	67-74	false
theophylline	42-53	aminopyrine	77-87	false
theophylline	42-53	antipyrine	93-102	false
phenytoin	56-64	diazepam	67-74	false
phenytoin	56-64	aminopyrine	77-87	false
phenytoin	56-64	antipyrine	93-102	false
diazepam	67-74	aminopyrine	77-87	false
diazepam	67-74	antipyrine	93-102	false
aminopyrine	77-87	antipyrine	93-102	false

Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
Antiepileptic Drugs	30-48	Felbatol	67-74	false
Antiepileptic Drugs	30-48	antiepileptic drugs	80-98	false
Antiepileptic Drugs	30-48	AEDs	101-104	false
Antiepileptic Drugs	30-48	AEDs	157-160	false
Felbatol	67-74	antiepileptic drugs	80-98	mechanism
Felbatol	67-74	AEDs	101-104	mechanism
Felbatol	67-74	AEDs	157-160	false
antiepileptic drugs	80-98	AEDs	101-104	false
antiepileptic drugs	80-98	AEDs	157-160	false
AEDs	101-104	AEDs	157-160	false

The net effect of these interactions is summarized in the following table: AED AED Felbatol
AED	75-77	AED	79-81	false
AED	75-77	Felbatol	83-90	false
AED	79-81	Felbatol	83-90	false

Carbamazepine (CBZ)
Carbamazepine	0-12	CBZ	15-17	false

Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
Felbatol	20-27	Antiepileptic Drugs	39-57	false
Felbatol	20-27	Phenytoin	59-67	false
Felbatol	20-27	Felbatol	70-77	false
Felbatol	20-27	phenytoin	115-123	false
Antiepileptic Drugs	39-57	Phenytoin	59-67	false
Antiepileptic Drugs	39-57	Felbatol	70-77	false
Antiepileptic Drugs	39-57	phenytoin	115-123	false
Phenytoin	59-67	Felbatol	70-77	false
Phenytoin	59-67	phenytoin	115-123	false
Felbatol	70-77	phenytoin	115-123	mechanism

In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.
phenytoin	57-65	phenytoin	98-106	false

Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.
felbamate	15-23	phenytoin	97-105	mechanism

In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
phenytoin	21-29	felbamate	82-90	false
phenytoin	21-29	phenytoin	115-123	false
felbamate	82-90	phenytoin	115-123	advise

In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.
phenytoin	55-63	Felbatol	91-98	false
phenytoin	55-63	phenytoin	121-129	false
phenytoin	55-63	Felbatol	167-174	false
Felbatol	91-98	phenytoin	121-129	false
Felbatol	91-98	Felbatol	167-174	false
phenytoin	121-129	Felbatol	167-174	false

Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
Carbamazepine	0-12	Felbatol	15-22	false
Carbamazepine	0-12	carbamazepine	63-75	false
Carbamazepine	0-12	carbamazepine epoxide	135-155	false
Felbatol	15-22	carbamazepine	63-75	mechanism
Felbatol	15-22	carbamazepine epoxide	135-155	false
carbamazepine	63-75	carbamazepine epoxide	135-155	false

In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8 2 micrograms/mL.
carbamazepine	59-71	carbamazepine	105-117	false

The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
carbamazepine	4-16	felbamate	76-84	mechanism

Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of felbamate.
Carbamazepine epoxide	0-20	felbamate	128-136	false

In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.
carbamazepine	39-51	carbamazepine epoxide	57-77	false

Valproate: Felbatol  causes an increase in steady-state valproate concentrations.
Valproate	0-8	Felbatol	11-18	false
Valproate	0-8	valproate	56-64	false
Felbatol	11-18	valproate	56-64	mechanism

In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63 16 micrograms/mL.
valproate	41-49	valproate	83-91	false

Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.
felbamate	15-23	valproate	71-79	mechanism

Corresponding values for free valproate Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol , respectively.
valproate	30-38	Felbatol	127-134	false

The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.
valproate	34-42	valproate	69-77	false
valproate	34-42	Felbatol	163-170	false
valproate	69-77	Felbatol	163-170	false

Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
Phenobarbital	0-12	felbamate	35-43	false
Phenobarbital	0-12	phenobarbital	50-62	false
Phenobarbital	0-12	phenobarbital	86-98	false
Phenobarbital	0-12	phenobarbital	173-185	false
Phenobarbital	0-12	phenobarbital	219-231	false
felbamate	35-43	phenobarbital	50-62	mechanism
felbamate	35-43	phenobarbital	86-98	false
felbamate	35-43	phenobarbital	173-185	false
felbamate	35-43	phenobarbital	219-231	false
phenobarbital	50-62	phenobarbital	86-98	false
phenobarbital	50-62	phenobarbital	173-185	false
phenobarbital	50-62	phenobarbital	219-231	false
phenobarbital	86-98	phenobarbital	173-185	false
phenobarbital	86-98	phenobarbital	219-231	false
phenobarbital	173-185	phenobarbital	219-231	false

Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
Antiepileptic Drugs	17-35	Felbatol	40-47	false
Antiepileptic Drugs	17-35	Phenytoin	50-58	false
Antiepileptic Drugs	17-35	Phenytoin	61-69	false
Antiepileptic Drugs	17-35	Felbatol	122-129	false
Antiepileptic Drugs	17-35	felbamate	133-141	false
Antiepileptic Drugs	17-35	phenytoin	192-200	false
Antiepileptic Drugs	17-35	Felbatol	282-289	false
Antiepileptic Drugs	17-35	Felbatol	324-331	false
Felbatol	40-47	Phenytoin	50-58	false
Felbatol	40-47	Phenytoin	61-69	false
Felbatol	40-47	Felbatol	122-129	false
Felbatol	40-47	felbamate	133-141	false
Felbatol	40-47	phenytoin	192-200	false
Felbatol	40-47	Felbatol	282-289	false
Felbatol	40-47	Felbatol	324-331	false
Phenytoin	50-58	Phenytoin	61-69	false
Phenytoin	50-58	Felbatol	122-129	false
Phenytoin	50-58	felbamate	133-141	false
Phenytoin	50-58	phenytoin	192-200	false
Phenytoin	50-58	Felbatol	282-289	false
Phenytoin	50-58	Felbatol	324-331	false
Phenytoin	61-69	Felbatol	122-129	mechanism
Phenytoin	61-69	felbamate	133-141	mechanism
Phenytoin	61-69	phenytoin	192-200	false
Phenytoin	61-69	Felbatol	282-289	false
Phenytoin	61-69	Felbatol	324-331	false
Felbatol	122-129	felbamate	133-141	false
Felbatol	122-129	phenytoin	192-200	false
Felbatol	122-129	Felbatol	282-289	false
Felbatol	122-129	Felbatol	324-331	false
felbamate	133-141	phenytoin	192-200	false
felbamate	133-141	Felbatol	282-289	false
felbamate	133-141	Felbatol	324-331	false
phenytoin	192-200	Felbatol	282-289	mechanism
phenytoin	192-200	Felbatol	324-331	false
Felbatol	282-289	Felbatol	324-331	false

Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
Carbamazepine	0-12	Carbamazepine	15-27	false
Carbamazepine	0-12	Felbatol	84-91	false
Carbamazepine	0-12	carbamazepine	142-154	false
Carbamazepine	0-12	Felbatol	240-247	false
Carbamazepine	0-12	Felbatol	282-289	false
Carbamazepine	15-27	Felbatol	84-91	mechanism
Carbamazepine	15-27	carbamazepine	142-154	false
Carbamazepine	15-27	Felbatol	240-247	false
Carbamazepine	15-27	Felbatol	282-289	false
Felbatol	84-91	carbamazepine	142-154	false
Felbatol	84-91	Felbatol	240-247	false
Felbatol	84-91	Felbatol	282-289	false
carbamazepine	142-154	Felbatol	240-247	mechanism
carbamazepine	142-154	Felbatol	282-289	false
Felbatol	240-247	Felbatol	282-289	false

Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.
Valproate	0-8	valproate	73-81	false
Valproate	0-8	Felbatol	103-110	false
Valproate	0-8	valproate	157-165	false
Valproate	0-8	Felbatol	225-232	false
Valproate	0-8	felbamate	236-244	false
valproate	73-81	Felbatol	103-110	false
valproate	73-81	valproate	157-165	false
valproate	73-81	Felbatol	225-232	false
valproate	73-81	felbamate	236-244	false
Felbatol	103-110	valproate	157-165	false
Felbatol	103-110	Felbatol	225-232	false
Felbatol	103-110	felbamate	236-244	false
valproate	157-165	Felbatol	225-232	false
valproate	157-165	felbamate	236-244	false
Felbatol	225-232	felbamate	236-244	false

Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
Phenobarbital	0-12	phenobarbital	31-43	false
Phenobarbital	0-12	felbamate	63-71	false
phenobarbital	31-43	felbamate	63-71	mechanism

Steady-state plasma felbamate concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of felbamate a day.
felbamate	20-28	felbamate	180-188	false

Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.
Antacids	11-18	Felbatol	23-30	false
Antacids	11-18	Felbatol	88-95	false
Antacids	11-18	antacids	172-179	false
Felbatol	23-30	Felbatol	88-95	false
Felbatol	23-30	antacids	172-179	false
Felbatol	88-95	antacids	172-179	false

Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
Erythromycin	11-22	Felbatol	27-34	false
Erythromycin	11-22	erythromycin	61-72	false
Erythromycin	11-22	felbamate	182-190	false
Felbatol	27-34	erythromycin	61-72	false
Felbatol	27-34	felbamate	182-190	false
erythromycin	61-72	felbamate	182-190	false

Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
Felbatol	11-18	Combination Oral Contraceptives	33-63	false
Felbatol	11-18	contraceptive	146-158	false
Felbatol	11-18	ethinyl estradiol	185-201	false
Felbatol	11-18	gestodene	213-221	false
Felbatol	11-18	felbamate	269-277	false
Felbatol	11-18	contraceptive	347-359	false
Combination Oral Contraceptives	33-63	contraceptive	146-158	false
Combination Oral Contraceptives	33-63	ethinyl estradiol	185-201	false
Combination Oral Contraceptives	33-63	gestodene	213-221	false
Combination Oral Contraceptives	33-63	felbamate	269-277	false
Combination Oral Contraceptives	33-63	contraceptive	347-359	false
contraceptive	146-158	ethinyl estradiol	185-201	false
contraceptive	146-158	gestodene	213-221	false
contraceptive	146-158	felbamate	269-277	false
contraceptive	146-158	contraceptive	347-359	false
ethinyl estradiol	185-201	gestodene	213-221	false
ethinyl estradiol	185-201	felbamate	269-277	false
ethinyl estradiol	185-201	contraceptive	347-359	false
gestodene	213-221	felbamate	269-277	false
gestodene	213-221	contraceptive	347-359	false
felbamate	269-277	contraceptive	347-359	false

Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
Felbamate	0-8	gestodene	54-62	mechanism
Felbamate	0-8	ethinyl estradiol	158-174	false
gestodene	54-62	ethinyl estradiol	158-174	false

CYP3A4 Inhibitors Felodipine is metabolized by CYP3A4.
CYP3A4	0-5	CYP3A4	47-52	false

Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
ketoconazole	44-55	itraconazole	58-69	false
ketoconazole	44-55	erythromycin	72-83	false
ketoconazole	44-55	cimetidine	104-113	false
ketoconazole	44-55	felodipine	121-130	false
ketoconazole	44-55	felodipine	192-201	false
itraconazole	58-69	erythromycin	72-83	false
itraconazole	58-69	cimetidine	104-113	false
itraconazole	58-69	felodipine	121-130	false
itraconazole	58-69	felodipine	192-201	false
erythromycin	72-83	cimetidine	104-113	false
erythromycin	72-83	felodipine	121-130	false
erythromycin	72-83	felodipine	192-201	false
cimetidine	104-113	felodipine	121-130	false
cimetidine	104-113	felodipine	192-201	false
felodipine	121-130	felodipine	192-201	false

These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).
itraconazole	59-70	CYP3A4	82-87	false

Caution should be used when CYP3A4 inhibitors are co-administered with felodipine.
CYP3A4	28-33	felodipine	71-80	false

The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.
felodipine	130-139	itraconazole	146-157	false
felodipine	130-139	felodipine	298-307	false
itraconazole	146-157	felodipine	298-307	false

Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.
felodipine	34-43	PLENDIL	46-52	false
felodipine	34-43	erythromycin	60-71	false
felodipine	34-43	felodipine	191-200	false
PLENDIL	46-52	erythromycin	60-71	false
PLENDIL	46-52	felodipine	191-200	false
erythromycin	60-71	felodipine	191-200	false

Grapefruit juice Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine.
felodipine	38-47	felodipine	171-180	false

Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.
felodipine	32-41	cimetidine	48-57	false
felodipine	32-41	felodipine	167-176	false
cimetidine	48-57	felodipine	167-176	false

Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.
felodipine	49-58	metoprolol	80-89	false
felodipine	49-58	felodipine	154-163	false
metoprolol	80-89	felodipine	154-163	false

In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.
beta blockers	40-52	metoprolol	64-73	false
beta blockers	40-52	felodipine	111-120	false
metoprolol	64-73	felodipine	111-120	false

Digoxin  When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.
PLENDIL	39-45	digoxin	71-77	false

Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
Anticonvulsants	0-14	felodipine	78-87	false
Anticonvulsants	0-14	anticonvulsant	148-161	false
Anticonvulsants	0-14	phenytoin	176-184	false
Anticonvulsants	0-14	carbamazepine	187-199	false
Anticonvulsants	0-14	phenobarbital	205-217	false
felodipine	78-87	anticonvulsant	148-161	mechanism
felodipine	78-87	phenytoin	176-184	mechanism
felodipine	78-87	carbamazepine	187-199	mechanism
felodipine	78-87	phenobarbital	205-217	mechanism
anticonvulsant	148-161	phenytoin	176-184	false
anticonvulsant	148-161	carbamazepine	187-199	false
anticonvulsant	148-161	phenobarbital	205-217	false
phenytoin	176-184	carbamazepine	187-199	false
phenytoin	176-184	phenobarbital	205-217	false
carbamazepine	187-199	phenobarbital	205-217	false

Tacrolimus  Felodipine may increase the blood concentration of tacrolimus.
Felodipine	12-21	tacrolimus	63-72	false

When given concomitantly with felodipine, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.
felodipine	30-39	tacrolimus	46-55	false

Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.
felodipine	102-111	indomethacin	142-153	false
felodipine	102-111	spironolactone	158-171	false
indomethacin	142-153	spironolactone	158-171	false

Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
Fenfluramine	0-11	antihypertensive drugs	49-70	effect
Fenfluramine	0-11	guanethidine	79-90	effect
Fenfluramine	0-11	methyldopa	93-102	effect
Fenfluramine	0-11	reserpine	105-113	effect
antihypertensive drugs	49-70	guanethidine	79-90	false
antihypertensive drugs	49-70	methyldopa	93-102	false
antihypertensive drugs	49-70	reserpine	105-113	false
guanethidine	79-90	methyldopa	93-102	false
guanethidine	79-90	reserpine	105-113	false
methyldopa	93-102	reserpine	105-113	false

Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.
CNS depressant drugs	6-25	fenfluramine	74-85	advise

Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.
Anticoagulants	5-18	COUMARIN ANTICOAGULANTS	53-75	false
Anticoagulants	5-18	TRICOR	107-112	false
COUMARIN ANTICOAGULANTS	53-75	TRICOR	107-112	advise

HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
HMG-CoA reductase inhibitors	0-27	TRICOR	50-55	false
HMG-CoA reductase inhibitors	0-27	HMG-CoA reductase inhibitors	61-88	false
TRICOR	50-55	HMG-CoA reductase inhibitors	61-88	advise

Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
Resins	0-5	bile acid sequestrants	14-35	false
Resins	0-5	TRICOR	99-104	false
Resins	0-5	bile acid binding resin	150-172	false
bile acid sequestrants	14-35	TRICOR	99-104	false
bile acid sequestrants	14-35	bile acid binding resin	150-172	false
TRICOR	99-104	bile acid binding resin	150-172	mechanism

Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
Cyclosporine	0-11	cyclosporine	22-33	false
Cyclosporine	0-11	fibrate drugs	196-208	false
Cyclosporine	0-11	TRICOR	220-225	false
cyclosporine	22-33	fibrate drugs	196-208	effect
cyclosporine	22-33	TRICOR	220-225	effect
fibrate drugs	196-208	TRICOR	220-225	false

The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
TRICOR	32-37	immunosuppressants	44-61	advise

Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
fenofibrate	83-93	fenofibric acid	99-113	false

Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .
fenofibrate	11-21	bile acid binding resin	83-105	advise

Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
fenofibrate	30-40	TRICOR	63-68	false
fenofibrate	30-40	pravastatin	76-86	mechanism
fenofibrate	30-40	pravastatin	179-189	false
TRICOR	63-68	pravastatin	76-86	mechanism
TRICOR	63-68	pravastatin	179-189	false
pravastatin	76-86	pravastatin	179-189	false

A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid.
pravastatin	17-27	fenofibric acid	91-105	false

Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
fenofibrate	30-40	TRICOR	64-69	false
fenofibrate	30-40	atorvastatin	77-88	mechanism
fenofibrate	30-40	atorvastatin	205-216	false
TRICOR	64-69	atorvastatin	77-88	mechanism
TRICOR	64-69	atorvastatin	205-216	false
atorvastatin	77-88	atorvastatin	205-216	false

The atorvastatin Cmax values were not significantly affected by fenofibrate.
atorvastatin	4-15	fenofibrate	64-74	false

The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin
fenofibric acid	24-38	atorvastatin	75-86	false

Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.
Beta-Blockers	23-35	fenoldopam	57-66	false
Beta-Blockers	23-35	beta-blockers	73-85	false
fenoldopam	57-66	beta-blockers	73-85	advise

Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin.
fenoldopam	96-105	digitalis	155-163	false
fenoldopam	96-105	nitroglycerin	180-192	false
digitalis	155-163	nitroglycerin	180-192	false

There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).
antihypertensive agents	45-67	alpha-blockers	77-90	false
antihypertensive agents	45-67	calcium channel-blockers	93-116	false
antihypertensive agents	45-67	ACE inhibitors	119-132	false
antihypertensive agents	45-67	diuretics	139-147	false
antihypertensive agents	45-67	thiazide	155-162	false
alpha-blockers	77-90	calcium channel-blockers	93-116	false
alpha-blockers	77-90	ACE inhibitors	119-132	false
alpha-blockers	77-90	diuretics	139-147	false
alpha-blockers	77-90	thiazide	155-162	false
calcium channel-blockers	93-116	ACE inhibitors	119-132	false
calcium channel-blockers	93-116	diuretics	139-147	false
calcium channel-blockers	93-116	thiazide	155-162	false
ACE inhibitors	119-132	diuretics	139-147	false
ACE inhibitors	119-132	thiazide	155-162	false
diuretics	139-147	thiazide	155-162	false

The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
aspirin	24-30	fenoprofen	68-77	mechanism
aspirin	24-30	hydroxylated fenoprofen	161-183	false
fenoprofen	68-77	hydroxylated fenoprofen	161-183	false

Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.
fenoprofen	46-55	aspirin	61-67	mechanism
fenoprofen	46-55	fenoprofen	128-137	false
aspirin	61-67	fenoprofen	128-137	false

Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
Nalfon	8-13	aspirin	93-99	false
Nalfon	8-13	aspirin	119-125	false
Nalfon	8-13	Nalfon	162-167	false
Nalfon	8-13	Nalfon	193-198	false
Nalfon	8-13	salicylates	204-214	false
aspirin	93-99	aspirin	119-125	false
aspirin	93-99	Nalfon	162-167	false
aspirin	93-99	Nalfon	193-198	false
aspirin	93-99	salicylates	204-214	false
aspirin	119-125	Nalfon	162-167	mechanism
aspirin	119-125	Nalfon	193-198	false
aspirin	119-125	salicylates	204-214	false
Nalfon	162-167	Nalfon	193-198	false
Nalfon	162-167	salicylates	204-214	false
Nalfon	193-198	salicylates	204-214	advise

Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
phenobarbital	26-38	fenoprofen	126-135	mechanism

When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
phenobarbital	5-17	Nalfon	81-86	advise

Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.
hydantoins	19-28	sulfonamides	31-42	false
hydantoins	19-28	sulfonylureas	48-60	false
sulfonamides	31-42	sulfonylureas	48-60	false

In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.
coumarin-type anticoagulants	22-49	Nalfon	68-73	effect

Patients treated with Nalfon may be resistant to the effects of loop diuretics.
Nalfon	22-27	loop diuretics	64-77	effect

In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
Nalfon	22-27	steroid	35-41	advise
Nalfon	22-27	steroid	75-81	false
Nalfon	22-27	steroid	163-169	false
steroid	35-41	steroid	75-81	false
steroid	35-41	steroid	163-169	false
steroid	75-81	steroid	163-169	false

Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC  is given concurrently with agents that affect CYP3A4 activity.
Fentanyl	54-61	DURAGESIC	194-202	false

The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
fentanyl	35-42	ritonavir	49-57	mechanism
fentanyl	35-42	ketoconazole	98-109	mechanism
fentanyl	35-42	itraconazole	112-123	mechanism
fentanyl	35-42	troleandomycin	126-139	mechanism
fentanyl	35-42	clarithromycin	142-155	mechanism
fentanyl	35-42	nelfinavir	158-167	mechanism
fentanyl	35-42	fentanyl	214-221	false
ritonavir	49-57	ketoconazole	98-109	false
ritonavir	49-57	itraconazole	112-123	false
ritonavir	49-57	troleandomycin	126-139	false
ritonavir	49-57	clarithromycin	142-155	false
ritonavir	49-57	nelfinavir	158-167	false
ritonavir	49-57	fentanyl	214-221	false
ketoconazole	98-109	itraconazole	112-123	false
ketoconazole	98-109	troleandomycin	126-139	false
ketoconazole	98-109	clarithromycin	142-155	false
ketoconazole	98-109	nelfinavir	158-167	false
ketoconazole	98-109	fentanyl	214-221	false
itraconazole	112-123	troleandomycin	126-139	false
itraconazole	112-123	clarithromycin	142-155	false
itraconazole	112-123	nelfinavir	158-167	false
itraconazole	112-123	fentanyl	214-221	false
troleandomycin	126-139	clarithromycin	142-155	false
troleandomycin	126-139	nelfinavir	158-167	false
troleandomycin	126-139	fentanyl	214-221	false
clarithromycin	142-155	nelfinavir	158-167	false
clarithromycin	142-155	fentanyl	214-221	false
nelfinavir	158-167	fentanyl	214-221	false

The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
diltiazem	55-63	erythromycin	69-80	false
diltiazem	55-63	fentanyl	99-106	mechanism
diltiazem	55-63	fentanyl	142-149	false
erythromycin	69-80	fentanyl	99-106	mechanism
erythromycin	69-80	fentanyl	142-149	false
fentanyl	99-106	fentanyl	142-149	false

Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
Central Nervous System Depressants	0-33	DURAGESIC	59-67	false
Central Nervous System Depressants	0-33	fentanyl	71-78	false
Central Nervous System Depressants	0-33	central nervous system depressants	111-144	false
Central Nervous System Depressants	0-33	opioids	182-188	false
Central Nervous System Depressants	0-33	sedatives	191-199	false
Central Nervous System Depressants	0-33	hypnotics	202-210	false
Central Nervous System Depressants	0-33	tranquilizers	213-225	false
Central Nervous System Depressants	0-33	benzodiazepines	234-248	false
Central Nervous System Depressants	0-33	anesthetics	260-270	false
Central Nervous System Depressants	0-33	phenothiazines	273-286	false
Central Nervous System Depressants	0-33	skeletal muscle relaxants	289-313	false
Central Nervous System Depressants	0-33	alcohol	320-326	false
DURAGESIC	59-67	fentanyl	71-78	false
DURAGESIC	59-67	central nervous system depressants	111-144	effect
DURAGESIC	59-67	opioids	182-188	effect
DURAGESIC	59-67	sedatives	191-199	effect
DURAGESIC	59-67	hypnotics	202-210	effect
DURAGESIC	59-67	tranquilizers	213-225	effect
DURAGESIC	59-67	benzodiazepines	234-248	effect
DURAGESIC	59-67	anesthetics	260-270	effect
DURAGESIC	59-67	phenothiazines	273-286	effect
DURAGESIC	59-67	skeletal muscle relaxants	289-313	effect
DURAGESIC	59-67	alcohol	320-326	effect
fentanyl	71-78	central nervous system depressants	111-144	effect
fentanyl	71-78	opioids	182-188	effect
fentanyl	71-78	sedatives	191-199	effect
fentanyl	71-78	hypnotics	202-210	effect
fentanyl	71-78	tranquilizers	213-225	effect
fentanyl	71-78	benzodiazepines	234-248	effect
fentanyl	71-78	anesthetics	260-270	effect
fentanyl	71-78	phenothiazines	273-286	effect
fentanyl	71-78	skeletal muscle relaxants	289-313	effect
fentanyl	71-78	alcohol	320-326	effect
central nervous system depressants	111-144	opioids	182-188	false
central nervous system depressants	111-144	sedatives	191-199	false
central nervous system depressants	111-144	hypnotics	202-210	false
central nervous system depressants	111-144	tranquilizers	213-225	false
central nervous system depressants	111-144	benzodiazepines	234-248	false
central nervous system depressants	111-144	anesthetics	260-270	false
central nervous system depressants	111-144	phenothiazines	273-286	false
central nervous system depressants	111-144	skeletal muscle relaxants	289-313	false
central nervous system depressants	111-144	alcohol	320-326	false
opioids	182-188	sedatives	191-199	false
opioids	182-188	hypnotics	202-210	false
opioids	182-188	tranquilizers	213-225	false
opioids	182-188	benzodiazepines	234-248	false
opioids	182-188	anesthetics	260-270	false
opioids	182-188	phenothiazines	273-286	false
opioids	182-188	skeletal muscle relaxants	289-313	false
opioids	182-188	alcohol	320-326	false
sedatives	191-199	hypnotics	202-210	false
sedatives	191-199	tranquilizers	213-225	false
sedatives	191-199	benzodiazepines	234-248	false
sedatives	191-199	anesthetics	260-270	false
sedatives	191-199	phenothiazines	273-286	false
sedatives	191-199	skeletal muscle relaxants	289-313	false
sedatives	191-199	alcohol	320-326	false
hypnotics	202-210	tranquilizers	213-225	false
hypnotics	202-210	benzodiazepines	234-248	false
hypnotics	202-210	anesthetics	260-270	false
hypnotics	202-210	phenothiazines	273-286	false
hypnotics	202-210	skeletal muscle relaxants	289-313	false
hypnotics	202-210	alcohol	320-326	false
tranquilizers	213-225	benzodiazepines	234-248	false
tranquilizers	213-225	anesthetics	260-270	false
tranquilizers	213-225	phenothiazines	273-286	false
tranquilizers	213-225	skeletal muscle relaxants	289-313	false
tranquilizers	213-225	alcohol	320-326	false
benzodiazepines	234-248	anesthetics	260-270	false
benzodiazepines	234-248	phenothiazines	273-286	false
benzodiazepines	234-248	skeletal muscle relaxants	289-313	false
benzodiazepines	234-248	alcohol	320-326	false
anesthetics	260-270	phenothiazines	273-286	false
anesthetics	260-270	skeletal muscle relaxants	289-313	false
anesthetics	260-270	alcohol	320-326	false
phenothiazines	273-286	skeletal muscle relaxants	289-313	false
phenothiazines	273-286	alcohol	320-326	false
skeletal muscle relaxants	289-313	alcohol	320-326	false

MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
MAO Inhibitors	0-13	DURAGESIC	16-24	false
MAO Inhibitors	0-13	MAOI	84-87	false
MAO Inhibitors	0-13	MAO inhibitors	153-166	false
MAO Inhibitors	0-13	opioid analgesics	191-207	false
DURAGESIC	16-24	MAOI	84-87	advise
DURAGESIC	16-24	MAO inhibitors	153-166	false
DURAGESIC	16-24	opioid analgesics	191-207	false
MAOI	84-87	MAO inhibitors	153-166	false
MAOI	84-87	opioid analgesics	191-207	false
MAO inhibitors	153-166	opioid analgesics	191-207	advise

Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.
Erythromycin	22-33	Ketoconazole	39-50	false
Erythromycin	22-33	Fexofenadine	52-63	false
Ketoconazole	39-50	Fexofenadine	52-63	false

However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
fexofenadine hydrochloride	31-56	ketoconazole	70-81	mechanism
fexofenadine hydrochloride	31-56	erythromycin	86-97	mechanism
fexofenadine hydrochloride	31-56	fexofenadine	141-152	false
ketoconazole	70-81	erythromycin	86-97	false
ketoconazole	70-81	fexofenadine	141-152	false
erythromycin	86-97	fexofenadine	141-152	false

Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.
Fexofenadine	0-11	erythromycin	61-72	false
Fexofenadine	0-11	ketoconazole	77-88	false
erythromycin	61-72	ketoconazole	77-88	false

In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).
fexofenadine hydrochloride	23-48	erythromycin	127-138	false
fexofenadine hydrochloride	23-48	ketoconazole	164-175	false
erythromycin	127-138	ketoconazole	164-175	false

No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.
fexofenadine hydrochloride	95-120	erythromycin	158-169	false
fexofenadine hydrochloride	95-120	ketoconazole	174-185	false
erythromycin	158-169	ketoconazole	174-185	false

The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)
fexofenadine	93-104	fexofenadine hydrochloride	162-187	false

These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
ketoconazole	28-39	erythromycin	44-55	false
ketoconazole	28-39	fexofenadine	84-95	mechanism
erythromycin	44-55	fexofenadine	84-95	mechanism

This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.
fexofenadine	49-60	ketoconazole	205-216	false
fexofenadine	49-60	fexofenadine	228-239	false
fexofenadine	49-60	erythromycin	275-286	false
ketoconazole	205-216	fexofenadine	228-239	mechanism
ketoconazole	205-216	erythromycin	275-286	false
fexofenadine	228-239	erythromycin	275-286	false

Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
Antacids	23-30	fexofenadine hydrochloride	60-85	false
Antacids	23-30	aluminum	131-138	false
Antacids	23-30	magnesium	144-152	false
Antacids	23-30	antacid	165-171	false
Antacids	23-30	Maalox	174-179	false
Antacids	23-30	fexofenadine	193-204	false
fexofenadine hydrochloride	60-85	aluminum	131-138	mechanism
fexofenadine hydrochloride	60-85	magnesium	144-152	mechanism
fexofenadine hydrochloride	60-85	antacid	165-171	mechanism
fexofenadine hydrochloride	60-85	Maalox	174-179	mechanism
fexofenadine hydrochloride	60-85	fexofenadine	193-204	false
aluminum	131-138	magnesium	144-152	false
aluminum	131-138	antacid	165-171	false
aluminum	131-138	Maalox	174-179	false
aluminum	131-138	fexofenadine	193-204	false
magnesium	144-152	antacid	165-171	false
magnesium	144-152	Maalox	174-179	false
magnesium	144-152	fexofenadine	193-204	false
antacid	165-171	Maalox	174-179	false
antacid	165-171	fexofenadine	193-204	false
Maalox	174-179	fexofenadine	193-204	false

ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
ALLEGRA	0-6	aluminum	49-56	advise
ALLEGRA	0-6	magnesium	62-70	advise
ALLEGRA	0-6	antacids	83-90	false
aluminum	49-56	magnesium	62-70	false
aluminum	49-56	antacids	83-90	false
magnesium	62-70	antacids	83-90	false

Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA should be taken with water
fexofenadine	38-49	ALLEGRA	75-81	false

Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.
antipyrine	47-56	digoxin	59-65	false
antipyrine	47-56	propranolol	68-78	false
antipyrine	47-56	theophylline	81-92	false
antipyrine	47-56	warfarin	99-106	false
digoxin	59-65	propranolol	68-78	false
digoxin	59-65	theophylline	81-92	false
digoxin	59-65	warfarin	99-106	false
propranolol	68-78	theophylline	81-92	false
propranolol	68-78	warfarin	99-106	false
theophylline	81-92	warfarin	99-106	false

Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
finasteride	84-94	acetaminophen	167-179	false
finasteride	84-94	acetylsalicylic acid	182-201	false
finasteride	84-94	analgesics	216-225	false
finasteride	84-94	angiotensin-converting enzyme (ACE) inhibitors	228-273	false
finasteride	84-94	anticonvulsants	276-290	false
finasteride	84-94	benzodiazepines	293-307	false
finasteride	84-94	beta blockers	310-322	false
finasteride	84-94	calcium-channel blockers	325-348	false
finasteride	84-94	nitrates	359-366	false
finasteride	84-94	diuretics	369-377	false
finasteride	84-94	H2 antagonists	380-393	false
finasteride	84-94	HMG-CoA reductase inhibitors	396-423	false
finasteride	84-94	prostaglandin synthetase inhibitors	426-460	false
finasteride	84-94	NSAIDs	483-488	false
finasteride	84-94	quinolone anti-infectives	496-520	false
acetaminophen	167-179	acetylsalicylic acid	182-201	false
acetaminophen	167-179	analgesics	216-225	false
acetaminophen	167-179	angiotensin-converting enzyme (ACE) inhibitors	228-273	false
acetaminophen	167-179	anticonvulsants	276-290	false
acetaminophen	167-179	benzodiazepines	293-307	false
acetaminophen	167-179	beta blockers	310-322	false
acetaminophen	167-179	calcium-channel blockers	325-348	false
acetaminophen	167-179	nitrates	359-366	false
acetaminophen	167-179	diuretics	369-377	false
acetaminophen	167-179	H2 antagonists	380-393	false
acetaminophen	167-179	HMG-CoA reductase inhibitors	396-423	false
acetaminophen	167-179	prostaglandin synthetase inhibitors	426-460	false
acetaminophen	167-179	NSAIDs	483-488	false
acetaminophen	167-179	quinolone anti-infectives	496-520	false
acetylsalicylic acid	182-201	analgesics	216-225	false
acetylsalicylic acid	182-201	angiotensin-converting enzyme (ACE) inhibitors	228-273	false
acetylsalicylic acid	182-201	anticonvulsants	276-290	false
acetylsalicylic acid	182-201	benzodiazepines	293-307	false
acetylsalicylic acid	182-201	beta blockers	310-322	false
acetylsalicylic acid	182-201	calcium-channel blockers	325-348	false
acetylsalicylic acid	182-201	nitrates	359-366	false
acetylsalicylic acid	182-201	diuretics	369-377	false
acetylsalicylic acid	182-201	H2 antagonists	380-393	false
acetylsalicylic acid	182-201	HMG-CoA reductase inhibitors	396-423	false
acetylsalicylic acid	182-201	prostaglandin synthetase inhibitors	426-460	false
acetylsalicylic acid	182-201	NSAIDs	483-488	false
acetylsalicylic acid	182-201	quinolone anti-infectives	496-520	false
analgesics	216-225	angiotensin-converting enzyme (ACE) inhibitors	228-273	false
analgesics	216-225	anticonvulsants	276-290	false
analgesics	216-225	benzodiazepines	293-307	false
analgesics	216-225	beta blockers	310-322	false
analgesics	216-225	calcium-channel blockers	325-348	false
analgesics	216-225	nitrates	359-366	false
analgesics	216-225	diuretics	369-377	false
analgesics	216-225	H2 antagonists	380-393	false
analgesics	216-225	HMG-CoA reductase inhibitors	396-423	false
analgesics	216-225	prostaglandin synthetase inhibitors	426-460	false
analgesics	216-225	NSAIDs	483-488	false
analgesics	216-225	quinolone anti-infectives	496-520	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	anticonvulsants	276-290	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	benzodiazepines	293-307	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	beta blockers	310-322	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	calcium-channel blockers	325-348	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	nitrates	359-366	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	diuretics	369-377	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	H2 antagonists	380-393	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	HMG-CoA reductase inhibitors	396-423	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	prostaglandin synthetase inhibitors	426-460	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	NSAIDs	483-488	false
angiotensin-converting enzyme (ACE) inhibitors	228-273	quinolone anti-infectives	496-520	false
anticonvulsants	276-290	benzodiazepines	293-307	false
anticonvulsants	276-290	beta blockers	310-322	false
anticonvulsants	276-290	calcium-channel blockers	325-348	false
anticonvulsants	276-290	nitrates	359-366	false
anticonvulsants	276-290	diuretics	369-377	false
anticonvulsants	276-290	H2 antagonists	380-393	false
anticonvulsants	276-290	HMG-CoA reductase inhibitors	396-423	false
anticonvulsants	276-290	prostaglandin synthetase inhibitors	426-460	false
anticonvulsants	276-290	NSAIDs	483-488	false
anticonvulsants	276-290	quinolone anti-infectives	496-520	false
benzodiazepines	293-307	beta blockers	310-322	false
benzodiazepines	293-307	calcium-channel blockers	325-348	false
benzodiazepines	293-307	nitrates	359-366	false
benzodiazepines	293-307	diuretics	369-377	false
benzodiazepines	293-307	H2 antagonists	380-393	false
benzodiazepines	293-307	HMG-CoA reductase inhibitors	396-423	false
benzodiazepines	293-307	prostaglandin synthetase inhibitors	426-460	false
benzodiazepines	293-307	NSAIDs	483-488	false
benzodiazepines	293-307	quinolone anti-infectives	496-520	false
beta blockers	310-322	calcium-channel blockers	325-348	false
beta blockers	310-322	nitrates	359-366	false
beta blockers	310-322	diuretics	369-377	false
beta blockers	310-322	H2 antagonists	380-393	false
beta blockers	310-322	HMG-CoA reductase inhibitors	396-423	false
beta blockers	310-322	prostaglandin synthetase inhibitors	426-460	false
beta blockers	310-322	NSAIDs	483-488	false
beta blockers	310-322	quinolone anti-infectives	496-520	false
calcium-channel blockers	325-348	nitrates	359-366	false
calcium-channel blockers	325-348	diuretics	369-377	false
calcium-channel blockers	325-348	H2 antagonists	380-393	false
calcium-channel blockers	325-348	HMG-CoA reductase inhibitors	396-423	false
calcium-channel blockers	325-348	prostaglandin synthetase inhibitors	426-460	false
calcium-channel blockers	325-348	NSAIDs	483-488	false
calcium-channel blockers	325-348	quinolone anti-infectives	496-520	false
nitrates	359-366	diuretics	369-377	false
nitrates	359-366	H2 antagonists	380-393	false
nitrates	359-366	HMG-CoA reductase inhibitors	396-423	false
nitrates	359-366	prostaglandin synthetase inhibitors	426-460	false
nitrates	359-366	NSAIDs	483-488	false
nitrates	359-366	quinolone anti-infectives	496-520	false
diuretics	369-377	H2 antagonists	380-393	false
diuretics	369-377	HMG-CoA reductase inhibitors	396-423	false
diuretics	369-377	prostaglandin synthetase inhibitors	426-460	false
diuretics	369-377	NSAIDs	483-488	false
diuretics	369-377	quinolone anti-infectives	496-520	false
H2 antagonists	380-393	HMG-CoA reductase inhibitors	396-423	false
H2 antagonists	380-393	prostaglandin synthetase inhibitors	426-460	false
H2 antagonists	380-393	NSAIDs	483-488	false
H2 antagonists	380-393	quinolone anti-infectives	496-520	false
HMG-CoA reductase inhibitors	396-423	prostaglandin synthetase inhibitors	426-460	false
HMG-CoA reductase inhibitors	396-423	NSAIDs	483-488	false
HMG-CoA reductase inhibitors	396-423	quinolone anti-infectives	496-520	false
prostaglandin synthetase inhibitors	426-460	NSAIDs	483-488	false
prostaglandin synthetase inhibitors	426-460	quinolone anti-infectives	496-520	false
NSAIDs	483-488	quinolone anti-infectives	496-520	false

In clinical studies with PROPECIA (finasteride, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.
PROPECIA	25-32	finasteride	35-45	false

Further, in clinical studies with PROSCAR (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.
PROSCAR	34-40	finasteride	43-53	false

TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.
TAMBOCOR	0-7	digitalis preparations	53-74	false
TAMBOCOR	0-7	beta-adrenergic blocking agents	79-109	false
digitalis preparations	53-74	beta-adrenergic blocking agents	79-109	false

During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
TAMBOCOR	48-55	digoxin	113-119	mechanism
TAMBOCOR	48-55	digoxin	151-157	false
digoxin	113-119	digoxin	151-157	false

In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
TAMBOCOR	48-55	propranolol	61-71	mechanism
TAMBOCOR	48-55	flecainide	94-103	false
TAMBOCOR	48-55	propranolol	141-151	false
propranolol	61-71	flecainide	94-103	false
propranolol	61-71	propranolol	141-151	false
flecainide	94-103	propranolol	141-151	false

In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects;
TAMBOCOR	34-41	propranolol	47-57	false

The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
TAMBOCOR	45-52	propranolol	58-68	effect

In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects.
TAMBOCOR	3-10	beta blockers	57-69	false

Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
beta blockers	72-84	flecainide	90-99	effect

TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction.
TAMBOCOR	0-7	diuretics	63-71	false

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
phenytoin	59-67	phenobarbital	70-82	false
phenytoin	59-67	carbamazepine	85-97	false
phenytoin	59-67	flecainide	145-154	mechanism
phenobarbital	70-82	carbamazepine	85-97	false
phenobarbital	70-82	flecainide	145-154	mechanism
carbamazepine	85-97	flecainide	145-154	mechanism

In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
cimetidine	30-39	flecainide	75-84	mechanism

When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
amiodarone	5-14	flecainide	28-37	mechanism
amiodarone	5-14	flecainide	55-64	false
amiodarone	5-14	flecainide	124-133	false
flecainide	28-37	flecainide	55-64	false
flecainide	28-37	flecainide	124-133	false
flecainide	55-64	flecainide	124-133	false

Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
quinidine	48-56	flecainide	104-113	mechanism
quinidine	48-56	flecainide	147-156	false
flecainide	104-113	flecainide	147-156	false

There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil.
TAMBOCOR	62-69	disopyramide	82-93	false
TAMBOCOR	62-69	verapamil	98-106	false
disopyramide	82-93	verapamil	98-106	false

Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
TAMBOCOR	104-111	disopyramide	134-145	false
TAMBOCOR	104-111	verapamil	151-159	false
TAMBOCOR	104-111	TAMBOCOR	202-209	false
disopyramide	134-145	verapamil	151-159	false
disopyramide	134-145	TAMBOCOR	202-209	advise
verapamil	151-159	TAMBOCOR	202-209	advise

There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.
TAMBOCOR	66-73	nifedipine	80-89	false
TAMBOCOR	66-73	diltiazem	94-102	false
nifedipine	80-89	diltiazem	94-102	false

Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
Cytosine arabinoside	0-19	cytostatic agent	24-39	false
Cytosine arabinoside	0-19	flucytosine	101-111	effect
cytostatic agent	24-39	flucytosine	101-111	false

The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.
FLUDARA	11-17	pentostatin	53-63	advise

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
Amphotericin B	0-13	potassium-depleting diuretics	18-46	false
Amphotericin B	0-13	benzothiadiazines	49-65	false
Amphotericin B	0-13	ethacrynic acid	86-100	false
Amphotericin B	0-13	furosemide	106-115	false
potassium-depleting diuretics	18-46	benzothiadiazines	49-65	false
potassium-depleting diuretics	18-46	ethacrynic acid	86-100	false
potassium-depleting diuretics	18-46	furosemide	106-115	false
benzothiadiazines	49-65	ethacrynic acid	86-100	false
benzothiadiazines	49-65	furosemide	106-115	false
ethacrynic acid	86-100	furosemide	106-115	false

Digitalis glycosides enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia.
Digitalis glycosides	0-19	digitalis	60-68	false

Antidiabetic drugs (oral agents and insulin) diminished antidiabetic effect.
Antidiabetic drugs	0-17	insulin	36-42	false

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.
salicylate	7-16	steroids	65-72	false
salicylate	7-16	aspirin	101-107	false
steroids	65-72	aspirin	101-107	effect

Monitor salicylate levels or the therapeutic effect for which aspirin is given;
salicylate	8-17	aspirin	62-68	false

Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
Barbiturates	0-11	phenytoin	14-22	false
Barbiturates	0-11	rifampin	28-35	false
Barbiturates	0-11	fludrocortisone acetate	70-92	mechanism
phenytoin	14-22	rifampin	28-35	false
phenytoin	14-22	fludrocortisone acetate	70-92	mechanism
rifampin	28-35	fludrocortisone acetate	70-92	mechanism

Observe the patient for possible diminished effect of steroid and increase the steroid dosage accordingly.
steroid	54-60	steroid	79-85	false

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
Anabolic steroids	0-16	androgens	47-55	false
Anabolic steroids	0-16	oxymetholone	65-76	false
Anabolic steroids	0-16	methandrostenolone	79-96	false
Anabolic steroids	0-16	norethandrolone	99-113	false
androgens	47-55	oxymetholone	65-76	false
androgens	47-55	methandrostenolone	79-96	false
androgens	47-55	norethandrolone	99-113	false
oxymetholone	65-76	methandrostenolone	79-96	false
oxymetholone	65-76	norethandrolone	99-113	false
methandrostenolone	79-96	norethandrolone	99-113	false

When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.
estrogen	5-12	corticosteroid	51-64	false
estrogen	5-12	estrogen	133-140	false
corticosteroid	51-64	estrogen	133-140	false

Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied;
central nervous system depressants	17-50	benzodiazepines	63-77	false

however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
ROMAZICON	52-60	narcotics	85-93	false
ROMAZICON	52-60	anesthetics	109-119	false
ROMAZICON	52-60	muscle relaxants	122-137	false
narcotics	85-93	anesthetics	109-119	false
narcotics	85-93	muscle relaxants	122-137	false
anesthetics	109-119	muscle relaxants	122-137	false

Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
ROMAZICON	43-51	cyclic antidepressants	203-224	effect
ROMAZICON	43-51	benzodiazepine	263-276	false
ROMAZICON	43-51	flumazenil	288-297	false
cyclic antidepressants	203-224	benzodiazepine	263-276	false
cyclic antidepressants	203-224	flumazenil	288-297	false
benzodiazepine	263-276	flumazenil	288-297	false

Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
ROMAZICON	9-17	benzodiazepine	121-134	effect

ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.
ROMAZICON	0-8	benzodiazepines	40-54	effect

The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.
zopiclone	79-87	ROMAZICON	142-150	effect

The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa.
benzodiazepines	24-38	flumazenil	73-82	false

There is no pharmacokinetic interaction between ethanol and flumazenil.
ethanol	48-54	flumazenil	60-69	false

Use in Ambulatory Patients The effects of ROMAZICON may wear off before a long-acting benzodiazepine is completely cleared from the body.
ROMAZICON	42-50	long-acting benzodiazepine	74-99	false

An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.
long-acting benzodiazepines	82-108	diazepam	119-126	false
long-acting benzodiazepines	82-108	short-acting benzodiazepines	147-174	false
long-acting benzodiazepines	82-108	midazolam	195-203	false
diazepam	119-126	short-acting benzodiazepines	147-174	false
diazepam	119-126	midazolam	195-203	false
short-acting benzodiazepines	147-174	midazolam	195-203	false

Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
benzodiazepines	84-98	benzodiazepine	215-228	false
benzodiazepines	84-98	alcohol	231-237	false
benzodiazepines	84-98	sedative	243-250	false
benzodiazepines	84-98	ROMAZICON	322-330	false
benzodiazepine	215-228	alcohol	231-237	false
benzodiazepine	215-228	sedative	243-250	false
benzodiazepine	215-228	ROMAZICON	322-330	false
alcohol	231-237	sedative	243-250	false
alcohol	231-237	ROMAZICON	322-330	false
sedative	243-250	ROMAZICON	322-330	false

Talk to your doctor if you are taking certain antibiotics such as erythromycin, clarithromycin or azithromycin.
antibiotics	46-56	erythromycin	66-77	false
antibiotics	46-56	clarithromycin	80-93	false
antibiotics	46-56	azithromycin	98-109	false
erythromycin	66-77	clarithromycin	80-93	false
erythromycin	66-77	azithromycin	98-109	false
clarithromycin	80-93	azithromycin	98-109	false

Caution should be exercised when taking this medicine certain antibiotics, such as erythromycin, clarithromycin, or azithromycin.
antibiotics	62-72	erythromycin	83-94	false
antibiotics	62-72	clarithromycin	97-110	false
antibiotics	62-72	azithromycin	116-127	false
erythromycin	83-94	clarithromycin	97-110	false
erythromycin	83-94	azithromycin	116-127	false
clarithromycin	97-110	azithromycin	116-127	false

Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.
escitalopram	28-39	non-selective MAO inhibitor	59-85	advise

Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.
MAO inhibitor	31-43	escitalopram	61-72	advise

Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
blood thinner	63-75	Coumadin	79-86	false
blood thinner	63-75	antidepressants	95-109	false
blood thinner	63-75	metoprolol	111-120	false
blood thinner	63-75	antihistamines	122-135	false
blood thinner	63-75	carbamazepine	137-149	false
blood thinner	63-75	Tegretol	152-159	false
blood thinner	63-75	cimetidine	162-171	false
blood thinner	63-75	Tagamet	174-180	false
blood thinner	63-75	estrogens	183-191	false
blood thinner	63-75	fluoxetine	193-202	false
blood thinner	63-75	Prozac	205-210	false
blood thinner	63-75	Sporanox	228-235	false
blood thinner	63-75	ketoconazole	238-249	false
blood thinner	63-75	Nizoral	252-258	false
blood thinner	63-75	levodopa	261-268	false
blood thinner	63-75	lithium	270-276	false
blood thinner	63-75	muscle relaxants	278-293	false
Coumadin	79-86	antidepressants	95-109	false
Coumadin	79-86	metoprolol	111-120	false
Coumadin	79-86	antihistamines	122-135	false
Coumadin	79-86	carbamazepine	137-149	false
Coumadin	79-86	Tegretol	152-159	false
Coumadin	79-86	cimetidine	162-171	false
Coumadin	79-86	Tagamet	174-180	false
Coumadin	79-86	estrogens	183-191	false
Coumadin	79-86	fluoxetine	193-202	false
Coumadin	79-86	Prozac	205-210	false
Coumadin	79-86	Sporanox	228-235	false
Coumadin	79-86	ketoconazole	238-249	false
Coumadin	79-86	Nizoral	252-258	false
Coumadin	79-86	levodopa	261-268	false
Coumadin	79-86	lithium	270-276	false
Coumadin	79-86	muscle relaxants	278-293	false
antidepressants	95-109	metoprolol	111-120	false
antidepressants	95-109	antihistamines	122-135	false
antidepressants	95-109	carbamazepine	137-149	false
antidepressants	95-109	Tegretol	152-159	false
antidepressants	95-109	cimetidine	162-171	false
antidepressants	95-109	Tagamet	174-180	false
antidepressants	95-109	estrogens	183-191	false
antidepressants	95-109	fluoxetine	193-202	false
antidepressants	95-109	Prozac	205-210	false
antidepressants	95-109	Sporanox	228-235	false
antidepressants	95-109	ketoconazole	238-249	false
antidepressants	95-109	Nizoral	252-258	false
antidepressants	95-109	levodopa	261-268	false
antidepressants	95-109	lithium	270-276	false
antidepressants	95-109	muscle relaxants	278-293	false
metoprolol	111-120	antihistamines	122-135	false
metoprolol	111-120	carbamazepine	137-149	false
metoprolol	111-120	Tegretol	152-159	false
metoprolol	111-120	cimetidine	162-171	false
metoprolol	111-120	Tagamet	174-180	false
metoprolol	111-120	estrogens	183-191	false
metoprolol	111-120	fluoxetine	193-202	false
metoprolol	111-120	Prozac	205-210	false
metoprolol	111-120	Sporanox	228-235	false
metoprolol	111-120	ketoconazole	238-249	false
metoprolol	111-120	Nizoral	252-258	false
metoprolol	111-120	levodopa	261-268	false
metoprolol	111-120	lithium	270-276	false
metoprolol	111-120	muscle relaxants	278-293	false
antihistamines	122-135	carbamazepine	137-149	false
antihistamines	122-135	Tegretol	152-159	false
antihistamines	122-135	cimetidine	162-171	false
antihistamines	122-135	Tagamet	174-180	false
antihistamines	122-135	estrogens	183-191	false
antihistamines	122-135	fluoxetine	193-202	false
antihistamines	122-135	Prozac	205-210	false
antihistamines	122-135	Sporanox	228-235	false
antihistamines	122-135	ketoconazole	238-249	false
antihistamines	122-135	Nizoral	252-258	false
antihistamines	122-135	levodopa	261-268	false
antihistamines	122-135	lithium	270-276	false
antihistamines	122-135	muscle relaxants	278-293	false
carbamazepine	137-149	Tegretol	152-159	false
carbamazepine	137-149	cimetidine	162-171	false
carbamazepine	137-149	Tagamet	174-180	false
carbamazepine	137-149	estrogens	183-191	false
carbamazepine	137-149	fluoxetine	193-202	false
carbamazepine	137-149	Prozac	205-210	false
carbamazepine	137-149	Sporanox	228-235	false
carbamazepine	137-149	ketoconazole	238-249	false
carbamazepine	137-149	Nizoral	252-258	false
carbamazepine	137-149	levodopa	261-268	false
carbamazepine	137-149	lithium	270-276	false
carbamazepine	137-149	muscle relaxants	278-293	false
Tegretol	152-159	cimetidine	162-171	false
Tegretol	152-159	Tagamet	174-180	false
Tegretol	152-159	estrogens	183-191	false
Tegretol	152-159	fluoxetine	193-202	false
Tegretol	152-159	Prozac	205-210	false
Tegretol	152-159	Sporanox	228-235	false
Tegretol	152-159	ketoconazole	238-249	false
Tegretol	152-159	Nizoral	252-258	false
Tegretol	152-159	levodopa	261-268	false
Tegretol	152-159	lithium	270-276	false
Tegretol	152-159	muscle relaxants	278-293	false
cimetidine	162-171	Tagamet	174-180	false
cimetidine	162-171	estrogens	183-191	false
cimetidine	162-171	fluoxetine	193-202	false
cimetidine	162-171	Prozac	205-210	false
cimetidine	162-171	Sporanox	228-235	false
cimetidine	162-171	ketoconazole	238-249	false
cimetidine	162-171	Nizoral	252-258	false
cimetidine	162-171	levodopa	261-268	false
cimetidine	162-171	lithium	270-276	false
cimetidine	162-171	muscle relaxants	278-293	false
Tagamet	174-180	estrogens	183-191	false
Tagamet	174-180	fluoxetine	193-202	false
Tagamet	174-180	Prozac	205-210	false
Tagamet	174-180	Sporanox	228-235	false
Tagamet	174-180	ketoconazole	238-249	false
Tagamet	174-180	Nizoral	252-258	false
Tagamet	174-180	levodopa	261-268	false
Tagamet	174-180	lithium	270-276	false
Tagamet	174-180	muscle relaxants	278-293	false
estrogens	183-191	fluoxetine	193-202	false
estrogens	183-191	Prozac	205-210	false
estrogens	183-191	Sporanox	228-235	false
estrogens	183-191	ketoconazole	238-249	false
estrogens	183-191	Nizoral	252-258	false
estrogens	183-191	levodopa	261-268	false
estrogens	183-191	lithium	270-276	false
estrogens	183-191	muscle relaxants	278-293	false
fluoxetine	193-202	Prozac	205-210	false
fluoxetine	193-202	Sporanox	228-235	false
fluoxetine	193-202	ketoconazole	238-249	false
fluoxetine	193-202	Nizoral	252-258	false
fluoxetine	193-202	levodopa	261-268	false
fluoxetine	193-202	lithium	270-276	false
fluoxetine	193-202	muscle relaxants	278-293	false
Prozac	205-210	Sporanox	228-235	false
Prozac	205-210	ketoconazole	238-249	false
Prozac	205-210	Nizoral	252-258	false
Prozac	205-210	levodopa	261-268	false
Prozac	205-210	lithium	270-276	false
Prozac	205-210	muscle relaxants	278-293	false
Sporanox	228-235	ketoconazole	238-249	false
Sporanox	228-235	Nizoral	252-258	false
Sporanox	228-235	levodopa	261-268	false
Sporanox	228-235	lithium	270-276	false
Sporanox	228-235	muscle relaxants	278-293	false
ketoconazole	238-249	Nizoral	252-258	false
ketoconazole	238-249	levodopa	261-268	false
ketoconazole	238-249	lithium	270-276	false
ketoconazole	238-249	muscle relaxants	278-293	false
Nizoral	252-258	levodopa	261-268	false
Nizoral	252-258	lithium	270-276	false
Nizoral	252-258	muscle relaxants	278-293	false
levodopa	261-268	lithium	270-276	false
levodopa	261-268	muscle relaxants	278-293	false
lithium	270-276	muscle relaxants	278-293	false

Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
oxyphenbutazone	29-43	androgens	49-57	mechanism
oxyphenbutazone	29-43	oxyphenbutazone	98-112	false
androgens	49-57	oxyphenbutazone	98-112	false

In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
androgens	47-55	insulin	99-105	effect

Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
Flupenthixol	19-30	Monoamine oxidase inhibitors	67-94	int
Flupenthixol	19-30	MAOI	97-100	int
Flupenthixol	19-30	MAOI	104-107	false
Flupenthixol	19-30	flupenthixol	136-147	false
Flupenthixol	19-30	Arecoline	168-176	false
Flupenthixol	19-30	Ethanol	194-200	false
Flupenthixol	19-30	Flupenthixol	203-214	false
Flupenthixol	19-30	Ethanol	220-226	false
Flupenthixol	19-30	Tricyclic antidepressants	260-284	false
Flupenthixol	19-30	Flupenthixol	287-298	false
Flupenthixol	19-30	Tricyclic antidepressants	324-348	false
Monoamine oxidase inhibitors	67-94	MAOI	97-100	false
Monoamine oxidase inhibitors	67-94	MAOI	104-107	false
Monoamine oxidase inhibitors	67-94	flupenthixol	136-147	false
Monoamine oxidase inhibitors	67-94	Arecoline	168-176	false
Monoamine oxidase inhibitors	67-94	Ethanol	194-200	false
Monoamine oxidase inhibitors	67-94	Flupenthixol	203-214	false
Monoamine oxidase inhibitors	67-94	Ethanol	220-226	false
Monoamine oxidase inhibitors	67-94	Tricyclic antidepressants	260-284	false
Monoamine oxidase inhibitors	67-94	Flupenthixol	287-298	false
Monoamine oxidase inhibitors	67-94	Tricyclic antidepressants	324-348	false
MAOI	97-100	MAOI	104-107	false
MAOI	97-100	flupenthixol	136-147	false
MAOI	97-100	Arecoline	168-176	false
MAOI	97-100	Ethanol	194-200	false
MAOI	97-100	Flupenthixol	203-214	false
MAOI	97-100	Ethanol	220-226	false
MAOI	97-100	Tricyclic antidepressants	260-284	false
MAOI	97-100	Flupenthixol	287-298	false
MAOI	97-100	Tricyclic antidepressants	324-348	false
MAOI	104-107	flupenthixol	136-147	effect
MAOI	104-107	Arecoline	168-176	false
MAOI	104-107	Ethanol	194-200	false
MAOI	104-107	Flupenthixol	203-214	false
MAOI	104-107	Ethanol	220-226	false
MAOI	104-107	Tricyclic antidepressants	260-284	false
MAOI	104-107	Flupenthixol	287-298	false
MAOI	104-107	Tricyclic antidepressants	324-348	false
flupenthixol	136-147	Arecoline	168-176	false
flupenthixol	136-147	Ethanol	194-200	false
flupenthixol	136-147	Flupenthixol	203-214	false
flupenthixol	136-147	Ethanol	220-226	false
flupenthixol	136-147	Tricyclic antidepressants	260-284	false
flupenthixol	136-147	Flupenthixol	287-298	false
flupenthixol	136-147	Tricyclic antidepressants	324-348	false
Arecoline	168-176	Ethanol	194-200	false
Arecoline	168-176	Flupenthixol	203-214	false
Arecoline	168-176	Ethanol	220-226	false
Arecoline	168-176	Tricyclic antidepressants	260-284	false
Arecoline	168-176	Flupenthixol	287-298	false
Arecoline	168-176	Tricyclic antidepressants	324-348	false
Ethanol	194-200	Flupenthixol	203-214	false
Ethanol	194-200	Ethanol	220-226	false
Ethanol	194-200	Tricyclic antidepressants	260-284	false
Ethanol	194-200	Flupenthixol	287-298	false
Ethanol	194-200	Tricyclic antidepressants	324-348	false
Flupenthixol	203-214	Ethanol	220-226	effect
Flupenthixol	203-214	Tricyclic antidepressants	260-284	false
Flupenthixol	203-214	Flupenthixol	287-298	false
Flupenthixol	203-214	Tricyclic antidepressants	324-348	false
Ethanol	220-226	Tricyclic antidepressants	260-284	false
Ethanol	220-226	Flupenthixol	287-298	false
Ethanol	220-226	Tricyclic antidepressants	324-348	false
Tricyclic antidepressants	260-284	Flupenthixol	287-298	false
Tricyclic antidepressants	260-284	Tricyclic antidepressants	324-348	false
Flupenthixol	287-298	Tricyclic antidepressants	324-348	effect

Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
Antacids	0-7	flurbiprofen	28-39	false
Antacids	0-7	antacid	89-95	false
Antacids	0-7	flurbiprofen	130-141	false
flurbiprofen	28-39	antacid	89-95	false
flurbiprofen	28-39	flurbiprofen	130-141	false
antacid	89-95	flurbiprofen	130-141	false

Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
Anticoagulants	0-13	Flurbiprofen	16-27	false
Anticoagulants	0-13	nonsteroidal anti-inflammatory drugs	40-75	false
Anticoagulants	0-13	anti-coagulants	145-159	false
Flurbiprofen	16-27	nonsteroidal anti-inflammatory drugs	40-75	false
Flurbiprofen	16-27	anti-coagulants	145-159	effect
nonsteroidal anti-inflammatory drugs	40-75	anti-coagulants	145-159	effect

The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.
flurbiprofen	52-63	anticoagulants	84-97	advise

Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.
Aspirin	0-6	aspirin	38-44	false
Aspirin	0-6	flurbiprofen	50-61	false
Aspirin	0-6	flurbiprofen	91-102	false
aspirin	38-44	flurbiprofen	50-61	mechanism
aspirin	38-44	flurbiprofen	91-102	false
flurbiprofen	50-61	flurbiprofen	91-102	false

This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).
aspirin	15-21	nonsteroidal anti-inflammatory drugs	72-107	false

Concurrent use of flurbiprofen and aspirin is therefore not recommended.
flurbiprofen	18-29	aspirin	35-41	advise

Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).
Beta-adrenergic Blocking Agents	0-30	flurbiprofen	47-58	false
Beta-adrenergic Blocking Agents	0-30	propranolol	90-100	false
Beta-adrenergic Blocking Agents	0-30	atenolol	106-113	false
flurbiprofen	47-58	propranolol	90-100	false
flurbiprofen	47-58	atenolol	106-113	false
propranolol	90-100	atenolol	106-113	false

Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.
Flurbiprofen	0-11	propranolol	80-90	effect
Flurbiprofen	0-11	atenolol	100-107	false
propranolol	80-90	atenolol	100-107	false

Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.
Flurbiprofen	0-11	propranolol	124-134	int

Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.
flurbiprofen	21-32	beta-blocker	40-51	advise

Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
Cimetidine	0-9	Ranitidine	12-21	false
Cimetidine	0-9	cimetidine	70-79	false
Cimetidine	0-9	ranitidine	84-93	false
Cimetidine	0-9	flurbiprofen	110-121	false
Cimetidine	0-9	flurbiprofen	257-268	false
Cimetidine	0-9	cimetidine	284-293	false
Ranitidine	12-21	cimetidine	70-79	false
Ranitidine	12-21	ranitidine	84-93	false
Ranitidine	12-21	flurbiprofen	110-121	false
Ranitidine	12-21	flurbiprofen	257-268	false
Ranitidine	12-21	cimetidine	284-293	false
cimetidine	70-79	ranitidine	84-93	false
cimetidine	70-79	flurbiprofen	110-121	false
cimetidine	70-79	flurbiprofen	257-268	false
cimetidine	70-79	cimetidine	284-293	false
ranitidine	84-93	flurbiprofen	110-121	false
ranitidine	84-93	flurbiprofen	257-268	false
ranitidine	84-93	cimetidine	284-293	false
flurbiprofen	110-121	flurbiprofen	257-268	false
flurbiprofen	110-121	cimetidine	284-293	false
flurbiprofen	257-268	cimetidine	284-293	mechanism

Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.
Digoxin	0-6	flurbiprofen	50-61	false
Digoxin	0-6	digoxin	67-73	false
flurbiprofen	50-61	digoxin	67-73	false

Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
Diuretics	0-8	flurbiprofen	56-67	false
Diuretics	0-8	nonsteroidal anti-inflammatory drugs	80-115	false
Diuretics	0-8	furosemide	152-161	false
flurbiprofen	56-67	nonsteroidal anti-inflammatory drugs	80-115	false
flurbiprofen	56-67	furosemide	152-161	effect
nonsteroidal anti-inflammatory drugs	80-115	furosemide	152-161	effect

Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
nonsteroidal anti-inflammatory drugs	6-41	thiazide diuretics	114-131	effect
nonsteroidal anti-inflammatory drugs	6-41	potassium-sparing diuretics	158-184	effect
thiazide diuretics	114-131	potassium-sparing diuretics	158-184	false

Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
flurbiprofen	19-30	furosemide	36-45	advise
flurbiprofen	19-30	diuretics	56-64	advise
furosemide	36-45	diuretics	56-64	false

Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
Hypoglycemic Agents	5-23	flurbiprofen	40-51	false
Hypoglycemic Agents	5-23	glyburide	109-117	false
Hypoglycemic Agents	5-23	metformin	126-134	false
Hypoglycemic Agents	5-23	chlorpropamide	142-155	false
Hypoglycemic Agents	5-23	phenformin	162-171	false
Hypoglycemic Agents	5-23	glyburide	183-191	false
Hypoglycemic Agents	5-23	phenformin	198-207	false
flurbiprofen	40-51	glyburide	109-117	false
flurbiprofen	40-51	metformin	126-134	false
flurbiprofen	40-51	chlorpropamide	142-155	false
flurbiprofen	40-51	phenformin	162-171	false
flurbiprofen	40-51	glyburide	183-191	false
flurbiprofen	40-51	phenformin	198-207	false
glyburide	109-117	metformin	126-134	false
glyburide	109-117	chlorpropamide	142-155	false
glyburide	109-117	phenformin	162-171	false
glyburide	109-117	glyburide	183-191	false
glyburide	109-117	phenformin	198-207	false
metformin	126-134	chlorpropamide	142-155	false
metformin	126-134	phenformin	162-171	false
metformin	126-134	glyburide	183-191	false
metformin	126-134	phenformin	198-207	false
chlorpropamide	142-155	phenformin	162-171	false
chlorpropamide	142-155	glyburide	183-191	false
chlorpropamide	142-155	phenformin	198-207	false
phenformin	162-171	glyburide	183-191	false
phenformin	162-171	phenformin	198-207	false
glyburide	183-191	phenformin	198-207	false

Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.
flurbiprofen	105-116	hypoglycemic agents	122-140	effect

Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
warfarin	79-86	flutamide	102-110	effect

Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.
anticoagulant	85-97	EULEXIN	126-132	false
anticoagulant	85-97	warfarin	179-186	false
EULEXIN	126-132	warfarin	179-186	advise

In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
serotonin reuptake inhibitor drug	30-62	monoamine oxidase inhibitors	84-111	effect
serotonin reuptake inhibitor drug	30-62	MAOI	114-117	effect
monoamine oxidase inhibitors	84-111	MAOI	114-117	false

Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
Fluvoxamine	34-44	MAOIs	86-90	advise
Fluvoxamine	34-44	MAOI	145-148	advise
MAOIs	86-90	MAOI	145-148	false

After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.
Fluvoxamine	15-25	MAOI	89-92	advise

Potential Terfenadine, Astemizole, and Cisapride Interactions
Terfenadine	10-20	Astemizole	23-32	false
Terfenadine	10-20	Cisapride	39-47	false
Astemizole	23-32	Cisapride	39-47	false

Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
Terfenadine	0-10	astemizole	13-22	false
Terfenadine	0-10	cisapride	28-36	false
Terfenadine	0-10	ketoconazole	129-140	mechanism
astemizole	13-22	cisapride	28-36	false
astemizole	13-22	ketoconazole	129-140	mechanism
cisapride	28-36	ketoconazole	129-140	mechanism

Increased plasma concentrations of terfenadine, astemizole, and cisapride cause QT prolongation and have been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal.
terfenadine	35-45	astemizole	48-57	false
terfenadine	35-45	cisapride	64-72	false
astemizole	48-57	cisapride	64-72	false

As noted below, a sub- for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by the IIIA4 isozyme.
fluvoxamine	27-37	alprazolam	59-68	false

Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
fluvoxamine	56-66	fluvoxamine	154-164	false
fluvoxamine	56-66	alprazolam	171-180	false
fluvoxamine	154-164	alprazolam	171-180	int

Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
fluvoxamine	37-47	terbinafine	88-98	advise
fluvoxamine	37-47	astemizole	101-110	advise
fluvoxamine	37-47	cisapride	116-124	advise
terbinafine	88-98	astemizole	101-110	false
terbinafine	88-98	cisapride	116-124	false
astemizole	101-110	cisapride	116-124	false

Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
Benzodiazepines	47-61	Benzodiazepines	64-78	false
Benzodiazepines	47-61	alprazolam	120-129	false
Benzodiazepines	47-61	midazolam	132-140	false
Benzodiazepines	47-61	triazolam	143-151	false
Benzodiazepines	47-61	fluvoxamine	251-261	false
Benzodiazepines	64-78	alprazolam	120-129	false
Benzodiazepines	64-78	midazolam	132-140	false
Benzodiazepines	64-78	triazolam	143-151	false
Benzodiazepines	64-78	fluvoxamine	251-261	mechanism
alprazolam	120-129	midazolam	132-140	false
alprazolam	120-129	triazolam	143-151	false
alprazolam	120-129	fluvoxamine	251-261	mechanism
midazolam	132-140	triazolam	143-151	false
midazolam	132-140	fluvoxamine	251-261	mechanism
triazolam	143-151	fluvoxamine	251-261	mechanism

The clearance of benzodiazepines metabolized by glucuronidation (e. g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine.
benzodiazepines	17-31	lorazepam	72-80	false
benzodiazepines	17-31	oxazepam	83-90	false
benzodiazepines	17-31	temazepam	93-101	false
benzodiazepines	17-31	fluvoxamine	134-144	false
lorazepam	72-80	oxazepam	83-90	false
lorazepam	72-80	temazepam	93-101	false
lorazepam	72-80	fluvoxamine	134-144	false
oxazepam	83-90	temazepam	93-101	false
oxazepam	83-90	fluvoxamine	134-144	false
temazepam	93-101	fluvoxamine	134-144	false

Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
Alprazolam	0-9	fluvoxamine maleate	17-35	false
Alprazolam	0-9	alprazolam	53-62	false
Alprazolam	0-9	alprazolam	194-203	false
Alprazolam	0-9	alprazolam	250-259	false
fluvoxamine maleate	17-35	alprazolam	53-62	mechanism
fluvoxamine maleate	17-35	alprazolam	194-203	false
fluvoxamine maleate	17-35	alprazolam	250-259	false
alprazolam	53-62	alprazolam	194-203	false
alprazolam	53-62	alprazolam	250-259	false
alprazolam	194-203	alprazolam	250-259	false

This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
fluvoxamine	72-82	fluvoxamine	170-180	false
fluvoxamine	72-82	alprazolam	256-265	false
fluvoxamine	72-82	Fluvoxamine	291-301	false
fluvoxamine	72-82	alprazolam	324-333	false
fluvoxamine	170-180	alprazolam	256-265	false
fluvoxamine	170-180	Fluvoxamine	291-301	false
fluvoxamine	170-180	alprazolam	324-333	false
alprazolam	256-265	Fluvoxamine	291-301	advise
alprazolam	256-265	alprazolam	324-333	false
Fluvoxamine	291-301	alprazolam	324-333	false

Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
Diazepam	0-7	Fluvoxamine	35-45	false
Diazepam	0-7	diazepam	59-66	false
Fluvoxamine	35-45	diazepam	59-66	advise

Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
fluvoxamine	8-18	diazepam	50-57	mechanism
fluvoxamine	8-18	N-desmethyldiazepam	86-104	mechanism
diazepam	50-57	N-desmethyldiazepam	86-104	false

Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
fluvoxamine	75-85	diazepam	91-98	advise
fluvoxamine	75-85	fluvoxamine	173-183	false
fluvoxamine	75-85	diazepam	234-241	false
diazepam	91-98	fluvoxamine	173-183	false
diazepam	91-98	diazepam	234-241	false
fluvoxamine	173-183	diazepam	234-241	false

In these subjects (R= B), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.
diazepam	43-50	N-desmethyldiazepam	83-101	false

Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
alprazolam	24-33	fluvoxamine	50-60	effect

Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
diazepam	13-20	fluvoxamine	26-36	advise

Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.
Theophylline	0-11	fluvoxamine	41-51	false
Theophylline	0-11	Theophylline	108-119	false
Theophylline	0-11	aminophylline	140-152	false
fluvoxamine	41-51	Theophylline	108-119	false
fluvoxamine	41-51	aminophylline	140-152	false
Theophylline	108-119	aminophylline	140-152	false

Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
theophylline	14-25	fluvoxamine maleate	51-69	advise
theophylline	14-25	theophylline	177-188	false
fluvoxamine maleate	51-69	theophylline	177-188	false

Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
Warfarin	0-7	fluvoxamine maleate	15-33	false
Warfarin	0-7	warfarin	83-90	false
Warfarin	0-7	warfarin	107-114	false
fluvoxamine maleate	15-33	warfarin	83-90	mechanism
fluvoxamine maleate	15-33	warfarin	107-114	false
warfarin	83-90	warfarin	107-114	false

Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
anticoagulants	29-42	Fluvoxamine	48-58	advise
anticoagulants	29-42	anticoagulant	123-135	false
Fluvoxamine	48-58	anticoagulant	123-135	false

Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
anticonvulsant medications	62-87	phenytoin	98-106	false
anticonvulsant medications	62-87	primidone	113-121	false
anticonvulsant medications	62-87	metformin	124-132	false
anticonvulsant medications	62-87	sulfasalazine	199-211	false
anticonvulsant medications	62-87	triamterene	298-308	false
anticonvulsant medications	62-87	diuretic	313-320	false
anticonvulsant medications	62-87	Methotrexate	323-334	false
anticonvulsant medications	62-87	vitamin B12	389-399	false
anticonvulsant medications	62-87	folic acid	405-414	false
phenytoin	98-106	primidone	113-121	false
phenytoin	98-106	metformin	124-132	false
phenytoin	98-106	sulfasalazine	199-211	false
phenytoin	98-106	triamterene	298-308	false
phenytoin	98-106	diuretic	313-320	false
phenytoin	98-106	Methotrexate	323-334	false
phenytoin	98-106	vitamin B12	389-399	false
phenytoin	98-106	folic acid	405-414	false
primidone	113-121	metformin	124-132	false
primidone	113-121	sulfasalazine	199-211	false
primidone	113-121	triamterene	298-308	false
primidone	113-121	diuretic	313-320	false
primidone	113-121	Methotrexate	323-334	false
primidone	113-121	vitamin B12	389-399	false
primidone	113-121	folic acid	405-414	false
metformin	124-132	sulfasalazine	199-211	false
metformin	124-132	triamterene	298-308	false
metformin	124-132	diuretic	313-320	false
metformin	124-132	Methotrexate	323-334	false
metformin	124-132	vitamin B12	389-399	false
metformin	124-132	folic acid	405-414	false
sulfasalazine	199-211	triamterene	298-308	false
sulfasalazine	199-211	diuretic	313-320	false
sulfasalazine	199-211	Methotrexate	323-334	false
sulfasalazine	199-211	vitamin B12	389-399	false
sulfasalazine	199-211	folic acid	405-414	false
triamterene	298-308	diuretic	313-320	false
triamterene	298-308	Methotrexate	323-334	false
triamterene	298-308	vitamin B12	389-399	false
triamterene	298-308	folic acid	405-414	false
diuretic	313-320	Methotrexate	323-334	false
diuretic	313-320	vitamin B12	389-399	false
diuretic	313-320	folic acid	405-414	false
Methotrexate	323-334	vitamin B12	389-399	false
Methotrexate	323-334	folic acid	405-414	false
vitamin B12	389-399	folic acid	405-414	int

Therefore, intake of supplemental folic acid should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent folic acid from masking symptoms of vitamin B12 deficiency.
folic acid	34-43	folic acid	118-127	false

It is important for older adults to be aware of the relationship between folic acid and vitamin B12 because they are at greater risk of having a vitamin B12 deficiency.
folic acid	73-82	vitamin B12	88-98	false

Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
Antizol	14-20	ethanol	124-130	mechanism

Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
ethanol	11-17	Antizol	56-62	mechanism

Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
Antizol	58-64	phenytoin	135-143	mechanism
Antizol	58-64	carbamazepine	146-158	mechanism
Antizol	58-64	cimetidine	161-170	mechanism
Antizol	58-64	ketoconazole	173-184	mechanism
phenytoin	135-143	carbamazepine	146-158	false
phenytoin	135-143	cimetidine	161-170	false
phenytoin	135-143	ketoconazole	173-184	false
carbamazepine	146-158	cimetidine	161-170	false
carbamazepine	146-158	ketoconazole	173-184	false
cimetidine	161-170	ketoconazole	173-184	false

In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
Fondaparinux	35-46	anticoagulants	77-90	false
Fondaparinux	35-46	warfarin	93-100	false
Fondaparinux	35-46	platelet inhibitors	104-122	false
Fondaparinux	35-46	acetylsalicylic acid	125-144	false
Fondaparinux	35-46	NSAIDs	148-153	false
Fondaparinux	35-46	piroxicam	156-164	false
Fondaparinux	35-46	digoxin	172-178	false
Fondaparinux	35-46	fondaparinux sodium	250-268	false
anticoagulants	77-90	warfarin	93-100	false
anticoagulants	77-90	platelet inhibitors	104-122	false
anticoagulants	77-90	acetylsalicylic acid	125-144	false
anticoagulants	77-90	NSAIDs	148-153	false
anticoagulants	77-90	piroxicam	156-164	false
anticoagulants	77-90	digoxin	172-178	false
anticoagulants	77-90	fondaparinux sodium	250-268	false
warfarin	93-100	platelet inhibitors	104-122	false
warfarin	93-100	acetylsalicylic acid	125-144	false
warfarin	93-100	NSAIDs	148-153	false
warfarin	93-100	piroxicam	156-164	false
warfarin	93-100	digoxin	172-178	false
warfarin	93-100	fondaparinux sodium	250-268	false
platelet inhibitors	104-122	acetylsalicylic acid	125-144	false
platelet inhibitors	104-122	NSAIDs	148-153	false
platelet inhibitors	104-122	piroxicam	156-164	false
platelet inhibitors	104-122	digoxin	172-178	false
platelet inhibitors	104-122	fondaparinux sodium	250-268	false
acetylsalicylic acid	125-144	NSAIDs	148-153	false
acetylsalicylic acid	125-144	piroxicam	156-164	false
acetylsalicylic acid	125-144	digoxin	172-178	false
acetylsalicylic acid	125-144	fondaparinux sodium	250-268	false
NSAIDs	148-153	piroxicam	156-164	false
NSAIDs	148-153	digoxin	172-178	false
NSAIDs	148-153	fondaparinux sodium	250-268	false
piroxicam	156-164	digoxin	172-178	false
piroxicam	156-164	fondaparinux sodium	250-268	false
digoxin	172-178	fondaparinux sodium	250-268	false

In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.
Fondaparinux	13-24	warfarin	69-76	false
Fondaparinux	13-24	acetylsalicylic acid	79-98	false
Fondaparinux	13-24	piroxicam	101-109	false
Fondaparinux	13-24	digoxin	116-122	false
Fondaparinux	13-24	digoxin	153-159	false
warfarin	69-76	acetylsalicylic acid	79-98	false
warfarin	69-76	piroxicam	101-109	false
warfarin	69-76	digoxin	116-122	false
warfarin	69-76	digoxin	153-159	false
acetylsalicylic acid	79-98	piroxicam	101-109	false
acetylsalicylic acid	79-98	digoxin	116-122	false
acetylsalicylic acid	79-98	digoxin	153-159	false
piroxicam	101-109	digoxin	116-122	false
piroxicam	101-109	digoxin	153-159	false
digoxin	116-122	digoxin	153-159	false

In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.
coumarin	86-93	fondaparinux	98-109	mechanism

Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.
fondaparinux	6-17	fondaparinux sodium	124-142	false

Short-Acting beta2-agonists: Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol.
Short-Acting beta2-agonists	0-26	bronchodilators	37-51	false
Short-Acting beta2-agonists	0-26	formoterol	159-168	false
bronchodilators	37-51	formoterol	159-168	false

Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.
sympathomimetic agents	36-57	FORADIL	101-107	effect

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
Monoamine Oxidase Inhibitors	0-27	Tricyclic Antidepressants	33-57	false
Monoamine Oxidase Inhibitors	0-27	FORADIL	60-66	false
Monoamine Oxidase Inhibitors	0-27	monoamine oxidase inhibitors	143-170	false
Monoamine Oxidase Inhibitors	0-27	tricyclic antidepressants	175-199	false
Monoamine Oxidase Inhibitors	0-27	formoterol	223-232	false
Tricyclic Antidepressants	33-57	FORADIL	60-66	false
Tricyclic Antidepressants	33-57	monoamine oxidase inhibitors	143-170	false
Tricyclic Antidepressants	33-57	tricyclic antidepressants	175-199	false
Tricyclic Antidepressants	33-57	formoterol	223-232	false
FORADIL	60-66	monoamine oxidase inhibitors	143-170	advise
FORADIL	60-66	tricyclic antidepressants	175-199	advise
FORADIL	60-66	formoterol	223-232	false
monoamine oxidase inhibitors	143-170	tricyclic antidepressants	175-199	false
monoamine oxidase inhibitors	143-170	formoterol	223-232	false
tricyclic antidepressants	175-199	formoterol	223-232	false

Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
Corticosteroids	0-14	Methylxanthines	17-31	false
Corticosteroids	0-14	Diuretics	37-45	false
Corticosteroids	0-14	xanthine derivatives	75-94	false
Corticosteroids	0-14	steroids	97-104	false
Corticosteroids	0-14	diuretics	110-118	false
Corticosteroids	0-14	beta2-agonists.	169-183	false
Methylxanthines	17-31	Diuretics	37-45	false
Methylxanthines	17-31	xanthine derivatives	75-94	false
Methylxanthines	17-31	steroids	97-104	false
Methylxanthines	17-31	diuretics	110-118	false
Methylxanthines	17-31	beta2-agonists.	169-183	false
Diuretics	37-45	xanthine derivatives	75-94	false
Diuretics	37-45	steroids	97-104	false
Diuretics	37-45	diuretics	110-118	false
Diuretics	37-45	beta2-agonists.	169-183	false
xanthine derivatives	75-94	steroids	97-104	false
xanthine derivatives	75-94	diuretics	110-118	false
xanthine derivatives	75-94	beta2-agonists.	169-183	effect
steroids	97-104	diuretics	110-118	false
steroids	97-104	beta2-agonists.	169-183	effect
diuretics	110-118	beta2-agonists.	169-183	effect

Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
quinidine	26-34	disopyramide	37-48	false
quinidine	26-34	procainamide	51-62	false
quinidine	26-34	phenothiazines	65-78	false
quinidine	26-34	antihistamines	81-94	false
quinidine	26-34	tricyclic antidepressants	101-125	false
disopyramide	37-48	procainamide	51-62	false
disopyramide	37-48	phenothiazines	65-78	false
disopyramide	37-48	antihistamines	81-94	false
disopyramide	37-48	tricyclic antidepressants	101-125	false
procainamide	51-62	phenothiazines	65-78	false
procainamide	51-62	antihistamines	81-94	false
procainamide	51-62	tricyclic antidepressants	101-125	false
phenothiazines	65-78	antihistamines	81-94	false
phenothiazines	65-78	tricyclic antidepressants	101-125	false
antihistamines	81-94	tricyclic antidepressants	101-125	false

It is important that patients understand how to use FORADIL  (formoterol fumarate) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.
FORADIL	52-58	formoterol fumarate	62-80	false

Acute symptoms should be treated with a short-acting, inhaled  beta2-agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used).
beta2-agonist	63-75	salbutamol	85-94	false

FORADIL should not be used as a substitute for oral or inhaled corticosteroids.
FORADIL	0-6	corticosteroids	63-77	false

Guardians of children who have been prescribed FORADIL should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of short-acting  beta2-agonists.
FORADIL	47-53	short-acting  beta2-agonists	196-223	false

A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
FOSCAVIR	31-38	pentamidine	56-66	int

Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
FOSCAVIR	66-73	pentamidine	91-101	effect

Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
foscarnet	11-19	FOSCAVIR	69-76	false
foscarnet	11-19	aminoglycosides	154-168	false
foscarnet	11-19	amphotericin B	171-184	false
foscarnet	11-19	pentamidine	202-212	false
FOSCAVIR	69-76	aminoglycosides	154-168	advise
FOSCAVIR	69-76	amphotericin B	171-184	advise
FOSCAVIR	69-76	pentamidine	202-212	advise
aminoglycosides	154-168	amphotericin B	171-184	false
aminoglycosides	154-168	pentamidine	202-212	false
amphotericin B	171-184	pentamidine	202-212	false

Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.
Ganciclovir	0-10	foscarnet	37-45	false
Ganciclovir	0-10	ganciclovir	51-61	false
foscarnet	37-45	ganciclovir	51-61	false

Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
Metoclopramide	0-13	MONUROL	41-47	false
Metoclopramide	0-13	metoclopramide	50-63	false
Metoclopramide	0-13	fosfomycin	172-181	false
MONUROL	41-47	metoclopramide	50-63	mechanism
MONUROL	41-47	fosfomycin	172-181	false
metoclopramide	50-63	fosfomycin	172-181	false

Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.
Cimetidine	0-9	Cimetidine	12-21	false
Cimetidine	0-9	fosfomycin	63-72	false
Cimetidine	0-9	MONUROL	99-105	false
Cimetidine	12-21	fosfomycin	63-72	false
Cimetidine	12-21	MONUROL	99-105	false
fosfomycin	63-72	MONUROL	99-105	false

Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
Diuretics	0-8	diuretics	23-31	false
Diuretics	0-8	fosinopril sodium	190-206	false
diuretics	23-31	fosinopril sodium	190-206	effect

The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.
diuretic	84-91	fosinopril sodium	157-173	effect

Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
Potassium	0-8	Potassium-Sparing Diuretics	26-52	false
Potassium	0-8	Fosinopril sodium	55-71	false
Potassium	0-8	thiazide diuretics	112-129	false
Potassium-Sparing Diuretics	26-52	Fosinopril sodium	55-71	false
Potassium-Sparing Diuretics	26-52	thiazide diuretics	112-129	false
Fosinopril sodium	55-71	thiazide diuretics	112-129	effect

Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
Potassium-sparing diuretics	0-26	spironolactone	29-42	false
Potassium-sparing diuretics	0-26	amiloride	45-53	false
Potassium-sparing diuretics	0-26	triamterene	55-65	false
Potassium-sparing diuretics	0-26	potassium	83-91	false
spironolactone	29-42	amiloride	45-53	false
spironolactone	29-42	triamterene	55-65	false
spironolactone	29-42	potassium	83-91	false
amiloride	45-53	triamterene	55-65	false
amiloride	45-53	potassium	83-91	false
triamterene	55-65	potassium	83-91	false

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
Lithium	0-6	lithium	25-31	false
Lithium	0-6	lithium	56-62	false
Lithium	0-6	ACE inhibitors	114-127	false
Lithium	0-6	lithium	149-155	false
lithium	25-31	lithium	56-62	false
lithium	25-31	ACE inhibitors	114-127	false
lithium	25-31	lithium	149-155	false
lithium	56-62	ACE inhibitors	114-127	false
lithium	56-62	lithium	149-155	false
ACE inhibitors	114-127	lithium	149-155	effect

Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
Antacids	0-7	antacid	67-73	false
Antacids	0-7	aluminum hydroxide	76-93	false
Antacids	0-7	magnesium hydroxide	96-114	false
Antacids	0-7	simethicone	121-131	false
Antacids	0-7	fosinopril	139-148	false
Antacids	0-7	fosinoprilat	196-207	false
Antacids	0-7	fosinopril	226-235	false
Antacids	0-7	antacids	273-280	false
Antacids	0-7	fosinopril	307-316	false
antacid	67-73	aluminum hydroxide	76-93	false
antacid	67-73	magnesium hydroxide	96-114	false
antacid	67-73	simethicone	121-131	false
antacid	67-73	fosinopril	139-148	mechanism
antacid	67-73	fosinoprilat	196-207	false
antacid	67-73	fosinopril	226-235	false
antacid	67-73	antacids	273-280	false
antacid	67-73	fosinopril	307-316	false
aluminum hydroxide	76-93	magnesium hydroxide	96-114	false
aluminum hydroxide	76-93	simethicone	121-131	false
aluminum hydroxide	76-93	fosinopril	139-148	mechanism
aluminum hydroxide	76-93	fosinoprilat	196-207	false
aluminum hydroxide	76-93	fosinopril	226-235	false
aluminum hydroxide	76-93	antacids	273-280	false
aluminum hydroxide	76-93	fosinopril	307-316	false
magnesium hydroxide	96-114	simethicone	121-131	false
magnesium hydroxide	96-114	fosinopril	139-148	mechanism
magnesium hydroxide	96-114	fosinoprilat	196-207	false
magnesium hydroxide	96-114	fosinopril	226-235	false
magnesium hydroxide	96-114	antacids	273-280	false
magnesium hydroxide	96-114	fosinopril	307-316	false
simethicone	121-131	fosinopril	139-148	mechanism
simethicone	121-131	fosinoprilat	196-207	false
simethicone	121-131	fosinopril	226-235	false
simethicone	121-131	antacids	273-280	false
simethicone	121-131	fosinopril	307-316	false
fosinopril	139-148	fosinoprilat	196-207	false
fosinopril	139-148	fosinopril	226-235	false
fosinopril	139-148	antacids	273-280	false
fosinopril	139-148	fosinopril	307-316	false
fosinoprilat	196-207	fosinopril	226-235	false
fosinoprilat	196-207	antacids	273-280	false
fosinoprilat	196-207	fosinopril	307-316	false
fosinopril	226-235	antacids	273-280	false
fosinopril	226-235	fosinopril	307-316	false
antacids	273-280	fosinopril	307-316	mechanism

In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
chlorthalidone	77-90	nifedipine	93-102	false
chlorthalidone	77-90	propanolol	105-114	false
chlorthalidone	77-90	hydrochlorothiazide	117-135	false
chlorthalidone	77-90	cimetidine	138-147	false
chlorthalidone	77-90	metoclopramide	150-163	false
chlorthalidone	77-90	propantheline	166-178	false
chlorthalidone	77-90	digoxin	181-187	false
chlorthalidone	77-90	warfarin	194-201	false
chlorthalidone	77-90	fosinoprilat	227-238	false
chlorthalidone	77-90	fosinopril	279-288	false
nifedipine	93-102	propanolol	105-114	false
nifedipine	93-102	hydrochlorothiazide	117-135	false
nifedipine	93-102	cimetidine	138-147	false
nifedipine	93-102	metoclopramide	150-163	false
nifedipine	93-102	propantheline	166-178	false
nifedipine	93-102	digoxin	181-187	false
nifedipine	93-102	warfarin	194-201	false
nifedipine	93-102	fosinoprilat	227-238	false
nifedipine	93-102	fosinopril	279-288	false
propanolol	105-114	hydrochlorothiazide	117-135	false
propanolol	105-114	cimetidine	138-147	false
propanolol	105-114	metoclopramide	150-163	false
propanolol	105-114	propantheline	166-178	false
propanolol	105-114	digoxin	181-187	false
propanolol	105-114	warfarin	194-201	false
propanolol	105-114	fosinoprilat	227-238	false
propanolol	105-114	fosinopril	279-288	false
hydrochlorothiazide	117-135	cimetidine	138-147	false
hydrochlorothiazide	117-135	metoclopramide	150-163	false
hydrochlorothiazide	117-135	propantheline	166-178	false
hydrochlorothiazide	117-135	digoxin	181-187	false
hydrochlorothiazide	117-135	warfarin	194-201	false
hydrochlorothiazide	117-135	fosinoprilat	227-238	false
hydrochlorothiazide	117-135	fosinopril	279-288	false
cimetidine	138-147	metoclopramide	150-163	false
cimetidine	138-147	propantheline	166-178	false
cimetidine	138-147	digoxin	181-187	false
cimetidine	138-147	warfarin	194-201	false
cimetidine	138-147	fosinoprilat	227-238	false
cimetidine	138-147	fosinopril	279-288	false
metoclopramide	150-163	propantheline	166-178	false
metoclopramide	150-163	digoxin	181-187	false
metoclopramide	150-163	warfarin	194-201	false
metoclopramide	150-163	fosinoprilat	227-238	false
metoclopramide	150-163	fosinopril	279-288	false
propantheline	166-178	digoxin	181-187	false
propantheline	166-178	warfarin	194-201	false
propantheline	166-178	fosinoprilat	227-238	false
propantheline	166-178	fosinopril	279-288	false
digoxin	181-187	warfarin	194-201	false
digoxin	181-187	fosinoprilat	227-238	false
digoxin	181-187	fosinopril	279-288	false
warfarin	194-201	fosinoprilat	227-238	false
warfarin	194-201	fosinopril	279-288	false
fosinoprilat	227-238	fosinopril	279-288	false

In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.
aspirin	46-52	fosinopril sodium	58-74	false
aspirin	46-52	fosinoprilat	108-119	false
fosinopril sodium	58-74	fosinoprilat	108-119	false

In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.
warfarin	44-51	warfarin	176-183	false

Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for Digoxin.
Fosinopril	33-42	digoxin	87-93	false
Fosinopril	33-42	Digoxin	134-140	false
digoxin	87-93	Digoxin	134-140	false

No drugs are known to interfere with the conversion of fosphenytoin to phenytoin.
fosphenytoin	55-66	phenytoin	71-79	false

Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin.
fosphenytoin	240-251	phenytoin	256-264	false

The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.
fosphenytoin	44-55	phenytoin	58-66	false
fosphenytoin	44-55	diazepam	73-80	false
fosphenytoin	44-55	diazepam	104-111	false
fosphenytoin	44-55	Cerebyx	117-123	false
phenytoin	58-66	diazepam	73-80	false
phenytoin	58-66	diazepam	104-111	false
phenytoin	58-66	Cerebyx	117-123	false
diazepam	73-80	diazepam	104-111	false
diazepam	73-80	Cerebyx	117-123	false
diazepam	104-111	Cerebyx	117-123	false

The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin.
Cerebyx	67-73	phenytoin	127-135	false

The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
phenytoin	97-105	alcohol	137-143	mechanism
phenytoin	97-105	amiodarone	153-162	mechanism
phenytoin	97-105	chlordiazepoxide	182-197	mechanism
phenytoin	97-105	cimetidine	200-209	mechanism
phenytoin	97-105	diazepam	212-219	mechanism
phenytoin	97-105	dicumarol	222-230	mechanism
phenytoin	97-105	disulfiram	233-242	mechanism
phenytoin	97-105	estrogens	245-253	mechanism
phenytoin	97-105	ethosuximide	256-267	mechanism
phenytoin	97-105	fluoxetine	270-279	mechanism
phenytoin	97-105	H2-antagonists	282-295	mechanism
phenytoin	97-105	halothane	298-306	mechanism
phenytoin	97-105	isoniazid	309-317	mechanism
phenytoin	97-105	methylphenidate	320-334	mechanism
phenytoin	97-105	phenothiazines	337-350	mechanism
phenytoin	97-105	phenylbutazone	353-366	mechanism
phenytoin	97-105	salicylates	369-379	mechanism
phenytoin	97-105	succinimides	382-393	mechanism
phenytoin	97-105	sulfonamides	396-407	mechanism
phenytoin	97-105	tolbutamide	410-420	mechanism
phenytoin	97-105	trazodone	423-431	mechanism
alcohol	137-143	amiodarone	153-162	false
alcohol	137-143	chlordiazepoxide	182-197	false
alcohol	137-143	cimetidine	200-209	false
alcohol	137-143	diazepam	212-219	false
alcohol	137-143	dicumarol	222-230	false
alcohol	137-143	disulfiram	233-242	false
alcohol	137-143	estrogens	245-253	false
alcohol	137-143	ethosuximide	256-267	false
alcohol	137-143	fluoxetine	270-279	false
alcohol	137-143	H2-antagonists	282-295	false
alcohol	137-143	halothane	298-306	false
alcohol	137-143	isoniazid	309-317	false
alcohol	137-143	methylphenidate	320-334	false
alcohol	137-143	phenothiazines	337-350	false
alcohol	137-143	phenylbutazone	353-366	false
alcohol	137-143	salicylates	369-379	false
alcohol	137-143	succinimides	382-393	false
alcohol	137-143	sulfonamides	396-407	false
alcohol	137-143	tolbutamide	410-420	false
alcohol	137-143	trazodone	423-431	false
amiodarone	153-162	chlordiazepoxide	182-197	false
amiodarone	153-162	cimetidine	200-209	false
amiodarone	153-162	diazepam	212-219	false
amiodarone	153-162	dicumarol	222-230	false
amiodarone	153-162	disulfiram	233-242	false
amiodarone	153-162	estrogens	245-253	false
amiodarone	153-162	ethosuximide	256-267	false
amiodarone	153-162	fluoxetine	270-279	false
amiodarone	153-162	H2-antagonists	282-295	false
amiodarone	153-162	halothane	298-306	false
amiodarone	153-162	isoniazid	309-317	false
amiodarone	153-162	methylphenidate	320-334	false
amiodarone	153-162	phenothiazines	337-350	false
amiodarone	153-162	phenylbutazone	353-366	false
amiodarone	153-162	salicylates	369-379	false
amiodarone	153-162	succinimides	382-393	false
amiodarone	153-162	sulfonamides	396-407	false
amiodarone	153-162	tolbutamide	410-420	false
amiodarone	153-162	trazodone	423-431	false
chlordiazepoxide	182-197	cimetidine	200-209	false
chlordiazepoxide	182-197	diazepam	212-219	false
chlordiazepoxide	182-197	dicumarol	222-230	false
chlordiazepoxide	182-197	disulfiram	233-242	false
chlordiazepoxide	182-197	estrogens	245-253	false
chlordiazepoxide	182-197	ethosuximide	256-267	false
chlordiazepoxide	182-197	fluoxetine	270-279	false
chlordiazepoxide	182-197	H2-antagonists	282-295	false
chlordiazepoxide	182-197	halothane	298-306	false
chlordiazepoxide	182-197	isoniazid	309-317	false
chlordiazepoxide	182-197	methylphenidate	320-334	false
chlordiazepoxide	182-197	phenothiazines	337-350	false
chlordiazepoxide	182-197	phenylbutazone	353-366	false
chlordiazepoxide	182-197	salicylates	369-379	false
chlordiazepoxide	182-197	succinimides	382-393	false
chlordiazepoxide	182-197	sulfonamides	396-407	false
chlordiazepoxide	182-197	tolbutamide	410-420	false
chlordiazepoxide	182-197	trazodone	423-431	false
cimetidine	200-209	diazepam	212-219	false
cimetidine	200-209	dicumarol	222-230	false
cimetidine	200-209	disulfiram	233-242	false
cimetidine	200-209	estrogens	245-253	false
cimetidine	200-209	ethosuximide	256-267	false
cimetidine	200-209	fluoxetine	270-279	false
cimetidine	200-209	H2-antagonists	282-295	false
cimetidine	200-209	halothane	298-306	false
cimetidine	200-209	isoniazid	309-317	false
cimetidine	200-209	methylphenidate	320-334	false
cimetidine	200-209	phenothiazines	337-350	false
cimetidine	200-209	phenylbutazone	353-366	false
cimetidine	200-209	salicylates	369-379	false
cimetidine	200-209	succinimides	382-393	false
cimetidine	200-209	sulfonamides	396-407	false
cimetidine	200-209	tolbutamide	410-420	false
cimetidine	200-209	trazodone	423-431	false
diazepam	212-219	dicumarol	222-230	false
diazepam	212-219	disulfiram	233-242	false
diazepam	212-219	estrogens	245-253	false
diazepam	212-219	ethosuximide	256-267	false
diazepam	212-219	fluoxetine	270-279	false
diazepam	212-219	H2-antagonists	282-295	false
diazepam	212-219	halothane	298-306	false
diazepam	212-219	isoniazid	309-317	false
diazepam	212-219	methylphenidate	320-334	false
diazepam	212-219	phenothiazines	337-350	false
diazepam	212-219	phenylbutazone	353-366	false
diazepam	212-219	salicylates	369-379	false
diazepam	212-219	succinimides	382-393	false
diazepam	212-219	sulfonamides	396-407	false
diazepam	212-219	tolbutamide	410-420	false
diazepam	212-219	trazodone	423-431	false
dicumarol	222-230	disulfiram	233-242	false
dicumarol	222-230	estrogens	245-253	false
dicumarol	222-230	ethosuximide	256-267	false
dicumarol	222-230	fluoxetine	270-279	false
dicumarol	222-230	H2-antagonists	282-295	false
dicumarol	222-230	halothane	298-306	false
dicumarol	222-230	isoniazid	309-317	false
dicumarol	222-230	methylphenidate	320-334	false
dicumarol	222-230	phenothiazines	337-350	false
dicumarol	222-230	phenylbutazone	353-366	false
dicumarol	222-230	salicylates	369-379	false
dicumarol	222-230	succinimides	382-393	false
dicumarol	222-230	sulfonamides	396-407	false
dicumarol	222-230	tolbutamide	410-420	false
dicumarol	222-230	trazodone	423-431	false
disulfiram	233-242	estrogens	245-253	false
disulfiram	233-242	ethosuximide	256-267	false
disulfiram	233-242	fluoxetine	270-279	false
disulfiram	233-242	H2-antagonists	282-295	false
disulfiram	233-242	halothane	298-306	false
disulfiram	233-242	isoniazid	309-317	false
disulfiram	233-242	methylphenidate	320-334	false
disulfiram	233-242	phenothiazines	337-350	false
disulfiram	233-242	phenylbutazone	353-366	false
disulfiram	233-242	salicylates	369-379	false
disulfiram	233-242	succinimides	382-393	false
disulfiram	233-242	sulfonamides	396-407	false
disulfiram	233-242	tolbutamide	410-420	false
disulfiram	233-242	trazodone	423-431	false
estrogens	245-253	ethosuximide	256-267	false
estrogens	245-253	fluoxetine	270-279	false
estrogens	245-253	H2-antagonists	282-295	false
estrogens	245-253	halothane	298-306	false
estrogens	245-253	isoniazid	309-317	false
estrogens	245-253	methylphenidate	320-334	false
estrogens	245-253	phenothiazines	337-350	false
estrogens	245-253	phenylbutazone	353-366	false
estrogens	245-253	salicylates	369-379	false
estrogens	245-253	succinimides	382-393	false
estrogens	245-253	sulfonamides	396-407	false
estrogens	245-253	tolbutamide	410-420	false
estrogens	245-253	trazodone	423-431	false
ethosuximide	256-267	fluoxetine	270-279	false
ethosuximide	256-267	H2-antagonists	282-295	false
ethosuximide	256-267	halothane	298-306	false
ethosuximide	256-267	isoniazid	309-317	false
ethosuximide	256-267	methylphenidate	320-334	false
ethosuximide	256-267	phenothiazines	337-350	false
ethosuximide	256-267	phenylbutazone	353-366	false
ethosuximide	256-267	salicylates	369-379	false
ethosuximide	256-267	succinimides	382-393	false
ethosuximide	256-267	sulfonamides	396-407	false
ethosuximide	256-267	tolbutamide	410-420	false
ethosuximide	256-267	trazodone	423-431	false
fluoxetine	270-279	H2-antagonists	282-295	false
fluoxetine	270-279	halothane	298-306	false
fluoxetine	270-279	isoniazid	309-317	false
fluoxetine	270-279	methylphenidate	320-334	false
fluoxetine	270-279	phenothiazines	337-350	false
fluoxetine	270-279	phenylbutazone	353-366	false
fluoxetine	270-279	salicylates	369-379	false
fluoxetine	270-279	succinimides	382-393	false
fluoxetine	270-279	sulfonamides	396-407	false
fluoxetine	270-279	tolbutamide	410-420	false
fluoxetine	270-279	trazodone	423-431	false
H2-antagonists	282-295	halothane	298-306	false
H2-antagonists	282-295	isoniazid	309-317	false
H2-antagonists	282-295	methylphenidate	320-334	false
H2-antagonists	282-295	phenothiazines	337-350	false
H2-antagonists	282-295	phenylbutazone	353-366	false
H2-antagonists	282-295	salicylates	369-379	false
H2-antagonists	282-295	succinimides	382-393	false
H2-antagonists	282-295	sulfonamides	396-407	false
H2-antagonists	282-295	tolbutamide	410-420	false
H2-antagonists	282-295	trazodone	423-431	false
halothane	298-306	isoniazid	309-317	false
halothane	298-306	methylphenidate	320-334	false
halothane	298-306	phenothiazines	337-350	false
halothane	298-306	phenylbutazone	353-366	false
halothane	298-306	salicylates	369-379	false
halothane	298-306	succinimides	382-393	false
halothane	298-306	sulfonamides	396-407	false
halothane	298-306	tolbutamide	410-420	false
halothane	298-306	trazodone	423-431	false
isoniazid	309-317	methylphenidate	320-334	false
isoniazid	309-317	phenothiazines	337-350	false
isoniazid	309-317	phenylbutazone	353-366	false
isoniazid	309-317	salicylates	369-379	false
isoniazid	309-317	succinimides	382-393	false
isoniazid	309-317	sulfonamides	396-407	false
isoniazid	309-317	tolbutamide	410-420	false
isoniazid	309-317	trazodone	423-431	false
methylphenidate	320-334	phenothiazines	337-350	false
methylphenidate	320-334	phenylbutazone	353-366	false
methylphenidate	320-334	salicylates	369-379	false
methylphenidate	320-334	succinimides	382-393	false
methylphenidate	320-334	sulfonamides	396-407	false
methylphenidate	320-334	tolbutamide	410-420	false
methylphenidate	320-334	trazodone	423-431	false
phenothiazines	337-350	phenylbutazone	353-366	false
phenothiazines	337-350	salicylates	369-379	false
phenothiazines	337-350	succinimides	382-393	false
phenothiazines	337-350	sulfonamides	396-407	false
phenothiazines	337-350	tolbutamide	410-420	false
phenothiazines	337-350	trazodone	423-431	false
phenylbutazone	353-366	salicylates	369-379	false
phenylbutazone	353-366	succinimides	382-393	false
phenylbutazone	353-366	sulfonamides	396-407	false
phenylbutazone	353-366	tolbutamide	410-420	false
phenylbutazone	353-366	trazodone	423-431	false
salicylates	369-379	succinimides	382-393	false
salicylates	369-379	sulfonamides	396-407	false
salicylates	369-379	tolbutamide	410-420	false
salicylates	369-379	trazodone	423-431	false
succinimides	382-393	sulfonamides	396-407	false
succinimides	382-393	tolbutamide	410-420	false
succinimides	382-393	trazodone	423-431	false
sulfonamides	396-407	tolbutamide	410-420	false
sulfonamides	396-407	trazodone	423-431	false
tolbutamide	410-420	trazodone	423-431	false

- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
phenytoin	33-41	carbamazepine	67-79	mechanism
phenytoin	33-41	alcohol	90-96	mechanism
phenytoin	33-41	reserpine	105-113	mechanism
carbamazepine	67-79	alcohol	90-96	false
carbamazepine	67-79	reserpine	105-113	false
alcohol	90-96	reserpine	105-113	false

- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
phenytoin	52-60	phenobarbital	86-98	mechanism
phenytoin	52-60	sodium valproate	120-135	mechanism
phenobarbital	86-98	sodium valproate	120-135	false

Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
phenytoin	26-34	phenobarbital	39-51	effect
phenytoin	26-34	valproic acid	54-66	effect
phenytoin	26-34	valproate	86-94	effect
phenobarbital	39-51	valproic acid	54-66	false
phenobarbital	39-51	valproate	86-94	false
valproic acid	54-66	valproate	86-94	false

- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted
tricyclic antidepressants	40-64	Cerebyx	119-125	effect

- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
phenytoin	38-46	anticoagulants	57-70	effect
phenytoin	38-46	corticosteroids	73-87	effect
phenytoin	38-46	coumarin	90-97	effect
phenytoin	38-46	digitoxin	100-108	effect
phenytoin	38-46	doxycycline	111-121	effect
phenytoin	38-46	estrogens	124-132	effect
phenytoin	38-46	furosemide	135-144	effect
phenytoin	38-46	contraceptives	152-165	effect
phenytoin	38-46	rifampin	168-175	effect
phenytoin	38-46	quinidine	178-186	effect
phenytoin	38-46	theophylline	189-200	effect
phenytoin	38-46	vitamin D	203-211	effect
anticoagulants	57-70	corticosteroids	73-87	false
anticoagulants	57-70	coumarin	90-97	false
anticoagulants	57-70	digitoxin	100-108	false
anticoagulants	57-70	doxycycline	111-121	false
anticoagulants	57-70	estrogens	124-132	false
anticoagulants	57-70	furosemide	135-144	false
anticoagulants	57-70	contraceptives	152-165	false
anticoagulants	57-70	rifampin	168-175	false
anticoagulants	57-70	quinidine	178-186	false
anticoagulants	57-70	theophylline	189-200	false
anticoagulants	57-70	vitamin D	203-211	false
corticosteroids	73-87	coumarin	90-97	false
corticosteroids	73-87	digitoxin	100-108	false
corticosteroids	73-87	doxycycline	111-121	false
corticosteroids	73-87	estrogens	124-132	false
corticosteroids	73-87	furosemide	135-144	false
corticosteroids	73-87	contraceptives	152-165	false
corticosteroids	73-87	rifampin	168-175	false
corticosteroids	73-87	quinidine	178-186	false
corticosteroids	73-87	theophylline	189-200	false
corticosteroids	73-87	vitamin D	203-211	false
coumarin	90-97	digitoxin	100-108	false
coumarin	90-97	doxycycline	111-121	false
coumarin	90-97	estrogens	124-132	false
coumarin	90-97	furosemide	135-144	false
coumarin	90-97	contraceptives	152-165	false
coumarin	90-97	rifampin	168-175	false
coumarin	90-97	quinidine	178-186	false
coumarin	90-97	theophylline	189-200	false
coumarin	90-97	vitamin D	203-211	false
digitoxin	100-108	doxycycline	111-121	false
digitoxin	100-108	estrogens	124-132	false
digitoxin	100-108	furosemide	135-144	false
digitoxin	100-108	contraceptives	152-165	false
digitoxin	100-108	rifampin	168-175	false
digitoxin	100-108	quinidine	178-186	false
digitoxin	100-108	theophylline	189-200	false
digitoxin	100-108	vitamin D	203-211	false
doxycycline	111-121	estrogens	124-132	false
doxycycline	111-121	furosemide	135-144	false
doxycycline	111-121	contraceptives	152-165	false
doxycycline	111-121	rifampin	168-175	false
doxycycline	111-121	quinidine	178-186	false
doxycycline	111-121	theophylline	189-200	false
doxycycline	111-121	vitamin D	203-211	false
estrogens	124-132	furosemide	135-144	false
estrogens	124-132	contraceptives	152-165	false
estrogens	124-132	rifampin	168-175	false
estrogens	124-132	quinidine	178-186	false
estrogens	124-132	theophylline	189-200	false
estrogens	124-132	vitamin D	203-211	false
furosemide	135-144	contraceptives	152-165	false
furosemide	135-144	rifampin	168-175	false
furosemide	135-144	quinidine	178-186	false
furosemide	135-144	theophylline	189-200	false
furosemide	135-144	vitamin D	203-211	false
contraceptives	152-165	rifampin	168-175	false
contraceptives	152-165	quinidine	178-186	false
contraceptives	152-165	theophylline	189-200	false
contraceptives	152-165	vitamin D	203-211	false
rifampin	168-175	quinidine	178-186	false
rifampin	168-175	theophylline	189-200	false
rifampin	168-175	vitamin D	203-211	false
quinidine	178-186	theophylline	189-200	false
quinidine	178-186	vitamin D	203-211	false
theophylline	189-200	vitamin D	203-211	false

Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.
phenytoin	75-83	Cerebyx	110-116	false

Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
ergotamine	67-76	ergot-type medications	92-113	false
ergotamine	67-76	dihydroergotamine	121-137	false
ergotamine	67-76	methysergide	142-153	false
ergotamine	67-76	FROVA	160-164	advise
ergot-type medications	92-113	dihydroergotamine	121-137	false
ergot-type medications	92-113	methysergide	142-153	false
ergot-type medications	92-113	FROVA	160-164	advise
dihydroergotamine	121-137	methysergide	142-153	false
dihydroergotamine	121-137	FROVA	160-164	advise
methysergide	142-153	FROVA	160-164	advise

Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
Selective serotonin reuptake inhibitors	0-38	SSRIs	41-45	false
Selective serotonin reuptake inhibitors	0-38	fluoxetine	55-64	false
Selective serotonin reuptake inhibitors	0-38	fluvoxamine	67-77	false
Selective serotonin reuptake inhibitors	0-38	paroxetine	80-89	false
Selective serotonin reuptake inhibitors	0-38	sertraline	92-101	false
Selective serotonin reuptake inhibitors	0-38	5-HT1 agonists	210-223	effect
SSRIs	41-45	fluoxetine	55-64	false
SSRIs	41-45	fluvoxamine	67-77	false
SSRIs	41-45	paroxetine	80-89	false
SSRIs	41-45	sertraline	92-101	false
SSRIs	41-45	5-HT1 agonists	210-223	effect
fluoxetine	55-64	fluvoxamine	67-77	false
fluoxetine	55-64	paroxetine	80-89	false
fluoxetine	55-64	sertraline	92-101	false
fluoxetine	55-64	5-HT1 agonists	210-223	effect
fluvoxamine	67-77	paroxetine	80-89	false
fluvoxamine	67-77	sertraline	92-101	false
fluvoxamine	67-77	5-HT1 agonists	210-223	effect
paroxetine	80-89	sertraline	92-101	false
paroxetine	80-89	5-HT1 agonists	210-223	effect
sertraline	92-101	5-HT1 agonists	210-223	effect

If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
frovatriptan	30-41	SSRI	50-53	advise

The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.
fulvestrant	25-35	fulvestrant	226-236	false

Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.
Furosemide	0-9	aminoglycoside antibiotics	50-75	effect

Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
Furosemide	0-9	ethacrynic acid	49-63	advise

Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
salicylates	33-43	furosemide	64-73	effect
salicylates	33-43	salicylate	116-125	false
furosemide	64-73	salicylate	116-125	false

Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
Furosemide	0-9	tubocurarine	79-90	effect
Furosemide	0-9	succinylcholine	125-139	effect
tubocurarine	79-90	succinylcholine	125-139	false

Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
Lithium	0-6	diuretics	43-51	advise
Lithium	0-6	lithium	73-79	false
Lithium	0-6	lithium	121-127	false
diuretics	43-51	lithium	73-79	false
diuretics	43-51	lithium	121-127	false
lithium	73-79	lithium	121-127	false

Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.
Furosemide	0-9	antihypertensive drugs	68-89	effect

Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
ganglionic adrenergic blocking drugs	25-34;50-74	peripheral adrenergic blocking drugs	39-74	false

Furosemide may decrease arterial responsiveness to norepinephrine.
Furosemide	0-9	norepinephrine	51-64	effect

Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
sucralfate	39-48	furosemide	54-63	effect
sucralfate	39-48	furosemide	132-141	false
furosemide	54-63	furosemide	132-141	false

The intake of furosemide and sucralfate should be separated by at least two hours.
furosemide	14-23	sucralfate	29-38	advise

Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
furosemide	101-110	acetylsalicylic acid	116-135	effect

There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
furosemide	130-139	NSAIDs	170-175	effect

Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
indomethacin	53-64	furosemide	125-134	effect

Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
indomethacin	24-35	furosemide	41-50	advise
indomethacin	24-35	furosemide	150-159	false
furosemide	41-50	furosemide	150-159	false

Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs.
Gabapentin	0-9	antiepileptic drugs	111-129	false

Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.
Phenytoin	0-8	Neurontin	72-80	false
Phenytoin	0-8	phenytoin	124-132	false
Phenytoin	0-8	gabapentin	169-178	false
Phenytoin	0-8	phenytoin	246-254	false
Phenytoin	0-8	phenytoin	260-268	false
Phenytoin	0-8	gabapentin	287-296	false
Neurontin	72-80	phenytoin	124-132	false
Neurontin	72-80	gabapentin	169-178	false
Neurontin	72-80	phenytoin	246-254	false
Neurontin	72-80	phenytoin	260-268	false
Neurontin	72-80	gabapentin	287-296	false
phenytoin	124-132	gabapentin	169-178	false
phenytoin	124-132	phenytoin	246-254	false
phenytoin	124-132	phenytoin	260-268	false
phenytoin	124-132	gabapentin	287-296	false
gabapentin	169-178	phenytoin	246-254	false
gabapentin	169-178	phenytoin	260-268	false
gabapentin	169-178	gabapentin	287-296	false
phenytoin	246-254	phenytoin	260-268	false
phenytoin	246-254	gabapentin	287-296	false
phenytoin	260-268	gabapentin	287-296	false

Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;
Carbamazepine	0-12	carbamazepine	42-54	false
Carbamazepine	0-12	carbamazepine 10, 11 epoxide	60-87	false
Carbamazepine	0-12	gabapentin	137-146	false
carbamazepine	42-54	carbamazepine 10, 11 epoxide	60-87	false
carbamazepine	42-54	gabapentin	137-146	false
carbamazepine 10, 11 epoxide	60-87	gabapentin	137-146	false

Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.
gabapentin	10-19	carbamazepine	56-68	false

Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;
Valproic Acid	0-12	valproic acid	50-62	false
Valproic Acid	0-12	gabapentin	111-120	false
valproic acid	50-62	gabapentin	111-120	false

N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic acid.
gabapentin	42-51	valproic acid	92-104	false

Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;
Phenobarbital	0-12	phenobarbital	72-84	false
Phenobarbital	0-12	gabapentin	89-98	false
phenobarbital	72-84	gabapentin	89-98	false

Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.
Naproxen	0-7	naproxen sodium	37-51	false
Naproxen	0-7	Neurontin	76-84	false
Naproxen	0-7	gabapentin	129-138	false
naproxen sodium	37-51	Neurontin	76-84	mechanism
naproxen sodium	37-51	gabapentin	129-138	false
Neurontin	76-84	gabapentin	129-138	false

Gabapentin had no effect on naproxen pharmacokinetic parameters.
Gabapentin	0-9	naproxen	28-35	false

Hydrocodone: Coadministration of Neurontin  (125 to 500 mg;
Hydrocodone	0-10	Neurontin	33-41	false

Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg Neurontin  and 21% to 22% lower, respectively, after administration of 500 mg Neurontin .
Neurontin	85-93	Neurontin	163-171	false

Hydrocodone increases gabapentin AUC values by 14%.
Hydrocodone	0-10	gabapentin	22-31	mechanism

Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
Morphine	0-7	morphine	77-84	false
Morphine	0-7	Neurontin	137-145	false
Morphine	0-7	gabapentin	169-178	false
Morphine	0-7	gabapentin	213-222	false
Morphine	0-7	morphine	245-252	false
morphine	77-84	Neurontin	137-145	mechanism
morphine	77-84	gabapentin	169-178	false
morphine	77-84	gabapentin	213-222	false
morphine	77-84	morphine	245-252	false
Neurontin	137-145	gabapentin	169-178	false
Neurontin	137-145	gabapentin	213-222	false
Neurontin	137-145	morphine	245-252	false
gabapentin	169-178	gabapentin	213-222	false
gabapentin	169-178	morphine	245-252	false
gabapentin	213-222	morphine	245-252	false

Morphine pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after morphine.
Morphine	0-7	Neurontin	81-89	false
Morphine	0-7	morphine	106-113	false
Neurontin	81-89	morphine	106-113	false

Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
Cimetidine	0-9	cimetidine	31-40	false
Cimetidine	0-9	gabapentin	99-108	false
cimetidine	31-40	gabapentin	99-108	mechanism

Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
cimetidine	5-14	gabapentin	62-71	mechanism

This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
gabapentin	36-45	cimetidine	50-59	mechanism

The effect of gabapentin on cimetidine was not evaluated.
gabapentin	14-23	cimetidine	28-37	false

Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
Contraceptive	5-17	norethindrone	90-102	false
Contraceptive	5-17	ethinyl estradiol	108-124	false
Contraceptive	5-17	norethindrone acetate	183-203	false
Contraceptive	5-17	ethinyl estradiol	219-235	false
Contraceptive	5-17	gabapentin	287-296	false
norethindrone	90-102	ethinyl estradiol	108-124	false
norethindrone	90-102	norethindrone acetate	183-203	false
norethindrone	90-102	ethinyl estradiol	219-235	false
norethindrone	90-102	gabapentin	287-296	false
ethinyl estradiol	108-124	norethindrone acetate	183-203	false
ethinyl estradiol	108-124	ethinyl estradiol	219-235	false
ethinyl estradiol	108-124	gabapentin	287-296	false
norethindrone acetate	183-203	ethinyl estradiol	219-235	false
norethindrone acetate	183-203	gabapentin	287-296	false
ethinyl estradiol	219-235	gabapentin	287-296	false

The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
norethindrone	12-24	gabapentin	73-82	mechanism

Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
Antacid	0-6	Maalox	9-14	false
Antacid	0-6	Maalox	19-24	false
Antacid	0-6	gabapentin	57-66	false
Maalox	9-14	Maalox	19-24	false
Maalox	9-14	gabapentin	57-66	false
Maalox	19-24	gabapentin	57-66	mechanism

This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.
gabapentin	51-60	Maalox	93-98	mechanism

It is recommended that gabapentin be taken at least 2 hours following Maalox administration.
gabapentin	23-32	Maalox	70-75	advise

Effect of Probenecid: Probenecid is a blocker of renal tubular secretion.
Probenecid	10-19	Probenecid	22-31	false

Gabapentin pharmacokinetic parameters without and with probenecid were comparable.
Gabapentin	0-9	probenecid	55-64	false

This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.
gabapentin	20-29	probenecid	106-115	false

Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein
gabapentin	149-158	antiepileptic drugs	179-197	false

In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).
rifampicin	54-63	phenytoin	68-76	false

International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.
warfarin	114-121	IRESSA	132-137	effect

Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
ketoconazole	62-73	itraconazole	79-90	false
ketoconazole	62-73	gefitinib	102-110	mechanism
ketoconazole	62-73	gefitinib	136-144	mechanism
itraconazole	79-90	gefitinib	102-110	mechanism
itraconazole	79-90	gefitinib	136-144	mechanism
gefitinib	102-110	gefitinib	136-144	false

Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
histamine H2-receptor antagonists	64-96	ranitidine	106-115	false
histamine H2-receptor antagonists	64-96	cimetidine	120-129	false
histamine H2-receptor antagonists	64-96	IRESSA	168-173	mechanism
ranitidine	106-115	cimetidine	120-129	false
ranitidine	106-115	IRESSA	168-173	mechanism
cimetidine	120-129	IRESSA	168-173	mechanism

Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.
IRESSA	36-41	vinorelbine	47-57	false
IRESSA	36-41	IRESSA	103-108	false
IRESSA	36-41	vinorelbine	151-161	false
vinorelbine	47-57	IRESSA	103-108	false
vinorelbine	47-57	vinorelbine	151-161	false
IRESSA	103-108	vinorelbine	151-161	effect

For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.
Gemzar	43-48	cisplatin	54-62	false

Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.
FACTIVE	34-40	theophylline	95-106	false
FACTIVE	34-40	digoxin	109-115	false
FACTIVE	34-40	ethinylestradiol	123-138	false
FACTIVE	34-40	contraceptive product	160-180	false
theophylline	95-106	digoxin	109-115	false
theophylline	95-106	ethinylestradiol	123-138	false
theophylline	95-106	contraceptive product	160-180	false
digoxin	109-115	ethinylestradiol	123-138	false
digoxin	109-115	contraceptive product	160-180	false
ethinylestradiol	123-138	contraceptive product	160-180	false

Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
FACTIVE	30-36	calcium carbonate	42-58	mechanism
FACTIVE	30-36	cimetidine	61-70	mechanism
FACTIVE	30-36	omeprazole	73-82	mechanism
FACTIVE	30-36	estrogen	91-98	mechanism
FACTIVE	30-36	progesterone	100-111	mechanism
FACTIVE	30-36	contraceptive	118-130	mechanism
FACTIVE	30-36	gemifloxacin	182-193	false
calcium carbonate	42-58	cimetidine	61-70	false
calcium carbonate	42-58	omeprazole	73-82	false
calcium carbonate	42-58	estrogen	91-98	false
calcium carbonate	42-58	progesterone	100-111	false
calcium carbonate	42-58	contraceptive	118-130	false
calcium carbonate	42-58	gemifloxacin	182-193	false
cimetidine	61-70	omeprazole	73-82	false
cimetidine	61-70	estrogen	91-98	false
cimetidine	61-70	progesterone	100-111	false
cimetidine	61-70	contraceptive	118-130	false
cimetidine	61-70	gemifloxacin	182-193	false
omeprazole	73-82	estrogen	91-98	false
omeprazole	73-82	progesterone	100-111	false
omeprazole	73-82	contraceptive	118-130	false
omeprazole	73-82	gemifloxacin	182-193	false
estrogen	91-98	progesterone	100-111	false
estrogen	91-98	contraceptive	118-130	false
estrogen	91-98	gemifloxacin	182-193	false
progesterone	100-111	contraceptive	118-130	false
progesterone	100-111	gemifloxacin	182-193	false
contraceptive	118-130	gemifloxacin	182-193	false

Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
FACTIVE	30-36	probenecid	43-52	mechanism
FACTIVE	30-36	gemifloxacin	105-116	false
probenecid	43-52	gemifloxacin	105-116	false

FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.
FACTIVE	0-6	warfarin	65-72	false
FACTIVE	0-6	warfarin	104-111	false
warfarin	65-72	warfarin	104-111	false

However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
quinolones	22-31	warfarin	92-99	effect
quinolones	22-31	quinolone antimicrobial	222-244	false
quinolones	22-31	warfarin	281-288	false
warfarin	92-99	quinolone antimicrobial	222-244	false
warfarin	92-99	warfarin	281-288	false
quinolone antimicrobial	222-244	warfarin	281-288	advise

The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
gemifloxacin	23-34	antacid	101-107	false
gemifloxacin	23-34	aluminum	120-127	mechanism
gemifloxacin	23-34	magnesium	133-141	mechanism
antacid	101-107	aluminum	120-127	false
antacid	101-107	magnesium	133-141	false
aluminum	120-127	magnesium	133-141	false

Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
Magnesium	0-8	aluminum	18-25	false
Magnesium	0-8	antacids	38-45	false
Magnesium	0-8	ferrous sulfate	68-82	false
Magnesium	0-8	iron	85-88	false
Magnesium	0-8	multivitamin preparations	92-116	false
Magnesium	0-8	zinc	129-132	false
Magnesium	0-8	Videx	161-165	false
Magnesium	0-8	didanosine	168-177	false
Magnesium	0-8	FACTIVE	307-313	advise
aluminum	18-25	antacids	38-45	false
aluminum	18-25	ferrous sulfate	68-82	false
aluminum	18-25	iron	85-88	false
aluminum	18-25	multivitamin preparations	92-116	false
aluminum	18-25	zinc	129-132	false
aluminum	18-25	Videx	161-165	false
aluminum	18-25	didanosine	168-177	false
aluminum	18-25	FACTIVE	307-313	advise
antacids	38-45	ferrous sulfate	68-82	false
antacids	38-45	iron	85-88	false
antacids	38-45	multivitamin preparations	92-116	false
antacids	38-45	zinc	129-132	false
antacids	38-45	Videx	161-165	false
antacids	38-45	didanosine	168-177	false
antacids	38-45	FACTIVE	307-313	false
ferrous sulfate	68-82	iron	85-88	false
ferrous sulfate	68-82	multivitamin preparations	92-116	false
ferrous sulfate	68-82	zinc	129-132	false
ferrous sulfate	68-82	Videx	161-165	false
ferrous sulfate	68-82	didanosine	168-177	false
ferrous sulfate	68-82	FACTIVE	307-313	advise
iron	85-88	multivitamin preparations	92-116	false
iron	85-88	zinc	129-132	false
iron	85-88	Videx	161-165	false
iron	85-88	didanosine	168-177	false
iron	85-88	FACTIVE	307-313	advise
multivitamin preparations	92-116	zinc	129-132	false
multivitamin preparations	92-116	Videx	161-165	false
multivitamin preparations	92-116	didanosine	168-177	false
multivitamin preparations	92-116	FACTIVE	307-313	advise
zinc	129-132	Videx	161-165	false
zinc	129-132	didanosine	168-177	false
zinc	129-132	FACTIVE	307-313	advise
Videx	161-165	didanosine	168-177	false
Videx	161-165	FACTIVE	307-313	advise
didanosine	168-177	FACTIVE	307-313	advise

Sucralfate should not be taken within 2 hours of FACTIVE.
Sucralfate	0-9	FACTIVE	49-55	advise

Results from existing clinical trials suggest no significant interactions between COPAXONE  and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days.
COPAXONE	82-89	corticosteroids	174-188	false

COPAXONE  has not been formally evaluated in combination with Interferon beta.
COPAXONE	0-7	Interferon beta	62-76	false

However, 10 patients who switched from therapy with Interferon beta to COPAXONE  did not report any serious and unexpected adverse reactions thought to be related to treatment.
Interferon beta	52-66	COPAXONE	71-78	false

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
sulfonylureas	27-39	nonsteroidal anti-inflammatory agents	87-123	effect
sulfonylureas	27-39	salicylates	172-182	effect
sulfonylureas	27-39	sulfonamides	185-196	effect
sulfonylureas	27-39	chloramphenicol	199-213	effect
sulfonylureas	27-39	probenecid	216-225	effect
sulfonylureas	27-39	coumarins	228-236	effect
sulfonylureas	27-39	monoamine oxidase inhibitors	239-266	effect
sulfonylureas	27-39	beta adrenergic blocking agents	273-303	effect
nonsteroidal anti-inflammatory agents	87-123	salicylates	172-182	false
nonsteroidal anti-inflammatory agents	87-123	sulfonamides	185-196	false
nonsteroidal anti-inflammatory agents	87-123	chloramphenicol	199-213	false
nonsteroidal anti-inflammatory agents	87-123	probenecid	216-225	false
nonsteroidal anti-inflammatory agents	87-123	coumarins	228-236	false
nonsteroidal anti-inflammatory agents	87-123	monoamine oxidase inhibitors	239-266	false
nonsteroidal anti-inflammatory agents	87-123	beta adrenergic blocking agents	273-303	false
salicylates	172-182	sulfonamides	185-196	false
salicylates	172-182	chloramphenicol	199-213	false
salicylates	172-182	probenecid	216-225	false
salicylates	172-182	coumarins	228-236	false
salicylates	172-182	monoamine oxidase inhibitors	239-266	false
salicylates	172-182	beta adrenergic blocking agents	273-303	false
sulfonamides	185-196	chloramphenicol	199-213	false
sulfonamides	185-196	probenecid	216-225	false
sulfonamides	185-196	coumarins	228-236	false
sulfonamides	185-196	monoamine oxidase inhibitors	239-266	false
sulfonamides	185-196	beta adrenergic blocking agents	273-303	false
chloramphenicol	199-213	probenecid	216-225	false
chloramphenicol	199-213	coumarins	228-236	false
chloramphenicol	199-213	monoamine oxidase inhibitors	239-266	false
chloramphenicol	199-213	beta adrenergic blocking agents	273-303	false
probenecid	216-225	coumarins	228-236	false
probenecid	216-225	monoamine oxidase inhibitors	239-266	false
probenecid	216-225	beta adrenergic blocking agents	273-303	false
coumarins	228-236	monoamine oxidase inhibitors	239-266	false
coumarins	228-236	beta adrenergic blocking agents	273-303	false
monoamine oxidase inhibitors	239-266	beta adrenergic blocking agents	273-303	false

These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
thiazides	24-32	diuretics	44-52	false
thiazides	24-32	corticosteroids	55-69	false
thiazides	24-32	thyroid products	89-104	false
thiazides	24-32	estrogens	107-115	false
thiazides	24-32	contraceptives	123-136	false
thiazides	24-32	phenytoin	139-147	false
thiazides	24-32	nicotinic acid	150-163	false
thiazides	24-32	calcium channel blocking drugs	185-214	false
thiazides	24-32	isoniazid	221-229	false
diuretics	44-52	corticosteroids	55-69	false
diuretics	44-52	thyroid products	89-104	false
diuretics	44-52	estrogens	107-115	false
diuretics	44-52	contraceptives	123-136	false
diuretics	44-52	phenytoin	139-147	false
diuretics	44-52	nicotinic acid	150-163	false
diuretics	44-52	calcium channel blocking drugs	185-214	false
diuretics	44-52	isoniazid	221-229	false
corticosteroids	55-69	thyroid products	89-104	false
corticosteroids	55-69	estrogens	107-115	false
corticosteroids	55-69	contraceptives	123-136	false
corticosteroids	55-69	phenytoin	139-147	false
corticosteroids	55-69	nicotinic acid	150-163	false
corticosteroids	55-69	calcium channel blocking drugs	185-214	false
corticosteroids	55-69	isoniazid	221-229	false
thyroid products	89-104	estrogens	107-115	false
thyroid products	89-104	contraceptives	123-136	false
thyroid products	89-104	phenytoin	139-147	false
thyroid products	89-104	nicotinic acid	150-163	false
thyroid products	89-104	calcium channel blocking drugs	185-214	false
thyroid products	89-104	isoniazid	221-229	false
estrogens	107-115	contraceptives	123-136	false
estrogens	107-115	phenytoin	139-147	false
estrogens	107-115	nicotinic acid	150-163	false
estrogens	107-115	calcium channel blocking drugs	185-214	false
estrogens	107-115	isoniazid	221-229	false
contraceptives	123-136	phenytoin	139-147	false
contraceptives	123-136	nicotinic acid	150-163	false
contraceptives	123-136	calcium channel blocking drugs	185-214	false
contraceptives	123-136	isoniazid	221-229	false
phenytoin	139-147	nicotinic acid	150-163	false
phenytoin	139-147	calcium channel blocking drugs	185-214	false
phenytoin	139-147	isoniazid	221-229	false
nicotinic acid	150-163	calcium channel blocking drugs	185-214	false
nicotinic acid	150-163	isoniazid	221-229	false
calcium channel blocking drugs	185-214	isoniazid	221-229	false

A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
glyburide	31-39	ciprofloxacin	45-57	int
glyburide	31-39	fluoroquinolone antibiotic	62-87	false
glyburide	31-39	glyburide	167-175	false
ciprofloxacin	45-57	fluoroquinolone antibiotic	62-87	false
ciprofloxacin	45-57	glyburide	167-175	false
fluoroquinolone antibiotic	62-87	glyburide	167-175	false

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
miconazole	37-46	hypoglycemic agents	57-75	effect

Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.
Metformin	0-8	glyburide	78-86	false

Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.
metformin	35-43	metformin	85-93	false

Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
glimepiride	14-24	aspirin	96-102	advise
glimepiride	14-24	salicylate	115-124	advise
glimepiride	14-24	magnesium/choline salicylate	134-161	advise
glimepiride	14-24	Trilisate	164-172	advise
glimepiride	14-24	salsalate	176-184	advise
glimepiride	14-24	Disalcid	187-194	advise
glimepiride	14-24	choline salicylate	206-223	advise
glimepiride	14-24	Arthropan	226-234	advise
glimepiride	14-24	magnesium salicylate	238-257	advise
glimepiride	14-24	Magan	260-264	advise
glimepiride	14-24	bismuth subsalicylate	271-291	advise
glimepiride	14-24	Pepto-Bismol	294-305	advise
aspirin	96-102	salicylate	115-124	false
aspirin	96-102	magnesium/choline salicylate	134-161	false
aspirin	96-102	Trilisate	164-172	false
aspirin	96-102	salsalate	176-184	false
aspirin	96-102	Disalcid	187-194	false
aspirin	96-102	choline salicylate	206-223	false
aspirin	96-102	Arthropan	226-234	false
aspirin	96-102	magnesium salicylate	238-257	false
aspirin	96-102	Magan	260-264	false
aspirin	96-102	bismuth subsalicylate	271-291	false
aspirin	96-102	Pepto-Bismol	294-305	false
salicylate	115-124	magnesium/choline salicylate	134-161	false
salicylate	115-124	Trilisate	164-172	false
salicylate	115-124	salsalate	176-184	false
salicylate	115-124	Disalcid	187-194	false
salicylate	115-124	choline salicylate	206-223	false
salicylate	115-124	Arthropan	226-234	false
salicylate	115-124	magnesium salicylate	238-257	false
salicylate	115-124	Magan	260-264	false
salicylate	115-124	bismuth subsalicylate	271-291	false
salicylate	115-124	Pepto-Bismol	294-305	false
magnesium/choline salicylate	134-161	Trilisate	164-172	false
magnesium/choline salicylate	134-161	salsalate	176-184	false
magnesium/choline salicylate	134-161	Disalcid	187-194	false
magnesium/choline salicylate	134-161	choline salicylate	206-223	false
magnesium/choline salicylate	134-161	Arthropan	226-234	false
magnesium/choline salicylate	134-161	magnesium salicylate	238-257	false
magnesium/choline salicylate	134-161	Magan	260-264	false
magnesium/choline salicylate	134-161	bismuth subsalicylate	271-291	false
magnesium/choline salicylate	134-161	Pepto-Bismol	294-305	false
Trilisate	164-172	salsalate	176-184	false
Trilisate	164-172	Disalcid	187-194	false
Trilisate	164-172	choline salicylate	206-223	false
Trilisate	164-172	Arthropan	226-234	false
Trilisate	164-172	magnesium salicylate	238-257	false
Trilisate	164-172	Magan	260-264	false
Trilisate	164-172	bismuth subsalicylate	271-291	false
Trilisate	164-172	Pepto-Bismol	294-305	false
salsalate	176-184	Disalcid	187-194	false
salsalate	176-184	choline salicylate	206-223	false
salsalate	176-184	Arthropan	226-234	false
salsalate	176-184	magnesium salicylate	238-257	false
salsalate	176-184	Magan	260-264	false
salsalate	176-184	bismuth subsalicylate	271-291	false
salsalate	176-184	Pepto-Bismol	294-305	false
Disalcid	187-194	choline salicylate	206-223	false
Disalcid	187-194	Arthropan	226-234	false
Disalcid	187-194	magnesium salicylate	238-257	false
Disalcid	187-194	Magan	260-264	false
Disalcid	187-194	bismuth subsalicylate	271-291	false
Disalcid	187-194	Pepto-Bismol	294-305	false
choline salicylate	206-223	Arthropan	226-234	false
choline salicylate	206-223	magnesium salicylate	238-257	false
choline salicylate	206-223	Magan	260-264	false
choline salicylate	206-223	bismuth subsalicylate	271-291	false
choline salicylate	206-223	Pepto-Bismol	294-305	false
Arthropan	226-234	magnesium salicylate	238-257	false
Arthropan	226-234	Magan	260-264	false
Arthropan	226-234	bismuth subsalicylate	271-291	false
Arthropan	226-234	Pepto-Bismol	294-305	false
magnesium salicylate	238-257	Magan	260-264	false
magnesium salicylate	238-257	bismuth subsalicylate	271-291	false
magnesium salicylate	238-257	Pepto-Bismol	294-305	false
Magan	260-264	bismuth subsalicylate	271-291	false
Magan	260-264	Pepto-Bismol	294-305	false
bismuth subsalicylate	271-291	Pepto-Bismol	294-305	false

- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
nonsteroidal anti-inflammatory drug	4-38	NSAID	41-45	false
nonsteroidal anti-inflammatory drug	4-38	ibuprofen	56-64	false
nonsteroidal anti-inflammatory drug	4-38	Motrin	67-72	false
nonsteroidal anti-inflammatory drug	4-38	Advil	75-79	false
nonsteroidal anti-inflammatory drug	4-38	Nuprin	82-87	false
nonsteroidal anti-inflammatory drug	4-38	ketoprofen	99-108	false
nonsteroidal anti-inflammatory drug	4-38	Orudis	111-116	false
nonsteroidal anti-inflammatory drug	4-38	Orudis KT	119-127	false
nonsteroidal anti-inflammatory drug	4-38	Oruvail	130-136	false
nonsteroidal anti-inflammatory drug	4-38	diclofenac	140-149	false
nonsteroidal anti-inflammatory drug	4-38	Voltaren	152-159	false
nonsteroidal anti-inflammatory drug	4-38	Cataflam	162-169	false
nonsteroidal anti-inflammatory drug	4-38	etodolac	173-180	false
nonsteroidal anti-inflammatory drug	4-38	Lodine	183-188	false
nonsteroidal anti-inflammatory drug	4-38	indomethacin	192-203	false
nonsteroidal anti-inflammatory drug	4-38	Indocin	206-212	false
nonsteroidal anti-inflammatory drug	4-38	nabumetone	216-225	false
nonsteroidal anti-inflammatory drug	4-38	Relafen	228-234	false
nonsteroidal anti-inflammatory drug	4-38	oxaprozin	238-246	false
nonsteroidal anti-inflammatory drug	4-38	Daypro	249-254	false
nonsteroidal anti-inflammatory drug	4-38	naproxen	262-269	false
nonsteroidal anti-inflammatory drug	4-38	Anaprox	272-278	false
nonsteroidal anti-inflammatory drug	4-38	Naprosyn	281-288	false
nonsteroidal anti-inflammatory drug	4-38	Aleve	291-295	false
NSAID	41-45	ibuprofen	56-64	false
NSAID	41-45	Motrin	67-72	false
NSAID	41-45	Advil	75-79	false
NSAID	41-45	Nuprin	82-87	false
NSAID	41-45	ketoprofen	99-108	false
NSAID	41-45	Orudis	111-116	false
NSAID	41-45	Orudis KT	119-127	false
NSAID	41-45	Oruvail	130-136	false
NSAID	41-45	diclofenac	140-149	false
NSAID	41-45	Voltaren	152-159	false
NSAID	41-45	Cataflam	162-169	false
NSAID	41-45	etodolac	173-180	false
NSAID	41-45	Lodine	183-188	false
NSAID	41-45	indomethacin	192-203	false
NSAID	41-45	Indocin	206-212	false
NSAID	41-45	nabumetone	216-225	false
NSAID	41-45	Relafen	228-234	false
NSAID	41-45	oxaprozin	238-246	false
NSAID	41-45	Daypro	249-254	false
NSAID	41-45	naproxen	262-269	false
NSAID	41-45	Anaprox	272-278	false
NSAID	41-45	Naprosyn	281-288	false
NSAID	41-45	Aleve	291-295	false
ibuprofen	56-64	Motrin	67-72	false
ibuprofen	56-64	Advil	75-79	false
ibuprofen	56-64	Nuprin	82-87	false
ibuprofen	56-64	ketoprofen	99-108	false
ibuprofen	56-64	Orudis	111-116	false
ibuprofen	56-64	Orudis KT	119-127	false
ibuprofen	56-64	Oruvail	130-136	false
ibuprofen	56-64	diclofenac	140-149	false
ibuprofen	56-64	Voltaren	152-159	false
ibuprofen	56-64	Cataflam	162-169	false
ibuprofen	56-64	etodolac	173-180	false
ibuprofen	56-64	Lodine	183-188	false
ibuprofen	56-64	indomethacin	192-203	false
ibuprofen	56-64	Indocin	206-212	false
ibuprofen	56-64	nabumetone	216-225	false
ibuprofen	56-64	Relafen	228-234	false
ibuprofen	56-64	oxaprozin	238-246	false
ibuprofen	56-64	Daypro	249-254	false
ibuprofen	56-64	naproxen	262-269	false
ibuprofen	56-64	Anaprox	272-278	false
ibuprofen	56-64	Naprosyn	281-288	false
ibuprofen	56-64	Aleve	291-295	false
Motrin	67-72	Advil	75-79	false
Motrin	67-72	Nuprin	82-87	false
Motrin	67-72	ketoprofen	99-108	false
Motrin	67-72	Orudis	111-116	false
Motrin	67-72	Orudis KT	119-127	false
Motrin	67-72	Oruvail	130-136	false
Motrin	67-72	diclofenac	140-149	false
Motrin	67-72	Voltaren	152-159	false
Motrin	67-72	Cataflam	162-169	false
Motrin	67-72	etodolac	173-180	false
Motrin	67-72	Lodine	183-188	false
Motrin	67-72	indomethacin	192-203	false
Motrin	67-72	Indocin	206-212	false
Motrin	67-72	nabumetone	216-225	false
Motrin	67-72	Relafen	228-234	false
Motrin	67-72	oxaprozin	238-246	false
Motrin	67-72	Daypro	249-254	false
Motrin	67-72	naproxen	262-269	false
Motrin	67-72	Anaprox	272-278	false
Motrin	67-72	Naprosyn	281-288	false
Motrin	67-72	Aleve	291-295	false
Advil	75-79	Nuprin	82-87	false
Advil	75-79	ketoprofen	99-108	false
Advil	75-79	Orudis	111-116	false
Advil	75-79	Orudis KT	119-127	false
Advil	75-79	Oruvail	130-136	false
Advil	75-79	diclofenac	140-149	false
Advil	75-79	Voltaren	152-159	false
Advil	75-79	Cataflam	162-169	false
Advil	75-79	etodolac	173-180	false
Advil	75-79	Lodine	183-188	false
Advil	75-79	indomethacin	192-203	false
Advil	75-79	Indocin	206-212	false
Advil	75-79	nabumetone	216-225	false
Advil	75-79	Relafen	228-234	false
Advil	75-79	oxaprozin	238-246	false
Advil	75-79	Daypro	249-254	false
Advil	75-79	naproxen	262-269	false
Advil	75-79	Anaprox	272-278	false
Advil	75-79	Naprosyn	281-288	false
Advil	75-79	Aleve	291-295	false
Nuprin	82-87	ketoprofen	99-108	false
Nuprin	82-87	Orudis	111-116	false
Nuprin	82-87	Orudis KT	119-127	false
Nuprin	82-87	Oruvail	130-136	false
Nuprin	82-87	diclofenac	140-149	false
Nuprin	82-87	Voltaren	152-159	false
Nuprin	82-87	Cataflam	162-169	false
Nuprin	82-87	etodolac	173-180	false
Nuprin	82-87	Lodine	183-188	false
Nuprin	82-87	indomethacin	192-203	false
Nuprin	82-87	Indocin	206-212	false
Nuprin	82-87	nabumetone	216-225	false
Nuprin	82-87	Relafen	228-234	false
Nuprin	82-87	oxaprozin	238-246	false
Nuprin	82-87	Daypro	249-254	false
Nuprin	82-87	naproxen	262-269	false
Nuprin	82-87	Anaprox	272-278	false
Nuprin	82-87	Naprosyn	281-288	false
Nuprin	82-87	Aleve	291-295	false
ketoprofen	99-108	Orudis	111-116	false
ketoprofen	99-108	Orudis KT	119-127	false
ketoprofen	99-108	Oruvail	130-136	false
ketoprofen	99-108	diclofenac	140-149	false
ketoprofen	99-108	Voltaren	152-159	false
ketoprofen	99-108	Cataflam	162-169	false
ketoprofen	99-108	etodolac	173-180	false
ketoprofen	99-108	Lodine	183-188	false
ketoprofen	99-108	indomethacin	192-203	false
ketoprofen	99-108	Indocin	206-212	false
ketoprofen	99-108	nabumetone	216-225	false
ketoprofen	99-108	Relafen	228-234	false
ketoprofen	99-108	oxaprozin	238-246	false
ketoprofen	99-108	Daypro	249-254	false
ketoprofen	99-108	naproxen	262-269	false
ketoprofen	99-108	Anaprox	272-278	false
ketoprofen	99-108	Naprosyn	281-288	false
ketoprofen	99-108	Aleve	291-295	false
Orudis	111-116	Orudis KT	119-127	false
Orudis	111-116	Oruvail	130-136	false
Orudis	111-116	diclofenac	140-149	false
Orudis	111-116	Voltaren	152-159	false
Orudis	111-116	Cataflam	162-169	false
Orudis	111-116	etodolac	173-180	false
Orudis	111-116	Lodine	183-188	false
Orudis	111-116	indomethacin	192-203	false
Orudis	111-116	Indocin	206-212	false
Orudis	111-116	nabumetone	216-225	false
Orudis	111-116	Relafen	228-234	false
Orudis	111-116	oxaprozin	238-246	false
Orudis	111-116	Daypro	249-254	false
Orudis	111-116	naproxen	262-269	false
Orudis	111-116	Anaprox	272-278	false
Orudis	111-116	Naprosyn	281-288	false
Orudis	111-116	Aleve	291-295	false
Orudis KT	119-127	Oruvail	130-136	false
Orudis KT	119-127	diclofenac	140-149	false
Orudis KT	119-127	Voltaren	152-159	false
Orudis KT	119-127	Cataflam	162-169	false
Orudis KT	119-127	etodolac	173-180	false
Orudis KT	119-127	Lodine	183-188	false
Orudis KT	119-127	indomethacin	192-203	false
Orudis KT	119-127	Indocin	206-212	false
Orudis KT	119-127	nabumetone	216-225	false
Orudis KT	119-127	Relafen	228-234	false
Orudis KT	119-127	oxaprozin	238-246	false
Orudis KT	119-127	Daypro	249-254	false
Orudis KT	119-127	naproxen	262-269	false
Orudis KT	119-127	Anaprox	272-278	false
Orudis KT	119-127	Naprosyn	281-288	false
Orudis KT	119-127	Aleve	291-295	false
Oruvail	130-136	diclofenac	140-149	false
Oruvail	130-136	Voltaren	152-159	false
Oruvail	130-136	Cataflam	162-169	false
Oruvail	130-136	etodolac	173-180	false
Oruvail	130-136	Lodine	183-188	false
Oruvail	130-136	indomethacin	192-203	false
Oruvail	130-136	Indocin	206-212	false
Oruvail	130-136	nabumetone	216-225	false
Oruvail	130-136	Relafen	228-234	false
Oruvail	130-136	oxaprozin	238-246	false
Oruvail	130-136	Daypro	249-254	false
Oruvail	130-136	naproxen	262-269	false
Oruvail	130-136	Anaprox	272-278	false
Oruvail	130-136	Naprosyn	281-288	false
Oruvail	130-136	Aleve	291-295	false
diclofenac	140-149	Voltaren	152-159	false
diclofenac	140-149	Cataflam	162-169	false
diclofenac	140-149	etodolac	173-180	false
diclofenac	140-149	Lodine	183-188	false
diclofenac	140-149	indomethacin	192-203	false
diclofenac	140-149	Indocin	206-212	false
diclofenac	140-149	nabumetone	216-225	false
diclofenac	140-149	Relafen	228-234	false
diclofenac	140-149	oxaprozin	238-246	false
diclofenac	140-149	Daypro	249-254	false
diclofenac	140-149	naproxen	262-269	false
diclofenac	140-149	Anaprox	272-278	false
diclofenac	140-149	Naprosyn	281-288	false
diclofenac	140-149	Aleve	291-295	false
Voltaren	152-159	Cataflam	162-169	false
Voltaren	152-159	etodolac	173-180	false
Voltaren	152-159	Lodine	183-188	false
Voltaren	152-159	indomethacin	192-203	false
Voltaren	152-159	Indocin	206-212	false
Voltaren	152-159	nabumetone	216-225	false
Voltaren	152-159	Relafen	228-234	false
Voltaren	152-159	oxaprozin	238-246	false
Voltaren	152-159	Daypro	249-254	false
Voltaren	152-159	naproxen	262-269	false
Voltaren	152-159	Anaprox	272-278	false
Voltaren	152-159	Naprosyn	281-288	false
Voltaren	152-159	Aleve	291-295	false
Cataflam	162-169	etodolac	173-180	false
Cataflam	162-169	Lodine	183-188	false
Cataflam	162-169	indomethacin	192-203	false
Cataflam	162-169	Indocin	206-212	false
Cataflam	162-169	nabumetone	216-225	false
Cataflam	162-169	Relafen	228-234	false
Cataflam	162-169	oxaprozin	238-246	false
Cataflam	162-169	Daypro	249-254	false
Cataflam	162-169	naproxen	262-269	false
Cataflam	162-169	Anaprox	272-278	false
Cataflam	162-169	Naprosyn	281-288	false
Cataflam	162-169	Aleve	291-295	false
etodolac	173-180	Lodine	183-188	false
etodolac	173-180	indomethacin	192-203	false
etodolac	173-180	Indocin	206-212	false
etodolac	173-180	nabumetone	216-225	false
etodolac	173-180	Relafen	228-234	false
etodolac	173-180	oxaprozin	238-246	false
etodolac	173-180	Daypro	249-254	false
etodolac	173-180	naproxen	262-269	false
etodolac	173-180	Anaprox	272-278	false
etodolac	173-180	Naprosyn	281-288	false
etodolac	173-180	Aleve	291-295	false
Lodine	183-188	indomethacin	192-203	false
Lodine	183-188	Indocin	206-212	false
Lodine	183-188	nabumetone	216-225	false
Lodine	183-188	Relafen	228-234	false
Lodine	183-188	oxaprozin	238-246	false
Lodine	183-188	Daypro	249-254	false
Lodine	183-188	naproxen	262-269	false
Lodine	183-188	Anaprox	272-278	false
Lodine	183-188	Naprosyn	281-288	false
Lodine	183-188	Aleve	291-295	false
indomethacin	192-203	Indocin	206-212	false
indomethacin	192-203	nabumetone	216-225	false
indomethacin	192-203	Relafen	228-234	false
indomethacin	192-203	oxaprozin	238-246	false
indomethacin	192-203	Daypro	249-254	false
indomethacin	192-203	naproxen	262-269	false
indomethacin	192-203	Anaprox	272-278	false
indomethacin	192-203	Naprosyn	281-288	false
indomethacin	192-203	Aleve	291-295	false
Indocin	206-212	nabumetone	216-225	false
Indocin	206-212	Relafen	228-234	false
Indocin	206-212	oxaprozin	238-246	false
Indocin	206-212	Daypro	249-254	false
Indocin	206-212	naproxen	262-269	false
Indocin	206-212	Anaprox	272-278	false
Indocin	206-212	Naprosyn	281-288	false
Indocin	206-212	Aleve	291-295	false
nabumetone	216-225	Relafen	228-234	false
nabumetone	216-225	oxaprozin	238-246	false
nabumetone	216-225	Daypro	249-254	false
nabumetone	216-225	naproxen	262-269	false
nabumetone	216-225	Anaprox	272-278	false
nabumetone	216-225	Naprosyn	281-288	false
nabumetone	216-225	Aleve	291-295	false
Relafen	228-234	oxaprozin	238-246	false
Relafen	228-234	Daypro	249-254	false
Relafen	228-234	naproxen	262-269	false
Relafen	228-234	Anaprox	272-278	false
Relafen	228-234	Naprosyn	281-288	false
Relafen	228-234	Aleve	291-295	false
oxaprozin	238-246	Daypro	249-254	false
oxaprozin	238-246	naproxen	262-269	false
oxaprozin	238-246	Anaprox	272-278	false
oxaprozin	238-246	Naprosyn	281-288	false
oxaprozin	238-246	Aleve	291-295	false
Daypro	249-254	naproxen	262-269	false
Daypro	249-254	Anaprox	272-278	false
Daypro	249-254	Naprosyn	281-288	false
Daypro	249-254	Aleve	291-295	false
naproxen	262-269	Anaprox	272-278	false
naproxen	262-269	Naprosyn	281-288	false
naproxen	262-269	Aleve	291-295	false
Anaprox	272-278	Naprosyn	281-288	false
Anaprox	272-278	Aleve	291-295	false
Naprosyn	281-288	Aleve	291-295	false

- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
sulfamethoxazole	29-44	trimethoprim	46-57	false
sulfamethoxazole	29-44	Bactrim	60-66	false
sulfamethoxazole	29-44	Septra	69-74	false
sulfamethoxazole	29-44	sulfisoxazole	78-90	false
sulfamethoxazole	29-44	Gantrisin	93-101	false
sulfamethoxazole	29-44	sulfasalazine	108-120	false
sulfamethoxazole	29-44	Azulfidine	123-132	false
trimethoprim	46-57	Bactrim	60-66	false
trimethoprim	46-57	Septra	69-74	false
trimethoprim	46-57	sulfisoxazole	78-90	false
trimethoprim	46-57	Gantrisin	93-101	false
trimethoprim	46-57	sulfasalazine	108-120	false
trimethoprim	46-57	Azulfidine	123-132	false
Bactrim	60-66	Septra	69-74	false
Bactrim	60-66	sulfisoxazole	78-90	false
Bactrim	60-66	Gantrisin	93-101	false
Bactrim	60-66	sulfasalazine	108-120	false
Bactrim	60-66	Azulfidine	123-132	false
Septra	69-74	sulfisoxazole	78-90	false
Septra	69-74	Gantrisin	93-101	false
Septra	69-74	sulfasalazine	108-120	false
Septra	69-74	Azulfidine	123-132	false
sulfisoxazole	78-90	Gantrisin	93-101	false
sulfisoxazole	78-90	sulfasalazine	108-120	false
sulfisoxazole	78-90	Azulfidine	123-132	false
Gantrisin	93-101	sulfasalazine	108-120	false
Gantrisin	93-101	Azulfidine	123-132	false
sulfasalazine	108-120	Azulfidine	123-132	false

- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);
monoamine oxidase inhibitor	4-30	MAOI	33-36	false
monoamine oxidase inhibitor	4-30	isocarboxazid	47-59	false
monoamine oxidase inhibitor	4-30	Marplan	62-68	false
monoamine oxidase inhibitor	4-30	tranylcypromine	72-86	false
monoamine oxidase inhibitor	4-30	Parnate	89-95	false
monoamine oxidase inhibitor	4-30	phenelzine	102-111	false
monoamine oxidase inhibitor	4-30	Nardil	114-119	false
MAOI	33-36	isocarboxazid	47-59	false
MAOI	33-36	Marplan	62-68	false
MAOI	33-36	tranylcypromine	72-86	false
MAOI	33-36	Parnate	89-95	false
MAOI	33-36	phenelzine	102-111	false
MAOI	33-36	Nardil	114-119	false
isocarboxazid	47-59	Marplan	62-68	false
isocarboxazid	47-59	tranylcypromine	72-86	false
isocarboxazid	47-59	Parnate	89-95	false
isocarboxazid	47-59	phenelzine	102-111	false
isocarboxazid	47-59	Nardil	114-119	false
Marplan	62-68	tranylcypromine	72-86	false
Marplan	62-68	Parnate	89-95	false
Marplan	62-68	phenelzine	102-111	false
Marplan	62-68	Nardil	114-119	false
tranylcypromine	72-86	Parnate	89-95	false
tranylcypromine	72-86	phenelzine	102-111	false
tranylcypromine	72-86	Nardil	114-119	false
Parnate	89-95	phenelzine	102-111	false
Parnate	89-95	Nardil	114-119	false
phenelzine	102-111	Nardil	114-119	false

- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;
beta-blocker	4-15	propranolol	25-35	false
beta-blocker	4-15	Inderal	38-44	false
beta-blocker	4-15	atenolol	48-55	false
beta-blocker	4-15	Tenormin	58-65	false
beta-blocker	4-15	acebutolol	69-78	false
beta-blocker	4-15	Sectral	81-87	false
beta-blocker	4-15	metoprolol	91-100	false
beta-blocker	4-15	Lopressor	103-111	false
propranolol	25-35	Inderal	38-44	false
propranolol	25-35	atenolol	48-55	false
propranolol	25-35	Tenormin	58-65	false
propranolol	25-35	acebutolol	69-78	false
propranolol	25-35	Sectral	81-87	false
propranolol	25-35	metoprolol	91-100	false
propranolol	25-35	Lopressor	103-111	false
Inderal	38-44	atenolol	48-55	false
Inderal	38-44	Tenormin	58-65	false
Inderal	38-44	acebutolol	69-78	false
Inderal	38-44	Sectral	81-87	false
Inderal	38-44	metoprolol	91-100	false
Inderal	38-44	Lopressor	103-111	false
atenolol	48-55	Tenormin	58-65	false
atenolol	48-55	acebutolol	69-78	false
atenolol	48-55	Sectral	81-87	false
atenolol	48-55	metoprolol	91-100	false
atenolol	48-55	Lopressor	103-111	false
Tenormin	58-65	acebutolol	69-78	false
Tenormin	58-65	Sectral	81-87	false
Tenormin	58-65	metoprolol	91-100	false
Tenormin	58-65	Lopressor	103-111	false
acebutolol	69-78	Sectral	81-87	false
acebutolol	69-78	metoprolol	91-100	false
acebutolol	69-78	Lopressor	103-111	false
Sectral	81-87	metoprolol	91-100	false
Sectral	81-87	Lopressor	103-111	false
metoprolol	91-100	Lopressor	103-111	false

- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
diuretic	4-11	hydrochlorothiazide	34-52	false
diuretic	4-11	HCTZ	55-58	false
diuretic	4-11	Hydrodiuril	61-71	false
diuretic	4-11	chlorothiazide	75-88	false
diuretic	4-11	Diuril	91-96	false
hydrochlorothiazide	34-52	HCTZ	55-58	false
hydrochlorothiazide	34-52	Hydrodiuril	61-71	false
hydrochlorothiazide	34-52	chlorothiazide	75-88	false
hydrochlorothiazide	34-52	Diuril	91-96	false
HCTZ	55-58	Hydrodiuril	61-71	false
HCTZ	55-58	chlorothiazide	75-88	false
HCTZ	55-58	Diuril	91-96	false
Hydrodiuril	61-71	chlorothiazide	75-88	false
Hydrodiuril	61-71	Diuril	91-96	false
chlorothiazide	75-88	Diuril	91-96	false

- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
steroid medicine	4-19	prednisone	29-38	false
steroid medicine	4-19	Deltasone	41-49	false
steroid medicine	4-19	Orasone	52-58	false
steroid medicine	4-19	methylprednisolone	70-87	false
steroid medicine	4-19	Medrol	90-95	false
steroid medicine	4-19	prednisolone	107-118	false
steroid medicine	4-19	Prelone	121-127	false
steroid medicine	4-19	Pediapred	130-138	false
prednisone	29-38	Deltasone	41-49	false
prednisone	29-38	Orasone	52-58	false
prednisone	29-38	methylprednisolone	70-87	false
prednisone	29-38	Medrol	90-95	false
prednisone	29-38	prednisolone	107-118	false
prednisone	29-38	Prelone	121-127	false
prednisone	29-38	Pediapred	130-138	false
Deltasone	41-49	Orasone	52-58	false
Deltasone	41-49	methylprednisolone	70-87	false
Deltasone	41-49	Medrol	90-95	false
Deltasone	41-49	prednisolone	107-118	false
Deltasone	41-49	Prelone	121-127	false
Deltasone	41-49	Pediapred	130-138	false
Orasone	52-58	methylprednisolone	70-87	false
Orasone	52-58	Medrol	90-95	false
Orasone	52-58	prednisolone	107-118	false
Orasone	52-58	Prelone	121-127	false
Orasone	52-58	Pediapred	130-138	false
methylprednisolone	70-87	Medrol	90-95	false
methylprednisolone	70-87	prednisolone	107-118	false
methylprednisolone	70-87	Prelone	121-127	false
methylprednisolone	70-87	Pediapred	130-138	false
Medrol	90-95	prednisolone	107-118	false
Medrol	90-95	Prelone	121-127	false
Medrol	90-95	Pediapred	130-138	false
prednisolone	107-118	Prelone	121-127	false
prednisolone	107-118	Pediapred	130-138	false
Prelone	121-127	Pediapred	130-138	false

- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;
phenothiazine	4-16	chlorpromazine	26-39	false
phenothiazine	4-16	Thorazine	42-50	false
phenothiazine	4-16	fluphenazine	54-65	false
phenothiazine	4-16	Prolixin	68-75	false
phenothiazine	4-16	Permitil	78-85	false
phenothiazine	4-16	prochlorperazine	89-104	false
phenothiazine	4-16	Compazine	107-115	false
phenothiazine	4-16	promethazine	119-130	false
phenothiazine	4-16	Phenergan	133-141	false
chlorpromazine	26-39	Thorazine	42-50	false
chlorpromazine	26-39	fluphenazine	54-65	false
chlorpromazine	26-39	Prolixin	68-75	false
chlorpromazine	26-39	Permitil	78-85	false
chlorpromazine	26-39	prochlorperazine	89-104	false
chlorpromazine	26-39	Compazine	107-115	false
chlorpromazine	26-39	promethazine	119-130	false
chlorpromazine	26-39	Phenergan	133-141	false
Thorazine	42-50	fluphenazine	54-65	false
Thorazine	42-50	Prolixin	68-75	false
Thorazine	42-50	Permitil	78-85	false
Thorazine	42-50	prochlorperazine	89-104	false
Thorazine	42-50	Compazine	107-115	false
Thorazine	42-50	promethazine	119-130	false
Thorazine	42-50	Phenergan	133-141	false
fluphenazine	54-65	Prolixin	68-75	false
fluphenazine	54-65	Permitil	78-85	false
fluphenazine	54-65	prochlorperazine	89-104	false
fluphenazine	54-65	Compazine	107-115	false
fluphenazine	54-65	promethazine	119-130	false
fluphenazine	54-65	Phenergan	133-141	false
Prolixin	68-75	Permitil	78-85	false
Prolixin	68-75	prochlorperazine	89-104	false
Prolixin	68-75	Compazine	107-115	false
Prolixin	68-75	promethazine	119-130	false
Prolixin	68-75	Phenergan	133-141	false
Permitil	78-85	prochlorperazine	89-104	false
Permitil	78-85	Compazine	107-115	false
Permitil	78-85	promethazine	119-130	false
Permitil	78-85	Phenergan	133-141	false
prochlorperazine	89-104	Compazine	107-115	false
prochlorperazine	89-104	promethazine	119-130	false
prochlorperazine	89-104	Phenergan	133-141	false
Compazine	107-115	promethazine	119-130	false
Compazine	107-115	Phenergan	133-141	false
promethazine	119-130	Phenergan	133-141	false

- phenytoin (Dilantin);
phenytoin	2-10	Dilantin	13-20	false

- isoniazid (Nydrazid);
isoniazid	2-10	Nydrazid	13-20	false

- rifampin (Rifadin, Rifamate);
rifampin	2-9	Rifadin	12-18	false
rifampin	2-9	Rifamate	21-28	false
Rifadin	12-18	Rifamate	21-28	false

Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
sulfonylureas	66-78	nonsteroidal anti-inflammatory agents	126-162	effect
sulfonylureas	66-78	azoles	170-175	effect
sulfonylureas	66-78	salicylates	224-234	effect
sulfonylureas	66-78	sulfonamides	237-248	effect
sulfonylureas	66-78	chloramphenicol	251-265	effect
sulfonylureas	66-78	probenecid	268-277	effect
sulfonylureas	66-78	coumarins	280-288	effect
sulfonylureas	66-78	monoamine oxidase inhibitors	291-318	effect
sulfonylureas	66-78	beta adrenergic blocking agents	325-355	effect
nonsteroidal anti-inflammatory agents	126-162	azoles	170-175	false
nonsteroidal anti-inflammatory agents	126-162	salicylates	224-234	false
nonsteroidal anti-inflammatory agents	126-162	sulfonamides	237-248	false
nonsteroidal anti-inflammatory agents	126-162	chloramphenicol	251-265	false
nonsteroidal anti-inflammatory agents	126-162	probenecid	268-277	false
nonsteroidal anti-inflammatory agents	126-162	coumarins	280-288	false
nonsteroidal anti-inflammatory agents	126-162	monoamine oxidase inhibitors	291-318	false
nonsteroidal anti-inflammatory agents	126-162	beta adrenergic blocking agents	325-355	false
azoles	170-175	salicylates	224-234	false
azoles	170-175	sulfonamides	237-248	false
azoles	170-175	chloramphenicol	251-265	false
azoles	170-175	probenecid	268-277	false
azoles	170-175	coumarins	280-288	false
azoles	170-175	monoamine oxidase inhibitors	291-318	false
azoles	170-175	beta adrenergic blocking agents	325-355	false
salicylates	224-234	sulfonamides	237-248	false
salicylates	224-234	chloramphenicol	251-265	false
salicylates	224-234	probenecid	268-277	false
salicylates	224-234	coumarins	280-288	false
salicylates	224-234	monoamine oxidase inhibitors	291-318	false
salicylates	224-234	beta adrenergic blocking agents	325-355	false
sulfonamides	237-248	chloramphenicol	251-265	false
sulfonamides	237-248	probenecid	268-277	false
sulfonamides	237-248	coumarins	280-288	false
sulfonamides	237-248	monoamine oxidase inhibitors	291-318	false
sulfonamides	237-248	beta adrenergic blocking agents	325-355	false
chloramphenicol	251-265	probenecid	268-277	false
chloramphenicol	251-265	coumarins	280-288	false
chloramphenicol	251-265	monoamine oxidase inhibitors	291-318	false
chloramphenicol	251-265	beta adrenergic blocking agents	325-355	false
probenecid	268-277	coumarins	280-288	false
probenecid	268-277	monoamine oxidase inhibitors	291-318	false
probenecid	268-277	beta adrenergic blocking agents	325-355	false
coumarins	280-288	monoamine oxidase inhibitors	291-318	false
coumarins	280-288	beta adrenergic blocking agents	325-355	false
monoamine oxidase inhibitors	291-318	beta adrenergic blocking agents	325-355	false

In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.
glipizide	65-73	tolbutamide	98-108	false
glipizide	65-73	salicylate	137-146	false
glipizide	65-73	dicumarol	151-159	false
tolbutamide	98-108	salicylate	137-146	false
tolbutamide	98-108	dicumarol	151-159	false
salicylate	137-146	dicumarol	151-159	false

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
thiazides	24-32	diuretics	44-52	false
thiazides	24-32	corticosteroids	55-69	false
thiazides	24-32	phenothiazines	72-85	false
thiazides	24-32	thyroid products	88-103	false
thiazides	24-32	estrogens	106-114	false
thiazides	24-32	contraceptives	122-135	false
thiazides	24-32	phenytoin	138-146	false
thiazides	24-32	nicotinic acid	149-162	false
thiazides	24-32	sympathomimetics	165-180	false
thiazides	24-32	calcium channel blocking drugs	183-212	false
thiazides	24-32	isoniazid	219-227	false
diuretics	44-52	corticosteroids	55-69	false
diuretics	44-52	phenothiazines	72-85	false
diuretics	44-52	thyroid products	88-103	false
diuretics	44-52	estrogens	106-114	false
diuretics	44-52	contraceptives	122-135	false
diuretics	44-52	phenytoin	138-146	false
diuretics	44-52	nicotinic acid	149-162	false
diuretics	44-52	sympathomimetics	165-180	false
diuretics	44-52	calcium channel blocking drugs	183-212	false
diuretics	44-52	isoniazid	219-227	false
corticosteroids	55-69	phenothiazines	72-85	false
corticosteroids	55-69	thyroid products	88-103	false
corticosteroids	55-69	estrogens	106-114	false
corticosteroids	55-69	contraceptives	122-135	false
corticosteroids	55-69	phenytoin	138-146	false
corticosteroids	55-69	nicotinic acid	149-162	false
corticosteroids	55-69	sympathomimetics	165-180	false
corticosteroids	55-69	calcium channel blocking drugs	183-212	false
corticosteroids	55-69	isoniazid	219-227	false
phenothiazines	72-85	thyroid products	88-103	false
phenothiazines	72-85	estrogens	106-114	false
phenothiazines	72-85	contraceptives	122-135	false
phenothiazines	72-85	phenytoin	138-146	false
phenothiazines	72-85	nicotinic acid	149-162	false
phenothiazines	72-85	sympathomimetics	165-180	false
phenothiazines	72-85	calcium channel blocking drugs	183-212	false
phenothiazines	72-85	isoniazid	219-227	false
thyroid products	88-103	estrogens	106-114	false
thyroid products	88-103	contraceptives	122-135	false
thyroid products	88-103	phenytoin	138-146	false
thyroid products	88-103	nicotinic acid	149-162	false
thyroid products	88-103	sympathomimetics	165-180	false
thyroid products	88-103	calcium channel blocking drugs	183-212	false
thyroid products	88-103	isoniazid	219-227	false
estrogens	106-114	contraceptives	122-135	false
estrogens	106-114	phenytoin	138-146	false
estrogens	106-114	nicotinic acid	149-162	false
estrogens	106-114	sympathomimetics	165-180	false
estrogens	106-114	calcium channel blocking drugs	183-212	false
estrogens	106-114	isoniazid	219-227	false
contraceptives	122-135	phenytoin	138-146	false
contraceptives	122-135	nicotinic acid	149-162	false
contraceptives	122-135	sympathomimetics	165-180	false
contraceptives	122-135	calcium channel blocking drugs	183-212	false
contraceptives	122-135	isoniazid	219-227	false
phenytoin	138-146	nicotinic acid	149-162	false
phenytoin	138-146	sympathomimetics	165-180	false
phenytoin	138-146	calcium channel blocking drugs	183-212	false
phenytoin	138-146	isoniazid	219-227	false
nicotinic acid	149-162	sympathomimetics	165-180	false
nicotinic acid	149-162	calcium channel blocking drugs	183-212	false
nicotinic acid	149-162	isoniazid	219-227	false
sympathomimetics	165-180	calcium channel blocking drugs	183-212	false
sympathomimetics	165-180	isoniazid	219-227	false
calcium channel blocking drugs	183-212	isoniazid	219-227	false

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
miconazole	37-46	hypoglycemic agents	57-75	int

The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
fluconazole	44-54	glipizide	60-68	int

All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days.
glipizide	22-30	fluconazole	77-87	false

The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
glipizide	36-44	fluconazole	56-66	mechanism

The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
Robinul	22-28	anticholinergics	51-66	effect
Robinul	22-28	phenothiazines	122-135	effect
Robinul	22-28	antiparkinson drugs	138-156	effect
Robinul	22-28	tricyclic antidepressants	162-186	effect
anticholinergics	51-66	phenothiazines	122-135	false
anticholinergics	51-66	antiparkinson drugs	138-156	false
anticholinergics	51-66	tricyclic antidepressants	162-186	false
phenothiazines	122-135	antiparkinson drugs	138-156	false
phenothiazines	122-135	tricyclic antidepressants	162-186	false
antiparkinson drugs	138-156	tricyclic antidepressants	162-186	false

Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
Robinul	30-36	potassium chloride	52-69	mechanism

These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.
androgens	60-68	estrogens	71-79	false
androgens	60-68	progestins	82-91	false
androgens	60-68	glucocorticoids	97-111	false
estrogens	71-79	progestins	82-91	false
estrogens	71-79	glucocorticoids	97-111	false
progestins	82-91	glucocorticoids	97-111	false

The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.
spironolactone	55-68	levodopa	93-100	false
spironolactone	55-68	contraceptives	126-139	false
spironolactone	55-68	digoxin	145-151	false
levodopa	93-100	contraceptives	126-139	false
levodopa	93-100	digoxin	145-151	false
contraceptives	126-139	digoxin	145-151	false

The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
Factrel	16-22	phenothiazines	42-55	effect
Factrel	16-22	dopamine antagonists	61-80	effect
phenothiazines	42-55	dopamine antagonists	61-80	false

Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.
Antacids	0-7	Sucralfate	10-19	false
Antacids	0-7	Multivitamins	37-49	false
Antacids	0-7	Quinolones	51-60	false
Sucralfate	10-19	Multivitamins	37-49	false
Sucralfate	10-19	Quinolones	51-60	false
Multivitamins	37-49	Quinolones	51-60	false

Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
quinolones	18-27	antacids	34-41	false
quinolones	18-27	aluminum	54-61	mechanism
quinolones	18-27	magnesium	64-72	mechanism
quinolones	18-27	calcium	78-84	mechanism
quinolones	18-27	sucralfate	92-101	mechanism
quinolones	18-27	iron	131-134	mechanism
quinolones	18-27	multivitamins	145-157	mechanism
quinolones	18-27	iron	170-173	mechanism
quinolones	18-27	zinc	178-181	mechanism
quinolones	18-27	VIDEX	255-259	mechanism
quinolones	18-27	didanosine	262-271	mechanism
quinolones	18-27	quinolones	394-403	false
antacids	34-41	aluminum	54-61	false
antacids	34-41	magnesium	64-72	false
antacids	34-41	calcium	78-84	false
antacids	34-41	sucralfate	92-101	false
antacids	34-41	iron	131-134	false
antacids	34-41	multivitamins	145-157	false
antacids	34-41	iron	170-173	false
antacids	34-41	zinc	178-181	false
antacids	34-41	VIDEX	255-259	false
antacids	34-41	didanosine	262-271	false
antacids	34-41	quinolones	394-403	false
aluminum	54-61	magnesium	64-72	false
aluminum	54-61	calcium	78-84	false
aluminum	54-61	sucralfate	92-101	false
aluminum	54-61	iron	131-134	false
aluminum	54-61	multivitamins	145-157	false
aluminum	54-61	iron	170-173	false
aluminum	54-61	zinc	178-181	false
aluminum	54-61	VIDEX	255-259	false
aluminum	54-61	didanosine	262-271	false
aluminum	54-61	quinolones	394-403	false
magnesium	64-72	calcium	78-84	false
magnesium	64-72	sucralfate	92-101	false
magnesium	64-72	iron	131-134	false
magnesium	64-72	multivitamins	145-157	false
magnesium	64-72	iron	170-173	false
magnesium	64-72	zinc	178-181	false
magnesium	64-72	VIDEX	255-259	false
magnesium	64-72	didanosine	262-271	false
magnesium	64-72	quinolones	394-403	false
calcium	78-84	sucralfate	92-101	false
calcium	78-84	iron	131-134	false
calcium	78-84	multivitamins	145-157	false
calcium	78-84	iron	170-173	false
calcium	78-84	zinc	178-181	false
calcium	78-84	VIDEX	255-259	false
calcium	78-84	didanosine	262-271	false
calcium	78-84	quinolones	394-403	false
sucralfate	92-101	iron	131-134	false
sucralfate	92-101	multivitamins	145-157	false
sucralfate	92-101	iron	170-173	false
sucralfate	92-101	zinc	178-181	false
sucralfate	92-101	VIDEX	255-259	false
sucralfate	92-101	didanosine	262-271	false
sucralfate	92-101	quinolones	394-403	false
iron	131-134	multivitamins	145-157	false
iron	131-134	iron	170-173	false
iron	131-134	zinc	178-181	false
iron	131-134	VIDEX	255-259	false
iron	131-134	didanosine	262-271	false
iron	131-134	quinolones	394-403	false
multivitamins	145-157	iron	170-173	false
multivitamins	145-157	zinc	178-181	false
multivitamins	145-157	VIDEX	255-259	false
multivitamins	145-157	didanosine	262-271	false
multivitamins	145-157	quinolones	394-403	false
iron	170-173	zinc	178-181	false
iron	170-173	VIDEX	255-259	false
iron	170-173	didanosine	262-271	false
iron	170-173	quinolones	394-403	false
zinc	178-181	VIDEX	255-259	false
zinc	178-181	didanosine	262-271	false
zinc	178-181	quinolones	394-403	false
VIDEX	255-259	didanosine	262-271	false
VIDEX	255-259	quinolones	394-403	false
didanosine	262-271	quinolones	394-403	false

Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
Caffeine	0-7	Theobromine	9-19	false
Caffeine	0-7	Grepafloxacin	21-33	false
Caffeine	0-7	quinolones	47-56	false
Caffeine	0-7	caffeine	89-96	false
Caffeine	0-7	theobromine	102-112	false
Theobromine	9-19	Grepafloxacin	21-33	false
Theobromine	9-19	quinolones	47-56	false
Theobromine	9-19	caffeine	89-96	false
Theobromine	9-19	theobromine	102-112	false
Grepafloxacin	21-33	quinolones	47-56	false
Grepafloxacin	21-33	caffeine	89-96	mechanism
Grepafloxacin	21-33	theobromine	102-112	mechanism
quinolones	47-56	caffeine	89-96	mechanism
quinolones	47-56	theobromine	102-112	mechanism
caffeine	89-96	theobromine	102-112	false

In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of caffeine and theobromine.
caffeine	112-119	theobromine	125-135	false

Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
Theophylline	0-11	Grepafloxacin	14-26	false
Theophylline	0-11	theophylline	76-87	false
Grepafloxacin	14-26	theophylline	76-87	mechanism

Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
theophylline	6-17	grepafloxacin	48-60	false
theophylline	6-17	theophylline	102-113	false
grepafloxacin	48-60	theophylline	102-113	mechanism

When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
grepafloxacin	38-50	theophylline	79-90	false
grepafloxacin	38-50	theophylline	97-108	false
grepafloxacin	38-50	grepafloxacin	180-192	false
grepafloxacin	38-50	theophylline	218-229	false
theophylline	79-90	theophylline	97-108	false
theophylline	79-90	grepafloxacin	180-192	false
theophylline	79-90	theophylline	218-229	false
theophylline	97-108	grepafloxacin	180-192	advise
theophylline	97-108	theophylline	218-229	false
grepafloxacin	180-192	theophylline	218-229	false

Warfarin: In subjects receiving warfarin, no significant change in clotting time was observed when grepafloxacin was coadministered.
Warfarin	0-7	warfarin	32-39	false
Warfarin	0-7	grepafloxacin	99-111	false
warfarin	32-39	grepafloxacin	99-111	false

However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
quinolones	22-31	warfarin	78-85	effect
quinolones	22-31	quinolone antimicrobial	196-218	false
quinolones	22-31	warfarin	241-248	false
warfarin	78-85	quinolone antimicrobial	196-218	false
warfarin	78-85	warfarin	241-248	false
quinolone antimicrobial	196-218	warfarin	241-248	advise

Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
grepafloxacin	97-109	theophylline	114-125	false
grepafloxacin	97-109	grepafloxacin	142-154	false
grepafloxacin	97-109	theophylline	165-176	false
theophylline	114-125	grepafloxacin	142-154	false
theophylline	114-125	theophylline	165-176	false
grepafloxacin	142-154	theophylline	165-176	mechanism

substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism.
grepafloxacin	53-65	theophylline	101-112	false

In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.
quinolones	19-28	cyclosporine	95-106	mechanism

include terfenadine, astemizole, cisapride, midazolam, and triazolam.
terfenadine	8-18	astemizole	21-30	false
terfenadine	8-18	cisapride	33-41	false
terfenadine	8-18	midazolam	44-52	false
terfenadine	8-18	triazolam	59-67	false
astemizole	21-30	cisapride	33-41	false
astemizole	21-30	midazolam	44-52	false
astemizole	21-30	triazolam	59-67	false
cisapride	33-41	midazolam	44-52	false
cisapride	33-41	triazolam	59-67	false
midazolam	44-52	triazolam	59-67	false

Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.
Nonsteroidal Anti-inflammatory Drugs	0-35	NSAIDs	38-43	false
Nonsteroidal Anti-inflammatory Drugs	0-35	nonsteroidal anti inflammatory drug	83-117	false
Nonsteroidal Anti-inflammatory Drugs	0-35	quinolone	126-134	false
NSAIDs	38-43	nonsteroidal anti inflammatory drug	83-117	false
NSAIDs	38-43	quinolone	126-134	false
nonsteroidal anti inflammatory drug	83-117	quinolone	126-134	effect

Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.
Antidiabetic Agents	0-18	quinolones	152-161	false
Antidiabetic Agents	0-18	antidiabetic agent	170-187	false
quinolones	152-161	antidiabetic agent	170-187	effect

Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
warfarin-type anticoagulant	12-38	griseofulvin	116-127	advise

Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.
barbiturates	19-30	griseofulvin	50-61	effect

The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
griseofulvin	34-45	contraceptives	96-109	effect

The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
codeine	11-17	alcohol	90-96	effect
codeine	11-17	antihistamines	99-112	effect
codeine	11-17	psychotropics	115-127	effect
alcohol	90-96	antihistamines	99-112	false
alcohol	90-96	psychotropics	115-127	false
antihistamines	99-112	psychotropics	115-127	false

Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
dextromethorphan	31-46	monoamine oxidase inhibitors	71-98	effect
dextromethorphan	31-46	MAOIs	101-105	effect
monoamine oxidase inhibitors	71-98	MAOIs	101-105	false

The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
dextromethorphan hydrobromide	11-39	alcohol	112-118	effect
dextromethorphan hydrobromide	11-39	antihistamines	121-134	effect
dextromethorphan hydrobromide	11-39	psychotropics	137-149	effect
alcohol	112-118	antihistamines	121-134	false
alcohol	112-118	psychotropics	137-149	false
antihistamines	121-134	psychotropics	137-149	false

The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.
guanfacine	42-51	CNS-depressant drug	73-91	effect

The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
guanfacine	22-31	phenobarbital	85-97	mechanism
guanfacine	22-31	phenytoin	102-110	mechanism
phenobarbital	85-97	phenytoin	102-110	false

TCAs decrease the hypotensive effect of guanfacine.
TCAs	0-3	guanfacine	40-49	effect

Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
Noncardioselective beta-blockers	0-31	nadolol	34-40	false
Noncardioselective beta-blockers	0-31	timolol	54-60	false
Noncardioselective beta-blockers	0-31	guanfacine	104-113	effect
nadolol	34-40	timolol	54-60	false
nadolol	34-40	guanfacine	104-113	effect
timolol	54-60	guanfacine	104-113	effect

The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.
guafacine	26-34	cardioselective beta-blocker	41-68	false

Anticoagulants: Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks.
Anticoagulants	0-13	anticoagulants	57-70	false
Anticoagulants	0-13	guanfacine	83-92	false
anticoagulants	57-70	guanfacine	83-92	false

In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported.
guanfacine	36-45	diuretics	78-86	false

The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
cardiac glycosides	68-85	sedatives	94-102	false
cardiac glycosides	68-85	hypnotics	108-116	false
cardiac glycosides	68-85	coronary vasodilators	125-145	false
cardiac glycosides	68-85	hypoglycemics	158-170	false
cardiac glycosides	68-85	NSAIDs	212-217	false
cardiac glycosides	68-85	antihyperlipidemics	225-243	false
cardiac glycosides	68-85	antigout drugs	251-264	false
cardiac glycosides	68-85	contraceptives	277-290	false
cardiac glycosides	68-85	bronchodilators	298-312	false
cardiac glycosides	68-85	insulin	320-326	false
cardiac glycosides	68-85	beta blockers	338-350	false
sedatives	94-102	hypnotics	108-116	false
sedatives	94-102	coronary vasodilators	125-145	false
sedatives	94-102	hypoglycemics	158-170	false
sedatives	94-102	NSAIDs	212-217	false
sedatives	94-102	antihyperlipidemics	225-243	false
sedatives	94-102	antigout drugs	251-264	false
sedatives	94-102	contraceptives	277-290	false
sedatives	94-102	bronchodilators	298-312	false
sedatives	94-102	insulin	320-326	false
sedatives	94-102	beta blockers	338-350	false
hypnotics	108-116	coronary vasodilators	125-145	false
hypnotics	108-116	hypoglycemics	158-170	false
hypnotics	108-116	NSAIDs	212-217	false
hypnotics	108-116	antihyperlipidemics	225-243	false
hypnotics	108-116	antigout drugs	251-264	false
hypnotics	108-116	contraceptives	277-290	false
hypnotics	108-116	bronchodilators	298-312	false
hypnotics	108-116	insulin	320-326	false
hypnotics	108-116	beta blockers	338-350	false
coronary vasodilators	125-145	hypoglycemics	158-170	false
coronary vasodilators	125-145	NSAIDs	212-217	false
coronary vasodilators	125-145	antihyperlipidemics	225-243	false
coronary vasodilators	125-145	antigout drugs	251-264	false
coronary vasodilators	125-145	contraceptives	277-290	false
coronary vasodilators	125-145	bronchodilators	298-312	false
coronary vasodilators	125-145	insulin	320-326	false
coronary vasodilators	125-145	beta blockers	338-350	false
hypoglycemics	158-170	NSAIDs	212-217	false
hypoglycemics	158-170	antihyperlipidemics	225-243	false
hypoglycemics	158-170	antigout drugs	251-264	false
hypoglycemics	158-170	contraceptives	277-290	false
hypoglycemics	158-170	bronchodilators	298-312	false
hypoglycemics	158-170	insulin	320-326	false
hypoglycemics	158-170	beta blockers	338-350	false
NSAIDs	212-217	antihyperlipidemics	225-243	false
NSAIDs	212-217	antigout drugs	251-264	false
NSAIDs	212-217	contraceptives	277-290	false
NSAIDs	212-217	bronchodilators	298-312	false
NSAIDs	212-217	insulin	320-326	false
NSAIDs	212-217	beta blockers	338-350	false
antihyperlipidemics	225-243	antigout drugs	251-264	false
antihyperlipidemics	225-243	contraceptives	277-290	false
antihyperlipidemics	225-243	bronchodilators	298-312	false
antihyperlipidemics	225-243	insulin	320-326	false
antihyperlipidemics	225-243	beta blockers	338-350	false
antigout drugs	251-264	contraceptives	277-290	false
antigout drugs	251-264	bronchodilators	298-312	false
antigout drugs	251-264	insulin	320-326	false
antigout drugs	251-264	beta blockers	338-350	false
contraceptives	277-290	bronchodilators	298-312	false
contraceptives	277-290	insulin	320-326	false
contraceptives	277-290	beta blockers	338-350	false
bronchodilators	298-312	insulin	320-326	false
bronchodilators	298-312	beta blockers	338-350	false
insulin	320-326	beta blockers	338-350	false

An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
lithium	261-267	HALDOL	274-279	effect

A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established;
lithium	81-87	HALDOL	93-98	false

As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
antipsychotic agents	14-33	HALDOL	60-65	false
antipsychotic agents	14-33	CNS depressants	98-112	effect
antipsychotic agents	14-33	anesthetics	122-132	effect
antipsychotic agents	14-33	opiates	135-141	effect
antipsychotic agents	14-33	alcohol	148-154	effect
HALDOL	60-65	CNS depressants	98-112	effect
HALDOL	60-65	anesthetics	122-132	effect
HALDOL	60-65	opiates	135-141	effect
HALDOL	60-65	alcohol	148-154	effect
CNS depressants	98-112	anesthetics	122-132	false
CNS depressants	98-112	opiates	135-141	false
CNS depressants	98-112	alcohol	148-154	false
anesthetics	122-132	opiates	135-141	false
anesthetics	122-132	alcohol	148-154	false
opiates	135-141	alcohol	148-154	false

In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
haloperidol	60-70	rifampin	76-83	mechanism
haloperidol	60-70	haloperidol	93-103	false
rifampin	76-83	haloperidol	93-103	false

In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
haloperidol	52-62	rifampin	68-75	false
haloperidol	52-62	rifampin	97-104	false
haloperidol	52-62	haloperidol	143-153	false
rifampin	68-75	rifampin	97-104	false
rifampin	68-75	haloperidol	143-153	false
rifampin	97-104	haloperidol	143-153	mechanism

Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
rifampin	62-69	haloperidol	106-116	advise

FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
FLUOTHANE	0-8	non-depolarising muscle relaxant	33-64	effect
FLUOTHANE	0-8	aminoglycosides	102-116	effect
non-depolarising muscle relaxant	33-64	aminoglycosides	102-116	false

FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
FLUOTHANE	0-8	tubocurarine	82-93	effect

Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
adrenaline	57-66	FLUOTHANE	99-107	advise

For this reason the dose of adrenaline should be restricted and an antiarrhythmic agent administered as appropriate.
adrenaline	28-37	antiarrhythmic agent	67-86	false

Caution should also be applied for other sympathomimetics, and for aminophylline and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.
sympathomimetics	41-56	aminophylline	67-79	false
sympathomimetics	41-56	theophylline	85-96	false
sympathomimetics	41-56	tricyclic antidepressants	102-126	false
aminophylline	67-79	theophylline	85-96	false
aminophylline	67-79	tricyclic antidepressants	102-126	false
theophylline	85-96	tricyclic antidepressants	102-126	false

Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral anticoagulants: Heparin sodium may prolong the one-stage prothrombin time.
Heparin	38-44	anticoagulants	59-72	false
Heparin	38-44	Heparin sodium	75-88	false
anticoagulants	59-72	Heparin sodium	75-88	false

Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
heparin sodium	16-29	dicumarol	45-53	advise
heparin sodium	16-29	warfarin sodium	58-72	advise
dicumarol	45-53	warfarin sodium	58-72	false

Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Platelet inhibitors	0-18	acetylsalicylic acid	35-54	false
Platelet inhibitors	0-18	dextran	57-63	false
Platelet inhibitors	0-18	phenylbutazone	66-79	false
Platelet inhibitors	0-18	ibuprofen	82-90	false
Platelet inhibitors	0-18	indomethacin	93-104	false
Platelet inhibitors	0-18	dipyridamole	107-118	false
Platelet inhibitors	0-18	hydroxychloroquine	121-138	false
Platelet inhibitors	0-18	heparin sodium	330-343	false
acetylsalicylic acid	35-54	dextran	57-63	false
acetylsalicylic acid	35-54	phenylbutazone	66-79	false
acetylsalicylic acid	35-54	ibuprofen	82-90	false
acetylsalicylic acid	35-54	indomethacin	93-104	false
acetylsalicylic acid	35-54	dipyridamole	107-118	false
acetylsalicylic acid	35-54	hydroxychloroquine	121-138	false
acetylsalicylic acid	35-54	heparin sodium	330-343	effect
dextran	57-63	phenylbutazone	66-79	false
dextran	57-63	ibuprofen	82-90	false
dextran	57-63	indomethacin	93-104	false
dextran	57-63	dipyridamole	107-118	false
dextran	57-63	hydroxychloroquine	121-138	false
dextran	57-63	heparin sodium	330-343	effect
phenylbutazone	66-79	ibuprofen	82-90	false
phenylbutazone	66-79	indomethacin	93-104	false
phenylbutazone	66-79	dipyridamole	107-118	false
phenylbutazone	66-79	hydroxychloroquine	121-138	false
phenylbutazone	66-79	heparin sodium	330-343	effect
ibuprofen	82-90	indomethacin	93-104	false
ibuprofen	82-90	dipyridamole	107-118	false
ibuprofen	82-90	hydroxychloroquine	121-138	false
ibuprofen	82-90	heparin sodium	330-343	effect
indomethacin	93-104	dipyridamole	107-118	false
indomethacin	93-104	hydroxychloroquine	121-138	false
indomethacin	93-104	heparin sodium	330-343	effect
dipyridamole	107-118	hydroxychloroquine	121-138	false
dipyridamole	107-118	heparin sodium	330-343	effect
hydroxychloroquine	121-138	heparin sodium	330-343	effect

The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.
heparin	28-34	antithrombin III	77-92	effect

Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).
heparin	51-57	antithrombin III	96-111	advise

Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
Heparin	17-23	Digitalis	33-41	false
Heparin	17-23	tetracyclines	44-56	false
Heparin	17-23	nicotine	59-66	false
Heparin	17-23	antihistamines	72-85	false
Heparin	17-23	heparin sodium	140-153	false
Digitalis	33-41	tetracyclines	44-56	false
Digitalis	33-41	nicotine	59-66	false
Digitalis	33-41	antihistamines	72-85	false
Digitalis	33-41	heparin sodium	140-153	effect
tetracyclines	44-56	nicotine	59-66	false
tetracyclines	44-56	antihistamines	72-85	false
tetracyclines	44-56	heparin sodium	140-153	effect
nicotine	59-66	antihistamines	72-85	false
nicotine	59-66	heparin sodium	140-153	effect
antihistamines	72-85	heparin sodium	140-153	effect

Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
Heparin Sodium	0-13	doxorubicin	50-60	false
Heparin Sodium	0-13	droperidol	63-72	false
Heparin Sodium	0-13	ciprofloxacin	75-87	false
Heparin Sodium	0-13	mitoxantrone	93-104	false
Heparin Sodium	0-13	heparin	173-179	false
doxorubicin	50-60	droperidol	63-72	false
doxorubicin	50-60	ciprofloxacin	75-87	false
doxorubicin	50-60	mitoxantrone	93-104	false
doxorubicin	50-60	heparin	173-179	false
droperidol	63-72	ciprofloxacin	75-87	false
droperidol	63-72	mitoxantrone	93-104	false
droperidol	63-72	heparin	173-179	false
ciprofloxacin	75-87	mitoxantrone	93-104	false
ciprofloxacin	75-87	heparin	173-179	false
mitoxantrone	93-104	heparin	173-179	false

Opioids are strong central nervous system depressants, but regular users develop physiological tolerance allowing gradually increased dosages.
Opioids	0-6	central nervous system depressants	19-52	false

In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
central nervous system depressants	26-59	heroin	62-67	effect

Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
heroin	22-27	central nervous system depressants	81-114	effect
heroin	22-27	alcohol	127-133	effect
heroin	22-27	benzodiazepines	136-150	effect
heroin	22-27	diazepam	160-167	effect
heroin	22-27	Valium	170-175	effect
heroin	22-27	methadone	204-212	effect
central nervous system depressants	81-114	alcohol	127-133	false
central nervous system depressants	81-114	benzodiazepines	136-150	false
central nervous system depressants	81-114	diazepam	160-167	false
central nervous system depressants	81-114	Valium	170-175	false
central nervous system depressants	81-114	methadone	204-212	false
alcohol	127-133	benzodiazepines	136-150	false
alcohol	127-133	diazepam	160-167	false
alcohol	127-133	Valium	170-175	false
alcohol	127-133	methadone	204-212	false
benzodiazepines	136-150	diazepam	160-167	false
benzodiazepines	136-150	Valium	170-175	false
benzodiazepines	136-150	methadone	204-212	false
diazepam	160-167	Valium	170-175	false
diazepam	160-167	methadone	204-212	false
Valium	170-175	methadone	204-212	false

Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms.
benzodiazepines	12-26	heroin	63-68	false

Cocaine sometimes proves to be fatal when used in combination with heroin.
Cocaine	0-6	heroin	67-72	effect

Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
Barbiturates	0-11	contraceptives	52-65	effect
Barbiturates	0-11	antibiotics	76-86	effect
Barbiturates	0-11	quinidine	89-97	effect
Barbiturates	0-11	theophylline	100-111	effect
Barbiturates	0-11	corticosteroids	114-128	effect
Barbiturates	0-11	anticoagulants	131-144	effect
Barbiturates	0-11	beta blockers	151-163	effect
contraceptives	52-65	antibiotics	76-86	false
contraceptives	52-65	quinidine	89-97	false
contraceptives	52-65	theophylline	100-111	false
contraceptives	52-65	corticosteroids	114-128	false
contraceptives	52-65	anticoagulants	131-144	false
contraceptives	52-65	beta blockers	151-163	false
antibiotics	76-86	quinidine	89-97	false
antibiotics	76-86	theophylline	100-111	false
antibiotics	76-86	corticosteroids	114-128	false
antibiotics	76-86	anticoagulants	131-144	false
antibiotics	76-86	beta blockers	151-163	false
quinidine	89-97	theophylline	100-111	false
quinidine	89-97	corticosteroids	114-128	false
quinidine	89-97	anticoagulants	131-144	false
quinidine	89-97	beta blockers	151-163	false
theophylline	100-111	corticosteroids	114-128	false
theophylline	100-111	anticoagulants	131-144	false
theophylline	100-111	beta blockers	151-163	false
corticosteroids	114-128	anticoagulants	131-144	false
corticosteroids	114-128	beta blockers	151-163	false
anticoagulants	131-144	beta blockers	151-163	false

MAO inhibitors should be used with caution in patients receiving hydralazine.
MAO inhibitors	0-13	hydralazine	65-75	advise

When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
antihypertensive drugs	27-48	diazoxide	59-67	effect
antihypertensive drugs	27-48	hydralazine	99-109	effect
diazoxide	59-67	hydralazine	99-109	false

Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
diazoxide	45-53	hydralazine	69-79	effect

Beta-blockers (metoprolol, propranolol) serum concentrations and pharmacologic effects may be increased.
Beta-blockers	0-12	metoprolol	15-24	false
Beta-blockers	0-12	propranolol	27-37	false
metoprolol	15-24	propranolol	27-37	false

Propranolol increases hydralazines serum concentrations.
Propranolol	0-10	hydralazine	22-32	mechanism

Acebutolol, atenolol, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.
Acebutolol	0-9	atenolol	12-19	false
Acebutolol	0-9	nadolol	26-32	false
atenolol	12-19	nadolol	26-32	false

NSAIDs may decrease the hemodynamic effects of hydralazine;
NSAIDs	0-5	hydralazine	47-57	effect

Alcohol, barbiturates, or narcotics: potentiation of orthostatic hypotension may occur.
Alcohol	0-6	barbiturates	9-20	false
Alcohol	0-6	narcotics	26-34	false
barbiturates	9-20	narcotics	26-34	false

Antidiabetic drugs: (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required.
Antidiabetic drugs	0-17	insulin	37-43	false
Antidiabetic drugs	0-17	antidiabetic drug	73-89	false
insulin	37-43	antidiabetic drug	73-89	false

Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
Cholestyramine	0-13	colestipol	19-28	false
Cholestyramine	0-13	resins	30-35	false
Cholestyramine	0-13	hydrochlorothiazide	52-70	false
Cholestyramine	0-13	anionic exchange resins	103-125	false
colestipol	19-28	resins	30-35	false
colestipol	19-28	hydrochlorothiazide	52-70	false
colestipol	19-28	anionic exchange resins	103-125	false
resins	30-35	hydrochlorothiazide	52-70	false
resins	30-35	anionic exchange resins	103-125	false
hydrochlorothiazide	52-70	anionic exchange resins	103-125	mechanism

Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
cholestyramine	23-36	colestipol	41-50	false
cholestyramine	23-36	resins	52-57	false
cholestyramine	23-36	hydrochlorothiazide	68-86	mechanism
colestipol	41-50	resins	52-57	false
colestipol	41-50	hydrochlorothiazide	68-86	mechanism
resins	52-57	hydrochlorothiazide	68-86	false

Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.
Corticosteroids	0-14	ACTH	17-20	false

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the muscle relaxant.
Skeletal muscle relaxants	0-24	tubocurarine	50-61	false
Skeletal muscle relaxants	0-24	muscle relaxant	106-120	false
tubocurarine	50-61	muscle relaxant	106-120	false

Lithium: generally should not be given with diuretics.
Lithium	0-6	diuretics	44-52	advise

Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
Diuretic agents	0-14	lithium	46-52	mechanism
Diuretic agents	0-14	lithium	77-83	effect
lithium	46-52	lithium	77-83	false

Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
lithium	32-38	Hydrochlorothiazide	90-108	advise

Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
Non-steroidal Anti-inflammatory Drugs	0-36	non-steroidal anti-inflammatory agent	81-117	false
Non-steroidal Anti-inflammatory Drugs	0-36	loop diuretics	189-192;226-234	false
Non-steroidal Anti-inflammatory Drugs	0-36	potassium-sparing diuretics	195-211;226-234	false
Non-steroidal Anti-inflammatory Drugs	0-36	thiazide diuretics	217-234	false
non-steroidal anti-inflammatory agent	81-117	loop diuretics	189-192;226-234	effect
non-steroidal anti-inflammatory agent	81-117	potassium-sparing diuretics	195-211;226-234	effect
non-steroidal anti-inflammatory agent	81-117	thiazide diuretics	217-234	effect
loop diuretics	189-192;226-234	potassium-sparing diuretics	195-211;226-234	false
loop diuretics	189-192;226-234	thiazide diuretics	217-234	false
potassium-sparing diuretics	195-211;226-234	thiazide diuretics	217-234	false

Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
Hydrochlorothiazide	16-34	non-steroidal anti-inflammatory agents	40-77	advise
Hydrochlorothiazide	16-34	diuretic	184-191	false
non-steroidal anti-inflammatory agents	40-77	diuretic	184-191	false

Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
narcotic analgesics	25-43	antipsychotics	46-59	false
narcotic analgesics	25-43	antianxiety agents	62-79	false
narcotic analgesics	25-43	CNS depressants	91-105	false
narcotic analgesics	25-43	alcohol	118-124	false
narcotic analgesics	25-43	hydrocodone	146-156	effect
narcotic analgesics	25-43	acetaminophen	162-174	false
antipsychotics	46-59	antianxiety agents	62-79	false
antipsychotics	46-59	CNS depressants	91-105	false
antipsychotics	46-59	alcohol	118-124	false
antipsychotics	46-59	hydrocodone	146-156	effect
antipsychotics	46-59	acetaminophen	162-174	false
antianxiety agents	62-79	CNS depressants	91-105	false
antianxiety agents	62-79	alcohol	118-124	false
antianxiety agents	62-79	hydrocodone	146-156	effect
antianxiety agents	62-79	acetaminophen	162-174	false
CNS depressants	91-105	alcohol	118-124	false
CNS depressants	91-105	hydrocodone	146-156	effect
CNS depressants	91-105	acetaminophen	162-174	false
alcohol	118-124	hydrocodone	146-156	effect
alcohol	118-124	acetaminophen	162-174	false
hydrocodone	146-156	acetaminophen	162-174	false

The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
MAO inhibitors	11-24	tricyclic antidepressants	29-53	false
MAO inhibitors	11-24	hydrocodone	60-70	effect
MAO inhibitors	11-24	antidepressant	123-136	false
MAO inhibitors	11-24	hydrocodone	141-151	false
tricyclic antidepressants	29-53	hydrocodone	60-70	effect
tricyclic antidepressants	29-53	antidepressant	123-136	false
tricyclic antidepressants	29-53	hydrocodone	141-151	false
hydrocodone	60-70	antidepressant	123-136	false
hydrocodone	60-70	hydrocodone	141-151	false
antidepressant	123-136	hydrocodone	141-151	false

The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.
anticholinergics	22-37	hydrocodone	44-54	effect

Antihypertensive medications, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery
Antihypertensive medications	0-27	diazoxide	48-56	false
Antihypertensive medications	0-27	anesthetic	65-74	false
Antihypertensive medications	0-27	skeletal-muscle relaxants	117-141	false
diazoxide	48-56	anesthetic	65-74	false
diazoxide	48-56	skeletal-muscle relaxants	117-141	false
anesthetic	65-74	skeletal-muscle relaxants	117-141	false

Amphotericin B or Corticosteroids or Corticotropin (ACTH)
Amphotericin B	0-13	Corticosteroids	18-32	false
Amphotericin B	0-13	Corticotropin	37-49	false
Amphotericin B	0-13	ACTH	52-55	false
Corticosteroids	18-32	Corticotropin	37-49	false
Corticosteroids	18-32	ACTH	52-55	false
Corticotropin	37-49	ACTH	52-55	false

(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)
thiazide diuretics	21-38	digitalis	71-79	effect

for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;
hypoglycemic medications	48-71	thiazide diuretic	107-123	advise

(Concurrent use with thiazide diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance.)
thiazide diuretics	21-38	lithium	80-86	false

(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
steroidal anti-inflammatory agent	23-55	loop diuretics	127-130;165-173	effect
steroidal anti-inflammatory agent	23-55	potassium sparing diuretics	133-149;165-173	effect
steroidal anti-inflammatory agent	23-55	thiazide diuretics	156-173	effect
loop diuretics	127-130;165-173	potassium sparing diuretics	133-149;165-173	false
loop diuretics	127-130;165-173	thiazide diuretics	156-173	false
potassium sparing diuretics	133-149;165-173	thiazide diuretics	156-173	false

Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)
hydroflumethiazide	16-33	nonsteroidal anti-inflammatory agents	39-75	advise
hydroflumethiazide	16-33	diuretic	182-189	false
nonsteroidal anti-inflammatory agents	39-75	diuretic	182-189	false

(Thiazides may decrease arterial responsiveness to norepinephrine.
Thiazides	1-9	norepinephrine	51-64	effect

(Thiazide drugs may increase the responsiveness to tubocurarine.)
Thiazide drugs	1-14	tubocurarine	51-62	effect

Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
narcotic analgesic	25-42	anesthetics	54-64	false
narcotic analgesic	25-42	phenothiazines	67-80	false
narcotic analgesic	25-42	tranquilizers	83-95	false
narcotic analgesic	25-42	sedative-hypnotics	98-115	false
narcotic analgesic	25-42	tricyclic antidepressants	118-142	false
narcotic analgesic	25-42	CNS depressants	153-167	false
narcotic analgesic	25-42	alcohol	180-186	false
narcotic analgesic	25-42	DILAUDID	208-215	effect
anesthetics	54-64	phenothiazines	67-80	false
anesthetics	54-64	tranquilizers	83-95	false
anesthetics	54-64	sedative-hypnotics	98-115	false
anesthetics	54-64	tricyclic antidepressants	118-142	false
anesthetics	54-64	CNS depressants	153-167	false
anesthetics	54-64	alcohol	180-186	false
anesthetics	54-64	DILAUDID	208-215	effect
phenothiazines	67-80	tranquilizers	83-95	false
phenothiazines	67-80	sedative-hypnotics	98-115	false
phenothiazines	67-80	tricyclic antidepressants	118-142	false
phenothiazines	67-80	CNS depressants	153-167	false
phenothiazines	67-80	alcohol	180-186	false
phenothiazines	67-80	DILAUDID	208-215	effect
tranquilizers	83-95	sedative-hypnotics	98-115	false
tranquilizers	83-95	tricyclic antidepressants	118-142	false
tranquilizers	83-95	CNS depressants	153-167	false
tranquilizers	83-95	alcohol	180-186	false
tranquilizers	83-95	DILAUDID	208-215	effect
sedative-hypnotics	98-115	tricyclic antidepressants	118-142	false
sedative-hypnotics	98-115	CNS depressants	153-167	false
sedative-hypnotics	98-115	alcohol	180-186	false
sedative-hypnotics	98-115	DILAUDID	208-215	effect
tricyclic antidepressants	118-142	CNS depressants	153-167	false
tricyclic antidepressants	118-142	alcohol	180-186	false
tricyclic antidepressants	118-142	DILAUDID	208-215	effect
CNS depressants	153-167	alcohol	180-186	false
CNS depressants	153-167	DILAUDID	208-215	effect
alcohol	180-186	DILAUDID	208-215	effect

Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary
hydroxyurea	6-16	uricosuric medication	76-96	effect

THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
HYDROXYZINE	27-37	CENTRAL NERVOUS SYSTEM DEPRESSANTS	100-133	effect
HYDROXYZINE	27-37	NARCOTICS	143-151	effect
HYDROXYZINE	27-37	NON-NARCOTIC ANALGESICS	154-176	effect
HYDROXYZINE	27-37	BARBITURATES	182-193	effect
CENTRAL NERVOUS SYSTEM DEPRESSANTS	100-133	NARCOTICS	143-151	false
CENTRAL NERVOUS SYSTEM DEPRESSANTS	100-133	NON-NARCOTIC ANALGESICS	154-176	false
CENTRAL NERVOUS SYSTEM DEPRESSANTS	100-133	BARBITURATES	182-193	false
NARCOTICS	143-151	NON-NARCOTIC ANALGESICS	154-176	false
NARCOTICS	143-151	BARBITURATES	182-193	false
NON-NARCOTIC ANALGESICS	154-176	BARBITURATES	182-193	false

Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.
central nervous system depressants	15-48	hydroxyzine	86-96	advise

Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.
CNS depressant drugs	65-84	alcohol	120-126	false

Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
LEVSIN	76-81	antimuscarinics	124-138	effect
LEVSIN	76-81	amantadine	141-150	effect
LEVSIN	76-81	haloperidol	153-163	effect
LEVSIN	76-81	phenothiazines	166-179	effect
LEVSIN	76-81	monoamine oxidase (MAO) inhibitors	182-215	effect
LEVSIN	76-81	tricyclic antidepressants	218-242	effect
LEVSIN	76-81	antihistamines	252-265	effect
antimuscarinics	124-138	amantadine	141-150	false
antimuscarinics	124-138	haloperidol	153-163	false
antimuscarinics	124-138	phenothiazines	166-179	false
antimuscarinics	124-138	monoamine oxidase (MAO) inhibitors	182-215	false
antimuscarinics	124-138	tricyclic antidepressants	218-242	false
antimuscarinics	124-138	antihistamines	252-265	false
amantadine	141-150	haloperidol	153-163	false
amantadine	141-150	phenothiazines	166-179	false
amantadine	141-150	monoamine oxidase (MAO) inhibitors	182-215	false
amantadine	141-150	tricyclic antidepressants	218-242	false
amantadine	141-150	antihistamines	252-265	false
haloperidol	153-163	phenothiazines	166-179	false
haloperidol	153-163	monoamine oxidase (MAO) inhibitors	182-215	false
haloperidol	153-163	tricyclic antidepressants	218-242	false
haloperidol	153-163	antihistamines	252-265	false
phenothiazines	166-179	monoamine oxidase (MAO) inhibitors	182-215	false
phenothiazines	166-179	tricyclic antidepressants	218-242	false
phenothiazines	166-179	antihistamines	252-265	false
monoamine oxidase (MAO) inhibitors	182-215	tricyclic antidepressants	218-242	false
monoamine oxidase (MAO) inhibitors	182-215	antihistamines	252-265	false
tricyclic antidepressants	218-242	antihistamines	252-265	false

Antacids may interfere with the absorption of LEVSIN.
Antacids	0-7	LEVSIN	46-51	mechanism

Calcium Supplements/Antacids
Calcium	0-6	Antacids	20-27	false

Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
calcium	20-26	aluminum	67-74	false
calcium	20-26	magnesium	77-85	false
calcium	20-26	iron	88-91	false
calcium	20-26	Ibandronate	137-147	mechanism
aluminum	67-74	magnesium	77-85	false
aluminum	67-74	iron	88-91	false
aluminum	67-74	Ibandronate	137-147	mechanism
magnesium	77-85	iron	88-91	false
magnesium	77-85	Ibandronate	137-147	mechanism
iron	88-91	Ibandronate	137-147	mechanism

Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
Ibandronate	0-10	antacids	118-125	advise
Ibandronate	0-10	vitamins	143-150	advise
antacids	118-125	vitamins	143-150	false

H2 Blockers and Proton Pump Inhibitors (PPIs)
H2 Blockers	0-10	Proton Pump Inhibitors	16-37	false
H2 Blockers	0-10	PPIs	40-43	false
Proton Pump Inhibitors	16-37	PPIs	40-43	false

Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).
Ibandronate	38-48	H2 blockers	136-146	false
Ibandronate	38-48	PPIs	152-155	false
H2 blockers	136-146	PPIs	152-155	false

Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.
Ibandronate	111-121	Ibandronate	188-198	false

Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Aspirin	0-6	Nonsteroidal Antiinflammatory Drug	8-41	false
Aspirin	0-6	NSAIDs	45-50	false
Nonsteroidal Antiinflammatory Drug	8-41	NSAIDs	45-50	false

In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.
aspirin	63-69	nonsteroidal anti-inflammatory drugs	75-110	false

Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).
aspirin	6-12	NSAID	17-21	false
aspirin	6-12	ibandronate	110-120	false
NSAID	17-21	ibandronate	110-120	false

Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.
aspirin	51-57	nonsteroidal anti-inflammatory drugs	63-98	false

The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).
aspirin	80-86	NSAIDs	91-96	false
aspirin	80-86	ibandronate	129-139	false
NSAIDs	91-96	ibandronate	129-139	false

However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
aspirin	15-21	NSAIDs	24-29	false
aspirin	15-21	bisphosphonates	36-50	false
aspirin	15-21	aspirin	159-165	false
aspirin	15-21	NSAIDs	170-175	false
aspirin	15-21	Ibandronate	182-192	false
NSAIDs	24-29	bisphosphonates	36-50	false
NSAIDs	24-29	aspirin	159-165	false
NSAIDs	24-29	NSAIDs	170-175	false
NSAIDs	24-29	Ibandronate	182-192	false
bisphosphonates	36-50	aspirin	159-165	false
bisphosphonates	36-50	NSAIDs	170-175	false
bisphosphonates	36-50	Ibandronate	182-192	false
aspirin	159-165	NSAIDs	170-175	false
aspirin	159-165	Ibandronate	182-192	advise
NSAIDs	170-175	Ibandronate	182-192	advise

Coumarin-Type Anticoagulants: Several short-term controlled studies failed to wshow that ibuprofen significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants.
Coumarin-Type Anticoagulants	0-27	ibuprofen	89-97	false
Coumarin-Type Anticoagulants	0-27	coumarin-type anticoagulants	215-242	false
ibuprofen	89-97	coumarin-type anticoagulants	215-242	false

However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
ibuprofen	49-57	nonsteroidal anti-inflammatory agents	69-105	false
ibuprofen	49-57	coumarin-type anticoagulants	145-172	effect
ibuprofen	49-57	ibuprofen	227-235	false
ibuprofen	49-57	anticoagulants	252-265	false
nonsteroidal anti-inflammatory agents	69-105	coumarin-type anticoagulants	145-172	effect
nonsteroidal anti-inflammatory agents	69-105	ibuprofen	227-235	false
nonsteroidal anti-inflammatory agents	69-105	anticoagulants	252-265	false
coumarin-type anticoagulants	145-172	ibuprofen	227-235	false
coumarin-type anticoagulants	145-172	anticoagulants	252-265	false
ibuprofen	227-235	anticoagulants	252-265	advise

Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
Aspirin	0-6	aspirin	35-41	false
Aspirin	0-6	nonsteroidal anti-inflammatory agents	54-90	false
Aspirin	0-6	ibuprofen	103-111	false
aspirin	35-41	nonsteroidal anti-inflammatory agents	54-90	effect
aspirin	35-41	ibuprofen	103-111	effect
nonsteroidal anti-inflammatory agents	54-90	ibuprofen	103-111	false

Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on ibuprofen blood levels.
aspirin	91-97	ibuprofen	102-110	false

Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
Methotrexate	0-11	Ibuprofen	14-22	false
Methotrexate	0-11	nonsteroidal anti-inflammatory drugs	42-77	false
Methotrexate	0-11	methotrexate	122-133	false
Ibuprofen	14-22	nonsteroidal anti-inflammatory drugs	42-77	false
Ibuprofen	14-22	methotrexate	122-133	mechanism
nonsteroidal anti-inflammatory drugs	42-77	methotrexate	122-133	mechanism

This may indicate that ibuprofen could enhance the toxicity of methotrexate.
ibuprofen	23-31	methotrexate	63-74	effect

Caution should be used if ibuprofen is administered concomitantly with methotrexate.
ibuprofen	26-34	methotrexate	71-82	advise

H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.
cimetidine	72-81	ranitidine	86-95	false
cimetidine	72-81	ibuprofen	102-110	false
cimetidine	72-81	ibuprofen	141-149	false
ranitidine	86-95	ibuprofen	102-110	false
ranitidine	86-95	ibuprofen	141-149	false
ibuprofen	102-110	ibuprofen	141-149	false

Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	0-9	ibuprofen	78-86	false
Furosemide	0-9	furosemide	125-134	false
Furosemide	0-9	thiazides	140-148	false
ibuprofen	78-86	furosemide	125-134	effect
ibuprofen	78-86	thiazides	140-148	effect
furosemide	125-134	thiazides	140-148	false

During concomitant therapy with ibuprofen, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
ibuprofen	32-40	diuretic	131-138	false

Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
Lithium	0-6	Ibuprofen	9-17	false
Lithium	0-6	lithium	51-57	false
Lithium	0-6	lithium	91-97	false
Ibuprofen	9-17	lithium	51-57	mechanism
Ibuprofen	9-17	lithium	91-97	false
lithium	51-57	lithium	91-97	false

The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.
lithium	17-23	lithium	80-86	false

Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
ibuprofen	11-19	lithium	25-31	advise
ibuprofen	11-19	lithium	115-121	false
lithium	25-31	lithium	115-121	false

Digoxin: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels.
Digoxin	0-6	digoxin	92-98	false

Coadministration of digoxin did not have effects on either the safety or efficacy of ibutilide in the clinical trials.
digoxin	20-26	ibutilide	85-93	false

Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
Calcium channel blocking agents	0-30	calcium channel blockers	53-76	false
Calcium channel blocking agents	0-30	ibutilide	138-146	false
calcium channel blockers	53-76	ibutilide	138-146	false

Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
Beta-adrenergic blocking agents	0-30	beta-adrenergic blocking agents	53-83	false
Beta-adrenergic blocking agents	0-30	ibutilide	145-153	false
beta-adrenergic blocking agents	53-83	ibutilide	145-153	false

In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored.
cardiac glycosides	18-35	digoxin	38-44	false

Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
Insulin	0-6	EXTRANEAL	93-101	false
Insulin	0-6	insulin	106-112	false
Insulin	0-6	insulin	158-164	false
Insulin	0-6	insulin	205-211	false
Insulin	0-6	EXTRANEAL	253-261	false
EXTRANEAL	93-101	insulin	106-112	false
EXTRANEAL	93-101	insulin	158-164	false
EXTRANEAL	93-101	insulin	205-211	false
EXTRANEAL	93-101	EXTRANEAL	253-261	false
insulin	106-112	insulin	158-164	false
insulin	106-112	insulin	205-211	false
insulin	106-112	EXTRANEAL	253-261	false
insulin	158-164	insulin	205-211	false
insulin	158-164	EXTRANEAL	253-261	false
insulin	205-211	EXTRANEAL	253-261	false

However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.
EXTRANEAL	85-93	insulin	120-126	advise

Heparin: No human drug interaction studies with heparin were conducted.
Heparin	0-6	heparin	48-54	false

In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL.
heparin	64-70	EXTRANEAL	77-85	false

Antibiotics: No human drug interaction studies with antibiotics were conducted.
Antibiotics	0-10	antibiotics	52-62	false

In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
vancomycin	74-83	cefazolin	86-94	false
vancomycin	74-83	ampicillin	97-106	false
vancomycin	74-83	ampicillin	109-118	false
vancomycin	74-83	ceftazidime	135-145	false
vancomycin	74-83	gentamicin	148-157	false
vancomycin	74-83	amphotericin	164-175	false
vancomycin	74-83	antibiotics	230-240	false
vancomycin	74-83	EXTRANEAL	247-255	false
cefazolin	86-94	ampicillin	97-106	false
cefazolin	86-94	ampicillin	109-118	false
cefazolin	86-94	ceftazidime	135-145	false
cefazolin	86-94	gentamicin	148-157	false
cefazolin	86-94	amphotericin	164-175	false
cefazolin	86-94	antibiotics	230-240	false
cefazolin	86-94	EXTRANEAL	247-255	false
ampicillin	97-106	ampicillin	109-118	false
ampicillin	97-106	ceftazidime	135-145	false
ampicillin	97-106	gentamicin	148-157	false
ampicillin	97-106	amphotericin	164-175	false
ampicillin	97-106	antibiotics	230-240	false
ampicillin	97-106	EXTRANEAL	247-255	false
ampicillin	109-118	ceftazidime	135-145	false
ampicillin	109-118	gentamicin	148-157	false
ampicillin	109-118	amphotericin	164-175	false
ampicillin	109-118	antibiotics	230-240	false
ampicillin	109-118	EXTRANEAL	247-255	false
ceftazidime	135-145	gentamicin	148-157	false
ceftazidime	135-145	amphotericin	164-175	false
ceftazidime	135-145	antibiotics	230-240	false
ceftazidime	135-145	EXTRANEAL	247-255	false
gentamicin	148-157	amphotericin	164-175	false
gentamicin	148-157	antibiotics	230-240	false
gentamicin	148-157	EXTRANEAL	247-255	false
amphotericin	164-175	antibiotics	230-240	false
amphotericin	164-175	EXTRANEAL	247-255	false
antibiotics	230-240	EXTRANEAL	247-255	false

Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
EPA	31-33	aspirin	51-57	int
EPA	31-33	non-steroidal anti-inflammatory drugs	69-105	int
EPA	31-33	ginkgo	153-158	int
EPA	31-33	Ginkgo biloba	161-173	int
aspirin	51-57	non-steroidal anti-inflammatory drugs	69-105	false
aspirin	51-57	ginkgo	153-158	false
aspirin	51-57	Ginkgo biloba	161-173	false
non-steroidal anti-inflammatory drugs	69-105	ginkgo	153-158	false
non-steroidal anti-inflammatory drugs	69-105	Ginkgo biloba	161-173	false
ginkgo	153-158	Ginkgo biloba	161-173	false

When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.
idoxuridine	19-29	boric acid	154-163	advise

Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.
Boric acid	0-9	idoxuridine	33-43	mechanism
Boric acid	0-9	idoxuridine	137-147	false
idoxuridine	33-43	idoxuridine	137-147	false

The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
ifosfamide	102-111	ifosfamide	125-134	false

In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.
iloprost	94-101	nifedipine	114-123	false
iloprost	94-101	diltiazem	126-134	false
iloprost	94-101	captopril	140-148	false
nifedipine	114-123	diltiazem	126-134	false
nifedipine	114-123	captopril	140-148	false
diltiazem	126-134	captopril	140-148	false

However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
iloprost	9-16	vasodilators	74-85	effect
iloprost	9-16	antihypertensive agents	91-113	effect
vasodilators	74-85	antihypertensive agents	91-113	false

Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.
iloprost	6-13	anticoagulants	135-148	effect

During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
iloprost	24-31	anticoagulants	60-73	false
iloprost	24-31	diuretics	76-84	false
iloprost	24-31	cardiac glycosides	87-104	false
iloprost	24-31	calcium channel blockers	107-130	false
iloprost	24-31	analgesics	133-142	false
iloprost	24-31	antipyretics	145-156	false
iloprost	24-31	nonsteroidal antiinflammatories	159-189	false
iloprost	24-31	corticosteroids	192-206	false
anticoagulants	60-73	diuretics	76-84	false
anticoagulants	60-73	cardiac glycosides	87-104	false
anticoagulants	60-73	calcium channel blockers	107-130	false
anticoagulants	60-73	analgesics	133-142	false
anticoagulants	60-73	antipyretics	145-156	false
anticoagulants	60-73	nonsteroidal antiinflammatories	159-189	false
anticoagulants	60-73	corticosteroids	192-206	false
diuretics	76-84	cardiac glycosides	87-104	false
diuretics	76-84	calcium channel blockers	107-130	false
diuretics	76-84	analgesics	133-142	false
diuretics	76-84	antipyretics	145-156	false
diuretics	76-84	nonsteroidal antiinflammatories	159-189	false
diuretics	76-84	corticosteroids	192-206	false
cardiac glycosides	87-104	calcium channel blockers	107-130	false
cardiac glycosides	87-104	analgesics	133-142	false
cardiac glycosides	87-104	antipyretics	145-156	false
cardiac glycosides	87-104	nonsteroidal antiinflammatories	159-189	false
cardiac glycosides	87-104	corticosteroids	192-206	false
calcium channel blockers	107-130	analgesics	133-142	false
calcium channel blockers	107-130	antipyretics	145-156	false
calcium channel blockers	107-130	nonsteroidal antiinflammatories	159-189	false
calcium channel blockers	107-130	corticosteroids	192-206	false
analgesics	133-142	antipyretics	145-156	false
analgesics	133-142	nonsteroidal antiinflammatories	159-189	false
analgesics	133-142	corticosteroids	192-206	false
antipyretics	145-156	nonsteroidal antiinflammatories	159-189	false
antipyretics	145-156	corticosteroids	192-206	false
nonsteroidal antiinflammatories	159-189	corticosteroids	192-206	false

Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin.
iloprost	24-31	digoxin	74-80	false

Acetylsalicylic acid did not alter the clearance (pharmacokinetics) of iloprost.
Acetylsalicylic acid	0-19	iloprost	71-78	false

Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
imatinib	21-28	imatinib	76-83	false
imatinib	21-28	Gleevec	150-156	false
imatinib	21-28	ketoconazole	202-213	false
imatinib	21-28	itraconazole	216-227	false
imatinib	21-28	erythromycin	230-241	false
imatinib	21-28	clarithromycin	244-257	false
imatinib	76-83	Gleevec	150-156	false
imatinib	76-83	ketoconazole	202-213	false
imatinib	76-83	itraconazole	216-227	false
imatinib	76-83	erythromycin	230-241	false
imatinib	76-83	clarithromycin	244-257	false
Gleevec	150-156	ketoconazole	202-213	advise
Gleevec	150-156	itraconazole	216-227	advise
Gleevec	150-156	erythromycin	230-241	advise
Gleevec	150-156	clarithromycin	244-257	advise
ketoconazole	202-213	itraconazole	216-227	false
ketoconazole	202-213	erythromycin	230-241	false
ketoconazole	202-213	clarithromycin	244-257	false
itraconazole	216-227	erythromycin	230-241	false
itraconazole	216-227	clarithromycin	244-257	false
erythromycin	230-241	clarithromycin	244-257	false

There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).
imatinib	47-54	Gleevec	61-67	false
imatinib	47-54	ketoconazole	92-103	false
Gleevec	61-67	ketoconazole	92-103	mechanism

Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.
imatinib	24-31	imatinib	141-148	false

Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St.
dexamethasone	41-53	phenytoin	56-64	false
dexamethasone	41-53	carbamazepine	67-79	false
dexamethasone	41-53	rifampin	82-89	false
dexamethasone	41-53	phenobarbital	92-104	false
phenytoin	56-64	carbamazepine	67-79	false
phenytoin	56-64	rifampin	82-89	false
phenytoin	56-64	phenobarbital	92-104	false
carbamazepine	67-79	rifampin	82-89	false
carbamazepine	67-79	phenobarbital	92-104	false
rifampin	82-89	phenobarbital	92-104	false

Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
rifampin	58-65	Gleevec	96-102	mechanism
rifampin	58-65	Gleevec	115-121	false
Gleevec	96-102	Gleevec	115-121	false

Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
Gleevec	58-64	Gleevec	66-72	false
Gleevec	58-64	simvastatin	109-119	false
Gleevec	58-64	Gleevec	213-219	false
Gleevec	66-72	simvastatin	109-119	mechanism
Gleevec	66-72	Gleevec	213-219	false
simvastatin	109-119	Gleevec	213-219	false

Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
Gleevec	53-59	cyclosporine	129-140	advise
Gleevec	53-59	pimozide	145-152	advise
cyclosporine	129-140	pimozide	145-152	false

Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
Gleevec	0-6	benzodiazepines	92-106	mechanism
Gleevec	0-6	dihydropyridine calcium channel blockers	109-148	mechanism
Gleevec	0-6	HMG-CoA reductase inhibitors	159-186	mechanism
benzodiazepines	92-106	dihydropyridine calcium channel blockers	109-148	false
benzodiazepines	92-106	HMG-CoA reductase inhibitors	159-186	false
dihydropyridine calcium channel blockers	109-148	HMG-CoA reductase inhibitors	159-186	false

Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin.
warfarin	8-15	heparin	139-145	false

Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
acetaminophen	21-33	Gleevec	88-94	mechanism

Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
decongestants	38-50	anesthetics	62-72	false
decongestants	38-50	sympathomimetic amine	92-112	false
decongestants	38-50	epinephrine	121-131	false
decongestants	38-50	norepinephrine	134-147	false
decongestants	38-50	tricyclic antidepressants	183-207	advise
anesthetics	62-72	sympathomimetic amine	92-112	false
anesthetics	62-72	epinephrine	121-131	false
anesthetics	62-72	norepinephrine	134-147	false
anesthetics	62-72	tricyclic antidepressants	183-207	advise
sympathomimetic amine	92-112	epinephrine	121-131	false
sympathomimetic amine	92-112	norepinephrine	134-147	false
sympathomimetic amine	92-112	tricyclic antidepressants	183-207	advise
epinephrine	121-131	norepinephrine	134-147	false
epinephrine	121-131	tricyclic antidepressants	183-207	advise
norepinephrine	134-147	tricyclic antidepressants	183-207	advise

Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.
Imipramine hydrochloride	0-23	CNS depressant drugs	55-74	effect

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
imipramine	28-37	cimetidine	127-136	mechanism
imipramine	28-37	fluoxetine	139-148	mechanism
imipramine	28-37	barbiturates	228-239	mechanism
imipramine	28-37	phenytoin	242-250	mechanism
imipramine	28-37	imipramine	286-295	false
cimetidine	127-136	fluoxetine	139-148	false
cimetidine	127-136	barbiturates	228-239	false
cimetidine	127-136	phenytoin	242-250	false
cimetidine	127-136	imipramine	286-295	false
fluoxetine	139-148	barbiturates	228-239	false
fluoxetine	139-148	phenytoin	242-250	false
fluoxetine	139-148	imipramine	286-295	false
barbiturates	228-239	phenytoin	242-250	false
barbiturates	228-239	imipramine	286-295	false
phenytoin	242-250	imipramine	286-295	false

Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
tricyclic antidepressants	69-93	TCAs	96-99	false

cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
cimetidine	0-9	antidepressants	66-80	false
cimetidine	0-9	phenothiazines	83-96	false
cimetidine	0-9	Type 1C antiarrhythmics	107-129	false
cimetidine	0-9	propafenone	131-141	false
cimetidine	0-9	flecainide	147-156	false
antidepressants	66-80	phenothiazines	83-96	false
antidepressants	66-80	Type 1C antiarrhythmics	107-129	false
antidepressants	66-80	propafenone	131-141	false
antidepressants	66-80	flecainide	147-156	false
phenothiazines	83-96	Type 1C antiarrhythmics	107-129	false
phenothiazines	83-96	propafenone	131-141	false
phenothiazines	83-96	flecainide	147-156	false
Type 1C antiarrhythmics	107-129	propafenone	131-141	false
Type 1C antiarrhythmics	107-129	flecainide	147-156	false
propafenone	131-141	flecainide	147-156	false

While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
selective serotonin reuptake inhibitors	14-52	SSRIs	55-59	false
selective serotonin reuptake inhibitors	14-52	fluoxetine	70-79	false
selective serotonin reuptake inhibitors	14-52	sertraline	82-91	false
selective serotonin reuptake inhibitors	14-52	paroxetine	98-107	false
SSRIs	55-59	fluoxetine	70-79	false
SSRIs	55-59	sertraline	82-91	false
SSRIs	55-59	paroxetine	98-107	false
fluoxetine	70-79	sertraline	82-91	false
fluoxetine	70-79	paroxetine	98-107	false
sertraline	82-91	paroxetine	98-107	false

The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.
SSRI	20-23	TCA	25-27	int
SSRI	20-23	SSRI	142-145	false
TCA	25-27	SSRI	142-145	false

Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	19-43	tricyclic antidepressant	156-179	false

It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
TCA	27-29	TCA	56-58	false

Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir.
indinavir	81-89	indinavir	138-146	false

Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.
CRIXIVAN	20-27	indinavir	95-103	false
CRIXIVAN	20-27	indinavir	158-166	false
indinavir	95-103	indinavir	158-166	false

Antiarrhythmics: amiodarone
Antiarrhythmics	0-14	amiodarone	17-26	false

Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
dihydroergotamine	19-35	ergonovine	38-47	false
dihydroergotamine	19-35	ergotamine	50-59	false
dihydroergotamine	19-35	methylergonovine	62-77	false
ergonovine	38-47	ergotamine	50-59	false
ergonovine	38-47	methylergonovine	62-77	false
ergotamine	50-59	methylergonovine	62-77	false

Sedative/hypnotics: midazolam, triazolam
Sedative	0-7	hypnotics	9-17	false
Sedative	0-7	midazolam	20-28	false
Sedative	0-7	triazolam	31-39	false
hypnotics	9-17	midazolam	20-28	false
hypnotics	9-17	triazolam	31-39	false
midazolam	20-28	triazolam	31-39	false

Neuroleptic: pimozide
Neuroleptic	0-10	pimozide	13-20	false

May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.
CRIXIVAN	66-73	protease inhibitors	94-112	false

Antimycobacterial: rifampin
Antimycobacterial	0-16	rifampin	19-26	false

May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.
CRIXIVAN	66-73	protease inhibitors	94-112	false
CRIXIVAN	66-73	antiretroviral agents	138-158	false
protease inhibitors	94-112	antiretroviral agents	138-158	false

HMG-CoA Reductase inhibitors: lovastatin, simvastatin
HMG-CoA Reductase inhibitors	0-27	lovastatin	30-39	false
HMG-CoA Reductase inhibitors	0-27	simvastatin	42-52	false
lovastatin	30-39	simvastatin	42-52	false

Protease inhibitor: atazanavir
Protease inhibitor	0-17	atazanavir	20-29	false

Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.
CRIXIVAN	5-12	atazanavir	18-27	false

Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
CRIXIVAN	74-81	atazanavir	87-96	advise

Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
CRIXIVAN	18-25	delavirdine	84-94	advise

Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
Indinavir	0-8	didanosine	14-23	advise

The optimal dose of indinavir, when given in combination with efavirenz, is not known.
indinavir	20-28	efavirenz	62-70	false

Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
indinavir	15-23	indinavir	93-101	false
indinavir	15-23	efavirenz	121-129	false
indinavir	93-101	efavirenz	121-129	mechanism

Indinavir concentrations may be decreased in the presence of nevirapine.
Indinavir	0-8	nevirapine	61-70	mechanism

indinavir concentration   ritonavir concentration
indinavir	0-8	ritonavir	26-34	false

Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.
indinavir	104-112	ritonavir	134-142	effect
indinavir	104-112	CRIXIVAN	165-172	false
ritonavir	134-142	CRIXIVAN	165-172	false

Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine
Antiarrhythmics	0-14	bepridil	17-24	false
Antiarrhythmics	0-14	lidocaine	27-35	false
Antiarrhythmics	0-14	quinidine	52-60	false
bepridil	17-24	lidocaine	27-35	false
bepridil	17-24	quinidine	52-60	false
lidocaine	27-35	quinidine	52-60	false

Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.
antiarrhythmics	81-95	CRIXIVAN	122-129	advise

Anticonvulsants: carbamazepine, phenobarbital, phenytoin
Anticonvulsants	0-14	carbamazepine	17-29	false
Anticonvulsants	0-14	phenobarbital	32-44	false
Anticonvulsants	0-14	phenytoin	47-55	false
carbamazepine	17-29	phenobarbital	32-44	false
carbamazepine	17-29	phenytoin	47-55	false
phenobarbital	32-44	phenytoin	47-55	false

CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
CRIXIVAN	0-7	indinavir	47-55	effect

Calcium Channel Blockers, Dihydropyridine: e.g., felodipine, nifedipine, nicardipine
Calcium Channel Blockers	0-23	Dihydropyridine	26-40	false
Calcium Channel Blockers	0-23	felodipine	49-58	false
Calcium Channel Blockers	0-23	nifedipine	61-70	false
Calcium Channel Blockers	0-23	nicardipine	73-83	false
Dihydropyridine	26-40	felodipine	49-58	false
Dihydropyridine	26-40	nifedipine	61-70	false
Dihydropyridine	26-40	nicardipine	73-83	false
felodipine	49-58	nifedipine	61-70	false
felodipine	49-58	nicardipine	73-83	false
nifedipine	61-70	nicardipine	73-83	false

clarithromycin concentration   indinavir concentration
clarithromycin	0-13	indinavir	31-39	false

HMG-CoA Reductase Inhibitor: atorvastatin
HMG-CoA Reductase Inhibitor	0-26	atorvastatin	29-40	false

Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
atorvastatin	28-39	HMG-CoA reductase inhibitors	78-105	false
atorvastatin	28-39	pravastatin	161-171	false
atorvastatin	28-39	fluvastatin	174-184	false
atorvastatin	28-39	rosuvastatin	190-201	false
atorvastatin	28-39	CRIXIVAN	223-230	advise
HMG-CoA reductase inhibitors	78-105	pravastatin	161-171	false
HMG-CoA reductase inhibitors	78-105	fluvastatin	174-184	false
HMG-CoA reductase inhibitors	78-105	rosuvastatin	190-201	false
HMG-CoA reductase inhibitors	78-105	CRIXIVAN	223-230	advise
pravastatin	161-171	fluvastatin	174-184	false
pravastatin	161-171	rosuvastatin	190-201	false
pravastatin	161-171	CRIXIVAN	223-230	false
fluvastatin	174-184	rosuvastatin	190-201	false
fluvastatin	174-184	CRIXIVAN	223-230	false
rosuvastatin	190-201	CRIXIVAN	223-230	false

Immunosuppressants: cyclosporine, tacrolimus, sirolimus
Immunosuppressants	0-17	cyclosporine	20-31	false
Immunosuppressants	0-17	tacrolimus	34-43	false
Immunosuppressants	0-17	sirolimus	46-54	false
cyclosporine	20-31	tacrolimus	34-43	false
cyclosporine	20-31	sirolimus	46-54	false
tacrolimus	34-43	sirolimus	46-54	false

Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
CRIXIVAN	18-25	itraconazole	85-96	advise

indinavir concentration   rifabutin concentration
indinavir	0-8	rifabutin	26-34	false

Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
rifabutin	18-26	CRIXIVAN	77-84	false
rifabutin	18-26	rifabutin	156-164	false
rifabutin	18-26	CRIXIVAN	170-177	false
CRIXIVAN	77-84	rifabutin	156-164	false
CRIXIVAN	77-84	CRIXIVAN	170-177	false
rifabutin	156-164	CRIXIVAN	170-177	advise

Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
Sildenafil	0-9	indinavir	108-116	advise

Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
Tadalafil	0-8	indinavir	107-115	advise

Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
Vardenafil	0-9	indinavir	108-116	advise

In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.
indomethacin	31-42	diflunisal	67-76	false
indomethacin	31-42	indomethacin	157-168	false
diflunisal	67-76	indomethacin	157-168	mechanism

In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.
INDOCIN	34-40	diflunisal	46-55	effect

Therefore, diflunisal and INDOCIN should not be used concomitantly.
diflunisal	11-20	INDOCIN	26-32	advise

In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.
aspirin	97-103	indomethacin	123-134	mechanism

The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
INDOCIN	23-29	NSAIDs	42-47	advise

Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants.
INDOCIN	33-39	anticoagulants	96-109	false

However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.
INDOCIN	45-51	anticoagulant	95-107	advise

In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.
anticoagulants	99-112	INDOCIN	118-124	effect

Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.
INDOCIN	33-39	anticoagulants	45-58	advise

When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.
INDOCIN	5-11	probenecid	44-53	mechanism
INDOCIN	5-11	indomethacin	77-88	false
probenecid	44-53	indomethacin	77-88	false

Caution should be used if INDOCIN is administered simultaneously with methotrexate.
INDOCIN	26-32	methotrexate	70-81	advise

INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
INDOCIN	0-6	methotrexate	63-74	mechanism

Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
non-steroidal anti-inflammatory drugs	18-54	cyclosporine	75-86	effect
non-steroidal anti-inflammatory drugs	18-54	cyclosporine	128-139	false
cyclosporine	75-86	cyclosporine	128-139	false

NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
NSAIDs	0-5	cyclosporine	54-65	advise

Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
INDOCIN	9-15	lithium	81-87	mechanism
INDOCIN	9-15	lithium	112-118	false
INDOCIN	9-15	lithium	199-205	false
lithium	81-87	lithium	112-118	false
lithium	81-87	lithium	199-205	false
lithium	112-118	lithium	199-205	false

As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.
INDOCIN	23-29	lithium	35-41	advise
INDOCIN	23-29	lithium	122-128	false
lithium	35-41	lithium	122-128	false

INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
INDOCIN	0-6	digoxin	33-39	mechanism
INDOCIN	0-6	digoxin	124-130	false
digoxin	33-39	digoxin	124-130	false

Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.
INDOCIN	16-22	digoxin	28-34	advise
INDOCIN	16-22	digoxin	66-72	false
digoxin	28-34	digoxin	66-72	false

In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
INDOCIN	40-46	loop diuretics	118-121;156-164	effect
INDOCIN	40-46	potassium-sparing diuretics	124-140;156-164	effect
INDOCIN	40-46	thiazide diuretics	147-164	effect
loop diuretics	118-121;156-164	potassium-sparing diuretics	124-140;156-164	false
loop diuretics	118-121;156-164	thiazide diuretics	147-164	false
potassium-sparing diuretics	124-140;156-164	thiazide diuretics	147-164	false

Therefore, when INDOCIN and INDOCIN.
INDOCIN	16-22	INDOCIN	28-34	false

(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
Indomethacin	1-12	diuretics	15-23	false
Indomethacin	1-12	diuretic	130-137	false
diuretics	15-23	diuretic	130-137	false

INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.
INDOCIN	0-6	furosemide	97-106	false

It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.
triamterene	42-52	INDOCIN	83-89	effect

INDOCIN and triamterene should not be administered together.
INDOCIN	0-6	triamterene	12-22	advise

INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.
INDOCIN	0-6	potassium-sparing diuretics	12-38	false

The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
INDOCIN	25-31	potassium-sparing diuretics	37-63	effect

Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.
diuretics	37-45	INDOCIN	152-158	effect

Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
beta-adrenoceptor blocking agents	43-75	non-steroidal antiinflammatory drugs	80-115	effect
beta-adrenoceptor blocking agents	43-75	INDOCIN	127-133	effect
non-steroidal antiinflammatory drugs	80-115	INDOCIN	127-133	false

INDOCIN can reduce the antihypertensive effects of captopril and losartan.
INDOCIN	0-6	captopril	51-59	effect
INDOCIN	0-6	losartan	65-72	effect
captopril	51-59	losartan	65-72	false

Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
etanercept	29-38	anakinra	74-81	effect
etanercept	29-38	interleukin-1 antagonist	87-110	false
anakinra	74-81	interleukin-1 antagonist	87-110	false

Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
TNFa-blocking agents	6-25	REMICADE	38-45	false
TNFa-blocking agents	6-25	anakinra	73-80	effect
REMICADE	38-45	anakinra	73-80	effect

In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.
MTX	57-59	nonsteroidal anti-inflammatory agents	66-102	false
MTX	57-59	folic acid	105-114	false
MTX	57-59	corticosteroids	117-131	false
MTX	57-59	narcotics	140-148	false
nonsteroidal anti-inflammatory agents	66-102	folic acid	105-114	false
nonsteroidal anti-inflammatory agents	66-102	corticosteroids	117-131	false
nonsteroidal anti-inflammatory agents	66-102	narcotics	140-148	false
folic acid	105-114	corticosteroids	117-131	false
folic acid	105-114	narcotics	140-148	false
corticosteroids	117-131	narcotics	140-148	false

Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates.
antibiotics	45-55	antivirals	58-67	false
antibiotics	45-55	corticosteroids	70-84	false
antibiotics	45-55	6-MP	87-90	false
antibiotics	45-55	AZA	92-94	false
antivirals	58-67	corticosteroids	70-84	false
antivirals	58-67	6-MP	87-90	false
antivirals	58-67	AZA	92-94	false
corticosteroids	70-84	6-MP	87-90	false
corticosteroids	70-84	AZA	92-94	false
6-MP	87-90	AZA	92-94	false

In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.
MTX	73-75	nonsteroidal anti-inflammatory agents	126-162	false
MTX	73-75	folic acid	165-174	false
MTX	73-75	corticosteroids	180-194	false
nonsteroidal anti-inflammatory agents	126-162	folic acid	165-174	false
nonsteroidal anti-inflammatory agents	126-162	corticosteroids	180-194	false
folic acid	165-174	corticosteroids	180-194	false

Patients with Crohn s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants.
immunosuppressants	43-60	immunosuppressants	135-152	false

Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.
infliximab	6-15	corticosteroids	136-150	false
infliximab	6-15	antibiotics	153-163	false
infliximab	6-15	metronidazole	166-178	false
infliximab	6-15	ciprofloxacin	183-195	false
corticosteroids	136-150	antibiotics	153-163	false
corticosteroids	136-150	metronidazole	166-178	false
corticosteroids	136-150	ciprofloxacin	183-195	false
antibiotics	153-163	metronidazole	166-178	false
antibiotics	153-163	ciprofloxacin	183-195	false
metronidazole	166-178	ciprofloxacin	183-195	false

The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
ACE inhibitors	157-170	disopyramide	173-184	false
ACE inhibitors	157-170	fibrates	187-194	false
ACE inhibitors	157-170	fluoxetine	197-206	false
ACE inhibitors	157-170	MAO inhibitors	209-222	false
ACE inhibitors	157-170	propoxyphene	225-236	false
ACE inhibitors	157-170	salicylates	239-249	false
ACE inhibitors	157-170	somatostatin analog	252-270	false
ACE inhibitors	157-170	octreotide	279-288	false
ACE inhibitors	157-170	sulfonamide antibiotics	292-314	false
disopyramide	173-184	fibrates	187-194	false
disopyramide	173-184	fluoxetine	197-206	false
disopyramide	173-184	MAO inhibitors	209-222	false
disopyramide	173-184	propoxyphene	225-236	false
disopyramide	173-184	salicylates	239-249	false
disopyramide	173-184	somatostatin analog	252-270	false
disopyramide	173-184	octreotide	279-288	false
disopyramide	173-184	sulfonamide antibiotics	292-314	false
fibrates	187-194	fluoxetine	197-206	false
fibrates	187-194	MAO inhibitors	209-222	false
fibrates	187-194	propoxyphene	225-236	false
fibrates	187-194	salicylates	239-249	false
fibrates	187-194	somatostatin analog	252-270	false
fibrates	187-194	octreotide	279-288	false
fibrates	187-194	sulfonamide antibiotics	292-314	false
fluoxetine	197-206	MAO inhibitors	209-222	false
fluoxetine	197-206	propoxyphene	225-236	false
fluoxetine	197-206	salicylates	239-249	false
fluoxetine	197-206	somatostatin analog	252-270	false
fluoxetine	197-206	octreotide	279-288	false
fluoxetine	197-206	sulfonamide antibiotics	292-314	false
MAO inhibitors	209-222	propoxyphene	225-236	false
MAO inhibitors	209-222	salicylates	239-249	false
MAO inhibitors	209-222	somatostatin analog	252-270	false
MAO inhibitors	209-222	octreotide	279-288	false
MAO inhibitors	209-222	sulfonamide antibiotics	292-314	false
propoxyphene	225-236	salicylates	239-249	false
propoxyphene	225-236	somatostatin analog	252-270	false
propoxyphene	225-236	octreotide	279-288	false
propoxyphene	225-236	sulfonamide antibiotics	292-314	false
salicylates	239-249	somatostatin analog	252-270	false
salicylates	239-249	octreotide	279-288	false
salicylates	239-249	sulfonamide antibiotics	292-314	false
somatostatin analog	252-270	octreotide	279-288	false
somatostatin analog	252-270	sulfonamide antibiotics	292-314	false
octreotide	279-288	sulfonamide antibiotics	292-314	false

The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
insulin	94-100	corticosteroids	103-117	false
insulin	94-100	danazol	120-126	false
insulin	94-100	diuretics	129-137	false
insulin	94-100	sympathomimetic agents	140-161	false
insulin	94-100	epinephrine	170-180	false
insulin	94-100	albuterol	183-191	false
insulin	94-100	terbutaline	194-204	false
insulin	94-100	isoniazid	208-216	false
insulin	94-100	phenothiazine derivatives	219-243	false
insulin	94-100	somatropin	246-255	false
insulin	94-100	thyroid hormones	258-273	false
insulin	94-100	estrogens	276-284	false
insulin	94-100	progestogens	287-298	false
insulin	94-100	contraceptives	315-328	false
corticosteroids	103-117	danazol	120-126	false
corticosteroids	103-117	diuretics	129-137	false
corticosteroids	103-117	sympathomimetic agents	140-161	false
corticosteroids	103-117	epinephrine	170-180	false
corticosteroids	103-117	albuterol	183-191	false
corticosteroids	103-117	terbutaline	194-204	false
corticosteroids	103-117	isoniazid	208-216	false
corticosteroids	103-117	phenothiazine derivatives	219-243	false
corticosteroids	103-117	somatropin	246-255	false
corticosteroids	103-117	thyroid hormones	258-273	false
corticosteroids	103-117	estrogens	276-284	false
corticosteroids	103-117	progestogens	287-298	false
corticosteroids	103-117	contraceptives	315-328	false
danazol	120-126	diuretics	129-137	false
danazol	120-126	sympathomimetic agents	140-161	false
danazol	120-126	epinephrine	170-180	false
danazol	120-126	albuterol	183-191	false
danazol	120-126	terbutaline	194-204	false
danazol	120-126	isoniazid	208-216	false
danazol	120-126	phenothiazine derivatives	219-243	false
danazol	120-126	somatropin	246-255	false
danazol	120-126	thyroid hormones	258-273	false
danazol	120-126	estrogens	276-284	false
danazol	120-126	progestogens	287-298	false
danazol	120-126	contraceptives	315-328	false
diuretics	129-137	sympathomimetic agents	140-161	false
diuretics	129-137	epinephrine	170-180	false
diuretics	129-137	albuterol	183-191	false
diuretics	129-137	terbutaline	194-204	false
diuretics	129-137	isoniazid	208-216	false
diuretics	129-137	phenothiazine derivatives	219-243	false
diuretics	129-137	somatropin	246-255	false
diuretics	129-137	thyroid hormones	258-273	false
diuretics	129-137	estrogens	276-284	false
diuretics	129-137	progestogens	287-298	false
diuretics	129-137	contraceptives	315-328	false
sympathomimetic agents	140-161	epinephrine	170-180	false
sympathomimetic agents	140-161	albuterol	183-191	false
sympathomimetic agents	140-161	terbutaline	194-204	false
sympathomimetic agents	140-161	isoniazid	208-216	false
sympathomimetic agents	140-161	phenothiazine derivatives	219-243	false
sympathomimetic agents	140-161	somatropin	246-255	false
sympathomimetic agents	140-161	thyroid hormones	258-273	false
sympathomimetic agents	140-161	estrogens	276-284	false
sympathomimetic agents	140-161	progestogens	287-298	false
sympathomimetic agents	140-161	contraceptives	315-328	false
epinephrine	170-180	albuterol	183-191	false
epinephrine	170-180	terbutaline	194-204	false
epinephrine	170-180	isoniazid	208-216	false
epinephrine	170-180	phenothiazine derivatives	219-243	false
epinephrine	170-180	somatropin	246-255	false
epinephrine	170-180	thyroid hormones	258-273	false
epinephrine	170-180	estrogens	276-284	false
epinephrine	170-180	progestogens	287-298	false
epinephrine	170-180	contraceptives	315-328	false
albuterol	183-191	terbutaline	194-204	false
albuterol	183-191	isoniazid	208-216	false
albuterol	183-191	phenothiazine derivatives	219-243	false
albuterol	183-191	somatropin	246-255	false
albuterol	183-191	thyroid hormones	258-273	false
albuterol	183-191	estrogens	276-284	false
albuterol	183-191	progestogens	287-298	false
albuterol	183-191	contraceptives	315-328	false
terbutaline	194-204	isoniazid	208-216	false
terbutaline	194-204	phenothiazine derivatives	219-243	false
terbutaline	194-204	somatropin	246-255	false
terbutaline	194-204	thyroid hormones	258-273	false
terbutaline	194-204	estrogens	276-284	false
terbutaline	194-204	progestogens	287-298	false
terbutaline	194-204	contraceptives	315-328	false
isoniazid	208-216	phenothiazine derivatives	219-243	false
isoniazid	208-216	somatropin	246-255	false
isoniazid	208-216	thyroid hormones	258-273	false
isoniazid	208-216	estrogens	276-284	false
isoniazid	208-216	progestogens	287-298	false
isoniazid	208-216	contraceptives	315-328	false
phenothiazine derivatives	219-243	somatropin	246-255	false
phenothiazine derivatives	219-243	thyroid hormones	258-273	false
phenothiazine derivatives	219-243	estrogens	276-284	false
phenothiazine derivatives	219-243	progestogens	287-298	false
phenothiazine derivatives	219-243	contraceptives	315-328	false
somatropin	246-255	thyroid hormones	258-273	false
somatropin	246-255	estrogens	276-284	false
somatropin	246-255	progestogens	287-298	false
somatropin	246-255	contraceptives	315-328	false
thyroid hormones	258-273	estrogens	276-284	false
thyroid hormones	258-273	progestogens	287-298	false
thyroid hormones	258-273	contraceptives	315-328	false
estrogens	276-284	progestogens	287-298	false
estrogens	276-284	contraceptives	315-328	false
progestogens	287-298	contraceptives	315-328	false

Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
Beta-blockers	0-12	clonidine	15-23	false
Beta-blockers	0-12	lithium	26-32	false
Beta-blockers	0-12	alcohol	45-51	false
Beta-blockers	0-12	insulin	122-128	effect
clonidine	15-23	lithium	26-32	false
clonidine	15-23	alcohol	45-51	false
clonidine	15-23	insulin	122-128	effect
lithium	26-32	alcohol	45-51	false
lithium	26-32	insulin	122-128	effect
alcohol	45-51	insulin	122-128	effect

In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
beta-blockers	77-89	clonidine	92-100	false
beta-blockers	77-89	guanethidine	103-114	false
beta-blockers	77-89	reserpine	121-129	false
clonidine	92-100	guanethidine	103-114	false
clonidine	92-100	reserpine	121-129	false
guanethidine	103-114	reserpine	121-129	false

The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
antidiabetic products	134-154	ACE inhibitors	157-170	false
antidiabetic products	134-154	disopyramide	173-184	false
antidiabetic products	134-154	fibrates	187-194	false
antidiabetic products	134-154	fluoxetine	197-206	false
antidiabetic products	134-154	monoamine oxidase (MAO) inhibitors	209-242	false
antidiabetic products	134-154	propoxyphene	245-256	false
antidiabetic products	134-154	salicylates	259-269	false
antidiabetic products	134-154	somatostatin analog	272-290	false
antidiabetic products	134-154	octreotide	299-308	false
antidiabetic products	134-154	sulfonamide antibiotics	312-334	false
ACE inhibitors	157-170	disopyramide	173-184	false
ACE inhibitors	157-170	fibrates	187-194	false
ACE inhibitors	157-170	fluoxetine	197-206	false
ACE inhibitors	157-170	monoamine oxidase (MAO) inhibitors	209-242	false
ACE inhibitors	157-170	propoxyphene	245-256	false
ACE inhibitors	157-170	salicylates	259-269	false
ACE inhibitors	157-170	somatostatin analog	272-290	false
ACE inhibitors	157-170	octreotide	299-308	false
ACE inhibitors	157-170	sulfonamide antibiotics	312-334	false
disopyramide	173-184	fibrates	187-194	false
disopyramide	173-184	fluoxetine	197-206	false
disopyramide	173-184	monoamine oxidase (MAO) inhibitors	209-242	false
disopyramide	173-184	propoxyphene	245-256	false
disopyramide	173-184	salicylates	259-269	false
disopyramide	173-184	somatostatin analog	272-290	false
disopyramide	173-184	octreotide	299-308	false
disopyramide	173-184	sulfonamide antibiotics	312-334	false
fibrates	187-194	fluoxetine	197-206	false
fibrates	187-194	monoamine oxidase (MAO) inhibitors	209-242	false
fibrates	187-194	propoxyphene	245-256	false
fibrates	187-194	salicylates	259-269	false
fibrates	187-194	somatostatin analog	272-290	false
fibrates	187-194	octreotide	299-308	false
fibrates	187-194	sulfonamide antibiotics	312-334	false
fluoxetine	197-206	monoamine oxidase (MAO) inhibitors	209-242	false
fluoxetine	197-206	propoxyphene	245-256	false
fluoxetine	197-206	salicylates	259-269	false
fluoxetine	197-206	somatostatin analog	272-290	false
fluoxetine	197-206	octreotide	299-308	false
fluoxetine	197-206	sulfonamide antibiotics	312-334	false
monoamine oxidase (MAO) inhibitors	209-242	propoxyphene	245-256	false
monoamine oxidase (MAO) inhibitors	209-242	salicylates	259-269	false
monoamine oxidase (MAO) inhibitors	209-242	somatostatin analog	272-290	false
monoamine oxidase (MAO) inhibitors	209-242	octreotide	299-308	false
monoamine oxidase (MAO) inhibitors	209-242	sulfonamide antibiotics	312-334	false
propoxyphene	245-256	salicylates	259-269	false
propoxyphene	245-256	somatostatin analog	272-290	false
propoxyphene	245-256	octreotide	299-308	false
propoxyphene	245-256	sulfonamide antibiotics	312-334	false
salicylates	259-269	somatostatin analog	272-290	false
salicylates	259-269	octreotide	299-308	false
salicylates	259-269	sulfonamide antibiotics	312-334	false
somatostatin analog	272-290	octreotide	299-308	false
somatostatin analog	272-290	sulfonamide antibiotics	312-334	false
octreotide	299-308	sulfonamide antibiotics	312-334	false

The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
corticosteroids	92-106	niacin	109-114	false
corticosteroids	92-106	danazol	117-123	false
corticosteroids	92-106	diuretics	126-134	false
corticosteroids	92-106	sympathomimetic agents	137-158	false
corticosteroids	92-106	epinephrine	167-177	false
corticosteroids	92-106	salbutamol	180-189	false
corticosteroids	92-106	terbutaline	192-202	false
corticosteroids	92-106	isoniazid	206-214	false
corticosteroids	92-106	phenothiazine derivatives	217-241	false
corticosteroids	92-106	somatropin	244-253	false
corticosteroids	92-106	thyroid hormones	256-271	false
corticosteroids	92-106	estrogens	274-282	false
corticosteroids	92-106	progestogens	285-296	false
corticosteroids	92-106	contraceptives	313-326	false
niacin	109-114	danazol	117-123	false
niacin	109-114	diuretics	126-134	false
niacin	109-114	sympathomimetic agents	137-158	false
niacin	109-114	epinephrine	167-177	false
niacin	109-114	salbutamol	180-189	false
niacin	109-114	terbutaline	192-202	false
niacin	109-114	isoniazid	206-214	false
niacin	109-114	phenothiazine derivatives	217-241	false
niacin	109-114	somatropin	244-253	false
niacin	109-114	thyroid hormones	256-271	false
niacin	109-114	estrogens	274-282	false
niacin	109-114	progestogens	285-296	false
niacin	109-114	contraceptives	313-326	false
danazol	117-123	diuretics	126-134	false
danazol	117-123	sympathomimetic agents	137-158	false
danazol	117-123	epinephrine	167-177	false
danazol	117-123	salbutamol	180-189	false
danazol	117-123	terbutaline	192-202	false
danazol	117-123	isoniazid	206-214	false
danazol	117-123	phenothiazine derivatives	217-241	false
danazol	117-123	somatropin	244-253	false
danazol	117-123	thyroid hormones	256-271	false
danazol	117-123	estrogens	274-282	false
danazol	117-123	progestogens	285-296	false
danazol	117-123	contraceptives	313-326	false
diuretics	126-134	sympathomimetic agents	137-158	false
diuretics	126-134	epinephrine	167-177	false
diuretics	126-134	salbutamol	180-189	false
diuretics	126-134	terbutaline	192-202	false
diuretics	126-134	isoniazid	206-214	false
diuretics	126-134	phenothiazine derivatives	217-241	false
diuretics	126-134	somatropin	244-253	false
diuretics	126-134	thyroid hormones	256-271	false
diuretics	126-134	estrogens	274-282	false
diuretics	126-134	progestogens	285-296	false
diuretics	126-134	contraceptives	313-326	false
sympathomimetic agents	137-158	epinephrine	167-177	false
sympathomimetic agents	137-158	salbutamol	180-189	false
sympathomimetic agents	137-158	terbutaline	192-202	false
sympathomimetic agents	137-158	isoniazid	206-214	false
sympathomimetic agents	137-158	phenothiazine derivatives	217-241	false
sympathomimetic agents	137-158	somatropin	244-253	false
sympathomimetic agents	137-158	thyroid hormones	256-271	false
sympathomimetic agents	137-158	estrogens	274-282	false
sympathomimetic agents	137-158	progestogens	285-296	false
sympathomimetic agents	137-158	contraceptives	313-326	false
epinephrine	167-177	salbutamol	180-189	false
epinephrine	167-177	terbutaline	192-202	false
epinephrine	167-177	isoniazid	206-214	false
epinephrine	167-177	phenothiazine derivatives	217-241	false
epinephrine	167-177	somatropin	244-253	false
epinephrine	167-177	thyroid hormones	256-271	false
epinephrine	167-177	estrogens	274-282	false
epinephrine	167-177	progestogens	285-296	false
epinephrine	167-177	contraceptives	313-326	false
salbutamol	180-189	terbutaline	192-202	false
salbutamol	180-189	isoniazid	206-214	false
salbutamol	180-189	phenothiazine derivatives	217-241	false
salbutamol	180-189	somatropin	244-253	false
salbutamol	180-189	thyroid hormones	256-271	false
salbutamol	180-189	estrogens	274-282	false
salbutamol	180-189	progestogens	285-296	false
salbutamol	180-189	contraceptives	313-326	false
terbutaline	192-202	isoniazid	206-214	false
terbutaline	192-202	phenothiazine derivatives	217-241	false
terbutaline	192-202	somatropin	244-253	false
terbutaline	192-202	thyroid hormones	256-271	false
terbutaline	192-202	estrogens	274-282	false
terbutaline	192-202	progestogens	285-296	false
terbutaline	192-202	contraceptives	313-326	false
isoniazid	206-214	phenothiazine derivatives	217-241	false
isoniazid	206-214	somatropin	244-253	false
isoniazid	206-214	thyroid hormones	256-271	false
isoniazid	206-214	estrogens	274-282	false
isoniazid	206-214	progestogens	285-296	false
isoniazid	206-214	contraceptives	313-326	false
phenothiazine derivatives	217-241	somatropin	244-253	false
phenothiazine derivatives	217-241	thyroid hormones	256-271	false
phenothiazine derivatives	217-241	estrogens	274-282	false
phenothiazine derivatives	217-241	progestogens	285-296	false
phenothiazine derivatives	217-241	contraceptives	313-326	false
somatropin	244-253	thyroid hormones	256-271	false
somatropin	244-253	estrogens	274-282	false
somatropin	244-253	progestogens	285-296	false
somatropin	244-253	contraceptives	313-326	false
thyroid hormones	256-271	estrogens	274-282	false
thyroid hormones	256-271	progestogens	285-296	false
thyroid hormones	256-271	contraceptives	313-326	false
estrogens	274-282	progestogens	285-296	false
estrogens	274-282	contraceptives	313-326	false
progestogens	285-296	contraceptives	313-326	false

Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
Beta-blockers	0-12	clonidine	15-23	false
Beta-blockers	0-12	lithium	26-32	false
Beta-blockers	0-12	alcohol	45-51	false
Beta-blockers	0-12	insulin	122-128	effect
clonidine	15-23	lithium	26-32	false
clonidine	15-23	alcohol	45-51	false
clonidine	15-23	insulin	122-128	effect
lithium	26-32	alcohol	45-51	false
lithium	26-32	insulin	122-128	effect
alcohol	45-51	insulin	122-128	effect

In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
beta-blockers	77-89	clonidine	92-100	false
beta-blockers	77-89	guanethidine	103-114	false
beta-blockers	77-89	reserpine	121-129	false
clonidine	92-100	guanethidine	103-114	false
clonidine	92-100	reserpine	121-129	false
guanethidine	103-114	reserpine	121-129	false

A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.
NovoLog	76-82	NPH human insulin	89-105	false
NovoLog	76-82	NovoLog	191-197	false
NovoLog	76-82	NovoLog	259-265	false
NPH human insulin	89-105	NovoLog	191-197	false
NPH human insulin	89-105	NovoLog	259-265	false
NovoLog	191-197	NovoLog	259-265	false

If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.
NovoLog	3-9	NPH human insulin	25-41	false
NovoLog	3-9	NovoLog	44-50	false
NPH human insulin	25-41	NovoLog	44-50	false

Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparations, NovoLog should not be mixed with these preparations.
NovoLog	50-56	zinc insulin	74-85	false
NovoLog	50-56	NovoLog	101-107	false
zinc insulin	74-85	NovoLog	101-107	false

The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .
NovoLog	22-28	insulins	35-42	false
NovoLog	22-28	insulin	64-70	false
insulins	35-42	insulin	64-70	false

When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent.
insulin	54-60	NovoLog	63-69	false
insulin	54-60	insulins	106-113	false
NovoLog	63-69	insulins	106-113	false

Also, the potential for hepatic injury should be considered when Rebif  is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on Rebif .
Rebif	65-69	Rebif	214-218	false

Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.
corticosteroid	93-106	ACTH	111-114	false
corticosteroid	93-106	Betaseron	219-227	false
ACTH	111-114	Betaseron	219-227	false

Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
Betaseron	0-8	antipyrine	128-137	mechanism
Betaseron	0-8	Betaseron	211-219	false
antipyrine	128-137	Betaseron	211-219	false

ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.
ATROVENT	0-7	sympathomimetic bronchodilators	84-114	false
ATROVENT	0-7	methylxanthines	117-131	false
ATROVENT	0-7	steroids	138-145	false
sympathomimetic bronchodilators	84-114	methylxanthines	117-131	false
sympathomimetic bronchodilators	84-114	steroids	138-145	false
methylxanthines	117-131	steroids	138-145	false

With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness.
albuterol	22-30	ATROVENT	105-112	false

Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
Anticholinergic agents	0-21	ipratropium bromide	33-51	false
Anticholinergic agents	0-21	anticholinergic medications	182-208	false
ipratropium bromide	33-51	anticholinergic medications	182-208	effect

Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.
ATROVENT	56-63	anticholinergic	95-109	advise

No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.
hydrochlorothiazide	119-137	digoxin	140-146	false
hydrochlorothiazide	119-137	warfarin	149-156	false
hydrochlorothiazide	119-137	nifedipine	163-172	false
digoxin	140-146	warfarin	149-156	false
digoxin	140-146	nifedipine	163-172	false
warfarin	149-156	nifedipine	163-172	false

In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.
sulphenazole	153-164	tolbutamide	167-177	false
sulphenazole	153-164	nifedipine	183-192	false
tolbutamide	167-177	nifedipine	183-192	false

However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.
irbesartan	61-70	warfarin	99-106	false

In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
warfarin	63-70	hydrochlorothiazide	73-91	false
warfarin	63-70	digoxin	97-103	false
warfarin	63-70	irbesartan	106-115	false
warfarin	63-70	warfarin	184-191	false
warfarin	63-70	digoxin	235-241	false
hydrochlorothiazide	73-91	digoxin	97-103	false
hydrochlorothiazide	73-91	irbesartan	106-115	false
hydrochlorothiazide	73-91	warfarin	184-191	false
hydrochlorothiazide	73-91	digoxin	235-241	false
digoxin	97-103	irbesartan	106-115	false
digoxin	97-103	warfarin	184-191	false
digoxin	97-103	digoxin	235-241	false
irbesartan	106-115	warfarin	184-191	false
irbesartan	106-115	digoxin	235-241	false
warfarin	184-191	digoxin	235-241	false

The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide
irbesartan	24-33	nifedipine	76-85	false
irbesartan	24-33	hydrochlorothiazide	90-108	false
nifedipine	76-85	hydrochlorothiazide	90-108	false

The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
CAMPTOSAR	23-31	antineoplastic agents	118-138	effect

Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.
CAMPTOSAR	56-64	dexamethasone	113-125	effect

The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).
prochlorperazine	115-130	CAMPTOSAR	168-176	effect

It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.
laxative	26-33	CAMPTOSAR	59-67	effect

In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
CAMPTOSAR	94-102	diuretics	140-148	false
CAMPTOSAR	94-102	CAMPTOSAR	169-177	false
diuretics	140-148	CAMPTOSAR	169-177	effect

Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
Isocarboxazid	0-12	Antabuse	72-79	advise
Isocarboxazid	0-12	disulfiram	82-91	advise
Antabuse	72-79	disulfiram	82-91	false

In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.
MAO inhibitor	63-75	disulfiram	82-91	effect

Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.
Isocarboxazid	19-31	psychotropic agents	43-61	advise

The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid.
Isocarboxazid	44-56	Isocarboxazid	205-217	false

May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).
beta-adrenergic blocking agents	33-63	adrenergic bronchodilators	128-153	false
beta-adrenergic blocking agents	33-63	disopyramide	182-193	false
beta-adrenergic blocking agents	33-63	quinidine	196-204	false
beta-adrenergic blocking agents	33-63	phenothiazines	207-220	false
beta-adrenergic blocking agents	33-63	procainamide	227-238	false
adrenergic bronchodilators	128-153	disopyramide	182-193	false
adrenergic bronchodilators	128-153	quinidine	196-204	false
adrenergic bronchodilators	128-153	phenothiazines	207-220	false
adrenergic bronchodilators	128-153	procainamide	227-238	false
disopyramide	182-193	quinidine	196-204	false
disopyramide	182-193	phenothiazines	207-220	false
disopyramide	182-193	procainamide	227-238	false
quinidine	196-204	phenothiazines	207-220	false
quinidine	196-204	procainamide	227-238	false
phenothiazines	207-220	procainamide	227-238	false

Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
Isoflurane	0-9	muscle relaxants	57-72	effect
Isoflurane	0-9	nondepolarizing muscle relaxants	88-119	effect
muscle relaxants	57-72	nondepolarizing muscle relaxants	88-119	false

Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
Acetaminophen	0-12	acetaminophen	34-46	false
Acetaminophen	0-12	Isoniazid	93-101	false
acetaminophen	34-46	Isoniazid	93-101	effect

It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
isoniazid	102-110	acetaminophen	116-128	effect

Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
isoniazid	38-46	acetaminophen	170-182	mechanism

Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
Carbamazepine	0-12	Isoniazid	15-23	false
Carbamazepine	0-12	carbamazepine	60-72	false
Carbamazepine	0-12	Carbamazepine	104-116	false
Carbamazepine	0-12	isoniazid	186-194	false
Carbamazepine	0-12	carbamazepine	219-231	false
Carbamazepine	0-12	anticonvulsant	312-325	false
Isoniazid	15-23	carbamazepine	60-72	mechanism
Isoniazid	15-23	Carbamazepine	104-116	false
Isoniazid	15-23	isoniazid	186-194	false
Isoniazid	15-23	carbamazepine	219-231	false
Isoniazid	15-23	anticonvulsant	312-325	false
carbamazepine	60-72	Carbamazepine	104-116	false
carbamazepine	60-72	isoniazid	186-194	false
carbamazepine	60-72	carbamazepine	219-231	false
carbamazepine	60-72	anticonvulsant	312-325	false
Carbamazepine	104-116	isoniazid	186-194	advise
Carbamazepine	104-116	carbamazepine	219-231	false
Carbamazepine	104-116	anticonvulsant	312-325	false
isoniazid	186-194	carbamazepine	219-231	false
isoniazid	186-194	anticonvulsant	312-325	false
carbamazepine	219-231	anticonvulsant	312-325	false

Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
Ketoconazole	0-11	Ketoconazole	39-50	false
Ketoconazole	0-11	Isoniazid	56-64	false
Ketoconazole	39-50	Isoniazid	56-64	int

Phenytoin: Isoniazid may increase serum levels of phenytoin.
Phenytoin	0-8	Isoniazid	11-19	false
Phenytoin	0-8	phenytoin	50-58	false
Isoniazid	11-19	phenytoin	50-58	mechanism

To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.
phenytoin	9-17	anticonvulsant	63-76	false

Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
isoniazid	74-82	theophylline	88-99	mechanism
isoniazid	74-82	theophylline	137-148	false
isoniazid	74-82	isoniazid	213-221	false
theophylline	88-99	theophylline	137-148	false
theophylline	88-99	isoniazid	213-221	false
theophylline	137-148	isoniazid	213-221	false

Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.
theophylline	31-42	theophylline	54-65	false
theophylline	31-42	theophylline	147-158	false
theophylline	54-65	theophylline	147-158	false

Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
Valproate	0-8	valproate	84-92	false
Valproate	0-8	isoniazid	120-128	false
valproate	84-92	isoniazid	120-128	mechanism

Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
valproate	7-15	isoniazid	56-64	false
valproate	7-15	valproate	70-78	false
valproate	7-15	valproate	139-147	false
isoniazid	56-64	valproate	70-78	advise
isoniazid	56-64	valproate	139-147	false
valproate	70-78	valproate	139-147	false

Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
Isoproterenol hydrochloride	0-26	epinephrine	42-52	advise

ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
ISUPREL	0-6	anesthetics	73-83	advise
ISUPREL	0-6	halothane	93-101	advise
ISUPREL	0-6	sympathomimetic amines	179-200	false
anesthetics	73-83	halothane	93-101	false
anesthetics	73-83	sympathomimetic amines	179-200	false
halothane	93-101	sympathomimetic amines	179-200	false

The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.
isosorbide dinitrate	28-47	vasodilators	85-96	effect

The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.
isosorbide mononitrate	28-49	vasodilators	87-98	effect

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
calcium channel blockers	66-89	organic nitrates	95-110	effect

Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
Vitamin A	0-8	Accutane	42-49	false
Vitamin A	0-8	vitamin A	54-62	false
Vitamin A	0-8	vitamin supplements	107-125	false
Vitamin A	0-8	vitamin A	138-146	false
Accutane	42-49	vitamin A	54-62	effect
Accutane	42-49	vitamin supplements	107-125	false
Accutane	42-49	vitamin A	138-146	false
vitamin A	54-62	vitamin supplements	107-125	false
vitamin A	54-62	vitamin A	138-146	false
vitamin supplements	107-125	vitamin A	138-146	false

Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
Tetracyclines	0-12	Accutane	42-49	false
Tetracyclines	0-12	tetracyclines	55-67	false
Tetracyclines	0-12	Accutane	95-102	false
Tetracyclines	0-12	tetracyclines	252-264	false
Accutane	42-49	tetracyclines	55-67	advise
Accutane	42-49	Accutane	95-102	false
Accutane	42-49	tetracyclines	252-264	false
tetracyclines	55-67	Accutane	95-102	false
tetracyclines	55-67	tetracyclines	252-264	false
Accutane	95-102	tetracyclines	252-264	effect

Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.
Progesterone	12-23	progesterone	51-62	false
Progesterone	12-23	estrogen	111-118	false
Progesterone	12-23	Accutane	173-180	false
progesterone	51-62	estrogen	111-118	false
progesterone	51-62	Accutane	173-180	effect
estrogen	111-118	Accutane	173-180	false

Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from women who have used combined oral contraceptives, as well as topical/injectable/implantable/insertable hormonal birth control products.
hormonal contraceptives	15-37	combined oral contraceptives	123-150	false

It is not known if hormonal contraceptives differ in their effectiveness when used with Accutane.
hormonal contraceptives	19-41	Accutane	88-95	false

Phenytoin: Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.
Phenytoin	0-8	Accutane	11-18	false
Phenytoin	0-8	phenytoin	72-80	false
Accutane	11-18	phenytoin	72-80	false

No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and Accutane.
phenytoin	112-120	Accutane	126-133	false

Systemic Corticosteroids: Systemic corticosteroids are known to cause osteoporosis.
Systemic Corticosteroids	0-23	Systemic corticosteroids	26-49	false

No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and Accutane.
systemic corticosteroids	112-135	Accutane	141-148	false

Nitroglycerin: DynaCirc  (isradipine) has been safely coadministered with nitroglycerin.
Nitroglycerin	0-12	DynaCirc	15-22	false
Nitroglycerin	0-12	isradipine	26-35	false
Nitroglycerin	0-12	nitroglycerin	74-86	false
DynaCirc	15-22	isradipine	26-35	false
DynaCirc	15-22	nitroglycerin	74-86	false
isradipine	26-35	nitroglycerin	74-86	false

Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
Hydrochlorothiazide	0-18	DynaCirc	103-110	false
Hydrochlorothiazide	0-18	isradipine	114-123	false
Hydrochlorothiazide	0-18	hydrochlorothiazide	130-148	false
DynaCirc	103-110	isradipine	114-123	false
DynaCirc	103-110	hydrochlorothiazide	130-148	false
isradipine	114-123	hydrochlorothiazide	130-148	false

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.
isradipine	49-58	hydrochlorothiazide	72-90	false
isradipine	49-58	isradipine	154-163	false
hydrochlorothiazide	72-90	isradipine	154-163	false

Propranolol: In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability.
Propranolol	0-10	propranolol	78-88	false
Propranolol	0-10	isradipine	152-161	false
propranolol	78-88	isradipine	152-161	false

propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
propranolol	0-10	isradipine	165-174	false
propranolol	0-10	propranolol	213-223	false
propranolol	0-10	propranolol	238-248	false
propranolol	0-10	isradipine	287-296	false
isradipine	165-174	propranolol	213-223	false
isradipine	165-174	propranolol	238-248	false
isradipine	165-174	isradipine	287-296	false
propranolol	213-223	propranolol	238-248	false
propranolol	213-223	isradipine	287-296	false
propranolol	238-248	isradipine	287-296	false

Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
Cimetidine	0-9	cimetidine	67-76	false
Cimetidine	0-9	isradipine	122-131	false
Cimetidine	0-9	isradipine	172-181	false
cimetidine	67-76	isradipine	122-131	mechanism
cimetidine	67-76	isradipine	172-181	false
isradipine	122-131	isradipine	172-181	false

If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
isradipine	3-12	cimetidine	68-77	advise

Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
Rifampicin	0-9	rifampicin	66-75	false
Rifampicin	0-9	isradipine	125-134	false
Rifampicin	0-9	isradipine	163-172	false
rifampicin	66-75	isradipine	125-134	mechanism
rifampicin	66-75	isradipine	163-172	false
isradipine	125-134	isradipine	163-172	false

If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
rifampicin	3-12	isradipine	35-44	mechanism
rifampicin	3-12	isradipine	197-206	false
isradipine	35-44	isradipine	197-206	false

Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.
Warfarin	0-7	isradipine	122-131	false
Warfarin	0-7	warfarin	145-152	false
Warfarin	0-7	warfarin	193-200	false
Warfarin	0-7	isradipine	302-311	false
isradipine	122-131	warfarin	145-152	false
isradipine	122-131	warfarin	193-200	false
isradipine	122-131	isradipine	302-311	false
warfarin	145-152	warfarin	193-200	false
warfarin	145-152	isradipine	302-311	false
warfarin	193-200	isradipine	302-311	false

Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.
warfarin	16-23	isradipine	29-38	false

Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.
Digoxin	0-6	DynaCirc	43-50	false
Digoxin	0-6	isradipine	54-63	false
Digoxin	0-6	digoxin	70-76	false
Digoxin	0-6	digoxin	176-182	false
DynaCirc	43-50	isradipine	54-63	false
DynaCirc	43-50	digoxin	70-76	false
DynaCirc	43-50	digoxin	176-182	false
isradipine	54-63	digoxin	70-76	false
isradipine	54-63	digoxin	176-182	false
digoxin	70-76	digoxin	176-182	false

Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
Fentanyl	0-7	fentanyl	65-72	false
Fentanyl	0-7	beta blocker	111-122	false
Fentanyl	0-7	calcium channel blocker	130-152	false
fentanyl	65-72	beta blocker	111-122	effect
fentanyl	65-72	calcium channel blocker	130-152	effect
beta blocker	111-122	calcium channel blocker	130-152	false

Even though such interactions have not been seen in clinical studies with DynaCirc  (isradipine), an increased volume of circulating fluids might be required if such an interaction were to occur.
DynaCirc	74-81	isradipine	85-94	false

Both itraconazole and its major metabolite, hydroxyitraconazole, are inhibitors of the cytochrome P450 3A4 enzyme system.
itraconazole	5-16	hydroxyitraconazole	44-62	false

Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
terfenadine	20-30	Itraconazole	37-48	mechanism
terfenadine	20-30	terfenadine	95-105	false
Itraconazole	37-48	terfenadine	95-105	false

Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
azole antifungal	13-28	ketoconazole	31-42	false
azole antifungal	13-28	astemizole	72-81	false
azole antifungal	13-28	astemizole	131-140	false
azole antifungal	13-28	desmethylastermizole	168-187	false
ketoconazole	31-42	astemizole	72-81	mechanism
ketoconazole	31-42	astemizole	131-140	false
ketoconazole	31-42	desmethylastermizole	168-187	false
astemizole	72-81	astemizole	131-140	false
astemizole	72-81	desmethylastermizole	168-187	false
astemizole	131-140	desmethylastermizole	168-187	false

In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
itraconazole	27-38	ketoconazole	58-69	false
itraconazole	27-38	astemizole	167-176	mechanism
ketoconazole	58-69	astemizole	167-176	false

Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
itraconazole	37-48	ketoconazole	54-65	false
itraconazole	37-48	astemizole	88-97	false
itraconazole	37-48	itraconazole	104-115	false
ketoconazole	54-65	astemizole	88-97	false
ketoconazole	54-65	itraconazole	104-115	false
astemizole	88-97	itraconazole	104-115	advise

Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
ketoconazole	47-58	cisapride	96-104	mechanism
ketoconazole	47-58	cisapride	161-169	false
cisapride	96-104	cisapride	161-169	false

Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
ketoconazole	43-54	cisapride	60-68	effect

In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
itraconazole	27-38	cisapride	133-141	mechanism

therefore concomitant administration of Itraconazole with cisapride is contraindicated.
Itraconazole	40-51	cisapride	58-66	advise

Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
Itraconazole	20-31	midazolam	43-51	mechanism
Itraconazole	20-31	triazolam	56-64	mechanism
midazolam	43-51	triazolam	56-64	false

Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
Itraconazole	20-31	cyclosporine	37-48	mechanism
Itraconazole	20-31	tacrolimus	51-60	mechanism
Itraconazole	20-31	digoxin	65-71	mechanism
cyclosporine	37-48	tacrolimus	51-60	false
cyclosporine	37-48	digoxin	65-71	false
tacrolimus	51-60	digoxin	65-71	false

Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
Cyclosporine	0-11	tacrolimus	14-23	false
Cyclosporine	0-11	digoxin	29-35	false
Cyclosporine	0-11	Itraconazole	93-104	advise
tacrolimus	14-23	digoxin	29-35	false
tacrolimus	14-23	Itraconazole	93-104	advise
digoxin	29-35	Itraconazole	93-104	advise

Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
HMG-CoA reductase inhibitors	55-82	immunosuppressive drugs	150-172	effect
HMG-CoA reductase inhibitors	55-82	cyclosporine	184-195	effect
immunosuppressive drugs	150-172	cyclosporine	184-195	false

When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
Itraconazole	5-16	phenytoin	42-50	mechanism
Itraconazole	5-16	rifampin	53-60	mechanism
Itraconazole	5-16	itraconazole	114-125	false
phenytoin	42-50	rifampin	53-60	false
phenytoin	42-50	itraconazole	114-125	false
rifampin	53-60	itraconazole	114-125	false

The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.
itraconazole	65-76	Itraconazole	153-164	false

Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
Itraconazole	71-82	phenytoin	88-96	mechanism
Itraconazole	71-82	phenytoin	126-134	false
phenytoin	88-96	phenytoin	126-134	false

therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
phenytoin	36-44	Itraconazole	106-117	advise

It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.
Itraconazole	26-37	coumarin	76-83	effect

Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.
Itraconazole	80-91	coumarin	97-104	advise

Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.
azole antifungal agents	25-47	isoniazid	90-98	mechanism

Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
Itraconazole	0-11	Itraconazole	60-71	false
Itraconazole	0-11	isoniazid	77-85	false
Itraconazole	60-71	isoniazid	77-85	advise

Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.
azole antifungal agents	74-96	hypoglycemic agents	107-125	effect

Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.
Itraconazole	64-75	hypoglycemic agents	86-104	advise

Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
Itraconazole	86-97	quinidine	103-111	effect

Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.
Itraconazole	60-71	dihydropyridine calcium channel blockers	77-116	effect

The results from a study in which eight HIV-infected individuals were treated with zidovudine, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole, 100 mg b.i.d.
zidovudine	83-92	zidovudine	152-161	false
zidovudine	83-92	Itraconazole	218-229	false
zidovudine	152-161	Itraconazole	218-229	false

In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
aminoglycoside	22-35	antibiotics	58-68	effect
aminoglycoside	22-35	penicillins	71-81	effect
aminoglycoside	22-35	cephalosporins	86-99	effect
antibiotics	58-68	penicillins	71-81	false
antibiotics	58-68	cephalosporins	86-99	false
penicillins	71-81	cephalosporins	86-99	false

Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
aminoglycoside	13-26	penicillin	34-43	mechanism
aminoglycoside	13-26	aminoglycoside	119-132	false
penicillin	34-43	aminoglycoside	119-132	false

Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
barbiturates	37-48	narcotics	57-65	false
barbiturates	37-48	ketamine	94-101	effect
narcotics	57-65	ketamine	94-101	effect

Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.
Ketamine	0-7	anesthetic agents	75-91	false

The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
NIZORAL	63-69	Ketoconazole	149-160	false
NIZORAL	63-69	terfenadine	196-206	false
NIZORAL	63-69	terfenadine	259-269	false
Ketoconazole	149-160	terfenadine	196-206	mechanism
Ketoconazole	149-160	terfenadine	259-269	false
terfenadine	196-206	terfenadine	259-269	false

Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
ketoconazole	40-51	astemizole	80-89	effect
ketoconazole	40-51	astemizole	131-140	false
ketoconazole	40-51	desmethylastemizole	168-186	false
astemizole	80-89	astemizole	131-140	false
astemizole	80-89	desmethylastemizole	168-186	false
astemizole	131-140	desmethylastemizole	168-186	false

Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
astemizole	20-29	ketoconazole	36-47	advise

Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
ketoconazole	47-58	cisapride	96-104	mechanism
ketoconazole	47-58	cisapride	156-164	false
cisapride	96-104	cisapride	156-164	false

Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
ketoconazole	43-54	cisapride	60-68	effect

Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
ketoconazole	40-51	cisapride	66-74	advise

Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
Ketoconazole	0-11	cyclosporine	49-60	mechanism
Ketoconazole	0-11	tacrolimus	63-72	mechanism
Ketoconazole	0-11	methylprednisolone	79-96	mechanism
cyclosporine	49-60	tacrolimus	63-72	false
cyclosporine	49-60	methylprednisolone	79-96	false
tacrolimus	63-72	methylprednisolone	79-96	false

Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with NIZORAL  Tablets.
cyclosporine	37-48	tacrolimus	51-60	false
cyclosporine	37-48	methylprednisolone	66-83	false
cyclosporine	37-48	NIZORAL	114-120	false
tacrolimus	51-60	methylprednisolone	66-83	false
tacrolimus	51-60	NIZORAL	114-120	false
methylprednisolone	66-83	NIZORAL	114-120	false

Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
NIZORAL	20-26	midazolam	42-50	mechanism
NIZORAL	20-26	triazolam	55-63	mechanism
midazolam	42-50	triazolam	55-63	false

It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
digoxin	39-45	ketoconazole	84-95	advise

When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
imidazole compounds	20-38	ketoconazole	45-56	false
imidazole compounds	20-38	coumarin	98-105	effect
ketoconazole	45-56	coumarin	98-105	effect

In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
imidazole drugs	31-45	coumarin drugs	51-64	advise

Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.
miconazole	87-96	imidazole	102-110	false
miconazole	87-96	hypoglycemic agents	122-140	effect
miconazole	87-96	ketoconazole	229-240	false
miconazole	87-96	imidazole	254-262	false
imidazole	102-110	hypoglycemic agents	122-140	false
imidazole	102-110	ketoconazole	229-240	false
imidazole	102-110	imidazole	254-262	false
hypoglycemic agents	122-140	ketoconazole	229-240	false
hypoglycemic agents	122-140	imidazole	254-262	false
ketoconazole	229-240	imidazole	254-262	false

Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
ketoconazole	30-41	phenytoin	56-64	mechanism

It is suggested to monitor both ketoconazole and phenytoin.
ketoconazole	32-43	phenytoin	49-57	advise

Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
rifampin	30-37	ketoconazole	44-55	mechanism

INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
INH	0-2	Isoniazid	5-13	false
INH	0-2	ketoconazole	43-54	mechanism
Isoniazid	5-13	ketoconazole	43-54	mechanism

After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
ketoconazole	42-53	loratadine	89-98	mechanism
ketoconazole	42-53	loratadine	136-145	false
loratadine	89-98	loratadine	136-145	false

Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole.
loratadine	78-87	ketoconazole	122-133	false

The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.
Orudis	69-74	ketoprofen	131-140	false

Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.
Antacids	0-7	magnesium hydroxide	40-58	false
Antacids	0-7	aluminum hydroxide	64-81	false
Antacids	0-7	ketoprofen	147-156	false
Antacids	0-7	Orudis	174-179	false
magnesium hydroxide	40-58	aluminum hydroxide	64-81	false
magnesium hydroxide	40-58	ketoprofen	147-156	false
magnesium hydroxide	40-58	Orudis	174-179	false
aluminum hydroxide	64-81	ketoprofen	147-156	false
aluminum hydroxide	64-81	Orudis	174-179	false
ketoprofen	147-156	Orudis	174-179	false

Aspirin: Ketoprofen does not alter aspirin absorption;
Aspirin	0-6	Ketoprofen	9-18	false
Aspirin	0-6	aspirin	35-41	false
Ketoprofen	9-18	aspirin	35-41	false

however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
aspirin	72-78	ketoprofen	90-99	mechanism
aspirin	72-78	ketoprofen	131-140	mechanism
aspirin	72-78	aspirin	184-190	false
aspirin	72-78	aspirin	212-218	false
ketoprofen	90-99	ketoprofen	131-140	false
ketoprofen	90-99	aspirin	184-190	false
ketoprofen	90-99	aspirin	212-218	false
ketoprofen	131-140	aspirin	184-190	false
ketoprofen	131-140	aspirin	212-218	false
aspirin	184-190	aspirin	212-218	false

Therefore, concurrent use of aspirin and ketoprofen is not recommended.
aspirin	29-35	ketoprofen	41-50	advise

Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
Diuretic	0-7	Hydrochlorothiazide	10-28	false
Diuretic	0-7	ketoprofen	56-65	false
Diuretic	0-7	hydrochlorothiazide	145-163	false
Hydrochlorothiazide	10-28	ketoprofen	56-65	effect
Hydrochlorothiazide	10-28	hydrochlorothiazide	145-163	false
ketoprofen	56-65	hydrochlorothiazide	145-163	false

Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.
Digoxin	0-6	ketoprofen	71-80	false
Digoxin	0-6	digoxin	86-92	false
Digoxin	0-6	ketoprofen	127-136	false
Digoxin	0-6	digoxin	172-178	false
ketoprofen	71-80	digoxin	86-92	false
ketoprofen	71-80	ketoprofen	127-136	false
ketoprofen	71-80	digoxin	172-178	false
digoxin	86-92	ketoprofen	127-136	false
digoxin	86-92	digoxin	172-178	false
ketoprofen	127-136	digoxin	172-178	false

Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.
Warfarin	0-7	ketoprofen	68-77	false
Warfarin	0-7	warfarin	130-137	false
ketoprofen	68-77	warfarin	130-137	false

Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.
warfarin	57-64	ketoprofen	110-119	false

Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.
ketoprofen	64-73	ketoprofen	142-151	false
ketoprofen	64-73	warfarin	157-164	false
ketoprofen	142-151	warfarin	157-164	advise

Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
Probenecid	0-9	Probenecid	12-21	false
Probenecid	0-9	ketoprofen	53-62	false
Probenecid	0-9	ketoprofen	100-109	false
Probenecid	12-21	ketoprofen	53-62	mechanism
Probenecid	12-21	ketoprofen	100-109	false
ketoprofen	53-62	ketoprofen	100-109	false

Therefore, the combination of ketoprofen and probenecid is not recommended.
ketoprofen	30-39	probenecid	45-54	advise

Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
Methotrexate	0-11	Ketoprofen	14-23	false
Methotrexate	0-11	NSAIDs	37-42	false
Methotrexate	0-11	methotrexate	85-96	false
Ketoprofen	14-23	NSAIDs	37-42	false
Ketoprofen	14-23	methotrexate	85-96	mechanism
NSAIDs	37-42	methotrexate	85-96	mechanism

Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.
Lithium	0-6	Nonsteroidal anti-inflammatory agents	9-45	false
Lithium	0-6	lithium	97-103	false
Nonsteroidal anti-inflammatory agents	9-45	lithium	97-103	mechanism

It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.
lithium	30-36	ketoprofen	63-72	false
lithium	30-36	lithium	97-103	false
ketoprofen	63-72	lithium	97-103	advise

Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
Warfarin	0-7	Digoxin	10-16	false
Warfarin	0-7	Salicylate	19-28	false
Warfarin	0-7	Heparin	35-41	false
Warfarin	0-7	warfarin	67-74	false
Warfarin	0-7	ketorolac tromethamine	123-144	false
Warfarin	0-7	ketorolac	176-184	false
Digoxin	10-16	Salicylate	19-28	false
Digoxin	10-16	Heparin	35-41	false
Digoxin	10-16	warfarin	67-74	false
Digoxin	10-16	ketorolac tromethamine	123-144	false
Digoxin	10-16	ketorolac	176-184	false
Salicylate	19-28	Heparin	35-41	false
Salicylate	19-28	warfarin	67-74	false
Salicylate	19-28	ketorolac tromethamine	123-144	false
Salicylate	19-28	ketorolac	176-184	false
Heparin	35-41	warfarin	67-74	false
Heparin	35-41	ketorolac tromethamine	123-144	false
Heparin	35-41	ketorolac	176-184	false
warfarin	67-74	ketorolac tromethamine	123-144	mechanism
warfarin	67-74	ketorolac	176-184	false
ketorolac tromethamine	123-144	ketorolac	176-184	false

Ketorolac does not alter digoxin protein binding.
Ketorolac	0-8	digoxin	25-31	false

In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.
salicylate	65-74	ketorolac	105-113	mechanism
salicylate	65-74	ketorolac	215-223	false
ketorolac	105-113	ketorolac	215-223	false

Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
digoxin	30-36	warfarin	39-46	false
digoxin	30-36	ibuprofen	49-57	false
digoxin	30-36	naproxen	60-67	false
digoxin	30-36	piroxicam	70-78	false
digoxin	30-36	acetaminophen	81-93	false
digoxin	30-36	phenytoin	96-104	false
digoxin	30-36	ketorolac tromethamine	135-156	false
warfarin	39-46	ibuprofen	49-57	false
warfarin	39-46	naproxen	60-67	false
warfarin	39-46	piroxicam	70-78	false
warfarin	39-46	acetaminophen	81-93	false
warfarin	39-46	phenytoin	96-104	false
warfarin	39-46	ketorolac tromethamine	135-156	false
ibuprofen	49-57	naproxen	60-67	false
ibuprofen	49-57	piroxicam	70-78	false
ibuprofen	49-57	acetaminophen	81-93	false
ibuprofen	49-57	phenytoin	96-104	false
ibuprofen	49-57	ketorolac tromethamine	135-156	false
naproxen	60-67	piroxicam	70-78	false
naproxen	60-67	acetaminophen	81-93	false
naproxen	60-67	phenytoin	96-104	false
naproxen	60-67	ketorolac tromethamine	135-156	false
piroxicam	70-78	acetaminophen	81-93	false
piroxicam	70-78	phenytoin	96-104	false
piroxicam	70-78	ketorolac tromethamine	135-156	false
acetaminophen	81-93	phenytoin	96-104	false
acetaminophen	81-93	ketorolac tromethamine	135-156	false
phenytoin	96-104	ketorolac tromethamine	135-156	false

In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin.
warfarin	101-108	warfarin	185-192	false

In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.
heparin	69-75	heparin	234-240	false

Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
TORADOL	73-79	warfarin	85-92	false
TORADOL	73-79	heparin	97-103	false
TORADOL	73-79	TORADOL	128-134	false
TORADOL	73-79	anticoagulants	155-168	false
warfarin	85-92	heparin	97-103	false
warfarin	85-92	TORADOL	128-134	false
warfarin	85-92	anticoagulants	155-168	false
heparin	97-103	TORADOL	128-134	false
heparin	97-103	anticoagulants	155-168	false
TORADOL	128-134	anticoagulants	155-168	advise

Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
Furosemide	0-9	TORADOL	12-18	false
Furosemide	0-9	diuretic	38-45	false
Furosemide	0-9	furosemide	59-68	false
TORADOL	12-18	diuretic	38-45	false
TORADOL	12-18	furosemide	59-68	effect
diuretic	38-45	furosemide	59-68	false

Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
Probenecid	0-9	TORADOL	42-48	false
Probenecid	0-9	probenecid	59-68	false
Probenecid	0-9	ketorolac	105-113	false
Probenecid	0-9	ketorolac	144-152	false
TORADOL	42-48	probenecid	59-68	mechanism
TORADOL	42-48	ketorolac	105-113	false
TORADOL	42-48	ketorolac	144-152	false
probenecid	59-68	ketorolac	105-113	false
probenecid	59-68	ketorolac	144-152	false
ketorolac	105-113	ketorolac	144-152	false

Therefore, concomitant use of TORADOL and probenecid is contraindicated.
TORADOL	30-36	probenecid	42-51	advise

Lithium: Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.
Lithium	0-6	lithium	29-35	false
Lithium	0-6	lithium	81-87	false
lithium	29-35	lithium	81-87	false

The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
TORADOL	14-20	lithium	32-38	false
TORADOL	14-20	lithium	85-91	false
TORADOL	14-20	TORADOL	114-120	false
lithium	32-38	lithium	85-91	false
lithium	32-38	TORADOL	114-120	false
lithium	85-91	TORADOL	114-120	mechanism

Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
Methotrexate	0-11	methotrexate	44-55	false
Methotrexate	0-11	NSAIDs	66-71	false
Methotrexate	0-11	methotrexate	118-129	false
Methotrexate	0-11	methotrexate	158-169	false
methotrexate	44-55	NSAIDs	66-71	mechanism
methotrexate	44-55	methotrexate	118-129	false
methotrexate	44-55	methotrexate	158-169	false
NSAIDs	66-71	methotrexate	118-129	false
NSAIDs	66-71	methotrexate	158-169	false
methotrexate	118-129	methotrexate	158-169	false

The effect of TORADOL on methotrexate clearance has not been studied.
TORADOL	14-20	methotrexate	25-36	false

Nondepolarizing Muscle Relaxants: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.
Nondepolarizing Muscle Relaxants	0-31	nondepolarizing muscle relaxants	137-168	false

The concurrent use of TORADOL with muscle relaxants has not been formally studied.
TORADOL	22-28	muscle relaxants	35-50	false

ACE Inhibitors: Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.
ACE Inhibitors	0-13	ACE inhibitors	35-48	false

Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
Antiepileptic Drugs	0-18	TORADOL	93-99	false
Antiepileptic Drugs	0-18	antiepileptic drugs	105-123	false
Antiepileptic Drugs	0-18	phenytoin	126-134	false
Antiepileptic Drugs	0-18	carbamazepine	137-149	false
TORADOL	93-99	antiepileptic drugs	105-123	effect
TORADOL	93-99	phenytoin	126-134	effect
TORADOL	93-99	carbamazepine	137-149	effect
antiepileptic drugs	105-123	phenytoin	126-134	false
antiepileptic drugs	105-123	carbamazepine	137-149	false
phenytoin	126-134	carbamazepine	137-149	false

Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
Psychoactive Drugs	0-17	TORADOL	59-65	false
Psychoactive Drugs	0-17	psychoactive drugs	95-112	false
Psychoactive Drugs	0-17	fluoxetine	115-124	false
Psychoactive Drugs	0-17	thiothixene	127-137	false
Psychoactive Drugs	0-17	alprazolam	140-149	false
TORADOL	59-65	psychoactive drugs	95-112	effect
TORADOL	59-65	fluoxetine	115-124	effect
TORADOL	59-65	thiothixene	127-137	effect
TORADOL	59-65	alprazolam	140-149	effect
psychoactive drugs	95-112	fluoxetine	115-124	false
psychoactive drugs	95-112	thiothixene	127-137	false
psychoactive drugs	95-112	alprazolam	140-149	false
fluoxetine	115-124	thiothixene	127-137	false
fluoxetine	115-124	alprazolam	140-149	false
thiothixene	127-137	alprazolam	140-149	false

Morphine: TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.
Morphine	0-7	morphine	63-70	false

Do not mix TORADOL and morphine in the same syringe.
TORADOL	11-17	morphine	23-30	false

Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.
Cyclosporine	0-11	L-arginine	15-24	false
Cyclosporine	0-11	cyclosporin	69-79	false
L-arginine	15-24	cyclosporin	69-79	effect

Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.
Ibuprofen	0-8	L-arginine	12-21	false
Ibuprofen	0-8	ibuprofen	54-62	false
L-arginine	12-21	ibuprofen	54-62	mechanism

Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.
nitrates	8-15	L-arginine	19-28	false
nitrates	8-15	nitrates	94-101	false
L-arginine	19-28	nitrates	94-101	effect

Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.
Sildenafil citrate	0-17	L-arginine	36-45	false
Sildenafil citrate	0-17	sildenafil citrate	84-101	false
L-arginine	36-45	sildenafil citrate	84-101	effect

Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
Human growth hormone	0-19	L-glutamine	42-52	false
Human growth hormone	0-19	human growth hormone	58-77	false
L-glutamine	42-52	human growth hormone	58-77	mechanism

Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
Indomethacin	0-11	L-glutamine	34-44	false
Indomethacin	0-11	indomethacin	50-61	false
Indomethacin	0-11	indomethacin	122-133	false
L-glutamine	34-44	indomethacin	50-61	effect
L-glutamine	34-44	indomethacin	122-133	false
indomethacin	50-61	indomethacin	122-133	false

Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.
Methotrexate	0-11	methotrexate	40-51	false
Methotrexate	0-11	L-glutamine	109-119	false
methotrexate	40-51	L-glutamine	109-119	effect

In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.
methotrexate	96-107	L-glutamine	150-160	effect

Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
Paclitaxel	0-9	L-glutamine	28-38	false
Paclitaxel	0-9	paclitaxel	112-121	false
Paclitaxel	0-9	paclitaxel	208-217	false
L-glutamine	28-38	paclitaxel	112-121	effect
L-glutamine	28-38	paclitaxel	208-217	false
paclitaxel	112-121	paclitaxel	208-217	false

Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
Medroxyprogesterone Acetate	0-26	L-histidine	30-40	false
Medroxyprogesterone Acetate	0-26	medroxyprogesterone acetate	100-126	false
L-histidine	30-40	medroxyprogesterone acetate	100-126	effect

H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
H1 Blockers	0-1;10-17	H2 Blockers	7-17	false
H1 Blockers	0-1;10-17	L-histidine	44-54	false
H1 Blockers	0-1;10-17	H1 blockers	121-122;131-138	false
H1 Blockers	0-1;10-17	H2 blockers	128-138	false
H2 Blockers	7-17	L-histidine	44-54	false
H2 Blockers	7-17	H1 blockers	121-122;131-138	false
H2 Blockers	7-17	H2 blockers	128-138	false
L-histidine	44-54	H1 blockers	121-122;131-138	effect
L-histidine	44-54	H2 blockers	128-138	effect
H1 blockers	121-122;131-138	H2 blockers	128-138	false

Concomitant use of calcium supplements and L-lysine may increase calcium absorption
calcium	19-25	L-lysine	43-50	mechanism
calcium	19-25	calcium	65-71	false
L-lysine	43-50	calcium	65-71	false

Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
Acetaminophen	0-12	methotrexate	18-29	false
Acetaminophen	0-12	L-methionine	33-44	false
Acetaminophen	0-12	acetaminophen	90-102	false
Acetaminophen	0-12	methotrexate	134-145	false
methotrexate	18-29	L-methionine	33-44	false
methotrexate	18-29	acetaminophen	90-102	false
methotrexate	18-29	methotrexate	134-145	false
L-methionine	33-44	acetaminophen	90-102	effect
L-methionine	33-44	methotrexate	134-145	effect
acetaminophen	90-102	methotrexate	134-145	false

Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
Gentamicin	0-9	Methionine	13-22	false
Gentamicin	0-9	gentamicin	68-77	false
Methionine	13-22	gentamicin	68-77	effect

Non-selective monoamine oxidase (MAO) inhibitors - including phenelzine sulfate, tranylcypromine sulfate and pargyline HC1.
Non-selective monoamine oxidase (MAO) inhibitors	0-47	phenelzine sulfate	61-78	false
Non-selective monoamine oxidase (MAO) inhibitors	0-47	tranylcypromine sulfate	81-103	false
Non-selective monoamine oxidase (MAO) inhibitors	0-47	pargyline	109-117	false
phenelzine sulfate	61-78	tranylcypromine sulfate	81-103	false
phenelzine sulfate	61-78	pargyline	109-117	false
tranylcypromine sulfate	81-103	pargyline	109-117	false

Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.
L-phenylalanine	19-33	non-selective MAO inhibitors	39-66	effect

Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
Selegiline	0-9	L-phenylalanine	13-27	false
Selegiline	0-9	selective MAO inhibitor	37-59	false
Selegiline	0-9	selegiline	61-70	false
L-phenylalanine	13-27	selective MAO inhibitor	37-59	false
L-phenylalanine	13-27	selegiline	61-70	effect
selective MAO inhibitor	37-59	selegiline	61-70	false

Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
Neuroleptic Drugs	0-16	L-phenylalanine	20-34	effect
Neuroleptic Drugs	0-16	neuroleptic drugs	92-108	false
L-phenylalanine	20-34	neuroleptic drugs	92-108	false

Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
Monoamine oxidase (MAO) inhibitors	0-33	isocarboxazid	43-55	false
Monoamine oxidase (MAO) inhibitors	0-33	Marplan	64-70	false
Monoamine oxidase (MAO) inhibitors	0-33	phenelzine	74-83	false
Monoamine oxidase (MAO) inhibitors	0-33	Nardil	92-97	false
Monoamine oxidase (MAO) inhibitors	0-33	procarbazine	101-112	false
Monoamine oxidase (MAO) inhibitors	0-33	Matulane	121-128	false
Monoamine oxidase (MAO) inhibitors	0-33	selegiline	132-141	false
Monoamine oxidase (MAO) inhibitors	0-33	Eldepryl	150-157	false
Monoamine oxidase (MAO) inhibitors	0-33	tranylcypromine	165-179	false
Monoamine oxidase (MAO) inhibitors	0-33	Parnate	188-194	false
Monoamine oxidase (MAO) inhibitors	0-33	L-tryptophan	225-236	false
isocarboxazid	43-55	Marplan	64-70	false
isocarboxazid	43-55	phenelzine	74-83	false
isocarboxazid	43-55	Nardil	92-97	false
isocarboxazid	43-55	procarbazine	101-112	false
isocarboxazid	43-55	Matulane	121-128	false
isocarboxazid	43-55	selegiline	132-141	false
isocarboxazid	43-55	Eldepryl	150-157	false
isocarboxazid	43-55	tranylcypromine	165-179	false
isocarboxazid	43-55	Parnate	188-194	false
isocarboxazid	43-55	L-tryptophan	225-236	false
Marplan	64-70	phenelzine	74-83	false
Marplan	64-70	Nardil	92-97	false
Marplan	64-70	procarbazine	101-112	false
Marplan	64-70	Matulane	121-128	false
Marplan	64-70	selegiline	132-141	false
Marplan	64-70	Eldepryl	150-157	false
Marplan	64-70	tranylcypromine	165-179	false
Marplan	64-70	Parnate	188-194	false
Marplan	64-70	L-tryptophan	225-236	false
phenelzine	74-83	Nardil	92-97	false
phenelzine	74-83	procarbazine	101-112	false
phenelzine	74-83	Matulane	121-128	false
phenelzine	74-83	selegiline	132-141	false
phenelzine	74-83	Eldepryl	150-157	false
phenelzine	74-83	tranylcypromine	165-179	false
phenelzine	74-83	Parnate	188-194	false
phenelzine	74-83	L-tryptophan	225-236	false
Nardil	92-97	procarbazine	101-112	false
Nardil	92-97	Matulane	121-128	false
Nardil	92-97	selegiline	132-141	false
Nardil	92-97	Eldepryl	150-157	false
Nardil	92-97	tranylcypromine	165-179	false
Nardil	92-97	Parnate	188-194	false
Nardil	92-97	L-tryptophan	225-236	false
procarbazine	101-112	Matulane	121-128	false
procarbazine	101-112	selegiline	132-141	false
procarbazine	101-112	Eldepryl	150-157	false
procarbazine	101-112	tranylcypromine	165-179	false
procarbazine	101-112	Parnate	188-194	false
procarbazine	101-112	L-tryptophan	225-236	false
Matulane	121-128	selegiline	132-141	false
Matulane	121-128	Eldepryl	150-157	false
Matulane	121-128	tranylcypromine	165-179	false
Matulane	121-128	Parnate	188-194	false
Matulane	121-128	L-tryptophan	225-236	false
selegiline	132-141	Eldepryl	150-157	false
selegiline	132-141	tranylcypromine	165-179	false
selegiline	132-141	Parnate	188-194	false
selegiline	132-141	L-tryptophan	225-236	false
Eldepryl	150-157	tranylcypromine	165-179	false
Eldepryl	150-157	Parnate	188-194	false
Eldepryl	150-157	L-tryptophan	225-236	false
tranylcypromine	165-179	Parnate	188-194	false
tranylcypromine	165-179	L-tryptophan	225-236	false
Parnate	188-194	L-tryptophan	225-236	false

Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
Non-selective MAO inhibitors	0-27	tranylcypromine sulfate	39-61	false
Non-selective MAO inhibitors	0-27	phenelzine sulfate	64-81	false
Non-selective MAO inhibitors	0-27	pargyline	88-96	false
Non-selective MAO inhibitors	0-27	L-tyrosine	122-131	false
Non-selective MAO inhibitors	0-27	MAO inhibitors	151-164	false
tranylcypromine sulfate	39-61	phenelzine sulfate	64-81	false
tranylcypromine sulfate	39-61	pargyline	88-96	false
tranylcypromine sulfate	39-61	L-tyrosine	122-131	false
tranylcypromine sulfate	39-61	MAO inhibitors	151-164	false
phenelzine sulfate	64-81	pargyline	88-96	false
phenelzine sulfate	64-81	L-tyrosine	122-131	false
phenelzine sulfate	64-81	MAO inhibitors	151-164	false
pargyline	88-96	L-tyrosine	122-131	false
pargyline	88-96	MAO inhibitors	151-164	false
L-tyrosine	122-131	MAO inhibitors	151-164	effect

In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.
labetalol HCl	39-51	tricyclic antidepressants	73-97	effect
labetalol HCl	39-51	labetalol HCl	162-174	false
tricyclic antidepressants	73-97	labetalol HCl	162-174	false

Cimetidine has been shown to increase the bioavailability of labetalol HCl.
Cimetidine	0-9	labetalol HCl	61-73	mechanism

Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.
halothane	33-41	labetalol HCl	85-97	effect

During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
labetalol HCl	47-59	halothane	81-89	effect
labetalol HCl	47-59	halothane	129-137	false
halothane	81-89	halothane	129-137	false

Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.
Labetalol HCl	0-12	nitroglycerin	56-68	effect

If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.
labetalol HCl	3-15	nitroglycerin	30-42	effect

Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
labetalol	24-32	calcium antagonist	61-78	advise
labetalol	24-32	verapamil	88-96	false
calcium antagonist	61-78	verapamil	88-96	false

Labetalol HCl has also been reported to produce a false positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A  (thin-layer chromatographic assay) and Emit-d.a.u.  (radioenzymatic assay).
Labetalol HCl	0-12	amphetamine	74-84	false

When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.
labetalol	33-41	amphetamine	74-84	false

Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.
antacids	77-84	lactulose	110-118	mechanism
antacids	77-84	lactulose	144-152	false
lactulose	110-118	lactulose	144-152	false

There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.
lamivudine	48-57	TMP	95-97	false
lamivudine	48-57	SMX	99-101	false
TMP	95-97	SMX	99-101	false

Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
Lamivudine	0-9	zalcitabine	15-25	effect

Therefore, use of lamivudine in combination with zalcitabine is not recommended
lamivudine	18-27	zalcitabine	49-59	advise

Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
lansoprazole	24-35	warfarin	155-162	false
lansoprazole	24-35	antipyrine	165-174	false
lansoprazole	24-35	indomethacin	177-188	false
lansoprazole	24-35	ibuprofen	191-199	false
lansoprazole	24-35	phenytoin	202-210	false
lansoprazole	24-35	propranolol	213-223	false
lansoprazole	24-35	prednisone	226-235	false
lansoprazole	24-35	diazepam	238-245	false
lansoprazole	24-35	clarithromycin	248-261	false
lansoprazole	24-35	terfenadine	267-277	false
warfarin	155-162	antipyrine	165-174	false
warfarin	155-162	indomethacin	177-188	false
warfarin	155-162	ibuprofen	191-199	false
warfarin	155-162	phenytoin	202-210	false
warfarin	155-162	propranolol	213-223	false
warfarin	155-162	prednisone	226-235	false
warfarin	155-162	diazepam	238-245	false
warfarin	155-162	clarithromycin	248-261	false
warfarin	155-162	terfenadine	267-277	false
antipyrine	165-174	indomethacin	177-188	false
antipyrine	165-174	ibuprofen	191-199	false
antipyrine	165-174	phenytoin	202-210	false
antipyrine	165-174	propranolol	213-223	false
antipyrine	165-174	prednisone	226-235	false
antipyrine	165-174	diazepam	238-245	false
antipyrine	165-174	clarithromycin	248-261	false
antipyrine	165-174	terfenadine	267-277	false
indomethacin	177-188	ibuprofen	191-199	false
indomethacin	177-188	phenytoin	202-210	false
indomethacin	177-188	propranolol	213-223	false
indomethacin	177-188	prednisone	226-235	false
indomethacin	177-188	diazepam	238-245	false
indomethacin	177-188	clarithromycin	248-261	false
indomethacin	177-188	terfenadine	267-277	false
ibuprofen	191-199	phenytoin	202-210	false
ibuprofen	191-199	propranolol	213-223	false
ibuprofen	191-199	prednisone	226-235	false
ibuprofen	191-199	diazepam	238-245	false
ibuprofen	191-199	clarithromycin	248-261	false
ibuprofen	191-199	terfenadine	267-277	false
phenytoin	202-210	propranolol	213-223	false
phenytoin	202-210	prednisone	226-235	false
phenytoin	202-210	diazepam	238-245	false
phenytoin	202-210	clarithromycin	248-261	false
phenytoin	202-210	terfenadine	267-277	false
propranolol	213-223	prednisone	226-235	false
propranolol	213-223	diazepam	238-245	false
propranolol	213-223	clarithromycin	248-261	false
propranolol	213-223	terfenadine	267-277	false
prednisone	226-235	diazepam	238-245	false
prednisone	226-235	clarithromycin	248-261	false
prednisone	226-235	terfenadine	267-277	false
diazepam	238-245	clarithromycin	248-261	false
diazepam	238-245	terfenadine	267-277	false
clarithromycin	248-261	terfenadine	267-277	false

When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
lansoprazole	5-16	theophylline	54-65	mechanism
lansoprazole	5-16	theophylline	127-138	false
theophylline	54-65	theophylline	127-138	false

Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
theophylline	75-86	lansoprazole	100-111	advise

Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.
Lansoprazole	0-11	amoxicillin	84-94	false

In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
lansoprazole	43-54	omeprazole	66-75	false
lansoprazole	43-54	sucralfate	130-139	false
lansoprazole	43-54	proton pump inhibitors	167-188	false
lansoprazole	43-54	sucralfate	307-316	false
omeprazole	66-75	sucralfate	130-139	false
omeprazole	66-75	proton pump inhibitors	167-188	false
omeprazole	66-75	sucralfate	307-316	false
sucralfate	130-139	proton pump inhibitors	167-188	false
sucralfate	130-139	sucralfate	307-316	false
proton pump inhibitors	167-188	sucralfate	307-316	mechanism

Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
proton pump inhibitors	11-32	sucralfate	79-88	advise

In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules;
antacids	20-27	lansoprazole	66-77	false

therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
lansoprazole	45-56	ketoconazole	171-182	mechanism
lansoprazole	45-56	ampicillin	185-194	mechanism
lansoprazole	45-56	iron	204-207	mechanism
lansoprazole	45-56	digoxin	216-222	mechanism
ketoconazole	171-182	ampicillin	185-194	false
ketoconazole	171-182	iron	204-207	false
ketoconazole	171-182	digoxin	216-222	false
ampicillin	185-194	iron	204-207	false
ampicillin	185-194	digoxin	216-222	false
iron	204-207	digoxin	216-222	false

Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.
Lapatinib	11-19	Lapatinib	77-85	false

Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.
Lapatinib	57-65	lapatinib	189-197	false

Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
Ketoconazole	0-11	ketoconazole	44-55	false
Ketoconazole	0-11	lapatinib	139-147	false
ketoconazole	44-55	lapatinib	139-147	mechanism

Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
Carbamazepine	0-12	carbamazepine	65-77	false
Carbamazepine	0-12	lapatinib	176-184	false
carbamazepine	65-77	lapatinib	176-184	mechanism

If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.
TYKERB	3-8	lapatinib	83-91	false

Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).
lapatinib	77-85	capecitabine	92-103	false
lapatinib	77-85	capecitabine	192-203	false
capecitabine	92-103	capecitabine	192-203	false

In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.
thimerosal	80-89	latanoprost	106-116	false

Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
Cholestyramine	0-13	Charcoal	19-26	false
Cholestyramine	0-13	cholestyramine	46-59	false
Cholestyramine	0-13	activated charcoal	64-81	false
Cholestyramine	0-13	leflunomide	208-218	false
Charcoal	19-26	cholestyramine	46-59	false
Charcoal	19-26	activated charcoal	64-81	false
Charcoal	19-26	leflunomide	208-218	false
cholestyramine	46-59	activated charcoal	64-81	false
cholestyramine	46-59	leflunomide	208-218	mechanism
activated charcoal	64-81	leflunomide	208-218	mechanism

In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
ARAVA	39-43	methotrexate	50-61	effect

NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.
NSAIDs	0-5	diclofenac	107-116	false
NSAIDs	0-5	ibuprofen	122-130	false
diclofenac	107-116	ibuprofen	122-130	false

Tolbutamide: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.
Tolbutamide	0-10	tolbutamide	112-122	false

Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
Rifampin	0-7	ARAVA	67-71	false
Rifampin	0-7	rifampin	113-120	false
Rifampin	0-7	ARAVA	181-185	false
ARAVA	67-71	rifampin	113-120	mechanism
ARAVA	67-71	ARAVA	181-185	false
rifampin	113-120	ARAVA	181-185	false

Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.
ARAVA	29-33	ARAVA	148-152	false
ARAVA	29-33	rifampin	158-165	false
ARAVA	148-152	rifampin	158-165	advise

Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.
Warfarin	0-7	ARAVA	62-66	false
Warfarin	0-7	warfarin	72-79	false
ARAVA	62-66	warfarin	72-79	effect

Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.
REVLIMID	81-88	lenalidomide	92-103	false
REVLIMID	81-88	lenalidomide	200-211	false
lenalidomide	92-103	lenalidomide	200-211	false

Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
lenalidomide	48-59	R- warfarin	114-115;124-131	false
lenalidomide	48-59	S- warfarin	121-131	false
R- warfarin	114-115;124-131	S- warfarin	121-131	false

Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide.
warfarin	39-46	lenalidomide	95-106	false

Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.
warfarin	77-84	lenalidomide	153-164	false

Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
thrombolytics	27-39	streptokinase	55-67	false
thrombolytics	27-39	REFLUDAN	158-165	false
streptokinase	55-67	REFLUDAN	158-165	false

Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.
coumarin derivatives	27-46	vitamin K antagonists	49-69	false

Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.
cimetidine	34-43	warfarin	49-56	false
cimetidine	34-43	Femara	97-102	false
warfarin	49-56	Femara	97-102	false

(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.
Femara	48-53	tamoxifen	59-67	mechanism
Femara	48-53	letrozole	108-116	false
tamoxifen	59-67	letrozole	108-116	false

Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
Folic acid	0-9	phenobarbital	71-83	effect
Folic acid	0-9	phenytoin	86-94	effect
Folic acid	0-9	primidone	100-108	effect
phenobarbital	71-83	phenytoin	86-94	false
phenobarbital	71-83	primidone	100-108	false
phenytoin	86-94	primidone	100-108	false

Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.
leucovorin	99-108	methotrexate	234-245	false

However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
leucovorin	23-32	methotrexate	88-99	effect

Leucovorin may enhance the toxicity of 5-fluorouracil.
Leucovorin	0-9	5-fluorouracil	39-52	effect

ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
ERGAMISOL	0-8	levamisole hydrochloride	12-35	false
ERGAMISOL	0-8	alcohol	124-130	effect
levamisole hydrochloride	12-35	alcohol	124-130	effect

Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
levamisole	118-127	warfarin sodium	133-147	advise
levamisole	118-127	warfarin sodium	232-246	false
levamisole	118-127	coumarin	257-264	false
warfarin sodium	133-147	warfarin sodium	232-246	false
warfarin sodium	133-147	coumarin	257-264	false
warfarin sodium	232-246	coumarin	257-264	false

In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.
levetiracetam	13-25	valproic acid	75-87	false

Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
phenytoin	90-98	valproate	101-109	false
phenytoin	90-98	contraceptive	117-129	false
phenytoin	90-98	digoxin	132-138	false
phenytoin	90-98	warfarin	141-148	false
phenytoin	90-98	probenecid	151-160	false
valproate	101-109	contraceptive	117-129	false
valproate	101-109	digoxin	132-138	false
valproate	101-109	warfarin	141-148	false
valproate	101-109	probenecid	151-160	false
contraceptive	117-129	digoxin	132-138	false
contraceptive	117-129	warfarin	141-148	false
contraceptive	117-129	probenecid	151-160	false
digoxin	132-138	warfarin	141-148	false
digoxin	132-138	probenecid	151-160	false
warfarin	141-148	probenecid	151-160	false

Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
Keppra	31-36	Antiepileptic Drugs	49-67	false
Keppra	31-36	AEDs	70-73	false
Keppra	31-36	Phenytoin	76-84	false
Keppra	31-36	Keppra	86-91	false
Keppra	31-36	phenytoin	162-170	false
Antiepileptic Drugs	49-67	AEDs	70-73	false
Antiepileptic Drugs	49-67	Phenytoin	76-84	false
Antiepileptic Drugs	49-67	Keppra	86-91	false
Antiepileptic Drugs	49-67	phenytoin	162-170	false
AEDs	70-73	Phenytoin	76-84	false
AEDs	70-73	Keppra	86-91	false
AEDs	70-73	phenytoin	162-170	false
Phenytoin	76-84	Keppra	86-91	false
Phenytoin	76-84	phenytoin	162-170	false
Keppra	86-91	phenytoin	162-170	false

Pharmacokinetics of levetiracetam were also not affected by phenytoin.
levetiracetam	20-32	phenytoin	60-68	false

Valproate Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.
Valproate	0-8	Keppra	10-15	false
Valproate	0-8	valproate	78-86	false
Keppra	10-15	valproate	78-86	false

Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.
Valproate	0-8	levetiracetam	66-78	false

Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
Keppra	36-41	AEDs	54-57	false
Keppra	36-41	carbamazepine	60-72	false
Keppra	36-41	gabapentin	75-84	false
Keppra	36-41	lamotrigine	87-97	false
Keppra	36-41	phenobarbital	100-112	false
Keppra	36-41	phenytoin	115-123	false
Keppra	36-41	primidone	126-134	false
Keppra	36-41	valproate	140-148	false
Keppra	36-41	levetiracetam	212-224	false
Keppra	36-41	AEDs	236-239	false
AEDs	54-57	carbamazepine	60-72	false
AEDs	54-57	gabapentin	75-84	false
AEDs	54-57	lamotrigine	87-97	false
AEDs	54-57	phenobarbital	100-112	false
AEDs	54-57	phenytoin	115-123	false
AEDs	54-57	primidone	126-134	false
AEDs	54-57	valproate	140-148	false
AEDs	54-57	levetiracetam	212-224	false
AEDs	54-57	AEDs	236-239	false
carbamazepine	60-72	gabapentin	75-84	false
carbamazepine	60-72	lamotrigine	87-97	false
carbamazepine	60-72	phenobarbital	100-112	false
carbamazepine	60-72	phenytoin	115-123	false
carbamazepine	60-72	primidone	126-134	false
carbamazepine	60-72	valproate	140-148	false
carbamazepine	60-72	levetiracetam	212-224	false
carbamazepine	60-72	AEDs	236-239	false
gabapentin	75-84	lamotrigine	87-97	false
gabapentin	75-84	phenobarbital	100-112	false
gabapentin	75-84	phenytoin	115-123	false
gabapentin	75-84	primidone	126-134	false
gabapentin	75-84	valproate	140-148	false
gabapentin	75-84	levetiracetam	212-224	false
gabapentin	75-84	AEDs	236-239	false
lamotrigine	87-97	phenobarbital	100-112	false
lamotrigine	87-97	phenytoin	115-123	false
lamotrigine	87-97	primidone	126-134	false
lamotrigine	87-97	valproate	140-148	false
lamotrigine	87-97	levetiracetam	212-224	false
lamotrigine	87-97	AEDs	236-239	false
phenobarbital	100-112	phenytoin	115-123	false
phenobarbital	100-112	primidone	126-134	false
phenobarbital	100-112	valproate	140-148	false
phenobarbital	100-112	levetiracetam	212-224	false
phenobarbital	100-112	AEDs	236-239	false
phenytoin	115-123	primidone	126-134	false
phenytoin	115-123	valproate	140-148	false
phenytoin	115-123	levetiracetam	212-224	false
phenytoin	115-123	AEDs	236-239	false
primidone	126-134	valproate	140-148	false
primidone	126-134	levetiracetam	212-224	false
primidone	126-134	AEDs	236-239	false
valproate	140-148	levetiracetam	212-224	false
valproate	140-148	AEDs	236-239	false
levetiracetam	212-224	AEDs	236-239	false

These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.
levetiracetam	25-37	AEDs	92-95	false
levetiracetam	25-37	AEDs	112-115	false
levetiracetam	25-37	levetiracetam	158-170	false
AEDs	92-95	AEDs	112-115	false
AEDs	92-95	levetiracetam	158-170	false
AEDs	112-115	levetiracetam	158-170	false

Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
AEDs	10-13	levetiracetam	104-116	false
AEDs	10-13	AEDs	167-170	false
levetiracetam	104-116	AEDs	167-170	mechanism

Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
Levetiracetam	35-47	carbamazepine	91-103	false
Levetiracetam	35-47	valproate	106-114	false
Levetiracetam	35-47	topiramate	117-126	false
Levetiracetam	35-47	lamotrigine	132-142	false
carbamazepine	91-103	valproate	106-114	false
carbamazepine	91-103	topiramate	117-126	false
carbamazepine	91-103	lamotrigine	132-142	false
valproate	106-114	topiramate	117-126	false
valproate	106-114	lamotrigine	132-142	false
topiramate	117-126	lamotrigine	132-142	false

Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
Contraceptives	29-42	Keppra	44-49	false
Contraceptives	29-42	contraceptive	123-135	false
Contraceptives	29-42	ethinyl estradiol	156-172	false
Contraceptives	29-42	levonorgestrel	186-199	false
Keppra	44-49	contraceptive	123-135	false
Keppra	44-49	ethinyl estradiol	156-172	false
Keppra	44-49	levonorgestrel	186-199	false
contraceptive	123-135	ethinyl estradiol	156-172	false
contraceptive	123-135	levonorgestrel	186-199	false
ethinyl estradiol	156-172	levonorgestrel	186-199	false

Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.
contraceptive	30-42	levetiracetam	86-98	false

Digoxin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.
Digoxin	0-6	Keppra	8-13	false
Digoxin	0-6	digoxin	107-113	false
Keppra	8-13	digoxin	107-113	false

Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.
digoxin	20-26	levetiracetam	70-82	false

Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.
Warfarin	0-7	Keppra	9-14	false
Warfarin	0-7	R warfarin	81-81;89-96	false
Warfarin	0-7	S warfarin	87-96	false
Keppra	9-14	R warfarin	81-81;89-96	false
Keppra	9-14	S warfarin	87-96	false
R warfarin	81-81;89-96	S warfarin	87-96	false

Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.
warfarin	20-27	levetiracetam	68-80	false

Probenecid: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.
Probenecid	0-9	Probenecid	12-21	false
Probenecid	0-9	levetiracetam	156-168	false
Probenecid	12-21	levetiracetam	156-168	false

The effect of Keppra  on probenecid was not studied.
Keppra	14-19	probenecid	25-34	false

Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.
BETAGAN	9-15	BETAGAN	117-123	false
BETAGAN	9-15	epinephrine	129-139	false
BETAGAN	117-123	epinephrine	129-139	effect

Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
beta-blocker	55-66	reserpine	144-152	advise

Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
beta-adrenergic blocking agents	19-49	calcium antagonists	89-107	advise

The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
beta-adrenergic blocking agents	23-53	digitalis	60-68	effect
beta-adrenergic blocking agents	23-53	calcium antagonist	74-91	effect
digitalis	60-68	calcium antagonist	74-91	false

Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.
Phenothiazine-related compounds	0-30	beta-adrenergic blocking agents	36-66	mechanism

Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.
Chirocaine	0-9	anesthetics	75-85	advise

In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.
levobupivacaine	86-100	desbutyl levobupivacaine	105-128	false
levobupivacaine	86-100	3-hydroxy levobupivacaine	134-158	false
desbutyl levobupivacaine	105-128	3-hydroxy levobupivacaine	134-158	false

Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine.
Chirocaine	57-66	Chirocaine	144-153	false

Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
levobupivacaine	86-100	phenytoin	156-164	mechanism
levobupivacaine	86-100	phenobarbital	167-179	mechanism
levobupivacaine	86-100	rifampin	182-189	mechanism
levobupivacaine	86-100	ketoconazole	237-248	mechanism
phenytoin	156-164	phenobarbital	167-179	false
phenytoin	156-164	rifampin	182-189	false
phenytoin	156-164	ketoconazole	237-248	false
phenobarbital	167-179	rifampin	182-189	false
phenobarbital	167-179	ketoconazole	237-248	false
rifampin	182-189	ketoconazole	237-248	false

macrolide antibiotics e.g., erythromycin;
macrolide antibiotics	0-20	erythromycin	28-39	false

and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).
calcium channel antagonists	4-30	verapamil	38-46	false
calcium channel antagonists	4-30	omeprazole	67-76	false
calcium channel antagonists	4-30	furafylline	102-112	false
calcium channel antagonists	4-30	clarithromycin	118-131	false
verapamil	38-46	omeprazole	67-76	false
verapamil	38-46	furafylline	102-112	false
verapamil	38-46	clarithromycin	118-131	false
omeprazole	67-76	furafylline	102-112	false
omeprazole	67-76	clarithromycin	118-131	false
furafylline	102-112	clarithromycin	118-131	false

Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.
levobupivacaine	40-54	levobupivacaine	142-156	false

However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
quinolones	45-54	theophylline	107-118	mechanism
quinolones	45-54	caffeine	154-161	mechanism
quinolones	45-54	anticoagulant	200-212	false
quinolones	45-54	warfarin	214-221	effect
quinolones	45-54	cyclosporine	345-356	effect
theophylline	107-118	caffeine	154-161	false
theophylline	107-118	anticoagulant	200-212	false
theophylline	107-118	warfarin	214-221	false
theophylline	107-118	cyclosporine	345-356	false
caffeine	154-161	anticoagulant	200-212	false
caffeine	154-161	warfarin	214-221	false
caffeine	154-161	cyclosporine	345-356	false
anticoagulant	200-212	warfarin	214-221	false
anticoagulant	200-212	cyclosporine	345-356	false
warfarin	214-221	cyclosporine	345-356	false

Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
Levo-Dromoran	54-66	central nervous system depressants	77-110	effect
Levo-Dromoran	54-66	alcohol	117-123	effect
Levo-Dromoran	54-66	sedatives	126-134	effect
Levo-Dromoran	54-66	hypnotics	137-145	effect
Levo-Dromoran	54-66	opioids	154-160	effect
Levo-Dromoran	54-66	anesthetics	171-181	effect
Levo-Dromoran	54-66	barbiturates	184-195	effect
Levo-Dromoran	54-66	tricyclic antidepressants	198-222	effect
Levo-Dromoran	54-66	phenothiazines	225-238	effect
Levo-Dromoran	54-66	tranquilizers	241-253	effect
Levo-Dromoran	54-66	skeletal muscle relaxants	256-280	effect
Levo-Dromoran	54-66	antihistamines	286-299	effect
central nervous system depressants	77-110	alcohol	117-123	false
central nervous system depressants	77-110	sedatives	126-134	false
central nervous system depressants	77-110	hypnotics	137-145	false
central nervous system depressants	77-110	opioids	154-160	false
central nervous system depressants	77-110	anesthetics	171-181	false
central nervous system depressants	77-110	barbiturates	184-195	false
central nervous system depressants	77-110	tricyclic antidepressants	198-222	false
central nervous system depressants	77-110	phenothiazines	225-238	false
central nervous system depressants	77-110	tranquilizers	241-253	false
central nervous system depressants	77-110	skeletal muscle relaxants	256-280	false
central nervous system depressants	77-110	antihistamines	286-299	false
alcohol	117-123	sedatives	126-134	false
alcohol	117-123	hypnotics	137-145	false
alcohol	117-123	opioids	154-160	false
alcohol	117-123	anesthetics	171-181	false
alcohol	117-123	barbiturates	184-195	false
alcohol	117-123	tricyclic antidepressants	198-222	false
alcohol	117-123	phenothiazines	225-238	false
alcohol	117-123	tranquilizers	241-253	false
alcohol	117-123	skeletal muscle relaxants	256-280	false
alcohol	117-123	antihistamines	286-299	false
sedatives	126-134	hypnotics	137-145	false
sedatives	126-134	opioids	154-160	false
sedatives	126-134	anesthetics	171-181	false
sedatives	126-134	barbiturates	184-195	false
sedatives	126-134	tricyclic antidepressants	198-222	false
sedatives	126-134	phenothiazines	225-238	false
sedatives	126-134	tranquilizers	241-253	false
sedatives	126-134	skeletal muscle relaxants	256-280	false
sedatives	126-134	antihistamines	286-299	false
hypnotics	137-145	opioids	154-160	false
hypnotics	137-145	anesthetics	171-181	false
hypnotics	137-145	barbiturates	184-195	false
hypnotics	137-145	tricyclic antidepressants	198-222	false
hypnotics	137-145	phenothiazines	225-238	false
hypnotics	137-145	tranquilizers	241-253	false
hypnotics	137-145	skeletal muscle relaxants	256-280	false
hypnotics	137-145	antihistamines	286-299	false
opioids	154-160	anesthetics	171-181	false
opioids	154-160	barbiturates	184-195	false
opioids	154-160	tricyclic antidepressants	198-222	false
opioids	154-160	phenothiazines	225-238	false
opioids	154-160	tranquilizers	241-253	false
opioids	154-160	skeletal muscle relaxants	256-280	false
opioids	154-160	antihistamines	286-299	false
anesthetics	171-181	barbiturates	184-195	false
anesthetics	171-181	tricyclic antidepressants	198-222	false
anesthetics	171-181	phenothiazines	225-238	false
anesthetics	171-181	tranquilizers	241-253	false
anesthetics	171-181	skeletal muscle relaxants	256-280	false
anesthetics	171-181	antihistamines	286-299	false
barbiturates	184-195	tricyclic antidepressants	198-222	false
barbiturates	184-195	phenothiazines	225-238	false
barbiturates	184-195	tranquilizers	241-253	false
barbiturates	184-195	skeletal muscle relaxants	256-280	false
barbiturates	184-195	antihistamines	286-299	false
tricyclic antidepressants	198-222	phenothiazines	225-238	false
tricyclic antidepressants	198-222	tranquilizers	241-253	false
tricyclic antidepressants	198-222	skeletal muscle relaxants	256-280	false
tricyclic antidepressants	198-222	antihistamines	286-299	false
phenothiazines	225-238	tranquilizers	241-253	false
phenothiazines	225-238	skeletal muscle relaxants	256-280	false
phenothiazines	225-238	antihistamines	286-299	false
tranquilizers	241-253	skeletal muscle relaxants	256-280	false
tranquilizers	241-253	antihistamines	286-299	false
skeletal muscle relaxants	256-280	antihistamines	286-299	false

Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.
MAO inhibitors	32-45	Levo-Dromoran	51-63	false
MAO inhibitors	32-45	MAO inhibitors	119-132	false
Levo-Dromoran	51-63	MAO inhibitors	119-132	advise

Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration.
Levo-Dromoran	56-68	levorphanol	277-287	false

Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
Mixed Agonist/Antagonist Opioid Analgesics	18-59	Agonist/antagonist analgesics	62-90	false
Mixed Agonist/Antagonist Opioid Analgesics	18-59	pentazocine	97-107	false
Mixed Agonist/Antagonist Opioid Analgesics	18-59	nalbuphine	110-119	false
Mixed Agonist/Antagonist Opioid Analgesics	18-59	butorphanol	122-132	false
Mixed Agonist/Antagonist Opioid Analgesics	18-59	dezocine	135-142	false
Mixed Agonist/Antagonist Opioid Analgesics	18-59	buprenorphine	148-160	false
Mixed Agonist/Antagonist Opioid Analgesics	18-59	pure agonist opioid analgesic	263-291	false
Mixed Agonist/Antagonist Opioid Analgesics	18-59	Levo-Dromoran	301-313	false
Agonist/antagonist analgesics	62-90	pentazocine	97-107	false
Agonist/antagonist analgesics	62-90	nalbuphine	110-119	false
Agonist/antagonist analgesics	62-90	butorphanol	122-132	false
Agonist/antagonist analgesics	62-90	dezocine	135-142	false
Agonist/antagonist analgesics	62-90	buprenorphine	148-160	false
Agonist/antagonist analgesics	62-90	pure agonist opioid analgesic	263-291	false
Agonist/antagonist analgesics	62-90	Levo-Dromoran	301-313	advise
pentazocine	97-107	nalbuphine	110-119	false
pentazocine	97-107	butorphanol	122-132	false
pentazocine	97-107	dezocine	135-142	false
pentazocine	97-107	buprenorphine	148-160	false
pentazocine	97-107	pure agonist opioid analgesic	263-291	false
pentazocine	97-107	Levo-Dromoran	301-313	advise
nalbuphine	110-119	butorphanol	122-132	false
nalbuphine	110-119	dezocine	135-142	false
nalbuphine	110-119	buprenorphine	148-160	false
nalbuphine	110-119	pure agonist opioid analgesic	263-291	false
nalbuphine	110-119	Levo-Dromoran	301-313	advise
butorphanol	122-132	dezocine	135-142	false
butorphanol	122-132	buprenorphine	148-160	false
butorphanol	122-132	pure agonist opioid analgesic	263-291	false
butorphanol	122-132	Levo-Dromoran	301-313	advise
dezocine	135-142	buprenorphine	148-160	false
dezocine	135-142	pure agonist opioid analgesic	263-291	false
dezocine	135-142	Levo-Dromoran	301-313	advise
buprenorphine	148-160	pure agonist opioid analgesic	263-291	false
buprenorphine	148-160	Levo-Dromoran	301-313	advise
pure agonist opioid analgesic	263-291	Levo-Dromoran	301-313	advise

In opioid-dependent patients, mixed agonist/antagonist analgesics may precipitate withdrawal symptoms.
opioid	3-8	mixed agonist/antagonist analgesics	30-64	false

No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.
Levosimendan	34-45	captopril	116-124	false
Levosimendan	34-45	beta-blockers	127-139	false
Levosimendan	34-45	felodipine	142-151	false
Levosimendan	34-45	digoxin	154-160	false
Levosimendan	34-45	warfarin	163-170	false
Levosimendan	34-45	isosorbide mononitrate	173-194	false
Levosimendan	34-45	carvedilol	197-206	false
Levosimendan	34-45	ethanol	209-215	false
Levosimendan	34-45	itraconazole	220-231	false
captopril	116-124	beta-blockers	127-139	false
captopril	116-124	felodipine	142-151	false
captopril	116-124	digoxin	154-160	false
captopril	116-124	warfarin	163-170	false
captopril	116-124	isosorbide mononitrate	173-194	false
captopril	116-124	carvedilol	197-206	false
captopril	116-124	ethanol	209-215	false
captopril	116-124	itraconazole	220-231	false
beta-blockers	127-139	felodipine	142-151	false
beta-blockers	127-139	digoxin	154-160	false
beta-blockers	127-139	warfarin	163-170	false
beta-blockers	127-139	isosorbide mononitrate	173-194	false
beta-blockers	127-139	carvedilol	197-206	false
beta-blockers	127-139	ethanol	209-215	false
beta-blockers	127-139	itraconazole	220-231	false
felodipine	142-151	digoxin	154-160	false
felodipine	142-151	warfarin	163-170	false
felodipine	142-151	isosorbide mononitrate	173-194	false
felodipine	142-151	carvedilol	197-206	false
felodipine	142-151	ethanol	209-215	false
felodipine	142-151	itraconazole	220-231	false
digoxin	154-160	warfarin	163-170	false
digoxin	154-160	isosorbide mononitrate	173-194	false
digoxin	154-160	carvedilol	197-206	false
digoxin	154-160	ethanol	209-215	false
digoxin	154-160	itraconazole	220-231	false
warfarin	163-170	isosorbide mononitrate	173-194	false
warfarin	163-170	carvedilol	197-206	false
warfarin	163-170	ethanol	209-215	false
warfarin	163-170	itraconazole	220-231	false
isosorbide mononitrate	173-194	carvedilol	197-206	false
isosorbide mononitrate	173-194	ethanol	209-215	false
isosorbide mononitrate	173-194	itraconazole	220-231	false
carvedilol	197-206	ethanol	209-215	false
carvedilol	197-206	itraconazole	220-231	false
ethanol	209-215	itraconazole	220-231	false

Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
Levothyroxine Sodium	0-19	levothyroxine sodium	90-109	false
Levothyroxine Sodium	0-19	aluminum hydoxide	144-160	false
Levothyroxine Sodium	0-19	cholestyramine	163-176	false
Levothyroxine Sodium	0-19	colestipol hydrochloride	185-208	false
Levothyroxine Sodium	0-19	ferrous sulfate	211-225	false
Levothyroxine Sodium	0-19	sodium polystyrene sulfonate	228-255	false
Levothyroxine Sodium	0-19	sucralfate	296-305	false
levothyroxine sodium	90-109	aluminum hydoxide	144-160	mechanism
levothyroxine sodium	90-109	cholestyramine	163-176	mechanism
levothyroxine sodium	90-109	colestipol hydrochloride	185-208	mechanism
levothyroxine sodium	90-109	ferrous sulfate	211-225	mechanism
levothyroxine sodium	90-109	sodium polystyrene sulfonate	228-255	mechanism
levothyroxine sodium	90-109	sucralfate	296-305	mechanism
aluminum hydoxide	144-160	cholestyramine	163-176	false
aluminum hydoxide	144-160	colestipol hydrochloride	185-208	false
aluminum hydoxide	144-160	ferrous sulfate	211-225	false
aluminum hydoxide	144-160	sodium polystyrene sulfonate	228-255	false
aluminum hydoxide	144-160	sucralfate	296-305	false
cholestyramine	163-176	colestipol hydrochloride	185-208	false
cholestyramine	163-176	ferrous sulfate	211-225	false
cholestyramine	163-176	sodium polystyrene sulfonate	228-255	false
cholestyramine	163-176	sucralfate	296-305	false
colestipol hydrochloride	185-208	ferrous sulfate	211-225	false
colestipol hydrochloride	185-208	sodium polystyrene sulfonate	228-255	false
colestipol hydrochloride	185-208	sucralfate	296-305	false
ferrous sulfate	211-225	sodium polystyrene sulfonate	228-255	false
ferrous sulfate	211-225	sucralfate	296-305	false
sodium polystyrene sulfonate	228-255	sucralfate	296-305	false

Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
levothyroxine sodium	67-86	androgens	169-177	mechanism
levothyroxine sodium	67-86	anabolic hormones	191-207	mechanism
levothyroxine sodium	67-86	asparaginase	210-221	mechanism
levothyroxine sodium	67-86	clofibrate	224-233	mechanism
levothyroxine sodium	67-86	estrogens	236-244	mechanism
levothyroxine sodium	67-86	estrogen-containing compounds	250-278	mechanism
levothyroxine sodium	67-86	5-fluorouracil	281-294	mechanism
levothyroxine sodium	67-86	furosemide	297-306	mechanism
levothyroxine sodium	67-86	glucocorticoids	309-323	mechanism
levothyroxine sodium	67-86	meclofenamic acid	326-342	mechanism
levothyroxine sodium	67-86	mefenamic acid	345-358	mechanism
levothyroxine sodium	67-86	methadone	361-369	mechanism
levothyroxine sodium	67-86	perphenazine	372-383	mechanism
levothyroxine sodium	67-86	phenylbutazone	386-399	mechanism
levothyroxine sodium	67-86	phenytoin	402-410	mechanism
levothyroxine sodium	67-86	salicylates	413-423	mechanism
levothyroxine sodium	67-86	tamoxifen	426-434	mechanism
androgens	169-177	anabolic hormones	191-207	false
androgens	169-177	asparaginase	210-221	false
androgens	169-177	clofibrate	224-233	false
androgens	169-177	estrogens	236-244	false
androgens	169-177	estrogen-containing compounds	250-278	false
androgens	169-177	5-fluorouracil	281-294	false
androgens	169-177	furosemide	297-306	false
androgens	169-177	glucocorticoids	309-323	false
androgens	169-177	meclofenamic acid	326-342	false
androgens	169-177	mefenamic acid	345-358	false
androgens	169-177	methadone	361-369	false
androgens	169-177	perphenazine	372-383	false
androgens	169-177	phenylbutazone	386-399	false
androgens	169-177	phenytoin	402-410	false
androgens	169-177	salicylates	413-423	false
androgens	169-177	tamoxifen	426-434	false
anabolic hormones	191-207	asparaginase	210-221	false
anabolic hormones	191-207	clofibrate	224-233	false
anabolic hormones	191-207	estrogens	236-244	false
anabolic hormones	191-207	estrogen-containing compounds	250-278	false
anabolic hormones	191-207	5-fluorouracil	281-294	false
anabolic hormones	191-207	furosemide	297-306	false
anabolic hormones	191-207	glucocorticoids	309-323	false
anabolic hormones	191-207	meclofenamic acid	326-342	false
anabolic hormones	191-207	mefenamic acid	345-358	false
anabolic hormones	191-207	methadone	361-369	false
anabolic hormones	191-207	perphenazine	372-383	false
anabolic hormones	191-207	phenylbutazone	386-399	false
anabolic hormones	191-207	phenytoin	402-410	false
anabolic hormones	191-207	salicylates	413-423	false
anabolic hormones	191-207	tamoxifen	426-434	false
asparaginase	210-221	clofibrate	224-233	false
asparaginase	210-221	estrogens	236-244	false
asparaginase	210-221	estrogen-containing compounds	250-278	false
asparaginase	210-221	5-fluorouracil	281-294	false
asparaginase	210-221	furosemide	297-306	false
asparaginase	210-221	glucocorticoids	309-323	false
asparaginase	210-221	meclofenamic acid	326-342	false
asparaginase	210-221	mefenamic acid	345-358	false
asparaginase	210-221	methadone	361-369	false
asparaginase	210-221	perphenazine	372-383	false
asparaginase	210-221	phenylbutazone	386-399	false
asparaginase	210-221	phenytoin	402-410	false
asparaginase	210-221	salicylates	413-423	false
asparaginase	210-221	tamoxifen	426-434	false
clofibrate	224-233	estrogens	236-244	false
clofibrate	224-233	estrogen-containing compounds	250-278	false
clofibrate	224-233	5-fluorouracil	281-294	false
clofibrate	224-233	furosemide	297-306	false
clofibrate	224-233	glucocorticoids	309-323	false
clofibrate	224-233	meclofenamic acid	326-342	false
clofibrate	224-233	mefenamic acid	345-358	false
clofibrate	224-233	methadone	361-369	false
clofibrate	224-233	perphenazine	372-383	false
clofibrate	224-233	phenylbutazone	386-399	false
clofibrate	224-233	phenytoin	402-410	false
clofibrate	224-233	salicylates	413-423	false
clofibrate	224-233	tamoxifen	426-434	false
estrogens	236-244	estrogen-containing compounds	250-278	false
estrogens	236-244	5-fluorouracil	281-294	false
estrogens	236-244	furosemide	297-306	false
estrogens	236-244	glucocorticoids	309-323	false
estrogens	236-244	meclofenamic acid	326-342	false
estrogens	236-244	mefenamic acid	345-358	false
estrogens	236-244	methadone	361-369	false
estrogens	236-244	perphenazine	372-383	false
estrogens	236-244	phenylbutazone	386-399	false
estrogens	236-244	phenytoin	402-410	false
estrogens	236-244	salicylates	413-423	false
estrogens	236-244	tamoxifen	426-434	false
estrogen-containing compounds	250-278	5-fluorouracil	281-294	false
estrogen-containing compounds	250-278	furosemide	297-306	false
estrogen-containing compounds	250-278	glucocorticoids	309-323	false
estrogen-containing compounds	250-278	meclofenamic acid	326-342	false
estrogen-containing compounds	250-278	mefenamic acid	345-358	false
estrogen-containing compounds	250-278	methadone	361-369	false
estrogen-containing compounds	250-278	perphenazine	372-383	false
estrogen-containing compounds	250-278	phenylbutazone	386-399	false
estrogen-containing compounds	250-278	phenytoin	402-410	false
estrogen-containing compounds	250-278	salicylates	413-423	false
estrogen-containing compounds	250-278	tamoxifen	426-434	false
5-fluorouracil	281-294	furosemide	297-306	false
5-fluorouracil	281-294	glucocorticoids	309-323	false
5-fluorouracil	281-294	meclofenamic acid	326-342	false
5-fluorouracil	281-294	mefenamic acid	345-358	false
5-fluorouracil	281-294	methadone	361-369	false
5-fluorouracil	281-294	perphenazine	372-383	false
5-fluorouracil	281-294	phenylbutazone	386-399	false
5-fluorouracil	281-294	phenytoin	402-410	false
5-fluorouracil	281-294	salicylates	413-423	false
5-fluorouracil	281-294	tamoxifen	426-434	false
furosemide	297-306	glucocorticoids	309-323	false
furosemide	297-306	meclofenamic acid	326-342	false
furosemide	297-306	mefenamic acid	345-358	false
furosemide	297-306	methadone	361-369	false
furosemide	297-306	perphenazine	372-383	false
furosemide	297-306	phenylbutazone	386-399	false
furosemide	297-306	phenytoin	402-410	false
furosemide	297-306	salicylates	413-423	false
furosemide	297-306	tamoxifen	426-434	false
glucocorticoids	309-323	meclofenamic acid	326-342	false
glucocorticoids	309-323	mefenamic acid	345-358	false
glucocorticoids	309-323	methadone	361-369	false
glucocorticoids	309-323	perphenazine	372-383	false
glucocorticoids	309-323	phenylbutazone	386-399	false
glucocorticoids	309-323	phenytoin	402-410	false
glucocorticoids	309-323	salicylates	413-423	false
glucocorticoids	309-323	tamoxifen	426-434	false
meclofenamic acid	326-342	mefenamic acid	345-358	false
meclofenamic acid	326-342	methadone	361-369	false
meclofenamic acid	326-342	perphenazine	372-383	false
meclofenamic acid	326-342	phenylbutazone	386-399	false
meclofenamic acid	326-342	phenytoin	402-410	false
meclofenamic acid	326-342	salicylates	413-423	false
meclofenamic acid	326-342	tamoxifen	426-434	false
mefenamic acid	345-358	methadone	361-369	false
mefenamic acid	345-358	perphenazine	372-383	false
mefenamic acid	345-358	phenylbutazone	386-399	false
mefenamic acid	345-358	phenytoin	402-410	false
mefenamic acid	345-358	salicylates	413-423	false
mefenamic acid	345-358	tamoxifen	426-434	false
methadone	361-369	perphenazine	372-383	false
methadone	361-369	phenylbutazone	386-399	false
methadone	361-369	phenytoin	402-410	false
methadone	361-369	salicylates	413-423	false
methadone	361-369	tamoxifen	426-434	false
perphenazine	372-383	phenylbutazone	386-399	false
perphenazine	372-383	phenytoin	402-410	false
perphenazine	372-383	salicylates	413-423	false
perphenazine	372-383	tamoxifen	426-434	false
phenylbutazone	386-399	phenytoin	402-410	false
phenylbutazone	386-399	salicylates	413-423	false
phenylbutazone	386-399	tamoxifen	426-434	false
phenytoin	402-410	salicylates	413-423	false
phenytoin	402-410	tamoxifen	426-434	false
salicylates	413-423	tamoxifen	426-434	false

Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
aminoglutethimide	228-244	p-aminosalicylic acid	247-267	false
aminoglutethimide	228-244	amiodarone	270-279	false
aminoglutethimide	228-244	androgens	282-290	false
aminoglutethimide	228-244	thiocyanate	339-349	false
aminoglutethimide	228-244	perchlorate	352-362	false
aminoglutethimide	228-244	pertechnetate	365-377	false
aminoglutethimide	228-244	antithyroid drugs	381-397	false
aminoglutethimide	228-244	b-adrenergic blocking agents	400-427	false
aminoglutethimide	228-244	carbamazepine	430-442	false
aminoglutethimide	228-244	chloral hydrate	445-459	false
aminoglutethimide	228-244	diazepam	462-469	false
aminoglutethimide	228-244	dopamine	472-479	false
aminoglutethimide	228-244	dopamine agonists	485-501	false
aminoglutethimide	228-244	ethionamide	504-514	false
aminoglutethimide	228-244	glucocorticoids	517-531	false
aminoglutethimide	228-244	heparin	534-540	false
aminoglutethimide	228-244	insulin	568-574	false
aminoglutethimide	228-244	iodine-containing compounds	611-637	false
aminoglutethimide	228-244	levodopa	640-647	false
aminoglutethimide	228-244	lovastatin	650-659	false
aminoglutethimide	228-244	lithium	662-668	false
aminoglutethimide	228-244	6-mercaptopurine	671-686	false
aminoglutethimide	228-244	metoclopramide	689-702	false
aminoglutethimide	228-244	mitotane	705-712	false
aminoglutethimide	228-244	nitroprusside	715-727	false
aminoglutethimide	228-244	phenobarbital	730-742	false
aminoglutethimide	228-244	phenytoin	745-753	false
aminoglutethimide	228-244	resorcinol	756-765	false
aminoglutethimide	228-244	rifampin	768-775	false
aminoglutethimide	228-244	somatostatin analogs	778-797	false
aminoglutethimide	228-244	sulfonamides	800-811	false
aminoglutethimide	228-244	sulfonylureas	814-826	false
aminoglutethimide	228-244	thiazide diuretics	829-846	false
p-aminosalicylic acid	247-267	amiodarone	270-279	false
p-aminosalicylic acid	247-267	androgens	282-290	false
p-aminosalicylic acid	247-267	thiocyanate	339-349	false
p-aminosalicylic acid	247-267	perchlorate	352-362	false
p-aminosalicylic acid	247-267	pertechnetate	365-377	false
p-aminosalicylic acid	247-267	antithyroid drugs	381-397	false
p-aminosalicylic acid	247-267	b-adrenergic blocking agents	400-427	false
p-aminosalicylic acid	247-267	carbamazepine	430-442	false
p-aminosalicylic acid	247-267	chloral hydrate	445-459	false
p-aminosalicylic acid	247-267	diazepam	462-469	false
p-aminosalicylic acid	247-267	dopamine	472-479	false
p-aminosalicylic acid	247-267	dopamine agonists	485-501	false
p-aminosalicylic acid	247-267	ethionamide	504-514	false
p-aminosalicylic acid	247-267	glucocorticoids	517-531	false
p-aminosalicylic acid	247-267	heparin	534-540	false
p-aminosalicylic acid	247-267	insulin	568-574	false
p-aminosalicylic acid	247-267	iodine-containing compounds	611-637	false
p-aminosalicylic acid	247-267	levodopa	640-647	false
p-aminosalicylic acid	247-267	lovastatin	650-659	false
p-aminosalicylic acid	247-267	lithium	662-668	false
p-aminosalicylic acid	247-267	6-mercaptopurine	671-686	false
p-aminosalicylic acid	247-267	metoclopramide	689-702	false
p-aminosalicylic acid	247-267	mitotane	705-712	false
p-aminosalicylic acid	247-267	nitroprusside	715-727	false
p-aminosalicylic acid	247-267	phenobarbital	730-742	false
p-aminosalicylic acid	247-267	phenytoin	745-753	false
p-aminosalicylic acid	247-267	resorcinol	756-765	false
p-aminosalicylic acid	247-267	rifampin	768-775	false
p-aminosalicylic acid	247-267	somatostatin analogs	778-797	false
p-aminosalicylic acid	247-267	sulfonamides	800-811	false
p-aminosalicylic acid	247-267	sulfonylureas	814-826	false
p-aminosalicylic acid	247-267	thiazide diuretics	829-846	false
amiodarone	270-279	androgens	282-290	false
amiodarone	270-279	thiocyanate	339-349	false
amiodarone	270-279	perchlorate	352-362	false
amiodarone	270-279	pertechnetate	365-377	false
amiodarone	270-279	antithyroid drugs	381-397	false
amiodarone	270-279	b-adrenergic blocking agents	400-427	false
amiodarone	270-279	carbamazepine	430-442	false
amiodarone	270-279	chloral hydrate	445-459	false
amiodarone	270-279	diazepam	462-469	false
amiodarone	270-279	dopamine	472-479	false
amiodarone	270-279	dopamine agonists	485-501	false
amiodarone	270-279	ethionamide	504-514	false
amiodarone	270-279	glucocorticoids	517-531	false
amiodarone	270-279	heparin	534-540	false
amiodarone	270-279	insulin	568-574	false
amiodarone	270-279	iodine-containing compounds	611-637	false
amiodarone	270-279	levodopa	640-647	false
amiodarone	270-279	lovastatin	650-659	false
amiodarone	270-279	lithium	662-668	false
amiodarone	270-279	6-mercaptopurine	671-686	false
amiodarone	270-279	metoclopramide	689-702	false
amiodarone	270-279	mitotane	705-712	false
amiodarone	270-279	nitroprusside	715-727	false
amiodarone	270-279	phenobarbital	730-742	false
amiodarone	270-279	phenytoin	745-753	false
amiodarone	270-279	resorcinol	756-765	false
amiodarone	270-279	rifampin	768-775	false
amiodarone	270-279	somatostatin analogs	778-797	false
amiodarone	270-279	sulfonamides	800-811	false
amiodarone	270-279	sulfonylureas	814-826	false
amiodarone	270-279	thiazide diuretics	829-846	false
androgens	282-290	thiocyanate	339-349	false
androgens	282-290	perchlorate	352-362	false
androgens	282-290	pertechnetate	365-377	false
androgens	282-290	antithyroid drugs	381-397	false
androgens	282-290	b-adrenergic blocking agents	400-427	false
androgens	282-290	carbamazepine	430-442	false
androgens	282-290	chloral hydrate	445-459	false
androgens	282-290	diazepam	462-469	false
androgens	282-290	dopamine	472-479	false
androgens	282-290	dopamine agonists	485-501	false
androgens	282-290	ethionamide	504-514	false
androgens	282-290	glucocorticoids	517-531	false
androgens	282-290	heparin	534-540	false
androgens	282-290	insulin	568-574	false
androgens	282-290	iodine-containing compounds	611-637	false
androgens	282-290	levodopa	640-647	false
androgens	282-290	lovastatin	650-659	false
androgens	282-290	lithium	662-668	false
androgens	282-290	6-mercaptopurine	671-686	false
androgens	282-290	metoclopramide	689-702	false
androgens	282-290	mitotane	705-712	false
androgens	282-290	nitroprusside	715-727	false
androgens	282-290	phenobarbital	730-742	false
androgens	282-290	phenytoin	745-753	false
androgens	282-290	resorcinol	756-765	false
androgens	282-290	rifampin	768-775	false
androgens	282-290	somatostatin analogs	778-797	false
androgens	282-290	sulfonamides	800-811	false
androgens	282-290	sulfonylureas	814-826	false
androgens	282-290	thiazide diuretics	829-846	false
thiocyanate	339-349	perchlorate	352-362	false
thiocyanate	339-349	pertechnetate	365-377	false
thiocyanate	339-349	antithyroid drugs	381-397	false
thiocyanate	339-349	b-adrenergic blocking agents	400-427	false
thiocyanate	339-349	carbamazepine	430-442	false
thiocyanate	339-349	chloral hydrate	445-459	false
thiocyanate	339-349	diazepam	462-469	false
thiocyanate	339-349	dopamine	472-479	false
thiocyanate	339-349	dopamine agonists	485-501	false
thiocyanate	339-349	ethionamide	504-514	false
thiocyanate	339-349	glucocorticoids	517-531	false
thiocyanate	339-349	heparin	534-540	false
thiocyanate	339-349	insulin	568-574	false
thiocyanate	339-349	iodine-containing compounds	611-637	false
thiocyanate	339-349	levodopa	640-647	false
thiocyanate	339-349	lovastatin	650-659	false
thiocyanate	339-349	lithium	662-668	false
thiocyanate	339-349	6-mercaptopurine	671-686	false
thiocyanate	339-349	metoclopramide	689-702	false
thiocyanate	339-349	mitotane	705-712	false
thiocyanate	339-349	nitroprusside	715-727	false
thiocyanate	339-349	phenobarbital	730-742	false
thiocyanate	339-349	phenytoin	745-753	false
thiocyanate	339-349	resorcinol	756-765	false
thiocyanate	339-349	rifampin	768-775	false
thiocyanate	339-349	somatostatin analogs	778-797	false
thiocyanate	339-349	sulfonamides	800-811	false
thiocyanate	339-349	sulfonylureas	814-826	false
thiocyanate	339-349	thiazide diuretics	829-846	false
perchlorate	352-362	pertechnetate	365-377	false
perchlorate	352-362	antithyroid drugs	381-397	false
perchlorate	352-362	b-adrenergic blocking agents	400-427	false
perchlorate	352-362	carbamazepine	430-442	false
perchlorate	352-362	chloral hydrate	445-459	false
perchlorate	352-362	diazepam	462-469	false
perchlorate	352-362	dopamine	472-479	false
perchlorate	352-362	dopamine agonists	485-501	false
perchlorate	352-362	ethionamide	504-514	false
perchlorate	352-362	glucocorticoids	517-531	false
perchlorate	352-362	heparin	534-540	false
perchlorate	352-362	insulin	568-574	false
perchlorate	352-362	iodine-containing compounds	611-637	false
perchlorate	352-362	levodopa	640-647	false
perchlorate	352-362	lovastatin	650-659	false
perchlorate	352-362	lithium	662-668	false
perchlorate	352-362	6-mercaptopurine	671-686	false
perchlorate	352-362	metoclopramide	689-702	false
perchlorate	352-362	mitotane	705-712	false
perchlorate	352-362	nitroprusside	715-727	false
perchlorate	352-362	phenobarbital	730-742	false
perchlorate	352-362	phenytoin	745-753	false
perchlorate	352-362	resorcinol	756-765	false
perchlorate	352-362	rifampin	768-775	false
perchlorate	352-362	somatostatin analogs	778-797	false
perchlorate	352-362	sulfonamides	800-811	false
perchlorate	352-362	sulfonylureas	814-826	false
perchlorate	352-362	thiazide diuretics	829-846	false
pertechnetate	365-377	antithyroid drugs	381-397	false
pertechnetate	365-377	b-adrenergic blocking agents	400-427	false
pertechnetate	365-377	carbamazepine	430-442	false
pertechnetate	365-377	chloral hydrate	445-459	false
pertechnetate	365-377	diazepam	462-469	false
pertechnetate	365-377	dopamine	472-479	false
pertechnetate	365-377	dopamine agonists	485-501	false
pertechnetate	365-377	ethionamide	504-514	false
pertechnetate	365-377	glucocorticoids	517-531	false
pertechnetate	365-377	heparin	534-540	false
pertechnetate	365-377	insulin	568-574	false
pertechnetate	365-377	iodine-containing compounds	611-637	false
pertechnetate	365-377	levodopa	640-647	false
pertechnetate	365-377	lovastatin	650-659	false
pertechnetate	365-377	lithium	662-668	false
pertechnetate	365-377	6-mercaptopurine	671-686	false
pertechnetate	365-377	metoclopramide	689-702	false
pertechnetate	365-377	mitotane	705-712	false
pertechnetate	365-377	nitroprusside	715-727	false
pertechnetate	365-377	phenobarbital	730-742	false
pertechnetate	365-377	phenytoin	745-753	false
pertechnetate	365-377	resorcinol	756-765	false
pertechnetate	365-377	rifampin	768-775	false
pertechnetate	365-377	somatostatin analogs	778-797	false
pertechnetate	365-377	sulfonamides	800-811	false
pertechnetate	365-377	sulfonylureas	814-826	false
pertechnetate	365-377	thiazide diuretics	829-846	false
antithyroid drugs	381-397	b-adrenergic blocking agents	400-427	false
antithyroid drugs	381-397	carbamazepine	430-442	false
antithyroid drugs	381-397	chloral hydrate	445-459	false
antithyroid drugs	381-397	diazepam	462-469	false
antithyroid drugs	381-397	dopamine	472-479	false
antithyroid drugs	381-397	dopamine agonists	485-501	false
antithyroid drugs	381-397	ethionamide	504-514	false
antithyroid drugs	381-397	glucocorticoids	517-531	false
antithyroid drugs	381-397	heparin	534-540	false
antithyroid drugs	381-397	insulin	568-574	false
antithyroid drugs	381-397	iodine-containing compounds	611-637	false
antithyroid drugs	381-397	levodopa	640-647	false
antithyroid drugs	381-397	lovastatin	650-659	false
antithyroid drugs	381-397	lithium	662-668	false
antithyroid drugs	381-397	6-mercaptopurine	671-686	false
antithyroid drugs	381-397	metoclopramide	689-702	false
antithyroid drugs	381-397	mitotane	705-712	false
antithyroid drugs	381-397	nitroprusside	715-727	false
antithyroid drugs	381-397	phenobarbital	730-742	false
antithyroid drugs	381-397	phenytoin	745-753	false
antithyroid drugs	381-397	resorcinol	756-765	false
antithyroid drugs	381-397	rifampin	768-775	false
antithyroid drugs	381-397	somatostatin analogs	778-797	false
antithyroid drugs	381-397	sulfonamides	800-811	false
antithyroid drugs	381-397	sulfonylureas	814-826	false
antithyroid drugs	381-397	thiazide diuretics	829-846	false
b-adrenergic blocking agents	400-427	carbamazepine	430-442	false
b-adrenergic blocking agents	400-427	chloral hydrate	445-459	false
b-adrenergic blocking agents	400-427	diazepam	462-469	false
b-adrenergic blocking agents	400-427	dopamine	472-479	false
b-adrenergic blocking agents	400-427	dopamine agonists	485-501	false
b-adrenergic blocking agents	400-427	ethionamide	504-514	false
b-adrenergic blocking agents	400-427	glucocorticoids	517-531	false
b-adrenergic blocking agents	400-427	heparin	534-540	false
b-adrenergic blocking agents	400-427	insulin	568-574	false
b-adrenergic blocking agents	400-427	iodine-containing compounds	611-637	false
b-adrenergic blocking agents	400-427	levodopa	640-647	false
b-adrenergic blocking agents	400-427	lovastatin	650-659	false
b-adrenergic blocking agents	400-427	lithium	662-668	false
b-adrenergic blocking agents	400-427	6-mercaptopurine	671-686	false
b-adrenergic blocking agents	400-427	metoclopramide	689-702	false
b-adrenergic blocking agents	400-427	mitotane	705-712	false
b-adrenergic blocking agents	400-427	nitroprusside	715-727	false
b-adrenergic blocking agents	400-427	phenobarbital	730-742	false
b-adrenergic blocking agents	400-427	phenytoin	745-753	false
b-adrenergic blocking agents	400-427	resorcinol	756-765	false
b-adrenergic blocking agents	400-427	rifampin	768-775	false
b-adrenergic blocking agents	400-427	somatostatin analogs	778-797	false
b-adrenergic blocking agents	400-427	sulfonamides	800-811	false
b-adrenergic blocking agents	400-427	sulfonylureas	814-826	false
b-adrenergic blocking agents	400-427	thiazide diuretics	829-846	false
carbamazepine	430-442	chloral hydrate	445-459	false
carbamazepine	430-442	diazepam	462-469	false
carbamazepine	430-442	dopamine	472-479	false
carbamazepine	430-442	dopamine agonists	485-501	false
carbamazepine	430-442	ethionamide	504-514	false
carbamazepine	430-442	glucocorticoids	517-531	false
carbamazepine	430-442	heparin	534-540	false
carbamazepine	430-442	insulin	568-574	false
carbamazepine	430-442	iodine-containing compounds	611-637	false
carbamazepine	430-442	levodopa	640-647	false
carbamazepine	430-442	lovastatin	650-659	false
carbamazepine	430-442	lithium	662-668	false
carbamazepine	430-442	6-mercaptopurine	671-686	false
carbamazepine	430-442	metoclopramide	689-702	false
carbamazepine	430-442	mitotane	705-712	false
carbamazepine	430-442	nitroprusside	715-727	false
carbamazepine	430-442	phenobarbital	730-742	false
carbamazepine	430-442	phenytoin	745-753	false
carbamazepine	430-442	resorcinol	756-765	false
carbamazepine	430-442	rifampin	768-775	false
carbamazepine	430-442	somatostatin analogs	778-797	false
carbamazepine	430-442	sulfonamides	800-811	false
carbamazepine	430-442	sulfonylureas	814-826	false
carbamazepine	430-442	thiazide diuretics	829-846	false
chloral hydrate	445-459	diazepam	462-469	false
chloral hydrate	445-459	dopamine	472-479	false
chloral hydrate	445-459	dopamine agonists	485-501	false
chloral hydrate	445-459	ethionamide	504-514	false
chloral hydrate	445-459	glucocorticoids	517-531	false
chloral hydrate	445-459	heparin	534-540	false
chloral hydrate	445-459	insulin	568-574	false
chloral hydrate	445-459	iodine-containing compounds	611-637	false
chloral hydrate	445-459	levodopa	640-647	false
chloral hydrate	445-459	lovastatin	650-659	false
chloral hydrate	445-459	lithium	662-668	false
chloral hydrate	445-459	6-mercaptopurine	671-686	false
chloral hydrate	445-459	metoclopramide	689-702	false
chloral hydrate	445-459	mitotane	705-712	false
chloral hydrate	445-459	nitroprusside	715-727	false
chloral hydrate	445-459	phenobarbital	730-742	false
chloral hydrate	445-459	phenytoin	745-753	false
chloral hydrate	445-459	resorcinol	756-765	false
chloral hydrate	445-459	rifampin	768-775	false
chloral hydrate	445-459	somatostatin analogs	778-797	false
chloral hydrate	445-459	sulfonamides	800-811	false
chloral hydrate	445-459	sulfonylureas	814-826	false
chloral hydrate	445-459	thiazide diuretics	829-846	false
diazepam	462-469	dopamine	472-479	false
diazepam	462-469	dopamine agonists	485-501	false
diazepam	462-469	ethionamide	504-514	false
diazepam	462-469	glucocorticoids	517-531	false
diazepam	462-469	heparin	534-540	false
diazepam	462-469	insulin	568-574	false
diazepam	462-469	iodine-containing compounds	611-637	false
diazepam	462-469	levodopa	640-647	false
diazepam	462-469	lovastatin	650-659	false
diazepam	462-469	lithium	662-668	false
diazepam	462-469	6-mercaptopurine	671-686	false
diazepam	462-469	metoclopramide	689-702	false
diazepam	462-469	mitotane	705-712	false
diazepam	462-469	nitroprusside	715-727	false
diazepam	462-469	phenobarbital	730-742	false
diazepam	462-469	phenytoin	745-753	false
diazepam	462-469	resorcinol	756-765	false
diazepam	462-469	rifampin	768-775	false
diazepam	462-469	somatostatin analogs	778-797	false
diazepam	462-469	sulfonamides	800-811	false
diazepam	462-469	sulfonylureas	814-826	false
diazepam	462-469	thiazide diuretics	829-846	false
dopamine	472-479	dopamine agonists	485-501	false
dopamine	472-479	ethionamide	504-514	false
dopamine	472-479	glucocorticoids	517-531	false
dopamine	472-479	heparin	534-540	false
dopamine	472-479	insulin	568-574	false
dopamine	472-479	iodine-containing compounds	611-637	false
dopamine	472-479	levodopa	640-647	false
dopamine	472-479	lovastatin	650-659	false
dopamine	472-479	lithium	662-668	false
dopamine	472-479	6-mercaptopurine	671-686	false
dopamine	472-479	metoclopramide	689-702	false
dopamine	472-479	mitotane	705-712	false
dopamine	472-479	nitroprusside	715-727	false
dopamine	472-479	phenobarbital	730-742	false
dopamine	472-479	phenytoin	745-753	false
dopamine	472-479	resorcinol	756-765	false
dopamine	472-479	rifampin	768-775	false
dopamine	472-479	somatostatin analogs	778-797	false
dopamine	472-479	sulfonamides	800-811	false
dopamine	472-479	sulfonylureas	814-826	false
dopamine	472-479	thiazide diuretics	829-846	false
dopamine agonists	485-501	ethionamide	504-514	false
dopamine agonists	485-501	glucocorticoids	517-531	false
dopamine agonists	485-501	heparin	534-540	false
dopamine agonists	485-501	insulin	568-574	false
dopamine agonists	485-501	iodine-containing compounds	611-637	false
dopamine agonists	485-501	levodopa	640-647	false
dopamine agonists	485-501	lovastatin	650-659	false
dopamine agonists	485-501	lithium	662-668	false
dopamine agonists	485-501	6-mercaptopurine	671-686	false
dopamine agonists	485-501	metoclopramide	689-702	false
dopamine agonists	485-501	mitotane	705-712	false
dopamine agonists	485-501	nitroprusside	715-727	false
dopamine agonists	485-501	phenobarbital	730-742	false
dopamine agonists	485-501	phenytoin	745-753	false
dopamine agonists	485-501	resorcinol	756-765	false
dopamine agonists	485-501	rifampin	768-775	false
dopamine agonists	485-501	somatostatin analogs	778-797	false
dopamine agonists	485-501	sulfonamides	800-811	false
dopamine agonists	485-501	sulfonylureas	814-826	false
dopamine agonists	485-501	thiazide diuretics	829-846	false
ethionamide	504-514	glucocorticoids	517-531	false
ethionamide	504-514	heparin	534-540	false
ethionamide	504-514	insulin	568-574	false
ethionamide	504-514	iodine-containing compounds	611-637	false
ethionamide	504-514	levodopa	640-647	false
ethionamide	504-514	lovastatin	650-659	false
ethionamide	504-514	lithium	662-668	false
ethionamide	504-514	6-mercaptopurine	671-686	false
ethionamide	504-514	metoclopramide	689-702	false
ethionamide	504-514	mitotane	705-712	false
ethionamide	504-514	nitroprusside	715-727	false
ethionamide	504-514	phenobarbital	730-742	false
ethionamide	504-514	phenytoin	745-753	false
ethionamide	504-514	resorcinol	756-765	false
ethionamide	504-514	rifampin	768-775	false
ethionamide	504-514	somatostatin analogs	778-797	false
ethionamide	504-514	sulfonamides	800-811	false
ethionamide	504-514	sulfonylureas	814-826	false
ethionamide	504-514	thiazide diuretics	829-846	false
glucocorticoids	517-531	heparin	534-540	false
glucocorticoids	517-531	insulin	568-574	false
glucocorticoids	517-531	iodine-containing compounds	611-637	false
glucocorticoids	517-531	levodopa	640-647	false
glucocorticoids	517-531	lovastatin	650-659	false
glucocorticoids	517-531	lithium	662-668	false
glucocorticoids	517-531	6-mercaptopurine	671-686	false
glucocorticoids	517-531	metoclopramide	689-702	false
glucocorticoids	517-531	mitotane	705-712	false
glucocorticoids	517-531	nitroprusside	715-727	false
glucocorticoids	517-531	phenobarbital	730-742	false
glucocorticoids	517-531	phenytoin	745-753	false
glucocorticoids	517-531	resorcinol	756-765	false
glucocorticoids	517-531	rifampin	768-775	false
glucocorticoids	517-531	somatostatin analogs	778-797	false
glucocorticoids	517-531	sulfonamides	800-811	false
glucocorticoids	517-531	sulfonylureas	814-826	false
glucocorticoids	517-531	thiazide diuretics	829-846	false
heparin	534-540	insulin	568-574	false
heparin	534-540	iodine-containing compounds	611-637	false
heparin	534-540	levodopa	640-647	false
heparin	534-540	lovastatin	650-659	false
heparin	534-540	lithium	662-668	false
heparin	534-540	6-mercaptopurine	671-686	false
heparin	534-540	metoclopramide	689-702	false
heparin	534-540	mitotane	705-712	false
heparin	534-540	nitroprusside	715-727	false
heparin	534-540	phenobarbital	730-742	false
heparin	534-540	phenytoin	745-753	false
heparin	534-540	resorcinol	756-765	false
heparin	534-540	rifampin	768-775	false
heparin	534-540	somatostatin analogs	778-797	false
heparin	534-540	sulfonamides	800-811	false
heparin	534-540	sulfonylureas	814-826	false
heparin	534-540	thiazide diuretics	829-846	false
insulin	568-574	iodine-containing compounds	611-637	false
insulin	568-574	levodopa	640-647	false
insulin	568-574	lovastatin	650-659	false
insulin	568-574	lithium	662-668	false
insulin	568-574	6-mercaptopurine	671-686	false
insulin	568-574	metoclopramide	689-702	false
insulin	568-574	mitotane	705-712	false
insulin	568-574	nitroprusside	715-727	false
insulin	568-574	phenobarbital	730-742	false
insulin	568-574	phenytoin	745-753	false
insulin	568-574	resorcinol	756-765	false
insulin	568-574	rifampin	768-775	false
insulin	568-574	somatostatin analogs	778-797	false
insulin	568-574	sulfonamides	800-811	false
insulin	568-574	sulfonylureas	814-826	false
insulin	568-574	thiazide diuretics	829-846	false
iodine-containing compounds	611-637	levodopa	640-647	false
iodine-containing compounds	611-637	lovastatin	650-659	false
iodine-containing compounds	611-637	lithium	662-668	false
iodine-containing compounds	611-637	6-mercaptopurine	671-686	false
iodine-containing compounds	611-637	metoclopramide	689-702	false
iodine-containing compounds	611-637	mitotane	705-712	false
iodine-containing compounds	611-637	nitroprusside	715-727	false
iodine-containing compounds	611-637	phenobarbital	730-742	false
iodine-containing compounds	611-637	phenytoin	745-753	false
iodine-containing compounds	611-637	resorcinol	756-765	false
iodine-containing compounds	611-637	rifampin	768-775	false
iodine-containing compounds	611-637	somatostatin analogs	778-797	false
iodine-containing compounds	611-637	sulfonamides	800-811	false
iodine-containing compounds	611-637	sulfonylureas	814-826	false
iodine-containing compounds	611-637	thiazide diuretics	829-846	false
levodopa	640-647	lovastatin	650-659	false
levodopa	640-647	lithium	662-668	false
levodopa	640-647	6-mercaptopurine	671-686	false
levodopa	640-647	metoclopramide	689-702	false
levodopa	640-647	mitotane	705-712	false
levodopa	640-647	nitroprusside	715-727	false
levodopa	640-647	phenobarbital	730-742	false
levodopa	640-647	phenytoin	745-753	false
levodopa	640-647	resorcinol	756-765	false
levodopa	640-647	rifampin	768-775	false
levodopa	640-647	somatostatin analogs	778-797	false
levodopa	640-647	sulfonamides	800-811	false
levodopa	640-647	sulfonylureas	814-826	false
levodopa	640-647	thiazide diuretics	829-846	false
lovastatin	650-659	lithium	662-668	false
lovastatin	650-659	6-mercaptopurine	671-686	false
lovastatin	650-659	metoclopramide	689-702	false
lovastatin	650-659	mitotane	705-712	false
lovastatin	650-659	nitroprusside	715-727	false
lovastatin	650-659	phenobarbital	730-742	false
lovastatin	650-659	phenytoin	745-753	false
lovastatin	650-659	resorcinol	756-765	false
lovastatin	650-659	rifampin	768-775	false
lovastatin	650-659	somatostatin analogs	778-797	false
lovastatin	650-659	sulfonamides	800-811	false
lovastatin	650-659	sulfonylureas	814-826	false
lovastatin	650-659	thiazide diuretics	829-846	false
lithium	662-668	6-mercaptopurine	671-686	false
lithium	662-668	metoclopramide	689-702	false
lithium	662-668	mitotane	705-712	false
lithium	662-668	nitroprusside	715-727	false
lithium	662-668	phenobarbital	730-742	false
lithium	662-668	phenytoin	745-753	false
lithium	662-668	resorcinol	756-765	false
lithium	662-668	rifampin	768-775	false
lithium	662-668	somatostatin analogs	778-797	false
lithium	662-668	sulfonamides	800-811	false
lithium	662-668	sulfonylureas	814-826	false
lithium	662-668	thiazide diuretics	829-846	false
6-mercaptopurine	671-686	metoclopramide	689-702	false
6-mercaptopurine	671-686	mitotane	705-712	false
6-mercaptopurine	671-686	nitroprusside	715-727	false
6-mercaptopurine	671-686	phenobarbital	730-742	false
6-mercaptopurine	671-686	phenytoin	745-753	false
6-mercaptopurine	671-686	resorcinol	756-765	false
6-mercaptopurine	671-686	rifampin	768-775	false
6-mercaptopurine	671-686	somatostatin analogs	778-797	false
6-mercaptopurine	671-686	sulfonamides	800-811	false
6-mercaptopurine	671-686	sulfonylureas	814-826	false
6-mercaptopurine	671-686	thiazide diuretics	829-846	false
metoclopramide	689-702	mitotane	705-712	false
metoclopramide	689-702	nitroprusside	715-727	false
metoclopramide	689-702	phenobarbital	730-742	false
metoclopramide	689-702	phenytoin	745-753	false
metoclopramide	689-702	resorcinol	756-765	false
metoclopramide	689-702	rifampin	768-775	false
metoclopramide	689-702	somatostatin analogs	778-797	false
metoclopramide	689-702	sulfonamides	800-811	false
metoclopramide	689-702	sulfonylureas	814-826	false
metoclopramide	689-702	thiazide diuretics	829-846	false
mitotane	705-712	nitroprusside	715-727	false
mitotane	705-712	phenobarbital	730-742	false
mitotane	705-712	phenytoin	745-753	false
mitotane	705-712	resorcinol	756-765	false
mitotane	705-712	rifampin	768-775	false
mitotane	705-712	somatostatin analogs	778-797	false
mitotane	705-712	sulfonamides	800-811	false
mitotane	705-712	sulfonylureas	814-826	false
mitotane	705-712	thiazide diuretics	829-846	false
nitroprusside	715-727	phenobarbital	730-742	false
nitroprusside	715-727	phenytoin	745-753	false
nitroprusside	715-727	resorcinol	756-765	false
nitroprusside	715-727	rifampin	768-775	false
nitroprusside	715-727	somatostatin analogs	778-797	false
nitroprusside	715-727	sulfonamides	800-811	false
nitroprusside	715-727	sulfonylureas	814-826	false
nitroprusside	715-727	thiazide diuretics	829-846	false
phenobarbital	730-742	phenytoin	745-753	false
phenobarbital	730-742	resorcinol	756-765	false
phenobarbital	730-742	rifampin	768-775	false
phenobarbital	730-742	somatostatin analogs	778-797	false
phenobarbital	730-742	sulfonamides	800-811	false
phenobarbital	730-742	sulfonylureas	814-826	false
phenobarbital	730-742	thiazide diuretics	829-846	false
phenytoin	745-753	resorcinol	756-765	false
phenytoin	745-753	rifampin	768-775	false
phenytoin	745-753	somatostatin analogs	778-797	false
phenytoin	745-753	sulfonamides	800-811	false
phenytoin	745-753	sulfonylureas	814-826	false
phenytoin	745-753	thiazide diuretics	829-846	false
resorcinol	756-765	rifampin	768-775	false
resorcinol	756-765	somatostatin analogs	778-797	false
resorcinol	756-765	sulfonamides	800-811	false
resorcinol	756-765	sulfonylureas	814-826	false
resorcinol	756-765	thiazide diuretics	829-846	false
rifampin	768-775	somatostatin analogs	778-797	false
rifampin	768-775	sulfonamides	800-811	false
rifampin	768-775	sulfonylureas	814-826	false
rifampin	768-775	thiazide diuretics	829-846	false
somatostatin analogs	778-797	sulfonamides	800-811	false
somatostatin analogs	778-797	sulfonylureas	814-826	false
somatostatin analogs	778-797	thiazide diuretics	829-846	false
sulfonamides	800-811	sulfonylureas	814-826	false
sulfonamides	800-811	thiazide diuretics	829-846	false
sulfonylureas	814-826	thiazide diuretics	829-846	false

Amiodarone: Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.
Amiodarone	0-9	Amiodarone	12-21	false

Anticoagulants (Oral): The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.
Anticoagulants	0-13	anticoagulants	57-70	false

Antidiabetic Agents (Insulin, Sulfonylureas): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
Antidiabetic Agents	0-18	Insulin	21-27	false
Antidiabetic Agents	0-18	Sulfonylureas	30-42	false
Antidiabetic Agents	0-18	insulin	63-69	false
Antidiabetic Agents	0-18	antidiabetic agents	79-97	false
Insulin	21-27	Sulfonylureas	30-42	false
Insulin	21-27	insulin	63-69	false
Insulin	21-27	antidiabetic agents	79-97	false
Sulfonylureas	30-42	insulin	63-69	false
Sulfonylureas	30-42	antidiabetic agents	79-97	false
insulin	63-69	antidiabetic agents	79-97	false

b-Adrenergic Blocking Agents: Actions of some of beta-blocking agents may be impaired when hypothyroid patients become euthyroid.
b-Adrenergic Blocking Agents	0-27	beta-blocking agents	49-68	false

Cytokines (interferon, interleukin): Cytokines have been reported to induce both hyperthyroidism and hypothyroidism.
Cytokines	0-8	interferon	11-20	false
Cytokines	0-8	interleukin	23-33	false
Cytokines	0-8	Cytokines	37-45	false
interferon	11-20	interleukin	23-33	false
interferon	11-20	Cytokines	37-45	false
interleukin	23-33	Cytokines	37-45	false

Digitalis Glycosides: Therapeutic effects of digitalis glycosides may be reduced.
Digitalis Glycosides	0-19	digitalis glycosides	45-64	false

Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
Ketamine	0-7	levothyroxine sodium	115-134	false
Ketamine	0-7	ketamine	140-147	false
levothyroxine sodium	115-134	ketamine	140-147	effect

Sodium Iodide (123I and 131I), Sodium Pertechnetate Tc99m: Uptake of radiolabeled ions may be decreased.
Sodium Iodide	0-12	Sodium Pertechnetate Tc99m	31-56	false

Somatrem/Somatropin: Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure.
Somatrem	0-7	Somatropin	9-18	false
Somatrem	0-7	thyroid hormone	49-63	false
Somatropin	9-18	thyroid hormone	49-63	false

Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin.
somatrem	67-74	somatropin	79-88	false

Theophylline: Theophylline clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.
Theophylline	0-11	Theophylline	14-25	false

The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
anesthetic solutions	28-47	epinephrine	60-70	false
anesthetic solutions	28-47	norepinephrine	75-88	false
anesthetic solutions	28-47	monoamine oxidase inhibitors	112-139	false
anesthetic solutions	28-47	tricyclic antidepressants	144-168	false
epinephrine	60-70	norepinephrine	75-88	false
epinephrine	60-70	monoamine oxidase inhibitors	112-139	effect
epinephrine	60-70	tricyclic antidepressants	144-168	effect
norepinephrine	75-88	monoamine oxidase inhibitors	112-139	effect
norepinephrine	75-88	tricyclic antidepressants	144-168	effect
monoamine oxidase inhibitors	112-139	tricyclic antidepressants	144-168	false

Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
Phenothiazines	0-13	butyrophenones	19-32	false
Phenothiazines	0-13	epinephrine	78-88	effect
butyrophenones	19-32	epinephrine	78-88	effect

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
vasopressor drugs	29-45	ergot-type oxytocic drugs	114-138	false

Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
Lincomycin	0-9	neuromuscular blocking agents	105-133	effect

Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
lincomycin	19-28	erythromycin	34-45	effect

Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
linezolid	11-19	adrenergic	60-69	int
linezolid	11-19	serotonergic agents	75-93	int
adrenergic	60-69	serotonergic agents	75-93	false

Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
Adrenergic Agents	0-16	ZYVOX	45-49	false
Adrenergic Agents	0-16	sympathomimetic agents	134-155	false
Adrenergic Agents	0-16	vasopressor	158-168	false
Adrenergic Agents	0-16	dopaminergic agents	173-191	false
ZYVOX	45-49	sympathomimetic agents	134-155	effect
ZYVOX	45-49	vasopressor	158-168	effect
ZYVOX	45-49	dopaminergic agents	173-191	effect
sympathomimetic agents	134-155	vasopressor	158-168	false
sympathomimetic agents	134-155	dopaminergic agents	173-191	false
vasopressor	158-168	dopaminergic agents	173-191	false

Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.
phenylpropanolamine	28-46	pseudoephedrine	52-66	false

Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.
adrenergic agents	17-33	dopamine	44-51	false
adrenergic agents	17-33	epinephrine	56-66	false
dopamine	44-51	epinephrine	56-66	false

Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.
Serotonergic Agents	0-18	linezolid	42-50	false
Serotonergic Agents	0-18	serotonergic agents	56-74	false
linezolid	42-50	serotonergic agents	56-74	false

Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
ZYVOX	79-83	serotonergic agents	89-107	effect
ZYVOX	79-83	antidepressants	120-134	effect
ZYVOX	79-83	selective serotonin reuptake inhibitors	144-182	effect
ZYVOX	79-83	SSRIs	185-189	effect
serotonergic agents	89-107	antidepressants	120-134	false
serotonergic agents	89-107	selective serotonin reuptake inhibitors	144-182	false
serotonergic agents	89-107	SSRIs	185-189	false
antidepressants	120-134	selective serotonin reuptake inhibitors	144-182	false
antidepressants	120-134	SSRIs	185-189	false
selective serotonin reuptake inhibitors	144-182	SSRIs	185-189	false

Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
ZYVOX	30-34	serotonergic agents	52-70	effect

If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).
ZYVOX	104-108	serotonergic agents	125-143	advise

Oral Anticoagulants: Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors.
Anticoagulants	5-18	Thyroid hormones	21-36	false

Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.
anticoagulants	28-41	thyroid	68-74	advise

Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.
Insulin	0-6	Hypoglycemics	16-28	false
Insulin	0-6	insulin	93-99	false
Insulin	0-6	hypoglycemic	109-120	false
Hypoglycemics	16-28	insulin	93-99	false
Hypoglycemics	16-28	hypoglycemic	109-120	false
insulin	93-99	hypoglycemic	109-120	false

Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.
insulin	19-25	hypoglycemics	35-47	false

Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
Cholestyramine	0-13	Cholestyramine	16-29	false
Cholestyramine	0-13	T4	42-43	false
Cholestyramine	0-13	T3	49-50	false
Cholestyramine	0-13	thyroid hormones	105-120	false
Cholestyramine	16-29	T4	42-43	mechanism
Cholestyramine	16-29	T3	49-50	mechanism
Cholestyramine	16-29	thyroid hormones	105-120	false
T4	42-43	T3	49-50	false
T4	42-43	thyroid hormones	105-120	false
T3	49-50	thyroid hormones	105-120	false

Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.
cholestyramine	64-77	thyroid hormones	83-98	advise

Estrogen, Oral Contraceptives: Estrogens tend to increase serum thyroxine-binding globulin (TBg).
Estrogen	0-7	Contraceptives	15-28	false
Estrogen	0-7	Estrogens	31-39	false
Contraceptives	15-28	Estrogens	31-39	false

In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.
levothyroxine	100-112	estrogens	136-144	mechanism
levothyroxine	100-112	thyroid	174-180	false
estrogens	136-144	thyroid	174-180	false

Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
thyroid	42-48	estrogens	138-146	advise
thyroid	42-48	estrogen	151-158	false
thyroid	42-48	contraceptives	176-189	advise
estrogens	138-146	estrogen	151-158	false
estrogens	138-146	contraceptives	176-189	false
estrogen	151-158	contraceptives	176-189	false

Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
Tricyclic Antidepressants	0-24	thyroid products	34-49	false
Tricyclic Antidepressants	0-24	imipramine	56-65	false
Tricyclic Antidepressants	0-24	tricyclic antidepressants	77-101	false
thyroid products	34-49	imipramine	56-65	effect
thyroid products	34-49	tricyclic antidepressants	77-101	effect
imipramine	56-65	tricyclic antidepressants	77-101	false

Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.
Digitalis	0-8	Thyroid preparations	11-30	false
Digitalis	0-8	digitalis	68-76	false
Thyroid preparations	11-30	digitalis	68-76	effect

Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.
Ketamine	0-7	thyroid preparation	45-63	false
Ketamine	0-7	anesthetic	82-91	false
thyroid preparation	45-63	anesthetic	82-91	effect

Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
Vasopressor	0-10	Thyroxine	14-22	false
Vasopressor	0-10	epinephrine	82-92	false
Vasopressor	0-10	norepinephrine	98-111	false
Thyroxine	14-22	epinephrine	82-92	effect
Thyroxine	14-22	norepinephrine	98-111	effect
epinephrine	82-92	norepinephrine	98-111	false

Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
thyroid hormone	136-150	androgens	161-169	false
thyroid hormone	136-150	corticosteroids	172-186	false
thyroid hormone	136-150	estrogens	189-197	false
thyroid hormone	136-150	contraceptives	205-218	false
thyroid hormone	136-150	estrogens	231-239	false
thyroid hormone	136-150	iodine	242-247	false
thyroid hormone	136-150	salicylates	314-324	false
androgens	161-169	corticosteroids	172-186	false
androgens	161-169	estrogens	189-197	false
androgens	161-169	contraceptives	205-218	false
androgens	161-169	estrogens	231-239	false
androgens	161-169	iodine	242-247	false
androgens	161-169	salicylates	314-324	false
corticosteroids	172-186	estrogens	189-197	false
corticosteroids	172-186	contraceptives	205-218	false
corticosteroids	172-186	estrogens	231-239	false
corticosteroids	172-186	iodine	242-247	false
corticosteroids	172-186	salicylates	314-324	false
estrogens	189-197	contraceptives	205-218	false
estrogens	189-197	estrogens	231-239	false
estrogens	189-197	iodine	242-247	false
estrogens	189-197	salicylates	314-324	false
contraceptives	205-218	estrogens	231-239	false
contraceptives	205-218	iodine	242-247	false
contraceptives	205-218	salicylates	314-324	false
estrogens	231-239	iodine	242-247	false
estrogens	231-239	salicylates	314-324	false
iodine	242-247	salicylates	314-324	false

Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.
estrogens	10-18	estrogen	24-31	false
estrogens	10-18	contraceptives	49-62	false
estrogen	24-31	contraceptives	49-62	false

Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy.
androgen	80-87	corticosteroid	92-105	false

Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
ammonium chloride	40-56	sodium acid phosphate	59-79	false
ammonium chloride	40-56	amphetamine	145-155	mechanism
sodium acid phosphate	59-79	amphetamine	145-155	mechanism

Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.
Adrenergic blockers	0-18	Adrenergic blockers	20-38	false
Adrenergic blockers	0-18	amphetamines	57-68	false
Adrenergic blockers	20-38	amphetamines	57-68	effect

Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
Antidepressants	0-14	tricyclic	17-25	false
Antidepressants	0-14	Amphetamines	27-38	false
Antidepressants	0-14	tricyclic antidepressants	68-92	false
Antidepressants	0-14	sympathomimetic agents	97-118	false
tricyclic	17-25	Amphetamines	27-38	false
tricyclic	17-25	tricyclic antidepressants	68-92	false
tricyclic	17-25	sympathomimetic agents	97-118	false
Amphetamines	27-38	tricyclic antidepressants	68-92	effect
Amphetamines	27-38	sympathomimetic agents	97-118	effect
tricyclic antidepressants	68-92	sympathomimetic agents	97-118	false

d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
d-amphetamine	0-12	desipramine	19-29	mechanism
d-amphetamine	0-12	protriptyline	34-46	mechanism
d-amphetamine	0-12	tricyclics	67-76	mechanism
d-amphetamine	0-12	d-amphetamine	141-153	false
desipramine	19-29	protriptyline	34-46	false
desipramine	19-29	tricyclics	67-76	false
desipramine	19-29	d-amphetamine	141-153	false
protriptyline	34-46	tricyclics	67-76	false
protriptyline	34-46	d-amphetamine	141-153	false
tricyclics	67-76	d-amphetamine	141-153	false

MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
MAO inhibitors	0-13	MAOI antidepressants	15-34	false
MAO inhibitors	0-13	furazolidone	64-75	false
MAO inhibitors	0-13	amphetamine	83-93	false
MAOI antidepressants	15-34	furazolidone	64-75	false
MAOI antidepressants	15-34	amphetamine	83-93	mechanism
furazolidone	64-75	amphetamine	83-93	mechanism

Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
Antihistamines	0-13	Amphetamines	16-27	false
Antihistamines	0-13	antihistamines	67-80	false
Amphetamines	16-27	antihistamines	67-80	effect

Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
Antihypertensives	0-16	Amphetamines	19-30	false
Antihypertensives	0-16	antihypertensives	74-90	false
Amphetamines	19-30	antihypertensives	74-90	effect

Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
Chlorpromazine	0-13	Chlorpromazine	16-29	false
Chlorpromazine	0-13	amphetamines	126-137	false
Chlorpromazine	0-13	amphetamine	164-174	false
Chlorpromazine	16-29	amphetamines	126-137	effect
Chlorpromazine	16-29	amphetamine	164-174	false
amphetamines	126-137	amphetamine	164-174	false

Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
Ethosuximide	0-11	Amphetamines	14-25	false
Ethosuximide	0-11	ethosuximide	62-73	false
Amphetamines	14-25	ethosuximide	62-73	mechanism

Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.
Haloperidol	0-10	Haloperidol	13-23	false
Haloperidol	0-10	amphetamines	101-112	false
Haloperidol	13-23	amphetamines	101-112	effect

Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
Lithium carbonate	0-16	amphetamines	60-71	false
Lithium carbonate	0-16	lithium carbonate	93-109	false
amphetamines	60-71	lithium carbonate	93-109	effect

Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
Meperidine	0-9	Amphetamines	12-23	false
Meperidine	0-9	meperidine	60-69	false
Amphetamines	12-23	meperidine	60-69	effect

Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.
Methenamine	0-10	amphetamines	41-52	false
Methenamine	0-10	methenamine	121-131	false
amphetamines	41-52	methenamine	121-131	mechanism

Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
Norepinephrine	0-13	Amphetamines	16-27	false
Norepinephrine	0-13	norepinephrine	62-75	false
Amphetamines	16-27	norepinephrine	62-75	effect

Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
Phenobarbital	0-12	Amphetamines	15-26	false
Phenobarbital	0-12	phenobarbital	63-75	false
Amphetamines	15-26	phenobarbital	63-75	mechanism

Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
Phenytoin	0-8	Amphetamines	11-22	false
Phenytoin	0-8	phenytoin	59-67	false
Amphetamines	11-22	phenytoin	59-67	mechanism

Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
Propoxyphene	0-11	propoxyphene	26-37	false
Propoxyphene	0-11	amphetamine	51-61	false
propoxyphene	26-37	amphetamine	51-61	effect

Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
Veratrum alkaloids	0-17	Amphetamines	20-31	false
Veratrum alkaloids	0-17	veratrum alkaloids	67-84	false
Amphetamines	20-31	veratrum alkaloids	67-84	effect

Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.
diuretics	56-64	PRINIVIL	240-247	effect

The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.
PRINIVIL	44-51	diuretic	98-105	false
PRINIVIL	44-51	PRINIVIL	175-182	false
diuretic	98-105	PRINIVIL	175-182	effect

If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
diuretic	35-42	PRINIVIL	67-74	advise

When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.
diuretic	7-14	PRINIVIL	63-70	effect

Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
ACE inhibitors	13-26	diuretics	48-56	false
ACE inhibitors	13-26	ACE inhibitor	88-100	false
ACE inhibitors	13-26	diuretic	141-148	false
diuretics	48-56	ACE inhibitor	88-100	false
diuretics	48-56	diuretic	141-148	false
ACE inhibitor	88-100	diuretic	141-148	advise

Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.
Non-steroidal Anti-inflammatory Agents	0-37	non-steroidal anti-inflammatory drugs	116-152	false
Non-steroidal Anti-inflammatory Agents	0-37	lisinopril	180-189	false
non-steroidal anti-inflammatory drugs	116-152	lisinopril	180-189	effect

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
NSAIDs	21-26	ACE inhibitors	72-85	effect
NSAIDs	21-26	lisinopril	98-107	effect
ACE inhibitors	72-85	lisinopril	98-107	false

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	66-71	ACE inhibitors	92-105	advise

In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
PRINIVIL	99-106	PRINIVIL	131-138	false
PRINIVIL	99-106	indomethacin	165-176	false
PRINIVIL	99-106	indomethacin	190-201	false
PRINIVIL	131-138	indomethacin	165-176	false
PRINIVIL	131-138	indomethacin	190-201	false
indomethacin	165-176	indomethacin	190-201	false

Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.
PRINIVIL	14-21	nitrates	56-63	false
PRINIVIL	14-21	digoxin	72-78	false
nitrates	56-63	digoxin	72-78	false

No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide.
PRINIVIL	67-74	propranolol	104-114	false
PRINIVIL	67-74	hydrochlorothiazide	119-137	false
propranolol	104-114	hydrochlorothiazide	119-137	false

Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.
PRINIVIL	35-42	thiazide-type diuretics	80-102	effect

Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
PRINIVIL	7-14	potassium-sparing diuretics	21-47	effect
PRINIVIL	7-14	spironolactone	56-69	effect
PRINIVIL	7-14	triamterene	72-82	effect
PRINIVIL	7-14	amiloride	88-96	effect
PRINIVIL	7-14	potassium	100-108	effect
potassium-sparing diuretics	21-47	spironolactone	56-69	false
potassium-sparing diuretics	21-47	triamterene	72-82	false
potassium-sparing diuretics	21-47	amiloride	88-96	false
potassium-sparing diuretics	21-47	potassium	100-108	false
spironolactone	56-69	triamterene	72-82	false
spironolactone	56-69	amiloride	88-96	false
spironolactone	56-69	potassium	100-108	false
triamterene	72-82	amiloride	88-96	false
triamterene	72-82	potassium	100-108	false
amiloride	88-96	potassium	100-108	false

Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
Lithium	0-6	Lithium	9-15	false
Lithium	0-6	lithium	66-72	false
Lithium	0-6	ACE inhibitors	144-157	false
Lithium	9-15	lithium	66-72	false
Lithium	9-15	ACE inhibitors	144-157	false
lithium	66-72	ACE inhibitors	144-157	effect

Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.
Lithium	0-6	lithium	64-70	false
Lithium	0-6	ACE inhibitor	80-92	false
lithium	64-70	ACE inhibitor	80-92	effect

It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
lithium	29-35	PRINIVIL	71-78	false
lithium	29-35	lithium	115-121	false
PRINIVIL	71-78	lithium	115-121	advise

- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
Lofexidine	2-11	alcohol	55-61	effect
Lofexidine	2-11	barbiturates	64-75	effect
Lofexidine	2-11	sedatives	87-95	effect
alcohol	55-61	barbiturates	64-75	false
alcohol	55-61	sedatives	87-95	false
barbiturates	64-75	sedatives	87-95	false

- Lofexidine may enhance the effects of anti-hypertensive drug therapy
Lofexidine	2-11	anti-hypertensive drug	40-61	effect

- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.
tricyclic antidepressants	21-45	lofexidine	74-83	effect

Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin.
Theophylline	0-11	theophylline	86-97	false
Theophylline	0-11	lomefloxacin	177-188	false
theophylline	86-97	lomefloxacin	177-188	false

In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.
theophylline	51-62	lomefloxacin	73-84	false
theophylline	51-62	theophylline	139-150	false
theophylline	51-62	theophylline	192-203	false
lomefloxacin	73-84	theophylline	139-150	false
lomefloxacin	73-84	theophylline	192-203	false
theophylline	139-150	theophylline	192-203	false

Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
Antacids	0-7	sucralfate	13-22	false
Antacids	0-7	Sucralfate	25-34	false
Antacids	0-7	antacids	40-47	false
Antacids	0-7	magnesium	60-68	false
Antacids	0-7	aluminum	73-80	false
Antacids	0-7	Videx	157-161	false
Antacids	0-7	didanosine	165-174	false
Antacids	0-7	lomefloxacin	280-291	false
sucralfate	13-22	Sucralfate	25-34	false
sucralfate	13-22	antacids	40-47	false
sucralfate	13-22	magnesium	60-68	false
sucralfate	13-22	aluminum	73-80	false
sucralfate	13-22	Videx	157-161	false
sucralfate	13-22	didanosine	165-174	false
sucralfate	13-22	lomefloxacin	280-291	false
Sucralfate	25-34	antacids	40-47	false
Sucralfate	25-34	magnesium	60-68	false
Sucralfate	25-34	aluminum	73-80	false
Sucralfate	25-34	Videx	157-161	false
Sucralfate	25-34	didanosine	165-174	false
Sucralfate	25-34	lomefloxacin	280-291	mechanism
antacids	40-47	magnesium	60-68	false
antacids	40-47	aluminum	73-80	false
antacids	40-47	Videx	157-161	false
antacids	40-47	didanosine	165-174	false
antacids	40-47	lomefloxacin	280-291	false
magnesium	60-68	aluminum	73-80	false
magnesium	60-68	Videx	157-161	false
magnesium	60-68	didanosine	165-174	false
magnesium	60-68	lomefloxacin	280-291	mechanism
aluminum	73-80	Videx	157-161	false
aluminum	73-80	didanosine	165-174	false
aluminum	73-80	lomefloxacin	280-291	mechanism
Videx	157-161	didanosine	165-174	false
Videx	157-161	lomefloxacin	280-291	mechanism
didanosine	165-174	lomefloxacin	280-291	mechanism

Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
Sucralfate	0-9	lomefloxacin	39-50	mechanism

Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
Magnesium	0-8	aluminum	15-22	false
Magnesium	0-8	antacids	35-42	false
Magnesium	0-8	lomefloxacin	77-88	mechanism
Magnesium	0-8	lomefloxacin	144-155	false
aluminum	15-22	antacids	35-42	false
aluminum	15-22	lomefloxacin	77-88	mechanism
aluminum	15-22	lomefloxacin	144-155	false
antacids	35-42	lomefloxacin	77-88	mechanism
antacids	35-42	lomefloxacin	144-155	false
lomefloxacin	77-88	lomefloxacin	144-155	false

Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;
antacid	24-30	lomefloxacin	36-47	mechanism

therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.
lomefloxacin	57-68	lomefloxacin	98-109	false

Caffeine: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.
Caffeine	0-7	caffeine	28-35	false
Caffeine	0-7	lomefloxacin	188-199	false
caffeine	28-35	lomefloxacin	188-199	false

This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine.
caffeine	116-123	paraxanthine	150-161	false

Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.
quinolones	6-15	caffeine	90-97	mechanism
quinolones	6-15	caffeine	228-235	false
caffeine	90-97	caffeine	228-235	false

Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.
Cimetidine	0-9	Cimetidine	12-21	false
Cimetidine	0-9	quinolones	88-97	false
Cimetidine	12-21	quinolones	88-97	mechanism

The interaction between lomefloxacin and cimetidine has not been studied.
lomefloxacin	24-35	cimetidine	41-50	false

Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
Cyclosporine	0-11	cyclosporine	39-50	false
Cyclosporine	0-11	cyclosporine	95-106	false
Cyclosporine	0-11	quinolone class	134-148	false
cyclosporine	39-50	cyclosporine	95-106	false
cyclosporine	39-50	quinolone class	134-148	false
cyclosporine	95-106	quinolone class	134-148	mechanism

Interaction between lomefloxacin and cyclosporine has not been studied.
lomefloxacin	20-31	cyclosporine	37-48	false

Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.
Omeprazole	0-9	lomefloxacin	49-60	false
Omeprazole	0-9	lomefloxacin	140-151	false
Omeprazole	0-9	omeprazole	194-203	false
lomefloxacin	49-60	lomefloxacin	140-151	false
lomefloxacin	49-60	omeprazole	194-203	false
lomefloxacin	140-151	omeprazole	194-203	false

Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.
Phenytoin	0-8	phenytoin	60-68	false
Phenytoin	0-8	phenytoin sodium	146-161	false
Phenytoin	0-8	lomefloxacin	210-221	false
phenytoin	60-68	phenytoin sodium	146-161	false
phenytoin	60-68	lomefloxacin	210-221	false
phenytoin sodium	146-161	lomefloxacin	210-221	false

Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.
Lomefloxacin	0-11	phenytoin	57-65	false

Probenecid: Probenecid slows the renal elimination of lome-floxacin.
Probenecid	0-9	Probenecid	12-21	false

Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
Terfenadine	0-10	terfenadine	103-113	false
Terfenadine	0-10	lomefloxacin	129-140	false
Terfenadine	0-10	lomefloxacin	196-207	false
Terfenadine	0-10	terfenadine	213-223	false
terfenadine	103-113	lomefloxacin	129-140	false
terfenadine	103-113	lomefloxacin	196-207	false
terfenadine	103-113	terfenadine	213-223	false
lomefloxacin	129-140	lomefloxacin	196-207	false
lomefloxacin	129-140	terfenadine	213-223	false
lomefloxacin	196-207	terfenadine	213-223	false

Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
Warfarin	0-7	Quinolones	10-19	false
Warfarin	0-7	anticoagulant	57-69	false
Warfarin	0-7	warfarin	72-79	false
Quinolones	10-19	anticoagulant	57-69	effect
Quinolones	10-19	warfarin	72-79	effect
anticoagulant	57-69	warfarin	72-79	false

However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.
warfarin	93-100	warfarin	198-205	false
warfarin	93-100	lomefloxacin	211-222	false
warfarin	198-205	lomefloxacin	211-222	false

Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
Probenecid	0-9	b-lactam antibiotics	26-45	false
Probenecid	0-9	loracarbef	67-76	false
Probenecid	0-9	probenecid	94-103	false
Probenecid	0-9	loracarbef	164-173	false
b-lactam antibiotics	26-45	loracarbef	67-76	false
b-lactam antibiotics	26-45	probenecid	94-103	mechanism
b-lactam antibiotics	26-45	loracarbef	164-173	false
loracarbef	67-76	probenecid	94-103	mechanism
loracarbef	67-76	loracarbef	164-173	false
probenecid	94-103	loracarbef	164-173	false

Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.
Loratadine	0-9	erythromycin	80-91	false
Loratadine	0-9	cimetidine	94-103	false
Loratadine	0-9	ketoconazole	110-121	false
erythromycin	80-91	cimetidine	94-103	false
erythromycin	80-91	ketoconazole	110-121	false
cimetidine	94-103	ketoconazole	110-121	false

Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
loratadine	59-68	descarboethoxyloratadine	77-100	false
loratadine	59-68	loratadine	146-155	false
loratadine	59-68	loratadine	294-303	false
descarboethoxyloratadine	77-100	loratadine	146-155	false
descarboethoxyloratadine	77-100	loratadine	294-303	false
loratadine	146-155	loratadine	294-303	false

No effects on plasma concentrations of cimetidine or ketoconazole were observed.
cimetidine	39-48	ketoconazole	53-64	false

Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
erythromycin	40-51	loratadine	92-101	mechanism
erythromycin	40-51	erythromycin	134-145	false
loratadine	92-101	erythromycin	134-145	false

TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and Descarboethoxyloratadine After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers
Loratadine	59-68	Descarboethoxyloratadine	74-97	false
Loratadine	59-68	Loratadine	134-143	false
Descarboethoxyloratadine	74-97	Loratadine	134-143	false

Loratadine Descarboethoxyloratadine
Loratadine	0-9	Descarboethoxyloratadine	11-34	false

There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine.
contraceptives	88-101	loratadine	107-116	false

Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
benzodiazepines	13-27	lorazepam	40-48	false
benzodiazepines	13-27	barbiturates	125-136	effect
benzodiazepines	13-27	alcohol	141-147	effect
lorazepam	40-48	barbiturates	125-136	effect
lorazepam	40-48	alcohol	141-147	effect
barbiturates	125-136	alcohol	141-147	false

Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
Lorazepam	11-19	benzodiazepines	54-68	false
Lorazepam	11-19	ethyl alcohol	144-156	effect
Lorazepam	11-19	phenothiazines	159-172	effect
Lorazepam	11-19	barbiturates	175-186	effect
Lorazepam	11-19	MAO inhibitors	189-202	effect
Lorazepam	11-19	antidepressants	215-229	effect
Lorazepam	11-19	scopolamine	236-246	false
Lorazepam	11-19	lorazepam	286-294	false
benzodiazepines	54-68	ethyl alcohol	144-156	effect
benzodiazepines	54-68	phenothiazines	159-172	effect
benzodiazepines	54-68	barbiturates	175-186	effect
benzodiazepines	54-68	MAO inhibitors	189-202	effect
benzodiazepines	54-68	antidepressants	215-229	effect
benzodiazepines	54-68	scopolamine	236-246	false
benzodiazepines	54-68	lorazepam	286-294	false
ethyl alcohol	144-156	phenothiazines	159-172	false
ethyl alcohol	144-156	barbiturates	175-186	false
ethyl alcohol	144-156	MAO inhibitors	189-202	false
ethyl alcohol	144-156	antidepressants	215-229	false
ethyl alcohol	144-156	scopolamine	236-246	false
ethyl alcohol	144-156	lorazepam	286-294	false
phenothiazines	159-172	barbiturates	175-186	false
phenothiazines	159-172	MAO inhibitors	189-202	false
phenothiazines	159-172	antidepressants	215-229	false
phenothiazines	159-172	scopolamine	236-246	false
phenothiazines	159-172	lorazepam	286-294	false
barbiturates	175-186	MAO inhibitors	189-202	false
barbiturates	175-186	antidepressants	215-229	false
barbiturates	175-186	scopolamine	236-246	false
barbiturates	175-186	lorazepam	286-294	false
MAO inhibitors	189-202	antidepressants	215-229	false
MAO inhibitors	189-202	scopolamine	236-246	false
MAO inhibitors	189-202	lorazepam	286-294	false
antidepressants	215-229	scopolamine	236-246	false
antidepressants	215-229	lorazepam	286-294	false
scopolamine	236-246	lorazepam	286-294	effect

No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.
hydrochlorothiazide	98-116	digoxin	119-125	false
hydrochlorothiazide	98-116	warfarin	128-135	false
hydrochlorothiazide	98-116	cimetidine	138-147	false
hydrochlorothiazide	98-116	phenobarbital	153-165	false
digoxin	119-125	warfarin	128-135	false
digoxin	119-125	cimetidine	138-147	false
digoxin	119-125	phenobarbital	153-165	false
warfarin	128-135	cimetidine	138-147	false
warfarin	128-135	phenobarbital	153-165	false
cimetidine	138-147	phenobarbital	153-165	false

Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.
Rifampin	0-7	losartan	73-80	mechanism

Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.
Ketoconazole	0-11	losartan	46-53	false
Ketoconazole	0-11	losartan	116-123	false
Ketoconazole	0-11	erythromycin	130-141	false
losartan	46-53	losartan	116-123	false
losartan	46-53	erythromycin	130-141	false
losartan	116-123	erythromycin	130-141	false

Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
Fluconazole	0-10	losartan	95-102	mechanism

As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
potassium-sparing diuretics	81-107	spironolactone	116-129	false
potassium-sparing diuretics	81-107	triamterene	132-142	false
potassium-sparing diuretics	81-107	amiloride	145-153	false
potassium-sparing diuretics	81-107	potassium	157-165	false
spironolactone	116-129	triamterene	132-142	false
spironolactone	116-129	amiloride	145-153	false
spironolactone	116-129	potassium	157-165	false
triamterene	132-142	amiloride	145-153	false
triamterene	132-142	potassium	157-165	false
amiloride	145-153	potassium	157-165	false

As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
antihypertensive agents	14-36	losartan	70-77	false
antihypertensive agents	14-36	non-steroidal anti-inflammatory drug	101-136	false
antihypertensive agents	14-36	indomethacin	138-149	false
losartan	70-77	non-steroidal anti-inflammatory drug	101-136	false
losartan	70-77	indomethacin	138-149	effect
non-steroidal anti-inflammatory drug	101-136	indomethacin	138-149	false

Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
Itraconazole	0-11	Ketoconazole	13-24	false
Itraconazole	0-11	Erythromycin	26-37	false
Itraconazole	0-11	Clarithromycin	39-52	false
Itraconazole	0-11	Telithromycin	54-66	false
Itraconazole	0-11	HIV protease inhibitors	68-90	false
Itraconazole	0-11	Nefazodone	92-101	false
Itraconazole	0-11	Cyclosporine	103-114	false
Ketoconazole	13-24	Erythromycin	26-37	false
Ketoconazole	13-24	Clarithromycin	39-52	false
Ketoconazole	13-24	Telithromycin	54-66	false
Ketoconazole	13-24	HIV protease inhibitors	68-90	false
Ketoconazole	13-24	Nefazodone	92-101	false
Ketoconazole	13-24	Cyclosporine	103-114	false
Erythromycin	26-37	Clarithromycin	39-52	false
Erythromycin	26-37	Telithromycin	54-66	false
Erythromycin	26-37	HIV protease inhibitors	68-90	false
Erythromycin	26-37	Nefazodone	92-101	false
Erythromycin	26-37	Cyclosporine	103-114	false
Clarithromycin	39-52	Telithromycin	54-66	false
Clarithromycin	39-52	HIV protease inhibitors	68-90	false
Clarithromycin	39-52	Nefazodone	92-101	false
Clarithromycin	39-52	Cyclosporine	103-114	false
Telithromycin	54-66	HIV protease inhibitors	68-90	false
Telithromycin	54-66	Nefazodone	92-101	false
Telithromycin	54-66	Cyclosporine	103-114	false
HIV protease inhibitors	68-90	Nefazodone	92-101	false
HIV protease inhibitors	68-90	Cyclosporine	103-114	false
Nefazodone	92-101	Cyclosporine	103-114	false

Gemfibrozil Other fibrates Niacin (nicotinic acid) (=1 g/day)
Gemfibrozil	0-10	fibrates	18-25	false
Gemfibrozil	0-10	Niacin	27-32	false
Gemfibrozil	0-10	nicotinic acid	35-48	false
fibrates	18-25	Niacin	27-32	false
fibrates	18-25	nicotinic acid	35-48	false
Niacin	27-32	nicotinic acid	35-48	false

Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
Danazol	0-6	danazol	91-97	false
Danazol	0-6	lovastatin	133-142	false
danazol	91-97	lovastatin	133-142	effect

Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
Amiodarone	0-9	Verapamil	14-22	false
Amiodarone	0-9	amiodarone	86-95	false
Amiodarone	0-9	verapamil	100-108	false
Amiodarone	0-9	HMG-CoA reductase inhibitor class	169-201	false
Verapamil	14-22	amiodarone	86-95	false
Verapamil	14-22	verapamil	100-108	false
Verapamil	14-22	HMG-CoA reductase inhibitor class	169-201	false
amiodarone	86-95	verapamil	100-108	false
amiodarone	86-95	HMG-CoA reductase inhibitor class	169-201	effect
verapamil	100-108	HMG-CoA reductase inhibitor class	169-201	effect

Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.
Coumarin Anticoagulant	0-21	lovastatin	60-69	false
Coumarin Anticoagulant	0-21	warfarin	91-98	false
lovastatin	60-69	warfarin	91-98	false

However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
HMG-CoA reductase inhibitor	17-43	warfarin	168-175	effect

Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
coumarin anticoagulant	93-114	lovastatin	136-145	effect

It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
anticoagulants	42-55	lovastatin	105-114	advise

Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.
Lovastatin	0-9	anticoagulants	116-129	false

Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol.
Propranolol	0-10	lovastatin	169-178	false
Propranolol	0-10	propranolol	184-194	false
lovastatin	169-178	propranolol	184-194	false

Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.
Digoxin	0-6	lovastatin	78-87	false
Digoxin	0-6	digoxin	93-99	false
Digoxin	0-6	digoxin	126-132	false
lovastatin	78-87	digoxin	93-99	false
lovastatin	78-87	digoxin	126-132	false
digoxin	93-99	digoxin	126-132	false

Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide
Hypoglycemic Agents	5-23	MEVACOR	56-62	false
Hypoglycemic Agents	5-23	glipizide	163-171	false
Hypoglycemic Agents	5-23	chlorpropamide	181-194	false
MEVACOR	56-62	glipizide	163-171	false
MEVACOR	56-62	chlorpropamide	181-194	false
glipizide	163-171	chlorpropamide	181-194	false

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
loxapine	122-129	lorazepam	135-143	effect

The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
lymecycline	18-28	iron	106-109	mechanism
lymecycline	18-28	zinc	114-117	mechanism
iron	106-109	zinc	114-117	false

Oral contraceptives may be less effective while you are taking lymecycline.
contraceptives	5-18	lymecycline	63-73	effect

Warfarin: Meclofenamate sodium enhances the effect of warfarin.
Warfarin	0-7	Meclofenamate sodium	10-29	effect
Warfarin	0-7	warfarin	54-61	false
Meclofenamate sodium	10-29	warfarin	54-61	false

Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.
meclofenamate sodium	16-35	warfarin	69-76	advise
meclofenamate sodium	16-35	warfarin	93-100	false
warfarin	69-76	warfarin	93-100	false

Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.
Aspirin	0-6	aspirin	38-44	false
Aspirin	0-6	meclofenamate sodium	56-75	false
aspirin	38-44	meclofenamate sodium	56-75	mechanism

The urinary excretion of meclofenamate sodium is unaffected by aspirin, indicating no change in meclofenamate sodium absorption.
meclofenamate sodium	25-44	aspirin	63-69	false
meclofenamate sodium	25-44	meclofenamate sodium	96-115	false
aspirin	63-69	meclofenamate sodium	96-115	false

Meclofenamate sodium does not affect serum salicylate levels.
Meclofenamate sodium	0-19	salicylate	43-52	false

Propoxyphene: The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of meclofenamate sodium.
Propoxyphene	0-11	propoxyphene hydrochloride	47-72	false
Propoxyphene	0-11	meclofenamate sodium	113-132	false
propoxyphene hydrochloride	47-72	meclofenamate sodium	113-132	false

Antacids: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of meclofenamate sodium.
Antacids	0-7	aluminum hydroxide	40-47;63-71	false
Antacids	0-7	magnesium hydroxide	53-71	false
Antacids	0-7	meclofenamate sodium	112-131	false
aluminum hydroxide	40-47;63-71	magnesium hydroxide	53-71	false
aluminum hydroxide	40-47;63-71	meclofenamate sodium	112-131	false
magnesium hydroxide	53-71	meclofenamate sodium	112-131	false

Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
Aspirin	0-6	NSAIDs	23-28	false
Aspirin	0-6	Ponstel	61-67	false
Aspirin	0-6	aspirin	73-79	false
NSAIDs	23-28	Ponstel	61-67	false
NSAIDs	23-28	aspirin	73-79	advise
Ponstel	61-67	aspirin	73-79	advise

Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
Methotrexate	0-11	NSAIDs	14-19	false
Methotrexate	0-11	methotrexate	65-76	false
NSAIDs	14-19	methotrexate	65-76	mechanism

Caution should be used when NSAIDs are administered concomitantly with methotrexate.
NSAIDs	28-33	methotrexate	71-82	advise

ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
ACE inhibitors	0-13	NSAIDs	37-42	false
ACE inhibitors	0-13	ACE inhibitors	88-101	false
NSAIDs	37-42	ACE inhibitors	88-101	effect

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	66-71	ACE inhibitors	92-105	advise

Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	0-9	NSAIDs	86-91	false
Furosemide	0-9	furosemide	130-139	false
Furosemide	0-9	thiazides	145-153	false
NSAIDs	86-91	furosemide	130-139	effect
NSAIDs	86-91	thiazides	145-153	effect
furosemide	130-139	thiazides	145-153	false

During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
Ponstel	30-36	furosemide	43-52	advise

Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	0-6	NSAIDs	9-14	false
Lithium	0-6	lithium	53-59	false
Lithium	0-6	lithium	93-99	false
NSAIDs	9-14	lithium	53-59	mechanism
NSAIDs	9-14	lithium	93-99	mechanism
lithium	53-59	lithium	93-99	false

Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
NSAIDs	11-16	lithium	22-28	advise
NSAIDs	11-16	lithium	112-118	false
lithium	22-28	lithium	112-118	false

Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
Warfarin	0-7	warfarin	25-32	false
Warfarin	0-7	NSAIDs	38-43	false
warfarin	25-32	NSAIDs	38-43	effect

Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
Antacids	0-7	antacid	56-62	false
Antacids	0-7	magnesium hydroxide	87-105	false
Antacids	0-7	mefenamic acid	122-135	false
Antacids	0-7	mefenamic acid	167-180	false
Antacids	0-7	fluconazole	271-281	false
Antacids	0-7	lovastatin	284-293	false
Antacids	0-7	trimethoprim	299-310	false
antacid	56-62	magnesium hydroxide	87-105	false
antacid	56-62	mefenamic acid	122-135	false
antacid	56-62	mefenamic acid	167-180	false
antacid	56-62	fluconazole	271-281	false
antacid	56-62	lovastatin	284-293	false
antacid	56-62	trimethoprim	299-310	false
magnesium hydroxide	87-105	mefenamic acid	122-135	mechanism
magnesium hydroxide	87-105	mefenamic acid	167-180	false
magnesium hydroxide	87-105	fluconazole	271-281	false
magnesium hydroxide	87-105	lovastatin	284-293	false
magnesium hydroxide	87-105	trimethoprim	299-310	false
mefenamic acid	122-135	mefenamic acid	167-180	false
mefenamic acid	122-135	fluconazole	271-281	false
mefenamic acid	122-135	lovastatin	284-293	false
mefenamic acid	122-135	trimethoprim	299-310	false
mefenamic acid	167-180	fluconazole	271-281	false
mefenamic acid	167-180	lovastatin	284-293	false
mefenamic acid	167-180	trimethoprim	299-310	false
fluconazole	271-281	lovastatin	284-293	false
fluconazole	271-281	trimethoprim	299-310	false
lovastatin	284-293	trimethoprim	299-310	false

There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol).
beta blocker	97-108	propranolol	111-121	false

Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
halofantrine	79-90	Mefloquine	147-156	advise

Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
Mefloquine	30-39	quinine	74-80	effect
Mefloquine	30-39	quinidine	83-91	effect
Mefloquine	30-39	chloroquine	97-107	effect
quinine	74-80	quinidine	83-91	false
quinine	74-80	chloroquine	97-107	false
quinidine	83-91	chloroquine	97-107	false

This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
Mefloquine	78-87	anti-arrhythmic	185-199	effect
Mefloquine	78-87	beta-adrenergic blocking agents	204-234	effect
Mefloquine	78-87	calcium channel blockers	237-260	effect
Mefloquine	78-87	antihistamines	263-276	effect
Mefloquine	78-87	H1-blocking agents	281-298	effect
Mefloquine	78-87	tricyclic antidepressants	301-325	effect
Mefloquine	78-87	phenothiazines	331-344	effect
anti-arrhythmic	185-199	beta-adrenergic blocking agents	204-234	false
anti-arrhythmic	185-199	calcium channel blockers	237-260	false
anti-arrhythmic	185-199	antihistamines	263-276	false
anti-arrhythmic	185-199	H1-blocking agents	281-298	false
anti-arrhythmic	185-199	tricyclic antidepressants	301-325	false
anti-arrhythmic	185-199	phenothiazines	331-344	false
beta-adrenergic blocking agents	204-234	calcium channel blockers	237-260	false
beta-adrenergic blocking agents	204-234	antihistamines	263-276	false
beta-adrenergic blocking agents	204-234	H1-blocking agents	281-298	false
beta-adrenergic blocking agents	204-234	tricyclic antidepressants	301-325	false
beta-adrenergic blocking agents	204-234	phenothiazines	331-344	false
calcium channel blockers	237-260	antihistamines	263-276	false
calcium channel blockers	237-260	H1-blocking agents	281-298	false
calcium channel blockers	237-260	tricyclic antidepressants	301-325	false
calcium channel blockers	237-260	phenothiazines	331-344	false
antihistamines	263-276	H1-blocking agents	281-298	false
antihistamines	263-276	tricyclic antidepressants	301-325	false
antihistamines	263-276	phenothiazines	331-344	false
H1-blocking agents	281-298	tricyclic antidepressants	301-325	false
H1-blocking agents	281-298	phenothiazines	331-344	false
tricyclic antidepressants	301-325	phenothiazines	331-344	false

In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
anticonvulsant	22-35	valproic acid	42-54	false
anticonvulsant	22-35	carbamazepine	57-69	false
anticonvulsant	22-35	phenobarbital	72-84	false
anticonvulsant	22-35	phenytoin	89-97	false
anticonvulsant	22-35	Mefloquine	124-133	effect
anticonvulsant	22-35	anticonvulsant	199-212	false
valproic acid	42-54	carbamazepine	57-69	false
valproic acid	42-54	phenobarbital	72-84	false
valproic acid	42-54	phenytoin	89-97	false
valproic acid	42-54	Mefloquine	124-133	effect
valproic acid	42-54	anticonvulsant	199-212	false
carbamazepine	57-69	phenobarbital	72-84	false
carbamazepine	57-69	phenytoin	89-97	false
carbamazepine	57-69	Mefloquine	124-133	effect
carbamazepine	57-69	anticonvulsant	199-212	false
phenobarbital	72-84	phenytoin	89-97	false
phenobarbital	72-84	Mefloquine	124-133	effect
phenobarbital	72-84	anticonvulsant	199-212	false
phenytoin	89-97	Mefloquine	124-133	effect
phenytoin	89-97	anticonvulsant	199-212	false
Mefloquine	124-133	anticonvulsant	199-212	false

When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.
Mefloquine	5-14	live typhoid vaccines	48-68	effect

Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.
Mefloquine	29-38	anticoagulants	118-131	advise

In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile.
sulfadoxine	54-64	pyrimethamine	70-82	false

Broad-Spectrum Antibiotics-Broad-spectrum antibiotics may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.
Broad-Spectrum Antibiotics	0-25	Broad-spectrum antibiotics	27-52	false
Broad-Spectrum Antibiotics	0-25	vitamin K	95-103	false
Broad-spectrum antibiotics	27-52	vitamin K	95-103	false

Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
Cephalosporins	0-13	Cephalosporins	15-28	false
Cephalosporins	0-13	cefmenoxime	79-89	false
Cephalosporins	0-13	cefoperazone	92-103	false
Cephalosporins	0-13	cefotetan	106-114	false
Cephalosporins	0-13	cefamandole	117-127	false
Cephalosporins	0-13	latamoxef	130-138	false
Cephalosporins	0-13	cefazolin	163-171	false
Cephalosporins	15-28	cefmenoxime	79-89	false
Cephalosporins	15-28	cefoperazone	92-103	false
Cephalosporins	15-28	cefotetan	106-114	false
Cephalosporins	15-28	cefamandole	117-127	false
Cephalosporins	15-28	latamoxef	130-138	false
Cephalosporins	15-28	cefazolin	163-171	false
cefmenoxime	79-89	cefoperazone	92-103	false
cefmenoxime	79-89	cefotetan	106-114	false
cefmenoxime	79-89	cefamandole	117-127	false
cefmenoxime	79-89	latamoxef	130-138	false
cefmenoxime	79-89	cefazolin	163-171	false
cefoperazone	92-103	cefotetan	106-114	false
cefoperazone	92-103	cefamandole	117-127	false
cefoperazone	92-103	latamoxef	130-138	false
cefoperazone	92-103	cefazolin	163-171	false
cefotetan	106-114	cefamandole	117-127	false
cefotetan	106-114	latamoxef	130-138	false
cefotetan	106-114	cefazolin	163-171	false
cefamandole	117-127	latamoxef	130-138	false
cefamandole	117-127	cefazolin	163-171	false
latamoxef	130-138	cefazolin	163-171	false

Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
Cholestyramine	0-13	cholestyramine	37-50	false
Cholestyramine	0-13	vitamin K	56-64	false
Cholestyramine	0-13	vitamin K	95-103	false
cholestyramine	37-50	vitamin K	56-64	mechanism
cholestyramine	37-50	vitamin K	95-103	false
vitamin K	56-64	vitamin K	95-103	false

Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.
Colestipol	0-9	colestipol	33-42	false
Colestipol	0-9	vitamin K	48-56	false
Colestipol	0-9	vitamin K	87-95	false
colestipol	33-42	vitamin K	48-56	mechanism
colestipol	33-42	vitamin K	87-95	false
vitamin K	48-56	vitamin K	87-95	false

Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.
Mineral Oil	0-10	mineral oil	34-44	false
Mineral Oil	0-10	vitamin K	50-58	false
Mineral Oil	0-10	vitamin K	89-97	false
mineral oil	34-44	vitamin K	50-58	mechanism
mineral oil	34-44	vitamin K	89-97	false
vitamin K	50-58	vitamin K	89-97	false

Orlistat-Orlistat may decrease the absorption of vitamin K.
Orlistat	0-7	Orlistat	9-16	false
Orlistat	0-7	vitamin K	49-57	false
Orlistat	9-16	vitamin K	49-57	mechanism

Salicylates-Salicylates in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.
Salicylates	0-10	Salicylates	12-22	false

Warfarin-Vitamin K can antagonize the effect of warfarin
Warfarin	0-7	Vitamin K	9-17	false
Warfarin	0-7	warfarin	48-55	false
Vitamin K	9-17	warfarin	48-55	effect

Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
Nabilone	0-7	psychoactive drugs	78-95	advise
Nabilone	0-7	CNS depressants	100-114	advise
Nabilone	0-7	alcohol	127-133	advise
Nabilone	0-7	barbiturates	136-147	advise
Nabilone	0-7	narcotic analgesics	153-171	advise
psychoactive drugs	78-95	CNS depressants	100-114	false
psychoactive drugs	78-95	alcohol	127-133	false
psychoactive drugs	78-95	barbiturates	136-147	false
psychoactive drugs	78-95	narcotic analgesics	153-171	false
CNS depressants	100-114	alcohol	127-133	false
CNS depressants	100-114	barbiturates	136-147	false
CNS depressants	100-114	narcotic analgesics	153-171	false
alcohol	127-133	barbiturates	136-147	false
alcohol	127-133	narcotic analgesics	153-171	false
barbiturates	136-147	narcotic analgesics	153-171	false

Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
Nabilone	0-7	diazepam	89-96	effect
Nabilone	0-7	secobarbitone sodium	99-118	effect
Nabilone	0-7	alcohol	121-127	effect
Nabilone	0-7	codeine	132-138	effect
diazepam	89-96	secobarbitone sodium	99-118	false
diazepam	89-96	alcohol	121-127	false
diazepam	89-96	codeine	132-138	false
secobarbitone sodium	99-118	alcohol	121-127	false
secobarbitone sodium	99-118	codeine	132-138	false
alcohol	121-127	codeine	132-138	false

Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
nabumetone	47-56	warfarin	63-70	advise
nabumetone	47-56	NSAIDs	117-122	false
warfarin	63-70	NSAIDs	117-122	int

Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.
aluminum	33-40	antacid	53-59	false
aluminum	33-40	6MNA	113-116	false
antacid	53-59	6MNA	113-116	false

When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.
beta-adrenergic receptor blocking agents	70-109	Anesthetics	112-122	int
beta-adrenergic receptor blocking agents	70-109	anesthetics	185-195	false
Anesthetics	112-122	anesthetics	185-195	false

Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia;
Antidiabetic drugs	0-17	insulin	36-42	false

Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
Tetracycline	0-11	bacteriostatic antibiotic	16-40	false
Tetracycline	0-11	penicillin	85-94	effect
bacteriostatic antibiotic	16-40	penicillin	85-94	false

Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
theophylline	26-37	quinolone	75-83	mechanism

There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
theophylline	27-38	quinolones	101-110	false
theophylline	27-38	theophylline	116-127	false
quinolones	101-110	theophylline	116-127	effect

Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.
theophylline	25-36	theophylline	87-98	false

Quinolones have been shown to interfere with the metabolism of caffeine.
Quinolones	0-9	caffeine	63-70	mechanism

Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
Quinolones	0-9	nalidixic acid	22-35	false
Quinolones	0-9	anticoagulant	74-86	false
Quinolones	0-9	warfarin	88-95	effect
nalidixic acid	22-35	anticoagulant	74-86	false
nalidixic acid	22-35	warfarin	88-95	effect
anticoagulant	74-86	warfarin	88-95	false

Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
Nitrofurantoin	0-13	nalidixic acid	57-70	effect

Antacids containing magnesium, aluminum, or calcium;
Antacids	0-7	magnesium	20-28	false
Antacids	0-7	aluminum	31-38	false
Antacids	0-7	calcium	44-50	false
magnesium	20-28	aluminum	31-38	false
magnesium	20-28	calcium	44-50	false
aluminum	31-38	calcium	44-50	false

sucralfate or divalent or trivalent cations such as iron;
sucralfate	0-9	iron	52-55	false

multivitamins containing zinc;
multivitamins	0-12	zinc	25-28	false

and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
Videx	4-8	Didanosine	13-22	false
Videx	4-8	quinolones	145-154	mechanism
Didanosine	13-22	quinolones	145-154	mechanism

Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.
cyclosporine	25-36	quinolones	90-99	false
cyclosporine	25-36	cyclosporine	105-116	false
quinolones	90-99	cyclosporine	105-116	mechanism

Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
cyclosporine	11-22	cyclosporine	73-84	false

Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.
REVIA	50-54	opiates	77-83	false

The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
REVIA	46-50	disulfiram	56-65	effect

Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
REVIA	62-66	thioridazine	72-83	effect

Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
REVIA	16-20	opioid	43-48	effect
REVIA	16-20	opioid analgesics	141-157	effect
opioid	43-48	opioid analgesics	141-157	false

In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
REVIA	92-96	opioid	113-118	effect

The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
NSAIDs	11-16	ACE inhibitors	48-61	effect

Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.
hydantoin	45-53	sulfonamide	56-66	false
hydantoin	45-53	sulfonylurea	71-82	false
sulfonamide	56-66	sulfonylurea	71-82	false

Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
naproxen	30-37	aspirin	43-49	advise
naproxen	30-37	naproxen	78-85	false
naproxen	30-37	aspirin	164-170	false
aspirin	43-49	naproxen	78-85	false
aspirin	43-49	aspirin	164-170	false
naproxen	78-85	aspirin	164-170	advise

Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.
lithium	20-26	lithium	69-75	false

Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
Naproxen	0-7	NSAIDs	19-24	false
Naproxen	0-7	propranolol	68-78	effect
Naproxen	0-7	beta-blockers	90-102	effect
NSAIDs	19-24	propranolol	68-78	effect
NSAIDs	19-24	beta-blockers	90-102	effect
propranolol	68-78	beta-blockers	90-102	false

Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
Probenecid	0-9	naproxen	40-47	mechanism

Caution should be used if naproxen is administered concomitantly with methotrexate.
naproxen	26-33	methotrexate	70-81	advise

Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
Naproxen	0-7	naproxen sodium	10-24	false
Naproxen	0-7	NSAIDs	36-41	false
Naproxen	0-7	methotrexate	97-108	mechanism
Naproxen	0-7	methotrexate	166-177	false
naproxen sodium	10-24	NSAIDs	36-41	false
naproxen sodium	10-24	methotrexate	97-108	mechanism
naproxen sodium	10-24	methotrexate	166-177	false
NSAIDs	36-41	methotrexate	97-108	mechanism
NSAIDs	36-41	methotrexate	166-177	false
methotrexate	97-108	methotrexate	166-177	false

Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
ergotamine	80-89	ergot-type medications	105-126	false
ergotamine	80-89	dihydroergotamine	134-150	false
ergotamine	80-89	methysergide	155-166	false
ergotamine	80-89	naratriptan	173-183	advise
ergot-type medications	105-126	dihydroergotamine	134-150	false
ergot-type medications	105-126	methysergide	155-166	false
ergot-type medications	105-126	naratriptan	173-183	advise
dihydroergotamine	134-150	methysergide	155-166	false
dihydroergotamine	134-150	naratriptan	173-183	advise
methysergide	155-166	naratriptan	173-183	advise

The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.
naratriptan	22-32	5-HT1 agonists	45-58	false

Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.
naratriptan	71-81	5-HT1 agonists	93-106	advise

Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
Selective serotonin reuptake inhibitors	0-38	SSRIs	41-45	false
Selective serotonin reuptake inhibitors	0-38	fluoxetine	55-64	false
Selective serotonin reuptake inhibitors	0-38	fluvoxamine	67-77	false
Selective serotonin reuptake inhibitors	0-38	paroxetine	80-89	false
Selective serotonin reuptake inhibitors	0-38	sertraline	92-101	false
SSRIs	41-45	fluoxetine	55-64	false
SSRIs	41-45	fluvoxamine	67-77	false
SSRIs	41-45	paroxetine	80-89	false
SSRIs	41-45	sertraline	92-101	false
fluoxetine	55-64	fluvoxamine	67-77	false
fluoxetine	55-64	paroxetine	80-89	false
fluoxetine	55-64	sertraline	92-101	false
fluvoxamine	67-77	paroxetine	80-89	false
fluvoxamine	67-77	sertraline	92-101	false
paroxetine	80-89	sertraline	92-101	false

If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
naratriptan	30-40	SSRI	49-52	advise

After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.
interferon beta-1a	23-40	AVONEX	43-48	false
interferon beta-1a	23-40	TYSABRI	82-88	mechanism
AVONEX	43-48	TYSABRI	82-88	mechanism

The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).
TYSABRI	22-28	AVONEX	105-110	false
TYSABRI	22-28	AVONEX	148-153	false
TYSABRI	22-28	TYSABRI	239-245	false
AVONEX	105-110	AVONEX	148-153	false
AVONEX	105-110	TYSABRI	239-245	false
AVONEX	148-153	TYSABRI	239-245	false

Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
TYSABRI	57-63	interferon beta-1a	82-99	false
TYSABRI	57-63	AVONEX	102-107	false
TYSABRI	57-63	glatiramer acetate	136-153	false
TYSABRI	57-63	beta-interferon	224-238	false
TYSABRI	57-63	glatiramer acetate	243-260	false
interferon beta-1a	82-99	AVONEX	102-107	false
interferon beta-1a	82-99	glatiramer acetate	136-153	false
interferon beta-1a	82-99	beta-interferon	224-238	false
interferon beta-1a	82-99	glatiramer acetate	243-260	false
AVONEX	102-107	glatiramer acetate	136-153	false
AVONEX	102-107	beta-interferon	224-238	false
AVONEX	102-107	glatiramer acetate	243-260	false
glatiramer acetate	136-153	beta-interferon	224-238	false
glatiramer acetate	136-153	glatiramer acetate	243-260	false
beta-interferon	224-238	glatiramer acetate	243-260	false

Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.
Starlix	0-6	tolbutamide	131-141	mechanism

Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.
Glyburide	0-8	Starlix	114-120	false
Glyburide	0-8	glyburide	183-191	false
Starlix	114-120	glyburide	183-191	false

Metformin: When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.
Metformin	0-8	Starlix	16-22	false
Metformin	0-8	metformin	99-107	false
Starlix	16-22	metformin	99-107	false

Digoxin: When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.
Digoxin	0-6	Starlix	14-20	false
Digoxin	0-6	digoxin	101-107	false
Starlix	14-20	digoxin	101-107	false

Warfarin: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.
Warfarin	0-7	Starlix	50-56	false
Warfarin	0-7	warfarin	147-154	false
Starlix	50-56	warfarin	147-154	false

Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.
Diclofenac	0-9	Starlix	57-63	false
Diclofenac	0-9	diclofenac	115-124	false
Starlix	57-63	diclofenac	115-124	false

In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
furosemide	70-79	propranolol	82-92	false
furosemide	70-79	captopril	95-103	false
furosemide	70-79	nicardipine	106-116	false
furosemide	70-79	pravastatin	119-129	false
furosemide	70-79	glyburide	132-140	false
furosemide	70-79	warfarin	143-150	false
furosemide	70-79	phenytoin	153-161	false
furosemide	70-79	acetylsalicylic acid	164-183	false
furosemide	70-79	tolbutamide	186-196	false
furosemide	70-79	metformin	203-211	false
furosemide	70-79	nateglinide	250-260	false
propranolol	82-92	captopril	95-103	false
propranolol	82-92	nicardipine	106-116	false
propranolol	82-92	pravastatin	119-129	false
propranolol	82-92	glyburide	132-140	false
propranolol	82-92	warfarin	143-150	false
propranolol	82-92	phenytoin	153-161	false
propranolol	82-92	acetylsalicylic acid	164-183	false
propranolol	82-92	tolbutamide	186-196	false
propranolol	82-92	metformin	203-211	false
propranolol	82-92	nateglinide	250-260	false
captopril	95-103	nicardipine	106-116	false
captopril	95-103	pravastatin	119-129	false
captopril	95-103	glyburide	132-140	false
captopril	95-103	warfarin	143-150	false
captopril	95-103	phenytoin	153-161	false
captopril	95-103	acetylsalicylic acid	164-183	false
captopril	95-103	tolbutamide	186-196	false
captopril	95-103	metformin	203-211	false
captopril	95-103	nateglinide	250-260	false
nicardipine	106-116	pravastatin	119-129	false
nicardipine	106-116	glyburide	132-140	false
nicardipine	106-116	warfarin	143-150	false
nicardipine	106-116	phenytoin	153-161	false
nicardipine	106-116	acetylsalicylic acid	164-183	false
nicardipine	106-116	tolbutamide	186-196	false
nicardipine	106-116	metformin	203-211	false
nicardipine	106-116	nateglinide	250-260	false
pravastatin	119-129	glyburide	132-140	false
pravastatin	119-129	warfarin	143-150	false
pravastatin	119-129	phenytoin	153-161	false
pravastatin	119-129	acetylsalicylic acid	164-183	false
pravastatin	119-129	tolbutamide	186-196	false
pravastatin	119-129	metformin	203-211	false
pravastatin	119-129	nateglinide	250-260	false
glyburide	132-140	warfarin	143-150	false
glyburide	132-140	phenytoin	153-161	false
glyburide	132-140	acetylsalicylic acid	164-183	false
glyburide	132-140	tolbutamide	186-196	false
glyburide	132-140	metformin	203-211	false
glyburide	132-140	nateglinide	250-260	false
warfarin	143-150	phenytoin	153-161	false
warfarin	143-150	acetylsalicylic acid	164-183	false
warfarin	143-150	tolbutamide	186-196	false
warfarin	143-150	metformin	203-211	false
warfarin	143-150	nateglinide	250-260	false
phenytoin	153-161	acetylsalicylic acid	164-183	false
phenytoin	153-161	tolbutamide	186-196	false
phenytoin	153-161	metformin	203-211	false
phenytoin	153-161	nateglinide	250-260	false
acetylsalicylic acid	164-183	tolbutamide	186-196	false
acetylsalicylic acid	164-183	metformin	203-211	false
acetylsalicylic acid	164-183	nateglinide	250-260	false
tolbutamide	186-196	metformin	203-211	false
tolbutamide	186-196	nateglinide	250-260	false
metformin	203-211	nateglinide	250-260	false

Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
nateglinide	11-21	propranolol	72-82	false
nateglinide	11-21	glyburide	85-93	false
nateglinide	11-21	nicardipine	96-106	false
nateglinide	11-21	warfarin	109-116	false
nateglinide	11-21	phenytoin	119-127	false
nateglinide	11-21	acetylsalicylic acid	130-149	false
nateglinide	11-21	tolbutamide	156-166	false
propranolol	72-82	glyburide	85-93	false
propranolol	72-82	nicardipine	96-106	false
propranolol	72-82	warfarin	109-116	false
propranolol	72-82	phenytoin	119-127	false
propranolol	72-82	acetylsalicylic acid	130-149	false
propranolol	72-82	tolbutamide	156-166	false
glyburide	85-93	nicardipine	96-106	false
glyburide	85-93	warfarin	109-116	false
glyburide	85-93	phenytoin	119-127	false
glyburide	85-93	acetylsalicylic acid	130-149	false
glyburide	85-93	tolbutamide	156-166	false
nicardipine	96-106	warfarin	109-116	false
nicardipine	96-106	phenytoin	119-127	false
nicardipine	96-106	acetylsalicylic acid	130-149	false
nicardipine	96-106	tolbutamide	156-166	false
warfarin	109-116	phenytoin	119-127	false
warfarin	109-116	acetylsalicylic acid	130-149	false
warfarin	109-116	tolbutamide	156-166	false
phenytoin	119-127	acetylsalicylic acid	130-149	false
phenytoin	119-127	tolbutamide	156-166	false
acetylsalicylic acid	130-149	tolbutamide	156-166	false

Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
nonsteroidal anti-inflammatory agents	25-61	NSAIDs	64-69	false
nonsteroidal anti-inflammatory agents	25-61	salicylates	73-83	false
nonsteroidal anti-inflammatory agents	25-61	monoamine oxidase inhibitors	86-113	false
nonsteroidal anti-inflammatory agents	25-61	non-selective beta-adrenergic-blocking agents	120-164	false
nonsteroidal anti-inflammatory agents	25-61	Starlix	208-214	effect
nonsteroidal anti-inflammatory agents	25-61	antidiabetic drugs	231-248	effect
NSAIDs	64-69	salicylates	73-83	false
NSAIDs	64-69	monoamine oxidase inhibitors	86-113	false
NSAIDs	64-69	non-selective beta-adrenergic-blocking agents	120-164	false
NSAIDs	64-69	Starlix	208-214	effect
NSAIDs	64-69	antidiabetic drugs	231-248	effect
salicylates	73-83	monoamine oxidase inhibitors	86-113	false
salicylates	73-83	non-selective beta-adrenergic-blocking agents	120-164	false
salicylates	73-83	Starlix	208-214	effect
salicylates	73-83	antidiabetic drugs	231-248	effect
monoamine oxidase inhibitors	86-113	non-selective beta-adrenergic-blocking agents	120-164	false
monoamine oxidase inhibitors	86-113	Starlix	208-214	effect
monoamine oxidase inhibitors	86-113	antidiabetic drugs	231-248	effect
non-selective beta-adrenergic-blocking agents	120-164	Starlix	208-214	effect
non-selective beta-adrenergic-blocking agents	120-164	antidiabetic drugs	231-248	effect
Starlix	208-214	antidiabetic drugs	231-248	false

Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
thiazides	24-32	corticosteroids	35-49	false
thiazides	24-32	thyroid products	52-67	false
thiazides	24-32	sympathomimetics	74-89	false
thiazides	24-32	Starlix	129-135	effect
thiazides	24-32	antidiabetic drugs	152-169	effect
corticosteroids	35-49	thyroid products	52-67	false
corticosteroids	35-49	sympathomimetics	74-89	false
corticosteroids	35-49	Starlix	129-135	effect
corticosteroids	35-49	antidiabetic drugs	152-169	effect
thyroid products	52-67	sympathomimetics	74-89	false
thyroid products	52-67	Starlix	129-135	effect
thyroid products	52-67	antidiabetic drugs	152-169	effect
sympathomimetics	74-89	Starlix	129-135	effect
sympathomimetics	74-89	antidiabetic drugs	152-169	effect
Starlix	129-135	antidiabetic drugs	152-169	false

In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled corticosteroids, with no evidence of increased frequency of adverse events or laboratory abnormalities.
Tilade	21-26	bronchodilators	116-130	false
Tilade	21-26	corticosteroids	145-159	false
bronchodilators	116-130	corticosteroids	145-159	false

Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.
VIRACEPT	20-27	dihydropyridine calcium channel blockers	77-116	false

Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.
VIRACEPT	20-27	nelfinavir	70-79	false

Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.
VIRACEPT	20-27	nelfinavir	71-80	false

Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.
VIRACEPT	101-108	dapsone	114-120	false
VIRACEPT	101-108	trimethoprim	123-134	false
VIRACEPT	101-108	sulfamethoxazole	136-151	false
VIRACEPT	101-108	clarithromycin	154-167	false
VIRACEPT	101-108	erythromycin	170-181	false
VIRACEPT	101-108	itraconazole	184-195	false
VIRACEPT	101-108	fluconazole	200-210	false
dapsone	114-120	trimethoprim	123-134	false
dapsone	114-120	sulfamethoxazole	136-151	false
dapsone	114-120	clarithromycin	154-167	false
dapsone	114-120	erythromycin	170-181	false
dapsone	114-120	itraconazole	184-195	false
dapsone	114-120	fluconazole	200-210	false
trimethoprim	123-134	sulfamethoxazole	136-151	false
trimethoprim	123-134	clarithromycin	154-167	false
trimethoprim	123-134	erythromycin	170-181	false
trimethoprim	123-134	itraconazole	184-195	false
trimethoprim	123-134	fluconazole	200-210	false
sulfamethoxazole	136-151	clarithromycin	154-167	false
sulfamethoxazole	136-151	erythromycin	170-181	false
sulfamethoxazole	136-151	itraconazole	184-195	false
sulfamethoxazole	136-151	fluconazole	200-210	false
clarithromycin	154-167	erythromycin	170-181	false
clarithromycin	154-167	itraconazole	184-195	false
clarithromycin	154-167	fluconazole	200-210	false
erythromycin	170-181	itraconazole	184-195	false
erythromycin	170-181	fluconazole	200-210	false
itraconazole	184-195	fluconazole	200-210	false

Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
VIRACEPT	45-52	Antiarrhythmics	54-68	advise
VIRACEPT	45-52	amiodarone	71-80	advise
VIRACEPT	45-52	quinidine	83-91	advise
VIRACEPT	45-52	Antihistamines	93-106	advise
VIRACEPT	45-52	astemizole	109-118	advise
VIRACEPT	45-52	terfenadine	121-131	advise
VIRACEPT	45-52	ergot derivatives	147-163	advise
VIRACEPT	45-52	Antimycobacterial agents	165-188	advise
VIRACEPT	45-52	rifampin	191-198	advise
VIRACEPT	45-52	Benzodiazepines	200-214	advise
VIRACEPT	45-52	midazolam	216-224	advise
VIRACEPT	45-52	triazolam	227-235	advise
VIRACEPT	45-52	cisapride	257-265	advise
Antiarrhythmics	54-68	amiodarone	71-80	false
Antiarrhythmics	54-68	quinidine	83-91	false
Antiarrhythmics	54-68	Antihistamines	93-106	false
Antiarrhythmics	54-68	astemizole	109-118	false
Antiarrhythmics	54-68	terfenadine	121-131	false
Antiarrhythmics	54-68	ergot derivatives	147-163	false
Antiarrhythmics	54-68	Antimycobacterial agents	165-188	false
Antiarrhythmics	54-68	rifampin	191-198	false
Antiarrhythmics	54-68	Benzodiazepines	200-214	false
Antiarrhythmics	54-68	midazolam	216-224	false
Antiarrhythmics	54-68	triazolam	227-235	false
Antiarrhythmics	54-68	cisapride	257-265	false
amiodarone	71-80	quinidine	83-91	false
amiodarone	71-80	Antihistamines	93-106	false
amiodarone	71-80	astemizole	109-118	false
amiodarone	71-80	terfenadine	121-131	false
amiodarone	71-80	ergot derivatives	147-163	false
amiodarone	71-80	Antimycobacterial agents	165-188	false
amiodarone	71-80	rifampin	191-198	false
amiodarone	71-80	Benzodiazepines	200-214	false
amiodarone	71-80	midazolam	216-224	false
amiodarone	71-80	triazolam	227-235	false
amiodarone	71-80	cisapride	257-265	false
quinidine	83-91	Antihistamines	93-106	false
quinidine	83-91	astemizole	109-118	false
quinidine	83-91	terfenadine	121-131	false
quinidine	83-91	ergot derivatives	147-163	false
quinidine	83-91	Antimycobacterial agents	165-188	false
quinidine	83-91	rifampin	191-198	false
quinidine	83-91	Benzodiazepines	200-214	false
quinidine	83-91	midazolam	216-224	false
quinidine	83-91	triazolam	227-235	false
quinidine	83-91	cisapride	257-265	false
Antihistamines	93-106	astemizole	109-118	false
Antihistamines	93-106	terfenadine	121-131	false
Antihistamines	93-106	ergot derivatives	147-163	false
Antihistamines	93-106	Antimycobacterial agents	165-188	false
Antihistamines	93-106	rifampin	191-198	false
Antihistamines	93-106	Benzodiazepines	200-214	false
Antihistamines	93-106	midazolam	216-224	false
Antihistamines	93-106	triazolam	227-235	false
Antihistamines	93-106	cisapride	257-265	false
astemizole	109-118	terfenadine	121-131	false
astemizole	109-118	ergot derivatives	147-163	false
astemizole	109-118	Antimycobacterial agents	165-188	false
astemizole	109-118	rifampin	191-198	false
astemizole	109-118	Benzodiazepines	200-214	false
astemizole	109-118	midazolam	216-224	false
astemizole	109-118	triazolam	227-235	false
astemizole	109-118	cisapride	257-265	false
terfenadine	121-131	ergot derivatives	147-163	false
terfenadine	121-131	Antimycobacterial agents	165-188	false
terfenadine	121-131	rifampin	191-198	false
terfenadine	121-131	Benzodiazepines	200-214	false
terfenadine	121-131	midazolam	216-224	false
terfenadine	121-131	triazolam	227-235	false
terfenadine	121-131	cisapride	257-265	false
ergot derivatives	147-163	Antimycobacterial agents	165-188	false
ergot derivatives	147-163	rifampin	191-198	false
ergot derivatives	147-163	Benzodiazepines	200-214	false
ergot derivatives	147-163	midazolam	216-224	false
ergot derivatives	147-163	triazolam	227-235	false
ergot derivatives	147-163	cisapride	257-265	false
Antimycobacterial agents	165-188	rifampin	191-198	false
Antimycobacterial agents	165-188	Benzodiazepines	200-214	false
Antimycobacterial agents	165-188	midazolam	216-224	false
Antimycobacterial agents	165-188	triazolam	227-235	false
Antimycobacterial agents	165-188	cisapride	257-265	false
rifampin	191-198	Benzodiazepines	200-214	false
rifampin	191-198	midazolam	216-224	false
rifampin	191-198	triazolam	227-235	false
rifampin	191-198	cisapride	257-265	false
Benzodiazepines	200-214	midazolam	216-224	false
Benzodiazepines	200-214	triazolam	227-235	false
Benzodiazepines	200-214	cisapride	257-265	false
midazolam	216-224	triazolam	227-235	false
midazolam	216-224	cisapride	257-265	false
triazolam	227-235	cisapride	257-265	false

Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
VIRACEPT	61-68	Antimycobacterial agents	70-93	advise
VIRACEPT	61-68	rifabutin	96-104	advise
Antimycobacterial agents	70-93	rifabutin	96-104	false

* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly
VIRACEPT	37-44	nelfinavir	84-93	false

Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;
Terfenadine	0-10	terfenadine	31-41	false
Terfenadine	0-10	VIRACEPT	48-55	false
Terfenadine	0-10	terfenadine	97-107	false
terfenadine	31-41	VIRACEPT	48-55	false
terfenadine	31-41	terfenadine	97-107	false
VIRACEPT	48-55	terfenadine	97-107	false

therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.
VIRACEPT	11-18	terfenadine	65-75	advise

Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.
VIRACEPT	41-48	astemizole	100-109	advise

Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
Indinavir	0-8	indinavir	31-39	false
Indinavir	0-8	VIRACEPT	46-53	false
Indinavir	0-8	nelfinavir	86-95	false
Indinavir	0-8	indinavir	130-138	false
indinavir	31-39	VIRACEPT	46-53	mechanism
indinavir	31-39	nelfinavir	86-95	false
indinavir	31-39	indinavir	130-138	false
VIRACEPT	46-53	nelfinavir	86-95	false
VIRACEPT	46-53	indinavir	130-138	false
nelfinavir	86-95	indinavir	130-138	false

Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
Ritonavir	0-8	ritonavir	31-39	false
Ritonavir	0-8	VIRACEPT	46-53	false
Ritonavir	0-8	nelfinavir	86-95	false
Ritonavir	0-8	ritonavir	134-142	false
ritonavir	31-39	VIRACEPT	46-53	mechanism
ritonavir	31-39	nelfinavir	86-95	false
ritonavir	31-39	ritonavir	134-142	false
VIRACEPT	46-53	nelfinavir	86-95	false
VIRACEPT	46-53	ritonavir	134-142	false
nelfinavir	86-95	ritonavir	134-142	false

Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
Saquinavir	0-9	saquinavir	32-41	false
Saquinavir	0-9	saquinavir	102-111	false
Saquinavir	0-9	VIRACEPT	126-133	false
Saquinavir	0-9	nelfinavir	166-175	false
Saquinavir	0-9	saquinavir	213-222	false
saquinavir	32-41	saquinavir	102-111	false
saquinavir	32-41	VIRACEPT	126-133	mechanism
saquinavir	32-41	nelfinavir	166-175	false
saquinavir	32-41	saquinavir	213-222	false
saquinavir	102-111	VIRACEPT	126-133	false
saquinavir	102-111	nelfinavir	166-175	false
saquinavir	102-111	saquinavir	213-222	false
VIRACEPT	126-133	nelfinavir	166-175	false
VIRACEPT	126-133	saquinavir	213-222	false
nelfinavir	166-175	saquinavir	213-222	false

Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.
Ketoconazole	0-11	ketoconazole	34-45	false
Ketoconazole	0-11	VIRACEPT	52-59	false
Ketoconazole	0-11	nelfinavir	91-100	false
ketoconazole	34-45	VIRACEPT	52-59	mechanism
ketoconazole	34-45	nelfinavir	91-100	false
VIRACEPT	52-59	nelfinavir	91-100	false

This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.
ketoconazole	92-103	VIRACEPT	109-116	false

Didanosine: It is recommended that didanosine be administered on an empty stomach;
Didanosine	0-9	didanosine	35-44	false

therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
nelfinavir	11-20	didanosine	102-111	advise

A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
zidovudine	37-46	VIRACEPT	69-76	advise

Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine.
VIRACEPT	77-84	lamivudine	110-119	false
VIRACEPT	77-84	stavudine	124-132	false
lamivudine	110-119	stavudine	124-132	false

Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
Rifabutin	0-8	rifabutin	31-39	false
Rifabutin	0-8	VIRACEPT	45-52	false
Rifabutin	0-8	nelfinavir	84-93	false
Rifabutin	0-8	rifabutin	129-137	false
rifabutin	31-39	VIRACEPT	45-52	mechanism
rifabutin	31-39	nelfinavir	84-93	false
rifabutin	31-39	rifabutin	129-137	false
VIRACEPT	45-52	nelfinavir	84-93	false
VIRACEPT	45-52	rifabutin	129-137	false
nelfinavir	84-93	rifabutin	129-137	false

It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.
rifabutin	35-43	VIRACEPT	106-113	advise

Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
Rifampin	0-7	rifampin	30-37	false
Rifampin	0-7	VIRACEPT	43-50	false
Rifampin	0-7	nelfinavir	83-92	false
rifampin	30-37	VIRACEPT	43-50	mechanism
rifampin	30-37	nelfinavir	83-92	false
VIRACEPT	43-50	nelfinavir	83-92	false

VIRACEPT and rifampin should not be coadministered.
VIRACEPT	0-7	rifampin	13-20	advise

Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
Ethinyl Estradiol	0-16	Norethindrone	22-34	false
Ethinyl Estradiol	0-16	VIRACEPT	57-64	false
Ethinyl Estradiol	0-16	OVCON-35	71-78	false
Ethinyl Estradiol	0-16	ethinyl estradiol	110-126	false
Ethinyl Estradiol	0-16	norethindrone	151-163	false
Norethindrone	22-34	VIRACEPT	57-64	false
Norethindrone	22-34	OVCON-35	71-78	false
Norethindrone	22-34	ethinyl estradiol	110-126	false
Norethindrone	22-34	norethindrone	151-163	false
VIRACEPT	57-64	OVCON-35	71-78	mechanism
VIRACEPT	57-64	ethinyl estradiol	110-126	false
VIRACEPT	57-64	norethindrone	151-163	false
OVCON-35	71-78	ethinyl estradiol	110-126	false
OVCON-35	71-78	norethindrone	151-163	false
ethinyl estradiol	110-126	norethindrone	151-163	false

Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.
aminoglycosides	66-80	polymyxins	86-95	false
aminoglycosides	66-80	neomycin sulfate	182-197	false
polymyxins	86-95	neomycin sulfate	182-197	false

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
neomycin	5-12	penicillin V	58-69	mechanism
neomycin	5-12	vitamin B-12	77-88	mechanism
neomycin	5-12	methotrexate	91-102	mechanism
neomycin	5-12	5-fluorouracil	108-121	mechanism
penicillin V	58-69	vitamin B-12	77-88	false
penicillin V	58-69	methotrexate	91-102	false
penicillin V	58-69	5-fluorouracil	108-121	false
vitamin B-12	77-88	methotrexate	91-102	false
vitamin B-12	77-88	5-fluorouracil	108-121	false
methotrexate	91-102	5-fluorouracil	108-121	false

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
neomycin sulfate	5-20	coumarin	48-55	effect
neomycin sulfate	5-20	anticoagulants	60-73	effect
coumarin	48-55	anticoagulants	60-73	false

Certain antibiotics, especially neomycin, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.
antibiotics	8-18	neomycin	32-39	false
antibiotics	8-18	streptomycin	42-53	false
antibiotics	8-18	kanamycin	59-67	false
neomycin	32-39	streptomycin	42-53	false
neomycin	32-39	kanamycin	59-67	false
streptomycin	42-53	kanamycin	59-67	false

These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.
antibiotics	6-16	anticholinesterase	149-166	advise

Local and some general anesthetics, antiarrhythmic agents and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;
anesthetics	23-33	antiarrhythmic agents	36-56	false

The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
Natrecor	25-32	vasodilators	42-53	false
Natrecor	25-32	nitroglycerin	63-75	false
Natrecor	25-32	nitroprusside	78-90	false
Natrecor	25-32	milrinone	93-101	false
Natrecor	25-32	ACE inhibitors	110-123	false
Natrecor	25-32	Natrecor	191-198	false
vasodilators	42-53	nitroglycerin	63-75	false
vasodilators	42-53	nitroprusside	78-90	false
vasodilators	42-53	milrinone	93-101	false
vasodilators	42-53	ACE inhibitors	110-123	false
vasodilators	42-53	Natrecor	191-198	false
nitroglycerin	63-75	nitroprusside	78-90	false
nitroglycerin	63-75	milrinone	93-101	false
nitroglycerin	63-75	ACE inhibitors	110-123	false
nitroglycerin	63-75	Natrecor	191-198	false
nitroprusside	78-90	milrinone	93-101	false
nitroprusside	78-90	ACE inhibitors	110-123	false
nitroprusside	78-90	Natrecor	191-198	false
milrinone	93-101	ACE inhibitors	110-123	false
milrinone	93-101	Natrecor	191-198	false
ACE inhibitors	110-123	Natrecor	191-198	false

Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
Netilmicin	0-9	loop diuretics	64-77	advise
Netilmicin	0-9	furosemide	87-96	advise
Netilmicin	0-9	ethacrynic acid	102-116	advise
loop diuretics	64-77	furosemide	87-96	false
loop diuretics	64-77	ethacrynic acid	102-116	false
furosemide	87-96	ethacrynic acid	102-116	false

The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
nevirapine	33-42	antithrombotic agent	52-71	false
nevirapine	33-42	warfarin	73-80	int
antithrombotic agent	52-71	warfarin	73-80	false

When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
warfarin	5-12	nevirapine	38-47	advise

Clarithromycin exposure was significantly decreased by nevirapine;
Clarithromycin	0-13	nevirapine	55-64	mechanism

Alternatives to clarithromycin,such as azithromycin, should be considered.
clarithromycin	16-29	azithromycin	39-50	false

Ethinyl estradiol and Norethindrone
Ethinyl estradiol	0-16	Norethindrone	22-34	false

Ethinyl estradiol Norethindrone
Ethinyl estradiol	0-16	Norethindrone	18-30	false

Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.
contraceptives	5-18	nevirapine	132-141	advise

Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
Nevirapine	0-9	ketoconazole	15-26	advise
Nevirapine	0-9	ketoconazole	88-99	false
ketoconazole	15-26	ketoconazole	88-99	false

Lopinavir/Ritonavir
Lopinavir	0-8	Ritonavir	10-18	false

A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
lopinavir	19-27	ritonavir	29-37	false
lopinavir	19-27	nevirapine	109-118	advise
ritonavir	29-37	nevirapine	109-118	advise

Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
Methadone	0-8	opiate	92-97	false
Methadone	0-8	Methadone	111-119	false
Methadone	0-8	nevirapine	151-160	false
Methadone	0-8	methadone	220-228	false
opiate	92-97	Methadone	111-119	false
opiate	92-97	nevirapine	151-160	false
opiate	92-97	methadone	220-228	false
Methadone	111-119	nevirapine	151-160	advise
Methadone	111-119	methadone	220-228	false
nevirapine	151-160	methadone	220-228	false

The appropriate dose for nelfinavir incombination with nevirapine, with respectto safety and efficacy, has not been established.
nelfinavir	25-34	nevirapine	55-64	false

Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
Nevirapine	0-9	rifampin	15-22	advise
Nevirapine	0-9	nevirapine	84-93	false
rifampin	15-22	nevirapine	84-93	false

Physicians needing to treatpatients co-infected with tuberculosis andusing a nevirapine containing regimen mayuse rifabutin instead.
nevirapine	77-86	rifabutin	114-122	false

aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
nevirapine	75-84	methadone	90-98	effect
nevirapine	75-84	methadone	165-173	false
methadone	90-98	methadone	165-173	false

Amiodarone, disopyramide, lidocaine
Amiodarone	0-9	disopyramide	12-23	false
Amiodarone	0-9	lidocaine	26-34	false
disopyramide	12-23	lidocaine	26-34	false

Carbamazepine, clonazepam, ethosuximide
Carbamazepine	0-12	clonazepam	15-24	false
Carbamazepine	0-12	ethosuximide	27-38	false
clonazepam	15-24	ethosuximide	27-38	false

Diltiazem, nifedipine, verapamil
Diltiazem	0-8	nifedipine	11-20	false
Diltiazem	0-8	verapamil	23-31	false
nifedipine	11-20	verapamil	23-31	false

Cyclosporin, tacrolimus, sirolimus
Cyclosporin	0-10	tacrolimus	13-22	false
Cyclosporin	0-10	sirolimus	25-33	false
tacrolimus	13-22	sirolimus	25-33	false

Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
Vitamin B3	17-26	Niacin	29-34	false
Vitamin B3	17-26	Antihypertensive	38-53	false
Vitamin B3	17-26	Nicotinic acid	64-77	false
Vitamin B3	17-26	ganglionic blocking agents	109-134	false
Niacin	29-34	Antihypertensive	38-53	false
Niacin	29-34	Nicotinic acid	64-77	false
Niacin	29-34	ganglionic blocking agents	109-134	false
Antihypertensive	38-53	Nicotinic acid	64-77	false
Antihypertensive	38-53	ganglionic blocking agents	109-134	false
Nicotinic acid	64-77	ganglionic blocking agents	109-134	effect

Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
Aspirin	0-6	aspirin	21-27	false
Aspirin	0-6	nicotinic acid	69-82	false
aspirin	21-27	nicotinic acid	69-82	mechanism

Beta-Blockers: In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with nicardipine HCl.
Beta-Blockers	0-12	adrenergic beta-receptor blockers	47-79	false
Beta-Blockers	0-12	nicardipine HCl	134-148	false
adrenergic beta-receptor blockers	47-79	nicardipine HCl	134-148	false

Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
Cimetidine	0-9	Cimetidine	12-21	false
Cimetidine	0-9	nicardipine HCl	33-47	false
Cimetidine	12-21	nicardipine HCl	33-47	mechanism

Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.
Digoxin	0-6	calcium blockers	14-29	false
Digoxin	0-6	digitalis preparations	65-86	false
calcium blockers	14-29	digitalis preparations	65-86	mechanism

Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.
Nicardipine HCl	0-14	digoxin	60-66	false
Nicardipine HCl	0-14	digoxin	84-90	false
Nicardipine HCl	0-14	nicardipine HCl	150-164	false
digoxin	60-66	digoxin	84-90	false
digoxin	60-66	nicardipine HCl	150-164	false
digoxin	84-90	nicardipine HCl	150-164	advise

Maalox * Coadministration of Maalox TC had no effect on nicardipine HCl absorption.
Maalox	0-5	Maalox TC	29-37	false
Maalox	0-5	nicardipine HCl	56-70	false
Maalox TC	29-37	nicardipine HCl	56-70	false

Cyclosporine: Concomitant administration of nicardipine and cyclosporine levels.
Cyclosporine	0-11	nicardipine	44-54	false
Cyclosporine	0-11	cyclosporine	60-71	false
nicardipine	44-54	cyclosporine	60-71	false

Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
cyclosporine	25-36	nicardipine	138-148	advise

When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
furosemide	35-44	propranolol	47-57	false
furosemide	35-44	dipyridamole	60-71	false
furosemide	35-44	warfarin	74-81	false
furosemide	35-44	quinidine	84-92	false
furosemide	35-44	naproxen	98-105	false
furosemide	35-44	nicardipine HCl	176-190	false
propranolol	47-57	dipyridamole	60-71	false
propranolol	47-57	warfarin	74-81	false
propranolol	47-57	quinidine	84-92	false
propranolol	47-57	naproxen	98-105	false
propranolol	47-57	nicardipine HCl	176-190	false
dipyridamole	60-71	warfarin	74-81	false
dipyridamole	60-71	quinidine	84-92	false
dipyridamole	60-71	naproxen	98-105	false
dipyridamole	60-71	nicardipine HCl	176-190	false
warfarin	74-81	quinidine	84-92	false
warfarin	74-81	naproxen	98-105	false
warfarin	74-81	nicardipine HCl	176-190	false
quinidine	84-92	naproxen	98-105	false
quinidine	84-92	nicardipine HCl	176-190	false
naproxen	98-105	nicardipine HCl	176-190	false

Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and theophylline.
nicotine	72-79	tricyclic antidepressants	169-193	false
nicotine	72-79	theophylline	199-210	false
tricyclic antidepressants	169-193	theophylline	199-210	false

Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
Beta-adrenergic Blocking Agents	0-30	nifedipine	147-156	false
Beta-adrenergic Blocking Agents	0-30	beta-blocking agents	162-181	false
nifedipine	147-156	beta-blocking agents	162-181	effect

Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
Nitrates	12-19	Nifedipine	22-31	false
Nitrates	12-19	nitrates	68-75	false
Nifedipine	22-31	nitrates	68-75	false

Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
Digitalis	0-8	digoxin	104-110	false
Digitalis	0-8	digoxin	164-170	false
Digitalis	0-8	nifedipine	176-185	false
Digitalis	0-8	digoxin	211-217	false
Digitalis	0-8	nifedipine	285-294	false
digoxin	104-110	digoxin	164-170	false
digoxin	104-110	nifedipine	176-185	false
digoxin	104-110	digoxin	211-217	false
digoxin	104-110	nifedipine	285-294	false
digoxin	164-170	nifedipine	176-185	int
digoxin	164-170	digoxin	211-217	false
digoxin	164-170	nifedipine	285-294	false
nifedipine	176-185	digoxin	211-217	false
nifedipine	176-185	nifedipine	285-294	false
digoxin	211-217	nifedipine	285-294	advise

Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
nifedipine	44-53	digoxin	60-66	false
nifedipine	44-53	digoxin	78-84	false
digoxin	60-66	digoxin	78-84	mechanism

Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
digoxin	65-71	digoxin	104-110	false
digoxin	65-71	nifedipine	178-187	false
digoxin	104-110	nifedipine	178-187	advise

Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
Quinidine	0-8	quinidine	94-102	false
Quinidine	0-8	nifedipine	108-117	false
Quinidine	0-8	quinidine	153-161	false
quinidine	94-102	nifedipine	108-117	mechanism
quinidine	94-102	quinidine	153-161	false
nifedipine	108-117	quinidine	153-161	false

Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.
Coumarin Anticoagulants	0-22	coumarin anticoagulants	103-125	false
Coumarin Anticoagulants	0-22	nifedipine	135-144	false
coumarin anticoagulants	103-125	nifedipine	135-144	effect

Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
Cimetidine	0-9	nifedipine	85-94	false
Cimetidine	0-9	cimetidine	172-181	false
Cimetidine	0-9	nifedipine	206-215	false
nifedipine	85-94	cimetidine	172-181	false
nifedipine	85-94	nifedipine	206-215	false
cimetidine	172-181	nifedipine	206-215	mechanism

The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine.
cimetidine	54-63	nifedipine	166-175	false

If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
nifedipine	3-12	cimetidine	68-77	advise

Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.
vitamin K antagonists	59-79	phenytoin	82-90	false
vitamin K antagonists	59-79	theophylline	97-108	false
phenytoin	82-90	theophylline	97-108	false

For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.
vitamin K antagonists	18-38	nilutamide	76-85	advise
vitamin K antagonists	18-38	vitamin K antagonists	167-187	false
nilutamide	76-85	vitamin K antagonists	167-187	false

It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .
calcium channel blockers	55-78	Nimotop	117-123	effect

In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;
Nimotop	11-17	antihypertensive compounds	73-98	effect

A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
nimodipine	74-83	cimetidine	183-192	false
nimodipine	74-83	nimodipine	214-223	false
cimetidine	183-192	nimodipine	214-223	mechanism

This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine, which could decrease first pass metabolism of nimodipine.
cimetidine	84-93	nimodipine	142-151	false

A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
nisoldipine	40-50	cimetidine 400 mg	100-116	mechanism

Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).
Ranitidine	0-9	nisoldipine	66-76	false

Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.
phenytoin	20-28	SULAR	41-45	mechanism
phenytoin	20-28	nisoldipine	89-99	false
SULAR	41-45	nisoldipine	89-99	false

Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.
SULAR	20-24	phenytoin	31-39	advise
SULAR	20-24	antihypertensive	103-118	false
phenytoin	31-39	antihypertensive	103-118	false

Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
nisoldipine	37-47	beta-blockers	53-65	false
nisoldipine	37-47	atenolol	68-75	false
nisoldipine	37-47	propranolol	78-88	false
beta-blockers	53-65	atenolol	68-75	false
beta-blockers	53-65	propranolol	78-88	false
atenolol	68-75	propranolol	78-88	false

Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
Propranolol	0-10	nisoldipine	93-103	effect

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.
SULAR	29-33	atenolol	71-78	effect
SULAR	29-33	antihypertensive	109-124	false
atenolol	71-78	antihypertensive	109-124	false

Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
Quinidine	0-8	nisoldipine	63-73	mechanism

The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.
nisoldipine	60-70	quinidine	89-97	mechanism

No significant interactions were found between nisoldipine and warfarin or digoxin.
nisoldipine	47-57	warfarin	63-70	false
nisoldipine	47-57	digoxin	75-81	false
warfarin	63-70	digoxin	75-81	false

Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
nitazoxanide	53-64	warfarin	207-214	mechanism

INOmax has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.
INOmax	0-5	tolazoline	34-43	false
INOmax	0-5	dopamine	46-53	false
INOmax	0-5	dobutamine	56-65	false
INOmax	0-5	steroids	68-75	false
INOmax	0-5	surfactant	78-87	false
tolazoline	34-43	dopamine	46-53	false
tolazoline	34-43	dobutamine	56-65	false
tolazoline	34-43	steroids	68-75	false
tolazoline	34-43	surfactant	78-87	false
dopamine	46-53	dobutamine	56-65	false
dopamine	46-53	steroids	68-75	false
dopamine	46-53	surfactant	78-87	false
dobutamine	56-65	steroids	68-75	false
dobutamine	56-65	surfactant	78-87	false
steroids	68-75	surfactant	78-87	false

Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
nitric oxide donor compounds	62-89	sodium nitroprusside	102-121	false
nitric oxide donor compounds	62-89	nitroglycerin	127-139	false
nitric oxide donor compounds	62-89	INOmax	175-180	effect
sodium nitroprusside	102-121	nitroglycerin	127-139	false
sodium nitroprusside	102-121	INOmax	175-180	effect
nitroglycerin	127-139	INOmax	175-180	effect

Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
Antacids	0-7	magnesium trisilicate	20-40	false
Antacids	0-7	nitrofurantoin	80-93	false
magnesium trisilicate	20-40	nitrofurantoin	80-93	mechanism

The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.
nitrofurantoin	61-74	magnesium trisilicate	96-116	mechanism

Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
Uricosuric drugs	0-15	probenecid	26-35	false
Uricosuric drugs	0-15	sulfinpyrazone	41-54	false
Uricosuric drugs	0-15	nitrofurantoin	96-109	mechanism
probenecid	26-35	sulfinpyrazone	41-54	false
probenecid	26-35	nitrofurantoin	96-109	mechanism
sulfinpyrazone	41-54	nitrofurantoin	96-109	mechanism

The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.
nitrofurantoin	26-39	antibacterial	155-167	false

The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.
nitroglycerin	28-40	vasodilators	78-89	effect

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
calcium channel blockers	66-89	nitrates	103-110	effect

The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
sodium nitroprusside	26-45	hypotensive drugs	82-98	effect
sodium nitroprusside	26-45	ganglionic blocking agents	111-136	effect
sodium nitroprusside	26-45	anesthetics	178-188	effect
hypotensive drugs	82-98	ganglionic blocking agents	111-136	false
hypotensive drugs	82-98	anesthetics	178-188	false
ganglionic blocking agents	111-136	anesthetics	178-188	false

No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
nizatidine	43-52	theophylline	58-69	false
nizatidine	43-52	chlordiazepoxide	72-87	false
nizatidine	43-52	lorazepam	90-98	false
nizatidine	43-52	lidocaine	101-109	false
nizatidine	43-52	phenytoin	112-120	false
nizatidine	43-52	warfarin	127-134	false
theophylline	58-69	chlordiazepoxide	72-87	false
theophylline	58-69	lorazepam	90-98	false
theophylline	58-69	lidocaine	101-109	false
theophylline	58-69	phenytoin	112-120	false
theophylline	58-69	warfarin	127-134	false
chlordiazepoxide	72-87	lorazepam	90-98	false
chlordiazepoxide	72-87	lidocaine	101-109	false
chlordiazepoxide	72-87	phenytoin	112-120	false
chlordiazepoxide	72-87	warfarin	127-134	false
lorazepam	90-98	lidocaine	101-109	false
lorazepam	90-98	phenytoin	112-120	false
lorazepam	90-98	warfarin	127-134	false
lidocaine	101-109	phenytoin	112-120	false
lidocaine	101-109	warfarin	127-134	false
phenytoin	112-120	warfarin	127-134	false

In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
aspirin	47-53	salicylate	81-90	false
aspirin	47-53	nizatidine	114-123	mechanism
salicylate	81-90	nizatidine	114-123	false

The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
progestin	21-29	anticonvulsants	98-112	false
progestin	21-29	phenytoin	114-122	effect
progestin	21-29	carbamazepine	125-137	effect
progestin	21-29	barbiturates	144-155	effect
progestin	21-29	antituberculosis drug	166-186	false
progestin	21-29	rifampin	188-195	effect
anticonvulsants	98-112	phenytoin	114-122	false
anticonvulsants	98-112	carbamazepine	125-137	false
anticonvulsants	98-112	barbiturates	144-155	false
anticonvulsants	98-112	antituberculosis drug	166-186	false
anticonvulsants	98-112	rifampin	188-195	false
phenytoin	114-122	carbamazepine	125-137	false
phenytoin	114-122	barbiturates	144-155	false
phenytoin	114-122	antituberculosis drug	166-186	false
phenytoin	114-122	rifampin	188-195	false
carbamazepine	125-137	barbiturates	144-155	false
carbamazepine	125-137	antituberculosis drug	166-186	false
carbamazepine	125-137	rifampin	188-195	false
barbiturates	144-155	antituberculosis drug	166-186	false
barbiturates	144-155	rifampin	188-195	false
antituberculosis drug	166-186	rifampin	188-195	false

Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
theophylline	26-37	quinolone	75-83	mechanism

There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
theophylline	27-38	norfloxacin	101-111	false
theophylline	27-38	theophylline	117-128	false
norfloxacin	101-111	theophylline	117-128	effect

Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
theophylline	25-36	theophylline	87-98	false

Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
cyclosporine	25-36	cyclosporine	81-92	false
cyclosporine	25-36	norfloxacin	99-109	false
cyclosporine	81-92	norfloxacin	99-109	mechanism

Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
cyclosporine	11-22	cyclosporine	73-84	false

Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
Quinolones	0-9	norfloxacin	22-32	false
Quinolones	0-9	anticoagulants	67-80	effect
Quinolones	0-9	warfarin	93-100	effect
norfloxacin	22-32	anticoagulants	67-80	effect
norfloxacin	22-32	warfarin	93-100	effect
anticoagulants	67-80	warfarin	93-100	false

The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
quinolones	34-43	norfloxacin	55-65	false
quinolones	34-43	glyburide	72-80	effect
quinolones	34-43	sulfonylurea agent	85-102	false
norfloxacin	55-65	glyburide	72-80	effect
norfloxacin	55-65	sulfonylurea agent	85-102	false
glyburide	72-80	sulfonylurea agent	85-102	false

Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
norfloxacin	32-42	probenecid	103-112	false
norfloxacin	32-42	norfloxacin	118-128	false
probenecid	103-112	norfloxacin	118-128	mechanism

The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
nitrofurantoin	23-36	nitrofurantoin	63-76	false
nitrofurantoin	23-36	Norfloxacin	121-131	false
nitrofurantoin	63-76	Norfloxacin	121-131	effect

Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
Multivitamins	0-12	iron	44-47	false
Multivitamins	0-12	zinc	52-55	false
Multivitamins	0-12	antacids	58-65	false
Multivitamins	0-12	sucralfate	70-79	false
Multivitamins	0-12	norfloxacin	172-182	advise
Multivitamins	0-12	norfloxacin	273-283	false
iron	44-47	zinc	52-55	false
iron	44-47	antacids	58-65	false
iron	44-47	sucralfate	70-79	false
iron	44-47	norfloxacin	172-182	advise
iron	44-47	norfloxacin	273-283	false
zinc	52-55	antacids	58-65	false
zinc	52-55	sucralfate	70-79	false
zinc	52-55	norfloxacin	172-182	advise
zinc	52-55	norfloxacin	273-283	false
antacids	58-65	sucralfate	70-79	false
antacids	58-65	norfloxacin	172-182	advise
antacids	58-65	norfloxacin	273-283	false
sucralfate	70-79	norfloxacin	172-182	advise
sucralfate	70-79	norfloxacin	273-283	false
norfloxacin	172-182	norfloxacin	273-283	false

Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
Videx	0-4	Didanosine	7-16	false
Videx	0-4	norfloxacin	178-188	advise
Videx	0-4	norfloxacin	289-299	false
Didanosine	7-16	norfloxacin	178-188	advise
Didanosine	7-16	norfloxacin	289-299	false
norfloxacin	178-188	norfloxacin	289-299	false

Some quinolones have also been shown to interfere with the metabolism of caffeine.
quinolones	5-14	caffeine	73-80	mechanism

A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
barbiturates	67-78	phenylbutazone	81-94	false
barbiturates	67-78	phenytoin sodium	97-112	false
barbiturates	67-78	carbamazepine	115-127	false
barbiturates	67-78	griseofulvin	130-141	false
barbiturates	67-78	topiramate	144-153	false
barbiturates	67-78	ampicillin	174-183	false
barbiturates	67-78	tetracyclines	189-201	false
phenylbutazone	81-94	phenytoin sodium	97-112	false
phenylbutazone	81-94	carbamazepine	115-127	false
phenylbutazone	81-94	griseofulvin	130-141	false
phenylbutazone	81-94	topiramate	144-153	false
phenylbutazone	81-94	ampicillin	174-183	false
phenylbutazone	81-94	tetracyclines	189-201	false
phenytoin sodium	97-112	carbamazepine	115-127	false
phenytoin sodium	97-112	griseofulvin	130-141	false
phenytoin sodium	97-112	topiramate	144-153	false
phenytoin sodium	97-112	ampicillin	174-183	false
phenytoin sodium	97-112	tetracyclines	189-201	false
carbamazepine	115-127	griseofulvin	130-141	false
carbamazepine	115-127	topiramate	144-153	false
carbamazepine	115-127	ampicillin	174-183	false
carbamazepine	115-127	tetracyclines	189-201	false
griseofulvin	130-141	topiramate	144-153	false
griseofulvin	130-141	ampicillin	174-183	false
griseofulvin	130-141	tetracyclines	189-201	false
topiramate	144-153	ampicillin	174-183	false
topiramate	144-153	tetracyclines	189-201	false
ampicillin	174-183	tetracyclines	189-201	false

A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. Johns Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. Johns Wort.
hormonal contraceptives	47-69	contraceptive	142-154	false

Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.
tricyclic antidepressants	37-61	cimetidine	108-117	mechanism

Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.
tricyclic antidepressants	147-171	cimetidine	178-187	effect

In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.
tricyclic antidepressants	71-95	cimetidine	169-178	mechanism

In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.
cimetidine	63-72	tricyclic antidepressants	130-154	mechanism

The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.
tricyclic antidepressants	28-52	cimetidine	96-105	effect

There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
antidepressants	90-104	nortriptyline	117-129	false
antidepressants	90-104	fluoxetine hydrochloride	137-160	mechanism
nortriptyline	117-129	fluoxetine hydrochloride	137-160	mechanism

Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other.
Fluoxetine	0-9	norfluoxetine	93-105	false

Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.
reserpine	18-26	tricyclic antidepressant	50-73	effect

Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
nortriptyline hydrochloride	73-99	anticholinergic drugs	120-140	advise
nortriptyline hydrochloride	73-99	sympathomimetic drugs	145-165	advise
anticholinergic drugs	120-140	sympathomimetic drugs	145-165	false

Such individuals are referred to as  poor metabolizers  of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants.
debrisoquin	73-83	dextromethorphan	86-101	false
debrisoquin	73-83	tricyclic antidepressants	112-136	false
dextromethorphan	86-101	tricyclic antidepressants	112-136	false

In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.
antidepressants	82-96	tricyclic antidepressants	99-123	false
antidepressants	82-96	selective serotonin reuptake inhibitors	126-164	false
tricyclic antidepressants	99-123	selective serotonin reuptake inhibitors	126-164	false

Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
tricyclic antidepressants	19-43	tricyclic antidepressant	160-183	false

Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
tricyclic antidepressants	32-56	antidepressants	131-145	advise
tricyclic antidepressants	32-56	phenothiazines	148-161	advise
tricyclic antidepressants	32-56	carbamazepine	164-176	advise
tricyclic antidepressants	32-56	Type 1C antiarrhythmics	183-205	advise
tricyclic antidepressants	32-56	propafenone	212-222	advise
tricyclic antidepressants	32-56	flecainide	225-234	advise
tricyclic antidepressants	32-56	encainide	241-249	advise
tricyclic antidepressants	32-56	quinidine	286-294	advise
antidepressants	131-145	phenothiazines	148-161	false
antidepressants	131-145	carbamazepine	164-176	false
antidepressants	131-145	Type 1C antiarrhythmics	183-205	false
antidepressants	131-145	propafenone	212-222	false
antidepressants	131-145	flecainide	225-234	false
antidepressants	131-145	encainide	241-249	false
antidepressants	131-145	quinidine	286-294	false
phenothiazines	148-161	carbamazepine	164-176	false
phenothiazines	148-161	Type 1C antiarrhythmics	183-205	false
phenothiazines	148-161	propafenone	212-222	false
phenothiazines	148-161	flecainide	225-234	false
phenothiazines	148-161	encainide	241-249	false
phenothiazines	148-161	quinidine	286-294	false
carbamazepine	164-176	Type 1C antiarrhythmics	183-205	false
carbamazepine	164-176	propafenone	212-222	false
carbamazepine	164-176	flecainide	225-234	false
carbamazepine	164-176	encainide	241-249	false
carbamazepine	164-176	quinidine	286-294	false
Type 1C antiarrhythmics	183-205	propafenone	212-222	false
Type 1C antiarrhythmics	183-205	flecainide	225-234	false
Type 1C antiarrhythmics	183-205	encainide	241-249	false
Type 1C antiarrhythmics	183-205	quinidine	286-294	false
propafenone	212-222	flecainide	225-234	false
propafenone	212-222	encainide	241-249	false
propafenone	212-222	quinidine	286-294	false
flecainide	225-234	encainide	241-249	false
flecainide	225-234	quinidine	286-294	false
encainide	241-249	quinidine	286-294	false

In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
AED	21-23	oxcarbazepine	99-111	mechanism
AED	21-23	MHD	117-119	false
oxcarbazepine	99-111	MHD	117-119	false

Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.
oxcarbazepine	25-37	MHD	99-101	false

Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.
OXC	36-38	MHD	44-46	false

The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.
OXC	30-32	MHD	38-40	false

Increases of 22% with MHD and 47% with oxcarbazepine were observed.
MHD	22-24	oxcarbazepine	39-51	false

As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, lamotrigine).
MHD	3-5	valproic acid	222-234	false
MHD	3-5	lamotrigine	237-247	false
valproic acid	222-234	lamotrigine	237-247	false

In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.
oxcarbazepine	13-25	MHD	31-33	false
oxcarbazepine	13-25	dihydropyridine calcium antagonists	140-174	false
oxcarbazepine	13-25	contraceptives	185-198	false
MHD	31-33	dihydropyridine calcium antagonists	140-174	false
MHD	31-33	contraceptives	185-198	false
dihydropyridine calcium antagonists	140-174	contraceptives	185-198	false

Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.
Antiepileptic drugs	0-18	Trileptal	52-60	false
Antiepileptic drugs	0-18	AEDs	72-75	false
Trileptal	52-60	AEDs	72-75	false

Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)
Trileptal	13-21	AED	26-28	false

Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)
AED	13-15	MHD	20-22	false

1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.
Trileptal	94-102	phenytoin	140-148	false
Trileptal	94-102	Trileptal	179-187	false
phenytoin	140-148	Trileptal	179-187	mechanism

Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.
Trileptal	31-39	phenytoin	119-127	advise

The increase of phenobarbital level, however, is small (15%) when given with Trileptal.
phenobarbital	16-28	Trileptal	77-85	mechanism

Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).
carbamazepine	49-61	phenytoin	64-72	false
carbamazepine	49-61	phenobarbital	78-90	false
carbamazepine	49-61	MHD	142-144	false
phenytoin	64-72	phenobarbital	78-90	false
phenytoin	64-72	MHD	142-144	false
phenobarbital	78-90	MHD	142-144	false

Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
contraceptives	9-22	Trileptal	45-53	false
contraceptives	9-22	contraceptive	68-80	false
contraceptives	9-22	ethinylestradiol	168-183	false
contraceptives	9-22	levonorgestrel	194-207	false
Trileptal	45-53	contraceptive	68-80	mechanism
Trileptal	45-53	ethinylestradiol	168-183	false
Trileptal	45-53	levonorgestrel	194-207	false
contraceptive	68-80	ethinylestradiol	168-183	false
contraceptive	68-80	levonorgestrel	194-207	false
ethinylestradiol	168-183	levonorgestrel	194-207	false

Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.
Trileptal	29-37	hormonal contraceptives	44-66	effect
Trileptal	29-37	contraceptives	85-98	false
hormonal contraceptives	44-66	contraceptives	85-98	false

Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].
Calcium Antagonist	0-17	Trileptal	57-65	false
Calcium Antagonist	0-17	felodipine	79-88	false
Trileptal	57-65	felodipine	79-88	mechanism

Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.
Verapamil	0-8	MHD	77-79	false

Other drug interactions Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.
Cimetidine	24-33	erythromycin	36-47	false
Cimetidine	24-33	dextropropoxyphene	53-70	false
Cimetidine	24-33	MHD	113-115	false
erythromycin	36-47	dextropropoxyphene	53-70	false
erythromycin	36-47	MHD	113-115	false
dextropropoxyphene	53-70	MHD	113-115	false

Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal.
warfarin	13-20	Trileptal	95-103	false

In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
TAXOL	45-49	cisplatin	71-79	false
TAXOL	45-49	TAXOL	169-173	false
TAXOL	45-49	cisplatin	191-199	false
TAXOL	45-49	TAXOL	239-243	false
TAXOL	45-49	cisplatin	252-260	false
cisplatin	71-79	TAXOL	169-173	false
cisplatin	71-79	cisplatin	191-199	false
cisplatin	71-79	TAXOL	239-243	false
cisplatin	71-79	cisplatin	252-260	false
TAXOL	169-173	cisplatin	191-199	effect
TAXOL	169-173	TAXOL	239-243	false
TAXOL	169-173	cisplatin	252-260	false
cisplatin	191-199	TAXOL	239-243	false
cisplatin	191-199	cisplatin	252-260	false
TAXOL	239-243	cisplatin	252-260	false

Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.
paclitaxel	68-77	TAXOL	115-119	false
paclitaxel	68-77	cisplatin	148-156	false
TAXOL	115-119	cisplatin	148-156	mechanism

Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
TAXOL	31-35	protease inhibitors	65-83	false
TAXOL	31-35	ritonavir	86-94	false
TAXOL	31-35	saquinavir	97-106	false
TAXOL	31-35	indinavir	109-117	false
TAXOL	31-35	nelfinavir	124-133	false
protease inhibitors	65-83	ritonavir	86-94	false
protease inhibitors	65-83	saquinavir	97-106	false
protease inhibitors	65-83	indinavir	109-117	false
protease inhibitors	65-83	nelfinavir	124-133	false
ritonavir	86-94	saquinavir	97-106	false
ritonavir	86-94	indinavir	109-117	false
ritonavir	86-94	nelfinavir	124-133	false
saquinavir	97-106	indinavir	109-117	false
saquinavir	97-106	nelfinavir	124-133	false
indinavir	109-117	nelfinavir	124-133	false

Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
doxorubicin	56-66	doxorubicinol	95-107	false
doxorubicin	56-66	paclitaxel	132-141	false
doxorubicin	56-66	doxorubicin	147-157	false
doxorubicinol	95-107	paclitaxel	132-141	false
doxorubicinol	95-107	doxorubicin	147-157	false
paclitaxel	132-141	doxorubicin	147-157	mechanism

Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
cyclosporin	131-141	teniposide	173-182	false
cyclosporin	131-141	TAXOL	238-242	advise
teniposide	173-182	TAXOL	238-242	advise

In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).
TAXOL	97-101	corticosteroids	131-145	false
TAXOL	97-101	dexamethasone	156-168	false
TAXOL	97-101	H2 antagonists	193-206	false
TAXOL	97-101	cimetidine	217-226	false
TAXOL	97-101	ranitidine	231-240	false
corticosteroids	131-145	dexamethasone	156-168	false
corticosteroids	131-145	H2 antagonists	193-206	false
corticosteroids	131-145	cimetidine	217-226	false
corticosteroids	131-145	ranitidine	231-240	false
dexamethasone	156-168	H2 antagonists	193-206	false
dexamethasone	156-168	cimetidine	217-226	false
dexamethasone	156-168	ranitidine	231-240	false
H2 antagonists	193-206	cimetidine	217-226	false
H2 antagonists	193-206	ranitidine	231-240	false
cimetidine	217-226	ranitidine	231-240	false

However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.
bronchodilators	86-100	TAXOL	177-181	false

Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
PEGASYS	15-21	theophylline	135-146	mechanism

Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
Theophylline	0-11	theophylline	114-125	false
Theophylline	0-11	PEGASYS	131-137	false
theophylline	114-125	PEGASYS	131-137	advise

In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, PEGASYS treatment did not affect ribavirin distribution or clearance.
PEGASYS	50-56	COPEGUS	78-84	false
PEGASYS	50-56	PEGASYS	87-93	false
PEGASYS	50-56	ribavirin	120-128	false
COPEGUS	78-84	PEGASYS	87-93	false
COPEGUS	78-84	ribavirin	120-128	false
PEGASYS	87-93	ribavirin	120-128	false

Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
Didanosine	21-30	COPEGUS	53-59	false
Didanosine	21-30	didanosine	65-74	false
COPEGUS	53-59	didanosine	65-74	advise

Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
Stavudine	0-8	Zidovudine	14-23	false
Stavudine	0-8	Ribavirin	25-33	false
Stavudine	0-8	stavudine	85-93	false
Stavudine	0-8	zidovudine	99-108	false
Zidovudine	14-23	Ribavirin	25-33	false
Zidovudine	14-23	stavudine	85-93	false
Zidovudine	14-23	zidovudine	99-108	false
Ribavirin	25-33	stavudine	85-93	effect
Ribavirin	25-33	zidovudine	99-108	effect
stavudine	85-93	zidovudine	99-108	false

Use With Ribavirin Ribavirin is genotoxic and mutagenic.
Ribavirin	9-17	Ribavirin	19-27	false

Pregnancy: Category X: Use With Ribavirin (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin.
Ribavirin	32-40	ribavirin	173-181	false

Nursing Mothers It is not known whether peginterferon or ribavirin or its components are excreted in human milk.
peginterferon	40-52	ribavirin	57-65	false

The effect of orally ingested peginterferon or ribavirin from breast milk on the nursing infant has not been evaluated.
peginterferon	30-42	ribavirin	47-55	false

Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue PEGASYS and COPEGUS treatment.
PEGASYS	152-158	COPEGUS	164-170	false

Pediatric Use The safety and effectiveness of PEGASYS, alone or in combination with COPEGUS in patients below the age of 18 years have not been established.
PEGASYS	46-52	COPEGUS	84-90	false

PEGASYS contains benzyl alcohol.
PEGASYS	0-6	benzyl alcohol	17-30	false

Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.
PEGASYS	20-26	COPEGUS	57-63	false

Adverse reactions related to alpha interferons, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of PEGASYS in this population.
alpha interferon	29-44	PEGASYS	186-192	false

PEGASYS and COPEGUS are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.
PEGASYS	0-6	COPEGUS	12-18	false

PEGASYS should be used with caution in patients with creatinine clearance  50 mL/min and COPEGUS should not be administered to patients with creatinine clearance  50 mL/min
PEGASYS	0-6	COPEGUS	89-95	false

Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
Aminoglycosides	0-14	piperacillin	31-42	false
Aminoglycosides	0-14	aminoglycoside	52-65	false
Aminoglycosides	0-14	aminoglycoside	122-135	false
piperacillin	31-42	aminoglycoside	52-65	effect
piperacillin	31-42	aminoglycoside	122-135	false
aminoglycoside	52-65	aminoglycoside	122-135	false

Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
Vecuronium	0-9	piperacillin	51-62	false
Vecuronium	0-9	vecuronium	137-146	false
piperacillin	51-62	vecuronium	137-146	effect

In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.
piperacillin	67-78	vecuronium	120-129	effect

Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
non-depolarizing muscle relaxants	112-144	piperacillin	184-195	effect

Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.
Probenecid	0-9	probenecid	36-45	false
Probenecid	0-9	PIPRACIL	81-88	false
Probenecid	0-9	piperacillin	114-125	false
probenecid	36-45	PIPRACIL	81-88	mechanism
probenecid	36-45	piperacillin	114-125	false
PIPRACIL	81-88	piperacillin	114-125	false

Anticoagulants: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.
Anticoagulants	0-13	heparin	148-154	false
Anticoagulants	0-13	anticoagulants	162-175	false
heparin	148-154	anticoagulants	162-175	false

Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.
Methotrexate	0-11	Piperacillin sodium	14-32	false
Methotrexate	0-11	methotrexate	62-73	false
Piperacillin sodium	14-32	methotrexate	62-73	mechanism

Drug/Laboratory Test Interactions As with other penicillins, the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper-reduction method.
penicillins	48-58	PIPRACIL	83-90	false

There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection.
piperacillin	132-143	tazobactam	145-154	false

Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
Phenothiazines	0-13	piperazine	24-33	false
Phenothiazines	0-13	phenothiazine	41-53	false
piperazine	24-33	phenothiazine	41-53	effect

Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
Pyrantel	0-7	Antiminth	16-24	false
Pyrantel	0-7	piperazine	36-45	false
Pyrantel	0-7	pyrantel	51-58	false
Pyrantel	0-7	piperazine	97-106	false
Antiminth	16-24	piperazine	36-45	false
Antiminth	16-24	pyrantel	51-58	false
Antiminth	16-24	piperazine	97-106	false
piperazine	36-45	pyrantel	51-58	effect
piperazine	36-45	piperazine	97-106	false
pyrantel	51-58	piperazine	97-106	false

ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
ACE inhibitors	0-13	NSAIDs	37-42	false
ACE inhibitors	0-13	Angiotensin Converting Enzyme (ACE) inhibitors	88-133	false
NSAIDs	37-42	Angiotensin Converting Enzyme (ACE) inhibitors	88-133	effect

In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
VIOXX	81-85	ACE inhibitor	96-108	false
VIOXX	81-85	benazepril	110-119	effect
VIOXX	81-85	ACE inhibitor	242-254	false
ACE inhibitor	96-108	benazepril	110-119	false
ACE inhibitor	96-108	ACE inhibitor	242-254	false
benazepril	110-119	ACE inhibitor	242-254	false

This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.
VIOXX	66-70	ACE inhibitors	91-104	advise

Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
Aspirin	0-6	aspirin	48-54	false
Aspirin	0-6	VIOXX	61-65	false
Aspirin	0-6	VIOXX	159-163	false
aspirin	48-54	VIOXX	61-65	effect
aspirin	48-54	VIOXX	159-163	false
VIOXX	61-65	VIOXX	159-163	false

In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.
aspirin	193-199	VIOXX	206-210	false
aspirin	193-199	ibuprofen	253-261	false
VIOXX	206-210	ibuprofen	253-261	false

Patients taking low-dose aspirin plus ibuprofen were not studied.
aspirin	25-31	ibuprofen	38-46	false

At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.
VIOXX	17-21	aspirin	115-121	false

Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.
VIOXX	41-45	aspirin	71-77	false

Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.
VIOXX	64-68	aspirin	74-80	false

Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
Cimetidine	0-9	cimetidine	49-58	false
Cimetidine	0-9	rofecoxib	103-111	false
cimetidine	49-58	rofecoxib	103-111	mechanism

Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.
Digoxin	0-6	Rofecoxib	9-17	false
Digoxin	0-6	digoxin	120-126	false
Rofecoxib	9-17	digoxin	120-126	false

Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	0-9	NSAIDs	86-91	false
Furosemide	0-9	furosemide	130-139	false
Furosemide	0-9	thiazides	145-153	false
NSAIDs	86-91	furosemide	130-139	effect
NSAIDs	86-91	thiazides	145-153	effect
furosemide	130-139	thiazides	145-153	false

Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.
Ketoconazole	0-11	Ketoconazole	14-25	false
Ketoconazole	0-11	rofecoxib	112-120	false
Ketoconazole	14-25	rofecoxib	112-120	false

Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	0-6	NSAIDs	9-14	false
Lithium	0-6	lithium	53-59	false
Lithium	0-6	lithium	93-99	false
NSAIDs	9-14	lithium	53-59	mechanism
NSAIDs	9-14	lithium	93-99	false
lithium	53-59	lithium	93-99	false

Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
VIOXX	11-15	lithium	21-27	advise
VIOXX	11-15	lithium	111-117	false
lithium	21-27	lithium	111-117	false

Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.
Methotrexate	0-11	VIOXX	13-17	false
Methotrexate	0-11	methotrexate	131-142	false
Methotrexate	0-11	methotrexate	205-216	false
VIOXX	13-17	methotrexate	131-142	false
VIOXX	13-17	methotrexate	205-216	false
methotrexate	131-142	methotrexate	205-216	false

At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
VIOXX	34-38	methotrexate	168-179	mechanism

At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
methotrexate	68-79	methotrexate	123-134	false
methotrexate	68-79	rofecoxib	166-174	false
methotrexate	68-79	methotrexate	186-197	false
methotrexate	123-134	rofecoxib	166-174	mechanism
methotrexate	123-134	methotrexate	186-197	false
rofecoxib	166-174	methotrexate	186-197	false

Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
methotrexate	23-34	VIOXX	76-80	false
methotrexate	23-34	methotrexate	86-97	false
VIOXX	76-80	methotrexate	86-97	advise

Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.
Contraceptives	5-18	Rofecoxib	20-28	false
Contraceptives	5-18	ethinyl estradiol	102-118	false
Contraceptives	5-18	norethindrone	124-136	false
Rofecoxib	20-28	ethinyl estradiol	102-118	false
Rofecoxib	20-28	norethindrone	124-136	false
ethinyl estradiol	102-118	norethindrone	124-136	false

Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.
Prednisone	0-9	prednisolone	11-22	false
Prednisone	0-9	Rofecoxib	25-33	false
Prednisone	0-9	prednisolone	107-118	false
Prednisone	0-9	prednisone	123-132	false
prednisolone	11-22	Rofecoxib	25-33	false
prednisolone	11-22	prednisolone	107-118	false
prednisolone	11-22	prednisone	123-132	false
Rofecoxib	25-33	prednisolone	107-118	false
Rofecoxib	25-33	prednisone	123-132	false
prednisolone	107-118	prednisone	123-132	false

Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
Rifampin	0-7	VIOXX	31-35	false
Rifampin	0-7	rifampin	42-49	false
Rifampin	0-7	rofecoxib	145-153	false
VIOXX	31-35	rifampin	42-49	mechanism
VIOXX	31-35	rofecoxib	145-153	false
rifampin	42-49	rofecoxib	145-153	false

Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.
VIOXX	45-49	VIOXX	113-117	false

Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.
Theophylline	0-11	VIOXX	13-17	false
Theophylline	0-11	theophylline	91-102	false
Theophylline	0-11	theophylline	200-211	false
VIOXX	13-17	theophylline	91-102	mechanism
VIOXX	13-17	theophylline	200-211	false
theophylline	91-102	theophylline	200-211	false

Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
theophylline	23-34	VIOXX	97-101	false
theophylline	23-34	theophylline	149-160	false
VIOXX	97-101	theophylline	149-160	advise

Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton).
amitriptyline	107-119	tacrine	122-128	false
amitriptyline	107-119	zileuton	135-142	false
tacrine	122-128	zileuton	135-142	false

Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
Warfarin	0-7	VIOXX	118-122	false
Warfarin	0-7	warfarin	154-161	false
VIOXX	118-122	warfarin	154-161	advise

In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
warfarin	71-78	rofecoxib	84-92	effect

In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
VIOXX	168-172	warfarin	192-199	effect

Several drug interaction studies have been completed with both INVIRASE and FORTOVASE.
INVIRASE	63-70	FORTOVASE	76-84	false

Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE.
FORTOVASE	48-56	INVIRASE	84-91	false

Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.
ritonavir	8-16	ritonavir	102-110	false

Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.
INVIRASE	68-75	ritonavir	81-89	false

Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir
INVIRASE	45-52	Ritonavir	54-62	false

Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
Antiarrhythmics	0-14	Amiodarone	17-26	false
Antiarrhythmics	0-14	bepridil	29-36	false
Antiarrhythmics	0-14	flecainide	39-48	false
Antiarrhythmics	0-14	propafenone	51-61	false
Antiarrhythmics	0-14	quinidine	64-72	false
Amiodarone	17-26	bepridil	29-36	false
Amiodarone	17-26	flecainide	39-48	false
Amiodarone	17-26	propafenone	51-61	false
Amiodarone	17-26	quinidine	64-72	false
bepridil	29-36	flecainide	39-48	false
bepridil	29-36	propafenone	51-61	false
bepridil	29-36	quinidine	64-72	false
flecainide	39-48	propafenone	51-61	false
flecainide	39-48	quinidine	64-72	false
propafenone	51-61	quinidine	64-72	false

Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.
Antihistamines	0-13	astemizole	16-25	false
Antihistamines	0-13	terfenadine	29-39	false
astemizole	16-25	terfenadine	29-39	false

Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
Ergot Derivatives	0-16	Dihydroergotamine	19-35	false
Ergot Derivatives	0-16	ergonovine	38-47	false
Ergot Derivatives	0-16	ergotamine	50-59	false
Ergot Derivatives	0-16	methylergonovine	62-77	false
Ergot Derivatives	0-16	ergot	169-173	false
Dihydroergotamine	19-35	ergonovine	38-47	false
Dihydroergotamine	19-35	ergotamine	50-59	false
Dihydroergotamine	19-35	methylergonovine	62-77	false
Dihydroergotamine	19-35	ergot	169-173	false
ergonovine	38-47	ergotamine	50-59	false
ergonovine	38-47	methylergonovine	62-77	false
ergonovine	38-47	ergot	169-173	false
ergotamine	50-59	methylergonovine	62-77	false
ergotamine	50-59	ergot	169-173	false
methylergonovine	62-77	ergot	169-173	false

Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.
Antimycobacterial Agents	0-23	rifampin	26-33	false
Antimycobacterial Agents	0-23	saquinavir	99-108	false
Antimycobacterial Agents	0-23	antiretroviral	116-129	false
Antimycobacterial Agents	0-23	saquinavir	176-185	false
rifampin	26-33	saquinavir	99-108	false
rifampin	26-33	antiretroviral	116-129	false
rifampin	26-33	saquinavir	176-185	false
saquinavir	99-108	antiretroviral	116-129	false
saquinavir	99-108	saquinavir	176-185	false
antiretroviral	116-129	saquinavir	176-185	false

Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.
saquinavir	64-73	FORTOVASE	76-84	false
saquinavir	64-73	protease inhibitor	99-116	false
saquinavir	64-73	saquinavir	147-156	false
FORTOVASE	76-84	protease inhibitor	99-116	false
FORTOVASE	76-84	saquinavir	147-156	false
protease inhibitor	99-116	saquinavir	147-156	false

No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules.
INVIRASE	50-57	ritonavir	59-67	false
INVIRASE	50-57	FORTOVASE	72-80	false
INVIRASE	50-57	ritonavir	82-90	false
ritonavir	59-67	FORTOVASE	72-80	false
ritonavir	59-67	ritonavir	82-90	false
FORTOVASE	72-80	ritonavir	82-90	false

HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.
HMG-CoA Reductase Inhibitors	0-27	lovastatin	30-39	false
HMG-CoA Reductase Inhibitors	0-27	simvastatin	42-52	false
lovastatin	30-39	simvastatin	42-52	false

Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
Sedatives	0-8	Hypnotics	10-18	false
Sedatives	0-8	triazolam	21-29	false
Sedatives	0-8	midazolam	32-40	false
Hypnotics	10-18	triazolam	21-29	false
Hypnotics	10-18	midazolam	32-40	false
triazolam	21-29	midazolam	32-40	false

Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
calcium channel blockers	122-145	dapsone	148-154	false
calcium channel blockers	122-145	disopyramide	157-168	false
calcium channel blockers	122-145	quinine	171-177	false
calcium channel blockers	122-145	amiodarone	180-189	false
calcium channel blockers	122-145	quinidine	192-200	false
calcium channel blockers	122-145	warfarin	203-210	false
calcium channel blockers	122-145	tacrolimus	213-222	false
calcium channel blockers	122-145	cyclosporine	225-236	false
calcium channel blockers	122-145	ergot derivatives	239-255	false
calcium channel blockers	122-145	pimozide	258-265	false
calcium channel blockers	122-145	carbamazepine	268-280	false
calcium channel blockers	122-145	fentanyl	283-290	false
calcium channel blockers	122-145	alfentanyl	293-302	false
calcium channel blockers	122-145	alprazolam	305-314	false
calcium channel blockers	122-145	triazolam	321-329	false
calcium channel blockers	122-145	saquinavir	397-406	mechanism
dapsone	148-154	disopyramide	157-168	false
dapsone	148-154	quinine	171-177	false
dapsone	148-154	amiodarone	180-189	false
dapsone	148-154	quinidine	192-200	false
dapsone	148-154	warfarin	203-210	false
dapsone	148-154	tacrolimus	213-222	false
dapsone	148-154	cyclosporine	225-236	false
dapsone	148-154	ergot derivatives	239-255	false
dapsone	148-154	pimozide	258-265	false
dapsone	148-154	carbamazepine	268-280	false
dapsone	148-154	fentanyl	283-290	false
dapsone	148-154	alfentanyl	293-302	false
dapsone	148-154	alprazolam	305-314	false
dapsone	148-154	triazolam	321-329	false
dapsone	148-154	saquinavir	397-406	mechanism
disopyramide	157-168	quinine	171-177	false
disopyramide	157-168	amiodarone	180-189	false
disopyramide	157-168	quinidine	192-200	false
disopyramide	157-168	warfarin	203-210	false
disopyramide	157-168	tacrolimus	213-222	false
disopyramide	157-168	cyclosporine	225-236	false
disopyramide	157-168	ergot derivatives	239-255	false
disopyramide	157-168	pimozide	258-265	false
disopyramide	157-168	carbamazepine	268-280	false
disopyramide	157-168	fentanyl	283-290	false
disopyramide	157-168	alfentanyl	293-302	false
disopyramide	157-168	alprazolam	305-314	false
disopyramide	157-168	triazolam	321-329	false
disopyramide	157-168	saquinavir	397-406	mechanism
quinine	171-177	amiodarone	180-189	false
quinine	171-177	quinidine	192-200	false
quinine	171-177	warfarin	203-210	false
quinine	171-177	tacrolimus	213-222	false
quinine	171-177	cyclosporine	225-236	false
quinine	171-177	ergot derivatives	239-255	false
quinine	171-177	pimozide	258-265	false
quinine	171-177	carbamazepine	268-280	false
quinine	171-177	fentanyl	283-290	false
quinine	171-177	alfentanyl	293-302	false
quinine	171-177	alprazolam	305-314	false
quinine	171-177	triazolam	321-329	false
quinine	171-177	saquinavir	397-406	mechanism
amiodarone	180-189	quinidine	192-200	false
amiodarone	180-189	warfarin	203-210	false
amiodarone	180-189	tacrolimus	213-222	false
amiodarone	180-189	cyclosporine	225-236	false
amiodarone	180-189	ergot derivatives	239-255	false
amiodarone	180-189	pimozide	258-265	false
amiodarone	180-189	carbamazepine	268-280	false
amiodarone	180-189	fentanyl	283-290	false
amiodarone	180-189	alfentanyl	293-302	false
amiodarone	180-189	alprazolam	305-314	false
amiodarone	180-189	triazolam	321-329	false
amiodarone	180-189	saquinavir	397-406	mechanism
quinidine	192-200	warfarin	203-210	false
quinidine	192-200	tacrolimus	213-222	false
quinidine	192-200	cyclosporine	225-236	false
quinidine	192-200	ergot derivatives	239-255	false
quinidine	192-200	pimozide	258-265	false
quinidine	192-200	carbamazepine	268-280	false
quinidine	192-200	fentanyl	283-290	false
quinidine	192-200	alfentanyl	293-302	false
quinidine	192-200	alprazolam	305-314	false
quinidine	192-200	triazolam	321-329	false
quinidine	192-200	saquinavir	397-406	mechanism
warfarin	203-210	tacrolimus	213-222	false
warfarin	203-210	cyclosporine	225-236	false
warfarin	203-210	ergot derivatives	239-255	false
warfarin	203-210	pimozide	258-265	false
warfarin	203-210	carbamazepine	268-280	false
warfarin	203-210	fentanyl	283-290	false
warfarin	203-210	alfentanyl	293-302	false
warfarin	203-210	alprazolam	305-314	false
warfarin	203-210	triazolam	321-329	false
warfarin	203-210	saquinavir	397-406	mechanism
tacrolimus	213-222	cyclosporine	225-236	false
tacrolimus	213-222	ergot derivatives	239-255	false
tacrolimus	213-222	pimozide	258-265	false
tacrolimus	213-222	carbamazepine	268-280	false
tacrolimus	213-222	fentanyl	283-290	false
tacrolimus	213-222	alfentanyl	293-302	false
tacrolimus	213-222	alprazolam	305-314	false
tacrolimus	213-222	triazolam	321-329	false
tacrolimus	213-222	saquinavir	397-406	mechanism
cyclosporine	225-236	ergot derivatives	239-255	false
cyclosporine	225-236	pimozide	258-265	false
cyclosporine	225-236	carbamazepine	268-280	false
cyclosporine	225-236	fentanyl	283-290	false
cyclosporine	225-236	alfentanyl	293-302	false
cyclosporine	225-236	alprazolam	305-314	false
cyclosporine	225-236	triazolam	321-329	false
cyclosporine	225-236	saquinavir	397-406	mechanism
ergot derivatives	239-255	pimozide	258-265	false
ergot derivatives	239-255	carbamazepine	268-280	false
ergot derivatives	239-255	fentanyl	283-290	false
ergot derivatives	239-255	alfentanyl	293-302	false
ergot derivatives	239-255	alprazolam	305-314	false
ergot derivatives	239-255	triazolam	321-329	false
ergot derivatives	239-255	saquinavir	397-406	mechanism
pimozide	258-265	carbamazepine	268-280	false
pimozide	258-265	fentanyl	283-290	false
pimozide	258-265	alfentanyl	293-302	false
pimozide	258-265	alprazolam	305-314	false
pimozide	258-265	triazolam	321-329	false
pimozide	258-265	saquinavir	397-406	mechanism
carbamazepine	268-280	fentanyl	283-290	false
carbamazepine	268-280	alfentanyl	293-302	false
carbamazepine	268-280	alprazolam	305-314	false
carbamazepine	268-280	triazolam	321-329	false
carbamazepine	268-280	saquinavir	397-406	mechanism
fentanyl	283-290	alfentanyl	293-302	false
fentanyl	283-290	alprazolam	305-314	false
fentanyl	283-290	triazolam	321-329	false
fentanyl	283-290	saquinavir	397-406	mechanism
alfentanyl	293-302	alprazolam	305-314	false
alfentanyl	293-302	triazolam	321-329	false
alfentanyl	293-302	saquinavir	397-406	mechanism
alprazolam	305-314	triazolam	321-329	false
alprazolam	305-314	saquinavir	397-406	mechanism
triazolam	321-329	saquinavir	397-406	mechanism

Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
INVIRASE	6-13	ritonavir	38-46	advise
INVIRASE	6-13	ritonavir	53-61	false
ritonavir	38-46	ritonavir	53-61	false

Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
phenobarbital	72-84	phenytoin	87-95	false
phenobarbital	72-84	dexamethasone	98-110	false
phenobarbital	72-84	carbamazepine	113-125	false
phenobarbital	72-84	saquinavir	169-178	mechanism
phenytoin	87-95	dexamethasone	98-110	false
phenytoin	87-95	carbamazepine	113-125	false
phenytoin	87-95	saquinavir	169-178	mechanism
dexamethasone	98-110	carbamazepine	113-125	false
dexamethasone	98-110	saquinavir	169-178	mechanism
carbamazepine	113-125	saquinavir	169-178	mechanism

Sulfacetamide preparations are incompatible with silver preparations.
Sulfacetamide	0-12	silver	49-54	int

Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
Sulfapyridine	0-12	Acetaminophen	56-68	int
Sulfapyridine	0-12	Tylenol	77-83	int
Acetaminophen	56-68	Tylenol	77-83	false

- Amiodarone (e.g., Cordarone) or
Amiodarone	2-11	Cordarone	20-28	false

- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
Anabolic steroids	2-18	nandrolone	21-30	false
Anabolic steroids	2-18	Anabolin	39-46	false
Anabolic steroids	2-18	oxandrolone	50-60	false
Anabolic steroids	2-18	Anavar	69-74	false
Anabolic steroids	2-18	oxymetholone	78-89	false
Anabolic steroids	2-18	Anadrol	98-104	false
Anabolic steroids	2-18	stanozolol	108-117	false
Anabolic steroids	2-18	Winstrol	126-133	false
nandrolone	21-30	Anabolin	39-46	false
nandrolone	21-30	oxandrolone	50-60	false
nandrolone	21-30	Anavar	69-74	false
nandrolone	21-30	oxymetholone	78-89	false
nandrolone	21-30	Anadrol	98-104	false
nandrolone	21-30	stanozolol	108-117	false
nandrolone	21-30	Winstrol	126-133	false
Anabolin	39-46	oxandrolone	50-60	false
Anabolin	39-46	Anavar	69-74	false
Anabolin	39-46	oxymetholone	78-89	false
Anabolin	39-46	Anadrol	98-104	false
Anabolin	39-46	stanozolol	108-117	false
Anabolin	39-46	Winstrol	126-133	false
oxandrolone	50-60	Anavar	69-74	false
oxandrolone	50-60	oxymetholone	78-89	false
oxandrolone	50-60	Anadrol	98-104	false
oxandrolone	50-60	stanozolol	108-117	false
oxandrolone	50-60	Winstrol	126-133	false
Anavar	69-74	oxymetholone	78-89	false
Anavar	69-74	Anadrol	98-104	false
Anavar	69-74	stanozolol	108-117	false
Anavar	69-74	Winstrol	126-133	false
oxymetholone	78-89	Anadrol	98-104	false
oxymetholone	78-89	stanozolol	108-117	false
oxymetholone	78-89	Winstrol	126-133	false
Anadrol	98-104	stanozolol	108-117	false
Anadrol	98-104	Winstrol	126-133	false
stanozolol	108-117	Winstrol	126-133	false

- Carbamazepine (e.g., Tegretol) or
Carbamazepine	2-14	Tegretol	23-30	false

- Carmustine (e.g., BiCNU) or
Carmustine	2-11	BiCNU	20-24	false

- Chloroquine (e.g., Aralen) or
Chloroquine	2-12	Aralen	21-26	false

- Dantrolene (e.g., Dantrium) or
Dantrolene	2-11	Dantrium	20-27	false

- Daunorubicin (e.g., Cerubidine) or
Daunorubicin	2-13	Cerubidine	22-31	false

- Disulfiram (e.g., Antabuse) or
Disulfiram	2-11	Antabuse	20-27	false

- Divalproex (e.g., Depakote) or
Divalproex	2-11	Depakote	20-27	false

- Etretinate (e.g., Tegison) or
Etretinate	2-11	Tegison	20-26	false

- Hydroxychloroquine (e.g., Plaquenil) or
Hydroxychloroquine	2-19	Plaquenil	28-36	false

- Mercaptopurine (e.g., Purinethol) or
Mercaptopurine	2-15	Purinethol	24-33	false

- Naltrexone (e.g., Trexan) (with long-term, high-dose use) or
Naltrexone	2-11	Trexan	20-25	false

- Oral contraceptives (birth control pills) containing estrogen or
contraceptives	7-20	estrogen	55-62	false

- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
Phenothiazines	2-15	acetophenazine	18-31	false
Phenothiazines	2-15	Tindal	40-45	false
Phenothiazines	2-15	chlorpromazine	49-62	false
Phenothiazines	2-15	Thorazine	71-79	false
Phenothiazines	2-15	fluphenazine	83-94	false
Phenothiazines	2-15	Prolixin	103-110	false
Phenothiazines	2-15	mesoridazine	114-125	false
Phenothiazines	2-15	Serentil	134-141	false
Phenothiazines	2-15	perphenazine	145-156	false
Phenothiazines	2-15	Trilafon	165-172	false
Phenothiazines	2-15	prochlorperazine	176-191	false
Phenothiazines	2-15	Compazine	200-208	false
Phenothiazines	2-15	promazine	212-220	false
Phenothiazines	2-15	Sparine	229-235	false
Phenothiazines	2-15	promethazine	239-250	false
Phenothiazines	2-15	Phenergan	259-267	false
Phenothiazines	2-15	thioridazine	271-282	false
Phenothiazines	2-15	Mellaril	291-298	false
Phenothiazines	2-15	trifluoperazine	302-316	false
Phenothiazines	2-15	Stelazine	325-333	false
Phenothiazines	2-15	triflupromazine	337-351	false
Phenothiazines	2-15	Vesprin	360-366	false
Phenothiazines	2-15	trimeprazine	370-381	false
Phenothiazines	2-15	Temaril	390-396	false
acetophenazine	18-31	Tindal	40-45	false
acetophenazine	18-31	chlorpromazine	49-62	false
acetophenazine	18-31	Thorazine	71-79	false
acetophenazine	18-31	fluphenazine	83-94	false
acetophenazine	18-31	Prolixin	103-110	false
acetophenazine	18-31	mesoridazine	114-125	false
acetophenazine	18-31	Serentil	134-141	false
acetophenazine	18-31	perphenazine	145-156	false
acetophenazine	18-31	Trilafon	165-172	false
acetophenazine	18-31	prochlorperazine	176-191	false
acetophenazine	18-31	Compazine	200-208	false
acetophenazine	18-31	promazine	212-220	false
acetophenazine	18-31	Sparine	229-235	false
acetophenazine	18-31	promethazine	239-250	false
acetophenazine	18-31	Phenergan	259-267	false
acetophenazine	18-31	thioridazine	271-282	false
acetophenazine	18-31	Mellaril	291-298	false
acetophenazine	18-31	trifluoperazine	302-316	false
acetophenazine	18-31	Stelazine	325-333	false
acetophenazine	18-31	triflupromazine	337-351	false
acetophenazine	18-31	Vesprin	360-366	false
acetophenazine	18-31	trimeprazine	370-381	false
acetophenazine	18-31	Temaril	390-396	false
Tindal	40-45	chlorpromazine	49-62	false
Tindal	40-45	Thorazine	71-79	false
Tindal	40-45	fluphenazine	83-94	false
Tindal	40-45	Prolixin	103-110	false
Tindal	40-45	mesoridazine	114-125	false
Tindal	40-45	Serentil	134-141	false
Tindal	40-45	perphenazine	145-156	false
Tindal	40-45	Trilafon	165-172	false
Tindal	40-45	prochlorperazine	176-191	false
Tindal	40-45	Compazine	200-208	false
Tindal	40-45	promazine	212-220	false
Tindal	40-45	Sparine	229-235	false
Tindal	40-45	promethazine	239-250	false
Tindal	40-45	Phenergan	259-267	false
Tindal	40-45	thioridazine	271-282	false
Tindal	40-45	Mellaril	291-298	false
Tindal	40-45	trifluoperazine	302-316	false
Tindal	40-45	Stelazine	325-333	false
Tindal	40-45	triflupromazine	337-351	false
Tindal	40-45	Vesprin	360-366	false
Tindal	40-45	trimeprazine	370-381	false
Tindal	40-45	Temaril	390-396	false
chlorpromazine	49-62	Thorazine	71-79	false
chlorpromazine	49-62	fluphenazine	83-94	false
chlorpromazine	49-62	Prolixin	103-110	false
chlorpromazine	49-62	mesoridazine	114-125	false
chlorpromazine	49-62	Serentil	134-141	false
chlorpromazine	49-62	perphenazine	145-156	false
chlorpromazine	49-62	Trilafon	165-172	false
chlorpromazine	49-62	prochlorperazine	176-191	false
chlorpromazine	49-62	Compazine	200-208	false
chlorpromazine	49-62	promazine	212-220	false
chlorpromazine	49-62	Sparine	229-235	false
chlorpromazine	49-62	promethazine	239-250	false
chlorpromazine	49-62	Phenergan	259-267	false
chlorpromazine	49-62	thioridazine	271-282	false
chlorpromazine	49-62	Mellaril	291-298	false
chlorpromazine	49-62	trifluoperazine	302-316	false
chlorpromazine	49-62	Stelazine	325-333	false
chlorpromazine	49-62	triflupromazine	337-351	false
chlorpromazine	49-62	Vesprin	360-366	false
chlorpromazine	49-62	trimeprazine	370-381	false
chlorpromazine	49-62	Temaril	390-396	false
Thorazine	71-79	fluphenazine	83-94	false
Thorazine	71-79	Prolixin	103-110	false
Thorazine	71-79	mesoridazine	114-125	false
Thorazine	71-79	Serentil	134-141	false
Thorazine	71-79	perphenazine	145-156	false
Thorazine	71-79	Trilafon	165-172	false
Thorazine	71-79	prochlorperazine	176-191	false
Thorazine	71-79	Compazine	200-208	false
Thorazine	71-79	promazine	212-220	false
Thorazine	71-79	Sparine	229-235	false
Thorazine	71-79	promethazine	239-250	false
Thorazine	71-79	Phenergan	259-267	false
Thorazine	71-79	thioridazine	271-282	false
Thorazine	71-79	Mellaril	291-298	false
Thorazine	71-79	trifluoperazine	302-316	false
Thorazine	71-79	Stelazine	325-333	false
Thorazine	71-79	triflupromazine	337-351	false
Thorazine	71-79	Vesprin	360-366	false
Thorazine	71-79	trimeprazine	370-381	false
Thorazine	71-79	Temaril	390-396	false
fluphenazine	83-94	Prolixin	103-110	false
fluphenazine	83-94	mesoridazine	114-125	false
fluphenazine	83-94	Serentil	134-141	false
fluphenazine	83-94	perphenazine	145-156	false
fluphenazine	83-94	Trilafon	165-172	false
fluphenazine	83-94	prochlorperazine	176-191	false
fluphenazine	83-94	Compazine	200-208	false
fluphenazine	83-94	promazine	212-220	false
fluphenazine	83-94	Sparine	229-235	false
fluphenazine	83-94	promethazine	239-250	false
fluphenazine	83-94	Phenergan	259-267	false
fluphenazine	83-94	thioridazine	271-282	false
fluphenazine	83-94	Mellaril	291-298	false
fluphenazine	83-94	trifluoperazine	302-316	false
fluphenazine	83-94	Stelazine	325-333	false
fluphenazine	83-94	triflupromazine	337-351	false
fluphenazine	83-94	Vesprin	360-366	false
fluphenazine	83-94	trimeprazine	370-381	false
fluphenazine	83-94	Temaril	390-396	false
Prolixin	103-110	mesoridazine	114-125	false
Prolixin	103-110	Serentil	134-141	false
Prolixin	103-110	perphenazine	145-156	false
Prolixin	103-110	Trilafon	165-172	false
Prolixin	103-110	prochlorperazine	176-191	false
Prolixin	103-110	Compazine	200-208	false
Prolixin	103-110	promazine	212-220	false
Prolixin	103-110	Sparine	229-235	false
Prolixin	103-110	promethazine	239-250	false
Prolixin	103-110	Phenergan	259-267	false
Prolixin	103-110	thioridazine	271-282	false
Prolixin	103-110	Mellaril	291-298	false
Prolixin	103-110	trifluoperazine	302-316	false
Prolixin	103-110	Stelazine	325-333	false
Prolixin	103-110	triflupromazine	337-351	false
Prolixin	103-110	Vesprin	360-366	false
Prolixin	103-110	trimeprazine	370-381	false
Prolixin	103-110	Temaril	390-396	false
mesoridazine	114-125	Serentil	134-141	false
mesoridazine	114-125	perphenazine	145-156	false
mesoridazine	114-125	Trilafon	165-172	false
mesoridazine	114-125	prochlorperazine	176-191	false
mesoridazine	114-125	Compazine	200-208	false
mesoridazine	114-125	promazine	212-220	false
mesoridazine	114-125	Sparine	229-235	false
mesoridazine	114-125	promethazine	239-250	false
mesoridazine	114-125	Phenergan	259-267	false
mesoridazine	114-125	thioridazine	271-282	false
mesoridazine	114-125	Mellaril	291-298	false
mesoridazine	114-125	trifluoperazine	302-316	false
mesoridazine	114-125	Stelazine	325-333	false
mesoridazine	114-125	triflupromazine	337-351	false
mesoridazine	114-125	Vesprin	360-366	false
mesoridazine	114-125	trimeprazine	370-381	false
mesoridazine	114-125	Temaril	390-396	false
Serentil	134-141	perphenazine	145-156	false
Serentil	134-141	Trilafon	165-172	false
Serentil	134-141	prochlorperazine	176-191	false
Serentil	134-141	Compazine	200-208	false
Serentil	134-141	promazine	212-220	false
Serentil	134-141	Sparine	229-235	false
Serentil	134-141	promethazine	239-250	false
Serentil	134-141	Phenergan	259-267	false
Serentil	134-141	thioridazine	271-282	false
Serentil	134-141	Mellaril	291-298	false
Serentil	134-141	trifluoperazine	302-316	false
Serentil	134-141	Stelazine	325-333	false
Serentil	134-141	triflupromazine	337-351	false
Serentil	134-141	Vesprin	360-366	false
Serentil	134-141	trimeprazine	370-381	false
Serentil	134-141	Temaril	390-396	false
perphenazine	145-156	Trilafon	165-172	false
perphenazine	145-156	prochlorperazine	176-191	false
perphenazine	145-156	Compazine	200-208	false
perphenazine	145-156	promazine	212-220	false
perphenazine	145-156	Sparine	229-235	false
perphenazine	145-156	promethazine	239-250	false
perphenazine	145-156	Phenergan	259-267	false
perphenazine	145-156	thioridazine	271-282	false
perphenazine	145-156	Mellaril	291-298	false
perphenazine	145-156	trifluoperazine	302-316	false
perphenazine	145-156	Stelazine	325-333	false
perphenazine	145-156	triflupromazine	337-351	false
perphenazine	145-156	Vesprin	360-366	false
perphenazine	145-156	trimeprazine	370-381	false
perphenazine	145-156	Temaril	390-396	false
Trilafon	165-172	prochlorperazine	176-191	false
Trilafon	165-172	Compazine	200-208	false
Trilafon	165-172	promazine	212-220	false
Trilafon	165-172	Sparine	229-235	false
Trilafon	165-172	promethazine	239-250	false
Trilafon	165-172	Phenergan	259-267	false
Trilafon	165-172	thioridazine	271-282	false
Trilafon	165-172	Mellaril	291-298	false
Trilafon	165-172	trifluoperazine	302-316	false
Trilafon	165-172	Stelazine	325-333	false
Trilafon	165-172	triflupromazine	337-351	false
Trilafon	165-172	Vesprin	360-366	false
Trilafon	165-172	trimeprazine	370-381	false
Trilafon	165-172	Temaril	390-396	false
prochlorperazine	176-191	Compazine	200-208	false
prochlorperazine	176-191	promazine	212-220	false
prochlorperazine	176-191	Sparine	229-235	false
prochlorperazine	176-191	promethazine	239-250	false
prochlorperazine	176-191	Phenergan	259-267	false
prochlorperazine	176-191	thioridazine	271-282	false
prochlorperazine	176-191	Mellaril	291-298	false
prochlorperazine	176-191	trifluoperazine	302-316	false
prochlorperazine	176-191	Stelazine	325-333	false
prochlorperazine	176-191	triflupromazine	337-351	false
prochlorperazine	176-191	Vesprin	360-366	false
prochlorperazine	176-191	trimeprazine	370-381	false
prochlorperazine	176-191	Temaril	390-396	false
Compazine	200-208	promazine	212-220	false
Compazine	200-208	Sparine	229-235	false
Compazine	200-208	promethazine	239-250	false
Compazine	200-208	Phenergan	259-267	false
Compazine	200-208	thioridazine	271-282	false
Compazine	200-208	Mellaril	291-298	false
Compazine	200-208	trifluoperazine	302-316	false
Compazine	200-208	Stelazine	325-333	false
Compazine	200-208	triflupromazine	337-351	false
Compazine	200-208	Vesprin	360-366	false
Compazine	200-208	trimeprazine	370-381	false
Compazine	200-208	Temaril	390-396	false
promazine	212-220	Sparine	229-235	false
promazine	212-220	promethazine	239-250	false
promazine	212-220	Phenergan	259-267	false
promazine	212-220	thioridazine	271-282	false
promazine	212-220	Mellaril	291-298	false
promazine	212-220	trifluoperazine	302-316	false
promazine	212-220	Stelazine	325-333	false
promazine	212-220	triflupromazine	337-351	false
promazine	212-220	Vesprin	360-366	false
promazine	212-220	trimeprazine	370-381	false
promazine	212-220	Temaril	390-396	false
Sparine	229-235	promethazine	239-250	false
Sparine	229-235	Phenergan	259-267	false
Sparine	229-235	thioridazine	271-282	false
Sparine	229-235	Mellaril	291-298	false
Sparine	229-235	trifluoperazine	302-316	false
Sparine	229-235	Stelazine	325-333	false
Sparine	229-235	triflupromazine	337-351	false
Sparine	229-235	Vesprin	360-366	false
Sparine	229-235	trimeprazine	370-381	false
Sparine	229-235	Temaril	390-396	false
promethazine	239-250	Phenergan	259-267	false
promethazine	239-250	thioridazine	271-282	false
promethazine	239-250	Mellaril	291-298	false
promethazine	239-250	trifluoperazine	302-316	false
promethazine	239-250	Stelazine	325-333	false
promethazine	239-250	triflupromazine	337-351	false
promethazine	239-250	Vesprin	360-366	false
promethazine	239-250	trimeprazine	370-381	false
promethazine	239-250	Temaril	390-396	false
Phenergan	259-267	thioridazine	271-282	false
Phenergan	259-267	Mellaril	291-298	false
Phenergan	259-267	trifluoperazine	302-316	false
Phenergan	259-267	Stelazine	325-333	false
Phenergan	259-267	triflupromazine	337-351	false
Phenergan	259-267	Vesprin	360-366	false
Phenergan	259-267	trimeprazine	370-381	false
Phenergan	259-267	Temaril	390-396	false
thioridazine	271-282	Mellaril	291-298	false
thioridazine	271-282	trifluoperazine	302-316	false
thioridazine	271-282	Stelazine	325-333	false
thioridazine	271-282	triflupromazine	337-351	false
thioridazine	271-282	Vesprin	360-366	false
thioridazine	271-282	trimeprazine	370-381	false
thioridazine	271-282	Temaril	390-396	false
Mellaril	291-298	trifluoperazine	302-316	false
Mellaril	291-298	Stelazine	325-333	false
Mellaril	291-298	triflupromazine	337-351	false
Mellaril	291-298	Vesprin	360-366	false
Mellaril	291-298	trimeprazine	370-381	false
Mellaril	291-298	Temaril	390-396	false
trifluoperazine	302-316	Stelazine	325-333	false
trifluoperazine	302-316	triflupromazine	337-351	false
trifluoperazine	302-316	Vesprin	360-366	false
trifluoperazine	302-316	trimeprazine	370-381	false
trifluoperazine	302-316	Temaril	390-396	false
Stelazine	325-333	triflupromazine	337-351	false
Stelazine	325-333	Vesprin	360-366	false
Stelazine	325-333	trimeprazine	370-381	false
Stelazine	325-333	Temaril	390-396	false
triflupromazine	337-351	Vesprin	360-366	false
triflupromazine	337-351	trimeprazine	370-381	false
triflupromazine	337-351	Temaril	390-396	false
Vesprin	360-366	trimeprazine	370-381	false
Vesprin	360-366	Temaril	390-396	false
trimeprazine	370-381	Temaril	390-396	false

- Plicamycin (e.g., Mithracin) or
Plicamycin	2-11	Mithracin	20-28	false

- Valproic acid (e.g., Depakene) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver
Valproic acid	2-14	Depakene	23-30	false
Valproic acid	2-14	sulfapyridine	40-52	false
Depakene	23-30	sulfapyridine	40-52	false

- Acetohydroxamic acid (e.g., Lithostat) or
Acetohydroxamic acid	2-21	Lithostat	30-38	false

- Furazolidone (e.g., Furoxone) or
Furazolidone	2-13	Furoxone	22-29	false

- Nitrofurantoin (e.g., Furadantin) or
Nitrofurantoin	2-15	Furadantin	24-33	false

- Procainamide (e.g., Pronestyl) or
Procainamide	2-13	Pronestyl	22-30	false

- Quinidine (e.g., Quinidex) or
Quinidine	2-10	Quinidex	19-26	false

- Quinine (e.g., Quinamm) or
Quinine	2-8	Quinamm	17-23	false

- Sulfoxone (e.g., Diasone) or
Sulfoxone	2-10	Diasone	19-25	false

- Vitamin K (e.g., AquaMEPHYTON, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood
Vitamin K	2-10	AquaMEPHYTON	19-30	false
Vitamin K	2-10	Synkayvite	33-42	false
Vitamin K	2-10	sulfapyridine	52-64	false
AquaMEPHYTON	19-30	Synkayvite	33-42	false
AquaMEPHYTON	19-30	sulfapyridine	52-64	false
Synkayvite	33-42	sulfapyridine	52-64	false

- Anticoagulants (blood thinners) or
Anticoagulants	2-15	blood thinner	18-30	false

- Ethotoin (e.g., Peganone) or
Ethotoin	2-9	Peganone	18-25	false

- Mephenytoin (e.g., Mesantoin) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines
Mephenytoin	2-12	Mesantoin	21-29	false
Mephenytoin	2-12	sulfapyridine	39-51	false
Mesantoin	21-29	sulfapyridine	39-51	false

- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
Antidiabetics	2-14	antidiabetics	72-84	false
Antidiabetics	2-14	sulfapyridine	91-103	false
Antidiabetics	2-14	antidiabetics	197-209	false
antidiabetics	72-84	sulfapyridine	91-103	effect
antidiabetics	72-84	antidiabetics	197-209	false
sulfapyridine	91-103	antidiabetics	197-209	false

- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
Methotrexate	2-13	Mexate	22-27	false
Methotrexate	2-13	methotrexate	37-48	false
Methotrexate	2-13	sulfapyridine	55-67	false
Methotrexate	2-13	methotrexate	156-167	false
Mexate	22-27	methotrexate	37-48	false
Mexate	22-27	sulfapyridine	55-67	false
Mexate	22-27	methotrexate	156-167	false
methotrexate	37-48	sulfapyridine	55-67	effect
methotrexate	37-48	methotrexate	156-167	false
sulfapyridine	55-67	methotrexate	156-167	false

- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood
Methyldopa	2-11	Aldomet	20-26	false
Methyldopa	2-11	methyldopa	36-45	false
Methyldopa	2-11	sulfapyridine	52-64	false
Aldomet	20-26	methyldopa	36-45	false
Aldomet	20-26	sulfapyridine	52-64	false
methyldopa	36-45	sulfapyridine	52-64	effect

- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
Phenytoin	2-10	Dilantin	19-26	false
Phenytoin	2-10	phenytoin	36-44	false
Phenytoin	2-10	sulfapyridine	51-63	false
Phenytoin	2-10	phenytoin	152-160	false
Dilantin	19-26	phenytoin	36-44	false
Dilantin	19-26	sulfapyridine	51-63	false
Dilantin	19-26	phenytoin	152-160	false
phenytoin	36-44	sulfapyridine	51-63	effect
phenytoin	36-44	phenytoin	152-160	false
sulfapyridine	51-63	phenytoin	152-160	false

In evaluating the potential for interactions among co-administered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration.
AEDs	87-90	AED	112-114	false

Phenytoin, phenobarbital and carbamazepine are ge nerally classified as enzyme inducers;
Phenytoin	0-8	phenobarbital	11-23	false
Phenytoin	0-8	carbamazepine	29-41	false
phenobarbital	11-23	carbamazepine	29-41	false

valproate and gabapentin are not.
valproate	0-8	gabapentin	14-23	false

GABITRIL is considered to be a non-enzyme inducing AED.
GABITRIL	0-7	AED	51-53	false

Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
GABITRIL	11-18	AEDs	49-52	false
GABITRIL	11-18	Phenytoin	57-65	false
GABITRIL	11-18	Tiagabine	68-76	false
GABITRIL	11-18	phenytoin	137-145	false
AEDs	49-52	Phenytoin	57-65	false
AEDs	49-52	Tiagabine	68-76	false
AEDs	49-52	phenytoin	137-145	false
Phenytoin	57-65	Tiagabine	68-76	false
Phenytoin	57-65	phenytoin	137-145	false
Tiagabine	68-76	phenytoin	137-145	false

Carbamazepine: Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.
Carbamazepine	0-12	Tiagabine	15-23	false
Carbamazepine	0-12	carbamazepine	84-96	false
Tiagabine	15-23	carbamazepine	84-96	false

Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
Valproate	0-8	Tiagabine	11-19	false
Valproate	0-8	valproate	74-82	false
Tiagabine	11-19	valproate	74-82	mechanism

Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.
Phenobarbital	0-12	Primidone	17-25	false
Phenobarbital	0-12	tiagabine	109-117	false
Phenobarbital	0-12	phenobarbital	142-154	false
Phenobarbital	0-12	primidone	159-167	false
Primidone	17-25	tiagabine	109-117	false
Primidone	17-25	phenobarbital	142-154	false
Primidone	17-25	primidone	159-167	false
tiagabine	109-117	phenobarbital	142-154	false
tiagabine	109-117	primidone	159-167	false
phenobarbital	142-154	primidone	159-167	false

The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.
tiagabine	16-24	phenobarbital	123-135	false
tiagabine	16-24	primidone	140-148	false
phenobarbital	123-135	primidone	140-148	false

Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
AEDs	37-40	GABITRIL	46-53	false
AEDs	37-40	Carbamazepine	57-69	false
AEDs	37-40	tiagabine	122-130	false
AEDs	37-40	carbamazepine	176-188	false
AEDs	37-40	AEDs	229-232	false
GABITRIL	46-53	Carbamazepine	57-69	false
GABITRIL	46-53	tiagabine	122-130	false
GABITRIL	46-53	carbamazepine	176-188	false
GABITRIL	46-53	AEDs	229-232	false
Carbamazepine	57-69	tiagabine	122-130	false
Carbamazepine	57-69	carbamazepine	176-188	false
Carbamazepine	57-69	AEDs	229-232	false
tiagabine	122-130	carbamazepine	176-188	mechanism
tiagabine	122-130	AEDs	229-232	false
carbamazepine	176-188	AEDs	229-232	false

Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
Phenytoin	0-8	tiagabine	61-69	false
Phenytoin	0-8	phenytoin	115-123	false
Phenytoin	0-8	AEDs	164-167	false
tiagabine	61-69	phenytoin	115-123	mechanism
tiagabine	61-69	AEDs	164-167	false
phenytoin	115-123	AEDs	164-167	false

Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
Phenobarbital	0-12	Primidone	15-23	false
Phenobarbital	0-12	tiagabine	77-85	false
Phenobarbital	0-12	phenobarbital	131-143	false
Phenobarbital	0-12	primidone	146-154	false
Phenobarbital	0-12	AEDs	195-198	false
Primidone	15-23	tiagabine	77-85	false
Primidone	15-23	phenobarbital	131-143	false
Primidone	15-23	primidone	146-154	false
Primidone	15-23	AEDs	195-198	false
tiagabine	77-85	phenobarbital	131-143	mechanism
tiagabine	77-85	primidone	146-154	mechanism
tiagabine	77-85	AEDs	195-198	false
phenobarbital	131-143	primidone	146-154	false
phenobarbital	131-143	AEDs	195-198	false
primidone	146-154	AEDs	195-198	false

Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
Valproate	0-8	tiagabine	27-35	false
Valproate	0-8	valproate	56-64	false
Valproate	0-8	tiagabine	95-103	false
Valproate	0-8	valproate	127-135	false
Valproate	0-8	tiagabine	161-169	false
tiagabine	27-35	valproate	56-64	false
tiagabine	27-35	tiagabine	95-103	false
tiagabine	27-35	valproate	127-135	false
tiagabine	27-35	tiagabine	161-169	false
valproate	56-64	tiagabine	95-103	false
valproate	56-64	valproate	127-135	false
valproate	56-64	tiagabine	161-169	false
tiagabine	95-103	valproate	127-135	false
tiagabine	95-103	tiagabine	161-169	false
valproate	127-135	tiagabine	161-169	mechanism

Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.
GABITRIL	15-22	Cimetidine	43-52	false
GABITRIL	15-22	cimetidine	77-86	false
GABITRIL	15-22	tiagabine	120-128	false
GABITRIL	15-22	tiagabine	159-167	false
Cimetidine	43-52	cimetidine	77-86	false
Cimetidine	43-52	tiagabine	120-128	false
Cimetidine	43-52	tiagabine	159-167	false
cimetidine	77-86	tiagabine	120-128	false
cimetidine	77-86	tiagabine	159-167	false
tiagabine	120-128	tiagabine	159-167	false

Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.
Theophylline	0-11	tiagabine	37-45	false
Theophylline	0-11	theophylline	86-97	false
tiagabine	37-45	theophylline	86-97	false

Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.
Warfarin	0-7	R-warfarin	91-100	false
Warfarin	0-7	S-warfarin	105-114	false
Warfarin	0-7	tiagabine	137-145	false
R-warfarin	91-100	S-warfarin	105-114	false
R-warfarin	91-100	tiagabine	137-145	false
S-warfarin	105-114	tiagabine	137-145	false

Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.
Digoxin	0-6	tiagabine	39-47	false
Digoxin	0-6	digoxin	101-107	false
Digoxin	0-6	digoxin	149-155	false
tiagabine	39-47	digoxin	101-107	false
tiagabine	39-47	digoxin	149-155	false
digoxin	101-107	digoxin	149-155	false

Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.
Ethanol	0-6	Triazolam	11-19	false
Ethanol	0-6	triazolam	90-98	false
Ethanol	0-6	tiagabine	115-123	false
Triazolam	11-19	triazolam	90-98	false
Triazolam	11-19	tiagabine	115-123	false
triazolam	90-98	tiagabine	115-123	false

The pharmacokinetics of ethanol were not affected by multiple-dose administration of tiagabine.
ethanol	24-30	tiagabine	85-93	false

Tiagabine has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or alcohol.
Tiagabine	0-8	alcohol	105-111	false

Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
ethanol	87-93	triazolam	98-106	false
ethanol	87-93	tiagabine	154-162	advise
triazolam	98-106	tiagabine	154-162	advise

Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.
Contraceptives	5-18	tiagabine	53-61	false
Contraceptives	5-18	contraceptives	129-142	false
tiagabine	53-61	contraceptives	129-142	false

Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.
Antipyrine	0-9	Antipyrine	13-22	false
Antipyrine	0-9	tiagabine	91-99	false
Antipyrine	13-22	tiagabine	91-99	false

This indicates that tiagabine does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of antipyrine.
tiagabine	20-28	antipyrine	144-153	false

Interaction of GABITRIL with Highly Protein Bound Drugs: In vitro data showed that tiagabine is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.
GABITRIL	15-22	tiagabine	83-91	false

The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form.
valdecoxib	34-43	valdecoxib	70-79	false

Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
Aspirin	0-6	aspirin	39-45	false
Aspirin	0-6	valdecoxib	52-61	false
Aspirin	0-6	valdecoxib	142-151	false
aspirin	39-45	valdecoxib	52-61	effect
aspirin	39-45	valdecoxib	142-151	false
valdecoxib	52-61	valdecoxib	142-151	false

Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.
valdecoxib	44-53	aspirin	79-85	false

In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
valdecoxib	85-94	valdecoxib	134-143	false
valdecoxib	85-94	aspirin	171-177	false
valdecoxib	134-143	aspirin	171-177	false

Methotrexate: Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.
Methotrexate	0-11	Valdecoxib 10 mg	14-29	false
Methotrexate	0-11	methotrexate	114-125	false
Valdecoxib 10 mg	14-29	methotrexate	114-125	false

ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
ACE-inhibitors	0-13	NSAIDs	36-41	false
ACE-inhibitors	0-13	ACE-inhibitors	87-100	false
NSAIDs	36-41	ACE-inhibitors	87-100	effect

This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.
BEXTRA	66-71	ACE-inhibitors	92-105	advise

Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
Furosemide	0-9	NSAIDs	86-91	false
Furosemide	0-9	furosemide	130-139	false
Furosemide	0-9	thiazides	145-153	false
NSAIDs	86-91	furosemide	130-139	effect
NSAIDs	86-91	thiazides	145-153	effect
furosemide	130-139	thiazides	145-153	false

Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
Anticonvulsants	0-14	Phenytoin	17-25	false
Anticonvulsants	0-14	valdecoxib	67-76	false
Anticonvulsants	0-14	phenytoin	191-199	false
Phenytoin	17-25	valdecoxib	67-76	false
Phenytoin	17-25	phenytoin	191-199	false
valdecoxib	67-76	phenytoin	191-199	mechanism

Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
valdecoxib	31-40	phenytoin	103-111	advise

Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).
Valdecoxib	0-9	phenytoin	86-94	false

Dextromethorphan: Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.
Dextromethorphan	0-15	Dextromethorphan	18-33	false

Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
valdecoxib	22-31	dextromethorphan	94-109	mechanism
valdecoxib	22-31	valdecoxib	158-167	false
dextromethorphan	94-109	valdecoxib	158-167	false

Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
dextromethorphan	8-23	valdecoxib	80-89	mechanism

Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
Lithium	0-6	Valdecoxib	9-18	false
Lithium	0-6	lithium	75-81	false
Lithium	0-6	lithium	176-182	false
Valdecoxib	9-18	lithium	75-81	mechanism
Valdecoxib	9-18	lithium	176-182	false
lithium	75-81	lithium	176-182	false

Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
Lithium	0-6	BEXTRA	98-103	false
Lithium	0-6	lithium	127-133	false
BEXTRA	98-103	lithium	127-133	advise

Lithium carbonate (450 mg BID for 7 days) had no effect on valdecoxib pharmacokinetics.
Lithium carbonate	0-16	valdecoxib	59-68	false

Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.
Warfarin	0-7	valdecoxib	24-33	false
Warfarin	0-7	warfarin	66-73	false
Warfarin	0-7	BEXTRA	145-150	false
valdecoxib	24-33	warfarin	66-73	false
valdecoxib	24-33	BEXTRA	145-150	false
warfarin	66-73	BEXTRA	145-150	false

Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
Valdecoxib	0-9	R-warfarin	78-87	mechanism
Valdecoxib	0-9	S-warfarin	93-102	mechanism
Valdecoxib	0-9	warfarin	207-214	effect
R-warfarin	78-87	S-warfarin	93-102	false
R-warfarin	78-87	warfarin	207-214	false
S-warfarin	93-102	warfarin	207-214	false

Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
Anticoagulant	0-12	BEXTRA	114-119	false
Anticoagulant	0-12	warfarin	143-150	false
BEXTRA	114-119	warfarin	143-150	advise

Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.
Fluconazole	0-10	Ketoconazole	16-27	false
Fluconazole	0-10	Ketoconazole	30-41	false
Fluconazole	0-10	fluconazole	47-57	false
Ketoconazole	16-27	Ketoconazole	30-41	false
Ketoconazole	16-27	fluconazole	47-57	false
Ketoconazole	30-41	fluconazole	47-57	false

Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
valdecoxib	42-51	ketoconazole	82-93	mechanism
valdecoxib	42-51	fluconazole	99-109	mechanism
valdecoxib	42-51	valdecoxib	158-167	false
ketoconazole	82-93	fluconazole	99-109	false
ketoconazole	82-93	valdecoxib	158-167	false
fluconazole	99-109	valdecoxib	158-167	false

Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
valdecoxib	25-34	fluconazole	79-89	mechanism
valdecoxib	25-34	ketoconazole	124-135	mechanism
fluconazole	79-89	ketoconazole	124-135	false

Glyburide: Glyburide is a CYP 2C9 substrate.
Glyburide	0-8	Glyburide	11-19	false

Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.
valdecoxib	20-29	glyburide	59-67	false
valdecoxib	20-29	glyburide	142-150	false
glyburide	59-67	glyburide	142-150	false

Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.
valdecoxib	20-29	glyburide	80-88	false
valdecoxib	20-29	glyburide	216-224	false
glyburide	80-88	glyburide	216-224	false

Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
valdecoxib	20-29	glyburide	80-88	mechanism
valdecoxib	20-29	glyburide	97-105	false
valdecoxib	20-29	glyburide	140-148	false
valdecoxib	20-29	glyburide	180-188	false
glyburide	80-88	glyburide	97-105	false
glyburide	80-88	glyburide	140-148	false
glyburide	80-88	glyburide	180-188	false
glyburide	97-105	glyburide	140-148	false
glyburide	97-105	glyburide	180-188	false
glyburide	140-148	glyburide	180-188	false

Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
valdecoxib	47-56	glyburide	197-205	false
valdecoxib	47-56	valdecoxib	236-245	false
glyburide	197-205	valdecoxib	236-245	advise

Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID) have not been studied.
glyburide	20-28	valdecoxib	59-68	false

Omeprazole: Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.
Omeprazole	0-9	Omeprazole	12-21	false

Valdecoxib steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of omeprazole (40 mg QD).
Valdecoxib	0-9	omeprazole	113-122	false

Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
valdecoxib	22-31	omeprazole	55-64	mechanism

Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib.
omeprazole	102-111	valdecoxib	117-126	false

However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.
omeprazole	51-60	omeprazole	135-144	false

Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.
valdecoxib	20-29	omeprazole	63-72	false

Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).
Contraceptives	5-18	Valdecoxib	21-30	false
Contraceptives	5-18	contraceptive	98-110	false
Contraceptives	5-18	norethindrone	112-124	false
Contraceptives	5-18	ethinyl estradiol	126-142	false
Contraceptives	5-18	Ortho-Novum	171-181	false
Valdecoxib	21-30	contraceptive	98-110	false
Valdecoxib	21-30	norethindrone	112-124	false
Valdecoxib	21-30	ethinyl estradiol	126-142	false
Valdecoxib	21-30	Ortho-Novum	171-181	false
contraceptive	98-110	norethindrone	112-124	false
contraceptive	98-110	ethinyl estradiol	126-142	false
contraceptive	98-110	Ortho-Novum	171-181	false
norethindrone	112-124	ethinyl estradiol	126-142	false
norethindrone	112-124	Ortho-Novum	171-181	false
ethinyl estradiol	126-142	Ortho-Novum	171-181	false

Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
valdecoxib	20-29	Ortho-Novum	35-45	mechanism
valdecoxib	20-29	norethindrone	79-91	false
valdecoxib	20-29	ethinyl estradiol	97-113	false
Ortho-Novum	35-45	norethindrone	79-91	false
Ortho-Novum	35-45	ethinyl estradiol	97-113	false
norethindrone	79-91	ethinyl estradiol	97-113	false

These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
norethindrone	29-41	ethinyl estradiol	47-63	false
norethindrone	29-41	contraceptive	123-135	false
norethindrone	29-41	valdecoxib	154-163	false
ethinyl estradiol	47-63	contraceptive	123-135	false
ethinyl estradiol	47-63	valdecoxib	154-163	false
contraceptive	123-135	valdecoxib	154-163	advise

Diazepam: Diazepam (Valium) is a CYP 3A4 and CYP 2C19 substrate.
Diazepam	0-7	Diazepam	10-17	false
Diazepam	0-7	Valium	20-25	false
Diazepam	10-17	Valium	20-25	false

Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
diazepam	19-26	valdecoxib	89-98	mechanism
diazepam	19-26	valdecoxib	150-159	false
diazepam	19-26	diazepam	233-240	false
valdecoxib	89-98	valdecoxib	150-159	false
valdecoxib	89-98	diazepam	233-240	false
valdecoxib	150-159	diazepam	233-240	false

Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
diazepam	37-44	valdecoxib	87-96	false
diazepam	37-44	diazepam	236-243	false
valdecoxib	87-96	diazepam	236-243	effect

Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.
Cimetidine	0-9	vardenafil	44-53	false
Cimetidine	0-9	vardenafil	113-122	false
Cimetidine	0-9	Vardenafil	156-165	false
vardenafil	44-53	vardenafil	113-122	false
vardenafil	44-53	Vardenafil	156-165	false
vardenafil	113-122	Vardenafil	156-165	false

Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
Erythromycin	0-11	vardenafil	58-67	mechanism
Erythromycin	0-11	Vardenafil	129-138	false
vardenafil	58-67	Vardenafil	129-138	false

It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
Vardenafil	54-63	erythromycin	115-126	advise

Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
Ketoconazole	0-11	vardenafil	64-73	mechanism
Ketoconazole	0-11	Vardenafil	135-144	false
vardenafil	64-73	Vardenafil	135-144	false

A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
Vardenafil	7-16	ketoconazole	94-105	advise

Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
ketoconazole	22-33	Vardenafil	122-131	false
ketoconazole	22-33	ketoconazole	206-217	false
Vardenafil	122-131	ketoconazole	206-217	advise

HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
HIV Protease Inhibitors	0-22	Indinavir	25-33	false
HIV Protease Inhibitors	0-22	Vardenafil	72-81	false
HIV Protease Inhibitors	0-22	vardenafil	123-132	false
HIV Protease Inhibitors	0-22	vardenafil	160-169	false
HIV Protease Inhibitors	0-22	vardenafil	201-210	false
Indinavir	25-33	Vardenafil	72-81	mechanism
Indinavir	25-33	vardenafil	123-132	false
Indinavir	25-33	vardenafil	160-169	false
Indinavir	25-33	vardenafil	201-210	false
Vardenafil	72-81	vardenafil	123-132	false
Vardenafil	72-81	vardenafil	160-169	false
Vardenafil	72-81	vardenafil	201-210	false
vardenafil	123-132	vardenafil	160-169	false
vardenafil	123-132	vardenafil	201-210	false
vardenafil	160-169	vardenafil	201-210	false

It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
Vardenafil	48-57	indinavir	114-122	advise

Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
Ritonavir	0-8	Vardenafil	47-56	mechanism
Ritonavir	0-8	vardenafil	97-106	false
Ritonavir	0-8	vardenafil	138-147	false
Vardenafil	47-56	vardenafil	97-106	false
Vardenafil	47-56	vardenafil	138-147	false
vardenafil	97-106	vardenafil	138-147	false

The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
vardenafil	67-76	ritonavir	81-89	mechanism

Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
Ritonavir	0-8	vardenafil	51-60	mechanism

Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
Vardenafil	62-71	ritonavir	128-136	advise

Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, Maalox, and ranitidine.
vardenafil	79-88	glyburide	115-123	false
vardenafil	79-88	warfarin	126-133	false
vardenafil	79-88	digoxin	136-142	false
vardenafil	79-88	Maalox	145-150	false
vardenafil	79-88	ranitidine	157-166	false
glyburide	115-123	warfarin	126-133	false
glyburide	115-123	digoxin	136-142	false
glyburide	115-123	Maalox	145-150	false
glyburide	115-123	ranitidine	157-166	false
warfarin	126-133	digoxin	136-142	false
warfarin	126-133	Maalox	145-150	false
warfarin	126-133	ranitidine	157-166	false
digoxin	136-142	Maalox	145-150	false
digoxin	136-142	ranitidine	157-166	false
Maalox	145-150	ranitidine	157-166	false

In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.
warfarin	7-14	vardenafil	23-32	false

In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
Nitrates	17-24	nitrates	77-84	false
Nitrates	17-24	vardenafil	121-130	false
Nitrates	17-24	Vardenafil	227-236	false
nitrates	77-84	vardenafil	121-130	mechanism
nitrates	77-84	Vardenafil	227-236	false
vardenafil	121-130	Vardenafil	227-236	false

These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.
Vardenafil	37-46	NTG	84-86	false

Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.
nitrates	43-50	Vardenafil	140-149	false
nitrates	43-50	nitrates	155-162	false
Vardenafil	140-149	nitrates	155-162	advise

Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.
Nifedipine	0-9	Vardenafil	12-21	false
Nifedipine	0-9	nifedipine	69-78	false
Nifedipine	0-9	nifedipine	192-201	false
Vardenafil	12-21	nifedipine	69-78	false
Vardenafil	12-21	nifedipine	192-201	false
nifedipine	69-78	nifedipine	192-201	false

Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.
Nifedipine	0-9	Vardenafil	46-55	false

In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
nifedipine	57-66	Vardenafil	69-78	effect

Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
Alpha-blockers	0-13	Vardenafil	21-30	false
Alpha-blockers	0-13	terazosin	131-139	false
Vardenafil	21-30	terazosin	131-139	effect

With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
Vardenafil	28-37	terazosin	49-57	effect

With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
Vardenafil	28-37	terazosin	49-57	effect

When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
Vardenafil	5-14	terazosin	42-50	effect
Vardenafil	5-14	Vardenafil	109-118	false
terazosin	42-50	Vardenafil	109-118	false

In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
tamsulosin	24-33	Vardenafil	86-95	false
tamsulosin	24-33	tamsulosin	107-116	false
Vardenafil	86-95	tamsulosin	107-116	effect

Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
Vardenafil	45-54	tamsulosin	66-75	effect

The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.
Vardenafil	37-46	alpha-blockers	53-66	false

Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.
Vardenafil	21-30	alpha-blocker	66-78	advise

Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
Ritonavir	0-8	indinavir	14-22	false
Ritonavir	0-8	Vardenafil	68-77	false
Ritonavir	0-8	ritonavir	95-103	false
Ritonavir	0-8	ritonavir	126-134	false
indinavir	14-22	Vardenafil	68-77	false
indinavir	14-22	ritonavir	95-103	false
indinavir	14-22	ritonavir	126-134	false
Vardenafil	68-77	ritonavir	95-103	mechanism
Vardenafil	68-77	ritonavir	126-134	false
ritonavir	95-103	ritonavir	126-134	false

Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
Vardenafil	32-41	indinavir	59-67	mechanism
Vardenafil	32-41	indinavir	90-98	false
indinavir	59-67	indinavir	90-98	false

Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.
Alcohol	0-6	Alcohol	9-15	false
Alcohol	0-6	vardenafil	103-112	false
Alcohol	9-15	vardenafil	103-112	false

Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).
Vardenafil	0-9	alcohol	65-71	false
Vardenafil	0-9	alcohol	155-161	false
alcohol	65-71	alcohol	155-161	false

Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).
Aspirin	0-6	Vardenafil	9-18	false
Aspirin	0-6	aspirin	97-103	false
Vardenafil	9-18	aspirin	97-103	false

Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).
Vardenafil	20-29	glyburide	72-80	false
Vardenafil	20-29	warfarin	123-130	false
glyburide	72-80	warfarin	123-130	false

Zidovudine: There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.
Zidovudine	0-9	ZDV	72-74	false
Zidovudine	0-9	zalcitabine	80-90	false
ZDV	72-74	zalcitabine	80-90	false

Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
Zalcitabine	0-10	ZDV	83-85	effect

In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.
didanosine	36-45	stavudine	51-59	false
didanosine	36-45	zalcitabine	127-137	false
stavudine	51-59	zalcitabine	127-137	false

Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
Lamivudine	0-9	lamivudine	104-113	false
Lamivudine	0-9	zalcitabine	139-149	false
lamivudine	104-113	zalcitabine	139-149	effect

Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
Zalcitabine	0-10	lamivudine	22-31	effect

however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine.
lamivudine	78-87	lamivudine	135-144	false
lamivudine	78-87	zalcitabine	206-216	false
lamivudine	135-144	zalcitabine	206-216	false

These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
zalcitabine	66-76	lamivudine	82-91	effect
zalcitabine	66-76	zalcitabine	173-183	false
zalcitabine	66-76	antiretroviral	216-229	false
zalcitabine	66-76	zalcitabine	241-251	false
lamivudine	82-91	zalcitabine	173-183	false
lamivudine	82-91	antiretroviral	216-229	false
lamivudine	82-91	zalcitabine	241-251	false
zalcitabine	173-183	antiretroviral	216-229	false
zalcitabine	173-183	zalcitabine	241-251	false
antiretroviral	216-229	zalcitabine	241-251	false

Concomitant use of zalcitabine and lamivudine is not recommended.
zalcitabine	19-29	lamivudine	35-44	advise

Saquinavir: The combination of HIVID, saquinavir, and ZDV has been studied (as triple combination) in adults.
Saquinavir	0-9	HIVID	31-35	false
Saquinavir	0-9	saquinavir	38-47	false
Saquinavir	0-9	ZDV	54-56	false
HIVID	31-35	saquinavir	38-47	false
HIVID	31-35	ZDV	54-56	false
saquinavir	38-47	ZDV	54-56	false

Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
antiretroviral nucleoside analogues	67-101	chloramphenicol	104-118	false
antiretroviral nucleoside analogues	67-101	cisplatin	121-129	false
antiretroviral nucleoside analogues	67-101	dapsone	132-138	false
antiretroviral nucleoside analogues	67-101	disulfiram	141-150	false
antiretroviral nucleoside analogues	67-101	ethionamide	153-163	false
antiretroviral nucleoside analogues	67-101	glutethimide	166-177	false
antiretroviral nucleoside analogues	67-101	gold	180-183	false
antiretroviral nucleoside analogues	67-101	hydralazine	186-196	false
antiretroviral nucleoside analogues	67-101	iodoquinol	199-208	false
antiretroviral nucleoside analogues	67-101	isoniazid	211-219	false
antiretroviral nucleoside analogues	67-101	metronidazole	222-234	false
antiretroviral nucleoside analogues	67-101	nitrofurantoin	237-250	false
antiretroviral nucleoside analogues	67-101	phenytoin	253-261	false
antiretroviral nucleoside analogues	67-101	ribavirin	264-272	false
antiretroviral nucleoside analogues	67-101	vincristine	279-289	false
chloramphenicol	104-118	cisplatin	121-129	false
chloramphenicol	104-118	dapsone	132-138	false
chloramphenicol	104-118	disulfiram	141-150	false
chloramphenicol	104-118	ethionamide	153-163	false
chloramphenicol	104-118	glutethimide	166-177	false
chloramphenicol	104-118	gold	180-183	false
chloramphenicol	104-118	hydralazine	186-196	false
chloramphenicol	104-118	iodoquinol	199-208	false
chloramphenicol	104-118	isoniazid	211-219	false
chloramphenicol	104-118	metronidazole	222-234	false
chloramphenicol	104-118	nitrofurantoin	237-250	false
chloramphenicol	104-118	phenytoin	253-261	false
chloramphenicol	104-118	ribavirin	264-272	false
chloramphenicol	104-118	vincristine	279-289	false
cisplatin	121-129	dapsone	132-138	false
cisplatin	121-129	disulfiram	141-150	false
cisplatin	121-129	ethionamide	153-163	false
cisplatin	121-129	glutethimide	166-177	false
cisplatin	121-129	gold	180-183	false
cisplatin	121-129	hydralazine	186-196	false
cisplatin	121-129	iodoquinol	199-208	false
cisplatin	121-129	isoniazid	211-219	false
cisplatin	121-129	metronidazole	222-234	false
cisplatin	121-129	nitrofurantoin	237-250	false
cisplatin	121-129	phenytoin	253-261	false
cisplatin	121-129	ribavirin	264-272	false
cisplatin	121-129	vincristine	279-289	false
dapsone	132-138	disulfiram	141-150	false
dapsone	132-138	ethionamide	153-163	false
dapsone	132-138	glutethimide	166-177	false
dapsone	132-138	gold	180-183	false
dapsone	132-138	hydralazine	186-196	false
dapsone	132-138	iodoquinol	199-208	false
dapsone	132-138	isoniazid	211-219	false
dapsone	132-138	metronidazole	222-234	false
dapsone	132-138	nitrofurantoin	237-250	false
dapsone	132-138	phenytoin	253-261	false
dapsone	132-138	ribavirin	264-272	false
dapsone	132-138	vincristine	279-289	false
disulfiram	141-150	ethionamide	153-163	false
disulfiram	141-150	glutethimide	166-177	false
disulfiram	141-150	gold	180-183	false
disulfiram	141-150	hydralazine	186-196	false
disulfiram	141-150	iodoquinol	199-208	false
disulfiram	141-150	isoniazid	211-219	false
disulfiram	141-150	metronidazole	222-234	false
disulfiram	141-150	nitrofurantoin	237-250	false
disulfiram	141-150	phenytoin	253-261	false
disulfiram	141-150	ribavirin	264-272	false
disulfiram	141-150	vincristine	279-289	false
ethionamide	153-163	glutethimide	166-177	false
ethionamide	153-163	gold	180-183	false
ethionamide	153-163	hydralazine	186-196	false
ethionamide	153-163	iodoquinol	199-208	false
ethionamide	153-163	isoniazid	211-219	false
ethionamide	153-163	metronidazole	222-234	false
ethionamide	153-163	nitrofurantoin	237-250	false
ethionamide	153-163	phenytoin	253-261	false
ethionamide	153-163	ribavirin	264-272	false
ethionamide	153-163	vincristine	279-289	false
glutethimide	166-177	gold	180-183	false
glutethimide	166-177	hydralazine	186-196	false
glutethimide	166-177	iodoquinol	199-208	false
glutethimide	166-177	isoniazid	211-219	false
glutethimide	166-177	metronidazole	222-234	false
glutethimide	166-177	nitrofurantoin	237-250	false
glutethimide	166-177	phenytoin	253-261	false
glutethimide	166-177	ribavirin	264-272	false
glutethimide	166-177	vincristine	279-289	false
gold	180-183	hydralazine	186-196	false
gold	180-183	iodoquinol	199-208	false
gold	180-183	isoniazid	211-219	false
gold	180-183	metronidazole	222-234	false
gold	180-183	nitrofurantoin	237-250	false
gold	180-183	phenytoin	253-261	false
gold	180-183	ribavirin	264-272	false
gold	180-183	vincristine	279-289	false
hydralazine	186-196	iodoquinol	199-208	false
hydralazine	186-196	isoniazid	211-219	false
hydralazine	186-196	metronidazole	222-234	false
hydralazine	186-196	nitrofurantoin	237-250	false
hydralazine	186-196	phenytoin	253-261	false
hydralazine	186-196	ribavirin	264-272	false
hydralazine	186-196	vincristine	279-289	false
iodoquinol	199-208	isoniazid	211-219	false
iodoquinol	199-208	metronidazole	222-234	false
iodoquinol	199-208	nitrofurantoin	237-250	false
iodoquinol	199-208	phenytoin	253-261	false
iodoquinol	199-208	ribavirin	264-272	false
iodoquinol	199-208	vincristine	279-289	false
isoniazid	211-219	metronidazole	222-234	false
isoniazid	211-219	nitrofurantoin	237-250	false
isoniazid	211-219	phenytoin	253-261	false
isoniazid	211-219	ribavirin	264-272	false
isoniazid	211-219	vincristine	279-289	false
metronidazole	222-234	nitrofurantoin	237-250	false
metronidazole	222-234	phenytoin	253-261	false
metronidazole	222-234	ribavirin	264-272	false
metronidazole	222-234	vincristine	279-289	false
nitrofurantoin	237-250	phenytoin	253-261	false
nitrofurantoin	237-250	ribavirin	264-272	false
nitrofurantoin	237-250	vincristine	279-289	false
phenytoin	253-261	ribavirin	264-272	false
phenytoin	253-261	vincristine	279-289	false
ribavirin	264-272	vincristine	279-289	false

Concomitant use of HIVID with didanosine is not recommended.
HIVID	19-23	didanosine	30-39	advise

Intravenous Pentamidine: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.
Pentamidine	12-22	HIVID	40-44	false

Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.
pentamidine	68-78	HIVID	84-88	effect

If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.
pentamidine	15-25	HIVID	95-99	advise

Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
Amphotericin	0-11	Foscarnet	14-22	false
Amphotericin	0-11	Aminoglycosides	29-43	false
Amphotericin	0-11	amphotericin	60-71	false
Amphotericin	0-11	foscarnet	74-82	false
Amphotericin	0-11	aminoglycosides	89-103	false
Amphotericin	0-11	HIVID	172-176	false
Amphotericin	0-11	zalcitabine	247-257	false
Foscarnet	14-22	Aminoglycosides	29-43	false
Foscarnet	14-22	amphotericin	60-71	false
Foscarnet	14-22	foscarnet	74-82	false
Foscarnet	14-22	aminoglycosides	89-103	false
Foscarnet	14-22	HIVID	172-176	false
Foscarnet	14-22	zalcitabine	247-257	false
Aminoglycosides	29-43	amphotericin	60-71	false
Aminoglycosides	29-43	foscarnet	74-82	false
Aminoglycosides	29-43	aminoglycosides	89-103	false
Aminoglycosides	29-43	HIVID	172-176	false
Aminoglycosides	29-43	zalcitabine	247-257	false
amphotericin	60-71	foscarnet	74-82	false
amphotericin	60-71	aminoglycosides	89-103	false
amphotericin	60-71	HIVID	172-176	effect
amphotericin	60-71	zalcitabine	247-257	mechanism
foscarnet	74-82	aminoglycosides	89-103	false
foscarnet	74-82	HIVID	172-176	effect
foscarnet	74-82	zalcitabine	247-257	mechanism
aminoglycosides	89-103	HIVID	172-176	effect
aminoglycosides	89-103	zalcitabine	247-257	mechanism
HIVID	172-176	zalcitabine	247-257	false

Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
Probenecid	0-9	Cimetidine	14-23	false
Probenecid	0-9	probenecid	56-65	false
Probenecid	0-9	cimetidine	70-79	false
Probenecid	0-9	zalcitabine	110-120	false
Probenecid	0-9	zalcitabine	179-189	false
Cimetidine	14-23	probenecid	56-65	false
Cimetidine	14-23	cimetidine	70-79	false
Cimetidine	14-23	zalcitabine	110-120	false
Cimetidine	14-23	zalcitabine	179-189	false
probenecid	56-65	cimetidine	70-79	false
probenecid	56-65	zalcitabine	110-120	mechanism
probenecid	56-65	zalcitabine	179-189	false
cimetidine	70-79	zalcitabine	110-120	mechanism
cimetidine	70-79	zalcitabine	179-189	false
zalcitabine	110-120	zalcitabine	179-189	false

Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.
zalcitabine	51-61	zalcitabine	121-131	false

Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
Magnesium	0-8	Aluminum	10-17	false
Magnesium	0-8	Antacid Products	30-45	false
Magnesium	0-8	zalcitabine	62-72	false
Magnesium	0-8	magnesium	141-149	false
Magnesium	0-8	aluminum	151-158	false
Magnesium	0-8	antacid products	171-186	false
Aluminum	10-17	Antacid Products	30-45	false
Aluminum	10-17	zalcitabine	62-72	false
Aluminum	10-17	magnesium	141-149	false
Aluminum	10-17	aluminum	151-158	false
Aluminum	10-17	antacid products	171-186	false
Antacid Products	30-45	zalcitabine	62-72	false
Antacid Products	30-45	magnesium	141-149	false
Antacid Products	30-45	aluminum	151-158	false
Antacid Products	30-45	antacid products	171-186	false
zalcitabine	62-72	magnesium	141-149	false
zalcitabine	62-72	aluminum	151-158	false
zalcitabine	62-72	antacid products	171-186	false
magnesium	141-149	aluminum	151-158	false
magnesium	141-149	antacid products	171-186	false
aluminum	151-158	antacid products	171-186	false

The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
zalcitabine	64-74	magnesium	130-138	advise
zalcitabine	64-74	aluminum	140-147	advise
zalcitabine	64-74	antacids	160-167	advise
magnesium	130-138	aluminum	140-147	false
magnesium	130-138	antacids	160-167	false
aluminum	140-147	antacids	160-167	false

Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
Metoclopramide	0-13	zalcitabine	75-85	false
Metoclopramide	0-13	metoclopramide	91-104	false
zalcitabine	75-85	metoclopramide	91-104	mechanism

Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
Doxorubicin	0-10	Doxorubicin	13-23	false
Doxorubicin	0-10	zalcitabine	46-56	false
Doxorubicin	13-23	zalcitabine	46-56	effect

CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
Ethanol	17-23	Sonata	26-31	false
Ethanol	17-23	ethanol	80-86	false
Ethanol	17-23	ethanol	152-158	false
Ethanol	17-23	ethanol	326-332	false
Sonata	26-31	ethanol	80-86	effect
Sonata	26-31	ethanol	152-158	false
Sonata	26-31	ethanol	326-332	false
ethanol	80-86	ethanol	152-158	false
ethanol	80-86	ethanol	326-332	false
ethanol	152-158	ethanol	326-332	false

zaleplon did not affect the pharmacokinetics of ethanol.
zaleplon	0-7	ethanol	48-54	false

Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
Imipramine	0-9	Sonata	48-53	false
Imipramine	0-9	imipramine	65-74	false
Sonata	48-53	imipramine	65-74	effect

Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.
Paroxetine	0-9	Sonata	49-54	false
Paroxetine	0-9	paroxetine	66-75	false
Sonata	49-54	paroxetine	66-75	false

Additionally, paroxetine did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.
paroxetine	14-23	Sonata	63-68	false
paroxetine	14-23	zaleplon	117-124	false
Sonata	63-68	zaleplon	117-124	false

Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
Thioridazine	0-11	Sonata	50-55	false
Thioridazine	0-11	thioridazine	67-78	false
Sonata	50-55	thioridazine	67-78	effect

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.
Venlafaxine	0-10	zaleplon	50-57	false
Venlafaxine	0-10	venlafaxine	87-97	false
Venlafaxine	0-10	zaleplon	204-211	false
Venlafaxine	0-10	venlafaxine	216-226	false
zaleplon	50-57	venlafaxine	87-97	false
zaleplon	50-57	zaleplon	204-211	false
zaleplon	50-57	venlafaxine	216-226	false
venlafaxine	87-97	zaleplon	204-211	false
venlafaxine	87-97	venlafaxine	216-226	false
zaleplon	204-211	venlafaxine	216-226	false

In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.
zaleplon	89-96	venlafaxine	102-112	false

Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
Promethazine	0-11	zaleplon	51-58	false
Promethazine	0-11	promethazine	64-75	false
Promethazine	0-11	zaleplon	169-176	false
zaleplon	51-58	promethazine	64-75	mechanism
zaleplon	51-58	zaleplon	169-176	false
promethazine	64-75	zaleplon	169-176	false

However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.
zaleplon	53-60	promethazine	66-77	false

Drugs That Induce CYP3A4 Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon.
Rifampin	25-32	zaleplon	87-94	false

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
rifampin	58-65	zaleplon	128-135	mechanism

An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital.
hypnotic agent	36-49	rifampin	112-119	false
hypnotic agent	36-49	phenytoin	122-130	false
hypnotic agent	36-49	carbamazepine	133-145	false
hypnotic agent	36-49	phenobarbital	152-164	false
rifampin	112-119	phenytoin	122-130	false
rifampin	112-119	carbamazepine	133-145	false
rifampin	112-119	phenobarbital	152-164	false
phenytoin	122-130	carbamazepine	133-145	false
phenytoin	122-130	phenobarbital	152-164	false
carbamazepine	133-145	phenobarbital	152-164	false

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.
zaleplon	85-92	5-oxo-desethylzaleplon	180-201	false
zaleplon	85-92	5-oxo-desethylzaleplon glucuronide	207-240	false
zaleplon	85-92	zaleplon	292-299	false
5-oxo-desethylzaleplon	180-201	5-oxo-desethylzaleplon glucuronide	207-240	false
5-oxo-desethylzaleplon	180-201	zaleplon	292-299	false
5-oxo-desethylzaleplon glucuronide	207-240	zaleplon	292-299	false

Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
zaleplon	42-49	erythromycin	56-67	mechanism
zaleplon	42-49	zaleplon	167-174	false
erythromycin	56-67	zaleplon	167-174	false

Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
ketoconazole	49-60	zaleplon	111-118	mechanism

Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
Diphenhydramine	0-14	Diphenhydramine	17-31	false

There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.
zaleplon	48-55	diphenhydramine	61-75	false

Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
Cimetidine	52-61	Cimetidine	64-73	false
Cimetidine	52-61	zaleplon	217-224	false
Cimetidine	64-73	zaleplon	217-224	mechanism

Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
Sonata	30-35	cimetidine	49-58	mechanism
Sonata	30-35	zaleplon	122-129	false
cimetidine	49-58	zaleplon	122-129	false

Drugs with a Narrow Therapeutic Index Digoxin: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).
Digoxin	38-44	Sonata	47-52	false
Digoxin	38-44	digoxin	127-133	false
Sonata	47-52	digoxin	127-133	false

Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.
Warfarin	0-7	Sonata	33-38	false
Warfarin	0-7	warfarin	104-111	false
Warfarin	0-7	warfarin	220-227	false
Sonata	33-38	warfarin	104-111	false
Sonata	33-38	warfarin	220-227	false
warfarin	104-111	warfarin	220-227	false

Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs.
Ibuprofen	33-41	Ibuprofen	44-52	false

There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug.
zaleplon	58-65	ibuprofen	71-79	false

This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
zaleplon	26-33	zaleplon	93-100	false

